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Human cancers can be classified based on gene expression signatures quantifying 
the degree of cell proliferation and a feature we term tissue remodelling. Yet, 
specific factors regulating the gene expression programs of cell proliferation and 
tissue remodelling are not well understood. In this work, I address this question 
using colorectal cancer as a case study. 
 
In an initial evaluation of clinical outcome prediction in the case study cohort, 
our classification based on cell proliferation and tissue remodelling signatures 
delivers a better patient stratification than a recently reported consensus 
molecular subtyping (CMS). Although the CMS scheme predicts a worse prognosis 
for patients with a mesenchymal signature (a feature that strongly overlaps with 
tissue remodelling), it cannot differentiate the remaining patients based on 
clinical outcome. I show that cell proliferation is the missing factor, which is 
associated with good prognosis. 
 
In the analyses of specific factors driving the tissue remodelling programme, I 
identify transcription factor KLF4 and microRNA mir-22 as putative regulators. 
Concordant with KLF4 role in immune cell regulation, KLF4 activity scores are 
significantly higher in colorectal tumours with predicted myeloid cells 
infiltration, suggesting its association with myeloid cell infiltration and poor 
prognosis in colorectal cancer. However, mir-22 is not associated with immune 
cell infiltration, suggesting it may be expressed in the tumour stroma as well. 
 
Lastly, I propose a network that may be regulated by IRF8, SPI1, KLF4 and mir-22 
in monocyte differentiation and in colorectal cancer. The correlation analysis 
suggests a negative feedback loop, whereby mir-22 may repress Irf8 gene to 
control the rate of IRF8 transcription. 
 
Taken together, I have identified specific regulators driving remodelling 
processes and their association with immune cell infiltration. In the future, it 
will be beneficial to conduct further studies to understand the mechanisms 
driving myeloid cell infiltration in colorectal cancer, particularly to propose 
treatments for patients exhibiting poor prognosis. 
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1.1 Molecular classifications of cancer 
Cancer patients had been previously classified based on tissue morphology as 
well as clinical and pathological features (Finak et al. 2006) (Onitilo et al. 2009) 
(Feeley et al. 2014). After the sequencing of the human genome (Lander et al. 
2001) (Venter et al. 2001), gene expression arrays were developed allowing 
researchers to investigate molecular features at the genome scale. In a 
pioneering work, Sorlie et al. performed an unbiased clustering analysis of gene 
expression profiles of 82 samples including 78 breast tumours and four normal 
tissues (Sorlie et al. 2001). They uncovered five major subtypes: normal-like, 
luminal A, luminal B, ERBB2+ and basal-like. Later on, Wang et al. recapitulated 
this analysis in a much larger cohort of 892 breast cancer patients (Wang et al. 
2012). These studies lead to two key conclusions. First, that gene expression 
profiles can be used to identify disease subgroups with significantly different 
prognosis. Second, that some molecular features specific to each subgroup can 
guide the development of stratified medicine. 
 
1.2 Gene signatures of cell proliferation and tissue remodelling 
Cell proliferation and tissue remodelling have been associated with metabolic 
changes that are required for the transformation of normal to cancerous cells 
and the high metabolic demands of cancer cells. A number of oncogenic and 
tumour suppressor pathway alterations have been reported to sustain 
metabolism required for cell proliferation and migration. MYC promotes 
proliferation by coordinating nutrients for cell division and DNA replication 
through its targets (Stine et al. 2015) and its deregulation has been implicated in 
cancer. P53 is a tumour suppressor with a pro-apoptotic function and over half 
of human cancers carry mutations in p53 gene (Ozaki and Nakagawara 2011). On 
the other hand, transforming growth factor beta (TGFβ) regulates cell invasion, 
immune system and modification of cellular microenvironment, which are 
hijacked by cancer cells (Massague 2008). However, an understanding of a 
preferential mode of increased cell proliferation or increased tissue remodelling 
required for cancer development is still lacking. 
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Several studies have reported the association of gene signatures of cell 
proliferation and tissue remodelling with prognosis. Poor prognosis in breast 
cancer has been shown to be highly correlated with cell proliferation (Venet et 
al. 2011) (van Diest et al. 2004) (Aleskandarany et al. 2012). Venet et al. 
constructed a meta-PCNA (proliferating cell nuclear antigen) gene signature that 
comprised of 1% of the genes that were most positively correlated with PCNA 
expression and also included other known proliferation markers, such as MKI67, 
TOP2A and MCM2 (Venet et al. 2011). They used 47 published signatures, 
compared the correlations with the meta-PCNA and found that majority of the 
genes that were associated with outcome in breast cancer were highly 
correlated with meta-PCNA (Venet et al. 2011). Their findings show that 58% of 
the breast cancer transcriptome is highly correlated with meta-PCNA and a 
signature does not necessarily need to be enriched with known proliferation 
genes to carry a strong proliferation signal (Venet et al. 2011). 
 
Shaul et at. studied metabolic gene expression profiles of human cancer cell 
lines and developed a mesenchymal metabolic signature (MMS) to investigate the 
aggressiveness of cancer cells (Shaul et al. 2014). They classified the cell lines 
into five groups based on tissue origin, i.e. melanoma cell lines, hematopoietic 
system cancers, neuroendocrine or neuroectodermal cancers, epithelial cancer 
cell lines and mesenchymal (from mixed lineage) (Shaul et al. 2014). The 
mesenchymal subtype has an increased expression of mesenchymal markers, 
such as vimentin, SNAI1/2, CDH2, TWIST1 and ZEB1 but a lower expression of 
CLDN1 and E-cadherin (Shaul et al. 2014). In a separate study, Aruga et al. 
investigated the relationships of clinicopathological features of lung squamous 
cell carcinoma with E-cadherin and vimentin (Aruga et al. 2018). They 
demonstrated epithelial-mesenchymal transition (EMT) phenotype to be a 
significant predictor of poor prognosis in lung squamous cell carcinoma (Aruga et 
al. 2018). 
 
The association of gene signatures with prognosis has also been investigated in 
the context of colorectal cancer. Anjomshoaa et al. developed a colon-specific 
gene proliferation signature (Anjomshoaa et al. 2008). They demonstrated that 
lower expression of gene proliferation signature was associated with increased 
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risk of recurrence and shorter disease-free survival in colorectal cancer, in 
contrary with previous reports in other cancer types (Anjomshoaa et al. 2008). In 
an independent study, Loboda et al. reported a signature of EMT was associated 
with poor prognosis in colorectal cancer (Loboda et al. 2011). These two studies 
are consistent with a previous report that showed metastatic colorectal tumours 
yielded a lower proliferative index than primary non-metastatic tumours 
(Ganepola et al. 2010). Collectively, these studies on colorectal cancer patient 
stratifications highlight that a down-regulation of cell proliferation signature and 
a signature of EMT (tissue remodelling) are associated with poor prognosis. This 
observation is opposed to breast cancer patient stratifications, which 
demonstrate cell proliferation is associated with poor prognosis (Venet et al. 
2011) (van Diest et al. 2004) (Aleskandarany et al. 2012). 
 
To investigate the selective mode of cell proliferation or tissue remodelling in 
different cancer types, a previous study in our laboratory had unified these two 
approaches. Using gene ontology (GO) terms, Market et al. developed cell 
proliferation and tissue remodelling gene signatures from literature reporting 
genes implicated in these two sets of processes. To define the cell proliferation 
signature, they included processes involved in or associated with cell cycle, 
namely G1/S transition, DNA replication, telomere organisation, DNA packaging, 
chromosome segregation, G2/M transition and cell division (Markert et al. 2012). 
For the tissue remodelling signature, they considered processes involving a 
change relative to the microenvironment or an interaction with the 
microenvironment. These include cell junction organisation, cell adhesion, cell 
migration, angiogenesis, cytokine production, inflammatory response and 
response to wounding (Markert et al. 2012). Cell proliferation was found to have 
a positive correlation with glycolysis, oxidative phosphorylation (OxPhos), and 
serine or glycine metabolism, whereas tissue remodelling was negatively 
correlated with OxPhos (Markert et al. 2012).  
 
In the same study, it was showed that tumour samples, including breast and 
colorectal cancer, could be classified based on the quantification of cell 
proliferation and tissue remodelling gene signatures (Markert et al. 2012). The 
majority of the tumour samples exhibit a significant up-regulation of either of 
these two gene signatures, highlighting the partially independent relationship of 
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cell proliferation and tissue remodelling (Markert et al. 2012). In this study, the 
prognostic values of these gene signatures were also demonstrated in different 
cancer types. Using patient survival data, cell proliferation was found to be 
indicative of poor prognosis in lung, prostate, breast and brain cancer, while 
tissue remodelling was found to be associated with poor prognosis in colorectal 
and ovarian cancer (Markert et al. 2012). In other words, patients with a 
proliferation signature manifest worst outcome in most cancer types being 
studied, while colorectal and ovarian tumours with a remodelling signature 
exhibit worse survival than those with a proliferation signature. Taken together, 
cell proliferation and tissue remodelling gene signatures serve as a universal 
scheme for patient stratification and this study highlights the dichotomy of cell 
proliferation and tissue remodelling programmes in different cancer types. 
However, at this point, we still do not know specific transcriptional regulations 
that drive the preferential mode of cell proliferation and tissue remodelling in 
cancer development and progression. 
 
1.3 Consensus molecular subtyping of colorectal cancer 
Recently, several groups of researchers formed a colorectal cancer subtyping 
consortium (CRCSC) and made use of gene expression profiles of a large 
colorectal cancer cohort from different published studies. They performed an 
unsupervised clustering to stratify colorectal tumours based on gene expression 
profiles. Their unsupervised approach resulted in a classification of colorectal 
patients into four subtypes, namely, CMS1, CMS2, CMS3 and CMS4, where CMS 
stands for consensus molecular subtypes (Guinney et al. 2015). They showed that 
CMS4 is the subtype that is indicative of worst prognosis and enriched for a gene 
signature of mesenchymal (Guinney et al. 2015). 
 
1.4 Regulation of cell proliferation and tissue remodelling 
As elaborated in section 1.2, several reports unanimously showed that a 
signature of EMT or tissue remodelling was indicative of worst prognosis, while 
cell proliferation was associated with good prognosis in colorectal cancer 
(Anjomshoaa et al. 2008) (Loboda et al. 2011) (Markert et al. 2012) (Guinney et 
al. 2015). However, the mechanisms driving increased tissue remodelling or 
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increased cell proliferation in different cancer types are still not well 
understood. 
 
Cells respond to changes in the environment by receiving and processing signals 
from outside the cells. Receptors of the cells bind to ligands that in turn 
activate intracellular signalling pathways. Intracellular signals are released 
inside the cells to activate pathways that regulate gene expression in response 
to the external stimuli. The biogenesis of gene expression is regulated by 
regulatory elements, such as transcription factors (TFs) and microRNAs 
(miRNAs). They control the dependencies of cell proliferation and tissue 
remodelling in the cells, as depicted in Figure 1-1. These regulatory mechanisms 
are hijacked in cancer cells, resulting in constitutively active growth and/or 
tissue remodelling signals that drive tumourigenesis. Therefore, the cell 
proliferation and tissue remodelling programmes can be regulated at multiple 
levels. 
 
Transcriptional regulation controls the gene expression program to maintain 
specific cell states. This regulation determines the number of RNA copies to be 
transcribed and when the gene transcription should happen. Transcription 
factors regulate gene transcription by binding enhancer elements and recruiting 
RNA polymerase II and cofactors to their target genes to initiate the 
transcription (Lee and Young 2013). Transcription factor MYC activates 
transcriptional programs promoting cell growth and proliferation but represses 
cell growth arrest (Dang 2013). The deregulation of its proto-oncogene MYC has 
been implicated in cancer, which causes the withdrawal of normal cell cycle into 
a G1-like state (Dang 2013). On the other hand, transcription factors Goosecoid, 
Snail, Twist and TGFβ can induce EMT program that promotes cancer cell 
invasiveness and migration and exhibits stem cell properties (Taube et al. 2010). 
Collectively, these studies show that there are some transcription factors that 





Figure 1-1. A model of regulatory of gene expression program 
 
Another potential layer of regulation is codon bias. Gingold et al. studied the 
differential regulation of the tRNAs and codon usage of the genes involved in 
proliferation and differentiation (Gingold et al. 2014). The genes that are 
involved in proliferation preferentially use codons ending with A or T nucleotide, 
while differentiation genes tend to use codons ending with G or C nucleotide 
(Gingold et al. 2014). In the study, they also confirmed the clear separation 
between genes involved in proliferation and differentiation processes as well as 
the promoters and histone modifications within proximity of the tRNAs involved 
in these processes (Gingold et al. 2014). Their findings suggested that 
proliferation genes that were induced in cancer had distinct codon usage from 
differentiation genes that were repressed in cancer (Gingold et al. 2014). 
Additionally, they reported that the proliferative status of a cell (differentiated, 
senescent and arrested) was reflected in the tRNA pool, while the tissue origin 
was contained in mRNA expression and there was a correlation between changes 










This study emphasises that the selective mode of proliferation and 
differentiation (remodelling) is also present in the tRNA pool and codon usage of 
genes. 
 
Finally, microRNAs and other non-coding RNAs are involved in the post-
transcriptional regulation of gene expression. In particular, microRNAs regulate 
gene transcription through RNA-induced silencing complex (RISC) where they 
assemble into the complex and activate the complex to the target gene 
(Macfarlane and Murphy 2010). The complementarity between microRNA and its 
target gene determines the silencing mechanism that is used, i.e. cleavage of 
target gene leading to its degradation or inhibition of its translation (Macfarlane 
and Murphy 2010). MicroRNAs play an important role in various metabolic and 
cellular pathways, including cell proliferation, differentiation and survival, and 
their dysregulation has been implicated in cancer (Macfarlane and Murphy 2010). 
The let-7 family of microRNAs regulate cell proliferation, while the microRNAs 
from the mir-15 and mir-16 family act as tumour suppressors through their pro-
apoptotic function and mir-21 suppresses genes that promote invasion and 
metastasis (Macfarlane and Murphy 2010). Taken together, this observation 
highlights that there are some microRNAs that specifically promote either the 
cell proliferation or tissue remodelling programme. 
 
When analysing gene expression profiles from human tumours we should also 
bear in mind that, in addition to the tumour cells, there may be other 
compartments of cells that have not been genetically altered. That includes the 
fibroblasts and blood vessels making up the tumour stroma and infiltrating 
immune cells as well. Various immune cell types from the lymphoid and myeloid 
lineages may be present in a tumour, including B cells, effector T cells, naive 
and memory lymphocytes, natural killer (NK) cells, macrophages, mast cells and 
dendritic cells (Fridman et al. 2012). Lymphocyte infiltration has been 
associated with an antitumour response and better prognosis (Angell and Galon 
2013) (James et al. 2017). Pollard described that macrophages recruited at the 
invasive front of breast tumours enhanced cancer cell migration and invasion by 
secreting chemotactic and chemokinetic factors, such as epidermal growth 
factor (EGF) (Pollard 2008). Collectively, these reports suggest that infiltration 
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of different immune cells plays different roles in malignancy, which is then 
reflected in patient outcome. 
 
1.5 The biology and development of colorectal cancer 
Colorectal cancer is the third-most common cancer and it is preceded by a 
polypoid precursor (Kuipers et al. 2015). Inflammatory bowel disease (IBD) is 
associated with an increased risk of colorectal cancer and the risk increases with 
the duration of IBD (Jess et al. 2012). A positive family history is also associated 
with an increased risk of colorectal cancer, whereby the two most common 
hereditary colorectal cancer syndromes are Lynch and familial adenomatous 
polyposis syndromes (Kuipers et al. 2015). A mutation of the DNA mismatch-
repair genes (MLH1, MSH2, MSH6, PMS2 and EPCAM) gives rise to Lynch syndrome 
(Kuipers et al. 2015). On the other hand, familial adenomatous polyposis 
syndrome is caused by a mutation in adenomatous polyposis coli (APC) gene, 
which controls the WNT signalling pathway activity (Vasen et al. 2015).  
 
The genetic mutations and epigenetic alterations in the colon result in the 
polyp, which is the transformation of normal colonic epithelium into colon 
adenocarcinoma (Grady and Carethers 2008). The loss of genomic stability can 
be observed in early neoplastic lesions of the colon and majority of them are 
aberrant crypt foci, adenomas and serrated polyps (Kuipers et al. 2015). Most 
colorectal cancer cells originate from a stem cell or stem-like cell that can be 
found in the base of the colonic crypts (Zeki et al. 2011). Mutations in the 
tumour suppressor genes or the oncogenes in these multipotent stem cells give 
rise to cancer stem cell formation, which is important for tumour initiation and 
maintenance (Kuipers et al. 2015). 
 
Most of the colorectal tumours originate from a polyp that arises from an 
aberrant crypt and develop into an early adenoma then further evolve into an 
advanced adenoma and finally a colorectal cancer (Kuipers et al. 2015). They 
arise via the tumour suppressor or serrated neoplasia molecular pathway 
(Goldstein 2006). Conventional tubular and tubulovillous adenomatous polyps are 
widely recognised premalignant precursor lesions arising from the tumour 
suppressor (chromosomal instability) pathway and biallelic inactivation of APC 
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(Goldstein 2006) (Grady and Pritchard 2014). In contrast, serrated polyps arise 
from the serrated neoplasia (mutator) pathway, which originate from the 
accumulation of insertion or deletion mutations in the genome and result in 
genomic instability and microsatellite unstable-high (MSI-H) adenocarcinomas 
(Goldstein 2006).  
 
The molecular and histological events that the serrated polyps go through are 
distinct from tubular adenomas and these polyps can be categorised into three 
categories, namely hyperplastic polyps, sessile serrated polyps (SSP) and 
traditional serrated adenomas (TSA) (Kuipers et al. 2015). A fraction of 
hyperplastic polyps advance into serrated adenomas (SSP or TSA) and a subset of 
the serrated adenomas advance into colorectal cancer (Grady and Pritchard 
2014). Serrated polyps that grow in the right colon, including the transverse 
colon, ascending colon and caecum, generally demonstrate microsatellite 
instability (MSI) and CpG island methylator phenotype (CIMP) (Kuipers et al. 
2015). On the other hand, the polyps that grow in the left colon, including the 
sigmoid colon, descending colon and rectum, are generally microsatellite stable 
(MSS) but carry KRAS mutations and some of these polyps have an attenuated 
CIMP (Kuipers et al. 2015).  
 
The most frequent mutations in colorectal cancer are APC, ARID1A, BRAF, 
CTNNB1, FAM123B, KRAS, PIK3CA, SMAD4, SOX9, TGFBR2, TP53 and ERBB2 that 
perturbs the key signalling pathways, namely WNT-β-catenin, EGFR-MAPK, TGFβ 
and PI3K pathways, or alters genes involved in proliferation and DNA repair 
(Kuipers et al. 2015). APC mutations can be observed in up to 70% of sporadic 
colorectal cancer (Grady and Pritchard 2014) and as mentioned previously, it 
leads to the familial adenomatous polyposis syndrome (Vasen et al. 2015). The 
mutations occur at the earliest stages of neoplasia and are associated with the 
conventional tubular adenoma pathway and chromosomal instability tumours 
(Grady and Pritchard 2014). The mutations in APC gene result in disrupted APC 
protein, which leads to an increase of WNT signalling by nuclear β-catenin 
stabilisation then an increase of the gene transcription of WNT targets (Grady 
and Pritchard 2014). An activating β-catenin (CTNNB1) mutation inhibits its 
degradation that is mediated by APC (Samowitz et al. 1999). The beta-catenin 
mutation occurs in colorectal neoplasia but it happens more frequently in small 
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adenomas than in large adenomas and invasive cancers, suggesting CTNNB1-
mutant adenomas often do not advance into carcinoma (Samowitz et al. 1999). 
 
KRAS is a proto-oncogene in the RAS family and it is frequently mutated in 
human cancer, including colorectal cancer. KRAS protein acts downstream of 
EGFR signalling via BRAF to activate MAPK signalling pathway and sustain cell 
growth and survival (Grady and Pritchard 2014). Mutations of codon 12 or 13 of 
KRAS can be observed in around 40% of colorectal tumours and it results in 
constitutive signalling by deregulating guanosine triphosphate hydrolase 
(GTPase)-activating proteins in KRAS-bound guanosine triphosphate (GTP) 
hydrolysis (Downward 2003). Although KRAS mutations take place after APC 
mutations in the progression from adenoma into carcinoma, it is considered as 
an early event in the tumourigenesis (Grady and Pritchard 2014). Using primary 
and metastatic colorectal tumours, Artale et al. demonstrated that acquired 
KRAS mutations were maintained throughout carcinogenesis, suggesting that 
KRAS mutations are not required for metastasis (Artale et al. 2008). 
 
Mutations in BRAF gene can be observed in around 10% to 15% of colorectal 
cancer and BRAF protein is a direct downstream effector of KRAS in the 
EGFR/RAS/RAF/MAPK signalling pathway (Grady and Pritchard 2014). Most of the 
BRAF mutations are a single base substitution of glutame for valine residue at 
codon 600 (V600E, sometimes also known as V599E) (Rajagopalan et al. 2002). 
Mutations of KRAS and BRAF genes occur at a similar stage of tumour initiation 
and an activating mutation of either KRAS or BRAF is sufficient to promote 
tumourigenesis (Rajagopalan et al. 2002). The frequency of BRAF mutations is 
higher in MSI than in MSS tumours (Lubomierski et al. 2005) and sessile serrated 
adenomas frequently carry BRAF mutations (Kambara et al. 2004). BRAF 
mutations are highly associated with CIMP tumours and the serrated neoplasia 
(mutator) pathway (Grady and Pritchard 2014). 
 
TGFβ signalling is a tumour suppressor pathway in the colon and its deregulation 
can be observed in the majority of colorectal tumours (Grady and Pritchard 
2014). Inactivating mutations occur in the receptor genes TGFBR2 and TGFBR1, 
post-receptor signalling pathway genes SMAD2 and SMAD4 as well as a TGFBR2 
family member ACVR2 (Deacu et al. 2004). Functionally significant mutations of 
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TGFBR2 have been reported in up to 30% of colorectal tumours and are linked 
with the malignant transformation into late adenomas (Grady and Pritchard 
2014). Mutations in TGFBR2 are more common in MSI than in MSS tumours (Grady 
et al. 1999). SMAD4 is located in the long arm of chromosome 18, which is 
commonly deleted in colorectal cancer and is correlated with adenoma 
formation and the progression of adenoma into carcinoma, suggesting that 
SMAD4 is a tumour suppressor gene (Takaku et al. 1998). Additionally, loss of 
SMAD4 protein expression was observed in 50% of colorectal tumours and both 
chromosome 18q deletion and inactivation of SMAD4 protein are associated with 
lymph node metastasis (Tanaka et al. 2008). 
 
Mutations of PI3K pathway genes occur in up to 40% of colorectal tumours (Grady 
and Pritchard 2014). The most frequently mutated gene in this pathway is 
PIK3CA and such mutations were reported in up to 32% of colorectal cancer 
(Samuels et al. 2004). PIK3CA mutation is linked with adenoma to carcinoma 
progression and it is usually observed late in tumourigenesis (Samuels et al. 
2004). PTEN mutation can also be observed in this pathway and it is a tumour 
suppressor gene that inhibits PI3K signalling in up to 9% chromosomal instable 
tumours and 30% MSI tumours (Danielsen et al. 2008). Additionally, PTEN protein 
expression is lost in around 30% of colorectal tumours (Yu et al. 2014). 
 
Apart from the four key signalling pathways discussed above, another widely 
studied molecular characteristic of colorectal cancer is microsatellite instability 
(MSI). It is a hypermutability phenotype of short repetitive sequences that is 
caused by impaired DNA mismatch repair (MMR) (Cortes-Ciriano et al. 2017). In 
sporadic cases, MSI arises from inactivation of MMR genes, such as MLH1, MSH2, 
MSH3, MSH6 and PMS2 (Cortes-Ciriano et al. 2017). It is associated with an 
increased risk of colorectal cancer for those with Lynch syndrome and majority 
of Lynch syndrome patients develop MSI colorectal cancer (Grady and Pritchard 
2014). Majority of sporadic MSI tumours (80%) have hypermethylation of MLH1 
promoter (Poynter et al. 2008). MSI also arises from the MSH2 inactivation or 
silencing of the MMR genes by miRNAs (Cortes-Ciriano et al. 2017). MSI tumours 
that frequently have BRAF V600E mutations are linked with the serrated 
neoplasia molecular pathway, whereas colorectal tumours with the Lynch 
syndrome (mutations in the MMR genes) do not carry BRAF mutation (Wang et al. 
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2003). MSI occurs in 15% of sporadic colorectal cancer (Vilar and Gruber 2010) 
and it is detected by the presence of 30% of unstable loci using a panel of two 
mononucleotide and three dinucleotide markers (Boland et al. 1998). Colorectal 
cancer patients with MSI tumours have been reported to have a better survival 
than those with MSS tumours (Popat et al. 2005). MSI leads to frameshift 
mutations and neoantigens that may be detected by the host immune system 
and the higher frequency of neoantigens in MSI may contribute to better 
prognosis (Xiao and Freeman 2015). Additionally, MSI colorectal tumours have a 
reduced rate of recurrence in early stages as compared to advanced stages of 
the disease (Halpern et al. 2017). 
 
The pathogenesis of colorectal cancer is also determined by its anatomical 
location and the molecular characteristics and histology are different between 
the distal (left side) and proximal (right side) colon (Baran et al. 2018). As 
mentioned above, colorectal tumours in the right side commonly demonstrate 
MSI, which is characterised by the mutations in MMR genes. These tumours 
usually show a flat morphology (Nawa et al. 2008). On the other hand, the left-
sided tumours are characterised by MSS pathway-related mutations, such as APC, 
KRAS, PIK3CA and p53, and demonstrate a polypoid-like morphology (Baran et al. 
2018). Tumours arising in the right colon demonstrate sessile serrated 
adenomas, while tumours in the left colon manifest tubulovillous 
adenocarcinomas (Baran et al. 2018) and the tumours arising from these 
adenomas have distinct molecular characteristics, as elaborated above. Because 
of their morphology, the left-sided tumours are easier to detect with 
colonoscopy than the right-sided tumours in early stages of carcinogenesis (Nawa 
et al. 2008). Additionally, left-sided colorectal tumours tend to metastasise into 
liver and lung, while the right-sided colorectal cancer patients tend to have 








1.6 Aim of thesis 
In my doctoral research, I study specific regulators driving the preferential mode 
of cell proliferation and tissue remodelling in cancer, with a specific focus on 
colorectal cancer. Breast cancer has been widely studied as a canonical example 
where cell proliferation is the major prognostic factor. We would like to study a 
cancer type where tissue remodelling is a predictor of worse prognosis. 
Therefore, the choice of colorectal cancer is mainly motivated by the fact that 
it is a canonical example where 1) cell proliferation is not a marker of poor 
prognosis and 2) tissue remodeling is associated with poor prognosis. 
Additionally, a large meta-cohort of colorectal cancer patient samples, reporting 
gene expression profiles for 2,423 patients, is publicly available. Working with a 
large size cohort busts the statistical power in deriving at sensible conclusions.  
 
First, I investigate the prognostic value of a colorectal cancer classification 
based on gene expression signatures quantifying the degree of cell proliferation 
and tissue remodelling using the datasets in the CRCSC cohort. Then I evaluate 
the performance of colorectal cancer classifications based on a recently 
reported unsupervised CMS approach and our gene signatures of cell 
proliferation and tissue remodelling. 
 
Afterwards, I study the transcriptional regulation of gene expression program 
that drives the selective mode of cell proliferation and tissue remodelling. I aim 
to uncover transcription factors and microRNAs that sustain either the cell 
proliferation or tissue remodelling transcriptional programme in different cancer 
types. Then I focus on specific transcription factors and microRNAs that promote 
the tissue remodelling programme, which lead to worse prognosis in colorectal 
cancer. 
 
Additionally, I assess the association between immune cell infiltration and these 
specific transcription factors and microRNAs to understand the causal 
relationship of poor prognosis in colorectal cancer. These findings will broaden 
our understanding of regulatory networks and the interaction of tumour cells 
with the microenvironment, beneficial for predicting putative targets for cancer 
therapies. 
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1.7 Chapter briefings 
Chapter 2 lists the datasets utilised in this thesis and describes the methods that 
are generic or utilised repeatedly in different chapters. On the other hand, 
methods that are specific to a chapter are detailed in the chapter itself. 
 
Chapter 3 presents the comparison of unsupervised and reductionist supervised 
clustering approaches of colorectal cancer patients based on the CMS scheme 
and our gene signatures of proliferation and remodelling (PR), respectively. In 
this chapter, I provide a mapping of sample group membership between both 
classifications and compare the performance of survival analyses based on both 
approaches. Additionally, I also investigate the interdependence of PR signatures 
as prognostic factors. Lastly, because of the interdependence of PR signatures, I 
determine if R signature alone can be applied for patient classification. 
 
In chapter 4, I identify specific transcription factors that sustain the 
transcriptional programmes of cell proliferation and tissue remodelling. Then I 
focus on transcription factors that sustain the tissue remodelling programme 
because tissue remodelling is indicative of worse prognosis in colorectal cancer. 
From the list of these transcription factors, I decide to do a further study on 
KLF4 and find that KLF4 may be driving tissue remodelling via myeloid cell 
infiltration. I also analyse the prognostic value of KLF4 transcription activity and 
the enrichment of KLF4 activity score with clinical variables. 
 
Chapter 5 evaluates specific microRNAs that promote the cell proliferation and 
tissue remodelling programmes. Similarly, I focus on microRNAs that sustain the 
tissue remodelling programme and decide to do a further study on mir-22. I find 
that mir-22 is not associated with immune cell infiltration. 
 
Finally, in chapter 6, I study the regulatory of monocyte differentiation and 
myeloid cell infiltration in colorectal cancer that may be driven by KLF4 and 
mir-22 and other regulators and conclude with various discussions. 
 
Please note that most of the results presented in chapters 3 and 4 have been 
published in the work titled “Analysis of cell proliferation and tissue remodelling 
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uncovers a KLF4 activity score associated with poor prognosis in colorectal 




2 Materials and Methods 
2.1 Publicly available datasets 
Throughout my doctoral research, I utilise various datasets from publicly 
available data, i.e. The Cancer Genome Atlas (TCGA), Gene Expression Omnibus 
(GEO) and Synapse, which hosts datasets originally used by the CRCSC 
consortium. 
 
2.1.1 The Cancer Genome Atlas 
Preliminary results presented in this thesis are based on the analyses of three 
datasets from TCGA with matching gene and microRNA (miRNA) expression of 
tumour samples. First, I use these datasets to assess the regulation of the cell 
proliferation and tissue remodelling programmes in different cancer types, 
focusing on mRNA and miRNA expression.  
 
Initially, we selected TCGA breast, lung, ovarian, and colorectal cancer 
datasets. This selection provides a good balance for the study, following a 
previous work in our laboratory that showed proliferation to be prognostic in 
breast and lung cancers, while remodelling was prognostic in colorectal and 
ovarian cancers (Markert et al. 2012). Later on, I could analyse only the breast, 
ovarian, and colorectal cancer datasets because the lung cancer dataset has only 
six samples with matching mRNA and miRNA expression, which are insufficient 
for deriving at sensible biological conclusions. On the other hand, the number of 
samples is 132, 184 and 472 in colorectal, breast and ovarian cancer datasets, 
respectively. These samples were quantified on an Agilent microarray platform 
and they had been previously quantile-normalised and mean-centred upon 
download. 
 
I then use the gene expression profiles from these datasets to infer transcription 
factor activities and establish the relationship between transcription activities 
and the gene signatures of cell proliferation or tissue remodelling. 
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2.1.2 Colorectal Cancer Subtyping Consortium 
The findings reported in the colorectal cancer case study are mainly based on 
the analyses performed on the datasets that were originally utilised by the 
CRCSC consortium. I retrieve normalised gene expression datasets of colorectal 
cancer samples from Synapse with a Synapse ID syn2634742. The data hosted 
under this Synapse ID consists of TCGA colorectal cancer dataset and ten GEO 
datasets with accession numbers: GSE13067, GSE13294, GSE14333, GSE17536, 
GSE20916, GSE2109, GSE23878, GSE33113, GSE37892 and GSE39582. I exclude 
overlapping samples in GSE14333 and GSE17536 from GSE14333. The GEO 
datasets were generated on an Affymetrix microarray platform, while the TCGA 
dataset was generated on an RNA-seq platform. 
 
Altogether, there are 2,434 samples in these datasets, including 2,207 samples 
with clinical information. Additionally, 129 out of 132 samples in TCGA 
colorectal cancer dataset mentioned in section 2.1.1 also appear in this cohort. 
 
This data is used to execute and compare classification approaches (in chapter 
3) and perform the analysis of gene expression program regulated by TFs and 
miRNAs in the case study in chapters 4 and 5, respectively. 
 
2.1.3 Gene Expression Omnibus 
I retrieve different datasets from GEO for various validation work. The data is 
typically retrieved in raw formats from the GEO website and normalised as 
described in section 2.2.2. 
 
Following is the list of the GEO datasets together with the accession numbers 
and aim of the validation: 
1). Human immune cell transcriptome data (GSE3982):  
-  to establish if TF activity inference model is valid in the context of 
pure immune cell populations in human 
2). Human immune cell subsets transcriptome data (GSE28492): 
- the miRNA dataset is utilised to determine if mir-22 expression is 
higher in phagocytes (myeloid cells) than in lymphoid cells in the 
context of pure immune cell populations 
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- the mRNA dataset is applied into TF inference model to examine the 
correlation of mir-22 expression with IRF8, KLF4 and SPI1 activity 
scores in pairwise comparisons 
 
2.2 Methods 
2.2.1 Gene signatures of cell proliferation and tissue remodelling 
Gene signatures of cell proliferation (P) and tissue remodelling (R) are obtained 
from a previous study in our laboratory, ref. (Markert et al. 2012). As elaborated 
in the introduction, cell proliferation gene signature includes processes involved 
in or associated with cell cycle. On the other hand, tissue remodelling gene 
signature includes processes that involve a change relative to the 
microenvironment. The gene signatures are comprised of GO term signatures 
from literature reporting genes implicated in corresponding processes. These 
processes together with their GO terms are as tabulated in Table 2-1. The list of 
genes for both P and R signatures can be found in Appendix. 
 
Table 2-1. Processes in gene signatures of cell proliferation and tissue 
remodelling 
		 		 		 		 		
		


































2.2.2 Normalisation of gene expression data 
As mentioned in section 2.1.2, the gene expression datasets from the CRCSC 
cohort had been previously normalised. The GEO datasets had been previously 
normalised using robust multi-array average (RMA) method. The TCGA dataset 
was previously normalised using RNA-Seq by Expectation Maximization (RSEM) 
method and log-transformed. For details on data normalisation and outlier 
sample detection as well as other pre-processing steps, please refer to the 
original research article (ref. (Guinney et al. 2015)). 
 
For each GEO dataset in the cohort, I include only probes with gene annotation 
for subsequent analyses. Then I select the most variable probe (a probe with 
largest interquartile range) for each gene. In contrast, the TCGA dataset comes 
with gene annotation and there is already one probe per gene. Subsequently, for 
each GEO and TCGA datasets in the cohort, I perform mean-centering for each 
gene by subtracting the expression values of all samples from the mean 
expression value across all samples. 
 
The GEO datasets used for validation work, as listed in section 2.1.3, are raw 
data upon retrieval. I quantile-normalise the gene expression data using 
‘preprocessCore’ bioconductor package and log2 transform it. Next, I perform 
the same steps above after normalisation, i.e. including only probes with gene 
annotation, selecting the most variable probe and mean-centring the expression 
values. 
 
Conversely, the TCGA datasets used for preliminary analyses, as mentioned in 
section 2.1.1, had been quantile-normalised and mean-centred. Therefore, no 
further pre-processing step is necessary for these datasets. 
 
2.2.3 Gene Set Enrichment Analysis 
I analyse enrichment of the gene signatures using gene set enrichment analysis 
(GSEA) (Subramanian et al. 2005). The inputs are a gene set (also referred to as 
a gene signature) and an array of expression values of genes across genome (all 
genes in the gene list) for a given sample. The output is the enrichment score of 
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a gene signature and it informs the extent of the correlation of the gene 
signature with expression values of all genes in the gene list for the 
corresponding sample. 
 
Specifically, given m genes in a gene signature L, I initially create a reference 
score vector by going through n genes in the dataset then assigning a score 
hg = 1/m g∈ L
−1/ (n−m) otherwise  for each gene g. This reference score vector is 
reused for all samples in the gene expression data. Before calculating the 
enrichment score, I sort the reference score vector based on the order of the 
sorted expression values (from highest to lowest) for a given sample. Next, I 
calculate a running enrichment score Ek for a sample k by summing the sorted 
reference score vector Eik = hgjk
j=1
i
∑ . After going through all hg in the sorted 
reference score vector, the enrichment of a gene signature L within the tail of 
low and high values in a sample is represented by Ek− =min
i





Subsequently, I adopt a permutation test as a non-parametric estimate of the 
statistical significance of the enrichment scores. I generate 100,000 
permutations (np) of the reference score vector and calculate the corresponding 
enrichment scores El- and El+ at both tails where l=1,…,np. Then I correct the 
statistical significance of Ek- and Ek+ based on a less bias estimate 
pk− = (1+ 1
l|El−≤Ek−
∑ ) / (1+ np)  and pk+ = (1+ 1
l|El+≥Ek+
∑ ) / (1+ np)
 
(North et al. 2002). Lastly, I 
report Ek+ as the enrichment score if pk+ < pk −  or Ek- if pk− < pk + . 
 
2.2.4 Correlation of gene expression with PR signatures 
For a given gene in the gene expression data, I correlate the expression values 
across all samples with the enrichment scores of all samples with P gene 
signature using Spearman’s rank correlation coefficient. The enrichment scores 
are calculated following the steps in section 2.2.3. Similarly, I also correlate the 
expression values with the enrichment scores of all samples with R gene 
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signature. Then I compare these two sets of results to examine and visualise the 
relationship between cell proliferation and tissue remodelling at gene expression 
level. 
 
2.2.5 Survival analysis 
I perform two types of survival analyses, i.e. univariate and multivariate survival 
analyses. In both types of analyses, I fit cox proportional hazards regression 
model. 
 
2.2.5.1 Univariate survival analysis 
I perform univariate survival analysis to assess the performance of a 
classification scheme in distinguishing different subtypes. I carry out the analysis 
using overall survival or relapse-free survival information and sample group 
membership based on the respective classifications. I report p-value from log-
rank test as the significance of the classification in predicting an event 
occurring, i.e. death or relapse in overall survival or relapse-free survival data, 
respectively. P-value < 0.05 is reported as a significant result in all cases. 
 
2.2.5.2 Multivariate survival analysis 
Using multivariate survival analysis, I determine if a covariate is able to predict 
an event occurring independently of other covariates, i.e. clinical variables in 
this case. Specifically, I analyse if P and R enrichment scores are independent 
prognostic factors after considering other clinical variables. The covariates 
included in the analysis are P and R enrichment scores, stage, age and gender. 
 
I carry out the analysis using overall survival or relapse-free survival information 
together with the covariates. I report p-value from Wald test as the significance 
of each covariate (P or R enrichment scores, stage, age or gender) in predicting 
an event occurring, i.e. death or relapse. P-value < 0.05 is reported as a 
significant result in all cases. 
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2.2.6 Multiple testing correction 
To address multiple testing problem, I correct the statistical significance 
following Benjamini-Hochberg (BH) procedure, controlling false discovery rate 
(FDR) at 0.05. I report the raw p-value together with a Boolean value indicating 
if it is significant after the correction. 
 
2.2.7 Estimation of immune cell types abundance 
I perform this analysis on the CRCSC cohort. First, I combine all GEO gene 
expression datasets in the CRCSC cohort and estimate the composition of 
immune cell types in all samples using CIBERSORT (Newman et al. 2015). For 
running ‘CIBERSORT’ function, I utilise LM22 signature genes file provided by 
CIBERSORT as ‘sig_matrix’ variable and the combined gene expression data as 
the mixture file. I run the function with 1,000 permutations and quantile 
normalisation. Next, I also perform the same analysis on the TCGA dataset in the 
CRCSC cohort then combine the results from CIBERSORT function for both GEO 
and TCGA datasets. I conduct the analysis this way because the GEO and TCGA 
datasets do not have the same number of probes or genes in each platform. If I 
merge all the datasets before running CIBERSORT, some genes that are not in 
common in these platforms will not be included and potentially important 
information may be lost in this case. 
 
2.2.8 Permutation test 
To determine the statistical significance of a correlation score, I permute 
Pearson correlation coefficient scores of 2 vectors of ranks for 100,000 times 
using two-tailed tests to assign p-values at lower and upper tails. The length of 
the vector equals to the number of samples or genes or transcription factors or 
miRNAs being tested. Then I calculate the p-value based on a less bias estimate, 
as described in section 2.2.3. Subsequently, I correct the p-value for multiple 
testing problem as elaborated in section 2.2.6. 
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2.2.9 Statistical significance test of TF or miRNA 
For a given TF (or miRNA), I correlate the activity scores (or the expression 
values) across all samples with the samples’ PR enrichment scores, as calculated 
in section 2.2.3, using Spearman’s rank correlation coefficient. To establish if a 
TF (or miRNA) is significantly correlated with a gene signature, I determine the 
statistical significance of the correlation following the method in section 2.2.8. 
 
I categorise a TF (or miRNA) to be significantly correlated with P signature (P+) 
if the correlation of its activity score (or expression value) with P enrichment 
score > 0 and p-value of the correlation remains significant after BH correction. 
Otherwise, I denote the TF (or miRNA) as not significantly correlated with P 
signature (P-). Similarly, I categorise a TF (or miRNA) to be significantly 
correlated with R signature (R+) if the correlation of its activity score (or 
expression value) with R enrichment score > 0 and p-value of the correlation 
remains significant after BH correction. Otherwise, I denote the TF (or miRNA) 
as R-. 
 
2.2.10 Statistical significance test of target genes enrichment 
This analysis is similar to the analysis in section 2.2.9. From the enrichment 
analysis of TF (or miRNA) targets, there is an enrichment score of P or R 
signature in the target genes of every TF (or miRNA). To determine if the target 
genes of a particular TF (or miRNA) are significantly enriched for a given gene 
signature, I estimate the statistical significance of the enrichment score 
following the method in section 2.2.8. 
 
I categorise the target genes of a TF (or miRNA) to be significantly enriched for P 
signature (P+) if they have P enrichment score > 0 and a p-value being significant 
after BH correction.	 Otherwise, I denote the target genes as not significantly 
enriched for P signature (P-). Similarly, I categorise the target genes of a TF (or 
miRNA) to be significantly enriched for R signature (R+) if they have R 
enrichment score > 0 and a p-value being significant after BH correction.	
Otherwise, I denote the target genes as not significantly enriched for R signature 
(R-).  
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3 Colorectal cancer classifications based on 
CMS versus PR schemes 
3.1 Background 
Here I study the prognostic values of cell proliferation and tissue remodelling 
gene signatures in the context of a colorectal cancer classification. In a recent 
report, the CRCSC consortium stratified colorectal cancer patients based on 
gene classifiers without using a prior biological knowledge. They demonstrated 
that the subtype that indicated worst prognosis (CMS4 subtype) was enriched for 
a signature of mesenchymal. Yet, cell proliferation gene signature was not 
studied in their approach and it might affect the ability of their approach to 
classify colorectal cancer patients beyond the CMS4 or the mesenchymal 
subtype. This motivates me to re-analyse this cohort of patients using our gene 
signatures of cell proliferation and tissue remodelling then compare the 
performance of both approaches in stratifying patients. 
 
Then I evaluate if there are overlaps of sample group membership between both 
approaches. Next, I assess if both PR signatures are independent prognostic 




3.2.1 Sample classification based on PR gene signatures 
I classify patient samples based on the enrichment of the cell proliferation and 
tissue remodelling gene signatures. The calculation of the enrichment scores and 
their statistical significance is as elaborated in section 2.2.3. If a sample has a 
significant up-regulation of cell proliferation signature (enrichment score for P 
signature > 0 with p-value < 0.05), I classify it as P+ and P- if otherwise. For 
reporting the significance of the enrichment score, I choose the smaller p-value 
from the two-tailed tests. Similarly, if a sample has a significant up-regulation of 
tissue remodelling signature (enrichment score for R signature > 0 with p-value < 
0.05), I classify it as R+ and R- if otherwise. By construction, this classification 
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results in four subtypes, namely P+/R+, P+/R-, P-/R+, and P-/R-, as presented in 
the following. 
 
3.2.2 Similarity of sample group membership between CMS and PR 
After excluding samples that were not assigned to a specific CMS group in the 
original analysis (ref. (Guinney et al. 2015)), I quantify the similarity of CMS and 
PR sample group memberships using a hypergeometric distribution (one-tailed 
version of Fisher’s exact test). I perform pairwise comparisons on all PR and CMS 
groups. The variables for the test are defined as follows. The population size (N) 
of the model is the number of samples classified into CMS groups. The number of 
success cases in the population (K) is the number of samples classified into PR 
groups. Subsequently, the number of draws (n) is the number of samples that 
belong to a particular CMS group. Then, the number of observed successes (k) is 
the number of samples that belong to both a particular CMS group and a 
particular PR group. I calculate the significance of the similarity of the sample 
group memberships using a cumulative hypergeometric distribution function 
where p-value is P(X ≥ k)  or the probability of getting the number of observed 
successes or more. 
 
3.2.3 Percentage of expressed genome with PR gene signatures 
Spearman’s rank correlation coefficient of the expression values of all samples 
with the enrichment scores with a gene signature is calculated as described in 
section 2.2.4. I determine the statistical significance of the correlation following 
the method in section 2.2.8. 
 
A gene is defined to be up-regulated for a given signature if its expression value 
has a positive correlation with the enrichment score of the signature and this 
correlation remains significant after BH correction. I specify the percentage of 
expressed genome with a gene signature to be the percentage of genes having a 
significant up-regulation of the signature but having a negative correlation with 
the other signature across genome. 
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3.2.4 Sample classification using four quartiles of R enrichment score 
The R enrichment score and the statistical significance based on a less bias 
estimate are obtained from the calculation in section 2.2.3. I classify the 
samples into four groups based on four quartiles of R enrichment score. I label 
the samples in first quartile as R--, second quartile as R-, third quartile as R+ 




3.3 Comparison of CMS versus PR classifications 
To assess the advantages and disadvantages of both classifications, I carry out a 
side-by-side comparison of the unsupervised versus supervised classifications, as 
illustrated in Figure 3-1. CMS classification represents the unsupervised 
clustering approach. The input of this scheme does not make use of prior 
biological knowledge, and hence it is unbiased and unsupervised. Contrarily, the 
PR classification represents the supervised clustering approach. This scheme is 
developed based on our observation that the hallmarks of cancer can be 
arranged into two groups of processes that promote cell proliferation or tissue 
remodelling (Figure 3-2, ref. (Markert et al. 2012)). It is supervised as it is based 
on prior biological knowledge and it may be biased towards previous knowledge. 
Very often, it is assumed that unsupervised approaches outperform supervised 
methods based on prior knowledge. However, this assumption does not hold true 
in general and it should be assessed in a case-by-case bases. 
 
 
Figure 3-1. Flow diagrams of patient stratification based on the unsupervised 
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Figure 3-2. The hallmarks of cancer drive two major features of cancer, cell 
proliferation and tissue remodelling 
 
To investigate the performance of the CMS and PR classification schemes with 
regard to prognosis, I perform a meta-analysis of a cohort of colorectal cancer 
patients recently reported by the CRCSC consortium. This cohort consists of gene 
expression profiles and survival information from different published studies. 
The samples had been previously classified based on the CMS scheme into four 
subtypes, namely, CMS1, CMS2, CMS3 and CMS4. I reclassify the same cohort of 
patients based on our PR scheme. I quantify the degree of cell proliferation and 
tissue remodelling in each sample, as described in section 3.2.1 and stratify all 
samples into four subtypes, namely P+/R+, P+/R-, P-/R+, and P-/R-. The 
assignment of each sample into the PR groups can be found in Appendix. 
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3.3.1 Mapping between CMS and PR sample group memberships 
To compare the sample group memberships and determine the overlaps between 
both classifications, I analyse the similarity of the sample group memberships in 
both the CMS and PR schemes, as detailed in section 3.2.2. Even though both 
classifications are performed separately, the resulting subtypes show some 
overlaps, as can be seen in Figure 3-3. CMS2 subtype maps to a great extent to 
our P+/R- subtype (p-value = 2.3×10-48, one-tailed Fisher’s exact test), whereas 
CMS4 subtype maps to a great extent to our P-/R+ subtype (p-value = 8.9×10-144, 
one-tailed Fisher’s exact test). The full list of overlap sizes between both 
classifications together with their statistical significances is presented in Table 
3-1. 
 
Table 3-1. Number of overlaps between subtypes in CMS and PR schemes 
		 		 		 		 		 		 		 		 		 		 		 		 		 		
		
	
P+/R+	(371)	 	 P+/R-	(716)	 	 P-/R-	(398)	 	 P-/R+	(490)	 		




























Figure 3-3. Mapping between CMS and PR groups. The grey lines connecting the 







The overlaps between the CMS and PR classifications can be elucidated by the 
high correlation between some genes and our gene signatures of cell 
proliferation and tissue remodelling. A high proportion of the expressed genome 
(34.25%) is significantly correlated with tissue remodelling enrichment score (p-
value < 0.05, permutation test for Spearman’s rank correlation coefficient). 
Likewise, there is 35.56% of the expressed genome that is significantly 
correlated with cell proliferation enrichment score (p-value < 0.05, permutation 
test for Spearman’s rank correlation coefficient). Consequently, any 
unsupervised clustering approach would reflect this strong signal. The 
calculation for the correlation of the proportion of expressed genome with the 
gene signatures can be found in section 3.2.3. 
 
Because the CMS classification is unsupervised, it does not include any 
information about proliferation or remodelling when assigning samples to 
different CMS subtypes. Therefore, one may ask how such classification ends up 
being correlated with our classification based on the gene signatures of 
proliferation and remodelling. As described in the introduction, there is a 
previous report indicating that a large proportion of the expressed genome is 
correlated with cell proliferation (Venet et al. 2011). To test this hypothesis in 
the context of the CRCSC cohort, I quantify the correlation between expression 
of a gene G and enrichment score of P or R signature across all samples, denoted 
by Spearman’s rank correlation coefficients S(G,P) or S(G,R), respectively. There 
is a significant negative correlation between S(G,P) and S(G,R) across genes (S = 
-0.70, p-value = 1×10-5, permutation test), as illustrated in Figure 3-4. In other 
words, there are a large number of genes whose expression are highly and 
positively correlated with P enrichment score but negatively correlated with R 
enrichment score. Likewise, there are a large number of genes whose expression 
are highly and positively correlated with R enrichment score but negatively 
correlated with P enrichment score. Taken together, this data demonstrates 
that how the partial overlap between the CMS and PR classifications is rooted 
can be explained by the fact that large proportions of the expressed genome are 





Figure 3-4. Scatter plot of Spearman’s rank correlation coefficients between 
gene expression and tissue remodelling signature (Y-axis) as a function of 
Spearman’s rank correlation between gene expression and cell proliferation 
signature (X-axis) in the CRCSC cohort. Each dot represents a gene and the 



















































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































3.4 Performance of CMS and PR survival analysis 
Now I proceed to evaluate the performance of the CMS and PR classifications 
with regard to outcome prognosis of colorectal cancer patients. The datasets 
brought together by the CRCSC consortium come with survival information. In 
this section, I compare the performance of both CMS and PR schemes in 
stratifying the patients’ overall and relapse-free survival. The method for this 
type of survival analysis is as described in section 2.2.5.1.  
 
In terms of predicting patient outcome, both approaches yield statistical 
significance in splitting survival curves (Figure 3-5). The CMS4 subtype in the 
unsupervised approach and the P-/R+ subtype in the supervised approach, which 
are associated with tissue remodelling, exhibit worst prognosis compared to the 
remaining groups in the respective schemes. However, the unsupervised 
approach cannot distinguish the remaining patients based on survival. In other 
words, the CMS scheme predicts a poor prognosis for patients with tissue 
remodelling, or mesenchymal features, but it is not able to set apart the rest of 
patients with respect to survival. On the other hand, in the PR classification, 
both of its two features are associated with clinical outcome. Apart from 
distinguishing the remodelling group (P-/R+), it yields the P+/R- group that 
exhibits significantly better prognosis than the P-/R- group. This observation 
indicates that the cell proliferation and tissue remodelling gene signatures are 






Figure 3-5. Kaplan-Meier plots of colorectal cancer subtypes survival based on 
the CMS and PR classification schemes. P-values indicate the statistical 
significance based on log-rank test. (a, b) CMS classification based on (a) overall 
survival and (b) relapse-free survival. (c, d) PR classification based on (c) overall 




Because the CMS scheme differentiates only patients with tissue remodelling 
(CMS4 subtype), I evaluate if our cell proliferation signature can further split the 
CMS4 subtype. To this end, I take the CMS4 samples only and split them into 
patients with a significant up-regulation of the cell proliferation signature 
(CMS4/P+) and the remaining (CMS4/P-). The CMS4/P+ group has a significantly 
better overall survival (Figure 3-6a, p-value = 0.01, log-rank test) and a trend of 
better relapse-free survival than the CMS4/P- group (Figure 3-6b, p-value = 0.14, 
log-rank test). This observation indicates that CMS classification is not 
exhaustive. The results also highlight that the cell proliferation signature serves 
as an additional prognostic factor, indicative of good prognosis in colorectal 
cancer, besides the tissue remodelling signature. 
 
 
Figure 3-6. Kaplan-Meier plots of CMS4 patients further stratified by P signature 
based on (a) overall survival and (b) relapse-free survival. P-values indicate the 




3.5 The interdependence of PR signatures as prognostic factors 
As cell proliferation is associated with good prognosis in colorectal cancer, we 
ask if the treatments might work better at targeting proliferating cells and 
patients with increased cell proliferation responded better to treatments. 
However, the information about which patients received treatment and the type 
of treatments given is not reported. Yet, we would like to evaluate if PR 
signatures can serve as an unbiased prognostic tool for patients who received 
treatments versus those who did not. Consequently, I cannot include treatment 
options as a covariate in the multivariate survival analysis. Nonetheless, age and 
stage are reported, which are two clinical variables commonly used for making 
treatment decisions. 
 
Here I establish whether P and R enrichment scores are independent prognostic 
factors when considering other clinical variables. This is achieved through a 
multivariate survival analysis, as outlined in section 2.2.5.2. I determine 
whether P and R enrichment scores are able to predict an event (death or 
relapse) occurring, independently of the clinical variables age, stage and 
gender.  
 
As expected, stage manifests a significant association with an increased risk of 
both death and relapse (Table 3-2). As can be observed from Table 3-2a, 
enrichment score of R exhibits a significant association with increased risk of 
relapse (hazard ratio = 4.60, 95% confidence interval (CI) = 1.14-18.52, p-value = 
0.03, Wald test). In contrast, P enrichment score is significantly associated with 
reduced risk of death (hazard ratio = 0.32, 95% CI = 0.10-0.99, p-value = 0.05, 
Wald test). 
 
Without considering R enrichment score in the analysis, P enrichment score 
exhibits a significant association with reduced risk of both death and relapse 
(Table 3-2b). Similarly, when P enrichment score is not considered, R 
enrichment score is significantly associated with increased risk of both death 
and relapse (Table 3-2c). 
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These results suggest that P and R enrichment scores are not independent 
prognostic factors. Indeed, there is a strong negative correlation between P and 
R enrichment scores (Spearman’s rank correlation coefficients = -0.44, p-value = 
1×10-5, permutation test). However, when being considered at the same time, 
both P and R enrichment scores are able to predict patient outcome, 
independently of other clinical variables. 
 
Table 3-2. Multivariate survival analysis considering clinical variables and 
enrichment scores of (a) P and R, (b) P only and (c) R only 
		 		 		 		 		 		 		 		 		 		 		
		
	  

















P	scores	 0.32	 0.10-0.99	 0.05	 	 0.41	 0.13-1.26	 0.12	 		
		
	
R	scores	 1.32	 0.37-4.70	 0.67	 	 4.60	 1.14-18.52	 0.03	 		
		
	
Stage	 1.98	 1.67-2.34	 2.6E-15	 	 2.86	 2.35-3.49	 <2e-16	 		
		
	
Age	 1.03	 1.02-1.04	 4.6E-09	 	 1.00	 0.99-1.01	 0.56	 		
		
	
Gender	 1.26	 0.99-1.61	 0.07	 	 1.36	 1.05-1.77	 0.02	 		
		 (b)	 P	




P	scores	 0.28	 0.11-0.76	 1.2E-02	 	 0.23	 0.08-0.62	 3.8E-03	 		
		
	
Stage	 1.98	 1.67-2.34	 2.1E-15	 	 2.87	 2.36-3.49	 <	2e-16	 		
		
	
Age	 1.03	 1.02-1.04	 4.8E-09	 	 1.00	 0.99-1.01	 0.58	 		
		
	
Gender	 1.26	 0.98-1.60	 0.07	 	 1.34	 1.03-1.74	 0.03	 		
		 (c)	 R	 	       		
		 	 R	scores	 2.46	 0.81-7.45	 1.1E-01	 	 7.76	 2.27-26.50	 1.1E-03	 		
		 	 Stage	 2.00	 1.69-2.37	 7.8E-16	 	 2.90	 2.38-3.54	 <	2e-16	 		
		 	 Age	 1.03	 1.02-1.04	 8.4E-09	 	 1.00	 0.99-1.01	 0.63	 		








3.6 Survival analysis using R enrichment score 
In section 3.3.1, I demonstrate that there is a significant negative correlation 
between cell proliferation and tissue remodelling across genes. Then in section 
3.5, I show that P and R enrichment scores are strongly inversely correlated. 
These observations raise the possibility that a finer gradation of one of the 
signatures (e.g. R) could substitute the PR scheme. To test this possibility, here I 
investigate if R enrichment score alone can serve as an independent prognostic 
factor, especially because tissue remodelling is associated with worse prognosis 
in colorectal cancer. 
 
To do this, I stratify the colorectal tumours in the CRCSC cohort into four groups 
based on four quartiles of the R enrichment score (see section 3.2.4), instead of 
the four groups determined by P and R signatures. Then I perform a univariate 
survival analysis as before (see method in section 2.2.5.1). 
 
This classification also yields statistical significance in splitting survival curves, 
where the R++ group exhibits worst overall and relapse-free survival (Figure 3-
7). With regard to relapse-free survival, which is a more accurate measure of 
the disease impact on survival, the R+ group comes as the second worst 
prognosis. This suggests that indeed we could substitute the PR classification for 
one with a finer gradation of R. However, we believe that having a positive 
marker (P+) is more informative from the point of view of treatment choice than 
a negative one (R- or R--). Furthermore, we should keep in mind that the PR 
classification can be deployed to other cancer types (Markert et al. 2012). 
Therefore, taken together, this evidence indicates that the PR classification is a 




Figure 3-7. Kaplan-Meier plots of colorectal cancer subtypes survival using R 
enrichment score based on (a) overall survival and (b) relapse-free survival. P-
values indicate the statistical significance based on log-rank test. 
 
3.7 Conclusions 
The CMS2 group in the unsupervised scheme maps significantly to the P+/R- 
group in our supervised scheme, while the CMS4 group maps significantly to our 
P-/R+ group. The overlaps can be explained by the fact that large proportions of 
the expressed genome are correlated with cell proliferation or tissue 
remodelling in colorectal tumours. Although the CMS4 subtype is indicative of 
worst prognosis, the unsupervised scheme cannot distinguish the remaining 
patients based on survival. On the other hand, our PR classification 
demonstrates that cell proliferation is associated with good prognosis, in 
addition to the current knowledge that tissue remodelling is indicative of worse 
prognosis in colorectal cancer. Both the cell proliferation and tissue remodelling 
gene signatures are relevant for patient stratification. 
 
Enrichment scores of PR can predict an event (death or relapse) occurring, 
independently of the clinical variables but they are interdependent. A 
classification with a finer gradation of R can substitute the PR classification. 
However, having a positive marker (P+) is more informative than a negative one 
(R- or R--) from the point of view of treatment decisions.  
 54 
4 Putative transcription factors driving PR 
programmes 
4.1 Background 
As noted previously, the expression of 35.56% and 34.25% of the genes is 
correlated with the P and R signatures, respectively. This suggests that there are 
gene regulation programs driving the P and R signatures. 
 
Transcription factors (TFs) regulate gene expression by binding to specific region 
of their target genes and controlling the transcription of DNA into mRNA. They 
function by allowing RNA polymerase to access a gene or preventing it from 
accessing a gene, resulting in gene activation or repression, respectively. Their 
activities control cell growth, cell types maintenance and transition among 
them. 
 
In chapter 3, I elaborate that tissue remodelling is associated with worse 
prognosis, whereas cell proliferation is associated with good prognosis in 
colorectal cancer. Yet, we do not have an understanding about specific 
regulators that drive increased tissue remodelling or increased cell proliferation 
in this disease. Here I address this question by investigating specific 
transcription factors that drive the transcriptional programmes of cell 
proliferation and tissue remodelling. 
 
4.2 Methods 
4.2.1 Identification of TF targets 
To identify target genes of human TFs, I retrieve Transcriptional Regulatory 
Relationships Unravelled by Sentence-based Text-mining (TTRUST) database 
(Han et al. 2015). At the time of download, the latest version of the database 
was version 1. It consists of annotations of 748 human TFs with 2,374 unique 
target genes and 8,015 transcriptional regulatory relationships. TTRUST is a 
manually curated database with experimentally validated interactions and it 
provides information on the mode of regulation, i.e. activating or repressing. 
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The database contains unknown interactions but I include only activating and 
repressing interactions for the analysis. 
 
4.2.2 Inference model of TF activity 
I infer TF activity scores using linear least squares model Gik = Σj Tij Ajk where Gik 
is expression of gene i in sample k, Ajk is activity of TF j in sample k and Tij is 
the transcription regulation derived from TRRUST database (section 4.2.1). In 
the model, Tij reflects the interactions between TFs and their target genes 
where it is 1, 0 or -1 if TF j activates, does not regulate or represses gene i, 
respectively. I fit in gene expression matrix G and the transcription regulation 
matrix T constructed from TRRUST database as two inputs for the model. I 
obtain inferred TF activity matrix A by solving linear equation system in the 
least squares sense. I retain only TFs with standard deviation of activity scores 
across all samples not equal to zero for further analyses. 
 
To measure significance, I adopt a permutation test as a non-parametric 
estimate for the statistical significance of observed activity score Xj0 of TF j 
being high in a given sample. For the colorectal cancer samples in the CRCSC 
cohort, I generate 100 permutations of gene expression values of the 2,423 
samples in the cohort. Then I infer the corresponding TF activity scores for these 
permuted gene expression values, obtaining Xjk reference scores for activity of 
each TF j where k = 1, …, n=242,300. I correct the statistical significance of Xj0 
being high based on a less bias estimate pj− = (1+ 1) / (1+ n)
Xjk≤Xj 0
∑  and 
pj+ = (1+ 1) / (1+ n)
Xjk≥Xj 0
∑  (North et al. 2002). I report pj+ as the statistical 
significance if pj+ < pj −  or pj- if pj− < pj + . Lastly, I specify a sample having a 
significant high TF j activity score if Xj0 > 0, pj < 0.05 and remains significant 




4.2.3 Enrichment analysis of TF targets 
This analysis is similar to the GSEA method in section 2.2.3 but the two inputs 
are different in this case. I swap the expression values and the gene signature in 
the original method with Spearman’s rank correlation of expression values with 
P or R enrichment score and target genes of a TF as the two inputs, respectively. 
 
Because TFs generally activate or repress target genes, I include only 
interactions that agree with a particular signature in the analysis. In other 
words, for testing the enrichment of P signature in the target genes, I consider 
only interactions that promote P or repress R. These include interactions with 
TFs activating target genes that are significantly and positively correlated with P 
and interactions with TFs repressing target genes that are significantly and 
positively correlated with R. In contrast, for testing the enrichment of R 
signature in the target genes, I consider only interactions that promote R or 
repress P. 
 
To ensure there is no bias introduced by TFs having few target genes, I include 
only TFs that have at least five target genes for the analysis. Then I create the 
reference score vector and calculate the enrichment score together with its 
statistical significance following the GSEA method in section 2.2.3. 
 
4.2.4 Sample classification into PK subtypes 
For this analysis, I classify patient samples based on P enrichment score and the 
level of KLF4 (kruppel-like factor 4) activity. The sample classification into P+ or 
P- is as explained in section 3.2.1. I retrieve putative KLF4 activity from the TF 
activity scores, as detailed in section 4.2.2. If a sample has a significant and 
positive KLF4 activity score, I classify it into K+ and K- if otherwise. 
 
4.2.5 Fisher’s exact test of KLF4 activity score with clinical variables 
To quantify the enrichment of KLF4 activity score with biomarkers and clinical 
variables, I adopt a hypergeometric distribution, which is one-tailed version of 
Fisher’s exact test. I perform the test for pairwise comparisons on high and low 
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levels of KLF4 activity versus all biomarkers and clinical variables. I characterise 
patients with a significant (p-value < 0.05) and positive KLF4 activity score to 
have high KLF4 activity. Similarly, I characterise patients with a significant and 
negative KLF4 activity score to have low KLF4 activity. For each test, I include 
only patients with available information on the corresponding biomarker or 
clinical variable. 
 
The variables for the statistical test are defined as follows. The population size 
(N) is the number of patients that have information on the corresponding 
biomarker or clinical variable. Next, the number of success cases in the 
population (K) is the number of patients with the corresponding level (high or 
low) of KLF4 activity being tested. Then, the number of draws (n) is the number 
of patients with the biomarker or clinical variable equals to the value or range 
being tested. Lastly, the number of observed successes (k) is the number of 
patients with the corresponding level of KLF4 activity and the biomarker or 
clinical variable being equal to the value or range being tested. I calculate the 
significance of the enrichment using a cumulative hypergeometric distribution 
function where p-value is P(X ≥ k)  or the probability of getting the number of 
observed successes or more. 
 
4.2.6 Processing of human immune cell dataset (GSE3982) 
I retrieve gene expression data files of the human immune cells from GEO with 
accession number GSE3982. Before combining the expression values from all 
data files into a single matrix, I correct the order of the probes so that it is the 
same across all files. After getting the combined expression value matrix, I 
quantile-normalise the expression values, annotate the probes with their gene 
names and mean-centre the expression values following the method in section 
2.2.2.  
 
I infer KLF4 activity using the TF activity inference model described above. Then 
I assign the samples into different groups, as tabulated in Table 4-1, for pairwise 




Table 4-1. List of samples in human immune cell transcriptome (GSE3982) 
		 Sample	ID	 Immune	cell	 Condition	 Group	 		
		 GSM90660	 Eosinophils	 control	 Granu_BME	 		
		 GSM92194	 Eosinophils	 control	 Granu_BME	 		
		 GSM90661	 Eosinophils	 PMA	stimulated	 Granu_BME_sti	 		
		 GSM90662	 Mast	cells	 control	 Granu_BME	 		
		 GSM90842	 Mast	cells	 control	 Granu_BME	 		
		 GSM90663	 Mast	cells	 IgE	stimulated	 Granu_BME_sti	 		
		 GSM90665	 Mast	cells	 IgE	stimulated	 Granu_BME_sti	 		
		 GSM90664	 Dendritic	cells	 LPS	stimulated	 Phago_sti	 		
		 GSM90837	 Dendritic	cells	 LPS	stimulated	 Phago_sti	 		
		 GSM90666	 Dendritic	cells	 control	 Phago	 		
		 GSM90836	 Dendritic	cells	 control	 Phago	 		
		 GSM90838	 Macrophages	 control	 Phago	 		
		 GSM90839	 Macrophages	 control	 Phago	 		
		 GSM90840	 Macrophages	 LPS	stimulated	 Phago_sti	 		
		 GSM90841	 Macrophages	 LPS	stimulated	 Phago_sti	 		
		 GSM90843	 Neutrophils	 control	 Phago	 		
		 GSM90844	 Neutrophils	 control	 Phago	 		
		 GSM90847	 Neutrophils	 LPS	stimulated	 Phago_sti	 		
		 GSM90845	 B	cells	 control	 Lym	 		
		 GSM90846	 B	cells	 control	 Lym	 		
		 GSM90848	 Basophils	 control	 Granu_BME	 		
		 GSM90853	 Basophils	 control	 Granu_BME	 		
		 GSM90849	 T	cells	 control	 Lym	 		
		 GSM90850	 T	cells	 control	 Lym	 		
		 GSM90854	 T	cells	 control	 Lym	 		
		 GSM90855	 T	cells	 control	 Lym	 		
		 GSM90851	 NK	cells	 control	 Lym	 		
		 GSM90852	 NK	cells	 control	 Lym	 		
		 GSM90856	 Th1	cells	 control	 Lym	 		
		 GSM90857	 Th1	cells	 control	 Lym	 		
		 GSM90858	 Th2	cells	 control	 Lym	 		














4.2.7 Estimation of immune cell types in PK subtypes 
I infer the composition of each immune cell type for all colorectal cancer 
samples in the CRCSC cohort using CIBERSORT (Newman et al. 2015), as 
elaborated in section 2.2.7. Then I correlate KLF4 activity score with the 
estimated composition of a particular immune cell type across all samples using 
Spearman’s rank correlation coefficient. This is performed for all immune cell 
types estimated by CIBERSORT. Subsequently, I estimate the statistical 
significance of the correlations based on a less bias estimate (permutation test 
in section 2.2.8) to identify immune cell types that are significantly correlated 
with KLF4 activity score. 
 
To assess the abundance of different immune cells in each PK subtypes, I group 
all samples that belong to a particular PK subtype together. Next, I visualise the 
inferred compositions of the immune cells of interest in the PK subtypes to 





4.3 Correlation of R signature with other related signatures 
The gene signatures of cell proliferation and tissue remodelling can be driven by 
multiple factors. The former can reflect an enrichment of epithelial cells at the 
expense of stromal cells. On the other hand, the latter can be the consequence 
of various processes, such as mesenchyme development, response to wounding 
and immune cell infiltration. 
 
Here I investigate the correlation of the R enrichment score with enrichment 
scores of other reported gene signatures associated with tissue remodelling 
processes, particularly because tissue remodelling is indicative of worse 
prognosis in colorectal cancer. As shown in Table 4-2, a previously reported gene 
signature of “Response to wounding” has the highest correlation with the R 
enrichment score (S = 0.95). The R enrichment score is also highly correlated 
with gene signatures of “Stromal tissue” (S = 0.90), “Immune cell infiltration” (S 
= 0.74), “Mesenchyme development” (S = 0.72) and “Epithelial mesenchymal 
transition” (S = 0.65). The statistical significances for these correlations are all 
1×10-5 and performed using permutation test (section 2.2.8). These associations 
suggest that the signal of tissue remodelling could reflect different biological 
processes, including high stromal cell content, immune cell infiltration and EMT. 
The lists of genes in these signatures can be found in Appendix. 
 
Table 4-2. Correlation of enrichment scores of R and tissue remodelling-
associated gene signatures 
		 Signature	 S	 P-value	
Number	
of	genes	 Source	 		
		 Response	to	wounding	 0.95	 1.0E-05	 1023	 GO:0009611	 		
		 Stromal	tissue	 0.90	 1.0E-05	 141	 Ref.	(Yoshihara	et	al.	2013)	 		
		 Immune	cell	infiltration	 0.74	 1.0E-05	 141	 Ref.	(Yoshihara	et	al.	2013)	 		
		 Mesenchyme	development	 0.72	 1.0E-05	 130	 GO:0060485	 		









4.4 Identification of TFs driving PR 
The colorectal cancer samples in the CRCSC cohort do not come with TF activity 
data (proteomics, ChIP-seq or similar). As we do not have access to these 
samples, I develop a linear regression inference model to predict TF activity, as 
detailed in section 4.2.2. This model takes gene expression profiles and 
annotations of TF targets together with their mode of regulation, either 
activation or repression, as the inputs. A representation of the method is as 
illustrated in Figure 4-1. The output is a putative transcriptional activity score 
for each TF annotated in TRRUST database, referred to as TF activity scores 
throughout this thesis. 
 
 
Figure 4-1. Schematic diagram of gene regulation and transcription factor 
activity inference 
 
I fit the gene expression profiles from the CRCSC cohort into the TF inference 
model and obtain the inferred TF activity for every annotated TF on each sample 
in the cohort, as outlined in Figure 4-2. Then I focus on associations between the 
TF activity scores and the PR gene signatures. For each transcription factor, I 
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calculate the Spearman’s rank correlation coefficient between the TF activity 
score and the P and R enrichment scores across all samples. The correlation is 
done following the method in section 2.2.4 but substituting gene expression with 
TF activity score. These correlation coefficients are represented by S(TF,P) and 
S(TF,R), respectively. S(TF,P) takes values between -1 and 1, whereby a value 
close to 1 indicating that the TF manifests a high activity score in samples with a 
high degree of cell proliferation, while a value close to -1 indicating that the TF 
manifests a low activity score in samples with a high degree of cell proliferation. 




Figure 4-2. Workflow of TF activity inference analysis and identification of TF 
regulation. Blue boxes indicate the pre-processing steps, while green boxes 




As can be observed in Figure 4-3, the TFs exhibiting high S(TF,P) have high but 
negative S(TF,R), and vice versa. Based on the Spearman’s rank correlation 
coefficient between S(TF,P) and S(TF,R), there is indeed a significant negative 
correlation between the tendency of TFs to have activity associated with the 
proliferation or remodelling programmes (S = -0.56, p-value = 1×10-5, 
permutation test). This suggests that the biases of PR in gene expression are 
driven by biases in the transcriptional programmes. We highlight that this 
negative correlation is highly significant, which implies that it cannot be 
deduced from the negative correlation reported for gene expression (Figure 3-4) 
alone. There is some information in the TF targets annotations that contributes 
to the emergence of the negative correlation in Figure 4-3. 
 
Afterwards, I focus on the TF targets and assess whether these targets go along 
with the P and R gene signatures. I identify target genes of TFs using TRRUST 
(see section 4.2.1). The expression of each of these target genes may or may not 
be correlated with the P gene signature. If the expression of a target gene is 
indeed positively correlated with P then it scores as a positive and the 
enrichment of these positives within the target list of a TF is used as putative 
evidence that this TF may regulate the cell proliferation programme. Similarly, 
if the expression of a target gene is indeed positively correlated with R then it 
scores as a positive and the enrichment of these positives within the target list 
of a TF is used as putative evidence that this TF may regulate the tissue 
remodelling programme (see section 4.2.3 for technical details). Subsequently, I 
assess regulatory relationships between the activity score of a TF and the 
expression of its targets, aiming to identify TFs whose activity scores are 
associated with PR enrichment scores and their targets are enriched for the PR 
signatures as well (Figure 4-2). This analysis can result in different patterns of 
regulations, depending on following factors: 
- the association between the TF activity scores and the PR enrichment 
scores 
- the mode of regulation of the TFs have on the target genes (activation or 
repression), and 
- the enrichment of the TF target genes with the P and R signatures 
(calculated based on the method in section 4.2.3). 
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The significance of the association of TF activity score with the P or R 
enrichment score is as calculated in section 2.2.9. The calculation for the 
significance of the enrichment of target genes with the gene signature is as 
described in section 2.2.10. 
 
From the biological point of view, transcription regulations that sustain one 
specific transcriptional programme are of more interest. This includes TFs having 
activity score significantly correlated with the P enrichment score and targeting 
genes significantly enriched for the P signature (P -> P) and TFs having the 
corresponding relationship with the R signature (R -> R). Following these 
particular patterns of regulations, I identify PROX1, RUNX3, SOX2 and TP53 as 
the TFs associated with the cell proliferation programme in colorectal cancer 
(Table 4-3 and Appendix, P -> P). Similarly, I identify CEBPB, CLOCK, CREB1, 
ERG, ESR1, ETS2, ETV4, FOXO3, GATA3, JUN, KLF4, NFE2L2, NR5A2, PML, PPARD, 
RELA, SNAI2, SPI1 and STAT1 as the TFs that promote the tissue remodelling 
programme (Table 4-3 and Appendix, R -> R). The master list of TFs together 
with their correlation of activity scores with the P and R enrichment scores and 
the enrichment scores of their targets with the PR signatures can be found in 
Appendix. 
 
In TRRUST database, BRCA1 is listed as a transcription factor and the results 
from the TF inference model indicate that BRCA1 also has a regulation pattern 
that is associated with tissue remodelling programme. BRCA1 can interact with 
RNA polymerase II holoenzyme components and its ectopic expression can induce 
transcription from various promoters (Monteiro 2000). The C terminus of BRCA1 
can activate transcription when fused to a GAL4 DNA-binding domain and a 
number of its interacting proteins have various roles in transcription (Monteiro 
2000). However, there is no evidence of sequence-specific binding to DNA by 
BRCA1 (Monteiro 2000). Therefore, I do not report BRCA1 as one of the TFs 




Figure 4-3. Scatter plot of Spearman’s rank correlation coefficients between TF 
activity scores and tissue remodelling signature (Y-axis) as a function of 
Spearman’s rank correlation between TF activity scores and cell proliferation 
signature (X-axis) in CRCSC cohort. Each symbol represents a transcription factor 
and the correlation is calculated across all patients. The transcription factor in 


















































































































































































































































































































































































































































































































I note that my findings are in agreement with literature reports. Some of these 
TFs that I find to be sustaining the tissue remodelling programme are associated 
with stroma or EMT or immune cell infiltration. Pitarresi et al. showed that gene 
expression of Ets2 was higher in stromal fibroblasts in pancreatic ductal 
adenocarcinoma tissues and transcription factor ETS2 established an immune-
suppressive microenvironment during the tumour initiation (Pitarresi et al. 
2016). In a different study, Wallace et al. reported that Ets2 in fibroblasts 
functioned by promoting tumour growth and angiogenesis (Wallace et al. 2013). 
In lung fibrosis, overexpression of SNAI2 (also known as SLUG) was demonstrated 
to be able to induce EMT, even without TGFβ1 treatment (Jayachandran et al. 
2009). KLF4 was reported to be an important regulator of monocyte/macrophage 
differentiation (Feinberg et al. 2007). PU.1 gene was shown to be expressed in 
hematopoietic tissues, specifically in B lymphoid and monocytic lineages and 
transcription factor SPI1 (also known as PU.1) was reported to regulate the 
development of B cell and myeloid lineage at the level of progenitors (Scott et 
al. 1994). STAT1 has been known to regulate the immune system, protect from 
pathogen infections (Meissl et al. 2017) and transduce the activities of various 
cytokines, such as type I-III interferons and various interleukins (Najjar and 




Table 4-3. List of putative transcription factors sustaining transcriptional 
programmes of (a) cell proliferation (P -> P) and (b) tissue remodelling (R -> R) 
in CRCSC cohort 
		 	 TF	 S(TF,P)	 P-value	 BH	 S(TF,R)	 P-value	 BH	 ES_P	 P-value	 BH	 ES_R	 P-value	 BH	 		
		 (a)	P	->	P	 	 	 	 	 	 	 	 	 	 	 	 	 		
		 	 PROX1	 0.53	 1.0E-05	 Y	 -0.24	 1.0E-05	 Y	 0.17	 1.0E-05	 Y	 0	 0.50	 N	 		
		 	 RUNX3	 0.18	 1.0E-05	 Y	 -0.11	 2.8E-03	 Y	 0.12	 2.2E-03	 Y	 -0.13	 1.2E-03	 Y	 		
		 	 SOX2	 0.19	 1.0E-05	 Y	 0.06	 0.08	 N	 0.08	 0.02	 Y	 0.00	 0.46	 N	 		
		 	 TP53	 0.09	 0.02	 Y	 -0.36	 1.0E-05	 Y	 0.25	 1.0E-05	 Y	 0.00	 0.49	 N	 		
		 (b)	R	->	R	 	 	 	 	 	 	 	 	 	 	 	 	 		
		 	 CEBPB	 -0.02	 0.29	 N	 0.12	 1.9E-03	 Y	 -0.08	 0.02	 Y	 0.44	 1.0E-05	 Y	 		
		 	 CLOCK	 -0.26	 1.0E-05	 Y	 0.17	 2.0E-05	 Y	 0	 0.50	 N	 0.39	 1.0E-05	 Y	 		
		 	 CREB1	 -0.32	 1.0E-05	 Y	 0.25	 1.0E-05	 Y	 0.08	 0.03	 N	 0.55	 1.0E-05	 Y	 		
		 	 ERG	 -0.03	 0.24	 N	 0.26	 1.0E-05	 Y	 0	 0.50	 N	 0.90	 1.0E-05	 Y	 		
		 	 ESR1	 -0.40	 1.0E-05	 Y	 0.14	 3.0E-04	 Y	 0.04	 0.16	 N	 0.34	 1.0E-05	 Y	 		
		 	 ETS2	 -0.22	 1.0E-05	 Y	 0.27	 1.0E-05	 Y	 0	 0.50	 N	 0.76	 1.0E-05	 Y	 		
		 	 ETV4	 -0.41	 1.0E-05	 Y	 0.62	 1.0E-05	 Y	 0	 0.50	 N	 0.66	 1.0E-05	 Y	 		
		 	 FOXO3	 -0.29	 1.0E-05	 Y	 0.48	 1.0E-05	 Y	 0	 0.50	 N	 0.27	 1.0E-05	 Y	 		
		 	 GATA3	 -0.03	 0.24	 N	 0.32	 1.0E-05	 Y	 -0.21	 1.0E-05	 Y	 0.48	 1.0E-05	 Y	 		
		 	 JUN	 -0.20	 1.0E-05	 Y	 0.15	 8.0E-05	 Y	 -0.20	 1.0E-05	 Y	 0.47	 1.0E-05	 Y	 		
		 	 KLF4	 -0.09	 0.02	 Y	 0.59	 1.0E-05	 Y	 -0.29	 1.0E-05	 Y	 0.18	 1.0E-05	 Y	 		
		 	 NFE2L2	 -0.06	 0.09	 N	 0.32	 1.0E-05	 Y	 0	 0.50	 N	 0.24	 1.0E-05	 Y	 		
		 	 NR5A2	 -0.33	 1.0E-05	 Y	 0.21	 1.0E-05	 Y	 0	 0.50	 N	 0.29	 1.0E-05	 Y	 		
		 	 PML	 -0.07	 0.06	 N	 0.61	 1.0E-05	 Y	 0	 0.50	 N	 0.30	 1.0E-05	 Y	 		
		 	 PPARD	 -0.14	 4.9E-04	 Y	 0.23	 1.0E-05	 Y	 0	 0.50	 N	 0.62	 1.0E-05	 Y	 		
		 	 RELA	 -0.11	 3.1E-03	 Y	 0.29	 1.0E-05	 Y	 -0.01	 0.41	 N	 0.43	 1.0E-05	 Y	 		
		 	 SNAI2	 -0.09	 0.02	 Y	 0.41	 1.0E-05	 Y	 -0.37	 1.0E-05	 Y	 0.54	 1.0E-05	 Y	 		
		 	 SPI1	 -0.03	 0.21	 N	 0.42	 1.0E-05	 Y	 0	 0.50	 N	 0.51	 1.0E-05	 Y	 		











4.4.1 Preliminary analyses using TCGA datasets 
To address the relevance of the candidate TFs in a wider context, I perform 
similar analysis in cohorts of colorectal cancer and other cancer types from 
TCGA. I make use of TCGA colorectal, breast, ovarian, and lung cancer gene 
expression datasets, as mentioned in section 2.1.1. However, I can study only 
the colorectal, breast, ovarian cancer datasets due to insufficient samples in the 
lung cancer dataset. As mentioned before, the number of samples is 132, 184 
and 472 in colorectal, breast and ovarian cancer datasets, respectively, and 129 
out of 132 samples in TCGA colorectal cancer (TCGACRC) dataset also appear in 
the CRCSC cohort. 
 
Using the inference model, I predict the TF activity score for every TF annotated 
on each sample in every TCGA gene expression dataset. I analyse these datasets 
following the methodology in Figure 4-2. As can be seen in Figure 4-4, there is a 
clear negative correlation between S(TF,P) and S(TF,R) across TFs in all three 
datasets, in agreement with the finding using the CRCSC cohort. 
 
Next, I identify transcription factors that promote a specific transcriptional 
programme of cell proliferation or tissue remodelling, as listed in Table 4-4, 
Table 4-5 and Table 4-6. These results demonstrate that KLF4 is one of the TFs 
that has a consistent pattern across all three datasets, as highlighted in bold in 
these three tables. Additionally, for KLF4, it exhibits a significant and positive 
S(TF,R) but significant and negative S(TF,P) and its target genes have a 
significant and positive R enrichment score but their P enrichment score is 
significant and negative. This finding partly leads me to conduct a further study 





Figure 4-4. Scatter plot of Spearman’s rank correlation coefficients between TF 
activity scores and tissue remodelling signature (Y-axis) as a function of 
Spearman’s rank correlation between TF activity scores and cell proliferation 
signature (X-axis) in TCGA (a) colorectal, (b) breast and (c) ovarian cancer 
datasets. Each symbol represents a transcription factor and the correlation is 





Table 4-4. List of putative transcription factors sustaining transcriptional 
programmes of (a) cell proliferation (P -> P) and (b) tissue remodelling (R -> R) 
in TCGA colorectal cancer dataset 
		 		 TF	 S(TF,P)	 P-value	 BH	 S(TF,R)	 P-value	 BH	 ES_P	 P-value	 BH	 ES_R	 P-value	 BH	 		
		 (a)	P	->	P	 		 		 		 		 		 		 		 		 		 		 		 		 		
		 	
GATA4	 0.15	 1.1E-04	 Y	 0	 0.50	 N	 0.17	 3.0E-05	 Y	 1.1E-03	 0.49	 N	 		
		 	
ATF3	 0.21	 1.0E-05	 Y	 0	 0.50	 N	 0.29	 1.0E-05	 Y	 -0.20	 1.0E-05	 Y	 		
		 	
SOX2	 0.32	 1.0E-05	 Y	 -0.28	 1.0E-05	 Y	 0.15	 8.0E-05	 Y	 -0.19	 1.0E-05	 Y	 		
		 	
NR1H4	 0.51	 1.0E-05	 Y	 4.8E-03	 0.45	 N	 0.20	 1.0E-05	 Y	 -0.23	 1.0E-05	 Y	 		
		 (b)	R	->	R	 		 		 		 		 		 		 		 		 		 		 		 		 		
		 	
KLF4	 -0.45	 1.0E-05	 Y	 0.16	 8.0E-05	 Y	 -0.26	 1.0E-05	 Y	 0.23	 1.0E-05	 Y	 		
		 	
GATA3	 -0.06	 0.08	 N	 0.31	 1.0E-05	 Y	 -0.04	 0.16	 N	 0.31	 1.0E-05	 Y	 		
		 	
PPARG	 -0.06	 0.09	 N	 0.15	 2.0E-04	 Y	 -0.31	 1.0E-05	 Y	 0.39	 1.0E-05	 Y	 		
		 	
CDX2	 0	 0.50	 N	 0.08	 0.03	 Y	 -0.14	 4.9E-04	 Y	 0.09	 0.01	 Y	 		
		 	
CLOCK	 0	 0.50	 N	 0.08	 0.04	 Y	 -0.36	 1.0E-05	 Y	 0.44	 1.0E-05	 Y	 		
		 	
ERG	 0	 0.50	 N	 0.76	 1.0E-05	 Y	 -0.28	 1.0E-05	 Y	 0.47	 1.0E-05	 Y	 		
		 	
ETS2	 0	 0.50	 N	 0.55	 1.0E-05	 Y	 -0.33	 1.0E-05	 Y	 0.25	 1.0E-05	 Y	 		
		 	
ETV4	 0	 0.50	 N	 0.52	 1.0E-05	 Y	 -0.37	 1.0E-05	 Y	 0.39	 1.0E-05	 Y	 		
		 	
FOXO3	 0	 0.50	 N	 0.18	 3.0E-05	 Y	 -0.42	 1.0E-05	 Y	 0.29	 1.0E-05	 Y	 		
		 	
MITF	 0	 0.50	 N	 0.45	 1.0E-05	 Y	 -0.03	 0.23	 N	 0.13	 9.8E-04	 Y	 		
		 	
RUNX1	 0	 0.50	 N	 0.07	 0.04	 Y	 -0.14	 4.9E-04	 Y	 0.28	 1.0E-05	 Y	 		
		 	










Table 4-5. List of putative transcription factors sustaining transcriptional 
programmes of (a) cell proliferation (P -> P) and (b) tissue remodelling (R -> R) 
in TCGA breast cancer dataset 
		 		 TF	 S(TF,P)	 P-value	 BH	 S(TF,R)	 P-value	 BH	 ES_P	 P-value	 BH	 ES_R	 P-value	 BH	 		
		 (a)	P	->	P	 		 		 		 		 		 		 		 		 		 		 		 		 		
		 	
FLI1	 0.45	 1.0E-05	 Y	 0	 0.50	 N	 0.38	 1.0E-05	 Y	 -0.30	 1.0E-05	 Y	 		
		 	
MYCN	 0.34	 1.0E-05	 Y	 0.05	 0.14	 N	 0.30	 1.0E-05	 Y	 -0.11	 4.0E-03	 Y	 		
		 	
PGR	 0.24	 1.0E-05	 Y	 0	 0.50	 N	 0.44	 1.0E-05	 Y	 -0.46	 1.0E-05	 Y	 		
		 	
RUNX3	 0.12	 1.6E-03	 Y	 0.04	 0.17	 N	 0.09	 0.02	 Y	 -0.17	 6.0E-05	 Y	 		
		 (b)	R	->	R	 		 		 		 		 		 		 		 		 		 		 		 		 		
		 	
GATA3	 0.03	 0.24	 N	 0.32	 1.0E-05	 Y	 0.06	 0.07	 N	 0.29	 1.0E-05	 Y	 		
		 	
APEX1	 0	 0.50	 N	 0.26	 1.0E-05	 Y	 -0.23	 1.0E-05	 Y	 0.42	 1.0E-05	 Y	 		
		 	
ERG	 0	 0.50	 N	 0.55	 1.0E-05	 Y	 0.04	 0.18	 N	 0.34	 1.0E-05	 Y	 		
		 	
ETS1	 0	 0.50	 N	 0.39	 1.0E-05	 Y	 -0.17	 3.0E-05	 Y	 0.15	 8.0E-05	 Y	 		
		 	
ETS2	 0	 0.50	 N	 0.51	 1.0E-05	 Y	 -0.30	 1.0E-05	 Y	 0.39	 1.0E-05	 Y	 		
		 	
ETV4	 0	 0.50	 N	 0.65	 1.0E-05	 Y	 -0.39	 1.0E-05	 Y	 0.19	 2.0E-05	 Y	 		
		 	
KLF10	 0	 0.50	 N	 0.21	 1.0E-05	 Y	 -0.51	 1.0E-05	 Y	 0.10	 6.0E-03	 Y	 		
		 	
MITF	 0	 0.50	 N	 0.63	 1.0E-05	 Y	 -0.08	 0.03	 Y	 0.18	 2.0E-05	 Y	 		
		 	
PML	 0	 0.50	 N	 0.34	 1.0E-05	 Y	 -0.17	 3.0E-05	 Y	 0.08	 0.04	 Y	 		
		 	
KLF4	 -0.11	 3.9E-03	 Y	 0.15	 1.3E-04	 Y	 -0.34	 1.0E-05	 Y	 0.25	 1.0E-05	 Y	 		
		 	
NR1I2	 -0.13	 7.7E-04	 Y	 0.36	 1.0E-05	 Y	 -0.02	 0.36	 N	 0.20	 1.0E-05	 Y	 		
		 	









Table 4-6. List of putative transcription factors sustaining transcriptional 
programmes of (a) cell proliferation (P -> P) and (b) tissue remodelling (R -> R) 
in TCGA ovarian cancer dataset 
		 		 TF	 S(TF,P)	 P-value	 BH	 S(TF,R)	 P-value	 BH	 ES_P	 P-value	 BH	 ES_R	 P-value	 BH	 		
		 (a)	P	->	P	 		 		 		 		 		 		 		 		 		 		 		 		 		
		
	
NR5A1	 0.50	 1.0E-05	 Y	 0	 0.50	 N	 0.10	 9.3E-03	 Y	 -0.12	 1.6E-03	 Y	 		
		
	
SOX2	 0.37	 1.0E-05	 Y	 0.06	 0.06	 N	 0.29	 1.0E-05	 Y	 -0.18	 2.0E-05	 Y	 		
		
	
TCF4	 0.28	 1.0E-05	 Y	 0	 0.50	 N	 0.13	 9.5E-04	 Y	 -0.27	 1.0E-05	 Y	 		
		 (b)	R	->	R	 		 		 		 		 		 		 		 		 		 		 		 		 		
		
	
ERG	 0.04	 0.18	 N	 0.35	 1.0E-05	 Y	 -0.31	 1.0E-05	 Y	 0.35	 1.0E-05	 Y	 		
		
	
ATF1	 0	 0.50	 N	 0.35	 1.0E-05	 Y	 -0.02	 0.32	 N	 0.13	 1.3E-03	 Y	 		
		
	
ATF2	 0	 0.50	 N	 0.43	 1.0E-05	 Y	 -0.03	 0.21	 N	 0.27	 1.0E-05	 Y	 		
		
	
ETS2	 0	 0.50	 N	 0.73	 1.0E-05	 Y	 -0.15	 1.7E-04	 Y	 0.14	 3.0E-04	 Y	 		
		
	
ETV4	 0	 0.50	 N	 0.43	 1.0E-05	 Y	 -0.15	 1.9E-04	 Y	 0.12	 1.8E-03	 Y	 		
		
	
FOXO3	 0	 0.50	 N	 0.22	 1.0E-05	 Y	 -0.28	 1.0E-05	 Y	 0.48	 1.0E-05	 Y	 		
		
	
HNF4A	 0	 0.50	 N	 0.36	 1.0E-05	 Y	 -0.46	 1.0E-05	 Y	 0.41	 1.0E-05	 Y	 		
		
	
IRF1	 0	 0.50	 N	 0.21	 1.0E-05	 Y	 -0.39	 1.0E-05	 Y	 0.34	 1.0E-05	 Y	 		
		
	
JUND	 0	 0.50	 N	 0.14	 2.9E-04	 Y	 -0.11	 3.5E-03	 Y	 0.10	 0.01	 Y	 		
		
	
MITF	 0	 0.50	 N	 0.58	 1.0E-05	 Y	 -0.13	 1.1E-03	 Y	 0.15	 8.0E-05	 Y	 		
		
	
NR1H4	 0	 0.50	 N	 0.33	 1.0E-05	 Y	 0.03	 0.26	 N	 0.16	 7.0E-05	 Y	 		
		
	
REL	 0	 0.50	 N	 0.63	 1.0E-05	 Y	 -0.10	 7.2E-03	 Y	 0.59	 1.0E-05	 Y	 		
		
	
RUNX1	 0	 0.50	 N	 0.27	 1.0E-05	 Y	 -0.08	 0.03	 Y	 0.22	 1.0E-05	 Y	 		
		
	
RUNX2	 0	 0.50	 N	 0.67	 1.0E-05	 Y	 -0.17	 4.0E-05	 Y	 0.22	 1.0E-05	 Y	 		
		
	
SMAD4	 0	 0.50	 N	 0.54	 1.0E-05	 Y	 -0.08	 0.03	 Y	 0.22	 1.0E-05	 Y	 		
		
	
CEBPB	 -0.05	 0.12	 N	 0.43	 1.0E-05	 Y	 -0.03	 0.27	 N	 0.14	 5.3E-04	 Y	 		
		
	
NFKB1	 -0.16	 9.0E-05	 Y	 0.50	 1.0E-05	 Y	 -0.16	 1.0E-04	 Y	 0.19	 2.0E-05	 Y	 		
		
	
GATA3	 -0.19	 1.0E-05	 Y	 0.33	 1.0E-05	 Y	 -0.08	 0.03	 Y	 0.30	 1.0E-05	 Y	 		
		
	
SPI1	 -0.27	 1.0E-05	 Y	 0.66	 1.0E-05	 Y	 0.02	 0.32	 N	 0.32	 1.0E-05	 Y	 		
		
	
PPARG	 -0.30	 1.0E-05	 Y	 0.35	 1.0E-05	 Y	 0.04	 0.18	 N	 0.17	 3.0E-05	 Y	 		
		
	
KLF4	 -0.34	 1.0E-05	 Y	 0.19	 2.0E-05	 Y	 -0.10	 9.8E-03	 Y	 0.25	 1.0E-05	 Y	 		
		
	














Then I quantify the similarity of these lists of TFs in Table 4-3 with Table 4-4, 
Table 4-5 and Table 4-6 (pairwise comparisons) using one-tailed version of 
Fisher’s exact test. In this case, the population size (N) is the number of 
combined TFs in both datasets being considered. The number of success cases in 
the population (K) is the number TFs in Table 4-3. The number of draws (n) is 
the number of TFs in the other list being considered (Table 4-4 or Table 4-5 or 
Table 4-6). Lastly, the number of observed successes (k) is the number of 
samples that belong to both tables. I calculate the significance of the similarity 
of both lists following the method in section 3.2.2. 
 
From the results, I note that the significance of Table 4-3 with Table 4-4, Table 
4-5 and Table 4-6 is 1.6×10-9, 5.4×10-8 and 1.1×10-7, respectively. In other words, 
the similarity of the lists of TFs associated with the cell proliferation or tissue 
remodelling programme in the CRCSC cohort and the TCGACRC dataset is the 
most significant one. Although the number of samples in the TCGACRC dataset is 
only about 5% of the CRCSC cohort, this observation highlights the consistency of 
the TF inference model in identifying TFs associated with these transcriptional 
programmes in colorectal cancer from different sources. Another interesting 
observation from these results is the similarities of these lists of TFs in the 
CRCSC cohort and TCGA breast and ovarian cancer datasets are also significant. 
Taken together, these findings demonstrate the reliability of the TF inference 
model in distinguishing TFs that promote a specific transcriptional programme 
across different cancer types. 
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4.5 Further study on KLF4 
I identify KLF4 as a putative TF promoting tissue remodelling programme in 
section 4.4. Specifically, in the CRCSC cohort the activity score of KLF4 is 
significantly and positively associated with R enrichment score (S = 0.59, p-value 
= 1×10-5, permutation test). Additionally, KLF4 targets are enriched for genes 
with expression significantly and positively associated with the R signature (ES = 
0.18, p-value = 1×10-5, GSEA method). 
 
KLF4 has been linked with pluripotency (Okita et al. 2007) and reported to be 
regulating differentiation of monocytes into myeloid cells (Feinberg et al. 2007). 
Here I interrogate the role of KLF4 in regulating the tissue remodelling 
programme as well as assess if the KLF4 activity score can substitute the tissue 
remodelling signature in predicting survival. The findings will hopefully advance 
our knowledge of tissue remodelling processes in colorectal cancer. 
 
4.5.1 Prognostic value of the KLF4 activity score 
As there is a strong association between the KLF4 activity score and the R 
enrichment score in CRCSC cohort, here I evaluate if the KLF4 activity score can 
substitute the tissue remodelling signature in predicting patient outcome. The 
scope of this analysis is to determine how the KLF4 activity score performs as a 
prognostic variable, substituting the R signature. 
 
I classify a sample into K+ if it has a significant and positive KLF4 activity score 
and K- if otherwise. The K status alone does not have a prognostic value either 
based on overall or relapse-free survival (Figure 4-5). Therefore, I consider 
adding cell proliferation signature and classify all samples into four PK subtypes 
(details in section 4.2.4), namely P+/K+, P+/K-, P-/K+, and P-/K-. The 
assignment of each sample into the PK groups can be found in Appendix. As 
illustrated in Figure 4-6, this PK classification yields a significant splitting of 
different subtypes based on both overall and relapse-free survival. This shows 





Figure 4-5. Kaplan-Meier plots of colorectal cancer subtypes stratified based on 
KLF4 activity score using (a) overall survival and (b) relapse-free survival. P-
values indicate statistical significance based on log-rank test. 
 
 
Figure 4-6. Kaplan-Meier plots of colorectal cancer subtypes stratified by cell 
proliferation signature and KLF4 activity score based on (a) overall survival and 





4.5.2 Enrichment of the KLF4 activity score with clinical variables 
I perform enrichment tests of the KLF4 activity score with all available 
biomarkers and clinical variables in the CRCSC cohort to examine the association 
of the KLF4 activity score with these covariates (one-tailed Fisher’s exact test in 
section 4.2.5). As tabulated in Table 4-7 and Table 4-8, high level of KLF4 
activity is significantly enriched for patients with: 
- BRAF mutation, 
- CIMP high,  
- MSI,  
- disease stage 1,  
- pT (primary tumour) stage 2, and 
- TNM (tumour, node and metastasis) stage I.  
On the contrary, low level of KLF4 activity is significantly associated with 
patients having: 
- MSS,  
- pT stage 3, and 
- TNM stage IIA. 
 
Andersen et al. demonstrated that KLF4 transcription factor was down-regulated 
and significantly associated with recurrent stage II MSS colorectal tumours 
(Andersen et al. 2009). This report is in agreement with my finding that suggests 
a significant association between low KLF4 activity and MSS. 
 
Patel et al. also evaluated if KLF4 protein expression is associated with clinical 
covariates in colorectal cancer. They found that there are decreasing odds of 
KLF4 protein expression in higher stages of the disease relative to stage 1 (Patel 
et al. 2010). My findings also suggest low KLF4 activity is significantly enriched 
for higher pT and TNM stages, whereas high KLF4 activity is significantly 
enriched for lower pT, TNM and disease stages. They reported gender to be 
associated with KLF4 protein expression where there are a higher proportion of 
men with KLF4-positive than women (Patel et al. 2010). However, my results 
suggest low KLF4 activity is enriched for male patients but I also note that its p-
value of 0.05 is in the margin of being significant. 
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One should be careful in making claims about the results in Table 4-7 and Table 
4-8, particularly because in some cases a lot of patients have missing 
information about the covariates. For example, there are only 87 patients with 
disease stage information though in total there are 2,207 patients listed in the 
clinical variable table provided by the CRCSC consortium. Further study needs to 
be conducted before the level of KLF4 activity score can be used to predict the 
extent of the clinical covariates. 
 
Table 4-7. Enrichment of KLF4 activity score with biomarkers and clinical 
variables 
		 Clinical	variable	 Number	of	patients	 Value	 KLF4	level	 P-value	 		
		
KRAS	mutation	 1,001	
no	 high	 0.09	 		
		 no	 low	 0.21	 		
		 yes	 high	 0.94	 		
		 yes	 low	 0.84	 		
		
BRAF	mutation	 968	
no	 high	 1	 		
		 no	 low	 0.09	 		
		 yes	 high	 4.2E-05	 		
		 yes	 low	 0.95	 		
		
CIMP	 1,062	
High	 high	 2.2E-06	 		
		 High	 low	 0.85	 		
		 Low	 high	 0.98	 		
		 Low	 low	 0.67	 		
		 Neg	 high	 0.99	 		
		 Neg	 low	 0.18	 		
		
MSI	or	MSS	 1,397	
MSI	 high	 5.6E-07	 		
		 MSI	 low	 0.99	 		
		 MSS	 high	 1	 		
		 MSS	 low	 0.01	 		
		
Age	 1,402	
>	60	 high	 0.06	 		
		 >	60	 low	 0.34	 		
		 <=	60	 high	 0.95	 		
		 <=	60	 low	 0.72	 		
		
Gender	 1,978	
female	 high	 0.28	 		
		 female	 low	 0.96	 		
		 male	 high	 0.76	 		






Table 4-8. Enrichment of KLF4 activity score with various disease stages 
		 Clinical	variable	 Number	of	patients	 Value	 KLF4	level	 P-value	 		
		
Grade	 87	
1	 high	 1	 		
		 1	 low	 1	 		
		 2	 high	 0.80	 		
		 2	 low	 0.12	 		
		 3	 high	 0.42	 		
		 3	 low	 0.97	 		
		
Stage	 1,838	
1	 high	 2.3E-03	 		
		 1	 low	 0.69	 		
		 2	 high	 0.98	 		
		 2	 low	 0.89	 		
		 3	 high	 0.41	 		
		 3	 low	 0.18	 		
		 4	 high	 0.88	 		
		 4	 low	 0.22	 		
		
pT	 1,204	
1	 high	 0.47	 		
		 1	 low	 0.99	 		
		 2	 high	 0.05	 		
		 2	 low	 1.00	 		
		 3	 high	 0.93	 		
		 3	 low	 0.02	 		
		 4	 high	 0.55	 		
		 4	 low	 0.48	 		
		
pN	 1,199	
0	 high	 0.34	 		
		 0	 low	 0.68	 		
		 1	 high	 0.64	 		
		 1	 low	 0.37	 		
		 2	 high	 0.59	 		
		 2	 low	 0.46	 		
		 3	 high	 1	 		
		 3	 low	 1	 		
		
pM	 1,145	
0	 high	 0.15	 		
		 0	 low	 0.86	 		
		 1	 high	 0.91	 		
		 1	 low	 0.20	 		
		
TNM	 1,191	
I	 high	 0.02	 		
		 I	 low	 1.00	 		
		 IIA	 high	 0.83	 		
		 IIA	 low	 0.03	 		
		 IIB/IIC	 high	 0.34	 		
		 IIB/IIC	 low	 0.86	 		
		 IIIA	 high	 0.89	 		
		 IIIA	 low	 0.86	 		
		 IIIB	 high	 0.12	 		
		 IIIB	 low	 0.82	 		
		 IIIC	 high	 0.92	 		
		 IIIC	 low	 0.20	 		
		 IV	 high	 0.90	 		











4.5.3 KLF4 targets driving the KLF4 transcriptional activity score 
To observe how KLF4 target genes drive KLF4 transcriptional activity in the 
inference model, first I examine the genes annotated as KLF4 targets based on 
TRRUST database. About half of the target genes manifest a significant 
association between their expression and the KLF4 activity scores (Figure 4-7 
and Table 4-9). Among those with a positive association, their correlation score 
is still far from a perfect correlation. These indicate that not all KLF4 targets 
contribute to the putative KLF4 transcriptional activity and there is no single 
target gene that can replace other target genes in deriving at the KLF4 activity 
score. This phenomenon is expected because a TF can regulate multiple target 
genes and a gene may be regulated by several TFs, as depicted in Figure 4-1. In 
other words, the KLF4 activity score is an aggregate signal considering the 
concomitant expression of multiple targets. 
 
The three most highly correlated genes in this analysis are IL1B, IL6 and CCNB1. 
To study their individual impact, I split the patients in the CRCSC cohort into 
three groups based on the level of the KLF4 activity score. If a sample has a 
significant and positive KLF4 activity score, I categorise it into ‘high’ group. 
Conversely, if a sample has a significant and negative KLF4 activity score, I 
categorise it into ‘low’ group. Otherwise, I denote it as ‘middle’. As shown in 
Figure 4-8, these three genes exhibit an increasing average expression from 
patient groups having low to high KLF4 activity score. This confirms the positive 
correlation between the expression of these genes and the KLF4 activity score. 
 
As can be seen in Figure 4-7 and Table 4-9, the two KLF4 target genes having 
highest correlation with the KLF4 activity score are IL1B and IL6 genes, which 
encode for cytokines that are secreted by immune cells. This observation leads 
us to hypothesise that KLF4 activity may be related to immune cells infiltrating 
the tumour. Additionally, KLF4 has been shown to be regulating myelopoiesis 
(Feinberg et al. 2007), further supporting the idea that the tissue remodelling 
gene signature may be partly associated with immune cell infiltration via the 




Figure 4-7. Volcano plot of statistical significance versus Spearman’s rank 
correlation between expression of annotated KLF4 target genes and KLF4 
activity score. Each point is a KLF4 target derived from TRRUST. Annotated 
genes from left to right in the figure are CDKN1B, NANOG, CCNB1, IL6 and IL1B. 
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Table 4-9. Correlation of KLF4 activity score with expression of its target genes 
		
KLF4	target	 Correlation	with	KLF4	activity	score	 P-value	 BH	 		
		 IL1B	 0.30	 1.0E-05	 Y	 		
		 IL6	 0.22	 1.0E-05	 Y	 		
		 CCNB1	 0.21	 1.0E-05	 Y	 		
		 BIRC5	 0.19	 1.0E-05	 Y	 		
		 GDF15	 0.15	 1.0E-05	 Y	 		
		 MMP2	 0.14	 1.0E-05	 Y	 		
		 ODC1	 0.13	 1.0E-05	 Y	 		
		 KRT19	 0.11	 1.0E-05	 Y	 		
		 TP53	 0.10	 1.0E-05	 Y	 		
		 THBD	 0.10	 1.0E-05	 Y	 		
		 CCND1	 0.09	 1.0E-05	 Y	 		
		 IFITM3	 0.09	 1.0E-05	 Y	 		
		 CDH5	 0.08	 5.0E-05	 Y	 		
		 LAMA3	 0.08	 7.0E-05	 Y	 		
		 HSPA8	 0.08	 7.0E-05	 Y	 		
		 ALPI	 0.05	 5.4E-03	 N	 		
		 BDKRB2	 0.05	 8.4E-03	 N	 		
		 VDR	 0.03	 0.06	 N	 		
		 CDKN1A	 0.03	 0.07	 N	 		
		 RARA	 0.02	 0.17	 N	 		
		 CDKN1C	 0.01	 0.29	 N	 		
		 GPA33	 0.01	 0.37	 N	 		
		 HDC	 0.00	 0.44	 N	 		
		 ATF3	 -0.04	 0.02	 N	 		
		 LXN	 -0.06	 8.4E-04	 Y	 		
		 CDH1	 -0.06	 7.2E-04	 Y	 		
		 NANOG	 -0.07	 1.2E-04	 Y	 		








Figure 4-8. Box plots of expression of top three KLF4 targets having positive 
correlation with KLF4 activity score: (a) IL1B, (b) IL6 and (c) CCNB1. Expression 
values are grouped into patient groups having high to middle to low KLF4 activity 
score. 
 
4.5.4 Validation of KLF4 activity in immune cells  
Because KLF4 activity is obtained from the TF activity inference model, there is 
a need to validate its robustness in a controlled scenario. As mentioned 
previously, KLF4 has been reported to be regulating myeloid differentiation 
(Feinberg et al. 2007). In line with this knowledge, I establish if the inference 
model is valid in pure immune cell populations then compare the level of 
inferred KLF4 activity in myeloid versus lymphoid cells. 
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To this end, I retrieve a publicly available human immune cell transcriptome 
dataset, quantifying genome-wide gene expression in immune cell types (ref. 
(Jeffrey et al. 2006), GEO accession number GSE3982). I pre-process this dataset 
and group the samples into different groups of immune cell types, as described 
in section 4.2.6. 
 
I apply the TF activity inference method using gene expression profiles from this 
dataset as the input and compute the KLF4 activity score for every sample. As 
can be observed in Figure 4-9, the inferred KLF4 activity is significantly higher in 
phagocytes (myeloid cells) versus lymphoid cells (p-value = 2.8×10-3, one tailed 
t-test). This observation of a high KLF4 activity score in the myeloid cells serves 
as both a confirmation that KLF4 regulates myelopoiesis and a validation of my 
TF activity inference model in a controlled scenario. 
 
 
Figure 4-9. Box plot of KLF4 activity scores across phagocytes (myeloid) versus 
lymphoid cells in human immune cell transcriptome dataset (GSE3982). 
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4.5.4.1 Activity scores of TFs promoting R programme in immune cells 
Here I evaluate other TFs that also promote the tissue remodelling programme 
and compare their activity scores in myeloid versus lymphoid cells using the 
same immune cell dataset as before (GSE3982). Among the TFs that sustain 
tissue remodelling (Table 4-3, R -> R), KLF4 is the TF with the strongest 
statistical significance for high activity score in myeloid as compared to 
lymphoid cells (Table 4-10). 
Table 4-10. Statistical significance of activity scores of TFs that promote R 
programme in myeloid versus lymphoid cells 
		 		 P-value	from	t-test	(myeloid	vs	lymphoid)	 		
		 TF	 Higher	in	myeloid	 Higher	in	lymphoid	 Two-tailed	 		
		 KLF4	 2.76E-03	 1	 5.52E-03	 		
		 CEBPB	 2.83E-03	 1	 5.65E-03	 		
		 STAT1	 5.99E-03	 0.99	 0.01	 		
		 ETS2	 0.02	 0.98	 0.03	 		
		 ESR1	 0.04	 0.96	 0.08	 		
		 CLOCK	 0.11	 0.89	 0.22	 		
		 FOXO3	 0.15	 0.85	 0.29	 		
		 ETV4	 0.17	 0.83	 0.34	 		
		 NR5A2	 0.17	 0.83	 0.33	 		
		 ERG	 0.19	 0.81	 0.38	 		
		 RELA	 0.31	 0.69	 0.62	 		
		 NFE2L2	 0.32	 0.68	 0.64	 		
		 JUN	 0.37	 0.63	 0.73	 		
		 CREB1	 0.41	 0.59	 0.82	 		
		 PML	 0.86	 0.14	 0.27	 		
		 SPI1	 0.88	 0.12	 0.24	 		
		 PPARD	 0.89	 0.11	 0.23	 		
		 GATA3	 0.99	 0.01	 0.03	 		
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4.5.5 Enrichment of myeloid versus lymphoid cells in PK subtypes 
We hypothesise that tissue remodelling processes are in part associated with 
immune cells infiltrating colorectal tumours. In this section, I investigate the 
association of the KLF4 activity score with immune cell infiltration. First, I 
estimate the composition of different immune cell types in the CRCSC cohort 
using a computational inference method CIBERSORT (Newman et al. 2015), as 
detailed in section 2.2.7. This method infers the composition of immune cell 
types in a mixed sample population using gene expression profiles as input. Then 
I correlate the KLF4 activity score with the estimated composition of immune 
cell types and assess the abundance of the immune cell types in the PK 
subtypes, as outlined in section 4.2.7. 
 
The results demonstrate that there is a significant positive correlation between 
the KLF4 activity score and the estimated fraction of various myeloid cell types: 
macrophages (M0, M1), neutrophils and dendritic cells (resting, activated) 
(Figure 4-10 and Table 4-11). On the other hand, there is a significant negative 
association or no association between the KLF4 activity score and majority of 
lymphoid cell types: B cells and T cells (Figure 4-10 and Table 4-11). In other 
words, the level of the KLF4 activity score can be used to predict the extent of 




Figure 4-10. Volcano plot of statistical significance versus Spearman’s rank 
correlation between estimated fractions of immune cells and KLF4 activity score 
in CRCSC cohort. Each point represents an immune cell type. Annotated immune 
cell types from left to right in the figure are mast cells (resting), B-cells (naive), 
neutrophils and macrophages (M0). 
 
Subsequently, I visualise the tail distribution of the estimated fractions of 
myeloid and lymphoid cells in the PK subtypes to determine if the KLF4 activity 
score is related to immune cell infiltration. The distribution of neutrophils 
enrichment for patients in K+ subtypes yields a longer tail than for K- patients, 
independently of the P status (Figure 4-11a, p-value = 3.23×10-11, two-sided 
Kolmogorov-Smirnov test). Similarly, the distribution of macrophages M0 
enrichment for K+ patients also yields a longer tail than for K- patients (Figure 4-
11b, p-value = 5.22×10-15, two-sided Kolmogorov-Smirnov test). Indeed, 
macrophages M0 and neutrophils are the two myeloid cell types with the highest 
positive correlation with the KLF4 activity score. In contrast, I observe an 
opposite pattern for B cells. The distribution of B cells (naive) enrichment for K- 
patients exhibits a longer tail than for K+ patients (Figure 4-11c, p-value = 
1.04×10-4, two-sided Kolmogorov-Smirnov test). These findings suggest the odds 
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of having a high KLF4 activity score increase with having a higher fraction of 
myeloid cells in a tumour sample. In other words, the results suggest that KLF4 
activity score is associated with myeloid cell infiltration. 
 
Table 4-11. Correlation of KLF4 activity score with estimated composition of 
immune cell types 
		
Immune	cell	type	 Correlation	with	KLF4	activity	score	 P-value	 BH	 		
		 Macrophages	M0	 0.23	 1.0E-05	 Y	 		
		 Neutrophils	 0.22	 1.0E-05	 Y	 		
		 Mast	cells	activated	 0.19	 1.0E-05	 Y	 		
		 Dendritic	cells	activated	 0.14	 1.0E-05	 Y	 		
		 NK	cells	resting	 0.13	 1.0E-05	 Y	 		
		 Macrophages	M1	 0.08	 6.0E-05	 Y	 		
		 Dendritic	cells	resting	 0.08	 1.0E-04	 Y	 		
		 T	cells	CD4	memory	activated	 0.03	 0.07	 N	 		
		 B	cells	memory	 0.03	 0.11	 N	 		
		 T	cells	follicular	helper	 0.02	 0.12	 N	 		
		 T	cells	CD4	naive	 0.01	 0.31	 N	 		
		 T	cells	regulatory	(Tregs)	 0.01	 0.32	 N	 		
		 T	cells	CD8	 -0.01	 0.24	 N	 		
		 NK	cells	activated	 -0.02	 0.20	 N	 		
		 Monocytes	 -0.04	 0.03	 N	 		
		 Eosinophils	 -0.05	 0.01	 Y	 		
		 Plasma	cells	 -0.06	 2.6E-03	 Y	 		
		 T	cells	gamma	delta	 -0.09	 1.0E-05	 Y	 		
		 Macrophages	M2	 -0.11	 1.0E-05	 Y	 		
		 T	cells	CD4	memory	resting	 -0.12	 1.0E-05	 Y	 		
		 B	cells	naive	 -0.14	 1.0E-05	 Y	 		









Figure 4-11. Tail distribution of the enrichment of (a) neutrophils, (b) 
macrophages M0 and (c) B cells (naive) across colorectal tumours in CRCSC 
cohort grouped according to their PK subtype. 
 
4.6 Conclusions 
Tissue remodelling signal could reflect various biological processes, such as high 
stromal cell content, immune cell infiltration and EMT. PROX1, RUNX3, SOX2 and 
TP53 are the putative TF regulators associated with the cell proliferation 
programme in the CRCSC cohort. Similarly, CEBPB, CLOCK, CREB1, ERG, ESR1, 
ETS2, ETV4, FOXO3, GATA3, JUN, KLF4, NFE2L2, NR5A2, PML, PPARD, RELA, 




The activity score of KLF4 can be used to substitute the tissue remodelling 
signature in stratifying patients. There is an association between high level of 
KLF4 activity and low stages of colorectal cancer. However, we should interpret 
the results with care, particularly because a lot of patients have missing 
information for some clinical variables. 
 
KLF4 activity score is significantly higher in phagocytes (myeloid cells) relative 
to lymphoid cells. Among the putative TF regulators that sustain tissue 
remodelling, KLF4 is the TF with the most statistical significance of high activity 
score in myeloid versus lymphoid cells. Additionally, KLF4 activity score is 







5 MicroRNAs driving PR programmes 
5.1 Background 
MicroRNAs (miRNAs) add another layer of regulation that could contribute to the 
dichotomy between the gene expression programs of cell proliferation and tissue 
remodelling. MiRNAs constitute 1% to 5% of RNAs encoded in the human genome 
and they regulate around 30% of protein-coding genes (Macfarlane and Murphy 
2010). Their expression is controlled by transcription factors or other miRNA in 
response to various internal and external stimuli (Kulshreshtha et al. 2007) 
(Davis and Ross 2008). Multiple miRNAs may work together to regulate a gene 
and a miRNA may control the expression of a number of target genes. MiRNAs 
function at the post-transcriptional level by assembling into the RNA-induced 
silencing complex and activating the complex (Macfarlane and Murphy 2010) to 
repress or silence the genes. They bind to target genes through sequence 
complementarity to degrade the mRNAs or inhibit their translation. MiRNAs 
regulate various cellular and metabolic pathways, particularly those regulating 
cell proliferation, differentiation and survival, and their dysregulation is 
associated with cancer as they can function as tumour suppressors or oncogenes 
(Macfarlane and Murphy 2010). 
 
As previously mentioned, I aim to uncover specific regulators that drive 
increased tissue remodelling or increased cell proliferation in colorectal cancer. 
In this chapter, I interrogate specific miRNAs that drive the cell proliferation and 
tissue remodelling programmes. 
 
5.2 Methods 
5.2.1 Processing of miRNA expression data 
We retrieve quantile-normalised and mean-centred miRNA expression datasets 
from TCGA. There is one probe for each miRNA in the expression data. I retain 
only miRNAs with standard deviation of expression values not equal to zero for 
further analyses. Some miRNAs are expressed at low levels and they are not 
included for subsequent analyses. To avoid any bias incurred by these miRNAs, I 
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then sort the expression data based on the average expression values and keep 
the top 95% miRNAs for further analyses. 
 
5.2.2 Identification of miRNA targets 
I retrieve miRWalk database (Dweep et al. 2011) to identify target genes of 
human miRNAs. The validated target module of miRWalk consists of 13,650 
publications documented on 3,081 experimentally validated miRNA-target 
interactions (Dweep and Gretz 2015). There are some differences in the 
annotations of miRNAs in miRWalk database and in TCGA datasets. Most miRNAs 
in miRWalk are annotated as their mature IDs, ending with 5p and 3p. On the 
other hand, some miRNAs in the TCGA dataset are annotated as their stem-loop 
IDs without the 5p or 3p ending. If a miRNA in the TCGA dataset is annotated 
with its stem-loop ID, I assign the target genes of this miRNA in its mature form 
to be its target genes. 
 
5.2.3 Enrichment analysis of miRNA targets 
This analysis is similar to the analysis in section 4.2.3 where I swap the two 
inputs of the GSEA method. In this case, the inputs are Spearman’s rank 
correlation of expression values with the P or R enrichment score and target 
genes of a miRNA, instead of expression values and gene signature in the original 
GSEA method. In contrast to enrichment analysis of TF targets, I include all 
interactions from miRWalk for this analysis. 
 
To ensure there is no bias introduced by miRNAs having a small number of target 
genes, I include only miRNAs that have at least ten target genes for further 
analyses. I then create the reference score vector and calculate the enrichment 




5.2.4 Processing of human immune cell subsets (GSE28492) 
I retrieve miRNA expression data files of the human immune cell subsets from 
GEO with an accession number GSE28492. I ensure that the order of the miRNA 
probes is the same across all data files before combining the miRNA expression 
values from all files into a single matrix. After obtaining the combined 
expression matrix, I annotate the probes with their miRNA IDs, quantile-
normalise and mean-centre the expression values following the steps in section 
2.2.2. Then I assign the samples into their immune cell groups, as tabulated in 
Table 5-1 and Table 5-2, for comparing mir-22 expression values in phagocytes 
(myeloid cells) versus lymphoid cells. 
 
5.2.5 Sample classification into Pmir22 subtypes 
I classify patient samples based on the P enrichment score and the level of mir-
22 expression values. The sample classification into P+ or P- is obtained from the 
results in section 3.2.1. 
 
Then I adopt a permutation test as a non-parametric estimate for the statistical 
significance of observed expression value Yj0 of miRNA j being high in a given 
sample. For the colorectal tumours in the TCGA dataset, I generate 1,000 
permutations of miRNA expression values of the 132 samples in the cohort. 
Subsequently, I obtain corresponding mir-22 expression values from these 
permuted miRNA expression values, resulting in Yjk reference scores for mir-22 
expression where k = 1, …, n=132,000. I correct the statistical significance of Yj0 
being high based on a less bias estimate pj− = (1+ 1) / (1+ n)
Yjk≤Yj 0
∑  and 
pj+ = (1+ 1) / (1+ n)
Yjk≥Yj 0
∑  (North et al. 2002). I report pj+ as the statistical 
significance if pj+ < pj −  or pj- if pj− < pj + . Finally, if a sample has a significant and 




Table 5-1. List of samples in human immune cell subsets (GSE28492) from Roche 
platform 
		 Sample	ID	 Immune	cell	 Group	 		
		 GSM703871	 Monocytes	 Phago	 		
		 GSM703872	 Monocytes	 Phago	 		
		 GSM703873	 Monocytes	 Phago	 		
		 GSM703874	 Monocytes	 Phago	 		
		 GSM703875	 Monocytes	 Phago	 		
		 GSM703876	 Monocytes	 Phago	 		
		 GSM703877	 Monocytes	 Phago	 		
		 GSM703878	 Monocytes	 Phago	 		
		 GSM703879	 Monocytes	 Phago	 		
		 GSM703880	 B	cells	 Lym	 		
		 GSM703881	 B	cells	 Lym	 		
		 GSM703882	 B	cells	 Lym	 		
		 GSM703883	 B	cells	 Lym	 		
		 GSM703884	 B	cells	 Lym	 		
		 GSM703885	 CD4+	T	cells	 Lym	 		
		 GSM703886	 CD4+	T	cells	 Lym	 		
		 GSM703887	 CD4+	T	cells	 Lym	 		
		 GSM703888	 CD4+	T	cells	 Lym	 		
		 GSM703889	 NK	cells	 Lym	 		
		 GSM703890	 NK	cells	 Lym	 		
		 GSM703891	 NK	cells	 Lym	 		
		 GSM703892	 NK	cells	 Lym	 		
		 GSM703893	 NK	cells	 Lym	 		
		 GSM703894	 CD8+	T	cells	 Lym	 		
		 GSM703895	 CD8+	T	cells	 Lym	 		
		 GSM703896	 CD8+	T	cells	 Lym	 		
		 GSM703897	 CD8+	T	cells	 Lym	 		
		 GSM703898	 CD8+	T	cells	 Lym	 		
		 GSM703899	 Eosinophils	 Granu	 		
		 GSM703900	 Eosinophils	 Granu	 		
		 GSM703901	 Eosinophils	 Granu	 		
		 GSM703902	 Eosinophils	 Granu	 		
		 GSM703903	 mDC	 Phago	 		
		 GSM703904	 mDC	 Phago	 		
		 GSM703905	 Neutrophils	 Phago	 		
		 GSM703906	 Neutrophils	 Phago	 		
		 GSM703907	 Neutrophils	 Phago	 		
		 GSM703908	 Neutrophils	 Phago	 		
		 GSM703909	 pDC	 Lym	 		
		 GSM703910	 pDC	 Lym	 		
		 GSM703911	 pDC	 Lym	 		
		 GSM703912	 pDC	 Lym	 		













Table 5-2. List of samples in human immune cell subsets (GSE28492) from HUG 
platform 
		 Sample	ID	 Immune	cell	 Group	 		
		 GSM704631	 CD4+	T	cells	 Lym	 		
		 GSM704633	 CD4+	T	cells	 Lym	 		
		 GSM704635	 CD4+	T	cells	 Lym	 		
		 GSM704636	 CD4+	T	cells	 Lym	 		
		 GSM704638	 CD4+	T	cells	 Lym	 		
		 GSM704640	 CD8+	T	cells	 Lym	 		
		 GSM704643	 CD8+	T	cells	 Lym	 		
		 GSM704645	 CD8+	T	cells	 Lym	 		
		 GSM704647	 CD8+	T	cells	 Lym	 		
		 GSM704649	 CD8+	T	cells	 Lym	 		
		 GSM704650	 Monocytes	 Phago	 		
		 GSM704652	 Monocytes	 Phago	 		
		 GSM704654	 Monocytes	 Phago	 		
		 GSM704656	 Monocytes	 Phago	 		
		 GSM704658	 Monocytes	 Phago	 		
		 GSM704660	 NK	cells	 Lym	 		
		 GSM704661	 NK	cells	 Lym	 		
		 GSM704663	 NK	cells	 Lym	 		
		 GSM704665	 NK	cells	 Lym	 		
		 GSM704667	 NK	cells	 Lym	 		
		 GSM704668	 B	cells	 Lym	 		
		 GSM704670	 B	cells	 Lym	 		
		 GSM704672	 B	cells	 Lym	 		
		 GSM704674	 B	cells	 Lym	 		
		 GSM704676	 B	cells	 Lym	 		
		 GSM704677	 Eosinophils	 Granu	 		
		 GSM704679	 Eosinophils	 Granu	 		
		 GSM704681	 Eosinophils	 Granu	 		
		 GSM704683	 Neutrophils	 Phago	 		
		 GSM704685	 Neutrophils	 Phago	 		
		 GSM704686	 Neutrophils	 Phago	 		
		 GSM704688	 Neutrophils	 Phago	 		











5.3 Identification of miRNAs driving PR 
To investigate candidate miRNAs driving the cell proliferation and tissue 
remodelling programmes in a wider context, I analyse the correlation of miRNA 
expression and the enrichment of miRNA targets with the PR signatures. The 
methodology is as outlined in Figure 5-1. I perform the analyses using gene and 
miRNA expression of the TCGA colorectal, breast and ovarian cancer datasets, as 
previously mentioned in section 4.4.1. As mentioned before, the number of 
samples is 132, 184 and 472 in colorectal, breast and ovarian cancer datasets, 
respectively. 
 
First, I select samples with matching gene and miRNA expression then pre-
process the miRNA expression datasets following the steps in section 5.2.1. 
Next, I focus on associations between miRNA expression values and the PR gene 
signatures for each dataset. For each miRNA, I calculate the Spearman’s rank 
correlation coefficient between the miRNA expression values and the P and R 
enrichment scores across all samples. The correlation is done following the 
method in section 2.2.4 but substituting gene expression with miRNA expression. 
These correlation coefficients are represented by S(M,P) and S(M,R), 
respectively. S(M,P) takes values between -1 and 1, whereby a value close to 1 
indicating that the miRNA exhibits high expression in samples with a high degree 
of cell proliferation and a value close to -1 indicating that the miRNA exhibits 
low expression in samples with a high degree of cell proliferation. Same 
interpretation for S(M,R) but with respect to the tissue remodelling gene 
signature. 
 
Similar to the pattern observed for TFs, the miRNAs yielding high S(M,P) have 
high but negative S(M,R), and vice versa (Figure 5-2). Based on the Spearman’s 
rank correlation coefficient between S(M,P) and S(M,R), there is a clear negative 
correlation between the tendency of miRNAs to be expressed together with the 
proliferation or remodelling programmes. In the colorectal cancer dataset, the 
correlation score is -0.31, while it is -0.50 and -0.37 in the breast and ovarian 
cancer datasets, respectively (p-value = 1×10-5 in all cases, permutation test). 
This suggests that the expression biases associated with the P and R programmes 
are also manifested at the level of miRNA expression. 
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Subsequently, I focus my attention on the miRNA targets and assess whether 
these targets themselves go along with the P and R gene expression signatures. I 
identify target genes of miRNAs using miRWalk (section 5.2.2). The expression of 
each of these target genes may or may not be correlated with the P gene 
signature. If the expression of a target gene is indeed positively correlated with 
P then it scores as a positive and the enrichment of these positives within the 
target list of a miRNA is used as a putative evidence that this miRNA may be 
involved in the regulation of cell proliferation programme. Similarly, if the 
expression of a target gene is indeed positively correlated with R then it scores 
as a positive and the enrichment of these positives within the target list of a 
miRNA is used as a putative evidence that this miRNA may be involved in the 
regulation of tissue remodelling programme (see section 5.2.3 for more 
technical details). Following the same rationale as before, I assess regulatory 
relationships between the expression of a miRNA and its targets, aiming to 
identify miRNAs whose expression values are associated with PR enrichment 
scores and their targets are enriched for the PR signatures as well (Figure 5-1). 
This analysis also results in different patterns of regulations, depending on: 
- the association between the miRNA expression values and the PR 
enrichment scores, and 
- the enrichment of the miRNA target genes with the P and R signatures. 
The significance of the association of miRNA expression value with the P or R 
enrichment score is as calculated in section 2.2.9. The calculation for the 
significance of the enrichment of target genes with the gene signature is as 





Figure 5-1. Workflow of identification of miRNA regulatory relationships. Blue 
boxes indicate the pre-processing steps, while green boxes indicate the 
processing steps. 
 
Given that miRNAs function by suppressing gene expression, I focus my attention 
on miRNAs whose expression is significantly correlated with one programme but 
target genes whose expression is correlated with the other programme. This 
includes miRNAs having expression values significantly correlated with the P 
gene signature and having a significant enrichment score for the R signature 
among its target genes (P -| R). Similarly, it includes miRNAs having expression 
values significantly correlated with the R gene signature and having a significant 
enrichment score for the P signature among its target genes (R -| P). Following 
these patterns of regulations, I identify mir-19a as the only miRNA that satisfies 
the pattern of a putative miRNA associated with the cell proliferation 
programme across all three datasets (Table 5-3, Table 5-4, Table 5-5 and 
Appendix, P -| R). Similarly, I identify mir-193a, mir-22 and mir-23b as miRNAs 
that satisfy the pattern of putative miRNA regulators promoting the tissue 
remodelling programme across all three datasets (Table 5-3, Table 5-4, Table 5-
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5 and Appendix, R -| P). These are as highlighted in bold in Table 5-3, Table 5-4 
and Table 5-5. The master list of miRNAs together with their correlation of 
expression values with the P and R enrichment scores and the enrichment scores 
of their targets with the PR signatures can be found in Appendix. 
 
 
Figure 5-2. Scatter plot of Spearman’s rank correlation coefficients between 
miRNA expression values and tissue remodelling signature (Y-axis) as a function 
of Spearman’s rank correlation between miRNA expression values and cell 
proliferation signature (X-axis) in TCGA (a) colorectal, (b) breast and (c) ovarian 
cancer datasets. Each symbol represents a miRNA and the correlation is 
calculated across all patients. 
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Table 5-3. List of putative miRNAs sustaining programmes of (a) cell 
proliferation (P -| R) and (b) tissue remodelling (R -| P) in TCGA colorectal 
cancer dataset 
		 miRNA	 S(M,P)	 P-value	 BH	 S(M,R)	 P-value	 BH	 ES_P	 P-value	 BH	 ES_R	 P-value	 BH	
(a)	P	-|	R	 	            
	 mir-625	 0.17	 4.0E-05	 Y	 0.04	 0.15	 N	 -0.06	 0.08	 N	 0.11	 6.1E-03	 Y	
	 mir-302a	 0.15	 3.0E-04	 Y	 -0.09	 0.02	 Y	 -0.27	 1.0E-05	 Y	 0.34	 1.0E-05	 Y	
	 mir-19a	 0.12	 2.5E-03	 Y	 -0.09	 0.02	 Y	 -0.03	 0.27	 N	 0.33	 1.0E-05	 Y	
	 mir-141	 0.09	 0.01	 Y	 -0.07	 0.04	 Y	 0.03	 0.23	 N	 0.13	 1.5E-03	 Y	
	 mir-346	 0.09	 0.02	 Y	 -0.09	 0.01	 Y	 0.02	 0.35	 N	 0.20	 1.0E-05	 Y	
	 mir-33a	 0.08	 0.02	 Y	 -0.06	 0.08	 N	 3.2E-03	 0.47	 N	 0.10	 9.3E-03	 Y	
(b)	R	-|	P	 		 		 		 		 		 		 		 		 		 		 		 		
	 mir-212	 0.07	 0.05	 N	 0.34	 1.0E-05	 Y	 0.30	 1.0E-05	 Y	 -0.14	 6.1E-04	 Y	
	 mir-615	 0.07	 0.05	 N	 0.24	 1.0E-05	 Y	 0.24	 1.0E-05	 Y	 -0.04	 0.18	 N	
	
mir-155	 0.05	 0.12	 N	 0.30	 1.0E-05	 Y	 0.18	 3.0E-05	 Y	 0.02	 0.34	 N	
	 mir-326	 0.05	 0.12	 N	 0.17	 6.0E-05	 Y	 0.13	 9.3E-04	 Y	 3.0E-03	 0.47	 N	
	 mir-31	 0.03	 0.28	 N	 0.32	 1.0E-05	 Y	 0.10	 8.5E-03	 Y	 0.04	 0.16	 N	
	 mir-330	 7.6E-05	 0.50	 N	 0.22	 1.0E-05	 Y	 0.26	 1.0E-05	 Y	 -0.03	 0.21	 N	
	 mir-221	 3.9E-05	 0.50	 N	 0.17	 6.0E-05	 Y	 0.15	 3.4E-04	 Y	 0.02	 0.28	 N	
	
mir-340	 -3.1E-03	 0.47	 N	 0.10	 0.01	 Y	 0.18	 4.0E-05	 Y	 -0.03	 0.22	 N	
	 mir-935	 -0.01	 0.39	 N	 0.09	 0.02	 Y	 0.27	 1.0E-05	 Y	 -0.10	 6.7E-03	 Y	
	 mir-1260	 -0.03	 0.27	 N	 0.09	 0.02	 Y	 0.22	 1.0E-05	 Y	 -0.09	 0.01	 Y	
	 mir-15a	 -0.03	 0.27	 N	 0.12	 2.8E-03	 Y	 0.11	 7.0E-03	 Y	 0.07	 0.05	 N	
	 mir-193b	 -0.03	 0.25	 N	 0.09	 0.02	 Y	 0.31	 1.0E-05	 Y	 -0.09	 0.01	 Y	
	 mir-34c	 -0.03	 0.24	 N	 0.36	 1.0E-05	 Y	 0.36	 1.0E-05	 Y	 -0.12	 2.4E-03	 Y	
	 let-7i	 -0.04	 0.18	 N	 0.28	 1.0E-05	 Y	 0.28	 1.0E-05	 Y	 0.02	 0.35	 N	
	 mir-342	 -0.05	 0.11	 N	 0.16	 1.0E-04	 Y	 0.26	 1.0E-05	 Y	 -0.14	 6.1E-04	 Y	
	 mir-126	 -0.06	 0.10	 N	 0.12	 3.1E-03	 Y	 0.21	 1.0E-05	 Y	 -0.04	 0.18	 N	
	 mir-149	 -0.07	 0.05	 N	 0.11	 5.2E-03	 Y	 0.25	 1.0E-05	 Y	 -0.08	 0.03	 Y	
	 mir-328	 -0.08	 0.04	 Y	 0.14	 5.9E-04	 Y	 0.37	 1.0E-05	 Y	 -0.10	 9.5E-03	 Y	
	 mir-214	 -0.08	 0.03	 Y	 0.20	 1.0E-05	 Y	 0.11	 4.9E-03	 Y	 -0.03	 0.28	 N	
	
mir-181b-1	 -0.08	 0.03	 Y	 0.09	 0.01	 Y	 0.22	 1.0E-05	 Y	 -0.11	 5.6E-03	 Y	
	 mir-10b	 -0.09	 0.02	 Y	 0.14	 5.7E-04	 Y	 0.22	 1.0E-05	 Y	 9.2E-03	 0.42	 N	
	 mir-34b	 -0.09	 0.01	 Y	 0.13	 1.1E-03	 Y	 0.33	 1.0E-05	 Y	 -0.08	 0.04	 Y	
	 mir-708	 -0.12	 2.1E-03	 Y	 0.27	 1.0E-05	 Y	 0.21	 1.0E-05	 Y	 0.02	 0.32	 N	
	 mir-199a-2	 -0.12	 1.6E-03	 Y	 0.19	 1.0E-05	 Y	 0.15	 2.0E-04	 Y	 0.03	 0.21	 N	
	 mir-199a-1	 -0.13	 6.7E-04	 Y	 0.19	 1.0E-05	 Y	 0.15	 2.0E-04	 Y	 0.03	 0.21	 N	
	 mir-125a	 -0.14	 3.7E-04	 Y	 0.15	 1.9E-04	 Y	 0.18	 4.0E-05	 Y	 -0.02	 0.36	 N	
	 let-7e	 -0.15	 2.1E-04	 Y	 0.09	 0.02	 Y	 0.22	 1.0E-05	 Y	 0.01	 0.37	 N	
	 mir-193a	 -0.17	 4.0E-05	 Y	 0.11	 5.8E-03	 Y	 0.10	 9.3E-03	 Y	 -0.13	 7.7E-04	 Y	
	 mir-497	 -0.18	 2.0E-05	 Y	 0.10	 8.5E-03	 Y	 0.36	 1.0E-05	 Y	 0.07	 0.06	 N	
	 mir-21	 -0.18	 1.0E-05	 Y	 0.22	 1.0E-05	 Y	 0.15	 2.0E-04	 Y	 0.02	 0.34	 N	
	 mir-125b-1	 -0.20	 1.0E-05	 Y	 0.30	 1.0E-05	 Y	 0.14	 4.4E-04	 Y	 -0.02	 0.32	 N	
	 mir-22	 -0.20	 1.0E-05	 Y	 0.26	 1.0E-05	 Y	 0.18	 4.0E-05	 Y	 5.1E-03	 0.45	 N	
	 let-7b	 -0.21	 1.0E-05	 Y	 0.17	 4.0E-05	 Y	 0.23	 1.0E-05	 Y	 -0.06	 0.08	 N	
	 mir-125b-2	 -0.22	 1.0E-05	 Y	 0.26	 1.0E-05	 Y	 0.32	 1.0E-05	 Y	 -0.11	 6.4E-03	 Y	
	 mir-23b	 -0.23	 1.0E-05	 Y	 0.12	 3.2E-03	 Y	 0.19	 1.0E-05	 Y	 0.02	 0.28	 N	
	
mir-30e	 -0.23	 1.0E-05	 Y	 0.11	 4.9E-03	 Y	 0.20	 1.0E-05	 Y	 -0.07	 0.04	 Y	
	
let-7a-1	 -0.25	 1.0E-05	 Y	 0.08	 0.03	 Y	 0.20	 1.0E-05	 Y	 -0.03	 0.25	 N	
	
let-7a-2	 -0.25	 1.0E-05	 Y	 0.09	 0.02	 Y	 0.20	 1.0E-05	 Y	 -0.03	 0.25	 N	
	
mir-99a	 -0.28	 1.0E-05	 Y	 0.22	 1.0E-05	 Y	 0.15	 3.6E-04	 Y	 2.3E-03	 0.48	 N	
	
mir-218-2	 -0.28	 1.0E-05	 Y	 0.30	 1.0E-05	 Y	 0.14	 5.1E-04	 Y	 -0.06	 0.08	 N	
	
mir-9-1	 -0.28	 1.0E-05	 Y	 0.15	 2.0E-04	 Y	 0.16	 1.0E-04	 Y	 4.6E-03	 0.46	 N	
	
mir-9-2	 -0.28	 1.0E-05	 Y	 0.16	 1.9E-04	 Y	 0.16	 1.0E-04	 Y	 4.6E-03	 0.46	 N	
	
mir-101-1	 -0.28	 1.0E-05	 Y	 0.19	 1.0E-05	 Y	 0.17	 4.0E-05	 Y	 -0.02	 0.34	 N	
	
mir-30a	 -0.28	 1.0E-05	 Y	 0.19	 1.0E-05	 Y	 0.20	 1.0E-05	 Y	 0.01	 0.38	 N	
	
let-7c	 -0.29	 1.0E-05	 Y	 0.26	 1.0E-05	 Y	 0.21	 1.0E-05	 Y	 -0.10	 7.3E-03	 Y	
	
mir-100	 -0.30	 1.0E-05	 Y	 0.36	 1.0E-05	 Y	 0.14	 3.8E-04	 Y	 -0.05	 0.13	 N	
	









Table 5-4. List of putative miRNAs sustaining programmes of (a) cell 
proliferation (P -| R) and (b) tissue remodelling (R -| P) in TCGA breast cancer 
dataset 
		 miRNA	 S(M,P)	 P-value	 BH	 S(M,R)	 P-value	 BH	 ES_P	 P-value	 BH	 ES_R	 P-value	 BH	
(a)	P	-|	R	 	            
	 mir-429	 0.09	 4.4E-03	 Y	 -0.10	 2.0E-03	 Y	 -0.13	 3.0E-04	 Y	 0.39	 1.0E-05	 Y	
	 mir-200c	 0.11	 6.4E-04	 Y	 -0.30	 1.0E-05	 Y	 -0.14	 6.0E-05	 Y	 0.28	 1.0E-05	 Y	
	 mir-141	 0.09	 5.9E-03	 Y	 -0.32	 1.0E-05	 Y	 0.04	 0.11	 N	 0.24	 1.0E-05	 Y	
	
mir-20b	 0.07	 0.03	 Y	 -0.03	 0.20	 N	 -0.16	 3.0E-05	 Y	 0.19	 1.0E-05	 Y	
	 mir-19a	 0.32	 1.0E-05	 Y	 -0.05	 0.08	 N	 -0.22	 1.0E-05	 Y	 0.15	 1.0E-05	 Y	
	 mir-19b-2	 0.14	 5.0E-05	 Y	 -0.13	 2.8E-04	 Y	 -0.04	 0.14	 N	 0.12	 3.1E-04	 Y	
	 mir-33a	 0.30	 1.0E-05	 Y	 -0.05	 0.07	 N	 -5.6E-03	 0.44	 N	 0.11	 7.1E-04	 Y	
	 mir-128-1	 0.14	 9.0E-05	 Y	 0.06	 0.05	 N	 0.04	 0.16	 N	 0.11	 1.2E-03	 Y	
	 mir-130b	 0.36	 1.0E-05	 Y	 0.02	 2.6E-01	 N	 -2.8E-03	 0.47	 N	 0.08	 0.01	 Y	
(b)	R	-|	P	 		 		 		 		 		 		 		 		 		 		 		 		
	 mir-195	 -0.39	 1.0E-05	 Y	 0.16	 1.0E-05	 Y	 0.18	 1.0E-05	 Y	 0.06	 0.05	 N	
	 mir-376a-2	 -0.24	 1.0E-05	 Y	 0.24	 1.0E-05	 Y	 0.11	 1.2E-03	 Y	 0.06	 0.06	 N	
	 mir-376a-1	 -0.31	 1.0E-05	 Y	 0.30	 1.0E-05	 Y	 0.11	 1.2E-03	 Y	 0.06	 0.06	 N	
	 mir-190	 -0.26	 1.0E-05	 Y	 0.08	 0.02	 Y	 0.14	 5.0E-05	 Y	 0.05	 0.07	 N	
	 mir-23a	 -0.10	 3.2E-03	 Y	 0.22	 1.0E-05	 Y	 0.15	 1.0E-05	 Y	 0.04	 0.14	 N	
	 mir-28	 -0.16	 2.0E-05	 Y	 0.24	 1.0E-05	 Y	 0.17	 1.0E-05	 Y	 0.04	 0.14	 N	
	
mir-10b	 -0.43	 1.0E-05	 Y	 0.26	 1.0E-05	 Y	 0.11	 1.6E-03	 Y	 0.03	 0.24	 N	
	 mir-1-2	 -0.25	 1.0E-05	 Y	 0.24	 1.0E-05	 Y	 0.10	 3.3E-03	 Y	 0.02	 0.30	 N	
	 mir-1-1	 -0.03	 0.23	 N	 0.09	 7.5E-03	 Y	 0.10	 3.3E-03	 Y	 0.02	 0.30	 N	
	 mir-101-2	 -0.19	 1.0E-05	 Y	 0.10	 3.0E-03	 Y	 0.12	 3.4E-04	 Y	 0.02	 0.30	 N	
	 mir-101-1	 -0.34	 1.0E-05	 Y	 0.12	 5.6E-04	 Y	 0.12	 3.4E-04	 Y	 0.02	 0.30	 N	
	 mir-652	 -0.02	 0.26	 N	 0.11	 1.4E-03	 Y	 0.21	 1.0E-05	 Y	 0.02	 0.33	 N	
	 mir-155	 0.03	 0.18	 N	 0.39	 1.0E-05	 Y	 0.13	 2.4E-04	 Y	 2.8E-03	 0.47	 N	
	
mir-21	 -0.14	 1.5E-04	 Y	 0.20	 1.0E-05	 Y	 0.13	 1.9E-04	 Y	 -9.9E-03	 0.39	 N	
	 mir-23b	 -0.16	 1.0E-05	 Y	 0.17	 1.0E-05	 Y	 0.13	 1.0E-04	 Y	 -0.01	 0.39	 N	
	 mir-708	 -0.27	 1.0E-05	 Y	 0.25	 1.0E-05	 Y	 0.23	 1.0E-05	 Y	 -0.02	 0.31	 N	
	 mir-424	 -0.17	 1.0E-05	 Y	 0.28	 1.0E-05	 Y	 0.22	 1.0E-05	 Y	 -0.02	 0.30	 N	
	 mir-874	 -0.24	 1.0E-05	 Y	 0.06	 0.04	 Y	 0.49	 1.0E-05	 Y	 -0.02	 0.29	 N	
	 mir-100	 -0.45	 1.0E-05	 Y	 0.42	 1.0E-05	 Y	 0.13	 1.3E-04	 Y	 -0.03	 0.24	 N	
	 mir-34a	 -0.20	 1.0E-05	 Y	 0.11	 9.3E-04	 Y	 0.21	 1.0E-05	 Y	 -0.03	 0.20	 N	
	 mir-598	 -0.17	 1.0E-05	 Y	 0.22	 1.0E-05	 Y	 0.33	 1.0E-05	 Y	 -0.03	 0.18	 N	
	 mir-605	 -0.13	 1.6E-04	 Y	 0.16	 1.0E-05	 Y	 0.18	 1.0E-05	 Y	 -0.04	 0.17	 N	
	 mir-26a-1	 -0.24	 1.0E-05	 Y	 0.15	 1.0E-05	 Y	 0.13	 1.9E-04	 Y	 -0.04	 0.13	 N	
	 mir-30e	 -0.17	 1.0E-05	 Y	 0.23	 1.0E-05	 Y	 0.12	 2.9E-04	 Y	 -0.04	 0.12	 N	
	 mir-125b-1	 -0.49	 1.0E-05	 Y	 0.41	 1.0E-05	 Y	 0.11	 1.0E-03	 Y	 -0.04	 0.11	 N	
	 mir-126	 -0.19	 1.0E-05	 Y	 0.25	 1.0E-05	 Y	 0.13	 1.7E-04	 Y	 -0.05	 0.07	 N	
	 mir-22	 -0.33	 1.0E-05	 Y	 0.39	 1.0E-05	 Y	 0.13	 1.0E-04	 Y	 -0.05	 0.07	 N	
	 mir-32	 0.06	 0.06	 N	 0.08	 0.01	 Y	 0.14	 9.0E-05	 Y	 -0.07	 0.02	 Y	
	 mir-222	 -0.10	 3.6E-03	 Y	 0.31	 1.0E-05	 Y	 0.17	 1.0E-05	 Y	 -0.08	 0.01	 Y	
	 mir-215	 7.2E-03	 0.42	 N	 0.23	 1.0E-05	 Y	 0.21	 1.0E-05	 Y	 -0.09	 5.9E-03	 Y	
	 mir-361	 -0.16	 3.0E-05	 Y	 0.18	 1.0E-05	 Y	 0.22	 1.0E-05	 Y	 -0.11	 1.1E-03	 Y	
	 mir-99a	 -0.49	 1.0E-05	 Y	 0.44	 1.0E-05	 Y	 0.14	 6.0E-05	 Y	 -0.11	 9.6E-04	 Y	
	 mir-196b	 -0.25	 1.0E-05	 Y	 0.35	 1.0E-05	 Y	 0.14	 6.0E-05	 Y	 -0.11	 8.4E-04	 Y	
	
let-7c	 -0.49	 1.0E-05	 Y	 0.46	 1.0E-05	 Y	 0.15	 1.0E-05	 Y	 -0.13	 3.0E-04	 Y	
	 mir-503	 -0.09	 7.4E-03	 Y	 0.24	 1.0E-05	 Y	 0.25	 1.0E-05	 Y	 -0.17	 1.0E-05	 Y	
	 mir-193a	 -0.13	 1.9E-04	 Y	 0.08	 0.01	 Y	 0.13	 1.4E-04	 Y	 -0.17	 1.0E-05	 Y	












Table 5-5. List of putative miRNAs sustaining programmes of (a) cell 
proliferation (P -| R) and (b) tissue remodelling (R -| P) in TCGA ovarian cancer 
dataset 
		 miRNA	 S(M,P)	 P-value	 BH	 S(M,R)	 P-value	 BH	 ES_P	 P-value	 BH	 ES_R	 P-value	 BH	
(a)	P	-|	R	 	            
	
mir-130a	 0.14	 2.5E-04	 Y	 -0.15	 2.6E-04	 Y	 -0.07	 0.04	 N	 0.39	 1.0E-05	 Y	
	 mir-19a	 0.14	 1.7E-04	 Y	 -0.12	 1.0E-03	 Y	 -0.12	 1.2E-03	 Y	 0.32	 1.0E-05	 Y	
	 mir-200a	 0.09	 0.02	 Y	 -0.15	 2.0E-04	 Y	 0.06	 0.06	 N	 0.32	 1.0E-05	 Y	
	 mir-138-2	 0.08	 0.02	 Y	 -0.03	 0.20	 N	 0.07	 0.04	 N	 0.19	 1.0E-05	 Y	
	 mir-18b	 0.18	 1.0E-05	 Y	 -0.06	 0.09	 N	 0.06	 0.06	 N	 0.16	 1.0E-05	 Y	
	 mir-625	 0.11	 5.3E-03	 Y	 -0.11	 4.3E-03	 Y	 -0.16	 3.0E-05	 Y	 0.15	 6.0E-05	 Y	
	 mir-335	 0.09	 0.01	 Y	 -0.12	 1.0E-03	 Y	 -0.15	 1.1E-04	 Y	 0.15	 1.1E-04	 Y	
	 mir-548b	 0.09	 0.02	 Y	 -0.04	 0.14	 N	 -0.03	 0.23	 N	 0.10	 8.3E-03	 Y	
(b)	R	-|	P	 		 		 		 		 		 		 		 		 		 		 		 		
	 mir-340	 0.02	 0.31	 N	 0.08	 0.03	 Y	 0.16	 1.0E-05	 Y	 0.07	 0.05	 N	
	 mir-125a	 -0.11	 3.3E-03	 Y	 0.07	 0.04	 Y	 0.10	 8.3E-03	 Y	 0.05	 0.10	 N	
	 mir-221	 -0.11	 3.0E-03	 Y	 0.16	 1.0E-05	 Y	 0.20	 1.0E-05	 Y	 0.05	 0.14	 N	
	 mir-181a-1	 -0.04	 0.15	 N	 0.17	 1.0E-05	 Y	 0.09	 0.02	 Y	 0.04	 0.16	 N	
	
mir-222	 -0.13	 8.1E-04	 Y	 0.18	 1.0E-05	 Y	 0.22	 1.0E-05	 Y	 0.04	 0.18	 N	
	 mir-22	 -0.02	 0.27	 N	 0.34	 1.0E-05	 Y	 0.19	 1.0E-05	 Y	 0.03	 0.25	 N	
	 mir-23b	 -0.03	 0.25	 N	 0.08	 0.02	 Y	 0.13	 7.3E-04	 Y	 0.02	 0.29	 N	
	 mir-34a	 -0.07	 0.04	 Y	 0.18	 1.0E-05	 Y	 0.23	 1.0E-05	 Y	 0.02	 0.32	 N	
	 mir-455	 -0.05	 0.10	 N	 0.21	 1.0E-05	 Y	 0.14	 4.4E-04	 Y	 0.02	 0.35	 N	
	 mir-181b-2	 0.04	 0.14	 N	 0.11	 4.8E-03	 Y	 0.15	 5.0E-05	 Y	 -4.1E-03	 0.46	 N	
	 let-7i	 -0.06	 0.08	 N	 0.11	 4.3E-03	 Y	 0.41	 1.0E-05	 Y	 -7.2E-03	 0.43	 N	
	 mir-342	 -0.02	 0.29	 N	 0.16	 1.0E-05	 Y	 0.18	 1.0E-05	 Y	 -0.01	 0.37	 N	
	 let-7e	 -5.1E-03	 0.45	 N	 0.14	 3.2E-04	 Y	 0.20	 1.0E-05	 Y	 -0.02	 0.34	 N	
	 let-7a-2	 -0.10	 6.4E-03	 Y	 0.14	 2.9E-04	 Y	 0.15	 1.2E-04	 Y	 -0.03	 0.26	 N	
	 let-7a-1	 -0.09	 0.01	 Y	 0.15	 1.7E-04	 Y	 0.15	 1.2E-04	 Y	 -0.03	 0.26	 N	
	 mir-605	 -0.05	 0.13	 N	 0.31	 1.0E-05	 Y	 0.15	 1.1E-04	 Y	 -0.03	 0.21	 N	
	 mir-193b	 -0.07	 0.05	 N	 0.08	 0.03	 Y	 0.25	 1.0E-05	 Y	 -0.04	 0.15	 N	
	 let-7b	 -0.15	 1.8E-04	 Y	 0.22	 1.0E-05	 Y	 0.18	 1.0E-05	 Y	 -0.04	 0.14	 N	
	 mir-193a	 -0.11	 4.5E-03	 Y	 0.17	 1.0E-05	 Y	 0.10	 7.5E-03	 Y	 -0.05	 0.09	 N	
	 mir-326	 0.01	 0.36	 N	 0.12	 2.5E-03	 Y	 0.15	 1.5E-04	 Y	 -0.06	 0.07	 N	











5.4 Further study on mir-22 
As emphasized in previous sections, our primary focus is on the identification of 
putative regulatory mechanisms of tissue remodelling in the context of 
colorectal cancer. To this end, in section 5.3, I identify mir-22, mir-193a and 
mir-23b as putative miRNAs promoting the tissue remodelling programme. I 
perform a literature search about previous investigations of these miRNAs, 
paying particular attention to their association with the work on the context of 
tissue remodelling and immune cells. I then decide to focus my attention on mir-
22 because there is some evidence on the regulation of immune cells 
differentiation by mir-22 and myeloid cell infiltration was found to be associated 
with tissue remodelling in colorectal cancer. 
 
Mir-22 has been previously reported to be regulating monocyte/macrophage 
differentiation and its expression was shown to be decreased in acute myeloid 
leukaemia (Shen et al. 2016). On a different study, it has been demonstrated 
that mir-22 expression enhances conventional dendritic cell (cDC) development 
but inhibits plasmacytoid dendritic cell (pDC) generation in murine (Li et al. 
2012). In line with these reports, we hypothesise that mir-22 may be regulating 
the immune cells of the myeloid lineage. Here I evaluate if there is also a higher 
mir-22 expression in myeloid as compared to lymphoid cells. Additionally, I 
investigate whether mir-22 is associated with immune cell infiltration in 
colorectal cancer. 
 
5.4.1 Observation of mir-22 expression in human immune cell subsets 
Previously I validate that KLF4 activity score is significantly higher in phagocytes 
(myeloid cells, myeloblast lineage) versus lymphoid cells in section 4.5.2. Here I 
establish if there is also a similar pattern of mir-22 expression in the immune 
cells. To facilitate this, I retrieve a different publicly available human immune 
cell transcriptome dataset, quantifying both genome-wide gene and miRNA 
expression in immune cell subsets (ref. (Allantaz et al. 2012), GEO accession 
number GSE28492). I pre-process the miRNA expression data (generated on 
Roche and HUG platforms) and assign the samples into different groups of 
immune cell types, as detailed in section 5.2.4. 
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As can be observed in Figure 5-3, the expression of mir-22 is significantly higher 
in phagocytes versus lymphoid cells (p-value = 2.54×10-5, one tailed t-test). This 
observation of a high mir-22 expression in myeloid cells further supports our 




Figure 5-3. Box plot of mir-22 expression values in phagocytes (myeloid cells) 
versus lymphoid cells in human immune cell subsets (GSE28492). 
 
5.4.2 Enrichment of myeloid versus lymphoid cells in Pmir22 subtypes 
Previously I elaborate that tissue remodelling processes are associated with KLF4 
activity score via myeloid cell infiltration. Here I evaluate if there is also an 
association between mir-22 expression value with immune cell infiltration, 
specifically the immune cells in the myeloid lineage. 
 
Using TCGACRC miRNA expression data, I correlate mir-22 expression value with 
the estimated fraction of immune cell types of these colorectal tumours. As 



















CRCSC cohort so I can reuse the inferred composition of the immune cell types 
previously obtained using CIBERSORT in section 4.5.4. 
 
In Figure 5-4, it can be observed that there is a significant positive correlation 
between mir-22 expression value and the inferred neutrophils fraction (Table 5-
6). On the other hand, there is a significant negative association between mir-22 
expression value and the estimated composition of T cells CD4 memory 
(activated) (Figure 5-4 and Table 5-6). In other words, the level of mir-22 
expression value is associated with inferred fraction of neutrophils, despite the 
low number of samples in this dataset. I note, however, that there is no 
significant association between the expression of mir-22 and other myeloid 






Figure 5-4. Volcano plot of statistical significance versus Spearman’s rank 
correlation between estimated fractions of immune cells and mir-22 expression 
values in TCGACRC dataset. Each point represents an immune cell type. 
Annotated immune cell types from left to right in the figure are T cells CD4 
memory (activated) and neutrophils. 
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Table 5-6. Correlation of mir-22 expression value with estimated fraction of 
immune cell types 
		
Immune	cell	type	 Correlation	with	mir-22	expression	value	 P-value	 BH	 		
		 Neutrophils	 0.18	 2.1E-02	 Y	 		
		 NK	cells	activated	 0.09	 1.5E-01	 N	 		
		 Eosinophils	 0.08	 1.7E-01	 N	 		
		 Macrophages	M2	 0.05	 2.8E-01	 N	 		
		 T	cells	follicular	helper	 0.05	 2.9E-01	 N	 		
		 T	cells	CD8	 0.05	 3.0E-01	 N	 		
		 T	cells	regulatory	(Tregs)		 0.04	 3.1E-01	 N	 		
		 Macrophages	M1	 0.04	 3.2E-01	 N	 		
		 Macrophages	M0	 0.03	 3.8E-01	 N	 		
		 Dendritic	cells	resting	 0.02	 4.1E-01	 N	 		
		 Monocytes	 0.02	 4.2E-01	 N	 		
		 B	cells	naive	 0.01	 4.5E-01	 N	 		
		 B	cells	memory	 0.01	 4.7E-01	 N	 		
		 T	cells	CD4	naive	 -0.01	 4.8E-01	 N	 		
		 Mast	cells	resting	 -0.01	 4.6E-01	 N	 		
		 Mast	cells	activated	 -0.04	 3.1E-01	 N	 		
		 Dendritic	cells	activated	 -0.07	 2.0E-01	 N	 		
		 T	cells	CD4	memory	resting	 -0.09	 1.5E-01	 N	 		
		 NK	cells	resting	 -0.11	 1.0E-01	 N	 		
		 T	cells	gamma	delta	 -0.14	 6.3E-02	 N	 		
		 Plasma	cells	 -0.14	 5.5E-02	 N	 		







Next, I classify the samples into Pmir22 subtypes following the steps in section 
5.2.5. The assignment of the samples into the Pmir22 groups can be found in 
Appendix. Then I assess the abundance of the immune cell types in the Pmir22 
subtypes following the method in section 4.2.7 but substituting the PK subtypes 
with the Pmir22 subtypes. 
 
Afterwards, I visualise the tail distribution of the estimated fractions of myeloid 
and lymphoid cells in the Pmir22 subtypes to determine if mir-22 expression 
value is related to immune cell infiltration. As illustrated in Figure 5-5, there is 
no clear separation of the tail distribution of macrophages M0, neutrophils, B 
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cells (naive) and T cells CD4 memory (activated) enrichment between mir22+ 
and mir22- patient groups. Also, the two-sided Kolmogorov-Smirnov test does 
not yield statistical significance for the comparison of estimated fraction of all 
four immune cell types in mir22+ and mir22- patient groups. These findings 
suggest the level of mir-22 expression is not a predictor of the composition of 
myeloid or lymphoid cells in a tumour sample. In other words, the results 
suggest that mir-22 expression value is not associated with immune cell 
infiltration and mir-22 may have other functions in other compartments of the 
tumours as well. 
 
 
Figure 5-5. Tail distribution of the enrichment of (a) macrophages M0, (b) 
neutrophils, (c) B cells (naive) and (d) T cells CD4 memory (activated) across 
TCGACRC grouped according to their Pmir22 subtype. 
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5.5 Conclusions 
Mir-19a is the putative miRNA regulator associated with the cell proliferation 
programme in all three datasets (TCGA colorectal, breast and ovarian cancer) 
analysed. Similarly, mir-193a, mir-22 and mir-23b are the putative miRNA 
regulators sustaining the tissue remodelling programme in the same datasets. 
Expression value of mir-22 is significantly higher in myeloid cells from the 
myeloblast lineage relative to other immune cell types. However, mir-22 
expression value has a weak association with immune cell composition in 
colorectal cancer. This observation suggests that mir-22 may be expressed in the 
tumour stroma, which may explain why it is less correlated with the presence of 




6.1 Putative regulatory network of infiltrating myeloid cells 
The observations made in this work suggest that a component of what we define 
by tissue remodelling based on gene expression signatures may be actually 
driven by immune cell infiltration. To shed further light in this direction, I make 
a final effort to put these observations together and draw a working model of a 
core regulatory network of myeloid cell infiltration of colorectal tumours. 
 
As mentioned previously, mir-22 has been shown to be a regulator of 
monocyte/macrophage differentiation in human (Shen et al. 2016) and cDC 
development in mouse (Li et al. 2012). Similarly, KLF4 has also been reported to 
regulate the differentiation of monocytes into myeloid cells (Feinberg et al. 
2007). Additionally, I have previously demonstrated that there is a higher KLF4 
activity score and mir-22 expression value in myeloid versus lymphoid cells. In 
line with this knowledge, I aim to delineate the network that is potentially 
regulated by both KLF4 and mir-22 in the context of monocyte/macrophage 
differentiation and in infiltrating myeloid cells in colorectal cancer. The findings 
will hopefully broaden our knowledge of tissue remodelling processes, motivate 
future work and enable us to propose further studies for targeting the network 
that may be regulated by both KLF4 and mir-22 in colorectal cancer. 
 
An earlier work by Tamura et al. established that interferon regulatory factor-8 
(IRF8), also known as interferon consensus sequence binding protein (ICSBP), 
directed the differentiation of myeloid progenitor cells into macrophages 
(Tamura et al. 2000). In the same study, they showed that IRF8 formed 
heterodimeric complexes with PU.1 (also known as SPI1) in the cells of the 
monocyte or macrophage lineage in mouse (Tamura et al. 2000). In a different 
study, Feinberg et al. reported that a suppression of KLF4 resulted in a 
significant decrease in PU.1 and differentiation markers of monocytes and Klf4 
gene was a downstream target of PU.1 (Feinberg et al. 2007). They also showed 
that KLF4 could induce the differentiation of monocytes into macrophages 
independently of PU.1 (Feinberg et al. 2007). Later on, Kurotaki et al. 
demonstrated that IRF8 functioned primarily as a transcriptional activator of 
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monocyte differentiation and IRF8 bound to distal H3K4me1 regions together 
with PU.1 (Kurotaki et al. 2013). They also elaborated that KLF4 acted 
downstream of IRF8 in inducing differentiation of monocytes/ macrophages and 
showed that IRF8 directly targeted Klf4 gene (Kurotaki et al. 2013). Li et al. 
then demonstrated that mir-22 enhanced development of cDC but inhibited 
generation of pDC and mir-22 negatively regulated Irf8 gene by repressing its 
transcription (Li et al. 2012). More recently, Shen et al. reported that PU.1 
transcriptionally regulated mir-22 and mir-22 was a regulator in 
monocyte/macrophage differentiation (Shen et al. 2016). Collectively, I propose 
a network regulated by IRF8, SPI1, KLF4 and mir-22 in the context of monocyte 
differentiation based on these regulations, as illustrated in Figure 6-1. 
 
 
Figure 6-1. A network potentially regulated by IRF8, SPI1, KLF4 and mir-22 in the 
context of monocyte/macrophage differentiation. Maroon arrows denote the 
interaction involves the transcription factors, whereas green lines denote the 
regulation happens at the gene transcription. 
 
Three out of the four nodes depicted in Figure 6-1 are identified as being 
associated with tissue remodelling in the previous chapters. In addition to the 
previously discussed KLF4 and mir-22, SPI1 was also identified as a TF whose 
activity score is positively correlated with tissue remodelling (Table 4-3). The 
next obvious question is whether the interactions between them are also 
supported by the genomics datasets characterising pure immune cell populations 
and the colorectal tumour samples. 
 
 111 
To interrogate the associations between the IRF8, SPI1 and KLF4 activity scores 
and mir-22 expression, I analyse gene expression profiles of isolated human 
immune cells (GSE28492). First, I infer TF activity scores of IRF8, SPI1 and KLF4 
using gene expression profiles in this dataset following the steps in section 4.2.2. 
Then I utilise mir-22 expression values from the samples in common between 
miRNA expression (obtained in section 5.2.4) and TF activity score matrices for 
correlating IRF8, KLF4, SPI1 and mir-22 in pairwise comparisons. To interrogate 
their associations in the context of colorectal tumour samples, I repeat the same 
analysis using the TCGACRC dataset to evaluate if this network is relevant in 
colorectal tumours. TF activity scores of IRF8, KLF4 and SPI1 are as obtained in 
section 4.2.2, while mir-22 expression is obtained from section 5.2.1. 
 
There is a significant and positive correlation between IRF8 and KLF4 activity 
scores in both immune cells and colorectal tumours (Table 6-1 and Table 6-2). 
The correlation between mir-22 expression value and IRF8 activity score is 
significant in GSE28492 dataset and it is positive in the TCGACRC dataset. The 
co-expression of the IRF8 activity score and the expression of its annotated 
negative regulator mir-22 suggests that there is a negative feedback loop, 
whereby mir-22 represses Irf8 gene to control the rate of IRF8 transcription. 
Future experimental work should interrogate whether this negative feedback is 
actually active in the context of myeloid cells infiltrating the colorectal tumour 
tissue. 
 
SPI1 activity score has no variance in the pure immune cells dataset, so I limit 
my analysis to the colorectal tumour samples dataset. There is a significant 
correlation between SPI1 and KLF4 activity scores (Table 6-2, S = 0.40, p-value = 
1×10-5, permutation test), while there is no significant correlation between IRF8 
and SPI1 in the colorectal tumour samples (Table 6-2, S = 0.12, p-value = 0.10, 
permutation test). The correlation between SPI1 activity score and mir-22  
expression value is very small and not significant (Table 6-2, S = 4.3×10-3, p-
value = 0.48, permutation test). To represent the signals observed in our data, I 
propose the putative network of infiltrating myeloid cells in colorectal tumours, 
as presented in Figure 6-2. The arrow between KLF4 and SPI1 in Figure 6-2 is to 
reflect the positive correlation of KLF4 and SPI1 transcriptional activity scores 
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and the fact that KLF4 can induce differentiation markers in PU.1-null myeloid 
cells to a similar level as the induction by PU.1 alone (Feinberg et al. 2007).  
 
Taken together, this evidence supports the association between IRF8 and KLF4 in 
the context of monocyte differentiation (Figure 6-1) and colorectal tumour 
samples (Figure 6-2). Furthermore, given that SPI1 and KLF4 activity scores are 
correlated but SPI1 and IRF8 activity score are not, this evidence suggests that 
SPI1 acts independently of IRF8. For mir-22, I find no evidence of its regulation 
by SPI1. I note that my analysis is not sufficient to pinpoint that mir-22 is 
regulated by SPI1. There could be other factors regulating mir-22 that are 
relevant and active in the colorectal tumour samples, for instance, in the stroma 
or tumour cells. 
 
 
Figure 6-2. A network potentially regulated by IRF8, SPI1, KLF4 and mir-22 in 
colorectal cancer. Maroon arrows denote the interaction involves the 
transcription factors, whereas green line denotes the suppression happens at the 
gene transcription. Dotted arrows reflect insignificant correlation between the 




Table 6-1. Correlation of IRF8 and KLF4 activity scores and mir-22 expression 
values in pairwise comparisons in human immune cell subsets (GSE28492)  
Cor						
P-value
	 IRF8	 KLF4	 mir-22	
IRF8	 		 3.7E-03	 1.6E-03	
KLF4	 0.31	 		 6.0E-05	





Table 6-2. Correlation of IRF8, KLF4 and SPI1 activity scores and mir-22 
expression values in pairwise comparisons in TCGACRC dataset 
Cor						
P-value
	 IRF8	 KLF4	 SPI1	 mir-22	
IRF8	 		 9.9E-04	 0.10	 0.07	
KLF4	 0.27	 		 1.0E-05	 1.2E-03	
SPI1	 0.12	 0.40	 		 0.48	







I have utilised a colorectal cancer case study. I have assessed the advantages 
and disadvantages of both unsupervised and supervised clustering approaches of 
patient classifications. Specifically, I have compared the performance of 
colorectal cancer patient stratification based on a recently reported 
unsupervised CMS clustering approach (ref. (Guinney et al. 2015)) versus a 
supervised clustering method using PR signatures (ref. (Markert et al. 2012)). 
Both classifications exhibit statistical significance in splitting overall and 
relapse-free survival curves. The CMS4 and P-/R+ subtypes yield worst prognosis 
as compared to the remaining subtypes in the unsupervised and supervised 
approaches, respectively. Yet, the unsupervised scheme cannot separate the 
remaining patients in the other three subtypes based on survival. In contrast, 
both cell proliferation and tissue remodelling in the supervised scheme predict 
clinical outcome. Our approach distinguishes P+/R- group that yields 
significantly better survival than P-/R- group. This observation shows that 
patient stratification based on the PR scheme highlights that cell proliferation is 
a relevant prognostic factor, in addition to tissue remodelling. They are both 
indicative of good and poor prognosis in colorectal cancer, respectively. 
 
At the moment, we have no clear explanation of why colorectal cancer patients 
with an up-regulation of cell proliferation signature have good prognosis. We 
speculate that the treatments received by these patients are designed to target 
proliferating cancer cells. Consequently, patients harbouring tumours with 
increased cell proliferation respond better to therapy. Another reasoning is 
because increased tissue remodelling is the characteristic of colorectal tumours 
causally linked to poor prognosis. As there is a negative correlation between cell 
proliferation and tissue remodelling, it gives rise to the association of cell 
proliferation with good prognosis. However, we should note that increased cell 
proliferation is an indicator of worse prognosis in other cancer types, such as 
breast (van Diest et al. 2004) and prostate cancer (Markert et al. 2011). As 
mentioned in the introduction, a previous work in our laboratory had elaborated 
the dichotomy of cell prognosis and tissue remodelling in patient outcome when 
considering different cancer types. In breast, brain, prostate and lung cancer, 
increased cell proliferation indicates poor prognosis. In contrast, increased 
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tissue remodelling is indicative of poor prognosis in colorectal and ovarian 
cancer. 
 
Subsequently, I study specific transcription factors that drive the transcriptional 
programmes of cell proliferation and tissue remodelling. Specifically, I aim to 
understand specific TFs that drive increased tissue remodelling, which is linked 
to poor prognosis in colorectal cancer. Among the TFs with activity score that is 
significantly associated with the tissue remodelling enrichment score, I choose 
KLF4 for a further study on the tissue remodelling transcriptional programme. I 
focus on KLF4 because it has been reported to be a regulator of myelopoiesis 
(Feinberg et al. 2007) and one of the reprogramming factors required in induced 
pluripotent stem cells (Okita et al. 2007). Both features can potentially 
contribute to poor clinical outcome and malignancy linked with tissue 
remodelling. Using an immune cell dataset, I have validated that KLF4 activity 
score is significantly higher in myeloid as compared to lymphoid cells, which 
agrees with its documented role in myelopoiesis (Feinberg et al. 2007). 
Additionally, I observe that KLF4 activity score is positively correlated with 
predicted infiltration of myeloid cells in colorectal tumours. Collectively, these 
findings suggest that myeloid cell infiltration gives rise to tissue remodelling 
processes in colorectal cancer and KLF4 sustains myelopoiesis in these 
infiltrating immune cells.  
 
When assessing the enrichment of KLF4 activity score with the biomarkers, I do 
not observe a significant correlation between the level of KLF4 activity and KRAS 
mutation although KRAS is highly mutated in colorectal cancer. An explanation 
for this observation is because KRAS mutations occur in an early stage of tumour 
initiation (Grady and Pritchard 2014) (Rajagopalan et al. 2002), whereas the 
samples in our data are already in the carcinoma stage. On the other hand, 
SMAD4 deletion occurs when the tumour progresses from adenoma into 
carcinoma (Takaku et al. 1998) and PIK3CA mutation is generally observed late 
in tumourigenesis (Samuels et al. 2004). If the information on SMAD4 deletion 
and PIK3CA mutation is available, it will be interesting to assess if the level of 
KLF4 activity is significantly correlated with these biomarkers. 
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I have uncovered specific microRNAs that regulate the cell proliferation and 
tissue remodelling programmes in the next part of my work. Among the miRNAs 
whose expression value is significantly correlated with tissue remodelling 
enrichment score, I select mir-22 for a further study. This is because mir-22 has 
been shown to be promoting differentiation of monocytes into macrophages 
(Shen et al. 2016). This leads me to hypothesise that there may be a network 
regulated by both KLF4 and mir-22 in monocyte differentiation. Using a different 
immune cell dataset, I have demonstrated that there is also a significantly 
higher mir-22 expression in myeloid versus lymphoid cells. However, I establish 
that mir-22 expression level does not predict the extent of the predicted 
infiltration from any immune cells in colorectal tumours. The results suggest 
that mir-22 signalling may also be present in other tumour compartments.  
 
My findings are consistent with the literature, whereby mir-22 has been reported 
to attenuate EMT and colon cancer metastasis by targeting T-cell lymphoma 
invasion and metastasis 1 (TIAM1) (Li et al. 2013). This further confirms the 
significant correlation between mir-22 expression and our tissue remodelling 
signature. Mir-22 has also been documented to regulate various cellular 
processes in cancer by accelerating senescence, inhibiting energy supply, 
blocking angiogenesis and promoting apoptosis in some cancer types (Wang et al. 
2017). Furthermore, mir-22 exhibits dual effects in various cancer types by 
inhibiting proliferation, invasion and metastasis in some cancer types but 
promoting proliferation, migration and invasion in other cancer types (Wang et 
al. 2017). Collectively, these reports demonstrate that mir-22 play various roles 
in cancer, in agreement with my observation that mir-22 is less correlated with 
the myeloid cells and its signalling may be present in the tumour stroma. Future 
work should investigate the role of mir-22 in colorectal cancer, particularly to 
uncover its role in regulating various cellular processes in colorectal cancer. 
 
In the last part of my work, I propose a network that may be regulated by IRF8, 
SPI1, KLF4 and mir-22 in the context of monocyte differentiation then assess its 
relevance in colorectal cancer dataset. KLF4 has been reported to act 
downstream of IRF8 in monocyte/macrophage differentiation (Kurotaki et al. 
2013), while IRF8 directs this differentiation (Tamura et al. 2000) and targets 
Klf4 gene (Kurotaki et al. 2013). IRF8 has been demonstrated to form 
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heterodimeric complexes with SPI1 in the monocyte or macrophage lineage 
(Tamura et al. 2000). Additionally, SPI1 has been shown to transcriptionally 
regulate mir-22, which regulates monocyte/macrophage differentiation (Shen et 
al. 2016) and suppresses Irf8 gene (Li et al. 2012). In the correlation analysis of 
IRF8, KLF4, SPI1 and mir-22, I have shown that IRF8 is positively correlated with 
KLF4, which agrees with their reported function in monocyte differentiation 
(Kurotaki et al. 2013). On the other hand, there is a positive correlation 
between IRF8 and mir-22, indicating a negative feedback loop between them. 
The significant and positive correlation between mir-22 and KLF4 supports my 
findings that both mir-22 and KLF4 are indeed in part associated with tissue 
remodelling processes. My results also demonstrate there is no regulation of mir-
22 by SPI1 but SPI1 has a positive correlation with IRF8 and a significant and 
positive correlation with KLF4. These suggest that SPI1 may not be involved in 
regulating myeloid cells beyond their maturation and as shown in a previous 
report, its primary role is in the regulation of myeloid and lymphoid lineage 
commitment (Scott et al. 1994). Future work should be carried out to establish if 
SPI1 regulates KLF4 in colorectal tumours with infiltrating myeloid cells or the 
regulation happens only in differentiating monocytes. 
 
Having identified these specific regulators driving tissue remodelling, there is a 
need to conduct further studies to understand the molecular pathways and 
specific factors driving the enrichment of myeloid cell infiltration in colorectal 
cancer. These studies will help identify therapies for colorectal cancer patients 
exhibiting poor prognosis, characterised by increased tissue remodelling. TGFβ 
drives tissue remodelling and plays an important role in the tumour 
microenvironment (Pickup et al. 2013). The role of TGFβ signalling in the 
exclusion of T cells has also been reported in genetically engineered colorectal 
cancer metastasis (Tauriello et al. 2018). Yet, it is not known how T cell 
exclusion affects myeloid cell abundance in colorectal tumours characterised by 
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Master list of TFs in CRCSC cohort together the correlation scores of their 
activity scores with PR signatures and enrichment scores of target genes with PR 
signatures 
 
TF	 S(TF,P)	 P-value	 BH	 S(TF,R)	 P-value	 BH	 ES_P	 P-value	 BH	 ES_R	 P-value	 BH	
LHX3	 -0.33	 1.0E-05	 Y	 0.74	 1.0E-05	 Y	 0	 0.50	 N	 0	 0.50	 N	
NFYB	 -0.24	 1.0E-05	 Y	 0.74	 1.0E-05	 Y	 0	 0.50	 N	 0	 0.50	 N	
RBL2	 -0.30	 1.0E-05	 Y	 0.70	 1.0E-05	 Y	 0	 0.50	 N	 0	 0.50	 N	
MAFF	 -0.23	 1.0E-05	 Y	 0.67	 1.0E-05	 Y	 0	 0.50	 N	 0	 0.50	 N	
SATB2	 -0.32	 1.0E-05	 Y	 0.67	 1.0E-05	 Y	 0	 0.50	 N	 0	 0.50	 N	
MAZ	 -0.37	 1.0E-05	 Y	 0.65	 1.0E-05	 Y	 0	 0.50	 N	 0	 0.50	 N	
MBD1	 -0.26	 1.0E-05	 Y	 0.64	 1.0E-05	 Y	 0	 0.50	 N	 0	 0.50	 N	
SREBF1	 -0.72	 1.0E-05	 Y	 0.64	 1.0E-05	 Y	 -0.03	 0.22	 N	 0	 0.50	 N	
RARG	 -0.11	 3.0E-03	 Y	 0.63	 1.0E-05	 Y	 0	 0.50	 N	 0	 0.50	 N	
ETV4	 -0.41	 1.0E-05	 Y	 0.62	 1.0E-05	 Y	 0	 0.50	 N	 0.66	 1.0E-05	 Y	
CTCFL	 0.02	 0.34	 N	 0.61	 1.0E-05	 Y	 0	 0.50	 N	 0	 0.50	 N	
PML	 -0.07	 0.06	 N	 0.61	 1.0E-05	 Y	 0	 0.50	 N	 0.30	 1.0E-05	 Y	
EHMT2	 -0.25	 1.0E-05	 Y	 0.61	 1.0E-05	 Y	 0	 0.50	 N	 0	 0.50	 N	
DDB2	 -0.09	 0.01	 Y	 0.61	 1.0E-05	 Y	 0	 0.50	 N	 0	 0.50	 N	
KLF4	 -0.09	 0.02	 Y	 0.59	 1.0E-05	 Y	 -0.29	 1.0E-05	 Y	 0.18	 1.0E-05	 Y	
ENO1	 -0.03	 0.22	 N	 0.59	 1.0E-05	 Y	 0	 0.50	 N	 0	 0.50	 N	
HDAC9	 -0.36	 1.0E-05	 Y	 0.59	 1.0E-05	 Y	 -0.29	 1.0E-05	 Y	 0	 0.50	 N	
TBP	 -0.41	 1.0E-05	 Y	 0.56	 1.0E-05	 Y	 0	 0.50	 N	 0	 0.50	 N	
MEN1	 -0.29	 1.0E-05	 Y	 0.55	 1.0E-05	 Y	 0	 0.50	 N	 0	 0.50	 N	
HIPK2	 -0.04	 0.18	 N	 0.55	 1.0E-05	 Y	 0	 0.50	 N	 0	 0.50	 N	
ESRRG	 -0.09	 0.02	 Y	 0.53	 1.0E-05	 Y	 0	 0.50	 N	 0	 0.50	 N	
AHR	 -0.09	 0.01	 Y	 0.53	 1.0E-05	 Y	 0	 0.50	 N	 0	 0.50	 N	
KLF5	 -0.21	 1.0E-05	 Y	 0.52	 1.0E-05	 Y	 0.80	 1.0E-05	 Y	 0.65	 1.0E-05	 Y	
CDX1	 -0.22	 1.0E-05	 Y	 0.51	 1.0E-05	 Y	 0	 0.50	 N	 0	 0.50	 N	
HEY2	 -0.46	 1.0E-05	 Y	 0.51	 1.0E-05	 Y	 0	 0.50	 N	 0	 0.50	 N	
HOXB13	 -0.06	 0.07	 N	 0.50	 1.0E-05	 Y	 0	 0.50	 N	 0	 0.50	 N	
HDAC1	 -0.29	 1.0E-05	 Y	 0.50	 1.0E-05	 Y	 -0.40	 1.0E-05	 Y	 -0.05	 0.12	 N	
SOX10	 -0.16	 6.0E-05	 Y	 0.49	 1.0E-05	 Y	 0	 0.50	 N	 0	 0.50	 N	
TRIB3	 -0.34	 1.0E-05	 Y	 0.49	 1.0E-05	 Y	 0	 0.50	 N	 0	 0.50	 N	
FOXO3	 -0.29	 1.0E-05	 Y	 0.48	 1.0E-05	 Y	 0	 0.50	 N	 0.27	 1.0E-05	 Y	
ARNT	 -0.19	 1.0E-05	 Y	 0.48	 1.0E-05	 Y	 0	 0.50	 N	 0	 0.50	 N	
PTTG1	 -0.26	 1.0E-05	 Y	 0.47	 1.0E-05	 Y	 0.23	 1.0E-05	 Y	 0.50	 1.0E-05	 Y	
CRTC1	 -0.42	 1.0E-05	 Y	 0.46	 1.0E-05	 Y	 0	 0.50	 N	 0	 0.50	 N	
NANOG	 -3.6E-
03	
0.47	 N	 0.46	 1.0E-05	 Y	 0.04	 0.18	 N	 0	 0.50	 N	
BTG2	 0.14	 3.8E-04	 Y	 0.44	 1.0E-05	 Y	 0	 0.50	 N	 0	 0.50	 N	
HNF4G	 -0.48	 1.0E-05	 Y	 0.44	 1.0E-05	 Y	 0	 0.50	 N	 0	 0.50	 N	
TCF19	 -0.68	 1.0E-05	 Y	 0.44	 1.0E-05	 Y	 0	 0.50	 N	 0	 0.50	 N	
E2F6	 -0.75	 1.0E-05	 Y	 0.43	 1.0E-05	 Y	 0	 0.50	 N	 0	 0.50	 N	
GCM2	 -0.17	 5.0E-05	 Y	 0.43	 1.0E-05	 Y	 0	 0.50	 N	 0	 0.50	 N	
MCM4	 -0.32	 1.0E-05	 Y	 0.43	 1.0E-05	 Y	 0	 0.50	 N	 0	 0.50	 N	
KAT6A	 -0.47	 1.0E-05	 Y	 0.43	 1.0E-05	 Y	 0	 0.50	 N	 0	 0.50	 N	
SPEN	 0.04	 0.17	 N	 0.43	 1.0E-05	 Y	 0	 0.50	 N	 0	 0.50	 N	
NCOA2	 -0.24	 1.0E-05	 Y	 0.42	 1.0E-05	 Y	 0	 0.50	 N	 0	 0.50	 N	
SPI1	 -0.03	 0.21	 N	 0.42	 1.0E-05	 Y	 0	 0.50	 N	 0.51	 1.0E-05	 Y	
GFI1	 -0.39	 1.0E-05	 Y	 0.42	 1.0E-05	 Y	 0	 0.50	 N	 0	 0.50	 N	
E2F1	 -0.81	 1.0E-05	 Y	 0.42	 1.0E-05	 Y	 0.55	 1.0E-05	 Y	 0.07	 0.05	 N	
CRABP2	 -0.43	 1.0E-05	 Y	 0.42	 1.0E-05	 Y	 0	 0.50	 N	 0	 0.50	 N	
EGR3	 -0.18	 1.0E-05	 Y	 0.41	 1.0E-05	 Y	 0	 0.50	 N	 0	 0.50	 N	
FOXL1	 -0.26	 1.0E-05	 Y	 0.41	 1.0E-05	 Y	 0	 0.50	 N	 0	 0.50	 N	
SNAI2	 -0.09	 0.02	 Y	 0.41	 1.0E-05	 Y	 -0.37	 1.0E-05	 Y	 0.54	 1.0E-05	 Y	
	 	 	 	 	 	 	 	 	 	 	 	 	SKI	 -0.14	 4.2E-04	 Y	 0.40	 1.0E-05	 Y	 0	 0.50	 N	 0	 0.50	 N	
ESRRA	 -0.37	 1.0E-05	 Y	 0.40	 1.0E-05	 Y	 0	 0.50	 N	 0	 0.50	 N	
SHOX	 0.09	 0.01	 Y	 0.40	 1.0E-05	 Y	 0	 0.50	 N	 0	 0.50	 N	
NFIL3	 -0.15	 1.8E-04	 Y	 0.40	 1.0E-05	 Y	 0	 0.50	 N	 0	 0.50	 N	
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DNMT1	 -0.45	 1.0E-05	 Y	 0.40	 1.0E-05	 Y	 0.03	 0.26	 N	 0	 0.50	 N	
LMO4	 -0.34	 1.0E-05	 Y	 0.40	 1.0E-05	 Y	 0	 0.50	 N	 0	 0.50	 N	
MCM2	 -0.60	 1.0E-05	 Y	 0.40	 1.0E-05	 Y	 0	 0.50	 N	 0	 0.50	 N	
DACH1	 -0.23	 1.0E-05	 Y	 0.40	 1.0E-05	 Y	 0	 0.50	 N	 0	 0.50	 N	
EPAS1	 -0.20	 1.0E-05	 Y	 0.39	 1.0E-05	 Y	 0	 0.50	 N	 0	 0.50	 N	
ATF5	 -0.12	 1.6E-03	 Y	 0.39	 1.0E-05	 Y	 0	 0.50	 N	 0	 0.50	 N	
SPIB	 -0.21	 1.0E-05	 Y	 0.39	 1.0E-05	 Y	 0	 0.50	 N	 0	 0.50	 N	
FOXL2	 -0.21	 1.0E-05	 Y	 0.38	 1.0E-05	 Y	 0	 0.50	 N	 0	 0.50	 N	
SMAD3	 -0.37	 1.0E-05	 Y	 0.37	 1.0E-05	 Y	 0	 0.50	 N	 0	 0.50	 N	
NOTCH3	 -0.17	 5.0E-05	 Y	 0.37	 1.0E-05	 Y	 0	 0.50	 N	 0	 0.50	 N	
MDM4	 -0.11	 3.3E-03	 Y	 0.37	 1.0E-05	 Y	 0	 0.50	 N	 0	 0.50	 N	
NR3C1	 -0.10	 8.4E-03	 Y	 0.37	 1.0E-05	 Y	 0.26	 1.0E-05	 Y	 0.23	 1.0E-05	 Y	
RBPJ	 0.09	 0.01	 Y	 0.37	 1.0E-05	 Y	 0	 0.50	 N	 0	 0.50	 N	
FOSL1	 0.02	 0.31	 N	 0.37	 1.0E-05	 Y	 0	 0.50	 N	 0	 0.50	 N	
TP73	 -0.64	 1.0E-05	 Y	 0.36	 1.0E-05	 Y	 0	 0.50	 N	 0	 0.50	 N	
STAT1	 -0.06	 0.07	 N	 0.36	 1.0E-05	 Y	 -0.36	 1.0E-05	 Y	 0.55	 1.0E-05	 Y	
HEY1	 -0.12	 2.4E-03	 Y	 0.35	 1.0E-05	 Y	 0	 0.50	 N	 0	 0.50	 N	
PURA	 -0.15	 1.8E-04	 Y	 0.35	 1.0E-05	 Y	 0	 0.50	 N	 0	 0.50	 N	
TEF	 -0.36	 1.0E-05	 Y	 0.35	 1.0E-05	 Y	 0	 0.50	 N	 0	 0.50	 N	
HSF4	 -0.11	 4.5E-03	 Y	 0.33	 1.0E-05	 Y	 0	 0.50	 N	 0	 0.50	 N	
TP63	 -0.26	 1.0E-05	 Y	 0.33	 1.0E-05	 Y	 0	 0.50	 N	 0	 0.50	 N	
GATA3	 -0.03	 0.24	 N	 0.32	 1.0E-05	 Y	 -0.21	 1.0E-05	 Y	 0.48	 1.0E-05	 Y	
CEBPZ	 -0.25	 1.0E-05	 Y	 0.32	 1.0E-05	 Y	 0	 0.50	 N	 0	 0.50	 N	
HOXC9	 -0.09	 0.01	 Y	 0.32	 1.0E-05	 Y	 0	 0.50	 N	 0	 0.50	 N	
TBX3	 -0.15	 2.1E-04	 Y	 0.32	 1.0E-05	 Y	 0	 0.50	 N	 0	 0.50	 N	
NFE2L2	 -0.06	 0.09	 N	 0.32	 1.0E-05	 Y	 0	 0.50	 N	 0.24	 1.0E-05	 Y	
ONECUT1	 -0.14	 4.7E-04	 Y	 0.31	 1.0E-05	 Y	 0	 0.50	 N	 0	 0.50	 N	
ARNTL2	 -0.07	 0.04	 Y	 0.31	 1.0E-05	 Y	 0	 0.50	 N	 0	 0.50	 N	




NFRKB	 -0.17	 2.0E-05	 Y	 0.31	 1.0E-05	 Y	 0	 0.50	 N	 0	 0.50	 N	
TAF1	 0.12	 1.4E-03	 Y	 0.31	 1.0E-05	 Y	 0	 0.50	 N	 0	 0.50	 N	
PKNOX1	 -0.29	 1.0E-05	 Y	 0.31	 1.0E-05	 Y	 0	 0.50	 N	 0	 0.50	 N	
SOX11	 -0.44	 1.0E-05	 Y	 0.31	 1.0E-05	 Y	 0	 0.50	 N	 0	 0.50	 N	
MYF6	 -0.30	 1.0E-05	 Y	 0.31	 1.0E-05	 Y	 0	 0.50	 N	 0	 0.50	 N	
PIAS4	 -0.13	 9.4E-04	 Y	 0.31	 1.0E-05	 Y	 0	 0.50	 N	 0	 0.50	 N	
TP53BP1	 -0.19	 1.0E-05	 Y	 0.30	 1.0E-05	 Y	 0	 0.50	 N	 0	 0.50	 N	
THRB	 -0.35	 1.0E-05	 Y	 0.30	 1.0E-05	 Y	 0	 0.50	 N	 0	 0.50	 N	
MECP2	 0.11	 3.8E-03	 Y	 0.30	 1.0E-05	 Y	 0	 0.50	 N	 0	 0.50	 N	
PLAG1	 -0.33	 1.0E-05	 Y	 0.30	 1.0E-05	 Y	 0	 0.50	 N	 0	 0.50	 N	
SIM2	 0.02	 0.28	 N	 0.30	 1.0E-05	 Y	 0	 0.50	 N	 0	 0.50	 N	
MYF5	 -0.12	 1.9E-03	 Y	 0.30	 1.0E-05	 Y	 0	 0.50	 N	 0	 0.50	 N	
RELA	 -0.11	 3.1E-03	 Y	 0.29	 1.0E-05	 Y	 -9.5E-
03	
0.41	 N	 0.43	 1.0E-05	 Y	
NFE2L1	 -0.06	 0.08	 N	 0.29	 1.0E-05	 Y	 0	 0.50	 N	 0	 0.50	 N	
KDM2A	 -0.27	 1.0E-05	 Y	 0.29	 1.0E-05	 Y	 0	 0.50	 N	 0	 0.50	 N	
RREB1	 -0.21	 1.0E-05	 Y	 0.29	 1.0E-05	 Y	 0	 0.50	 N	 0	 0.50	 N	
SIRT1	 0.13	 1.3E-03	 Y	 0.29	 1.0E-05	 Y	 -0.08	 0.02	 Y	 -0.15	 1.2E-04	 Y	
MLXIPL	 0.04	 0.17	 N	 0.29	 1.0E-05	 Y	 0	 0.50	 N	 0	 0.50	 N	
NCOA1	 -0.20	 1.0E-05	 Y	 0.29	 1.0E-05	 Y	 0	 0.50	 N	 0	 0.50	 N	
RELB	 -0.25	 1.0E-05	 Y	 0.29	 1.0E-05	 Y	 0	 0.50	 N	 0	 0.50	 N	
BCL11B	 0.02	 0.31	 N	 0.28	 1.0E-05	 Y	 0	 0.50	 N	 0	 0.50	 N	
FUS	 -0.13	 9.6E-04	 Y	 0.28	 1.0E-05	 Y	 0	 0.50	 N	 0	 0.50	 N	
SKIL	 -0.20	 1.0E-05	 Y	 0.28	 1.0E-05	 Y	 0	 0.50	 N	 0	 0.50	 N	
MTA1	 -0.12	 2.7E-03	 Y	 0.28	 1.0E-05	 Y	 0	 0.50	 N	 0	 0.50	 N	
NFIC	 -0.23	 1.0E-05	 Y	 0.28	 1.0E-05	 Y	 0	 0.50	 N	 0	 0.50	 N	
APEX1	 -0.10	 9.8E-03	 Y	 0.28	 1.0E-05	 Y	 0	 0.50	 N	 0	 0.50	 N	
POU1F1	 -0.19	 1.0E-05	 Y	 0.27	 1.0E-05	 Y	 0	 0.50	 N	 0	 0.50	 N	
ETS2	 -0.22	 1.0E-05	 Y	 0.27	 1.0E-05	 Y	 0	 0.50	 N	 0.76	 1.0E-05	 Y	
SMARCA4	 -0.30	 1.0E-05	 Y	 0.27	 1.0E-05	 Y	 0	 0.50	 N	 0	 0.50	 N	
MED23	 -0.15	 1.2E-04	 Y	 0.27	 1.0E-05	 Y	 0	 0.50	 N	 0	 0.50	 N	
RFX1	 -0.18	 1.0E-05	 Y	 0.27	 1.0E-05	 Y	 0	 0.50	 N	 0	 0.50	 N	
TOB1	 -0.05	 0.10	 N	 0.27	 1.0E-05	 Y	 0	 0.50	 N	 0	 0.50	 N	
HDAC5	 0.12	 2.2E-03	 Y	 0.26	 1.0E-05	 Y	 0	 0.50	 N	 0	 0.50	 N	
HCFC1	 0.05	 0.11	 N	 0.26	 1.0E-05	 Y	 0	 0.50	 N	 0	 0.50	 N	
ANKRD1	 0.18	 1.0E-05	 Y	 0.26	 1.0E-05	 Y	 0	 0.50	 N	 0	 0.50	 N	
TBX21	 -0.12	 2.0E-03	 Y	 0.26	 1.0E-05	 Y	 0	 0.50	 N	 0	 0.50	 N	
TF master list in CRCSC cohort 129 
LHX2	 -0.32	 1.0E-05	 Y	 0.26	 1.0E-05	 Y	 0	 0.50	 N	 0	 0.50	 N	
SMAD4	 -0.30	 1.0E-05	 Y	 0.26	 1.0E-05	 Y	 0	 0.50	 N	 0	 0.50	 N	
ERG	 -0.03	 0.24	 N	 0.26	 1.0E-05	 Y	 0	 0.50	 N	 0.90	 1.0E-05	 Y	
ELF4	 0.04	 0.18	 N	 0.26	 1.0E-05	 Y	 0	 0.50	 N	 0	 0.50	 N	
CREB1	 -0.32	 1.0E-05	 Y	 0.25	 1.0E-05	 Y	 0.08	 0.03	 N	 0.55	 1.0E-05	 Y	
IRF8	 0.23	 1.0E-05	 Y	 0.25	 1.0E-05	 Y	 0	 0.50	 N	 0	 0.50	 N	
RBMX	 0.13	 6.0E-04	 Y	 0.25	 1.0E-05	 Y	 -0.22	 1.0E-05	 Y	 0	 0.50	 N	
KLF12	 -0.21	 1.0E-05	 Y	 0.25	 1.0E-05	 Y	 0	 0.50	 N	 0	 0.50	 N	
ING4	 -0.24	 1.0E-05	 Y	 0.25	 1.0E-05	 Y	 -0.16	 7.0E-05	 Y	 0	 0.50	 N	
PRDM1	 0.24	 1.0E-05	 Y	 0.25	 1.0E-05	 Y	 0	 0.50	 N	 0	 0.50	 N	
NCOR2	 0.09	 0.01	 Y	 0.24	 1.0E-05	 Y	 0	 0.50	 N	 0	 0.50	 N	
NCOA4	 0.16	 5.0E-05	 Y	 0.24	 1.0E-05	 Y	 0	 0.50	 N	 0	 0.50	 N	
FOXN1	 -0.15	 1.3E-04	 Y	 0.24	 1.0E-05	 Y	 0	 0.50	 N	 0	 0.50	 N	
ARID3A	 -0.02	 0.32	 N	 0.23	 1.0E-05	 Y	 0	 0.50	 N	 0	 0.50	 N	
TEAD1	 -0.32	 1.0E-05	 Y	 0.23	 1.0E-05	 Y	 0	 0.50	 N	 0	 0.50	 N	
NR2C2	 0.04	 0.19	 N	 0.23	 1.0E-05	 Y	 0	 0.50	 N	 0	 0.50	 N	
LHX4	 -0.25	 1.0E-05	 Y	 0.23	 1.0E-05	 Y	 0	 0.50	 N	 0	 0.50	 N	
NAB2	 -0.10	 0.01	 Y	 0.23	 1.0E-05	 Y	 0	 0.50	 N	 0	 0.50	 N	
PPARD	 -0.14	 4.9E-04	 Y	 0.23	 1.0E-05	 Y	 0	 0.50	 N	 0.62	 1.0E-05	 Y	
SP1	 -0.02	 0.35	 N	 0.22	 1.0E-05	 Y	 0.27	 1.0E-05	 Y	 0.39	 1.0E-05	 Y	
HDAC11	 -0.01	 0.43	 N	 0.22	 1.0E-05	 Y	 0	 0.50	 N	 0	 0.50	 N	
PBX2	 -0.15	 1.3E-04	 Y	 0.22	 1.0E-05	 Y	 0	 0.50	 N	 0	 0.50	 N	
PDX1	 -0.01	 0.39	 N	 0.22	 1.0E-05	 Y	 0	 0.50	 N	 0	 0.50	 N	
ETV2	 -0.31	 1.0E-05	 Y	 0.22	 1.0E-05	 Y	 0	 0.50	 N	 0	 0.50	 N	
ILF2	 0.03	 0.22	 N	 0.22	 1.0E-05	 Y	 0	 0.50	 N	 0	 0.50	 N	
IFI16	 0.16	 2.0E-05	 Y	 0.22	 1.0E-05	 Y	 0	 0.50	 N	 0	 0.50	 N	
LRRFIP1	 -0.17	 4.0E-05	 Y	 0.22	 1.0E-05	 Y	 0	 0.50	 N	 0	 0.50	 N	
E2F3	 -0.27	 1.0E-05	 Y	 0.21	 1.0E-05	 Y	 0	 0.50	 N	 0	 0.50	 N	
APBB1	 -0.43	 1.0E-05	 Y	 0.21	 1.0E-05	 Y	 0	 0.50	 N	 0	 0.50	 N	
MEF2A	 0.07	 0.04	 N	 0.21	 1.0E-05	 Y	 0	 0.50	 N	 0	 0.50	 N	
EN1	 -0.25	 1.0E-05	 Y	 0.21	 1.0E-05	 Y	 0	 0.50	 N	 0	 0.50	 N	
DDIT3	 -0.04	 0.16	 N	 0.21	 1.0E-05	 Y	 0	 0.50	 N	 0	 0.50	 N	
NFIB	 0.15	 8.0E-05	 Y	 0.21	 1.0E-05	 Y	 0	 0.50	 N	 0	 0.50	 N	
NR5A2	 -0.33	 1.0E-05	 Y	 0.21	 1.0E-05	 Y	 0	 0.50	 N	 0.29	 1.0E-05	 Y	
ELF1	 0.21	 1.0E-05	 Y	 0.21	 1.0E-05	 Y	 0	 0.50	 N	 0	 0.50	 N	
LDB1	 -0.25	 1.0E-05	 Y	 0.21	 1.0E-05	 Y	 0	 0.50	 N	 0	 0.50	 N	
TLX1	 0.12	 2.4E-03	 Y	 0.21	 1.0E-05	 Y	 0	 0.50	 N	 0	 0.50	 N	
E4F1	 -0.02	 0.28	 N	 0.20	 1.0E-05	 Y	 0	 0.50	 N	 0	 0.50	 N	
PAX3	 -0.22	 1.0E-05	 Y	 0.20	 1.0E-05	 Y	 0	 0.50	 N	 0	 0.50	 N	
HHEX	 -0.11	 3.1E-03	 Y	 0.20	 1.0E-05	 Y	 0	 0.50	 N	 0	 0.50	 N	
SP2	 -0.16	 6.0E-05	 Y	 0.19	 1.0E-05	 Y	 0	 0.50	 N	 0	 0.50	 N	
E2F7	 -0.31	 1.0E-05	 Y	 0.19	 1.0E-05	 Y	 0	 0.50	 N	 0	 0.50	 N	
EIF2AK2	 0.18	 1.0E-05	 Y	 0.19	 1.0E-05	 Y	 0	 0.50	 N	 0	 0.50	 N	
TFAP2B	 -0.05	 0.14	 N	 0.19	 1.0E-05	 Y	 0	 0.50	 N	 0	 0.50	 N	
KLF8	 -0.28	 1.0E-05	 Y	 0.19	 1.0E-05	 Y	 0	 0.50	 N	 0	 0.50	 N	
FOXF1	 -0.27	 1.0E-05	 Y	 0.19	 1.0E-05	 Y	 0	 0.50	 N	 0	 0.50	 N	
ATF2	 0.25	 1.0E-05	 Y	 0.19	 1.0E-05	 Y	 0	 0.50	 N	 0.73	 1.0E-05	 Y	
HIC1	 0.18	 1.0E-05	 Y	 0.18	 1.0E-05	 Y	 0	 0.50	 N	 0	 0.50	 N	
ARID1B	 -0.22	 1.0E-05	 Y	 0.17	 1.0E-05	 Y	 0	 0.50	 N	 0	 0.50	 N	
PHOX2A	 0.10	 6.3E-03	 Y	 0.17	 1.0E-05	 Y	 0	 0.50	 N	 0	 0.50	 N	
PARP1	 0.04	 0.15	 N	 0.17	 1.0E-05	 Y	 -0.44	 1.0E-05	 Y	 0	 0.50	 N	
TCF4	 -0.35	 1.0E-05	 Y	 0.17	 2.0E-05	 Y	 0.38	 1.0E-05	 Y	 0	 0.50	 N	
TAF4	 -0.03	 0.26	 N	 0.17	 2.0E-05	 Y	 0	 0.50	 N	 0	 0.50	 N	
CLOCK	 -0.26	 1.0E-05	 Y	 0.17	 2.0E-05	 Y	 0	 0.50	 N	 0.39	 1.0E-05	 Y	
NRF1	 -0.04	 0.17	 N	 0.16	 2.0E-05	 Y	 0	 0.50	 N	 0	 0.50	 N	
NR1H2	 -0.15	 2.1E-04	 Y	 0.16	 4.0E-05	 Y	 0	 0.50	 N	 0	 0.50	 N	
TCF7L2	 -0.29	 1.0E-05	 Y	 0.16	 4.0E-05	 Y	 0	 0.50	 N	 0	 0.50	 N	
NPM1	 -0.14	 3.3E-04	 Y	 0.16	 4.0E-05	 Y	 0	 0.50	 N	 0	 0.50	 N	
HOXA5	 -0.10	 8.1E-03	 Y	 0.16	 5.0E-05	 Y	 0	 0.50	 N	 0	 0.50	 N	
MSX2	 0.12	 2.4E-03	 Y	 0.16	 5.0E-05	 Y	 0	 0.50	 N	 0	 0.50	 N	
GATA4	 -0.13	 9.3E-04	 Y	 0.16	 5.0E-05	 Y	 -0.15	 1.3E-04	 Y	 0	 0.50	 N	
JUN	 -0.20	 1.0E-05	 Y	 0.15	 8.0E-05	 Y	 -0.20	 1.0E-05	 Y	 0.47	 1.0E-05	 Y	
ERCC2	 0.05	 0.11	 N	 0.15	 1.2E-04	 Y	 0	 0.50	 N	 0	 0.50	 N	
REST	 -0.13	 8.1E-04	 Y	 0.15	 1.3E-04	 Y	 -0.59	 1.0E-05	 Y	 -0.06	 0.06	 N	
TFDP1	 0.19	 1.0E-05	 Y	 0.15	 2.1E-04	 Y	 0.95	 1.0E-05	 Y	 0	 0.50	 N	
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ETV5	 0.15	 2.1E-04	 Y	 0.15	 2.1E-04	 Y	 0	 0.50	 N	 0	 0.50	 N	
DLX3	 -0.06	 0.09	 N	 0.14	 2.4E-04	 Y	 0	 0.50	 N	 0	 0.50	 N	
EAPP	 0.21	 1.0E-05	 Y	 0.14	 2.5E-04	 Y	 0	 0.50	 N	 0	 0.50	 N	
HIRA	 -6.1E-
04	
0.50	 N	 0.14	 2.7E-04	 Y	 0	 0.50	 N	 0	 0.50	 N	
ESR1	 -0.40	 1.0E-05	 Y	 0.14	 3.0E-04	 Y	 0.04	 0.16	 N	 0.34	 1.0E-05	 Y	
PRDM14	 0.21	 1.0E-05	 Y	 0.14	 4.0E-04	 Y	 0	 0.50	 N	 0	 0.50	 N	
NR2F2	 0.01	 0.40	 N	 0.14	 4.0E-04	 Y	 0	 0.50	 N	 0	 0.50	 N	
FOXP2	 -0.37	 1.0E-05	 Y	 0.13	 6.2E-04	 Y	 0	 0.50	 N	 0	 0.50	 N	
AES	 0.06	 0.09	 N	 0.13	 6.4E-04	 Y	 0	 0.50	 N	 0	 0.50	 N	
KLF3	 0.15	 1.2E-04	 Y	 0.13	 6.7E-04	 Y	 0	 0.50	 N	 0	 0.50	 N	
MYOD1	 -0.07	 0.06	 N	 0.13	 1.2E-03	 Y	 0	 0.50	 N	 0	 0.50	 N	
IRF9	 -0.19	 1.0E-05	 Y	 0.13	 1.2E-03	 Y	 0	 0.50	 N	 0	 0.50	 N	
GBX2	 -0.11	 3.5E-03	 Y	 0.12	 1.6E-03	 Y	 0	 0.50	 N	 0	 0.50	 N	
CEBPB	 -0.02	 0.29	 N	 0.12	 1.9E-03	 Y	 -0.08	 0.02	 Y	 0.44	 1.0E-05	 Y	
BCL3	 -0.11	 4.7E-03	 Y	 0.12	 2.1E-03	 Y	 0	 0.50	 N	 0	 0.50	 N	
CRX	 0.01	 0.42	 N	 0.12	 2.1E-03	 Y	 0	 0.50	 N	 0	 0.50	 N	
FOXO1	 -0.13	 7.9E-04	 Y	 0.12	 2.7E-03	 Y	 0	 0.50	 N	 0	 0.50	 N	
MTF1	 -0.04	 0.20	 N	 0.11	 2.8E-03	 Y	 0	 0.50	 N	 0	 0.50	 N	
GTF2I	 -0.24	 1.0E-05	 Y	 0.11	 3.8E-03	 Y	 0	 0.50	 N	 0	 0.50	 N	
BCL6	 -0.01	 0.41	 N	 0.11	 4.0E-03	 Y	 -0.26	 1.0E-05	 Y	 0	 0.50	 N	
ETV3	 0.03	 0.23	 N	 0.11	 4.4E-03	 Y	 0	 0.50	 N	 0	 0.50	 N	
HDAC10	 0.03	 0.20	 N	 0.11	 5.2E-03	 Y	 0	 0.50	 N	 0	 0.50	 N	
SATB1	 0.04	 0.16	 N	 0.10	 7.9E-03	 Y	 0	 0.50	 N	 0	 0.50	 N	
FOSB	 -0.18	 1.0E-05	 Y	 0.10	 8.1E-03	 Y	 0	 0.50	 N	 0	 0.50	 N	
HDGF	 0.04	 0.14	 N	 0.10	 8.6E-03	 Y	 0	 0.50	 N	 0	 0.50	 N	
NFYC	 0.22	 1.0E-05	 Y	 0.10	 8.9E-03	 Y	 0	 0.50	 N	 0	 0.50	 N	
ELK3	 0.02	 0.30	 N	 0.10	 0.01	 Y	 0	 0.50	 N	 0	 0.50	 N	




PHOX2B	 0.21	 1.0E-05	 Y	 0.10	 0.01	 Y	 0	 0.50	 N	 0	 0.50	 N	
GTF3A	 0.12	 1.8E-03	 Y	 0.10	 0.01	 Y	 0	 0.50	 N	 0	 0.50	 N	
PAX2	 -0.40	 1.0E-05	 Y	 0.09	 0.02	 Y	 0	 0.50	 N	 0	 0.50	 N	
OTX2	 -0.06	 0.08	 N	 0.09	 0.02	 Y	 0	 0.50	 N	 0	 0.50	 N	
STAT5B	 0.01	 0.42	 N	 0.09	 0.02	 Y	 0	 0.50	 N	 0	 0.50	 N	
RFWD2	 0.03	 0.25	 N	 0.08	 0.02	 Y	 0	 0.50	 N	 0	 0.50	 N	
SF1	 0.35	 1.0E-05	 Y	 0.08	 0.02	 Y	 0	 0.50	 N	 0	 0.50	 N	
HEXIM1	 -0.20	 1.0E-05	 Y	 0.08	 0.03	 Y	 0	 0.50	 N	 0	 0.50	 N	
LYL1	 0.08	 0.04	 Y	 0.08	 0.03	 Y	 0	 0.50	 N	 0	 0.50	 N	
E2F4	 -0.06	 0.07	 N	 0.08	 0.04	 N	 0	 0.50	 N	 -0.87	 1.0E-05	 Y	
NPAS2	 0.08	 0.03	 Y	 0.07	 0.04	 N	 0	 0.50	 N	 0	 0.50	 N	
GLI3	 -0.03	 0.25	 N	 0.07	 0.05	 N	 0	 0.50	 N	 0	 0.50	 N	
NR2F6	 -0.18	 1.0E-05	 Y	 0.07	 0.05	 N	 0	 0.50	 N	 0	 0.50	 N	
AIP	 0.07	 0.05	 N	 0.07	 0.05	 N	 0	 0.50	 N	 0	 0.50	 N	
RUNX2	 0.24	 1.0E-05	 Y	 0.07	 0.05	 N	 0	 0.50	 N	 0.66	 1.0E-05	 Y	
PPARGC1
A	
-0.18	 2.0E-05	 Y	 0.07	 0.05	 N	 0	 0.50	 N	 0	 0.50	 N	
SUGP1	 0.08	 0.03	 Y	 0.07	 0.06	 N	 0	 0.50	 N	 0	 0.50	 N	
SRCAP	 -0.06	 0.09	 N	 0.06	 0.07	 N	 0	 0.50	 N	 0	 0.50	 N	
SP3	 -0.08	 0.03	 Y	 0.06	 0.07	 N	 -0.03	 0.22	 N	 0.32	 1.0E-05	 Y	
STAT3	 -0.27	 1.0E-05	 Y	 0.06	 0.07	 N	 0.10	 6.3E-03	 Y	 0.52	 1.0E-05	 Y	




ETV6	 -0.31	 1.0E-05	 Y	 0.06	 0.08	 N	 0	 0.50	 N	 0	 0.50	 N	
SIRT2	 -0.05	 0.13	 N	 0.06	 0.08	 N	 0	 0.50	 N	 0	 0.50	 N	
L3MBTL1	 -0.09	 0.02	 Y	 0.06	 0.08	 N	 0	 0.50	 N	 0	 0.50	 N	
HAX1	 -0.04	 0.15	 N	 0.06	 0.09	 N	 0	 0.50	 N	 0	 0.50	 N	
HNF4A	 -0.29	 1.0E-05	 Y	 0.06	 0.09	 N	 0.13	 1.1E-03	 Y	 -0.02	 0.29	 N	
HOXC10	 -0.22	 1.0E-05	 Y	 0.05	 0.10	 N	 0	 0.50	 N	 0	 0.50	 N	
IKZF1	 0.18	 1.0E-05	 Y	 0.05	 0.10	 N	 0	 0.50	 N	 0	 0.50	 N	
GCM1	 -0.02	 0.34	 N	 0.05	 0.11	 N	 0	 0.50	 N	 0	 0.50	 N	
ATF3	 0.04	 0.18	 N	 0.05	 0.11	 N	 0.32	 1.0E-05	 Y	 0	 0.50	 N	
GATA6	 -0.22	 1.0E-05	 Y	 0.05	 0.13	 N	 0	 0.50	 N	 0	 0.50	 N	
IRF7	 0.19	 1.0E-05	 Y	 0.04	 0.15	 N	 0	 0.50	 N	 0	 0.50	 N	
KDM4C	 0.37	 1.0E-05	 Y	 0.04	 0.18	 N	 0	 0.50	 N	 0	 0.50	 N	
IRF5	 -0.12	 1.9E-03	 Y	 0.04	 0.19	 N	 0	 0.50	 N	 0	 0.50	 N	
MEIS1	 0.07	 0.06	 N	 0.04	 0.19	 N	 0	 0.50	 N	 0	 0.50	 N	
NR4A2	 0.35	 1.0E-05	 Y	 0.04	 0.20	 N	 0	 0.50	 N	 0	 0.50	 N	
KAT2B	 2.7E-04	 0.50	 N	 0.03	 0.20	 N	 0	 0.50	 N	 0	 0.50	 N	
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HOXB1	 -0.13	 9.6E-04	 Y	 0.03	 0.20	 N	 0	 0.50	 N	 0	 0.50	 N	
OTX1	 -0.33	 1.0E-05	 Y	 0.03	 0.22	 N	 0	 0.50	 N	 0	 0.50	 N	
ING2	 0.07	 0.05	 N	 0.03	 0.22	 N	 0	 0.50	 N	 0	 0.50	 N	
TFDP3	 -3.0E-
03	
0.47	 N	 0.03	 0.22	 N	 0	 0.50	 N	 0	 0.50	 N	
MCM6	 0.16	 5.0E-05	 Y	 0.03	 0.23	 N	 0	 0.50	 N	 0	 0.50	 N	
NR4A3	 0.12	 1.9E-03	 Y	 0.03	 0.24	 N	 0	 0.50	 N	 0	 0.50	 N	
SMAD7	 0.07	 0.05	 N	 0.03	 0.24	 N	 0	 0.50	 N	 0	 0.50	 N	
LMO3	 -0.04	 0.20	 N	 0.03	 0.26	 N	 0	 0.50	 N	 0	 0.50	 N	
PITX2	 -0.25	 1.0E-05	 Y	 0.02	 0.28	 N	 0	 0.50	 N	 0	 0.50	 N	
POU2F1	 -0.16	 6.0E-05	 Y	 0.02	 0.30	 N	 0	 0.50	 N	 0.53	 1.0E-05	 Y	
IRF2	 0.14	 3.5E-04	 Y	 0.02	 0.31	 N	 0	 0.50	 N	 0	 0.50	 N	
NR2F1	 -0.35	 1.0E-05	 Y	 0.02	 0.33	 N	 0	 0.50	 N	 0	 0.50	 N	
SALL4	 -0.11	 4.2E-03	 Y	 0.02	 0.34	 N	 0	 0.50	 N	 0	 0.50	 N	
FOXQ1	 -0.12	 2.2E-03	 Y	 0.01	 0.38	 N	 0	 0.50	 N	 0	 0.50	 N	
NCOA3	 -0.04	 0.19	 N	 6.0E-03	 0.44	 N	 0	 0.50	 N	 0	 0.50	 N	
PCGF2	 0.05	 0.10	 N	 5.6E-03	 0.44	 N	 0	 0.50	 N	 0	 0.50	 N	
BTAF1	 0.21	 1.0E-05	 Y	 5.1E-03	 0.45	 N	 0	 0.50	 N	 0	 0.50	 N	
RARA	 -0.10	 9.7E-03	 Y	 -1.2E-
05	
0.50	 N	 0	 0.50	 N	 0.33	 1.0E-05	 Y	
NR1I3	 -0.11	 5.0E-03	 Y	 -2.0E-
03	
0.48	 N	 0	 0.50	 N	 0	 0.50	 N	
MAFB	 0.03	 0.22	 N	 -2.6E-
03	
0.48	 N	 0	 0.50	 N	 0	 0.50	 N	
CTNNB1	 -0.06	 0.07	 N	 -3.3E-
03	
0.47	 N	 0	 0.50	 N	 0	 0.50	 N	
ID1	 0.17	 2.0E-05	 Y	 -3.4E-
03	
0.47	 N	 0	 0.50	 N	 0	 0.50	 N	
HLF	 -0.13	 9.4E-04	 Y	 -3.5E-
03	
0.47	 N	 0	 0.50	 N	 0	 0.50	 N	
NR1H4	 0.19	 1.0E-05	 Y	 -3.9E-
03	
0.46	 N	 0.28	 1.0E-05	 Y	 0.37	 1.0E-05	 Y	
NFYA	 0.03	 0.24	 N	 -0.01	 0.41	 N	 0	 0.50	 N	 0.45	 1.0E-05	 Y	
EGR2	 -0.02	 0.28	 N	 -0.01	 0.40	 N	 0	 0.50	 N	 0	 0.50	 N	
NR5A1	 -0.26	 1.0E-05	 Y	 -0.01	 0.39	 N	 0	 0.50	 N	 0.27	 1.0E-05	 Y	
POU4F2	 -0.24	 1.0E-05	 Y	 -0.01	 0.37	 N	 0	 0.50	 N	 0	 0.50	 N	
MSX1	 0.04	 0.20	 N	 -0.01	 0.37	 N	 0	 0.50	 N	 0	 0.50	 N	
BTF3	 0.07	 0.04	 Y	 -0.02	 0.36	 N	 -0.32	 1.0E-05	 Y	 0	 0.50	 N	
E2F8	 -0.07	 0.04	 Y	 -0.02	 0.35	 N	 0	 0.50	 N	 0	 0.50	 N	
GFI1B	 -0.26	 1.0E-05	 Y	 -0.02	 0.35	 N	 0	 0.50	 N	 0	 0.50	 N	
JDP2	 0.01	 0.37	 N	 -0.02	 0.32	 N	 0	 0.50	 N	 0	 0.50	 N	
MAX	 0.30	 1.0E-05	 Y	 -0.02	 0.31	 N	 0	 0.50	 N	 0	 0.50	 N	
RFX5	 -0.02	 0.28	 N	 -0.02	 0.30	 N	 0	 0.50	 N	 0	 0.50	 N	
SERTAD1	 -0.24	 1.0E-05	 Y	 -0.02	 0.29	 N	 0	 0.50	 N	 0	 0.50	 N	
NR4A1	 -0.12	 2.6E-03	 Y	 -0.02	 0.28	 N	 0	 0.50	 N	 0	 0.50	 N	
SMURF2	 -0.21	 1.0E-05	 Y	 -0.03	 0.27	 N	 0	 0.50	 N	 0	 0.50	 N	
MYOG	 0.08	 0.03	 Y	 -0.03	 0.26	 N	 0	 0.50	 N	 0	 0.50	 N	
POLR1A	 0.12	 1.8E-03	 Y	 -0.03	 0.25	 N	 0	 0.50	 N	 0	 0.50	 N	
KLF13	 0.15	 2.2E-04	 Y	 -0.03	 0.23	 N	 0	 0.50	 N	 0	 0.50	 N	
THRA	 -0.19	 1.0E-05	 Y	 -0.03	 0.22	 N	 0	 0.50	 N	 0	 0.50	 N	
TEAD4	 0.27	 1.0E-05	 Y	 -0.03	 0.21	 N	 0	 0.50	 N	 0	 0.50	 N	
STAT5A	 -0.01	 0.43	 N	 -0.04	 0.20	 N	 0	 0.50	 N	 0	 0.50	 N	
NRL	 0.01	 0.41	 N	 -0.04	 0.20	 N	 0	 0.50	 N	 0	 0.50	 N	
GABPA	 -0.17	 4.0E-05	 Y	 -0.04	 0.19	 N	 0	 0.50	 N	 0	 0.50	 N	
TGIF1	 -0.24	 1.0E-05	 Y	 -0.04	 0.18	 N	 0	 0.50	 N	 0	 0.50	 N	
RB1	 0.07	 0.04	 Y	 -0.04	 0.16	 N	 -8.5E-
03	
0.42	 N	 -0.58	 1.0E-05	 Y	
ECD	 0.16	 5.0E-05	 Y	 -0.05	 0.14	 N	 0	 0.50	 N	 0	 0.50	 N	
PAWR	 0.06	 0.09	 N	 -0.05	 0.11	 N	 0	 0.50	 N	 0	 0.50	 N	
CITED2	 -0.31	 1.0E-05	 Y	 -0.05	 0.10	 N	 0	 0.50	 N	 0	 0.50	 N	
HNF1A	 -0.16	 7.0E-05	 Y	 -0.06	 0.10	 N	 0	 0.50	 N	 0	 0.50	 N	
SPIC	 0.03	 0.23	 N	 -0.06	 0.09	 N	 0	 0.50	 N	 0	 0.50	 N	
TBPL1	 0.02	 0.28	 N	 -0.06	 0.08	 N	 0	 0.50	 N	 0	 0.50	 N	
SP4	 -0.22	 1.0E-05	 Y	 -0.06	 0.08	 N	 0	 0.50	 N	 0	 0.50	 N	
NKX3-1	 -0.01	 0.38	 N	 -0.06	 0.08	 N	 0	 0.50	 N	 0	 0.50	 N	
GLI1	 0.36	 1.0E-05	 Y	 -0.06	 0.07	 N	 0	 0.50	 N	 0	 0.50	 N	
PLAGL1	 0.14	 3.0E-04	 Y	 -0.06	 0.07	 N	 0	 0.50	 N	 0	 0.50	 N	
PPARG	 0.16	 4.0E-05	 Y	 -0.06	 0.07	 N	 -0.16	 6.0E-05	 Y	 0.31	 1.0E-05	 Y	
POU4F1	 -0.14	 6.5E-04	 Y	 -0.06	 0.06	 N	 0	 0.50	 N	 0	 0.50	 N	
SOX4	 -0.07	 0.04	 Y	 -0.06	 0.06	 N	 0	 0.50	 N	 0	 0.50	 N	
FOS	 -0.06	 0.08	 N	 -0.07	 0.06	 N	 -0.04	 0.15	 N	 0.48	 1.0E-05	 Y	
DBP	 -0.02	 0.34	 N	 -0.07	 0.06	 N	 0	 0.50	 N	 0	 0.50	 N	
SOX9	 -2.0E-
03	
0.48	 N	 -0.07	 0.06	 N	 -0.13	 6.6E-04	 Y	 0.25	 1.0E-05	 Y	
TRERF1	 -0.26	 1.0E-05	 Y	 -0.07	 0.05	 N	 -0.45	 1.0E-05	 Y	 0	 0.50	 N	
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TBX5	 -0.14	 3.7E-04	 Y	 -0.07	 0.05	 N	 0	 0.50	 N	 0	 0.50	 N	
SIX1	 0.15	 1.3E-04	 Y	 -0.07	 0.05	 N	 0	 0.50	 N	 0	 0.50	 N	
HIF1A	 -0.14	 3.3E-04	 Y	 -0.07	 0.05	 N	 0.28	 1.0E-05	 Y	 0.50	 1.0E-05	 Y	
AR	 0.03	 0.21	 N	 -0.07	 0.04	 N	 -0.26	 1.0E-05	 Y	 0.24	 1.0E-05	 Y	
HLTF	 0.04	 0.19	 N	 -0.08	 0.04	 N	 0	 0.50	 N	 0	 0.50	 N	
PITX1	 0.23	 1.0E-05	 Y	 -0.08	 0.04	 Y	 -0.32	 1.0E-05	 Y	 0	 0.50	 N	
NHLH2	 -0.03	 0.22	 N	 -0.08	 0.03	 Y	 0	 0.50	 N	 0	 0.50	 N	
CBX8	 0.31	 1.0E-05	 Y	 -0.08	 0.03	 Y	 0	 0.50	 N	 0	 0.50	 N	
SRY	 -0.14	 3.2E-04	 Y	 -0.08	 0.03	 Y	 0	 0.50	 N	 0	 0.50	 N	
ELL	 -0.06	 0.09	 N	 -0.08	 0.02	 Y	 0	 0.50	 N	 0	 0.50	 N	
SOX17	 -0.11	 4.9E-03	 Y	 -0.09	 0.02	 Y	 0	 0.50	 N	 0	 0.50	 N	
MXI1	 -0.16	 6.0E-05	 Y	 -0.09	 0.02	 Y	 0	 0.50	 N	 0	 0.50	 N	
DEK	 0.08	 0.03	 Y	 -0.09	 0.02	 Y	 0	 0.50	 N	 0	 0.50	 N	
RXRA	 -0.08	 0.03	 Y	 -0.09	 0.02	 Y	 0	 0.50	 N	 0	 0.50	 N	
ID2	 -0.21	 1.0E-05	 Y	 -0.09	 0.01	 Y	 0	 0.50	 N	 0	 0.50	 N	
FOSL2	 -0.17	 2.0E-05	 Y	 -0.10	 0.01	 Y	 0	 0.50	 N	 0	 0.50	 N	
STAT6	 -0.19	 1.0E-05	 Y	 -0.10	 0.01	 Y	 0	 0.50	 N	 0.59	 1.0E-05	 Y	
RUNX1	 -0.05	 0.11	 N	 -0.10	 9.2E-03	 Y	 0	 0.50	 N	 0.25	 1.0E-05	 Y	
ID4	 -0.15	 1.8E-04	 Y	 -0.10	 7.1E-03	 Y	 0	 0.50	 N	 0	 0.50	 N	
RFX3	 0.30	 1.0E-05	 Y	 -0.10	 6.6E-03	 Y	 0	 0.50	 N	 0	 0.50	 N	
NFATC2	 -0.10	 9.0E-03	 Y	 -0.10	 6.6E-03	 Y	 0	 0.50	 N	 0	 0.50	 N	
JUND	 -0.02	 0.31	 N	 -0.11	 5.4E-03	 Y	 0	 0.50	 N	 0	 0.50	 N	
NCOR1	 -0.06	 0.06	 N	 -0.11	 4.3E-03	 Y	 0	 0.50	 N	 0	 0.50	 N	
NFIA	 -0.31	 1.0E-05	 Y	 -0.11	 3.3E-03	 Y	 0	 0.50	 N	 0	 0.50	 N	
RUNX3	 0.18	 1.0E-05	 Y	 -0.11	 2.8E-03	 Y	 0.12	 2.2E-03	 Y	 -0.13	 1.2E-03	 Y	
ATF1	 0.15	 8.0E-05	 Y	 -0.12	 2.7E-03	 Y	 0	 0.50	 N	 0.77	 1.0E-05	 Y	
ISL1	 0.20	 1.0E-05	 Y	 -0.12	 2.2E-03	 Y	 0	 0.50	 N	 0	 0.50	 N	
NFATC1	 0.16	 5.0E-05	 Y	 -0.12	 2.0E-03	 Y	 0	 0.50	 N	 0	 0.50	 N	
MAF	 -0.16	 9.0E-05	 Y	 -0.12	 2.0E-03	 Y	 0	 0.50	 N	 0	 0.50	 N	
CEBPA	 -0.05	 0.13	 N	 -0.12	 1.8E-03	 Y	 0	 0.50	 N	 0.25	 1.0E-05	 Y	
ESR2	 -0.06	 0.09	 N	 -0.12	 1.8E-03	 Y	 0	 0.50	 N	 0	 0.50	 N	
JUNB	 0.25	 1.0E-05	 Y	 -0.12	 1.6E-03	 Y	 0	 0.50	 N	 0	 0.50	 N	
NFATC3	 0.38	 1.0E-05	 Y	 -0.12	 1.5E-03	 Y	 0	 0.50	 N	 0	 0.50	 N	
ASCL1	 -0.17	 4.0E-05	 Y	 -0.13	 1.2E-03	 Y	 0	 0.50	 N	 0	 0.50	 N	
DLX5	 0.09	 0.01	 Y	 -0.13	 1.2E-03	 Y	 0	 0.50	 N	 0	 0.50	 N	
ATF4	 0.19	 1.0E-05	 Y	 -0.13	 1.1E-03	 Y	 0.43	 1.0E-05	 Y	 0.45	 1.0E-05	 Y	
PIAS1	 0.43	 1.0E-05	 Y	 -0.13	 1.0E-03	 Y	 0	 0.50	 N	 0	 0.50	 N	
NR1I2	 -0.01	 0.44	 N	 -0.13	 9.8E-04	 Y	 0	 0.50	 N	 0.38	 1.0E-05	 Y	
FOXH1	 0.29	 1.0E-05	 Y	 -0.13	 6.8E-04	 Y	 0	 0.50	 N	 0	 0.50	 N	
ATF6	 0.07	 0.05	 N	 -0.14	 5.7E-04	 Y	 0	 0.50	 N	 0	 0.50	 N	
ARNTL	 0.14	 2.5E-04	 Y	 -0.14	 4.9E-04	 Y	 0	 0.50	 N	 0	 0.50	 N	
CUX1	 -0.23	 1.0E-05	 Y	 -0.14	 4.7E-04	 Y	 0	 0.50	 N	 0	 0.50	 N	
PITX3	 0.10	 7.9E-03	 Y	 -0.14	 2.7E-04	 Y	 0	 0.50	 N	 0	 0.50	 N	
IRF3	 0.19	 1.0E-05	 Y	 -0.14	 2.6E-04	 Y	 0	 0.50	 N	 0	 0.50	 N	
GZF1	 -0.11	 5.8E-03	 Y	 -0.15	 2.2E-04	 Y	 0	 0.50	 N	 0	 0.50	 N	
FOXE1	 0.02	 0.28	 N	 -0.15	 2.2E-04	 Y	 0	 0.50	 N	 0	 0.50	 N	
STAT4	 0.12	 2.1E-03	 Y	 -0.15	 1.8E-04	 Y	 0	 0.50	 N	 0	 0.50	 N	
HAND2	 -0.05	 0.12	 N	 -0.15	 1.8E-04	 Y	 0	 0.50	 N	 0	 0.50	 N	
CBX7	 0.17	 1.0E-05	 Y	 -0.15	 1.7E-04	 Y	 0	 0.50	 N	 0	 0.50	 N	
MXD1	 0.08	 0.02	 Y	 -0.15	 1.2E-04	 Y	 0	 0.50	 N	 0	 0.50	 N	
FOXM1	 -0.02	 0.28	 N	 -0.16	 7.0E-05	 Y	 0	 0.50	 N	 0	 0.50	 N	
RUVBL1	 -0.07	 0.06	 N	 -0.16	 6.0E-05	 Y	 0	 0.50	 N	 0	 0.50	 N	
FOXO4	 0.13	 6.2E-04	 Y	 -0.16	 6.0E-05	 Y	 0	 0.50	 N	 0	 0.50	 N	
HMGA2	 0.01	 0.40	 N	 -0.16	 6.0E-05	 Y	 0	 0.50	 N	 0	 0.50	 N	
REL	 -0.13	 8.1E-04	 Y	 -0.16	 6.0E-05	 Y	 0	 0.50	 N	 0.45	 1.0E-05	 Y	
PBX1	 0.05	 0.14	 N	 -0.17	 6.0E-05	 Y	 0	 0.50	 N	 0	 0.50	 N	
HOXA9	 -0.02	 0.30	 N	 -0.17	 2.0E-05	 Y	 0	 0.50	 N	 0	 0.50	 N	
MLLT10	 0.35	 1.0E-05	 Y	 -0.17	 2.0E-05	 Y	 0	 0.50	 N	 0	 0.50	 N	
MAML1	 0.21	 1.0E-05	 Y	 -0.18	 2.0E-05	 Y	 0	 0.50	 N	 0	 0.50	 N	
MTA2	 0.13	 7.5E-04	 Y	 -0.18	 2.0E-05	 Y	 0	 0.50	 N	 0	 0.50	 N	
PGR	 0.04	 0.15	 N	 -0.18	 2.0E-05	 Y	 -0.11	 4.2E-03	 Y	 0.60	 1.0E-05	 Y	
EGR1	 0.01	 0.41	 N	 -0.18	 1.0E-05	 Y	 0.30	 1.0E-05	 Y	 0.44	 1.0E-05	 Y	
FOXA2	 -0.10	 8.3E-03	 Y	 -0.18	 1.0E-05	 Y	 0	 0.50	 N	 0	 0.50	 N	
PLAGL2	 0.09	 0.02	 Y	 -0.18	 1.0E-05	 Y	 0	 0.50	 N	 0	 0.50	 N	
PIAS2	 -0.16	 6.0E-05	 Y	 -0.18	 1.0E-05	 Y	 0	 0.50	 N	 0	 0.50	 N	
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EP300	 0.10	 7.4E-03	 Y	 -0.18	 1.0E-05	 Y	 0.33	 1.0E-05	 Y	 0.17	 1.0E-05	 Y	
SNAI1	 -0.20	 1.0E-05	 Y	 -0.19	 1.0E-05	 Y	 0	 0.50	 N	 0	 0.50	 N	
HR	 0.07	 0.06	 N	 -0.19	 1.0E-05	 Y	 0	 0.50	 N	 0	 0.50	 N	
ILF3	 -0.09	 0.01	 Y	 -0.19	 1.0E-05	 Y	 0	 0.50	 N	 0	 0.50	 N	
MITF	 0.09	 0.01	 Y	 -0.19	 1.0E-05	 Y	 0	 0.50	 N	 0.73	 1.0E-05	 Y	
NR0B2	 0.22	 1.0E-05	 Y	 -0.19	 1.0E-05	 Y	 0	 0.50	 N	 0	 0.50	 N	
FOXF2	 0.11	 4.3E-03	 Y	 -0.19	 1.0E-05	 Y	 0	 0.50	 N	 0	 0.50	 N	
TCF12	 -0.13	 8.1E-04	 Y	 -0.19	 1.0E-05	 Y	 0	 0.50	 N	 0	 0.50	 N	
EHF	 -0.03	 0.25	 N	 -0.19	 1.0E-05	 Y	 0	 0.50	 N	 0	 0.50	 N	
MBD2	 -0.12	 1.8E-03	 Y	 -0.20	 1.0E-05	 Y	 0	 0.50	 N	 0	 0.50	 N	
NELFCD	 -0.23	 1.0E-05	 Y	 -0.20	 1.0E-05	 Y	 0	 0.50	 N	 0	 0.50	 N	
NPAS1	 -0.21	 1.0E-05	 Y	 -0.20	 1.0E-05	 Y	 0	 0.50	 N	 0	 0.50	 N	
NEUROD
1	
-0.02	 0.36	 N	 -0.20	 1.0E-05	 Y	 0	 0.50	 N	 0	 0.50	 N	
SOX6	 -0.10	 7.7E-03	 Y	 -0.20	 1.0E-05	 Y	 0	 0.50	 N	 0	 0.50	 N	
MYOCD	 0.17	 2.0E-05	 Y	 -0.20	 1.0E-05	 Y	 0	 0.50	 N	 0	 0.50	 N	
NFKBIB	 0.17	 1.0E-05	 Y	 -0.20	 1.0E-05	 Y	 0	 0.50	 N	 0	 0.50	 N	
DR1	 0.22	 1.0E-05	 Y	 -0.20	 1.0E-05	 Y	 0	 0.50	 N	 0	 0.50	 N	
EVX1	 0.27	 1.0E-05	 Y	 -0.21	 1.0E-05	 Y	 0	 0.50	 N	 0	 0.50	 N	
ATM	 0.09	 0.01	 Y	 -0.21	 1.0E-05	 Y	 0.31	 1.0E-05	 Y	 0.34	 1.0E-05	 Y	
HMGA1	 -0.25	 1.0E-05	 Y	 -0.21	 1.0E-05	 Y	 0	 0.50	 N	 0	 0.50	 N	
PA2G4	 -0.18	 1.0E-05	 Y	 -0.22	 1.0E-05	 Y	 0	 0.50	 N	 0	 0.50	 N	
KAT5	 0.06	 0.08	 N	 -0.22	 1.0E-05	 Y	 0	 0.50	 N	 0	 0.50	 N	
NUPR1	 0.10	 0.01	 Y	 -0.22	 1.0E-05	 Y	 0	 0.50	 N	 0	 0.50	 N	
BCL11A	 -0.14	 3.9E-04	 Y	 -0.22	 1.0E-05	 Y	 0	 0.50	 N	 0	 0.50	 N	
KLF15	 0.32	 1.0E-05	 Y	 -0.22	 1.0E-05	 Y	 0	 0.50	 N	 0	 0.50	 N	
RBBP7	 0.11	 3.2E-03	 Y	 -0.22	 1.0E-05	 Y	 0	 0.50	 N	 0	 0.50	 N	
RARB	 0.05	 0.14	 N	 -0.22	 1.0E-05	 Y	 0	 0.50	 N	 0	 0.50	 N	
ABL1	 -0.05	 0.12	 N	 -0.22	 1.0E-05	 Y	 0	 0.50	 N	 0	 0.50	 N	
ELF2	 -0.09	 0.02	 Y	 -0.22	 1.0E-05	 Y	 0	 0.50	 N	 0	 0.50	 N	
ATRX	 0.02	 0.34	 N	 -0.22	 1.0E-05	 Y	 0	 0.50	 N	 0	 0.50	 N	
RBL1	 0.36	 1.0E-05	 Y	 -0.23	 1.0E-05	 Y	 0	 0.50	 N	 0	 0.50	 N	
IKBKB	 0.23	 1.0E-05	 Y	 -0.23	 1.0E-05	 Y	 0	 0.50	 N	 0	 0.50	 N	
PAX4	 0.29	 1.0E-05	 Y	 -0.23	 1.0E-05	 Y	 0	 0.50	 N	 0	 0.50	 N	
HMGB2	 -0.07	 0.04	 Y	 -0.23	 1.0E-05	 Y	 0	 0.50	 N	 0	 0.50	 N	
MKL1	 -0.02	 0.33	 N	 -0.23	 1.0E-05	 Y	 0	 0.50	 N	 0	 0.50	 N	
KLF2	 0.02	 0.32	 N	 -0.23	 1.0E-05	 Y	 0	 0.50	 N	 0.29	 1.0E-05	 Y	
FOXD3	 0.27	 1.0E-05	 Y	 -0.24	 1.0E-05	 Y	 0	 0.50	 N	 0	 0.50	 N	
MSC	 -0.08	 0.03	 Y	 -0.24	 1.0E-05	 Y	 0	 0.50	 N	 -0.15	 1.4E-04	 Y	
PAX8	 0.48	 1.0E-05	 Y	 -0.24	 1.0E-05	 Y	 0	 0.50	 N	 0	 0.50	 N	
GLI2	 0.42	 1.0E-05	 Y	 -0.24	 1.0E-05	 Y	 0	 0.50	 N	 0.63	 1.0E-05	 Y	
SPDEF	 -0.07	 0.06	 N	 -0.24	 1.0E-05	 Y	 0	 0.50	 N	 0	 0.50	 N	
SUPT3H	 -0.05	 0.12	 N	 -0.24	 1.0E-05	 Y	 0	 0.50	 N	 0	 0.50	 N	
ATOH1	 0.11	 4.2E-03	 Y	 -0.24	 1.0E-05	 Y	 0	 0.50	 N	 0	 0.50	 N	
PROX1	 0.53	 1.0E-05	 Y	 -0.24	 1.0E-05	 Y	 0.17	 1.0E-05	 Y	 0	 0.50	 N	
BACH1	 0.07	 0.04	 N	 -0.24	 1.0E-05	 Y	 0	 0.50	 N	 0	 0.50	 N	
SETBP1	 0.03	 0.22	 N	 -0.25	 1.0E-05	 Y	 0	 0.50	 N	 0	 0.50	 N	
BHLHE41	 0.22	 1.0E-05	 Y	 -0.25	 1.0E-05	 Y	 0	 0.50	 N	 0	 0.50	 N	
FHL2	 0.20	 1.0E-05	 Y	 -0.25	 1.0E-05	 Y	 0	 0.50	 N	 0	 0.50	 N	
MTA3	 0.05	 0.14	 N	 -0.25	 1.0E-05	 Y	 0	 0.50	 N	 0	 0.50	 N	
FOXC1	 0.07	 0.04	 Y	 -0.25	 1.0E-05	 Y	 0	 0.50	 N	 0	 0.50	 N	
SALL3	 -0.04	 0.15	 N	 -0.25	 1.0E-05	 Y	 0	 0.50	 N	 0	 0.50	 N	
PIAS3	 0.23	 1.0E-05	 Y	 -0.25	 1.0E-05	 Y	 0	 0.50	 N	 0	 0.50	 N	
NELFB	 -0.11	 3.7E-03	 Y	 -0.25	 1.0E-05	 Y	 0	 0.50	 N	 0	 0.50	 N	
FOXA1	 -0.11	 4.0E-03	 Y	 -0.25	 1.0E-05	 Y	 0	 0.50	 N	 0	 0.50	 N	
POU2AF1	 0.31	 1.0E-05	 Y	 -0.25	 1.0E-05	 Y	 0	 0.50	 N	 0	 0.50	 N	
HDAC4	 0.22	 1.0E-05	 Y	 -0.26	 1.0E-05	 Y	 -0.06	 0.09	 N	 0	 0.50	 N	
HOXC13	 -0.16	 6.0E-05	 Y	 -0.26	 1.0E-05	 Y	 0	 0.50	 N	 0	 0.50	 N	
ARID1A	 0.36	 1.0E-05	 Y	 -0.26	 1.0E-05	 Y	 0	 0.50	 N	 0	 0.50	 N	
ERF	 0.02	 0.32	 N	 -0.26	 1.0E-05	 Y	 0	 0.50	 N	 0	 0.50	 N	
NCOA6	 -0.12	 1.9E-03	 Y	 -0.26	 1.0E-05	 Y	 0	 0.50	 N	 0	 0.50	 N	
KLF6	 0.27	 1.0E-05	 Y	 -0.26	 1.0E-05	 Y	 0	 0.50	 N	 0	 0.50	 N	
KLF9	 2.1E-04	 0.50	 N	 -0.26	 1.0E-05	 Y	 0	 0.50	 N	 0	 0.50	 N	
FOXP1	 -0.02	 0.36	 N	 -0.27	 1.0E-05	 Y	 0	 0.50	 N	 0	 0.50	 N	
ETS1	 0.22	 1.0E-05	 Y	 -0.27	 1.0E-05	 Y	 -0.08	 0.03	 N	 0.57	 1.0E-05	 Y	
CREM	 -0.16	 6.0E-05	 Y	 -0.27	 1.0E-05	 Y	 -0.36	 1.0E-05	 Y	 0	 0.50	 N	
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CREB5	 -0.09	 0.01	 Y	 -0.27	 1.0E-05	 Y	 -0.01	 0.37	 N	 0	 0.50	 N	
MED1	 0.30	 1.0E-05	 Y	 -0.27	 1.0E-05	 Y	 0	 0.50	 N	 0	 0.50	 N	
HOPX	 0.20	 1.0E-05	 Y	 -0.27	 1.0E-05	 Y	 0	 0.50	 N	 0	 0.50	 N	
PER1	 0.04	 0.14	 N	 -0.28	 1.0E-05	 Y	 0	 0.50	 N	 0	 0.50	 N	
FOXG1	 -0.02	 0.30	 N	 -0.28	 1.0E-05	 Y	 0	 0.50	 N	 0	 0.50	 N	
PTMA	 0.27	 1.0E-05	 Y	 -0.28	 1.0E-05	 Y	 0	 0.50	 N	 0	 0.50	 N	
SMARCA1	 -0.04	 0.16	 N	 -0.29	 1.0E-05	 Y	 0	 0.50	 N	 0	 0.50	 N	
LEF1	 -0.13	 9.6E-04	 Y	 -0.29	 1.0E-05	 Y	 -0.17	 4.0E-05	 Y	 0.50	 1.0E-05	 Y	
NRIP1	 0.48	 1.0E-05	 Y	 -0.29	 1.0E-05	 Y	 0	 0.50	 N	 0	 0.50	 N	
NR2E3	 -0.14	 3.4E-04	 Y	 -0.29	 1.0E-05	 Y	 0	 0.50	 N	 0	 0.50	 N	
CEBPG	 0.29	 1.0E-05	 Y	 -0.29	 1.0E-05	 Y	 0	 0.50	 N	 0	 0.50	 N	
CTCF	 0.17	 1.0E-05	 Y	 -0.29	 1.0E-05	 Y	 0	 0.50	 N	 -0.04	 0.17	 N	
TBX2	 0.01	 0.41	 N	 -0.30	 1.0E-05	 Y	 0	 0.50	 N	 0	 0.50	 N	
ELK1	 -8.0E-
04	
0.49	 N	 -0.30	 1.0E-05	 Y	 0	 0.50	 N	 0	 0.50	 N	
CEBPD	 -0.04	 0.17	 N	 -0.30	 1.0E-05	 Y	 0	 0.50	 N	 0	 0.50	 N	
HSF1	 -0.10	 6.6E-03	 Y	 -0.30	 1.0E-05	 Y	 -0.28	 1.0E-05	 Y	 0	 0.50	 N	
CHD4	 -0.13	 9.1E-04	 Y	 -0.30	 1.0E-05	 Y	 0	 0.50	 N	 0	 0.50	 N	
ONECUT2	 -0.11	 4.2E-03	 Y	 -0.31	 1.0E-05	 Y	 0	 0.50	 N	 0	 0.50	 N	
POU5F1	 -0.10	 7.6E-03	 Y	 -0.31	 1.0E-05	 Y	 -0.30	 1.0E-05	 Y	 0	 0.50	 N	
AATF	 0.20	 1.0E-05	 Y	 -0.31	 1.0E-05	 Y	 0	 0.50	 N	 0	 0.50	 N	
PAX5	 0.37	 1.0E-05	 Y	 -0.32	 1.0E-05	 Y	 -0.03	 0.23	 N	 0.49	 1.0E-05	 Y	
SND1	 0.15	 1.2E-04	 Y	 -0.32	 1.0E-05	 Y	 0	 0.50	 N	 0	 0.50	 N	
IRF4	 0.15	 1.3E-04	 Y	 -0.33	 1.0E-05	 Y	 0	 0.50	 N	 0	 0.50	 N	
HOXA7	 0.26	 1.0E-05	 Y	 -0.33	 1.0E-05	 Y	 0	 0.50	 N	 0	 0.50	 N	
CTBP1	 0.15	 8.0E-05	 Y	 -0.33	 1.0E-05	 Y	 0	 0.50	 N	 0	 0.50	 N	
SFPQ	 0.37	 1.0E-05	 Y	 -0.33	 1.0E-05	 Y	 0	 0.50	 N	 0	 0.50	 N	
ELK4	 0.16	 4.0E-05	 Y	 -0.33	 1.0E-05	 Y	 0	 0.50	 N	 0	 0.50	 N	
SOX3	 0.17	 2.0E-05	 Y	 -0.33	 1.0E-05	 Y	 0	 0.50	 N	 0	 0.50	 N	
STAT2	 0.19	 1.0E-05	 Y	 -0.34	 1.0E-05	 Y	 0	 0.50	 N	 0	 0.50	 N	
RAD51	 0.02	 0.35	 N	 -0.34	 1.0E-05	 Y	 0	 0.50	 N	 0	 0.50	 N	
MLLT3	 0.04	 0.16	 N	 -0.34	 1.0E-05	 Y	 0	 0.50	 N	 0	 0.50	 N	
LMX1B	 0.25	 1.0E-05	 Y	 -0.34	 1.0E-05	 Y	 0	 0.50	 N	 0	 0.50	 N	
EZH2	 0.24	 1.0E-05	 Y	 -0.34	 1.0E-05	 Y	 -0.21	 1.0E-05	 Y	 0.18	 1.0E-05	 Y	
NFIX	 -0.05	 0.12	 N	 -0.34	 1.0E-05	 Y	 0	 0.50	 N	 0	 0.50	 N	
MYCN	 0.02	 0.33	 N	 -0.34	 1.0E-05	 Y	 0.35	 1.0E-05	 Y	 0.28	 1.0E-05	 Y	
HES1	 0.10	 6.5E-03	 Y	 -0.35	 1.0E-05	 Y	 -0.29	 1.0E-05	 Y	 0	 0.50	 N	
NR1H3	 0.54	 1.0E-05	 Y	 -0.35	 1.0E-05	 Y	 0	 0.50	 N	 0	 0.50	 N	
NFKB2	 -0.07	 0.05	 N	 -0.35	 1.0E-05	 Y	 0	 0.50	 N	 0	 0.50	 N	
HOXA1	 0.22	 1.0E-05	 Y	 -0.35	 1.0E-05	 Y	 0	 0.50	 N	 0	 0.50	 N	
NR3C2	 0.13	 6.0E-04	 Y	 -0.35	 1.0E-05	 Y	 0	 0.50	 N	 0	 0.50	 N	
SREBF2	 0.15	 7.0E-05	 Y	 -0.35	 1.0E-05	 Y	 0	 0.50	 N	 0	 0.50	 N	




NKX2-5	 0.27	 1.0E-05	 Y	 -0.36	 1.0E-05	 Y	 0	 0.50	 N	 0	 0.50	 N	
RORA	 0.13	 1.3E-03	 Y	 -0.36	 1.0E-05	 Y	 0	 0.50	 N	 0	 0.50	 N	
DEAF1	 -0.09	 0.02	 Y	 -0.36	 1.0E-05	 Y	 0	 0.50	 N	 0	 0.50	 N	
NF1	 0.37	 1.0E-05	 Y	 -0.37	 1.0E-05	 Y	 0	 0.50	 N	 0	 0.50	 N	
PAX6	 0.16	 5.0E-05	 Y	 -0.37	 1.0E-05	 Y	 0	 0.50	 N	 0	 0.50	 N	
CEBPE	 0.10	 9.3E-03	 Y	 -0.37	 1.0E-05	 Y	 0	 0.50	 N	 0	 0.50	 N	
MYB	 -0.21	 1.0E-05	 Y	 -0.37	 1.0E-05	 Y	 0.28	 1.0E-05	 Y	 0.73	 1.0E-05	 Y	
TFAP2C	 0.14	 4.2E-04	 Y	 -0.37	 1.0E-05	 Y	 0	 0.50	 N	 0	 0.50	 N	
CIITA	 -0.02	 0.35	 N	 -0.38	 1.0E-05	 Y	 0	 0.50	 N	 0.60	 1.0E-05	 Y	
HSF2	 0.24	 1.0E-05	 Y	 -0.38	 1.0E-05	 Y	 0	 0.50	 N	 0	 0.50	 N	
KHDRBS1	 -0.26	 1.0E-05	 Y	 -0.39	 1.0E-05	 Y	 0	 0.50	 N	 0	 0.50	 N	
HINFP	 0.01	 0.45	 N	 -0.39	 1.0E-05	 Y	 0	 0.50	 N	 0	 0.50	 N	
ELF3	 0.37	 1.0E-05	 Y	 -0.39	 1.0E-05	 Y	 0	 0.50	 N	 0	 0.50	 N	
DNMT3L	 0.54	 1.0E-05	 Y	 -0.39	 1.0E-05	 Y	 0	 0.50	 N	 0	 0.50	 N	
BARD1	 0.02	 0.31	 N	 -0.39	 1.0E-05	 Y	 0	 0.50	 N	 0	 0.50	 N	
HOXC6	 -0.18	 1.0E-05	 Y	 -0.39	 1.0E-05	 Y	 0	 0.50	 N	 0	 0.50	 N	
MAFA	 0.15	 1.2E-04	 Y	 -0.40	 1.0E-05	 Y	 0	 0.50	 N	 0	 0.50	 N	
NEUROG
3	
0.26	 1.0E-05	 Y	 -0.40	 1.0E-05	 Y	 0	 0.50	 N	 0	 0.50	 N	
PHB2	 0.02	 0.31	 N	 -0.40	 1.0E-05	 Y	 0	 0.50	 N	 0	 0.50	 N	
LMO2	 0.25	 1.0E-05	 Y	 -0.40	 1.0E-05	 Y	 0	 0.50	 N	 0	 0.50	 N	
HBP1	 0.29	 1.0E-05	 Y	 -0.40	 1.0E-05	 Y	 0	 0.50	 N	 0	 0.50	 N	
SP7	 0.70	 1.0E-05	 Y	 -0.41	 1.0E-05	 Y	 0	 0.50	 N	 0	 0.50	 N	
NFAT5	 0.41	 1.0E-05	 Y	 -0.41	 1.0E-05	 Y	 0	 0.50	 N	 0	 0.50	 N	
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LIMD1	 0.31	 1.0E-05	 Y	 -0.41	 1.0E-05	 Y	 0	 0.50	 N	 0	 0.50	 N	
POU2F2	 0.38	 1.0E-05	 Y	 -0.41	 1.0E-05	 Y	 0	 0.50	 N	 0	 0.50	 N	
BRD7	 0.31	 1.0E-05	 Y	 -0.41	 1.0E-05	 Y	 0	 0.50	 N	 0	 0.50	 N	
KLF11	 -0.30	 1.0E-05	 Y	 -0.42	 1.0E-05	 Y	 0	 0.50	 N	 0	 0.50	 N	
NKX2-1	 -0.06	 0.08	 N	 -0.42	 1.0E-05	 Y	 0	 0.50	 N	 0	 0.50	 N	
RNF14	 0.23	 1.0E-05	 Y	 -0.42	 1.0E-05	 Y	 0	 0.50	 N	 0	 0.50	 N	
CREBBP	 0.01	 0.42	 N	 -0.42	 1.0E-05	 Y	 0	 0.50	 N	 0	 0.50	 N	
MYBL2	 0.18	 1.0E-05	 Y	 -0.42	 1.0E-05	 Y	 0	 0.50	 N	 0	 0.50	 N	
SMARCB1	 0.13	 1.2E-03	 Y	 -0.43	 1.0E-05	 Y	 0	 0.50	 N	 0	 0.50	 N	
CDCA7L	 -0.05	 0.11	 N	 -0.43	 1.0E-05	 Y	 0	 0.50	 N	 0	 0.50	 N	
CREB3L1	 0.24	 1.0E-05	 Y	 -0.44	 1.0E-05	 Y	 0	 0.50	 N	 0	 0.50	 N	
HES6	 -0.08	 0.02	 Y	 -0.44	 1.0E-05	 Y	 0	 0.50	 N	 0	 0.50	 N	
SRF	 2.8E-03	 0.47	 N	 -0.44	 1.0E-05	 Y	 0	 0.50	 N	 0.82	 1.0E-05	 Y	
NFKBIA	 -0.01	 0.37	 N	 -0.45	 1.0E-05	 Y	 -0.23	 1.0E-05	 Y	 0	 0.50	 N	
NR0B1	 0.31	 1.0E-05	 Y	 -0.45	 1.0E-05	 Y	 -0.54	 1.0E-05	 Y	 0	 0.50	 N	
CREB3	 0.19	 1.0E-05	 Y	 -0.45	 1.0E-05	 Y	 0	 0.50	 N	 0	 0.50	 N	
SSB	 0.24	 1.0E-05	 Y	 -0.45	 1.0E-05	 Y	 0	 0.50	 N	 0	 0.50	 N	
FLI1	 0.23	 1.0E-05	 Y	 -0.46	 1.0E-05	 Y	 0	 0.50	 N	 0.42	 1.0E-05	 Y	
PER2	 0.12	 2.2E-03	 Y	 -0.46	 1.0E-05	 Y	 0	 0.50	 N	 0	 0.50	 N	
KLF10	 -0.02	 0.32	 N	 -0.47	 1.0E-05	 Y	 0	 0.50	 N	 0	 0.50	 N	
MZF1	 0.31	 1.0E-05	 Y	 -0.47	 1.0E-05	 Y	 0	 0.50	 N	 0	 0.50	 N	
MYC	 0.24	 1.0E-05	 Y	 -0.47	 1.0E-05	 Y	 0.39	 1.0E-05	 Y	 0.35	 1.0E-05	 Y	
EWSR1	 -0.04	 0.15	 N	 -0.48	 1.0E-05	 Y	 0	 0.50	 N	 0	 0.50	 N	
HOXD9	 -0.07	 0.04	 Y	 -0.49	 1.0E-05	 Y	 0	 0.50	 N	 0	 0.50	 N	
DNMT3A	 0.07	 0.04	 Y	 -0.49	 1.0E-05	 Y	 0	 0.50	 N	 0	 0.50	 N	
APC	 0.14	 3.2E-04	 Y	 -0.49	 1.0E-05	 Y	 0	 0.50	 N	 0	 0.50	 N	
HOXB7	 0.54	 1.0E-05	 Y	 -0.49	 1.0E-05	 Y	 0	 0.50	 N	 0.57	 1.0E-05	 Y	
KLF16	 -0.03	 0.26	 N	 -0.50	 1.0E-05	 Y	 0	 0.50	 N	 0	 0.50	 N	
KCNIP3	 0.03	 0.21	 N	 -0.50	 1.0E-05	 Y	 0	 0.50	 N	 0	 0.50	 N	
CBX6	 -0.02	 0.29	 N	 -0.50	 1.0E-05	 Y	 0	 0.50	 N	 0	 0.50	 N	
NFKB1	 -0.04	 0.16	 N	 -0.50	 1.0E-05	 Y	 -3.3E-
04	
0.50	 N	 0.46	 1.0E-05	 Y	
TFAP4	 0.39	 1.0E-05	 Y	 -0.50	 1.0E-05	 Y	 0	 0.50	 N	 0	 0.50	 N	
MEF2D	 0.74	 1.0E-05	 Y	 -0.50	 1.0E-05	 Y	 0	 0.50	 N	 0	 0.50	 N	
HDAC2	 0.35	 1.0E-05	 Y	 -0.50	 1.0E-05	 Y	 -0.08	 0.03	 N	 -0.45	 1.0E-05	 Y	
TFCP2	 0.77	 1.0E-05	 Y	 -0.50	 1.0E-05	 Y	 0	 0.50	 N	 0	 0.50	 N	
SIN3A	 0.37	 1.0E-05	 Y	 -0.50	 1.0E-05	 Y	 0	 0.50	 N	 0	 0.50	 N	
HDAC3	 0.19	 1.0E-05	 Y	 -0.51	 1.0E-05	 Y	 0	 0.50	 N	 0	 0.50	 N	
NKX2-2	 0.17	 2.0E-05	 Y	 -0.51	 1.0E-05	 Y	 0	 0.50	 N	 0	 0.50	 N	
PPARA	 0.02	 0.28	 N	 -0.52	 1.0E-05	 Y	 -0.22	 1.0E-05	 Y	 0.59	 1.0E-05	 Y	
COPS5	 0.20	 1.0E-05	 Y	 -0.53	 1.0E-05	 Y	 0	 0.50	 N	 0	 0.50	 N	
HTATIP2	 0.08	 0.03	 Y	 -0.53	 1.0E-05	 Y	 0	 0.50	 N	 0	 0.50	 N	
DLX4	 0.40	 1.0E-05	 Y	 -0.54	 1.0E-05	 Y	 0	 0.50	 N	 0	 0.50	 N	
TAL1	 0.03	 0.21	 N	 -0.55	 1.0E-05	 Y	 0	 0.50	 N	 0	 0.50	 N	
GATA1	 0.36	 1.0E-05	 Y	 -0.55	 1.0E-05	 Y	 0	 0.50	 N	 0.54	 1.0E-05	 Y	
NR1D1	 0.16	 5.0E-05	 Y	 -0.56	 1.0E-05	 Y	 0	 0.50	 N	 0	 0.50	 N	
FOXP3	 0.21	 1.0E-05	 Y	 -0.57	 1.0E-05	 Y	 0	 0.50	 N	 0	 0.50	 N	
SLC2A4R
G	
0.30	 1.0E-05	 Y	 -0.57	 1.0E-05	 Y	 0	 0.50	 N	 0	 0.50	 N	
TCFL5	 0.29	 1.0E-05	 Y	 -0.57	 1.0E-05	 Y	 0	 0.50	 N	 0	 0.50	 N	
HOXA10	 0.23	 1.0E-05	 Y	 -0.59	 1.0E-05	 Y	 0	 0.50	 N	 0.13	 1.2E-03	 Y	
GATA2	 4.6E-03	 0.45	 N	 -0.59	 1.0E-05	 Y	 0	 0.50	 N	 0	 0.50	 N	
ING1	 0.16	 5.0E-05	 Y	 -0.59	 1.0E-05	 Y	 0	 0.50	 N	 0	 0.50	 N	
RB1CC1	 0.08	 0.03	 Y	 -0.60	 1.0E-05	 Y	 0	 0.50	 N	 0	 0.50	 N	
MEF2C	 0.54	 1.0E-05	 Y	 -0.60	 1.0E-05	 Y	 0	 0.50	 N	 0	 0.50	 N	
HOXA11	 0.09	 0.01	 Y	 -0.61	 1.0E-05	 Y	 0	 0.50	 N	 0	 0.50	 N	
TNFAIP3	 0.08	 0.03	 Y	 -0.61	 1.0E-05	 Y	 0	 0.50	 N	 0	 0.50	 N	
TFAP2A	 0.34	 1.0E-05	 Y	 -0.64	 1.0E-05	 Y	 -0.20	 1.0E-05	 Y	 0.64	 1.0E-05	 Y	
TCF3	 0.04	 0.16	 N	 -0.65	 1.0E-05	 Y	 0	 0.50	 N	 -0.23	 1.0E-05	 Y	
HDAC7	 0.56	 1.0E-05	 Y	 -0.65	 1.0E-05	 Y	 -0.67	 1.0E-05	 Y	 0	 0.50	 N	
SRSF1	 0.18	 1.0E-05	 Y	 -0.69	 1.0E-05	 Y	 0	 0.50	 N	 0	 0.50	 N	




Master list of TFs in TCGA colorectal cancer dataset together the correlation 
scores of their activity scores with PR signatures and enrichment scores of target 
genes with PR signatures 
 
TF	 S(TF,P)	 P-value	 BH	 S(TF,R)	 P-value	 BH	 ES_P	 P-value	 BH	 ES_R	 P-value	 BH	
SERTAD1	 -0.40	 1.0E-05	 Y	 0.72	 1.0E-05	 Y	 0	 0.50	 N	 0	 0.50	 N	
POLR1A	 -0.20	 1.0E-05	 Y	 0.71	 1.0E-05	 Y	 0	 0.50	 N	 0	 0.50	 N	
LIMD1	 -0.41	 1.0E-05	 Y	 0.64	 1.0E-05	 Y	 0	 0.50	 N	 0	 0.50	 N	
CDX1	 -0.16	 9.0E-05	 Y	 0.61	 1.0E-05	 Y	 0	 0.50	 N	 0	 0.50	 N	
KCNIP3	 -0.47	 1.0E-05	 Y	 0.60	 1.0E-05	 Y	 0	 0.50	 N	 0	 0.50	 N	
BTG2	 0.04	 0.18	 N	 0.60	 1.0E-05	 Y	 0	 0.50	 N	 0	 0.50	 N	
BTAF1	 -0.11	 4.4E-03	 Y	 0.58	 1.0E-05	 Y	 0	 0.50	 N	 0	 0.50	 N	
ENO1	 0.01	 0.40	 N	 0.56	 1.0E-05	 Y	 0	 0.50	 N	 0	 0.50	 N	
CTCFL	 -0.02	 0.34	 N	 0.56	 1.0E-05	 Y	 0	 0.50	 N	 0	 0.50	 N	
AHR	 -0.22	 1.0E-05	 Y	 0.56	 1.0E-05	 Y	 0	 0.50	 N	 0	 0.50	 N	
MYOD1	 -0.65	 1.0E-05	 Y	 0.56	 1.0E-05	 Y	 0	 0.50	 N	 0	 0.50	 N	
TBP	 -0.18	 2.0E-05	 Y	 0.56	 1.0E-05	 Y	 0	 0.50	 N	 0	 0.50	 N	
NFYC	 -0.29	 1.0E-05	 Y	 0.55	 1.0E-05	 Y	 0	 0.50	 N	 0	 0.50	 N	
IRF9	 -0.32	 1.0E-05	 Y	 0.55	 1.0E-05	 Y	 0	 0.50	 N	 0	 0.50	 N	
SKI	 -0.21	 1.0E-05	 Y	 0.53	 1.0E-05	 Y	 0	 0.50	 N	 0	 0.50	 N	
ESRRG	 -0.02	 0.31	 N	 0.52	 1.0E-05	 Y	 0	 0.50	 N	 0	 0.50	 N	
FOXL1	 -0.23	 1.0E-05	 Y	 0.51	 1.0E-05	 Y	 0	 0.50	 N	 0	 0.50	 N	
MAX	 -0.29	 1.0E-05	 Y	 0.51	 1.0E-05	 Y	 0	 0.50	 N	 0	 0.50	 N	
KLF6	 -0.22	 1.0E-05	 Y	 0.50	 1.0E-05	 Y	 0	 0.50	 N	 0	 0.50	 N	
MCM2	 -0.29	 1.0E-05	 Y	 0.50	 1.0E-05	 Y	 0	 0.50	 N	 0	 0.50	 N	
HDAC1	 -0.26	 1.0E-05	 Y	 0.49	 1.0E-05	 Y	 -0.40	 1.0E-05	 Y	 -0.20	 1.0E-05	 Y	
CEBPB	 -0.21	 1.0E-05	 Y	 0.49	 1.0E-05	 Y	 0.13	 1.5E-03	 Y	 0.08	 0.02	 Y	
SPIB	 -0.04	 0.15	 N	 0.49	 1.0E-05	 Y	 0	 0.50	 N	 0	 0.50	 N	
MBD2	 -0.37	 1.0E-05	 Y	 0.49	 1.0E-05	 Y	 0	 0.50	 N	 0	 0.50	 N	
RB1	 0.08	 0.03	 Y	 0.48	 1.0E-05	 Y	 -0.35	 1.0E-05	 Y	 -0.49	 1.0E-05	 Y	
PRDM1	 -0.31	 1.0E-05	 Y	 0.48	 1.0E-05	 Y	 0	 0.50	 N	 0	 0.50	 N	
HOXB13	 0.04	 0.16	 N	 0.47	 1.0E-05	 Y	 0	 0.50	 N	 0	 0.50	 N	
ERG	 -0.28	 1.0E-05	 Y	 0.47	 1.0E-05	 Y	 0	 0.50	 N	 0.76	 1.0E-05	 Y	
SOX11	 -0.12	 2.0E-03	 Y	 0.47	 1.0E-05	 Y	 0	 0.50	 N	 0	 0.50	 N	
IFI16	 -0.24	 1.0E-05	 Y	 0.47	 1.0E-05	 Y	 0	 0.50	 N	 0	 0.50	 N	
SND1	 -0.24	 1.0E-05	 Y	 0.47	 1.0E-05	 Y	 0	 0.50	 N	 0	 0.50	 N	
CRABP2	 -0.15	 1.9E-04	 Y	 0.46	 1.0E-05	 Y	 0	 0.50	 N	 0	 0.50	 N	
SMARCB1	 -0.36	 1.0E-05	 Y	 0.45	 1.0E-05	 Y	 0	 0.50	 N	 0	 0.50	 N	
CLOCK	 -0.36	 1.0E-05	 Y	 0.44	 1.0E-05	 Y	 0	 0.50	 N	 0.08	 0.04	 Y	
KDM4C	 -0.39	 1.0E-05	 Y	 0.44	 1.0E-05	 Y	 0	 0.50	 N	 0	 0.50	 N	
ARID3A	 -0.21	 1.0E-05	 Y	 0.43	 1.0E-05	 Y	 0	 0.50	 N	 0	 0.50	 N	
STAT2	 -0.28	 1.0E-05	 Y	 0.43	 1.0E-05	 Y	 0	 0.50	 N	 0	 0.50	 N	
PPARGC1A	 -0.24	 1.0E-05	 Y	 0.43	 1.0E-05	 Y	 0	 0.50	 N	 0	 0.50	 N	
MCM6	 -0.45	 1.0E-05	 Y	 0.43	 1.0E-05	 Y	 0	 0.50	 N	 0	 0.50	 N	
SPIC	 -0.19	 1.0E-05	 Y	 0.42	 1.0E-05	 Y	 0	 0.50	 N	 0	 0.50	 N	
ATF5	 -0.39	 1.0E-05	 Y	 0.42	 1.0E-05	 Y	 0	 0.50	 N	 0	 0.50	 N	
TRIB3	 -0.30	 1.0E-05	 Y	 0.42	 1.0E-05	 Y	 0	 0.50	 N	 0	 0.50	 N	
FOXM1	 -0.36	 1.0E-05	 Y	 0.42	 1.0E-05	 Y	 0	 0.50	 N	 0	 0.50	 N	
NCOR1	 -0.30	 1.0E-05	 Y	 0.41	 1.0E-05	 Y	 0	 0.50	 N	 0	 0.50	 N	
SLC2A4RG	 -0.17	 6.0E-05	 Y	 0.40	 1.0E-05	 Y	 0	 0.50	 N	 0	 0.50	 N	
TBX21	 -0.33	 1.0E-05	 Y	 0.40	 1.0E-05	 Y	 0	 0.50	 N	 0	 0.50	 N	
CEBPZ	 -0.46	 1.0E-05	 Y	 0.39	 1.0E-05	 Y	 0	 0.50	 N	 0	 0.50	 N	
NCOA4	 -0.19	 1.0E-05	 Y	 0.39	 1.0E-05	 Y	 0	 0.50	 N	 0	 0.50	 N	
TP53BP1	 -0.17	 3.0E-05	 Y	 0.39	 1.0E-05	 Y	 0	 0.50	 N	 0	 0.50	 N	
ETV4	 -0.37	 1.0E-05	 Y	 0.39	 1.0E-05	 Y	 0	 0.50	 N	 0.52	 1.0E-05	 Y	
PPARG	 -0.31	 1.0E-05	 Y	 0.39	 1.0E-05	 Y	 -0.06	 0.09	 N	 0.15	 2.0E-04	 Y	
EAPP	 0.06	 0.07	 N	 0.39	 1.0E-05	 Y	 0	 0.50	 N	 0	 0.50	 N	
SKIL	 -0.20	 1.0E-05	 Y	 0.39	 1.0E-05	 Y	 0	 0.50	 N	 0	 0.50	 N	
EGR3	 -0.35	 1.0E-05	 Y	 0.38	 1.0E-05	 Y	 0	 0.50	 N	 0	 0.50	 N	
NR1H3	 -0.35	 1.0E-05	 Y	 0.38	 1.0E-05	 Y	 0	 0.50	 N	 0	 0.50	 N	
NCOA2	 -0.08	 0.03	 Y	 0.38	 1.0E-05	 Y	 0	 0.50	 N	 0	 0.50	 N	
MTA3	 -0.28	 1.0E-05	 Y	 0.37	 1.0E-05	 Y	 0	 0.50	 N	 0	 0.50	 N	
DDB2	 -0.01	 0.38	 N	 0.37	 1.0E-05	 Y	 0	 0.50	 N	 0	 0.50	 N	
MKL1	 -0.37	 1.0E-05	 Y	 0.37	 1.0E-05	 Y	 0	 0.50	 N	 0	 0.50	 N	
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RBMX	 -0.20	 1.0E-05	 Y	 0.37	 1.0E-05	 Y	 -0.68	 1.0E-05	 Y	 0	 0.50	 N	
POU2AF1	 -0.56	 1.0E-05	 Y	 0.36	 1.0E-05	 Y	 0	 0.50	 N	 0	 0.50	 N	
SIX1	 -0.15	 2.7E-04	 Y	 0.36	 1.0E-05	 Y	 0	 0.50	 N	 0	 0.50	 N	
TP63	 -0.07	 0.05	 Y	 0.36	 1.0E-05	 Y	 0	 0.50	 N	 0	 0.50	 N	
SFPQ	 0.11	 4.7E-03	 Y	 0.36	 1.0E-05	 Y	 0	 0.50	 N	 0	 0.50	 N	
TP73	 -0.53	 1.0E-05	 Y	 0.34	 1.0E-05	 Y	 0	 0.50	 N	 0	 0.50	 N	
HIPK2	 8.2E-03	 0.42	 N	 0.34	 1.0E-05	 Y	 0	 0.50	 N	 0	 0.50	 N	
EHMT2	 -0.03	 0.21	 N	 0.34	 1.0E-05	 Y	 0	 0.50	 N	 0	 0.50	 N	
ARNTL	 -0.07	 0.04	 Y	 0.34	 1.0E-05	 Y	 0	 0.50	 N	 0	 0.50	 N	
SREBF2	 -0.61	 1.0E-05	 Y	 0.33	 1.0E-05	 Y	 0	 0.50	 N	 0	 0.50	 N	
NFIX	 -0.08	 0.02	 Y	 0.33	 1.0E-05	 Y	 0	 0.50	 N	 0	 0.50	 N	
HDAC9	 -0.36	 1.0E-05	 Y	 0.33	 1.0E-05	 Y	 -0.41	 1.0E-05	 Y	 0	 0.50	 N	
PITX1	 -0.07	 0.04	 Y	 0.33	 1.0E-05	 Y	 -0.70	 1.0E-05	 Y	 0	 0.50	 N	
HDAC10	 -0.19	 1.0E-05	 Y	 0.33	 1.0E-05	 Y	 0	 0.50	 N	 0	 0.50	 N	
NR0B1	 -0.05	 0.12	 N	 0.33	 1.0E-05	 Y	 -0.47	 1.0E-05	 Y	 0	 0.50	 N	
CREB1	 -0.28	 1.0E-05	 Y	 0.32	 1.0E-05	 Y	 0.26	 1.0E-05	 Y	 0.37	 1.0E-05	 Y	
HOXC9	 -0.01	 0.38	 N	 0.32	 1.0E-05	 Y	 0	 0.50	 N	 0	 0.50	 N	
CRTC1	 -0.32	 1.0E-05	 Y	 0.31	 1.0E-05	 Y	 0	 0.50	 N	 0	 0.50	 N	
TLX1	 -0.21	 1.0E-05	 Y	 0.31	 1.0E-05	 Y	 0	 0.50	 N	 0	 0.50	 N	
RFX5	 0.11	 3.8E-03	 Y	 0.31	 1.0E-05	 Y	 0	 0.50	 N	 0	 0.50	 N	
IRF1	 -0.39	 1.0E-05	 Y	 0.31	 1.0E-05	 Y	 -0.11	 3.7E-03	 Y	 0.05	 0.12	 N	
APBB1	 -0.45	 1.0E-05	 Y	 0.31	 1.0E-05	 Y	 0	 0.50	 N	 0	 0.50	 N	
GATA3	 -0.04	 0.16	 N	 0.31	 1.0E-05	 Y	 -0.06	 0.08	 N	 0.31	 1.0E-05	 Y	
PLAG1	 -0.29	 1.0E-05	 Y	 0.30	 1.0E-05	 Y	 0	 0.50	 N	 0	 0.50	 N	
ELF4	 -0.23	 1.0E-05	 Y	 0.30	 1.0E-05	 Y	 0	 0.50	 N	 0	 0.50	 N	
DLX3	 0.01	 0.37	 N	 0.29	 1.0E-05	 Y	 0	 0.50	 N	 0	 0.50	 N	
FOXO3	 -0.42	 1.0E-05	 Y	 0.29	 1.0E-05	 Y	 0	 0.50	 N	 0.18	 3.0E-05	 Y	
E2F6	 -0.66	 1.0E-05	 Y	 0.29	 1.0E-05	 Y	 0	 0.50	 N	 0	 0.50	 N	
KLF8	 0.08	 0.03	 Y	 0.29	 1.0E-05	 Y	 0	 0.50	 N	 0	 0.50	 N	
HNF4A	 -0.26	 1.0E-05	 Y	 0.29	 1.0E-05	 Y	 0.03	 0.20	 N	 -0.11	 5.2E-03	 Y	
AES	 0.02	 0.35	 N	 0.28	 1.0E-05	 Y	 0	 0.50	 N	 0	 0.50	 N	
RUNX1	 -0.14	 4.9E-04	 Y	 0.28	 1.0E-05	 Y	 0	 0.50	 N	 0.07	 0.04	 Y	
LRRFIP1	 -0.25	 1.0E-05	 Y	 0.28	 1.0E-05	 Y	 0	 0.50	 N	 0	 0.50	 N	
NFIC	 -0.41	 1.0E-05	 Y	 0.28	 1.0E-05	 Y	 0	 0.50	 N	 0	 0.50	 N	
TEF	 -0.45	 1.0E-05	 Y	 0.28	 1.0E-05	 Y	 0	 0.50	 N	 0	 0.50	 N	
FOXL2	 -0.30	 1.0E-05	 Y	 0.28	 1.0E-05	 Y	 0	 0.50	 N	 0	 0.50	 N	
HCFC1	 0.16	 8.0E-05	 Y	 0.28	 1.0E-05	 Y	 0	 0.50	 N	 0	 0.50	 N	
ASCL1	 -0.34	 1.0E-05	 Y	 0.28	 1.0E-05	 Y	 0	 0.50	 N	 0	 0.50	 N	
REL	 0.14	 3.9E-04	 Y	 0.27	 1.0E-05	 Y	 0	 0.50	 N	 0.42	 1.0E-05	 Y	
STAT5B	 -0.21	 1.0E-05	 Y	 0.27	 1.0E-05	 Y	 0	 0.50	 N	 0	 0.50	 N	
GLI1	 -0.01	 0.37	 N	 0.27	 1.0E-05	 Y	 0	 0.50	 N	 0	 0.50	 N	
ESR1	 -0.47	 1.0E-05	 Y	 0.26	 1.0E-05	 Y	 0.21	 1.0E-05	 Y	 0.05	 0.13	 N	
DDIT3	 0.01	 0.37	 N	 0.26	 1.0E-05	 Y	 0	 0.50	 N	 0	 0.50	 N	
ETS2	 -0.33	 1.0E-05	 Y	 0.25	 1.0E-05	 Y	 0	 0.50	 N	 0.55	 1.0E-05	 Y	
TBX5	 -0.32	 1.0E-05	 Y	 0.25	 1.0E-05	 Y	 0	 0.50	 N	 0	 0.50	 N	
LHX2	 -0.27	 1.0E-05	 Y	 0.25	 1.0E-05	 Y	 0	 0.50	 N	 0	 0.50	 N	
NR2F2	 -0.31	 1.0E-05	 Y	 0.24	 1.0E-05	 Y	 0	 0.50	 N	 0	 0.50	 N	
MEF2D	 -0.14	 3.3E-04	 Y	 0.24	 1.0E-05	 Y	 0	 0.50	 N	 0	 0.50	 N	
HEY1	 -0.26	 1.0E-05	 Y	 0.24	 1.0E-05	 Y	 0	 0.50	 N	 0	 0.50	 N	
MDM4	 -0.10	 6.9E-03	 Y	 0.24	 1.0E-05	 Y	 0	 0.50	 N	 0	 0.50	 N	
MED1	 0.15	 9.0E-05	 Y	 0.24	 1.0E-05	 Y	 0	 0.50	 N	 0	 0.50	 N	
SP2	 -0.21	 1.0E-05	 Y	 0.23	 1.0E-05	 Y	 0	 0.50	 N	 0	 0.50	 N	
TRERF1	 -0.40	 1.0E-05	 Y	 0.23	 1.0E-05	 Y	 -0.66	 1.0E-05	 Y	 0	 0.50	 N	
STAT4	 1.5E-03	 0.49	 N	 0.23	 1.0E-05	 Y	 0	 0.50	 N	 0	 0.50	 N	
ELF1	 0.13	 7.9E-04	 Y	 0.23	 1.0E-05	 Y	 0	 0.50	 N	 0	 0.50	 N	
APC	 -0.19	 1.0E-05	 Y	 0.23	 1.0E-05	 Y	 0	 0.50	 N	 0	 0.50	 N	
STAT5A	 -0.02	 0.34	 N	 0.23	 1.0E-05	 Y	 0	 0.50	 N	 0	 0.50	 N	
ID4	 -0.54	 1.0E-05	 Y	 0.23	 1.0E-05	 Y	 0	 0.50	 N	 0	 0.50	 N	
KLF4	 -0.26	 1.0E-05	 Y	 0.23	 1.0E-05	 Y	 -0.45	 1.0E-05	 Y	 0.16	 8.0E-05	 Y	
ARNTL2	 -0.23	 1.0E-05	 Y	 0.23	 1.0E-05	 Y	 0	 0.50	 N	 0	 0.50	 N	
NR2E3	 -0.08	 0.03	 Y	 0.23	 1.0E-05	 Y	 0	 0.50	 N	 0	 0.50	 N	
HNF4G	 -0.15	 2.1E-04	 Y	 0.23	 1.0E-05	 Y	 0	 0.50	 N	 0	 0.50	 N	
CRX	 -0.26	 1.0E-05	 Y	 0.23	 1.0E-05	 Y	 0	 0.50	 N	 0	 0.50	 N	
POU2F2	 -0.08	 0.04	 Y	 0.22	 1.0E-05	 Y	 0	 0.50	 N	 0	 0.50	 N	
RARB	 -0.24	 1.0E-05	 Y	 0.22	 1.0E-05	 Y	 0	 0.50	 N	 0	 0.50	 N	
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PAWR	 0.14	 2.9E-04	 Y	 0.22	 1.0E-05	 Y	 0	 0.50	 N	 0	 0.50	 N	
KLF5	 -0.11	 3.3E-03	 Y	 0.22	 1.0E-05	 Y	 0.88	 1.0E-05	 Y	 0.44	 1.0E-05	 Y	
E2F1	 -0.57	 1.0E-05	 Y	 0.22	 1.0E-05	 Y	 0.62	 1.0E-05	 Y	 -0.09	 0.02	 Y	
PER1	 -0.14	 6.0E-04	 Y	 0.22	 1.0E-05	 Y	 0	 0.50	 N	 0	 0.50	 N	
POU5F1	 -0.39	 1.0E-05	 Y	 0.22	 1.0E-05	 Y	 -0.21	 1.0E-05	 Y	 0	 0.50	 N	
EPAS1	 0.02	 0.32	 N	 0.22	 1.0E-05	 Y	 0	 0.50	 N	 0	 0.50	 N	
KLF15	 -0.27	 1.0E-05	 Y	 0.22	 1.0E-05	 Y	 0	 0.50	 N	 0	 0.50	 N	
PURA	 0.02	 0.31	 N	 0.22	 1.0E-05	 Y	 0	 0.50	 N	 0	 0.50	 N	
TFDP1	 0.18	 2.0E-05	 Y	 0.21	 1.0E-05	 Y	 0.92	 1.0E-05	 Y	 0	 0.50	 N	
ATF2	 0.24	 1.0E-05	 Y	 0.21	 1.0E-05	 Y	 0	 0.50	 N	 0.51	 1.0E-05	 Y	
EIF2AK2	 -0.22	 1.0E-05	 Y	 0.21	 1.0E-05	 Y	 0	 0.50	 N	 0	 0.50	 N	
MSX1	 0.13	 1.1E-03	 Y	 0.21	 1.0E-05	 Y	 0	 0.50	 N	 0	 0.50	 N	
ESRRA	 -0.46	 1.0E-05	 Y	 0.21	 1.0E-05	 Y	 0	 0.50	 N	 0	 0.50	 N	
REST	 -0.06	 0.07	 N	 0.21	 1.0E-05	 Y	 -0.50	 1.0E-05	 Y	 -0.09	 0.02	 Y	
NHLH2	 0.11	 4.2E-03	 Y	 0.21	 1.0E-05	 Y	 0	 0.50	 N	 0	 0.50	 N	
RELB	 0.04	 0.17	 N	 0.21	 1.0E-05	 Y	 0	 0.50	 N	 0	 0.50	 N	
SMAD7	 -0.15	 1.9E-04	 Y	 0.21	 1.0E-05	 Y	 0	 0.50	 N	 0	 0.50	 N	
TAF4	 -0.12	 1.8E-03	 Y	 0.21	 1.0E-05	 Y	 0	 0.50	 N	 0	 0.50	 N	
PIAS1	 -0.25	 1.0E-05	 Y	 0.20	 2.0E-05	 Y	 0	 0.50	 N	 0	 0.50	 N	
KAT5	 -0.03	 0.20	 N	 0.20	 2.0E-05	 Y	 0	 0.50	 N	 0	 0.50	 N	
NFIL3	 -0.15	 2.8E-04	 Y	 0.20	 2.0E-05	 Y	 0	 0.50	 N	 0	 0.50	 N	
ELK3	 0.10	 7.7E-03	 Y	 0.19	 2.0E-05	 Y	 0	 0.50	 N	 0	 0.50	 N	
PHOX2B	 0.08	 0.04	 Y	 0.19	 2.0E-05	 Y	 0	 0.50	 N	 0	 0.50	 N	
NCOA3	 -0.06	 0.08	 N	 0.19	 2.0E-05	 Y	 0	 0.50	 N	 0	 0.50	 N	
NRF1	 -0.35	 1.0E-05	 Y	 0.19	 2.0E-05	 Y	 0	 0.50	 N	 0	 0.50	 N	
MEF2C	 -0.20	 1.0E-05	 Y	 0.19	 2.0E-05	 Y	 0	 0.50	 N	 0	 0.50	 N	
NRIP1	 0.11	 5.2E-03	 Y	 0.19	 2.0E-05	 Y	 0	 0.50	 N	 0	 0.50	 N	
KLF13	 -0.07	 0.04	 Y	 0.19	 2.0E-05	 Y	 0	 0.50	 N	 0	 0.50	 N	
ARNT	 -1.1E-03	 0.49	 N	 0.19	 2.0E-05	 Y	 0	 0.50	 N	 0	 0.50	 N	
SREBF1	 -0.04	 0.18	 N	 0.19	 2.0E-05	 Y	 0.04	 0.14	 N	 0	 0.50	 N	
POU1F1	 -0.16	 9.0E-05	 Y	 0.18	 2.0E-05	 Y	 0	 0.50	 N	 0	 0.50	 N	
MTA2	 0.03	 0.25	 N	 0.18	 2.0E-05	 Y	 0	 0.50	 N	 0	 0.50	 N	
PIAS2	 0.32	 1.0E-05	 Y	 0.18	 3.0E-05	 Y	 0	 0.50	 N	 0	 0.50	 N	
RUNX3	 -0.13	 1.2E-03	 Y	 0.18	 3.0E-05	 Y	 -0.34	 1.0E-05	 Y	 -0.03	 0.26	 N	
NFIB	 0.04	 0.19	 N	 0.18	 3.0E-05	 Y	 0	 0.50	 N	 0	 0.50	 N	
TOB1	 -1.5E-03	 0.49	 N	 0.17	 3.0E-05	 Y	 0	 0.50	 N	 0	 0.50	 N	
NELFB	 -0.21	 1.0E-05	 Y	 0.17	 3.0E-05	 Y	 0	 0.50	 N	 0	 0.50	 N	
RFX3	 -0.11	 3.0E-03	 Y	 0.17	 3.0E-05	 Y	 0	 0.50	 N	 0	 0.50	 N	
RFX1	 -0.11	 4.5E-03	 Y	 0.17	 6.0E-05	 Y	 0	 0.50	 N	 0	 0.50	 N	
APEX1	 -0.35	 1.0E-05	 Y	 0.17	 6.0E-05	 Y	 0	 0.50	 N	 0	 0.50	 N	
HOPX	 0.17	 3.0E-05	 Y	 0.17	 6.0E-05	 Y	 0	 0.50	 N	 0	 0.50	 N	
KHDRBS1	 0.12	 2.3E-03	 Y	 0.17	 6.0E-05	 Y	 0	 0.50	 N	 0	 0.50	 N	
DNMT1	 -0.34	 1.0E-05	 Y	 0.16	 6.0E-05	 Y	 0.37	 1.0E-05	 Y	 0	 0.50	 N	
MED23	 -0.15	 2.7E-04	 Y	 0.16	 6.0E-05	 Y	 0	 0.50	 N	 0	 0.50	 N	
GFI1	 -0.28	 1.0E-05	 Y	 0.16	 8.0E-05	 Y	 0	 0.50	 N	 0	 0.50	 N	
PROX1	 -0.16	 1.0E-04	 Y	 0.16	 8.0E-05	 Y	 0.37	 1.0E-05	 Y	 0	 0.50	 N	
LMX1B	 -0.11	 4.0E-03	 Y	 0.16	 8.0E-05	 Y	 0	 0.50	 N	 0	 0.50	 N	
FOXP2	 -0.33	 1.0E-05	 Y	 0.16	 8.0E-05	 Y	 0	 0.50	 N	 0	 0.50	 N	
MTA1	 -0.05	 0.12	 N	 0.16	 8.0E-05	 Y	 0	 0.50	 N	 0	 0.50	 N	
MAF	 -0.28	 1.0E-05	 Y	 0.15	 1.0E-04	 Y	 0	 0.50	 N	 0	 0.50	 N	
SATB2	 0.11	 5.3E-03	 Y	 0.15	 1.3E-04	 Y	 0	 0.50	 N	 0	 0.50	 N	
FOSL1	 -0.20	 1.0E-05	 Y	 0.15	 1.3E-04	 Y	 0	 0.50	 N	 0	 0.50	 N	
NPAS1	 0.18	 3.0E-05	 Y	 0.15	 1.7E-04	 Y	 0	 0.50	 N	 0	 0.50	 N	
NCOA1	 -0.14	 3.7E-04	 Y	 0.15	 2.0E-04	 Y	 0	 0.50	 N	 0	 0.50	 N	
DACH1	 -0.23	 1.0E-05	 Y	 0.14	 2.9E-04	 Y	 0	 0.50	 N	 0	 0.50	 N	
LMO3	 0.05	 0.11	 N	 0.14	 3.2E-04	 Y	 0	 0.50	 N	 0	 0.50	 N	
IRF2	 -0.16	 9.0E-05	 Y	 0.14	 3.2E-04	 Y	 0	 0.50	 N	 0	 0.50	 N	
BCL6	 -0.19	 1.0E-05	 Y	 0.14	 3.7E-04	 Y	 -0.33	 1.0E-05	 Y	 0	 0.50	 N	
TEAD1	 -6.0E-03	 0.44	 N	 0.14	 3.9E-04	 Y	 0	 0.50	 N	 0	 0.50	 N	
SOX17	 -0.48	 1.0E-05	 Y	 0.14	 3.9E-04	 Y	 0	 0.50	 N	 0	 0.50	 N	
RAD51	 -0.06	 0.07	 N	 0.14	 5.2E-04	 Y	 0	 0.50	 N	 0	 0.50	 N	
MITF	 -0.03	 0.23	 N	 0.13	 9.8E-04	 Y	 0	 0.50	 N	 0.45	 1.0E-05	 Y	
BACH1	 -0.10	 8.3E-03	 Y	 0.13	 1.2E-03	 Y	 0	 0.50	 N	 0	 0.50	 N	
HDAC5	 0.16	 8.0E-05	 Y	 0.12	 1.7E-03	 Y	 0	 0.50	 N	 0	 0.50	 N	
MZF1	 -0.27	 1.0E-05	 Y	 0.12	 1.8E-03	 Y	 0	 0.50	 N	 0	 0.50	 N	
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FOSB	 -0.28	 1.0E-05	 Y	 0.12	 2.0E-03	 Y	 0	 0.50	 N	 0	 0.50	 N	
SIN3A	 0.23	 1.0E-05	 Y	 0.12	 2.5E-03	 Y	 0	 0.50	 N	 0	 0.50	 N	
TFAP2B	 -0.19	 1.0E-05	 Y	 0.12	 2.7E-03	 Y	 0	 0.50	 N	 0	 0.50	 N	
AIP	 -0.20	 1.0E-05	 Y	 0.11	 3.1E-03	 Y	 0	 0.50	 N	 0	 0.50	 N	
CBX8	 0.29	 1.0E-05	 Y	 0.11	 3.4E-03	 Y	 0	 0.50	 N	 0	 0.50	 N	
LHX4	 -0.05	 0.12	 N	 0.11	 3.4E-03	 Y	 0	 0.50	 N	 0	 0.50	 N	
L3MBTL1	 -0.24	 1.0E-05	 Y	 0.11	 3.6E-03	 Y	 0	 0.50	 N	 0	 0.50	 N	
PAX4	 -0.46	 1.0E-05	 Y	 0.11	 4.6E-03	 Y	 0	 0.50	 N	 0	 0.50	 N	
NR4A3	 0.33	 1.0E-05	 Y	 0.11	 5.7E-03	 Y	 0	 0.50	 N	 0	 0.50	 N	
SMAD4	 -0.51	 1.0E-05	 Y	 0.10	 6.0E-03	 Y	 0	 0.50	 N	 0	 0.50	 N	
ERCC2	 0.20	 2.0E-05	 Y	 0.10	 6.0E-03	 Y	 0	 0.50	 N	 0	 0.50	 N	
ETV2	 -0.27	 1.0E-05	 Y	 0.10	 6.7E-03	 Y	 0	 0.50	 N	 0	 0.50	 N	
JDP2	 -0.22	 1.0E-05	 Y	 0.10	 7.6E-03	 Y	 0	 0.50	 N	 0	 0.50	 N	
E2F7	 -0.02	 0.36	 N	 0.10	 8.6E-03	 Y	 0	 0.50	 N	 0	 0.50	 N	
STAT6	 -0.24	 1.0E-05	 Y	 0.10	 8.8E-03	 Y	 0	 0.50	 N	 0.26	 1.0E-05	 Y	
GTF3A	 -0.25	 1.0E-05	 Y	 0.10	 8.9E-03	 Y	 0	 0.50	 N	 0	 0.50	 N	
RBPJ	 0.08	 0.04	 Y	 0.10	 9.2E-03	 Y	 0	 0.50	 N	 0	 0.50	 N	
SIM2	 0.29	 1.0E-05	 Y	 0.10	 9.5E-03	 Y	 0	 0.50	 N	 0	 0.50	 N	
STAT3	 0.08	 0.04	 Y	 0.10	 9.8E-03	 Y	 0.23	 1.0E-05	 Y	 0.35	 1.0E-05	 Y	
FOXH1	 0.14	 3.2E-04	 Y	 0.10	 0.01	 Y	 0	 0.50	 N	 0	 0.50	 N	
FOXF1	 -0.24	 1.0E-05	 Y	 0.10	 0.01	 Y	 0	 0.50	 N	 0	 0.50	 N	
TCF7L2	 0.04	 0.18	 N	 0.10	 0.01	 Y	 0	 0.50	 N	 0	 0.50	 N	
NFKB1	 -0.26	 1.0E-05	 Y	 0.10	 0.01	 Y	 0.12	 2.6E-03	 Y	 0.36	 1.0E-05	 Y	
DBP	 -0.05	 0.10	 N	 0.09	 0.01	 Y	 0	 0.50	 N	 0	 0.50	 N	
CDX2	 -0.14	 4.9E-04	 Y	 0.09	 0.01	 Y	 0	 0.50	 N	 0.08	 0.03	 Y	
MYCN	 -0.07	 0.04	 Y	 0.09	 0.02	 Y	 0.40	 1.0E-05	 Y	 0.12	 1.8E-03	 Y	
JUNB	 -0.43	 1.0E-05	 Y	 0.09	 0.02	 Y	 0	 0.50	 N	 0	 0.50	 N	
DLX5	 -0.02	 0.31	 N	 0.09	 0.02	 Y	 0	 0.50	 N	 0	 0.50	 N	
SOX6	 -0.09	 0.02	 Y	 0.08	 0.02	 Y	 0	 0.50	 N	 0	 0.50	 N	
MXI1	 0.15	 1.3E-04	 Y	 0.08	 0.02	 Y	 0	 0.50	 N	 0	 0.50	 N	
ARID1A	 0.09	 0.01	 Y	 0.08	 0.03	 Y	 0	 0.50	 N	 0	 0.50	 N	
ISL1	 -0.22	 1.0E-05	 Y	 0.08	 0.03	 Y	 0	 0.50	 N	 0	 0.50	 N	
SRCAP	 -0.05	 0.10	 N	 0.08	 0.03	 Y	 0	 0.50	 N	 0	 0.50	 N	
RNF14	 -9.0E-03	 0.42	 N	 0.08	 0.03	 Y	 0	 0.50	 N	 0	 0.50	 N	
HOXB1	 0.15	 1.4E-04	 Y	 0.08	 0.03	 Y	 0	 0.50	 N	 0	 0.50	 N	
HNF1A	 -0.39	 1.0E-05	 Y	 0.08	 0.03	 Y	 0	 0.50	 N	 0	 0.50	 N	
FOXN1	 -0.09	 0.02	 Y	 0.08	 0.03	 Y	 0	 0.50	 N	 0	 0.50	 N	
ETV3	 -0.05	 0.12	 N	 0.08	 0.04	 Y	 0	 0.50	 N	 0	 0.50	 N	
FHL2	 -0.17	 3.0E-05	 Y	 0.07	 0.04	 Y	 0	 0.50	 N	 0	 0.50	 N	
ETV6	 -0.28	 1.0E-05	 Y	 0.07	 0.04	 Y	 0	 0.50	 N	 0	 0.50	 N	
THRA	 -0.26	 1.0E-05	 Y	 0.07	 0.05	 Y	 0	 0.50	 N	 0	 0.50	 N	
BCL3	 -0.09	 0.02	 Y	 0.07	 0.05	 N	 0	 0.50	 N	 0	 0.50	 N	
SP3	 -0.08	 0.02	 Y	 0.07	 0.05	 N	 0.12	 2.3E-03	 Y	 0.03	 0.20	 N	
ARID1B	 -0.25	 1.0E-05	 Y	 0.07	 0.05	 N	 0	 0.50	 N	 0	 0.50	 N	
PBX1	 0.35	 1.0E-05	 Y	 0.07	 0.05	 N	 0	 0.50	 N	 0	 0.50	 N	
HDGF	 -0.04	 0.18	 N	 0.07	 0.06	 N	 0	 0.50	 N	 0	 0.50	 N	
CTNNB1	 -0.12	 1.9E-03	 Y	 0.07	 0.06	 N	 0	 0.50	 N	 0	 0.50	 N	
NR2F6	 0.16	 8.0E-05	 Y	 0.06	 0.07	 N	 0	 0.50	 N	 0	 0.50	 N	
HOXC10	 -0.23	 1.0E-05	 Y	 0.06	 0.07	 N	 0	 0.50	 N	 0	 0.50	 N	
PAX2	 -0.09	 0.02	 Y	 0.06	 0.07	 N	 0	 0.50	 N	 0	 0.50	 N	
ESR2	 0.04	 0.16	 N	 0.06	 0.07	 N	 0	 0.50	 N	 0	 0.50	 N	
E2F3	 -0.20	 1.0E-05	 Y	 0.06	 0.07	 N	 0	 0.50	 N	 0	 0.50	 N	
THRB	 -0.12	 2.6E-03	 Y	 0.06	 0.08	 N	 0	 0.50	 N	 0	 0.50	 N	
CITED2	 -0.40	 1.0E-05	 Y	 0.06	 0.09	 N	 0	 0.50	 N	 0	 0.50	 N	
SIRT2	 0.24	 1.0E-05	 Y	 0.06	 0.09	 N	 0	 0.50	 N	 0	 0.50	 N	
MECP2	 0.34	 1.0E-05	 Y	 0.06	 0.09	 N	 0	 0.50	 N	 0	 0.50	 N	
PLAGL1	 -0.27	 1.0E-05	 Y	 0.06	 0.09	 N	 0	 0.50	 N	 0	 0.50	 N	
NR5A2	 -0.14	 5.9E-04	 Y	 0.05	 0.10	 N	 0	 0.50	 N	 -0.03	 0.25	 N	
SUPT3H	 -0.05	 0.10	 N	 0.05	 0.10	 N	 0	 0.50	 N	 0	 0.50	 N	
PRDM14	 0.33	 1.0E-05	 Y	 0.05	 0.11	 N	 0	 0.50	 N	 0	 0.50	 N	
RFWD2	 0.02	 0.36	 N	 0.05	 0.11	 N	 0	 0.50	 N	 0	 0.50	 N	
FOXQ1	 -0.05	 0.13	 N	 0.05	 0.12	 N	 0	 0.50	 N	 0	 0.50	 N	
TCF19	 -0.48	 1.0E-05	 Y	 0.05	 0.13	 N	 0	 0.50	 N	 0	 0.50	 N	
GTF2I	 -0.05	 0.10	 N	 0.05	 0.13	 N	 0	 0.50	 N	 0	 0.50	 N	
MAFA	 0.19	 2.0E-05	 Y	 0.05	 0.14	 N	 0	 0.50	 N	 0	 0.50	 N	
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ILF3	 -0.22	 1.0E-05	 Y	 0.04	 0.17	 N	 0	 0.50	 N	 0	 0.50	 N	
LMO2	 -0.30	 1.0E-05	 Y	 0.04	 0.17	 N	 0	 0.50	 N	 0	 0.50	 N	
PCGF2	 0.14	 2.9E-04	 Y	 0.04	 0.18	 N	 0	 0.50	 N	 0	 0.50	 N	
OTX2	 -0.30	 1.0E-05	 Y	 0.04	 0.19	 N	 0	 0.50	 N	 0	 0.50	 N	
NPM1	 0.13	 1.3E-03	 Y	 0.04	 0.19	 N	 0	 0.50	 N	 0	 0.50	 N	
MLLT10	 -0.08	 0.02	 Y	 0.03	 0.22	 N	 0	 0.50	 N	 0	 0.50	 N	
MYOCD	 0.05	 0.11	 N	 0.03	 0.24	 N	 0	 0.50	 N	 0	 0.50	 N	
SMARCA1	 0.02	 0.30	 N	 0.03	 0.24	 N	 0	 0.50	 N	 0	 0.50	 N	
HEY2	 -0.19	 1.0E-05	 Y	 0.02	 0.28	 N	 0	 0.50	 N	 0	 0.50	 N	
CBX7	 0.23	 1.0E-05	 Y	 0.02	 0.28	 N	 0	 0.50	 N	 0	 0.50	 N	
GFI1B	 -0.18	 1.0E-05	 Y	 0.02	 0.29	 N	 0	 0.50	 N	 0	 0.50	 N	
SETBP1	 -0.09	 0.02	 Y	 0.02	 0.30	 N	 0	 0.50	 N	 0	 0.50	 N	
NFYB	 -0.13	 1.1E-03	 Y	 0.02	 0.30	 N	 0	 0.50	 N	 0	 0.50	 N	
PITX2	 0.40	 1.0E-05	 Y	 0.02	 0.31	 N	 0	 0.50	 N	 0	 0.50	 N	
E4F1	 -0.02	 0.28	 N	 0.02	 0.31	 N	 0	 0.50	 N	 0	 0.50	 N	
NELFCD	 0.20	 2.0E-05	 Y	 0.02	 0.32	 N	 0	 0.50	 N	 0	 0.50	 N	
GCM2	 -0.03	 0.24	 N	 0.02	 0.32	 N	 0	 0.50	 N	 0	 0.50	 N	
SF1	 -0.04	 0.20	 N	 0.02	 0.33	 N	 0	 0.50	 N	 0	 0.50	 N	
RB1CC1	 -0.14	 5.8E-04	 Y	 0.02	 0.34	 N	 0	 0.50	 N	 0	 0.50	 N	
CEBPA	 -0.26	 1.0E-05	 Y	 0.01	 0.37	 N	 0	 0.50	 N	 -0.10	 0.01	 Y	
SOX10	 -0.03	 0.21	 N	 0.01	 0.38	 N	 0	 0.50	 N	 0	 0.50	 N	
DEK	 -0.15	 2.5E-04	 Y	 0.01	 0.40	 N	 0	 0.50	 N	 0	 0.50	 N	
FOXD3	 0.37	 1.0E-05	 Y	 6.9E-03	 0.43	 N	 0	 0.50	 N	 0	 0.50	 N	
ILF2	 0.12	 2.5E-03	 Y	 6.3E-03	 0.44	 N	 0	 0.50	 N	 0	 0.50	 N	
KLF2	 0.35	 1.0E-05	 Y	 5.7E-03	 0.45	 N	 0	 0.50	 N	 0.18	 3.0E-05	 Y	
TAF1	 0.24	 1.0E-05	 Y	 4.3E-03	 0.46	 N	 0	 0.50	 N	 0	 0.50	 N	
RUNX2	 -0.13	 1.1E-03	 Y	 2.6E-03	 0.48	 N	 0	 0.50	 N	 0.60	 1.0E-05	 Y	
CTBP1	 -0.10	 8.9E-03	 Y	 2.1E-03	 0.48	 N	 0	 0.50	 N	 0	 0.50	 N	
GATA4	 0.17	 3.0E-05	 Y	 1.1E-03	 0.49	 N	 0.15	 1.1E-04	 Y	 0	 0.50	 N	
SPI1	 0.08	 0.02	 Y	 5.1E-04	 0.50	 N	 0	 0.50	 N	 0.53	 1.0E-05	 Y	
SATB1	 -0.17	 5.0E-05	 Y	 2.4E-05	 0.50	 N	 0	 0.50	 N	 0	 0.50	 N	
PKNOX1	 0.03	 0.27	 N	 -5.4E-04	 0.49	 N	 0	 0.50	 N	 0	 0.50	 N	
SOX3	 0.34	 1.0E-05	 Y	 -1.7E-03	 0.48	 N	 0	 0.50	 N	 0	 0.50	 N	
GCM1	 -0.05	 0.13	 N	 -2.8E-03	 0.47	 N	 0	 0.50	 N	 0	 0.50	 N	
NFIA	 0.28	 1.0E-05	 Y	 -4.5E-03	 0.46	 N	 0	 0.50	 N	 0	 0.50	 N	
MAFB	 0.02	 0.30	 N	 -6.6E-03	 0.44	 N	 0	 0.50	 N	 0	 0.50	 N	
HDAC4	 0.08	 0.02	 Y	 -7.5E-03	 0.43	 N	 -0.33	 1.0E-05	 Y	 0	 0.50	 N	
HDAC11	 0.26	 1.0E-05	 Y	 -8.1E-03	 0.42	 N	 0	 0.50	 N	 0	 0.50	 N	
TFDP3	 -7.6E-03	 0.43	 N	 -0.01	 0.40	 N	 0	 0.50	 N	 0	 0.50	 N	
NR1I2	 0.32	 1.0E-05	 Y	 -0.01	 0.37	 N	 0	 0.50	 N	 0.26	 1.0E-05	 Y	
NR1D1	 0.11	 3.5E-03	 Y	 -0.02	 0.34	 N	 0	 0.50	 N	 0	 0.50	 N	
ATRX	 -0.05	 0.10	 N	 -0.02	 0.33	 N	 0	 0.50	 N	 0	 0.50	 N	
PITX3	 -0.30	 1.0E-05	 Y	 -0.02	 0.31	 N	 0	 0.50	 N	 0	 0.50	 N	
SSB	 -0.03	 0.27	 N	 -0.02	 0.28	 N	 0	 0.50	 N	 0	 0.50	 N	
ECD	 0.14	 2.6E-04	 Y	 -0.03	 0.27	 N	 0	 0.50	 N	 0	 0.50	 N	
HES1	 0.08	 0.02	 Y	 -0.03	 0.26	 N	 -0.37	 1.0E-05	 Y	 0	 0.50	 N	
CUX1	 -0.20	 1.0E-05	 Y	 -0.03	 0.25	 N	 0	 0.50	 N	 0	 0.50	 N	
POU4F2	 -0.09	 0.01	 Y	 -0.03	 0.25	 N	 0	 0.50	 N	 0	 0.50	 N	
EN1	 0.21	 1.0E-05	 Y	 -0.03	 0.24	 N	 0	 0.50	 N	 0	 0.50	 N	
GBX2	 -0.02	 0.28	 N	 -0.03	 0.23	 N	 0	 0.50	 N	 0	 0.50	 N	
HIC1	 0.02	 0.36	 N	 -0.03	 0.22	 N	 0	 0.50	 N	 0	 0.50	 N	
HSF4	 0.17	 3.0E-05	 Y	 -0.03	 0.21	 N	 0	 0.50	 N	 0	 0.50	 N	
ANKRD1	 0.12	 2.9E-03	 Y	 -0.03	 0.21	 N	 0	 0.50	 N	 0	 0.50	 N	
MLXIPL	 0.25	 1.0E-05	 Y	 -0.03	 0.21	 N	 0	 0.50	 N	 0	 0.50	 N	
NFATC3	 0.28	 1.0E-05	 Y	 -0.03	 0.21	 N	 0	 0.50	 N	 0	 0.50	 N	
MYF5	 0.02	 0.28	 N	 -0.04	 0.19	 N	 0	 0.50	 N	 0	 0.50	 N	
ATM	 0.15	 8.0E-05	 Y	 -0.04	 0.19	 N	 -0.02	 0.33	 N	 0.23	 1.0E-05	 Y	
RUVBL1	 0.39	 1.0E-05	 Y	 -0.04	 0.18	 N	 0	 0.50	 N	 0	 0.50	 N	
HOXD9	 -0.03	 0.21	 N	 -0.04	 0.15	 N	 0	 0.50	 N	 0	 0.50	 N	
ATF1	 0.08	 0.03	 Y	 -0.04	 0.15	 N	 0	 0.50	 N	 0.58	 1.0E-05	 Y	
NR1I3	 0.23	 1.0E-05	 Y	 -0.05	 0.14	 N	 0	 0.50	 N	 0	 0.50	 N	
RBL2	 0.23	 1.0E-05	 Y	 -0.05	 0.14	 N	 0	 0.50	 N	 0	 0.50	 N	
JUND	 0.29	 1.0E-05	 Y	 -0.05	 0.13	 N	 0	 0.50	 N	 0	 0.50	 N	
SHOX	 0.01	 0.40	 N	 -0.05	 0.12	 N	 0	 0.50	 N	 0	 0.50	 N	
FOXO4	 0.17	 6.0E-05	 Y	 -0.05	 0.11	 N	 0	 0.50	 N	 0	 0.50	 N	
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SALL3	 -0.20	 1.0E-05	 Y	 -0.05	 0.11	 N	 0	 0.50	 N	 0	 0.50	 N	
HAX1	 -0.11	 3.6E-03	 Y	 -0.05	 0.11	 N	 0	 0.50	 N	 0	 0.50	 N	
SP1	 0.29	 1.0E-05	 Y	 -0.05	 0.10	 N	 0.32	 1.0E-05	 Y	 0.32	 1.0E-05	 Y	
KLF16	 0.02	 0.29	 N	 -0.05	 0.10	 N	 0	 0.50	 N	 0	 0.50	 N	
HOXA5	 -0.03	 0.21	 N	 -0.05	 0.10	 N	 0	 0.50	 N	 0	 0.50	 N	
LEF1	 0.09	 0.01	 Y	 -0.06	 0.09	 N	 -0.10	 7.0E-03	 Y	 0.07	 0.04	 N	
EGR2	 -0.02	 0.29	 N	 -0.06	 0.09	 N	 0	 0.50	 N	 0	 0.50	 N	
NR3C2	 0.29	 1.0E-05	 Y	 -0.06	 0.09	 N	 0	 0.50	 N	 0	 0.50	 N	
TEAD4	 0.35	 1.0E-05	 Y	 -0.06	 0.08	 N	 0	 0.50	 N	 0	 0.50	 N	
BCL11B	 -8.5E-04	 0.49	 N	 -0.06	 0.08	 N	 0	 0.50	 N	 0	 0.50	 N	
ELL	 -0.28	 1.0E-05	 Y	 -0.06	 0.07	 N	 0	 0.50	 N	 0	 0.50	 N	
RELA	 -0.26	 1.0E-05	 Y	 -0.06	 0.07	 N	 0.10	 8.1E-03	 Y	 0.33	 1.0E-05	 Y	
FUS	 -0.03	 0.27	 N	 -0.06	 0.07	 N	 0	 0.50	 N	 0	 0.50	 N	
NFATC2	 0.30	 1.0E-05	 Y	 -0.06	 0.07	 N	 0	 0.50	 N	 0	 0.50	 N	
AR	 0.20	 2.0E-05	 Y	 -0.07	 0.06	 N	 -0.23	 1.0E-05	 Y	 0.28	 1.0E-05	 Y	
ELK4	 -0.06	 0.08	 N	 -0.07	 0.05	 N	 0	 0.50	 N	 0	 0.50	 N	
GLI2	 0.36	 1.0E-05	 Y	 -0.07	 0.05	 N	 0	 0.50	 N	 0.10	 7.7E-03	 Y	
TBX2	 -0.08	 0.03	 Y	 -0.07	 0.05	 Y	 0	 0.50	 N	 0	 0.50	 N	
NPAS2	 -0.03	 0.26	 N	 -0.07	 0.04	 Y	 0	 0.50	 N	 0	 0.50	 N	
GLI3	 0.07	 0.05	 N	 -0.07	 0.04	 Y	 0	 0.50	 N	 0	 0.50	 N	
NFAT5	 0.22	 1.0E-05	 Y	 -0.07	 0.04	 Y	 0	 0.50	 N	 0	 0.50	 N	
PLAGL2	 0.27	 1.0E-05	 Y	 -0.08	 0.03	 Y	 0	 0.50	 N	 0	 0.50	 N	
TCF4	 -0.17	 4.0E-05	 Y	 -0.08	 0.02	 Y	 0.14	 3.2E-04	 Y	 0	 0.50	 N	
HHEX	 0.17	 3.0E-05	 Y	 -0.08	 0.02	 Y	 0	 0.50	 N	 0	 0.50	 N	
SNAI2	 0.04	 0.15	 N	 -0.08	 0.02	 Y	 -0.18	 1.0E-05	 Y	 0.46	 1.0E-05	 Y	
CTCF	 -0.10	 5.9E-03	 Y	 -0.08	 0.02	 Y	 0	 0.50	 N	 -0.48	 1.0E-05	 Y	
HOXC13	 -0.25	 1.0E-05	 Y	 -0.09	 0.02	 Y	 0	 0.50	 N	 0	 0.50	 N	
ETS1	 0.05	 0.12	 N	 -0.09	 0.02	 Y	 0.17	 6.0E-05	 Y	 0.34	 1.0E-05	 Y	
NR3C1	 0.16	 7.0E-05	 Y	 -0.09	 0.02	 Y	 -0.06	 0.09	 N	 -0.06	 0.09	 N	
NKX2-1	 -0.05	 0.14	 N	 -0.09	 0.02	 Y	 0	 0.50	 N	 0	 0.50	 N	
SNAI1	 -0.04	 0.16	 N	 -0.09	 0.02	 Y	 0	 0.50	 N	 0	 0.50	 N	
NAB2	 0.14	 5.6E-04	 Y	 -0.09	 0.02	 Y	 0	 0.50	 N	 0	 0.50	 N	
MBD1	 0.27	 1.0E-05	 Y	 -0.09	 0.01	 Y	 0	 0.50	 N	 0	 0.50	 N	
NR5A1	 0.10	 1.0E-02	 Y	 -0.09	 0.01	 Y	 0	 0.50	 N	 0.07	 0.04	 N	
GATA6	 -0.25	 1.0E-05	 Y	 -0.10	 9.8E-03	 Y	 0	 0.50	 N	 0	 0.50	 N	
NFYA	 0.12	 2.6E-03	 Y	 -0.10	 9.7E-03	 Y	 0	 0.50	 N	 0.36	 1.0E-05	 Y	
PML	 0.17	 6.0E-05	 Y	 -0.10	 8.7E-03	 Y	 0	 0.50	 N	 0.32	 1.0E-05	 Y	
ING4	 0.15	 2.1E-04	 Y	 -0.10	 7.2E-03	 Y	 0.08	 0.02	 N	 0	 0.50	 N	
IRF3	 0.09	 0.02	 Y	 -0.11	 5.0E-03	 Y	 0	 0.50	 N	 0	 0.50	 N	
NFE2L2	 0.36	 1.0E-05	 Y	 -0.11	 3.7E-03	 Y	 0	 0.50	 N	 0.14	 2.6E-04	 Y	
NCOR2	 -7.7E-03	 0.43	 N	 -0.11	 3.1E-03	 Y	 0	 0.50	 N	 0	 0.50	 N	
HDAC2	 0.31	 1.0E-05	 Y	 -0.11	 3.0E-03	 Y	 -0.51	 1.0E-05	 Y	 -0.57	 1.0E-05	 Y	
ELF3	 0.19	 2.0E-05	 Y	 -0.11	 3.0E-03	 Y	 0	 0.50	 N	 0	 0.50	 N	
ATF4	 -0.11	 4.4E-03	 Y	 -0.12	 1.7E-03	 Y	 0.58	 1.0E-05	 Y	 0.42	 1.0E-05	 Y	
PAX3	 -0.31	 1.0E-05	 Y	 -0.12	 1.7E-03	 Y	 0	 0.50	 N	 0	 0.50	 N	
HMGA1	 -0.15	 2.7E-04	 Y	 -0.12	 1.6E-03	 Y	 0	 0.50	 N	 0	 0.50	 N	
MYOG	 -0.06	 0.08	 N	 -0.12	 1.6E-03	 Y	 0	 0.50	 N	 0	 0.50	 N	
PAX6	 0.55	 1.0E-05	 Y	 -0.13	 1.1E-03	 Y	 0	 0.50	 N	 0	 0.50	 N	
PPARA	 -0.20	 1.0E-05	 Y	 -0.13	 1.1E-03	 Y	 -0.45	 1.0E-05	 Y	 0.09	 0.01	 Y	
MCM4	 -0.10	 8.3E-03	 Y	 -0.13	 9.9E-04	 Y	 0	 0.50	 N	 0	 0.50	 N	
NF1	 -0.02	 0.33	 N	 -0.13	 9.4E-04	 Y	 0	 0.50	 N	 0	 0.50	 N	
NR4A2	 0.06	 0.07	 N	 -0.13	 9.2E-04	 Y	 0	 0.50	 N	 0	 0.50	 N	
EP300	 0.04	 0.19	 N	 -0.13	 7.6E-04	 Y	 0.33	 1.0E-05	 Y	 0.16	 8.0E-05	 Y	
TBX3	 0.25	 1.0E-05	 Y	 -0.14	 5.8E-04	 Y	 0	 0.50	 N	 0	 0.50	 N	
HLF	 -0.17	 6.0E-05	 Y	 -0.14	 5.1E-04	 Y	 0	 0.50	 N	 0	 0.50	 N	
MAZ	 -0.12	 1.5E-03	 Y	 -0.14	 5.0E-04	 Y	 0	 0.50	 N	 0	 0.50	 N	
MTF1	 0.16	 8.0E-05	 Y	 -0.14	 4.9E-04	 Y	 0	 0.50	 N	 0	 0.50	 N	
FOXF2	 0.22	 1.0E-05	 Y	 -0.14	 4.6E-04	 Y	 0	 0.50	 N	 0	 0.50	 N	
ONECUT2	 0.14	 2.5E-04	 Y	 -0.14	 4.3E-04	 Y	 0	 0.50	 N	 0	 0.50	 N	
IKZF1	 0.19	 2.0E-05	 Y	 -0.14	 4.0E-04	 Y	 0	 0.50	 N	 0	 0.50	 N	
FOXA2	 -0.03	 0.27	 N	 -0.14	 3.7E-04	 Y	 0	 0.50	 N	 0	 0.50	 N	
TCF12	 -0.17	 5.0E-05	 Y	 -0.14	 3.4E-04	 Y	 0	 0.50	 N	 0	 0.50	 N	
SMARCA4	 -0.19	 1.0E-05	 Y	 -0.14	 3.3E-04	 Y	 0	 0.50	 N	 0	 0.50	 N	
SUGP1	 0.14	 3.9E-04	 Y	 -0.14	 3.2E-04	 Y	 0	 0.50	 N	 0	 0.50	 N	
FOSL2	 0.17	 6.0E-05	 Y	 -0.14	 3.1E-04	 Y	 0	 0.50	 N	 0	 0.50	 N	
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PAX5	 0.20	 2.0E-05	 Y	 -0.15	 2.7E-04	 Y	 -0.07	 0.04	 N	 0.20	 2.0E-05	 Y	
DR1	 0.05	 0.10	 N	 -0.15	 2.5E-04	 Y	 0	 0.50	 N	 0	 0.50	 N	
ELF2	 -0.15	 2.8E-04	 Y	 -0.15	 1.6E-04	 Y	 0	 0.50	 N	 0	 0.50	 N	
NUPR1	 0.17	 6.0E-05	 Y	 -0.16	 1.0E-04	 Y	 0	 0.50	 N	 0	 0.50	 N	
PIAS3	 -0.24	 1.0E-05	 Y	 -0.16	 8.0E-05	 Y	 0	 0.50	 N	 0	 0.50	 N	
FOXE1	 -0.01	 0.39	 N	 -0.16	 7.0E-05	 Y	 0	 0.50	 N	 0	 0.50	 N	
FOS	 -0.17	 4.0E-05	 Y	 -0.17	 6.0E-05	 Y	 -0.14	 4.9E-04	 Y	 0.28	 1.0E-05	 Y	
KDM2A	 0.11	 5.2E-03	 Y	 -0.17	 6.0E-05	 Y	 0	 0.50	 N	 0	 0.50	 N	
FOXC1	 0.15	 8.0E-05	 Y	 -0.17	 6.0E-05	 Y	 0	 0.50	 N	 0	 0.50	 N	
SMAD3	 0.29	 1.0E-05	 Y	 -0.17	 6.0E-05	 Y	 0	 0.50	 N	 0	 0.50	 N	
NRL	 0.34	 1.0E-05	 Y	 -0.17	 4.0E-05	 Y	 0	 0.50	 N	 0	 0.50	 N	
KLF10	 -0.30	 1.0E-05	 Y	 -0.17	 4.0E-05	 Y	 0	 0.50	 N	 0	 0.50	 N	
TBPL1	 -2.4E-04	 0.50	 N	 -0.17	 3.0E-05	 Y	 0	 0.50	 N	 0	 0.50	 N	
SP7	 0.09	 0.01	 Y	 -0.17	 3.0E-05	 Y	 0	 0.50	 N	 0	 0.50	 N	
HR	 0.21	 1.0E-05	 Y	 -0.18	 2.0E-05	 Y	 0	 0.50	 N	 0	 0.50	 N	
SOX9	 0.23	 1.0E-05	 Y	 -0.18	 2.0E-05	 Y	 0.18	 2.0E-05	 Y	 0.10	 7.3E-03	 Y	
HIF1A	 -0.08	 0.03	 Y	 -0.18	 2.0E-05	 Y	 0.34	 1.0E-05	 Y	 0.29	 1.0E-05	 Y	
NOTCH3	 0.15	 2.0E-04	 Y	 -0.18	 2.0E-05	 Y	 0	 0.50	 N	 0	 0.50	 N	
PPARD	 -0.12	 2.0E-03	 Y	 -0.18	 1.0E-05	 Y	 0	 0.50	 N	 0.06	 0.09	 N	
TFAP2C	 -0.10	 6.3E-03	 Y	 -0.18	 1.0E-05	 Y	 0	 0.50	 N	 0	 0.50	 N	
CREBBP	 -0.18	 1.0E-05	 Y	 -0.18	 1.0E-05	 Y	 0	 0.50	 N	 0	 0.50	 N	
NR2C2	 0.17	 5.0E-05	 Y	 -0.18	 1.0E-05	 Y	 0	 0.50	 N	 0	 0.50	 N	
EVX1	 0.32	 1.0E-05	 Y	 -0.19	 1.0E-05	 Y	 0	 0.50	 N	 0	 0.50	 N	
IRF4	 0.29	 1.0E-05	 Y	 -0.19	 1.0E-05	 Y	 0	 0.50	 N	 0	 0.50	 N	
SOX2	 0.15	 8.0E-05	 Y	 -0.19	 1.0E-05	 Y	 0.32	 1.0E-05	 Y	 -0.28	 1.0E-05	 Y	
E2F4	 -0.14	 5.3E-04	 Y	 -0.19	 1.0E-05	 Y	 0	 0.50	 N	 -0.66	 1.0E-05	 Y	
MYC	 0.08	 0.02	 Y	 -0.19	 1.0E-05	 Y	 0.46	 1.0E-05	 Y	 0.28	 1.0E-05	 Y	
IRF8	 0.10	 7.1E-03	 Y	 -0.19	 1.0E-05	 Y	 0	 0.50	 N	 0	 0.50	 N	
OTX1	 0.15	 2.0E-04	 Y	 -0.19	 1.0E-05	 Y	 0	 0.50	 N	 0	 0.50	 N	
CEBPE	 -0.11	 4.3E-03	 Y	 -0.19	 1.0E-05	 Y	 0	 0.50	 N	 0	 0.50	 N	
IKBKB	 0.34	 1.0E-05	 Y	 -0.19	 1.0E-05	 Y	 0	 0.50	 N	 0	 0.50	 N	
MEF2A	 0.13	 7.5E-04	 Y	 -0.20	 1.0E-05	 Y	 0	 0.50	 N	 0	 0.50	 N	
ATF3	 0.29	 1.0E-05	 Y	 -0.20	 1.0E-05	 Y	 0.21	 1.0E-05	 Y	 0	 0.50	 N	
ETV5	 0.02	 0.33	 N	 -0.20	 1.0E-05	 Y	 0	 0.50	 N	 0	 0.50	 N	
BCL11A	 -0.23	 1.0E-05	 Y	 -0.20	 1.0E-05	 Y	 0	 0.50	 N	 0	 0.50	 N	
RBL1	 -0.02	 0.30	 N	 -0.20	 1.0E-05	 Y	 0	 0.50	 N	 0	 0.50	 N	
HOXA9	 -0.03	 0.26	 N	 -0.21	 1.0E-05	 Y	 0	 0.50	 N	 0	 0.50	 N	
NR4A1	 -0.15	 2.7E-04	 Y	 -0.21	 1.0E-05	 Y	 0	 0.50	 N	 0	 0.50	 N	
SPEN	 -0.04	 0.16	 N	 -0.21	 1.0E-05	 Y	 0	 0.50	 N	 0	 0.50	 N	
PER2	 -0.12	 2.1E-03	 Y	 -0.21	 1.0E-05	 Y	 0	 0.50	 N	 0	 0.50	 N	
IRF7	 0.32	 1.0E-05	 Y	 -0.22	 1.0E-05	 Y	 0	 0.50	 N	 0	 0.50	 N	
KLF12	 -0.28	 1.0E-05	 Y	 -0.22	 1.0E-05	 Y	 0	 0.50	 N	 0	 0.50	 N	
RARG	 9.9E-03	 0.41	 N	 -0.22	 1.0E-05	 Y	 0	 0.50	 N	 0	 0.50	 N	
POU3F2	 0.09	 0.01	 Y	 -0.22	 1.0E-05	 Y	 0	 0.50	 N	 0	 0.50	 N	
HBP1	 0.39	 1.0E-05	 Y	 -0.22	 1.0E-05	 Y	 0	 0.50	 N	 0	 0.50	 N	
ING2	 0.20	 2.0E-05	 Y	 -0.22	 1.0E-05	 Y	 0	 0.50	 N	 0	 0.50	 N	
ATF6	 0.14	 5.0E-04	 Y	 -0.22	 1.0E-05	 Y	 0	 0.50	 N	 0	 0.50	 N	
NEUROG3	 0.15	 1.3E-04	 Y	 -0.22	 1.0E-05	 Y	 0	 0.50	 N	 0	 0.50	 N	
HLTF	 -0.24	 1.0E-05	 Y	 -0.22	 1.0E-05	 Y	 0	 0.50	 N	 0	 0.50	 N	
FLI1	 0.15	 2.0E-04	 Y	 -0.23	 1.0E-05	 Y	 0	 0.50	 N	 0.38	 1.0E-05	 Y	
ID2	 0.21	 1.0E-05	 Y	 -0.23	 1.0E-05	 Y	 0	 0.50	 N	 0	 0.50	 N	
NR1H4	 0.20	 1.0E-05	 Y	 -0.23	 1.0E-05	 Y	 0.51	 1.0E-05	 Y	 4.8E-03	 0.45	 N	
NR2F1	 0.35	 1.0E-05	 Y	 -0.23	 1.0E-05	 Y	 0	 0.50	 N	 0	 0.50	 N	
BTF3	 0.41	 1.0E-05	 Y	 -0.24	 1.0E-05	 Y	 -0.16	 1.0E-04	 Y	 0	 0.50	 N	
ATOH1	 0.39	 1.0E-05	 Y	 -0.24	 1.0E-05	 Y	 0	 0.50	 N	 0	 0.50	 N	
PDX1	 -0.08	 0.03	 Y	 -0.24	 1.0E-05	 Y	 0	 0.50	 N	 0	 0.50	 N	
PTTG1	 0.40	 1.0E-05	 Y	 -0.24	 1.0E-05	 Y	 0.14	 2.9E-04	 Y	 0.50	 1.0E-05	 Y	
MAFF	 0.19	 2.0E-05	 Y	 -0.24	 1.0E-05	 Y	 0	 0.50	 N	 0	 0.50	 N	
MYBL2	 0.21	 1.0E-05	 Y	 -0.24	 1.0E-05	 Y	 0	 0.50	 N	 0	 0.50	 N	
HINFP	 0.02	 0.28	 N	 -0.24	 1.0E-05	 Y	 0	 0.50	 N	 0	 0.50	 N	
KLF9	 0.24	 1.0E-05	 Y	 -0.24	 1.0E-05	 Y	 0	 0.50	 N	 0	 0.50	 N	
HEXIM1	 -0.07	 0.05	 N	 -0.25	 1.0E-05	 Y	 0	 0.50	 N	 0	 0.50	 N	
NFE2L1	 0.11	 3.7E-03	 Y	 -0.25	 1.0E-05	 Y	 0	 0.50	 N	 0	 0.50	 N	
PA2G4	 0.01	 0.40	 N	 -0.25	 1.0E-05	 Y	 0	 0.50	 N	 0	 0.50	 N	
HAND2	 0.02	 0.30	 N	 -0.26	 1.0E-05	 Y	 0	 0.50	 N	 0	 0.50	 N	
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HOXB7	 0.50	 1.0E-05	 Y	 -0.26	 1.0E-05	 Y	 0	 0.50	 N	 0.21	 1.0E-05	 Y	
KLF3	 0.13	 1.3E-03	 Y	 -0.26	 1.0E-05	 Y	 0	 0.50	 N	 0	 0.50	 N	
CEBPG	 0.52	 1.0E-05	 Y	 -0.26	 1.0E-05	 Y	 0	 0.50	 N	 0	 0.50	 N	
RXRA	 0.17	 3.0E-05	 Y	 -0.26	 1.0E-05	 Y	 0	 0.50	 N	 0	 0.50	 N	
MYB	 0.08	 0.03	 Y	 -0.26	 1.0E-05	 Y	 0.24	 1.0E-05	 Y	 0.49	 1.0E-05	 Y	
NR1H2	 -0.13	 9.5E-04	 Y	 -0.26	 1.0E-05	 Y	 0	 0.50	 N	 0	 0.50	 N	
HMGB2	 0.14	 2.7E-04	 Y	 -0.26	 1.0E-05	 Y	 0	 0.50	 N	 0	 0.50	 N	
NKX3-1	 0.41	 1.0E-05	 Y	 -0.27	 1.0E-05	 Y	 0	 0.50	 N	 0	 0.50	 N	
HDAC3	 0.17	 3.0E-05	 Y	 -0.27	 1.0E-05	 Y	 0	 0.50	 N	 0	 0.50	 N	
MAML1	 0.25	 1.0E-05	 Y	 -0.27	 1.0E-05	 Y	 0	 0.50	 N	 0	 0.50	 N	
E2F8	 0.05	 0.11	 N	 -0.27	 1.0E-05	 Y	 0	 0.50	 N	 0	 0.50	 N	
DLX4	 0.30	 1.0E-05	 Y	 -0.27	 1.0E-05	 Y	 0	 0.50	 N	 0	 0.50	 N	
GABPA	 -0.02	 0.31	 N	 -0.27	 1.0E-05	 Y	 0	 0.50	 N	 0	 0.50	 N	
MEIS1	 0.43	 1.0E-05	 Y	 -0.27	 1.0E-05	 Y	 0	 0.50	 N	 0	 0.50	 N	
ABL1	 -0.05	 0.10	 N	 -0.27	 1.0E-05	 Y	 0	 0.50	 N	 0	 0.50	 N	
KLF11	 -0.27	 1.0E-05	 Y	 -0.27	 1.0E-05	 Y	 0	 0.50	 N	 0	 0.50	 N	
DNMT3L	 0.59	 1.0E-05	 Y	 -0.27	 1.0E-05	 Y	 0	 0.50	 N	 0	 0.50	 N	
CDCA7L	 -0.20	 1.0E-05	 Y	 -0.28	 1.0E-05	 Y	 0	 0.50	 N	 0	 0.50	 N	
PARP1	 -0.06	 0.08	 N	 -0.28	 1.0E-05	 Y	 -0.27	 1.0E-05	 Y	 0	 0.50	 N	
CEBPD	 0.04	 0.19	 N	 -0.29	 1.0E-05	 Y	 0	 0.50	 N	 0	 0.50	 N	
HIRA	 0.30	 1.0E-05	 Y	 -0.29	 1.0E-05	 Y	 0	 0.50	 N	 0	 0.50	 N	
ONECUT1	 0.06	 0.08	 N	 -0.29	 1.0E-05	 Y	 0	 0.50	 N	 0	 0.50	 N	
FOXA1	 0.10	 9.4E-03	 Y	 -0.29	 1.0E-05	 Y	 0	 0.50	 N	 0	 0.50	 N	
NEUROD1	 -0.21	 1.0E-05	 Y	 -0.29	 1.0E-05	 Y	 0	 0.50	 N	 0	 0.50	 N	
TGIF1	 -0.10	 5.8E-03	 Y	 -0.29	 1.0E-05	 Y	 0	 0.50	 N	 0	 0.50	 N	
IRF5	 -0.15	 2.5E-04	 Y	 -0.29	 1.0E-05	 Y	 0	 0.50	 N	 0	 0.50	 N	
BARD1	 -0.05	 0.10	 N	 -0.29	 1.0E-05	 Y	 0	 0.50	 N	 0	 0.50	 N	
SIRT1	 0.35	 1.0E-05	 Y	 -0.29	 1.0E-05	 Y	 -0.19	 1.0E-05	 Y	 -0.43	 1.0E-05	 Y	
EGR1	 0.19	 2.0E-05	 Y	 -0.30	 1.0E-05	 Y	 0.14	 4.5E-04	 Y	 0.26	 1.0E-05	 Y	
JUN	 0.11	 3.5E-03	 Y	 -0.30	 1.0E-05	 Y	 0.03	 0.22	 N	 0.30	 1.0E-05	 Y	
PTMA	 0.50	 1.0E-05	 Y	 -0.31	 1.0E-05	 Y	 0	 0.50	 N	 0	 0.50	 N	
TAL1	 0.19	 2.0E-05	 Y	 -0.31	 1.0E-05	 Y	 0	 0.50	 N	 0	 0.50	 N	
SALL4	 0.24	 1.0E-05	 Y	 -0.31	 1.0E-05	 Y	 0	 0.50	 N	 0	 0.50	 N	
ID1	 0.36	 1.0E-05	 Y	 -0.31	 1.0E-05	 Y	 0	 0.50	 N	 0	 0.50	 N	
SRSF1	 0.04	 0.16	 N	 -0.31	 1.0E-05	 Y	 0	 0.50	 N	 0	 0.50	 N	
PAX8	 0.28	 1.0E-05	 Y	 -0.31	 1.0E-05	 Y	 0	 0.50	 N	 0	 0.50	 N	
KAT2B	 -4.9E-03	 0.45	 N	 -0.31	 1.0E-05	 Y	 0	 0.50	 N	 0	 0.50	 N	
SPDEF	 0.50	 1.0E-05	 Y	 -0.32	 1.0E-05	 Y	 0	 0.50	 N	 0	 0.50	 N	
LMO4	 0.32	 1.0E-05	 Y	 -0.32	 1.0E-05	 Y	 0	 0.50	 N	 0	 0.50	 N	
BHLHE41	 0.34	 1.0E-05	 Y	 -0.32	 1.0E-05	 Y	 0	 0.50	 N	 0	 0.50	 N	
HOXA1	 0.09	 0.01	 Y	 -0.32	 1.0E-05	 Y	 0	 0.50	 N	 0	 0.50	 N	
SRF	 0.26	 1.0E-05	 Y	 -0.32	 1.0E-05	 Y	 0	 0.50	 N	 0.71	 1.0E-05	 Y	
PHOX2A	 -0.07	 0.05	 N	 -0.32	 1.0E-05	 Y	 0	 0.50	 N	 0	 0.50	 N	
SP4	 0.08	 0.02	 Y	 -0.33	 1.0E-05	 Y	 0	 0.50	 N	 0	 0.50	 N	
CREB3	 0.13	 1.5E-03	 Y	 -0.33	 1.0E-05	 Y	 0	 0.50	 N	 0	 0.50	 N	
BRD7	 0.46	 1.0E-05	 Y	 -0.33	 1.0E-05	 Y	 0	 0.50	 N	 0	 0.50	 N	
ERF	 0.07	 0.04	 Y	 -0.33	 1.0E-05	 Y	 0	 0.50	 N	 0	 0.50	 N	
HSF2	 0.19	 2.0E-05	 Y	 -0.33	 1.0E-05	 Y	 0	 0.50	 N	 0	 0.50	 N	
MSC	 0.12	 1.9E-03	 Y	 -0.33	 1.0E-05	 Y	 0	 0.50	 N	 0.16	 8.0E-05	 Y	
MSX2	 0.13	 1.3E-03	 Y	 -0.33	 1.0E-05	 Y	 0	 0.50	 N	 0	 0.50	 N	
NFATC1	 0.13	 7.9E-04	 Y	 -0.33	 1.0E-05	 Y	 0	 0.50	 N	 0	 0.50	 N	
TFAP4	 0.34	 1.0E-05	 Y	 -0.33	 1.0E-05	 Y	 0	 0.50	 N	 0	 0.50	 N	
TFCP2	 0.71	 1.0E-05	 Y	 -0.34	 1.0E-05	 Y	 0	 0.50	 N	 0	 0.50	 N	
NANOG	 0.22	 1.0E-05	 Y	 -0.34	 1.0E-05	 Y	 0.05	 0.13	 N	 0	 0.50	 N	
POU2F1	 0.33	 1.0E-05	 Y	 -0.34	 1.0E-05	 Y	 0	 0.50	 N	 0.33	 1.0E-05	 Y	
FOXO1	 -8.3E-04	 0.49	 N	 -0.34	 1.0E-05	 Y	 0	 0.50	 N	 0	 0.50	 N	
SMURF2	 -0.04	 0.16	 N	 -0.34	 1.0E-05	 Y	 0	 0.50	 N	 0	 0.50	 N	
ELK1	 -0.15	 1.1E-04	 Y	 -0.35	 1.0E-05	 Y	 0	 0.50	 N	 0	 0.50	 N	
CREB3L1	 0.13	 6.4E-04	 Y	 -0.35	 1.0E-05	 Y	 0	 0.50	 N	 0	 0.50	 N	
DEAF1	 0.12	 2.1E-03	 Y	 -0.36	 1.0E-05	 Y	 0	 0.50	 N	 0	 0.50	 N	
MXD1	 0.31	 1.0E-05	 Y	 -0.36	 1.0E-05	 Y	 0	 0.50	 N	 0	 0.50	 N	
HMGA2	 0.09	 0.02	 Y	 -0.36	 1.0E-05	 Y	 0	 0.50	 N	 0	 0.50	 N	
PBX2	 0.18	 2.0E-05	 Y	 -0.36	 1.0E-05	 Y	 0	 0.50	 N	 0	 0.50	 N	
RARA	 7.8E-04	 0.49	 N	 -0.36	 1.0E-05	 Y	 0	 0.50	 N	 0.28	 1.0E-05	 Y	
NKX2-5	 -0.03	 0.24	 N	 -0.37	 1.0E-05	 Y	 0	 0.50	 N	 0	 0.50	 N	
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NKX2-2	 -0.16	 1.0E-04	 Y	 -0.37	 1.0E-05	 Y	 0	 0.50	 N	 0	 0.50	 N	
EWSR1	 -0.13	 1.3E-03	 Y	 -0.37	 1.0E-05	 Y	 0	 0.50	 N	 0	 0.50	 N	
CREM	 0.17	 6.0E-05	 Y	 -0.38	 1.0E-05	 Y	 -0.62	 1.0E-05	 Y	 0	 0.50	 N	
EHF	 -0.04	 0.15	 N	 -0.38	 1.0E-05	 Y	 0	 0.50	 N	 0	 0.50	 N	
FOXP1	 -0.10	 7.4E-03	 Y	 -0.38	 1.0E-05	 Y	 0	 0.50	 N	 0	 0.50	 N	
FOXG1	 0.02	 0.30	 N	 -0.38	 1.0E-05	 Y	 0	 0.50	 N	 0	 0.50	 N	
MLLT3	 0.25	 1.0E-05	 Y	 -0.38	 1.0E-05	 Y	 0	 0.50	 N	 0	 0.50	 N	
PIAS4	 0.18	 3.0E-05	 Y	 -0.39	 1.0E-05	 Y	 0	 0.50	 N	 0	 0.50	 N	
EZH2	 0.39	 1.0E-05	 Y	 -0.39	 1.0E-05	 Y	 -0.29	 1.0E-05	 Y	 -0.02	 0.29	 N	
ING1	 0.38	 1.0E-05	 Y	 -0.39	 1.0E-05	 Y	 0	 0.50	 N	 0	 0.50	 N	
NR0B2	 0.32	 1.0E-05	 Y	 -0.40	 1.0E-05	 Y	 0	 0.50	 N	 0	 0.50	 N	
CREB5	 0.16	 8.0E-05	 Y	 -0.40	 1.0E-05	 Y	 -0.22	 1.0E-05	 Y	 0	 0.50	 N	
HDAC7	 0.54	 1.0E-05	 Y	 -0.40	 1.0E-05	 Y	 -0.73	 1.0E-05	 Y	 0	 0.50	 N	
AATF	 0.19	 2.0E-05	 Y	 -0.40	 1.0E-05	 Y	 0	 0.50	 N	 0	 0.50	 N	
MYF6	 0.42	 1.0E-05	 Y	 -0.40	 1.0E-05	 Y	 0	 0.50	 N	 0	 0.50	 N	
HES6	 0.29	 1.0E-05	 Y	 -0.40	 1.0E-05	 Y	 0	 0.50	 N	 0	 0.50	 N	
HOXC6	 -0.17	 4.0E-05	 Y	 -0.40	 1.0E-05	 Y	 0	 0.50	 N	 0	 0.50	 N	
GZF1	 0.12	 2.5E-03	 Y	 -0.41	 1.0E-05	 Y	 0	 0.50	 N	 0	 0.50	 N	
NFKBIB	 -0.17	 6.0E-05	 Y	 -0.41	 1.0E-05	 Y	 0	 0.50	 N	 0	 0.50	 N	
TP53	 0.21	 1.0E-05	 Y	 -0.41	 1.0E-05	 Y	 -5.0E-
04	
0.49	 N	 -0.07	 0.05	 N	
DNMT3A	 -0.13	 8.9E-04	 Y	 -0.42	 1.0E-05	 Y	 0	 0.50	 N	 0	 0.50	 N	
PGR	 0.14	 3.0E-04	 Y	 -0.42	 1.0E-05	 Y	 -0.05	 0.12	 N	 0.31	 1.0E-05	 Y	
HOXA10	 0.29	 1.0E-05	 Y	 -0.43	 1.0E-05	 Y	 0	 0.50	 N	 -0.35	 1.0E-05	 Y	
TCF3	 -0.05	 0.12	 N	 -0.43	 1.0E-05	 Y	 0	 0.50	 N	 -0.43	 1.0E-05	 Y	
MEN1	 0.83	 1.0E-05	 Y	 -0.43	 1.0E-05	 Y	 0	 0.50	 N	 0	 0.50	 N	
HTATIP2	 0.20	 2.0E-05	 Y	 -0.43	 1.0E-05	 Y	 0	 0.50	 N	 0	 0.50	 N	
NCOA6	 0.34	 1.0E-05	 Y	 -0.43	 1.0E-05	 Y	 0	 0.50	 N	 0	 0.50	 N	
NFKB2	 -7.3E-03	 0.43	 N	 -0.44	 1.0E-05	 Y	 0	 0.50	 N	 0	 0.50	 N	
LYL1	 0.23	 1.0E-05	 Y	 -0.44	 1.0E-05	 Y	 0	 0.50	 N	 0	 0.50	 N	
RBBP7	 -0.07	 0.05	 N	 -0.45	 1.0E-05	 Y	 0	 0.50	 N	 0	 0.50	 N	
CHD4	 0.02	 0.28	 N	 -0.45	 1.0E-05	 Y	 0	 0.50	 N	 0	 0.50	 N	
STAT1	 0.20	 2.0E-05	 Y	 -0.46	 1.0E-05	 Y	 -0.22	 1.0E-05	 Y	 0.44	 1.0E-05	 Y	
LDB1	 -0.12	 1.7E-03	 Y	 -0.46	 1.0E-05	 Y	 0	 0.50	 N	 0	 0.50	 N	
PHB2	 0.28	 1.0E-05	 Y	 -0.46	 1.0E-05	 Y	 0	 0.50	 N	 0	 0.50	 N	
SOX4	 0.50	 1.0E-05	 Y	 -0.47	 1.0E-05	 Y	 0	 0.50	 N	 0	 0.50	 N	
KAT6A	 0.17	 6.0E-05	 Y	 -0.47	 1.0E-05	 Y	 0	 0.50	 N	 0	 0.50	 N	
NFRKB	 0.29	 1.0E-05	 Y	 -0.47	 1.0E-05	 Y	 0	 0.50	 N	 0	 0.50	 N	
HSF1	 0.22	 1.0E-05	 Y	 -0.49	 1.0E-05	 Y	 -0.25	 1.0E-05	 Y	 0	 0.50	 N	
CIITA	 0.20	 2.0E-05	 Y	 -0.49	 1.0E-05	 Y	 0	 0.50	 N	 0.53	 1.0E-05	 Y	
RORA	 0.38	 1.0E-05	 Y	 -0.49	 1.0E-05	 Y	 0	 0.50	 N	 0	 0.50	 N	
TFAP2A	 0.31	 1.0E-05	 Y	 -0.51	 1.0E-05	 Y	 -0.15	 1.6E-04	 Y	 0.49	 1.0E-05	 Y	
LHX3	 0.08	 0.03	 Y	 -0.52	 1.0E-05	 Y	 0	 0.50	 N	 0	 0.50	 N	
TNFAIP3	 -0.12	 2.3E-03	 Y	 -0.53	 1.0E-05	 Y	 0	 0.50	 N	 0	 0.50	 N	
RREB1	 0.29	 1.0E-05	 Y	 -0.55	 1.0E-05	 Y	 0	 0.50	 N	 0	 0.50	 N	
COPS5	 0.40	 1.0E-05	 Y	 -0.55	 1.0E-05	 Y	 0	 0.50	 N	 0	 0.50	 N	
HOXA11	 0.09	 0.01	 Y	 -0.55	 1.0E-05	 Y	 0	 0.50	 N	 0	 0.50	 N	
FOXP3	 0.23	 1.0E-05	 Y	 -0.55	 1.0E-05	 Y	 0	 0.50	 N	 0	 0.50	 N	
CBX6	 -0.01	 0.40	 N	 -0.56	 1.0E-05	 Y	 0	 0.50	 N	 0	 0.50	 N	
GATA1	 0.42	 1.0E-05	 Y	 -0.57	 1.0E-05	 Y	 0	 0.50	 N	 0.37	 1.0E-05	 Y	
HOXA7	 0.31	 1.0E-05	 Y	 -0.59	 1.0E-05	 Y	 0	 0.50	 N	 0	 0.50	 N	
NFKBIA	 0.29	 1.0E-05	 Y	 -0.60	 1.0E-05	 Y	 -0.67	 1.0E-05	 Y	 0	 0.50	 N	
TCFL5	 0.24	 1.0E-05	 Y	 -0.63	 1.0E-05	 Y	 0	 0.50	 N	 0	 0.50	 N	
POU4F1	 0.13	 1.0E-03	 Y	 -0.63	 1.0E-05	 Y	 0	 0.50	 N	 0	 0.50	 N	
GATA2	 0.09	 0.02	 Y	 -0.64	 1.0E-05	 Y	 0	 0.50	 N	 0	 0.50	 N	
SRY	 0.28	 1.0E-05	 Y	 -0.71	 1.0E-05	 Y	 0	 0.50	 N	 0	 0.50	 N	







Master list of TFs in TCGA breast cancer dataset together the correlation scores 
of their activity scores with PR signatures and enrichment scores of target genes 
with PR signatures 
 
TF	 S(TF,P)	 P-value	 BH	 S(TF,R)	 P-value	 BH	 ES_P	 P-value	 BH	 ES_R	 P-value	 BH	
SREBF2	 -0.68	 1.0E-05	 Y	 0.67	 1.0E-05	 Y	 0.10	 8.5E-03	 Y	 0	 0.50	 N	
DDB2	 -0.31	 1.0E-05	 Y	 0.66	 1.0E-05	 Y	 0	 0.50	 N	 0	 0.50	 N	
SIRT2	 -0.36	 1.0E-05	 Y	 0.63	 1.0E-05	 Y	 0	 0.50	 N	 0	 0.50	 N	
MEF2D	 -0.36	 1.0E-05	 Y	 0.61	 1.0E-05	 Y	 0	 0.50	 N	 0	 0.50	 N	
LIMD1	 -0.41	 1.0E-05	 Y	 0.57	 1.0E-05	 Y	 0	 0.50	 N	 0	 0.50	 N	
E2F6	 -0.76	 1.0E-05	 Y	 0.54	 1.0E-05	 Y	 0	 0.50	 N	 0	 0.50	 N	
TBP	 -0.68	 1.0E-05	 Y	 0.53	 1.0E-05	 Y	 0	 0.50	 N	 0	 0.50	 N	
FOXM1	 -0.51	 1.0E-05	 Y	 0.53	 1.0E-05	 Y	 0	 0.50	 N	 0	 0.50	 N	
GFI1	 -0.52	 1.0E-05	 Y	 0.50	 1.0E-05	 Y	 0	 0.50	 N	 0	 0.50	 N	
CTCFL	 -0.35	 1.0E-05	 Y	 0.48	 1.0E-05	 Y	 0	 0.50	 N	 0	 0.50	 N	
PPARA	 -0.45	 1.0E-05	 Y	 0.48	 1.0E-05	 Y	 -0.65	 1.0E-05	 Y	 0.32	 1.0E-05	 Y	
TCF19	 -0.72	 1.0E-05	 Y	 0.47	 1.0E-05	 Y	 0	 0.50	 N	 0	 0.50	 N	
SKI	 -0.23	 1.0E-05	 Y	 0.47	 1.0E-05	 Y	 0	 0.50	 N	 0	 0.50	 N	
MCM2	 -0.36	 1.0E-05	 Y	 0.47	 1.0E-05	 Y	 0	 0.50	 N	 0	 0.50	 N	
CDX1	 -0.17	 6.0E-05	 Y	 0.47	 1.0E-05	 Y	 0	 0.50	 N	 0	 0.50	 N	
HEY2	 -0.31	 1.0E-05	 Y	 0.47	 1.0E-05	 Y	 0	 0.50	 N	 0	 0.50	 N	
MCM6	 -0.64	 1.0E-05	 Y	 0.46	 1.0E-05	 Y	 0	 0.50	 N	 0	 0.50	 N	
TFAP2B	 -0.19	 1.0E-05	 Y	 0.46	 1.0E-05	 Y	 0	 0.50	 N	 0	 0.50	 N	
CRTC1	 -0.49	 1.0E-05	 Y	 0.46	 1.0E-05	 Y	 0	 0.50	 N	 0	 0.50	 N	
RNF14	 -0.33	 1.0E-05	 Y	 0.46	 1.0E-05	 Y	 0	 0.50	 N	 0	 0.50	 N	
NCOA4	 -0.34	 1.0E-05	 Y	 0.46	 1.0E-05	 Y	 0	 0.50	 N	 0	 0.50	 N	
MBD2	 -0.34	 1.0E-05	 Y	 0.46	 1.0E-05	 Y	 0	 0.50	 N	 0	 0.50	 N	
POLR1A	 -0.17	 3.0E-05	 Y	 0.45	 1.0E-05	 Y	 0	 0.50	 N	 0	 0.50	 N	
FOXO3	 -0.21	 1.0E-05	 Y	 0.45	 1.0E-05	 Y	 0	 0.50	 N	 0.04	 0.19	 N	
NR2F2	 -0.40	 1.0E-05	 Y	 0.45	 1.0E-05	 Y	 0	 0.50	 N	 0	 0.50	 N	
ELK3	 -0.07	 0.06	 N	 0.45	 1.0E-05	 Y	 0	 0.50	 N	 0	 0.50	 N	
SETBP1	 -0.32	 1.0E-05	 Y	 0.45	 1.0E-05	 Y	 0	 0.50	 N	 0	 0.50	 N	
TP63	 -0.34	 1.0E-05	 Y	 0.44	 1.0E-05	 Y	 0	 0.50	 N	 0	 0.50	 N	
IRF8	 -0.15	 1.0E-04	 Y	 0.44	 1.0E-05	 Y	 0	 0.50	 N	 0	 0.50	 N	
DNMT1	 -0.47	 1.0E-05	 Y	 0.44	 1.0E-05	 Y	 -0.05	 0.13	 N	 0	 0.50	 N	
HDAC9	 -0.34	 1.0E-05	 Y	 0.43	 1.0E-05	 Y	 -0.34	 1.0E-05	 Y	 0	 0.50	 N	
STAT5B	 -0.32	 1.0E-05	 Y	 0.43	 1.0E-05	 Y	 0	 0.50	 N	 0	 0.50	 N	
APEX1	 -0.23	 1.0E-05	 Y	 0.42	 1.0E-05	 Y	 0	 0.50	 N	 0.26	 1.0E-05	 Y	
NFYC	 -0.01	 0.39	 N	 0.42	 1.0E-05	 Y	 0	 0.50	 N	 0	 0.50	 N	
CTCF	 -0.08	 0.03	 Y	 0.41	 1.0E-05	 Y	 0	 0.50	 N	 0	 0.50	 N	
SOX11	 -0.33	 1.0E-05	 Y	 0.41	 1.0E-05	 Y	 0	 0.50	 N	 0	 0.50	 N	
ENO1	 -0.22	 1.0E-05	 Y	 0.41	 1.0E-05	 Y	 0	 0.50	 N	 0	 0.50	 N	
TRIB3	 -0.31	 1.0E-05	 Y	 0.41	 1.0E-05	 Y	 0	 0.50	 N	 0	 0.50	 N	
ESRRA	 -0.62	 1.0E-05	 Y	 0.41	 1.0E-05	 Y	 0	 0.50	 N	 0	 0.50	 N	
SERTAD1	 -0.34	 1.0E-05	 Y	 0.41	 1.0E-05	 Y	 0	 0.50	 N	 0	 0.50	 N	
SPIB	 -0.04	 0.15	 N	 0.40	 1.0E-05	 Y	 0	 0.50	 N	 0	 0.50	 N	
SMAD4	 -0.57	 1.0E-05	 Y	 0.40	 1.0E-05	 Y	 0	 0.50	 N	 0	 0.50	 N	
FOXL1	 -0.04	 0.18	 N	 0.40	 1.0E-05	 Y	 0	 0.50	 N	 0	 0.50	 N	
ATF5	 -0.33	 1.0E-05	 Y	 0.40	 1.0E-05	 Y	 0	 0.50	 N	 0	 0.50	 N	
SIX1	 -0.06	 0.07	 N	 0.40	 1.0E-05	 Y	 0	 0.50	 N	 0	 0.50	 N	
PER1	 -0.35	 1.0E-05	 Y	 0.40	 1.0E-05	 Y	 0	 0.50	 N	 0	 0.50	 N	
DACH1	 -0.41	 1.0E-05	 Y	 0.39	 1.0E-05	 Y	 0	 0.50	 N	 0	 0.50	 N	
ARNTL2	 -0.29	 1.0E-05	 Y	 0.39	 1.0E-05	 Y	 0	 0.50	 N	 0	 0.50	 N	
ETS2	 -0.30	 1.0E-05	 Y	 0.39	 1.0E-05	 Y	 0	 0.50	 N	 0.51	 1.0E-05	 Y	
PIAS1	 -0.32	 1.0E-05	 Y	 0.39	 1.0E-05	 Y	 0	 0.50	 N	 0	 0.50	 N	
AHR	 -0.20	 1.0E-05	 Y	 0.38	 1.0E-05	 Y	 0	 0.50	 N	 0	 0.50	 N	
RBMX	 0.08	 0.04	 Y	 0.38	 1.0E-05	 Y	 -0.62	 1.0E-05	 Y	 0	 0.50	 N	
HDAC1	 -0.20	 1.0E-05	 Y	 0.38	 1.0E-05	 Y	 -0.45	 1.0E-05	 Y	 -0.15	 2.1E-04	 Y	
EIF2AK2	 -0.12	 2.7E-03	 Y	 0.38	 1.0E-05	 Y	 0	 0.50	 N	 0	 0.50	 N	
PAX4	 -0.18	 2.0E-05	 Y	 0.38	 1.0E-05	 Y	 0	 0.50	 N	 0	 0.50	 N	
PURA	 -0.35	 1.0E-05	 Y	 0.38	 1.0E-05	 Y	 0	 0.50	 N	 0	 0.50	 N	
PPARGC1
A	
-0.37	 1.0E-05	 Y	 0.37	 1.0E-05	 Y	 0	 0.50	 N	 0	 0.50	 N	
	 	 	 	 	 	 	 	 	 	 	 	 	EGR3	 -0.08	 0.03	 Y	 0.36	 1.0E-05	 Y	 0	 0.50	 N	 0	 0.50	 N	
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AES	 -0.26	 1.0E-05	 Y	 0.36	 1.0E-05	 Y	 0	 0.50	 N	 0	 0.50	 N	
PLAGL1	 -0.62	 1.0E-05	 Y	 0.36	 1.0E-05	 Y	 0	 0.50	 N	 0	 0.50	 N	
SLC2A4R
G	
-0.12	 2.1E-03	 Y	 0.36	 1.0E-05	 Y	 0	 0.50	 N	 0	 0.50	 N	
MAF	 -0.09	 0.02	 Y	 0.36	 1.0E-05	 Y	 0	 0.50	 N	 0	 0.50	 N	
E2F1	 -0.75	 1.0E-05	 Y	 0.36	 1.0E-05	 Y	 0.61	 1.0E-05	 Y	 0.12	 1.8E-03	 Y	
ESRRG	 -0.12	 2.5E-03	 Y	 0.35	 1.0E-05	 Y	 0	 0.50	 N	 0	 0.50	 N	
HIPK2	 0.06	 0.08	 N	 0.35	 1.0E-05	 Y	 0	 0.50	 N	 0	 0.50	 N	
JUNB	 -0.41	 1.0E-05	 Y	 0.34	 1.0E-05	 Y	 0	 0.50	 N	 0	 0.50	 N	
CEBPZ	 -0.17	 4.0E-05	 Y	 0.34	 1.0E-05	 Y	 0	 0.50	 N	 0	 0.50	 N	
ERG	 0.04	 0.18	 N	 0.34	 1.0E-05	 Y	 0	 0.50	 N	 0.55	 1.0E-05	 Y	
THRB	 0.01	 0.38	 N	 0.34	 1.0E-05	 Y	 0	 0.50	 N	 0	 0.50	 N	
IRF9	 0.08	 0.03	 Y	 0.34	 1.0E-05	 Y	 0	 0.50	 N	 0	 0.50	 N	
NR0B1	 -0.10	 7.0E-03	 Y	 0.34	 1.0E-05	 Y	 0	 0.50	 N	 0	 0.50	 N	
MKL1	 -0.17	 3.0E-05	 Y	 0.33	 1.0E-05	 Y	 0	 0.50	 N	 0	 0.50	 N	
ETV3	 -0.16	 1.0E-04	 Y	 0.33	 1.0E-05	 Y	 0	 0.50	 N	 0	 0.50	 N	
ELF4	 -0.20	 1.0E-05	 Y	 0.33	 1.0E-05	 Y	 0	 0.50	 N	 0	 0.50	 N	
NR1H3	 -0.10	 8.6E-03	 Y	 0.33	 1.0E-05	 Y	 0	 0.50	 N	 0	 0.50	 N	
FOXN1	 -0.36	 1.0E-05	 Y	 0.33	 1.0E-05	 Y	 0	 0.50	 N	 0	 0.50	 N	
HOXC9	 0.05	 0.10	 N	 0.32	 1.0E-05	 Y	 0	 0.50	 N	 0	 0.50	 N	
REST	 -0.07	 0.04	 Y	 0.32	 1.0E-05	 Y	 -0.34	 1.0E-05	 Y	 0	 0.50	 N	
POU5F1	 -0.36	 1.0E-05	 Y	 0.32	 1.0E-05	 Y	 -0.16	 1.0E-04	 Y	 0	 0.50	 N	
NFYB	 -0.12	 1.4E-03	 Y	 0.32	 1.0E-05	 Y	 0	 0.50	 N	 0	 0.50	 N	
TFDP1	 -0.14	 4.9E-04	 Y	 0.32	 1.0E-05	 Y	 0.94	 1.0E-05	 Y	 0	 0.50	 N	
STAT2	 -0.04	 0.16	 N	 0.32	 1.0E-05	 Y	 0	 0.50	 N	 0	 0.50	 N	
NFIB	 -0.09	 0.01	 Y	 0.31	 1.0E-05	 Y	 0	 0.50	 N	 0	 0.50	 N	
AIP	 -0.03	 0.21	 N	 0.31	 1.0E-05	 Y	 0	 0.50	 N	 0	 0.50	 N	
FUS	 -0.20	 1.0E-05	 Y	 0.31	 1.0E-05	 Y	 0	 0.50	 N	 0	 0.50	 N	
BTG2	 -0.06	 0.08	 N	 0.31	 1.0E-05	 Y	 0	 0.50	 N	 0	 0.50	 N	
MTA3	 -0.24	 1.0E-05	 Y	 0.31	 1.0E-05	 Y	 0	 0.50	 N	 0	 0.50	 N	
MED1	 -0.07	 0.04	 Y	 0.30	 1.0E-05	 Y	 0	 0.50	 N	 0	 0.50	 N	
STAT5A	 -0.05	 0.12	 N	 0.30	 1.0E-05	 Y	 0	 0.50	 N	 0	 0.50	 N	
HOXB13	 -0.18	 1.0E-05	 Y	 0.30	 1.0E-05	 Y	 0	 0.50	 N	 0	 0.50	 N	
ARNT	 0.04	 0.17	 N	 0.30	 1.0E-05	 Y	 0	 0.50	 N	 0	 0.50	 N	
NCOA1	 -0.28	 1.0E-05	 Y	 0.30	 1.0E-05	 Y	 0	 0.50	 N	 0	 0.50	 N	
SF1	 0.03	 0.25	 N	 0.30	 1.0E-05	 Y	 0	 0.50	 N	 0	 0.50	 N	
GATA3	 0.06	 0.07	 N	 0.29	 1.0E-05	 Y	 0.03	 0.24	 N	 0.32	 1.0E-05	 Y	
HEY1	 -0.13	 9.7E-04	 Y	 0.29	 1.0E-05	 Y	 -0.33	 1.0E-05	 Y	 0	 0.50	 N	
MED23	 -0.19	 1.0E-05	 Y	 0.29	 1.0E-05	 Y	 0	 0.50	 N	 0	 0.50	 N	
L3MBTL1	 -3.2E-03	 0.47	 N	 0.28	 1.0E-05	 Y	 0	 0.50	 N	 0	 0.50	 N	
GTF3A	 -0.28	 1.0E-05	 Y	 0.28	 1.0E-05	 Y	 0	 0.50	 N	 0	 0.50	 N	
SPIC	 -0.05	 0.10	 N	 0.28	 1.0E-05	 Y	 0	 0.50	 N	 0	 0.50	 N	
MAX	 -0.25	 1.0E-05	 Y	 0.28	 1.0E-05	 Y	 0	 0.50	 N	 0	 0.50	 N	
TEF	 -0.04	 0.14	 N	 0.28	 1.0E-05	 Y	 0	 0.50	 N	 0	 0.50	 N	
SMARCB1	 0.13	 1.3E-03	 Y	 0.28	 1.0E-05	 Y	 0	 0.50	 N	 0	 0.50	 N	
MZF1	 -0.16	 9.0E-05	 Y	 0.28	 1.0E-05	 Y	 0	 0.50	 N	 0	 0.50	 N	
CREB1	 -0.05	 0.14	 N	 0.27	 1.0E-05	 Y	 0.10	 6.0E-03	 Y	 0.34	 1.0E-05	 Y	
HNF1A	 -0.34	 1.0E-05	 Y	 0.27	 1.0E-05	 Y	 0	 0.50	 N	 0	 0.50	 N	
POU2AF1	 -0.25	 1.0E-05	 Y	 0.27	 1.0E-05	 Y	 0	 0.50	 N	 0	 0.50	 N	
TP73	 -0.59	 1.0E-05	 Y	 0.26	 1.0E-05	 Y	 0	 0.50	 N	 0	 0.50	 N	
CITED2	 -0.28	 1.0E-05	 Y	 0.26	 1.0E-05	 Y	 0	 0.50	 N	 0	 0.50	 N	
FOSL1	 -0.30	 1.0E-05	 Y	 0.26	 1.0E-05	 Y	 0	 0.50	 N	 0	 0.50	 N	
SALL3	 -0.13	 9.3E-04	 Y	 0.26	 1.0E-05	 Y	 0	 0.50	 N	 0	 0.50	 N	
MTA2	 0.07	 0.05	 N	 0.25	 1.0E-05	 Y	 0	 0.50	 N	 0	 0.50	 N	
RARB	 -0.12	 1.4E-03	 Y	 0.25	 1.0E-05	 Y	 0	 0.50	 N	 0	 0.50	 N	
ARID1B	 -0.06	 0.08	 N	 0.25	 1.0E-05	 Y	 0	 0.50	 N	 0	 0.50	 N	
NCOA3	 -0.21	 1.0E-05	 Y	 0.25	 1.0E-05	 Y	 0	 0.50	 N	 0	 0.50	 N	
MBD1	 -0.22	 1.0E-05	 Y	 0.25	 1.0E-05	 Y	 0	 0.50	 N	 0	 0.50	 N	
NFYA	 -0.03	 0.23	 N	 0.25	 1.0E-05	 Y	 0	 0.50	 N	 0	 0.50	 N	
KLF4	 -0.34	 1.0E-05	 Y	 0.25	 1.0E-05	 Y	 -0.11	 3.9E-03	 Y	 0.15	 1.3E-04	 Y	
TCF7L2	 -0.14	 4.9E-04	 Y	 0.25	 1.0E-05	 Y	 0	 0.50	 N	 0	 0.50	 N	
APBB1	 -0.41	 1.0E-05	 Y	 0.25	 1.0E-05	 Y	 0	 0.50	 N	 0	 0.50	 N	
PKNOX1	 -0.26	 1.0E-05	 Y	 0.25	 1.0E-05	 Y	 0	 0.50	 N	 0	 0.50	 N	
E2F3	 -0.27	 1.0E-05	 Y	 0.24	 1.0E-05	 Y	 0	 0.50	 N	 0	 0.50	 N	
ERCC2	 -0.10	 0.01	 Y	 0.24	 1.0E-05	 Y	 0	 0.50	 N	 0	 0.50	 N	
NCOA2	 0.09	 0.02	 Y	 0.24	 1.0E-05	 Y	 0	 0.50	 N	 0	 0.50	 N	
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SOX17	 -0.58	 1.0E-05	 Y	 0.24	 1.0E-05	 Y	 0	 0.50	 N	 0	 0.50	 N	
HDAC5	 -0.34	 1.0E-05	 Y	 0.24	 1.0E-05	 Y	 -0.22	 1.0E-05	 Y	 0	 0.50	 N	
NR2C2	 0.12	 2.5E-03	 Y	 0.24	 1.0E-05	 Y	 0	 0.50	 N	 0	 0.50	 N	
JUN	 -0.24	 1.0E-05	 Y	 0.23	 1.0E-05	 Y	 0.22	 1.0E-05	 Y	 0.45	 1.0E-05	 Y	
NFIX	 -0.29	 1.0E-05	 Y	 0.23	 1.0E-05	 Y	 0	 0.50	 N	 0	 0.50	 N	
TLX1	 0.16	 7.0E-05	 Y	 0.22	 1.0E-05	 Y	 0	 0.50	 N	 0	 0.50	 N	
NCOR1	 -0.14	 4.5E-04	 Y	 0.22	 1.0E-05	 Y	 0	 0.50	 N	 0	 0.50	 N	
HOXC10	 0.11	 4.7E-03	 Y	 0.22	 1.0E-05	 Y	 0	 0.50	 N	 0	 0.50	 N	
KLF6	 -0.09	 0.01	 Y	 0.22	 1.0E-05	 Y	 0	 0.50	 N	 0	 0.50	 N	
NELFCD	 -0.12	 1.4E-03	 Y	 0.22	 1.0E-05	 Y	 0	 0.50	 N	 0	 0.50	 N	
RAD51	 -0.11	 5.2E-03	 Y	 0.21	 1.0E-05	 Y	 0	 0.50	 N	 0	 0.50	 N	
KLF15	 -0.02	 0.34	 N	 0.21	 1.0E-05	 Y	 0	 0.50	 N	 0	 0.50	 N	
E2F8	 5.4E-03	 0.45	 N	 0.21	 1.0E-05	 Y	 0	 0.50	 N	 0	 0.50	 N	
ARID3A	 -0.37	 1.0E-05	 Y	 0.21	 1.0E-05	 Y	 0	 0.50	 N	 0	 0.50	 N	
NFIA	 -0.19	 1.0E-05	 Y	 0.21	 1.0E-05	 Y	 0	 0.50	 N	 0	 0.50	 N	
PLAG1	 -0.09	 0.01	 Y	 0.21	 1.0E-05	 Y	 0	 0.50	 N	 0	 0.50	 N	
NR1I2	 -0.02	 0.36	 N	 0.20	 1.0E-05	 Y	 -0.13	 7.7E-04	 Y	 0.36	 1.0E-05	 Y	
HOPX	 0.11	 4.6E-03	 Y	 0.20	 2.0E-05	 Y	 0	 0.50	 N	 0	 0.50	 N	
MTA1	 -0.09	 0.02	 Y	 0.20	 2.0E-05	 Y	 0	 0.50	 N	 0	 0.50	 N	
SOX10	 0.17	 6.0E-05	 Y	 0.20	 2.0E-05	 Y	 0	 0.50	 N	 0	 0.50	 N	
GCM2	 0.06	 0.09	 N	 0.20	 2.0E-05	 Y	 0	 0.50	 N	 0	 0.50	 N	
SREBF1	 -0.13	 9.0E-04	 Y	 0.20	 2.0E-05	 Y	 -0.28	 1.0E-05	 Y	 0	 0.50	 N	
APC	 -0.12	 1.5E-03	 Y	 0.20	 2.0E-05	 Y	 0	 0.50	 N	 0	 0.50	 N	
RB1CC1	 -0.25	 1.0E-05	 Y	 0.20	 2.0E-05	 Y	 0	 0.50	 N	 0	 0.50	 N	
SMAD7	 -0.19	 1.0E-05	 Y	 0.20	 2.0E-05	 Y	 0	 0.50	 N	 0	 0.50	 N	
IFI16	 -0.20	 1.0E-05	 Y	 0.19	 2.0E-05	 Y	 0	 0.50	 N	 0	 0.50	 N	
SIN3A	 -0.09	 0.01	 Y	 0.19	 2.0E-05	 Y	 0	 0.50	 N	 0	 0.50	 N	
GATA4	 -0.24	 1.0E-05	 Y	 0.19	 2.0E-05	 Y	 0	 0.50	 N	 0	 0.50	 N	
TBPL1	 -0.18	 1.0E-05	 Y	 0.19	 2.0E-05	 Y	 0	 0.50	 N	 0	 0.50	 N	
ETV4	 -0.39	 1.0E-05	 Y	 0.19	 2.0E-05	 Y	 0	 0.50	 N	 0.65	 1.0E-05	 Y	
PCGF2	 0.08	 0.03	 Y	 0.18	 2.0E-05	 Y	 0	 0.50	 N	 0	 0.50	 N	
MITF	 -0.08	 0.03	 Y	 0.18	 2.0E-05	 Y	 0	 0.50	 N	 0.63	 1.0E-05	 Y	
PDX1	 -0.14	 2.8E-04	 Y	 0.18	 3.0E-05	 Y	 0	 0.50	 N	 0	 0.50	 N	
JUND	 0.08	 0.02	 Y	 0.17	 3.0E-05	 Y	 -0.17	 3.0E-05	 Y	 0.40	 1.0E-05	 Y	
HNF4G	 -0.42	 1.0E-05	 Y	 0.17	 3.0E-05	 Y	 0	 0.50	 N	 0	 0.50	 N	
TGIF1	 -0.20	 1.0E-05	 Y	 0.17	 3.0E-05	 Y	 0	 0.50	 N	 0	 0.50	 N	
CRX	 0.06	 0.08	 N	 0.17	 3.0E-05	 Y	 0	 0.50	 N	 0	 0.50	 N	
NPM1	 0.21	 1.0E-05	 Y	 0.17	 5.0E-05	 Y	 0	 0.50	 N	 0	 0.50	 N	
PPARG	 0.13	 1.2E-03	 Y	 0.17	 6.0E-05	 Y	 -0.20	 1.0E-05	 Y	 0.27	 1.0E-05	 Y	
NR4A1	 6.6E-03	 0.44	 N	 0.17	 6.0E-05	 Y	 0	 0.50	 N	 0	 0.50	 N	
EZH2	 0.14	 3.7E-04	 Y	 0.17	 6.0E-05	 Y	 -0.26	 1.0E-05	 Y	 0.10	 7.2E-03	 Y	
ID4	 -0.41	 1.0E-05	 Y	 0.17	 6.0E-05	 Y	 0	 0.50	 N	 0	 0.50	 N	
HCFC1	 -0.13	 1.2E-03	 Y	 0.17	 6.0E-05	 Y	 0	 0.50	 N	 0	 0.50	 N	
EN1	 0.07	 0.05	 N	 0.16	 7.0E-05	 Y	 0	 0.50	 N	 0	 0.50	 N	
PITX1	 0.07	 0.05	 N	 0.16	 8.0E-05	 Y	 -0.71	 1.0E-05	 Y	 0	 0.50	 N	
PITX3	 -0.47	 1.0E-05	 Y	 0.16	 8.0E-05	 Y	 0	 0.50	 N	 0	 0.50	 N	
BCL3	 -0.27	 1.0E-05	 Y	 0.16	 8.0E-05	 Y	 0	 0.50	 N	 0	 0.50	 N	
ETS1	 -0.17	 3.0E-05	 Y	 0.15	 8.0E-05	 Y	 0	 0.50	 N	 0.39	 1.0E-05	 Y	
KLF8	 -0.11	 5.2E-03	 Y	 0.15	 8.0E-05	 Y	 0	 0.50	 N	 0	 0.50	 N	
E2F7	 -0.10	 7.2E-03	 Y	 0.15	 1.0E-04	 Y	 0	 0.50	 N	 0	 0.50	 N	
FOXF1	 -0.12	 1.4E-03	 Y	 0.15	 1.1E-04	 Y	 0	 0.50	 N	 0	 0.50	 N	
TFAP2C	 -0.46	 1.0E-05	 Y	 0.15	 1.8E-04	 Y	 0	 0.50	 N	 0	 0.50	 N	
JDP2	 0.02	 0.32	 N	 0.15	 2.1E-04	 Y	 0	 0.50	 N	 0	 0.50	 N	
SMARCA1	 -0.33	 1.0E-05	 Y	 0.15	 2.4E-04	 Y	 0	 0.50	 N	 0	 0.50	 N	
TOB1	 0.09	 0.01	 Y	 0.14	 3.8E-04	 Y	 0	 0.50	 N	 0	 0.50	 N	
ELF2	 -0.07	 0.05	 N	 0.14	 3.8E-04	 Y	 0	 0.50	 N	 0	 0.50	 N	
RFX5	 0.20	 2.0E-05	 Y	 0.14	 3.8E-04	 Y	 0	 0.50	 N	 0	 0.50	 N	
NFE2L2	 -0.03	 0.22	 N	 0.14	 4.2E-04	 Y	 0	 0.50	 N	 0	 0.50	 N	
NPAS2	 -0.24	 1.0E-05	 Y	 0.14	 4.5E-04	 Y	 0	 0.50	 N	 0	 0.50	 N	
TRERF1	 -0.35	 1.0E-05	 Y	 0.14	 4.5E-04	 Y	 0	 0.50	 N	 0	 0.50	 N	
DLX3	 -0.08	 0.03	 Y	 0.14	 4.9E-04	 Y	 0	 0.50	 N	 0	 0.50	 N	
FOXC1	 -0.06	 0.08	 N	 0.14	 4.9E-04	 Y	 0	 0.50	 N	 0	 0.50	 N	
SND1	 -0.17	 6.0E-05	 Y	 0.14	 6.0E-04	 Y	 0	 0.50	 N	 0	 0.50	 N	
ESR1	 -0.27	 1.0E-05	 Y	 0.13	 6.4E-04	 Y	 0.34	 1.0E-05	 Y	 0.18	 3.0E-05	 Y	
TEAD1	 -0.19	 1.0E-05	 Y	 0.13	 6.5E-04	 Y	 0	 0.50	 N	 0	 0.50	 N	
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HOXC6	 -0.12	 1.7E-03	 Y	 0.13	 1.1E-03	 Y	 0	 0.50	 N	 0	 0.50	 N	
GCM1	 -0.02	 0.32	 N	 0.13	 1.1E-03	 Y	 0	 0.50	 N	 0	 0.50	 N	
SIM2	 0.02	 0.28	 N	 0.13	 1.2E-03	 Y	 0	 0.50	 N	 0	 0.50	 N	
LHX2	 -0.06	 0.06	 N	 0.12	 1.6E-03	 Y	 0	 0.50	 N	 0	 0.50	 N	
RFX1	 -0.33	 1.0E-05	 Y	 0.12	 2.1E-03	 Y	 0	 0.50	 N	 0	 0.50	 N	
ETV2	 -0.15	 1.6E-04	 Y	 0.12	 2.1E-03	 Y	 0	 0.50	 N	 0	 0.50	 N	
NEUROD
1	
-0.27	 1.0E-05	 Y	 0.12	 2.2E-03	 Y	 0	 0.50	 N	 0	 0.50	 N	
GTF2I	 -0.24	 1.0E-05	 Y	 0.12	 2.4E-03	 Y	 0	 0.50	 N	 0	 0.50	 N	
PRDM1	 -0.30	 1.0E-05	 Y	 0.12	 2.5E-03	 Y	 0	 0.50	 N	 0	 0.50	 N	
KAT2B	 -0.37	 1.0E-05	 Y	 0.12	 2.5E-03	 Y	 0	 0.50	 N	 0	 0.50	 N	
KAT5	 -0.09	 0.02	 Y	 0.12	 2.6E-03	 Y	 0	 0.50	 N	 0	 0.50	 N	
BCL11B	 0.03	 0.23	 N	 0.11	 3.0E-03	 Y	 0	 0.50	 N	 0	 0.50	 N	
ELK1	 -0.24	 1.0E-05	 Y	 0.11	 3.2E-03	 Y	 0	 0.50	 N	 0	 0.50	 N	
LMO2	 -0.27	 1.0E-05	 Y	 0.11	 3.3E-03	 Y	 0	 0.50	 N	 0	 0.50	 N	
PAX8	 -6.3E-03	 0.44	 N	 0.11	 3.8E-03	 Y	 0	 0.50	 N	 0	 0.50	 N	
ESR2	 0.04	 0.19	 N	 0.11	 5.5E-03	 Y	 0	 0.50	 N	 0	 0.50	 N	
KLF10	 -0.51	 1.0E-05	 Y	 0.10	 6.0E-03	 Y	 0	 0.50	 N	 0.21	 1.0E-05	 Y	
HOXA5	 0.04	 0.19	 N	 0.10	 6.2E-03	 Y	 0	 0.50	 N	 0	 0.50	 N	
SP7	 -0.03	 0.26	 N	 0.10	 6.5E-03	 Y	 0	 0.50	 N	 0	 0.50	 N	
MECP2	 -0.09	 0.01	 Y	 0.10	 7.4E-03	 Y	 0	 0.50	 N	 0	 0.50	 N	
GFI1B	 0.08	 0.03	 Y	 0.10	 7.7E-03	 Y	 0	 0.50	 N	 0	 0.50	 N	
DLX5	 -2.4E-03	 0.48	 N	 0.10	 8.6E-03	 Y	 0	 0.50	 N	 0	 0.50	 N	
HHEX	 0.31	 1.0E-05	 Y	 0.10	 9.8E-03	 Y	 0	 0.50	 N	 0	 0.50	 N	
RBPJ	 -0.40	 1.0E-05	 Y	 0.10	 1.0E-02	 Y	 0	 0.50	 N	 0	 0.50	 N	
FOSB	 -0.22	 1.0E-05	 Y	 0.10	 0.01	 Y	 0	 0.50	 N	 0	 0.50	 N	
HR	 -0.03	 0.24	 N	 0.09	 0.01	 Y	 0	 0.50	 N	 0	 0.50	 N	
GBX2	 -0.16	 1.0E-04	 Y	 0.09	 0.01	 Y	 0	 0.50	 N	 0	 0.50	 N	
REL	 0.22	 1.0E-05	 Y	 0.09	 0.01	 Y	 0	 0.50	 N	 0.53	 1.0E-05	 Y	
RB1	 -0.05	 0.13	 N	 0.09	 0.02	 Y	 -0.16	 9.0E-05	 Y	 -0.67	 1.0E-05	 Y	
PHB2	 -0.30	 1.0E-05	 Y	 0.09	 0.02	 Y	 0	 0.50	 N	 0	 0.50	 N	
ELK4	 0.02	 0.28	 N	 0.09	 0.02	 Y	 0	 0.50	 N	 0	 0.50	 N	
HOXB1	 -0.19	 1.0E-05	 Y	 0.08	 0.02	 Y	 0	 0.50	 N	 0	 0.50	 N	
SPI1	 0.11	 5.3E-03	 Y	 0.08	 0.02	 Y	 -0.24	 1.0E-05	 Y	 0.40	 1.0E-05	 Y	
HDAC11	 -0.12	 1.6E-03	 Y	 0.08	 0.02	 Y	 0	 0.50	 N	 0	 0.50	 N	
BRD7	 -3.5E-03	 0.47	 N	 0.08	 0.03	 Y	 0	 0.50	 N	 0	 0.50	 N	
HAX1	 -0.01	 0.39	 N	 0.08	 0.03	 Y	 0	 0.50	 N	 0	 0.50	 N	
HMGA1	 -0.09	 0.02	 Y	 0.08	 0.03	 Y	 0	 0.50	 N	 0.05	 0.12	 N	
HOXC13	 -0.22	 1.0E-05	 Y	 0.08	 0.04	 Y	 0	 0.50	 N	 0	 0.50	 N	
PML	 -0.17	 3.0E-05	 Y	 0.08	 0.04	 Y	 0	 0.50	 N	 0.34	 1.0E-05	 Y	
ANKRD1	 0.02	 0.33	 N	 0.07	 0.04	 N	 0	 0.50	 N	 0	 0.50	 N	
BTAF1	 0.25	 1.0E-05	 Y	 0.07	 0.04	 N	 0	 0.50	 N	 0	 0.50	 N	
SATB2	 -0.04	 0.19	 N	 0.07	 0.04	 N	 0	 0.50	 N	 0	 0.50	 N	
POU1F1	 0.15	 2.3E-04	 Y	 0.07	 0.05	 N	 0	 0.50	 N	 0	 0.50	 N	
KHDRBS1	 0.29	 1.0E-05	 Y	 0.07	 0.05	 N	 0	 0.50	 N	 0	 0.50	 N	
NFE2L1	 0.03	 0.27	 N	 0.07	 0.06	 N	 0	 0.50	 N	 0	 0.50	 N	
NFIL3	 -0.06	 0.08	 N	 0.07	 0.06	 N	 0	 0.50	 N	 0	 0.50	 N	
CEBPB	 0.09	 0.02	 Y	 0.07	 0.06	 N	 0.32	 1.0E-05	 Y	 0.33	 1.0E-05	 Y	
RXRA	 -0.14	 3.2E-04	 Y	 0.06	 0.06	 N	 0	 0.50	 N	 0	 0.50	 N	
ONECUT2	 -0.18	 2.0E-05	 Y	 0.06	 0.07	 N	 0	 0.50	 N	 0	 0.50	 N	
EP300	 0.05	 0.12	 N	 0.06	 0.08	 N	 0.37	 1.0E-05	 Y	 0.11	 5.2E-03	 Y	
EHMT2	 -0.02	 0.29	 N	 0.06	 0.08	 N	 0	 0.50	 N	 0	 0.50	 N	
TBX5	 0.04	 0.19	 N	 0.06	 0.09	 N	 0	 0.50	 N	 0	 0.50	 N	
NAB2	 0.02	 0.28	 N	 0.06	 0.09	 N	 0	 0.50	 N	 0	 0.50	 N	
SUGP1	 -0.11	 5.5E-03	 Y	 0.06	 0.09	 N	 0	 0.50	 N	 0	 0.50	 N	
PAX2	 -0.14	 3.3E-04	 Y	 0.05	 0.09	 N	 0	 0.50	 N	 0	 0.50	 N	
NFKB1	 -0.20	 1.0E-05	 Y	 0.05	 0.10	 N	 -0.04	 0.15	 N	 0.43	 1.0E-05	 Y	
TBX21	 0.01	 0.40	 N	 0.05	 0.10	 N	 0	 0.50	 N	 0	 0.50	 N	
RFX3	 0.15	 8.0E-05	 Y	 0.05	 0.12	 N	 0	 0.50	 N	 0	 0.50	 N	
ABL1	 -0.05	 0.12	 N	 0.04	 0.14	 N	 0	 0.50	 N	 0.42	 1.0E-05	 Y	
MSX1	 -0.07	 0.04	 N	 0.04	 0.15	 N	 0	 0.50	 N	 0	 0.50	 N	
KLF13	 0.37	 1.0E-05	 Y	 0.04	 0.15	 N	 0	 0.50	 N	 0	 0.50	 N	
SSB	 -0.14	 5.9E-04	 Y	 0.04	 0.16	 N	 0	 0.50	 N	 0	 0.50	 N	
CDX2	 0.06	 0.09	 N	 0.04	 0.16	 N	 0.15	 2.0E-04	 Y	 0.29	 1.0E-05	 Y	
LMO3	 0.18	 2.0E-05	 Y	 0.04	 0.17	 N	 0	 0.50	 N	 0	 0.50	 N	
PA2G4	 0.06	 0.08	 N	 0.04	 0.19	 N	 0	 0.50	 N	 0	 0.50	 N	
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PAX5	 0.32	 1.0E-05	 Y	 0.04	 0.19	 N	 0	 0.50	 N	 0.43	 1.0E-05	 Y	
RUNX2	 -0.30	 1.0E-05	 Y	 0.04	 0.20	 N	 0	 0.50	 N	 0.60	 1.0E-05	 Y	
FOXL2	 -0.15	 2.8E-04	 Y	 0.03	 0.22	 N	 0	 0.50	 N	 0	 0.50	 N	
KLF12	 -0.30	 1.0E-05	 Y	 0.03	 0.22	 N	 0	 0.50	 N	 0	 0.50	 N	
PIAS3	 0.12	 1.8E-03	 Y	 0.03	 0.22	 N	 0	 0.50	 N	 0	 0.50	 N	
GATA6	 -0.03	 0.21	 N	 0.03	 0.23	 N	 0	 0.50	 N	 0	 0.50	 N	
FOXO1	 0.19	 2.0E-05	 Y	 0.03	 0.23	 N	 -0.33	 1.0E-05	 Y	 0.39	 1.0E-05	 Y	
KDM4C	 -0.15	 1.0E-04	 Y	 0.03	 0.24	 N	 0	 0.50	 N	 0	 0.50	 N	
MDM4	 -0.25	 1.0E-05	 Y	 0.03	 0.24	 N	 0	 0.50	 N	 0	 0.50	 N	
DR1	 0.34	 1.0E-05	 Y	 0.03	 0.26	 N	 0	 0.50	 N	 0	 0.50	 N	
NR5A2	 0.11	 5.0E-03	 Y	 0.03	 0.27	 N	 0	 0.50	 N	 0	 0.50	 N	
MYOD1	 -0.27	 1.0E-05	 Y	 0.02	 0.28	 N	 0	 0.50	 N	 0	 0.50	 N	
STAT6	 -0.07	 0.04	 Y	 0.02	 0.29	 N	 0	 0.50	 N	 0.38	 1.0E-05	 Y	
CREBBP	 0.08	 0.03	 Y	 0.02	 0.32	 N	 0	 0.50	 N	 0.34	 1.0E-05	 Y	
ING4	 -0.11	 4.0E-03	 Y	 0.02	 0.32	 N	 0	 0.50	 N	 0	 0.50	 N	
NR1H4	 0.19	 2.0E-05	 Y	 0.02	 0.34	 N	 0.28	 1.0E-05	 Y	 0.36	 1.0E-05	 Y	
RELA	 -0.31	 1.0E-05	 Y	 0.02	 0.35	 N	 0.02	 0.28	 N	 0.42	 1.0E-05	 Y	
PAX3	 -0.18	 1.0E-05	 Y	 0.02	 0.35	 N	 0	 0.50	 N	 0	 0.50	 N	
IRF1	 -0.19	 1.0E-05	 Y	 0.02	 0.36	 N	 0	 0.50	 N	 -0.12	 1.5E-03	 Y	
SUPT3H	 0.23	 1.0E-05	 Y	 0.01	 0.37	 N	 0	 0.50	 N	 0	 0.50	 N	
TAF4	 -0.09	 0.02	 Y	 0.01	 0.40	 N	 0	 0.50	 N	 0	 0.50	 N	
ELL	 -0.09	 0.01	 Y	 0.01	 0.40	 N	 0	 0.50	 N	 0	 0.50	 N	
ISL1	 -0.09	 0.01	 Y	 9.9E-03	 0.41	 N	 0	 0.50	 N	 0	 0.50	 N	
EWSR1	 7.3E-03	 0.43	 N	 9.8E-03	 0.41	 N	 0	 0.50	 N	 0	 0.50	 N	
IRF3	 2.0E-03	 0.48	 N	 4.7E-03	 0.46	 N	 0	 0.50	 N	 0	 0.50	 N	
HES1	 0.02	 0.36	 N	 2.5E-03	 0.48	 N	 0	 0.50	 N	 0	 0.50	 N	
KCNIP3	 -0.37	 1.0E-05	 Y	 1.7E-03	 0.48	 N	 0	 0.50	 N	 0	 0.50	 N	
HNF4A	 -0.20	 1.0E-05	 Y	 -8.6E-
04	
0.49	 N	 0.48	 1.0E-05	 Y	 0	 0.50	 N	
SP3	 -0.19	 1.0E-05	 Y	 -2.1E-
03	
0.48	 N	 0.26	 1.0E-05	 Y	 0.24	 1.0E-05	 Y	
ATF2	 0.41	 1.0E-05	 Y	 -4.2E-
03	
0.46	 N	 0	 0.50	 N	 0.47	 1.0E-05	 Y	
MYB	 0.11	 5.3E-03	 Y	 -6.1E-
03	
0.44	 N	 0	 0.50	 N	 0.55	 1.0E-05	 Y	
CRABP2	 -0.13	 8.4E-04	 Y	 -6.7E-
03	
0.44	 N	 0	 0.50	 N	 0	 0.50	 N	
SKIL	 -0.13	 1.2E-03	 Y	 -7.0E-
03	
0.43	 N	 0	 0.50	 N	 0	 0.50	 N	
NEUROG
3	
0.04	 0.16	 N	 -7.6E-
03	
0.43	 N	 0	 0.50	 N	 0	 0.50	 N	
ECD	 -0.20	 1.0E-05	 Y	 -7.7E-
03	
0.43	 N	 0	 0.50	 N	 0	 0.50	 N	
HINFP	 0.13	 7.4E-04	 Y	 -8.6E-
03	
0.42	 N	 0	 0.50	 N	 0	 0.50	 N	
NRF1	 -0.07	 0.06	 N	 -8.9E-
03	
0.42	 N	 0	 0.50	 N	 0	 0.50	 N	
TCF4	 0.05	 0.14	 N	 -9.3E-
03	
0.41	 N	 0.30	 1.0E-05	 Y	 0	 0.50	 N	
ARNTL	 0.14	 6.0E-04	 Y	 -0.01	 0.38	 N	 0	 0.50	 N	 0.08	 0.04	 N	
EGR2	 0.23	 1.0E-05	 Y	 -0.01	 0.37	 N	 0	 0.50	 N	 0	 0.50	 N	
FOXP1	 0.25	 1.0E-05	 Y	 -0.01	 0.37	 N	 0	 0.50	 N	 0	 0.50	 N	
THRA	 0.09	 0.02	 Y	 -0.01	 0.37	 N	 0	 0.50	 N	 0	 0.50	 N	
FOXO4	 0.34	 1.0E-05	 Y	 -0.02	 0.34	 N	 0	 0.50	 N	 0	 0.50	 N	
MYF5	 0.13	 8.4E-04	 Y	 -0.02	 0.33	 N	 0	 0.50	 N	 0	 0.50	 N	
TAF1	 -0.23	 1.0E-05	 Y	 -0.02	 0.32	 N	 0	 0.50	 N	 0	 0.50	 N	
RFWD2	 -0.38	 1.0E-05	 Y	 -0.02	 0.32	 N	 0	 0.50	 N	 0	 0.50	 N	
PIAS4	 0.15	 1.0E-04	 Y	 -0.02	 0.31	 N	 0	 0.50	 N	 0	 0.50	 N	
HDAC10	 0.22	 1.0E-05	 Y	 -0.02	 0.31	 N	 0	 0.50	 N	 0	 0.50	 N	
TBX2	 0.42	 1.0E-05	 Y	 -0.02	 0.30	 N	 0	 0.50	 N	 0	 0.50	 N	
KLF5	 0.35	 1.0E-05	 Y	 -0.03	 0.27	 N	 0	 0.50	 N	 0	 0.50	 N	
TBX3	 0.25	 1.0E-05	 Y	 -0.03	 0.27	 N	 0	 0.50	 N	 0	 0.50	 N	
MEF2A	 7.0E-03	 0.43	 N	 -0.03	 0.26	 N	 0	 0.50	 N	 0	 0.50	 N	
HMGB2	 -0.08	 0.03	 Y	 -0.03	 0.25	 N	 0	 0.50	 N	 0	 0.50	 N	
NFIC	 -0.20	 1.0E-05	 Y	 -0.03	 0.25	 N	 0	 0.50	 N	 0.26	 1.0E-05	 Y	
RELB	 -0.20	 1.0E-05	 Y	 -0.03	 0.25	 N	 0	 0.50	 N	 0	 0.50	 N	
MYOG	 -0.05	 0.12	 N	 -0.03	 0.25	 N	 0	 0.50	 N	 0	 0.50	 N	
FOXE1	 -0.11	 4.0E-03	 Y	 -0.03	 0.24	 N	 0	 0.50	 N	 0	 0.50	 N	
IKZF1	 0.10	 6.7E-03	 Y	 -0.03	 0.24	 N	 0	 0.50	 N	 0	 0.50	 N	
MXI1	 0.12	 1.9E-03	 Y	 -0.03	 0.23	 N	 0	 0.50	 N	 0	 0.50	 N	
POU4F2	 0.03	 0.25	 N	 -0.03	 0.22	 N	 0	 0.50	 N	 0	 0.50	 N	
NF1	 0.09	 0.02	 Y	 -0.03	 0.22	 N	 0	 0.50	 N	 0	 0.50	 N	
PAWR	 0.01	 0.37	 N	 -0.03	 0.22	 N	 0	 0.50	 N	 0	 0.50	 N	
FHL2	 -0.07	 0.05	 N	 -0.03	 0.21	 N	 0	 0.50	 N	 0	 0.50	 N	
BCL11A	 -0.03	 0.20	 N	 -0.04	 0.19	 N	 0	 0.50	 N	 0	 0.50	 N	
NR4A2	 -0.17	 3.0E-05	 Y	 -0.04	 0.17	 N	 0	 0.50	 N	 0	 0.50	 N	
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GZF1	 0.02	 0.28	 N	 -0.05	 0.12	 N	 0	 0.50	 N	 0	 0.50	 N	
ILF3	 0.16	 8.0E-05	 Y	 -0.05	 0.11	 N	 0	 0.50	 N	 0	 0.50	 N	
MCM4	 -0.34	 1.0E-05	 Y	 -0.05	 0.11	 N	 0	 0.50	 N	 0	 0.50	 N	
PHOX2B	 -0.08	 0.02	 Y	 -0.05	 0.11	 N	 0	 0.50	 N	 0	 0.50	 N	
SP2	 0.24	 1.0E-05	 Y	 -0.06	 0.09	 N	 0	 0.50	 N	 0	 0.50	 N	
FOXA2	 -0.21	 1.0E-05	 Y	 -0.06	 0.08	 N	 0	 0.50	 N	 0	 0.50	 N	
ELF1	 -0.19	 1.0E-05	 Y	 -0.06	 0.08	 N	 0	 0.50	 N	 0	 0.50	 N	
SRSF1	 -0.16	 1.0E-04	 Y	 -0.06	 0.06	 N	 0	 0.50	 N	 0	 0.50	 N	
PITX2	 -0.01	 0.38	 N	 -0.06	 0.06	 N	 0	 0.50	 N	 0	 0.50	 N	
ETV5	 0.29	 1.0E-05	 Y	 -0.06	 0.06	 N	 0	 0.50	 N	 0	 0.50	 N	
AR	 -0.03	 0.25	 N	 -0.07	 0.05	 N	 -0.11	 4.8E-03	 Y	 0.07	 0.05	 N	
ID2	 -0.30	 1.0E-05	 Y	 -0.07	 0.04	 N	 0	 0.50	 N	 0	 0.50	 N	
RUNX1	 0.01	 0.40	 N	 -0.07	 0.04	 Y	 0	 0.50	 N	 0.31	 1.0E-05	 Y	
NR1D1	 -0.20	 1.0E-05	 Y	 -0.08	 0.04	 Y	 0	 0.50	 N	 0	 0.50	 N	
NRIP1	 0.06	 0.08	 N	 -0.08	 0.03	 Y	 0	 0.50	 N	 0	 0.50	 N	
NELFB	 0.07	 0.06	 N	 -0.08	 0.02	 Y	 0	 0.50	 N	 0	 0.50	 N	
CLOCK	 -0.14	 3.0E-04	 Y	 -0.08	 0.02	 Y	 0	 0.50	 N	 0.08	 0.04	 N	
FOXF2	 -0.15	 1.0E-04	 Y	 -0.08	 0.02	 Y	 0	 0.50	 N	 0	 0.50	 N	
ASCL1	 -0.03	 0.22	 N	 -0.08	 0.02	 Y	 0	 0.50	 N	 0	 0.50	 N	
ILF2	 0.07	 0.04	 Y	 -0.09	 0.02	 Y	 0	 0.50	 N	 0	 0.50	 N	
NUPR1	 0.23	 1.0E-05	 Y	 -0.09	 0.02	 Y	 0	 0.50	 N	 0	 0.50	 N	
ETV6	 -0.14	 3.2E-04	 Y	 -0.09	 0.01	 Y	 0	 0.50	 N	 0	 0.50	 N	
FOS	 0.05	 0.10	 N	 -0.09	 0.01	 Y	 -0.09	 0.01	 Y	 0.29	 1.0E-05	 Y	
NFATC1	 0.44	 1.0E-05	 Y	 -0.10	 0.01	 Y	 0	 0.50	 N	 0	 0.50	 N	
CDCA7L	 -0.16	 1.0E-04	 Y	 -0.10	 9.5E-03	 Y	 0	 0.50	 N	 0	 0.50	 N	
MYOCD	 -0.04	 0.17	 N	 -0.10	 6.3E-03	 Y	 0	 0.50	 N	 0	 0.50	 N	
TP53BP1	 -0.04	 0.18	 N	 -0.10	 5.9E-03	 Y	 0	 0.50	 N	 0	 0.50	 N	
SNAI2	 -0.05	 0.12	 N	 -0.11	 5.7E-03	 Y	 -0.72	 1.0E-05	 Y	 0.11	 3.4E-03	 Y	
SOX2	 0.10	 8.5E-03	 Y	 -0.11	 5.4E-03	 Y	 0	 0.50	 N	 0.07	 0.05	 N	
RBL1	 -0.11	 5.2E-03	 Y	 -0.11	 4.9E-03	 Y	 0	 0.50	 N	 0	 0.50	 N	
NR4A3	 0.47	 1.0E-05	 Y	 -0.11	 4.9E-03	 Y	 0	 0.50	 N	 0	 0.50	 N	
NFATC3	 -0.07	 0.04	 Y	 -0.11	 4.7E-03	 Y	 0	 0.50	 N	 0	 0.50	 N	
LHX4	 0.02	 0.34	 N	 -0.11	 4.5E-03	 Y	 0	 0.50	 N	 0	 0.50	 N	
FOXG1	 0.11	 3.2E-03	 Y	 -0.11	 4.4E-03	 Y	 0	 0.50	 N	 0	 0.50	 N	
MYCN	 0.30	 1.0E-05	 Y	 -0.11	 4.0E-03	 Y	 0.34	 1.0E-05	 Y	 0.05	 0.14	 N	
SNAI1	 0.06	 0.09	 N	 -0.11	 3.9E-03	 Y	 0	 0.50	 N	 0	 0.50	 N	
NR5A1	 0.04	 0.16	 N	 -0.11	 3.8E-03	 Y	 0.13	 9.5E-04	 Y	 0	 0.50	 N	
KLF9	 0.13	 1.2E-03	 Y	 -0.11	 3.5E-03	 Y	 0	 0.50	 N	 0	 0.50	 N	
NR3C2	 0.08	 0.03	 Y	 -0.11	 2.9E-03	 Y	 0	 0.50	 N	 0	 0.50	 N	
MEF2C	 0.21	 1.0E-05	 Y	 -0.12	 2.7E-03	 Y	 0	 0.50	 N	 0	 0.50	 N	
NANOG	 0.07	 0.05	 N	 -0.12	 2.4E-03	 Y	 0	 0.50	 N	 -0.21	 1.0E-05	 Y	
SFPQ	 0.15	 9.0E-05	 Y	 -0.12	 2.1E-03	 Y	 0	 0.50	 N	 0	 0.50	 N	
ATM	 0.29	 1.0E-05	 Y	 -0.13	 1.3E-03	 Y	 0	 0.50	 N	 -0.02	 0.29	 N	
RBL2	 -0.14	 5.5E-04	 Y	 -0.13	 8.4E-04	 Y	 0	 0.50	 N	 0	 0.50	 N	
ONECUT1	 0.02	 0.36	 N	 -0.13	 7.9E-04	 Y	 0	 0.50	 N	 0	 0.50	 N	
IRF7	 0.24	 1.0E-05	 Y	 -0.13	 7.2E-04	 Y	 0	 0.50	 N	 0	 0.50	 N	
FOXD3	 0.19	 2.0E-05	 Y	 -0.14	 5.8E-04	 Y	 0	 0.50	 N	 0	 0.50	 N	
LEF1	 0.06	 0.06	 N	 -0.14	 5.4E-04	 Y	 0	 0.50	 N	 0.30	 1.0E-05	 Y	
MLXIPL	 -0.03	 0.22	 N	 -0.14	 4.9E-04	 Y	 0	 0.50	 N	 0	 0.50	 N	
LMX1B	 0.42	 1.0E-05	 Y	 -0.14	 4.3E-04	 Y	 0	 0.50	 N	 0	 0.50	 N	
ING2	 0.27	 1.0E-05	 Y	 -0.15	 2.7E-04	 Y	 0	 0.50	 N	 0	 0.50	 N	
CTBP1	 -0.25	 1.0E-05	 Y	 -0.15	 2.7E-04	 Y	 0	 0.50	 N	 0	 0.50	 N	
MAZ	 0.31	 1.0E-05	 Y	 -0.15	 1.6E-04	 Y	 0	 0.50	 N	 0	 0.50	 N	
HSF2	 0.14	 3.8E-04	 Y	 -0.15	 1.1E-04	 Y	 0	 0.50	 N	 0	 0.50	 N	
IRF4	 0.12	 1.6E-03	 Y	 -0.15	 1.0E-04	 Y	 0	 0.50	 N	 0	 0.50	 N	
NR1I3	 0.30	 1.0E-05	 Y	 -0.16	 1.0E-04	 Y	 0	 0.50	 N	 0	 0.50	 N	
CEBPD	 -0.15	 2.4E-04	 Y	 -0.16	 1.0E-04	 Y	 0	 0.50	 N	 0	 0.50	 N	
DBP	 -0.17	 6.0E-05	 Y	 -0.16	 1.0E-04	 Y	 0	 0.50	 N	 0	 0.50	 N	
GABPA	 -0.21	 1.0E-05	 Y	 -0.16	 1.0E-04	 Y	 0	 0.50	 N	 0	 0.50	 N	
MAFF	 0.29	 1.0E-05	 Y	 -0.16	 1.0E-04	 Y	 0	 0.50	 N	 0	 0.50	 N	
MLLT10	 0.09	 0.02	 Y	 -0.16	 9.0E-05	 Y	 0	 0.50	 N	 0	 0.50	 N	
ATOH1	 0.03	 0.26	 N	 -0.16	 9.0E-05	 Y	 0	 0.50	 N	 0	 0.50	 N	
DEK	 -0.05	 0.12	 N	 -0.16	 9.0E-05	 Y	 0	 0.50	 N	 0	 0.50	 N	
POU2F1	 0.15	 8.0E-05	 Y	 -0.16	 9.0E-05	 Y	 0	 0.50	 N	 0.71	 1.0E-05	 Y	
NFRKB	 -0.20	 1.0E-05	 Y	 -0.16	 8.0E-05	 Y	 0	 0.50	 N	 0	 0.50	 N	
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SRCAP	 0.16	 8.0E-05	 Y	 -0.16	 6.0E-05	 Y	 0	 0.50	 N	 0	 0.50	 N	
RUNX3	 0.09	 0.02	 Y	 -0.17	 6.0E-05	 Y	 0.12	 1.6E-03	 Y	 0.04	 0.17	 N	
MTF1	 0.24	 1.0E-05	 Y	 -0.17	 6.0E-05	 Y	 0	 0.50	 N	 0	 0.50	 N	
POU3F2	 0.28	 1.0E-05	 Y	 -0.17	 6.0E-05	 Y	 0	 0.50	 N	 0	 0.50	 N	
RORA	 0.30	 1.0E-05	 Y	 -0.17	 6.0E-05	 Y	 0	 0.50	 N	 0	 0.50	 N	
HOXB7	 -0.25	 1.0E-05	 Y	 -0.17	 5.0E-05	 Y	 0	 0.50	 N	 0	 0.50	 N	
HDAC4	 0.35	 1.0E-05	 Y	 -0.17	 3.0E-05	 Y	 -0.21	 1.0E-05	 Y	 0	 0.50	 N	
KAT6A	 0.11	 3.5E-03	 Y	 -0.17	 3.0E-05	 Y	 0	 0.50	 N	 0	 0.50	 N	
PARP1	 -0.17	 3.0E-05	 Y	 -0.17	 3.0E-05	 Y	 -0.39	 1.0E-05	 Y	 0.26	 1.0E-05	 Y	
IRF2	 0.26	 1.0E-05	 Y	 -0.18	 2.0E-05	 Y	 0	 0.50	 N	 0	 0.50	 N	
HLF	 0.09	 0.02	 Y	 -0.18	 2.0E-05	 Y	 0	 0.50	 N	 0	 0.50	 N	
SMURF2	 0.21	 1.0E-05	 Y	 -0.18	 2.0E-05	 Y	 0	 0.50	 N	 0	 0.50	 N	
NOTCH3	 -0.17	 3.0E-05	 Y	 -0.18	 2.0E-05	 Y	 0	 0.50	 N	 0	 0.50	 N	
STAT3	 0.28	 1.0E-05	 Y	 -0.18	 1.0E-05	 Y	 0.17	 5.0E-05	 Y	 0.39	 1.0E-05	 Y	
HTATIP2	 0.39	 1.0E-05	 Y	 -0.18	 1.0E-05	 Y	 0	 0.50	 N	 0	 0.50	 N	
EAPP	 0.21	 1.0E-05	 Y	 -0.18	 1.0E-05	 Y	 0	 0.50	 N	 0	 0.50	 N	
HBP1	 0.24	 1.0E-05	 Y	 -0.18	 1.0E-05	 Y	 0	 0.50	 N	 0	 0.50	 N	
SPEN	 -0.02	 0.28	 N	 -0.19	 1.0E-05	 Y	 0	 0.50	 N	 0	 0.50	 N	
ARID1A	 0.27	 1.0E-05	 Y	 -0.19	 1.0E-05	 Y	 0	 0.50	 N	 0	 0.50	 N	
DDIT3	 0.16	 8.0E-05	 Y	 -0.19	 1.0E-05	 Y	 0.03	 0.22	 N	 0	 0.50	 N	
NKX2-2	 3.3E-03	 0.47	 N	 -0.19	 1.0E-05	 Y	 0	 0.50	 N	 0	 0.50	 N	
SOX9	 -0.01	 0.38	 N	 -0.19	 1.0E-05	 Y	 0	 0.50	 N	 -0.18	 1.0E-05	 Y	
RUVBL1	 0.27	 1.0E-05	 Y	 -0.19	 1.0E-05	 Y	 0	 0.50	 N	 0	 0.50	 N	
MAML1	 -0.07	 0.05	 N	 -0.19	 1.0E-05	 Y	 0	 0.50	 N	 0	 0.50	 N	
HOXA1	 0.26	 1.0E-05	 Y	 -0.19	 1.0E-05	 Y	 0	 0.50	 N	 0	 0.50	 N	
POU2F2	 0.29	 1.0E-05	 Y	 -0.19	 1.0E-05	 Y	 0	 0.50	 N	 0	 0.50	 N	
ATF1	 0.11	 3.4E-03	 Y	 -0.19	 1.0E-05	 Y	 0	 0.50	 N	 0.40	 1.0E-05	 Y	
NFATC2	 0.32	 1.0E-05	 Y	 -0.19	 1.0E-05	 Y	 0	 0.50	 N	 0	 0.50	 N	
CREB3	 -0.17	 3.0E-05	 Y	 -0.20	 1.0E-05	 Y	 0	 0.50	 N	 0	 0.50	 N	
NRL	 0.24	 1.0E-05	 Y	 -0.20	 1.0E-05	 Y	 0	 0.50	 N	 0	 0.50	 N	
CHD4	 -0.27	 1.0E-05	 Y	 -0.20	 1.0E-05	 Y	 0	 0.50	 N	 0	 0.50	 N	
MYBL2	 0.12	 2.3E-03	 Y	 -0.20	 1.0E-05	 Y	 0	 0.50	 N	 0	 0.50	 N	
SATB1	 0.01	 0.40	 N	 -0.20	 1.0E-05	 Y	 0	 0.50	 N	 0	 0.50	 N	
HEXIM1	 0.10	 8.7E-03	 Y	 -0.20	 1.0E-05	 Y	 0	 0.50	 N	 0	 0.50	 N	
SALL4	 0.17	 3.0E-05	 Y	 -0.20	 1.0E-05	 Y	 0	 0.50	 N	 0	 0.50	 N	
FOXP2	 -0.06	 0.09	 N	 -0.20	 1.0E-05	 Y	 0	 0.50	 N	 0	 0.50	 N	
PRDM14	 -0.02	 0.30	 N	 -0.20	 1.0E-05	 Y	 0	 0.50	 N	 0	 0.50	 N	
ATF3	 0.25	 1.0E-05	 Y	 -0.20	 1.0E-05	 Y	 -0.12	 1.8E-03	 Y	 0	 0.50	 N	
HOXA11	 -0.04	 0.20	 N	 -0.21	 1.0E-05	 Y	 0	 0.50	 N	 0	 0.50	 N	
GLI1	 0.29	 1.0E-05	 Y	 -0.21	 1.0E-05	 Y	 0	 0.50	 N	 0	 0.50	 N	
MAFB	 0.03	 0.21	 N	 -0.21	 1.0E-05	 Y	 0	 0.50	 N	 0	 0.50	 N	
MAFA	 0.07	 0.05	 N	 -0.22	 1.0E-05	 Y	 0	 0.50	 N	 0	 0.50	 N	
NR2E3	 0.23	 1.0E-05	 Y	 -0.22	 1.0E-05	 Y	 0	 0.50	 N	 0	 0.50	 N	
HSF4	 0.01	 0.40	 N	 -0.22	 1.0E-05	 Y	 0	 0.50	 N	 0	 0.50	 N	
ATF4	 0.05	 0.12	 N	 -0.22	 1.0E-05	 Y	 0.44	 1.0E-05	 Y	 0.52	 1.0E-05	 Y	
SHOX	 0.08	 0.03	 Y	 -0.22	 1.0E-05	 Y	 0	 0.50	 N	 0	 0.50	 N	
STAT4	 0.16	 8.0E-05	 Y	 -0.22	 1.0E-05	 Y	 0	 0.50	 N	 0	 0.50	 N	
FOSL2	 -0.07	 0.05	 N	 -0.23	 1.0E-05	 Y	 0	 0.50	 N	 0	 0.50	 N	
STAT1	 0.20	 2.0E-05	 Y	 -0.23	 1.0E-05	 Y	 -0.05	 0.13	 N	 0.41	 1.0E-05	 Y	
NCOR2	 -0.10	 5.8E-03	 Y	 -0.23	 1.0E-05	 Y	 0	 0.50	 N	 0	 0.50	 N	
PLAGL2	 0.14	 3.9E-04	 Y	 -0.24	 1.0E-05	 Y	 0	 0.50	 N	 0	 0.50	 N	
RARA	 0.06	 0.06	 N	 -0.24	 1.0E-05	 Y	 0.17	 6.0E-05	 Y	 0.19	 2.0E-05	 Y	
SOX6	 0.36	 1.0E-05	 Y	 -0.24	 1.0E-05	 Y	 0	 0.50	 N	 0	 0.50	 N	
ATRX	 -0.08	 0.03	 Y	 -0.24	 1.0E-05	 Y	 0	 0.50	 N	 0	 0.50	 N	
MSC	 0.14	 4.8E-04	 Y	 -0.24	 1.0E-05	 Y	 0	 0.50	 N	 0	 0.50	 N	
GLI2	 -0.14	 5.0E-04	 Y	 -0.25	 1.0E-05	 Y	 0	 0.50	 N	 0.42	 1.0E-05	 Y	
CEBPE	 0.25	 1.0E-05	 Y	 -0.25	 1.0E-05	 Y	 0	 0.50	 N	 0	 0.50	 N	
TCFL5	 0.14	 3.7E-04	 Y	 -0.25	 1.0E-05	 Y	 0	 0.50	 N	 0	 0.50	 N	
HLTF	 0.10	 9.2E-03	 Y	 -0.25	 1.0E-05	 Y	 0	 0.50	 N	 0	 0.50	 N	
HAND2	 -0.07	 0.04	 Y	 -0.25	 1.0E-05	 Y	 0	 0.50	 N	 0	 0.50	 N	
FOXH1	 0.26	 1.0E-05	 Y	 -0.25	 1.0E-05	 Y	 0	 0.50	 N	 0	 0.50	 N	
E4F1	 -0.09	 0.02	 Y	 -0.25	 1.0E-05	 Y	 0	 0.50	 N	 0	 0.50	 N	
TNFAIP3	 0.21	 1.0E-05	 Y	 -0.25	 1.0E-05	 Y	 0	 0.50	 N	 0	 0.50	 N	
BACH1	 0.17	 6.0E-05	 Y	 -0.25	 1.0E-05	 Y	 0	 0.50	 N	 0	 0.50	 N	
TAL1	 -7.0E-03	 0.43	 N	 -0.25	 1.0E-05	 Y	 0	 0.50	 N	 0	 0.50	 N	
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SP1	 0.36	 1.0E-05	 Y	 -0.25	 1.0E-05	 Y	 0.33	 1.0E-05	 Y	 0.36	 1.0E-05	 Y	
CREM	 0.03	 0.27	 N	 -0.26	 1.0E-05	 Y	 -0.28	 1.0E-05	 Y	 0	 0.50	 N	
OTX1	 0.08	 0.03	 Y	 -0.26	 1.0E-05	 Y	 0	 0.50	 N	 0	 0.50	 N	
HIF1A	 -0.17	 4.0E-05	 Y	 -0.26	 1.0E-05	 Y	 0.08	 0.04	 Y	 0.42	 1.0E-05	 Y	
TCF12	 8.9E-03	 0.42	 N	 -0.27	 1.0E-05	 Y	 0	 0.50	 N	 0	 0.50	 N	
EVX1	 0.22	 1.0E-05	 Y	 -0.27	 1.0E-05	 Y	 0	 0.50	 N	 0	 0.50	 N	
HSF1	 -4.9E-03	 0.45	 N	 -0.27	 1.0E-05	 Y	 0	 0.50	 N	 0	 0.50	 N	
FOXA1	 0.03	 0.25	 N	 -0.27	 1.0E-05	 Y	 0	 0.50	 N	 0	 0.50	 N	
NR2F6	 0.24	 1.0E-05	 Y	 -0.27	 1.0E-05	 Y	 0	 0.50	 N	 0	 0.50	 N	
KLF2	 0.31	 1.0E-05	 Y	 -0.27	 1.0E-05	 Y	 0	 0.50	 N	 0.24	 1.0E-05	 Y	
OTX2	 -8.3E-03	 0.42	 N	 -0.28	 1.0E-05	 Y	 0	 0.50	 N	 0	 0.50	 N	
CBX8	 0.07	 0.06	 N	 -0.28	 1.0E-05	 Y	 0	 0.50	 N	 0	 0.50	 N	
CBX7	 0.18	 2.0E-05	 Y	 -0.28	 1.0E-05	 Y	 0	 0.50	 N	 0	 0.50	 N	
PROX1	 0.19	 2.0E-05	 Y	 -0.28	 1.0E-05	 Y	 0.03	 0.24	 N	 0	 0.50	 N	
LRRFIP1	 0.05	 0.13	 N	 -0.28	 1.0E-05	 Y	 0	 0.50	 N	 0	 0.50	 N	
NFKBIA	 -0.10	 5.8E-03	 Y	 -0.28	 1.0E-05	 Y	 -0.44	 1.0E-05	 Y	 0	 0.50	 N	
TFAP4	 0.19	 2.0E-05	 Y	 -0.29	 1.0E-05	 Y	 0	 0.50	 N	 0	 0.50	 N	
LDB1	 0.06	 0.06	 N	 -0.29	 1.0E-05	 Y	 0	 0.50	 N	 0	 0.50	 N	
KLF3	 0.14	 4.9E-04	 Y	 -0.30	 1.0E-05	 Y	 0	 0.50	 N	 0	 0.50	 N	
MXD1	 0.16	 8.0E-05	 Y	 -0.30	 1.0E-05	 Y	 0	 0.50	 N	 0	 0.50	 N	
NPAS1	 0.24	 1.0E-05	 Y	 -0.30	 1.0E-05	 Y	 0	 0.50	 N	 0	 0.50	 N	
TEAD4	 0.25	 1.0E-05	 Y	 -0.30	 1.0E-05	 Y	 0	 0.50	 N	 0	 0.50	 N	
ID1	 0.23	 1.0E-05	 Y	 -0.30	 1.0E-05	 Y	 0	 0.50	 N	 0	 0.50	 N	
ING1	 0.16	 6.0E-05	 Y	 -0.30	 1.0E-05	 Y	 0	 0.50	 N	 0	 0.50	 N	
BCL6	 -7.3E-03	 0.43	 N	 -0.30	 1.0E-05	 Y	 -0.35	 1.0E-05	 Y	 0	 0.50	 N	
FLI1	 0.38	 1.0E-05	 Y	 -0.30	 1.0E-05	 Y	 0.45	 1.0E-05	 Y	 0	 0.50	 N	
KLF16	 7.8E-03	 0.43	 N	 -0.31	 1.0E-05	 Y	 0	 0.50	 N	 0	 0.50	 N	
MSX2	 -0.05	 0.14	 N	 -0.31	 1.0E-05	 Y	 0	 0.50	 N	 0	 0.50	 N	
HDGF	 0.16	 7.0E-05	 Y	 -0.31	 1.0E-05	 Y	 0	 0.50	 N	 0	 0.50	 N	
NHLH2	 0.24	 1.0E-05	 Y	 -0.31	 1.0E-05	 Y	 0	 0.50	 N	 0	 0.50	 N	
ATF6	 0.32	 1.0E-05	 Y	 -0.32	 1.0E-05	 Y	 0	 0.50	 N	 0	 0.50	 N	
NR3C1	 0.03	 0.21	 N	 -0.32	 1.0E-05	 Y	 0	 0.50	 N	 -0.06	 0.09	 N	
CUX1	 0.15	 1.7E-04	 Y	 -0.32	 1.0E-05	 Y	 0	 0.50	 N	 0	 0.50	 N	
NKX3-1	 0.43	 1.0E-05	 Y	 -0.32	 1.0E-05	 Y	 0	 0.50	 N	 0	 0.50	 N	
HOXD9	 0.13	 1.1E-03	 Y	 -0.32	 1.0E-05	 Y	 0	 0.50	 N	 0	 0.50	 N	
PER2	 0.08	 0.03	 Y	 -0.32	 1.0E-05	 Y	 0	 0.50	 N	 0	 0.50	 N	
IRF5	 0.07	 0.04	 N	 -0.32	 1.0E-05	 Y	 0	 0.50	 N	 0	 0.50	 N	
EHF	 0.06	 0.06	 N	 -0.32	 1.0E-05	 Y	 0	 0.50	 N	 0	 0.50	 N	
FOXQ1	 0.30	 1.0E-05	 Y	 -0.32	 1.0E-05	 Y	 0	 0.50	 N	 0	 0.50	 N	
BARD1	 -0.08	 0.03	 Y	 -0.33	 1.0E-05	 Y	 0	 0.50	 N	 0	 0.50	 N	
PTTG1	 0.26	 1.0E-05	 Y	 -0.34	 1.0E-05	 Y	 0	 0.50	 N	 0.54	 1.0E-05	 Y	
PBX1	 0.41	 1.0E-05	 Y	 -0.34	 1.0E-05	 Y	 0	 0.50	 N	 0	 0.50	 N	
EGR1	 0.07	 0.05	 N	 -0.34	 1.0E-05	 Y	 0.22	 1.0E-05	 Y	 0.34	 1.0E-05	 Y	
HOXA7	 0.02	 0.35	 N	 -0.34	 1.0E-05	 Y	 0	 0.50	 N	 0	 0.50	 N	
HMGA2	 0.27	 1.0E-05	 Y	 -0.34	 1.0E-05	 Y	 0	 0.50	 N	 0	 0.50	 N	
KLF11	 0.09	 0.01	 Y	 -0.34	 1.0E-05	 Y	 0	 0.50	 N	 0	 0.50	 N	
SMARCA4	 -0.03	 0.25	 N	 -0.35	 1.0E-05	 Y	 0	 0.50	 N	 0	 0.50	 N	
DEAF1	 0.08	 0.02	 Y	 -0.35	 1.0E-05	 Y	 0	 0.50	 N	 0	 0.50	 N	
SMAD3	 0.41	 1.0E-05	 Y	 -0.35	 1.0E-05	 Y	 0	 0.50	 N	 -3.1E-
03	
0.47	 N	
CEBPG	 0.26	 1.0E-05	 Y	 -0.35	 1.0E-05	 Y	 0	 0.50	 N	 0	 0.50	 N	
HDAC3	 0.25	 1.0E-05	 Y	 -0.35	 1.0E-05	 Y	 0	 0.50	 N	 0	 0.50	 N	
MYF6	 0.19	 2.0E-05	 Y	 -0.35	 1.0E-05	 Y	 0	 0.50	 N	 0	 0.50	 N	
HIRA	 0.34	 1.0E-05	 Y	 -0.35	 1.0E-05	 Y	 0	 0.50	 N	 0	 0.50	 N	
KDM2A	 0.40	 1.0E-05	 Y	 -0.36	 1.0E-05	 Y	 0	 0.50	 N	 0	 0.50	 N	
MLLT3	 0.27	 1.0E-05	 Y	 -0.36	 1.0E-05	 Y	 0	 0.50	 N	 0	 0.50	 N	
NFKBIB	 0.33	 1.0E-05	 Y	 -0.36	 1.0E-05	 Y	 0	 0.50	 N	 0	 0.50	 N	
DNMT3A	 0.26	 1.0E-05	 Y	 -0.36	 1.0E-05	 Y	 0	 0.50	 N	 0	 0.50	 N	
RARG	 0.28	 1.0E-05	 Y	 -0.37	 1.0E-05	 Y	 0	 0.50	 N	 0	 0.50	 N	
CEBPA	 0.19	 2.0E-05	 Y	 -0.37	 1.0E-05	 Y	 0	 0.50	 N	 0.42	 1.0E-05	 Y	
PTMA	 0.29	 1.0E-05	 Y	 -0.37	 1.0E-05	 Y	 0	 0.50	 N	 0	 0.50	 N	
EPAS1	 0.17	 6.0E-05	 Y	 -0.37	 1.0E-05	 Y	 0	 0.50	 N	 0.65	 1.0E-05	 Y	
CREB5	 0.27	 1.0E-05	 Y	 -0.37	 1.0E-05	 Y	 0	 0.50	 N	 0	 0.50	 N	
ERF	 0.01	 0.37	 N	 -0.37	 1.0E-05	 Y	 0	 0.50	 N	 0	 0.50	 N	
HIC1	 0.29	 1.0E-05	 Y	 -0.37	 1.0E-05	 Y	 0	 0.50	 N	 0	 0.50	 N	
TCF3	 0.04	 0.17	 N	 -0.37	 1.0E-05	 Y	 0	 0.50	 N	 -0.31	 1.0E-05	 Y	
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NFKB2	 0.25	 1.0E-05	 Y	 -0.38	 1.0E-05	 Y	 0	 0.50	 N	 0	 0.50	 N	
E2F4	 0.36	 1.0E-05	 Y	 -0.38	 1.0E-05	 Y	 0	 0.50	 N	 -0.96	 1.0E-05	 Y	
BHLHE41	 0.11	 3.2E-03	 Y	 -0.38	 1.0E-05	 Y	 0	 0.50	 N	 0	 0.50	 N	
NCOA6	 0.20	 2.0E-05	 Y	 -0.39	 1.0E-05	 Y	 0	 0.50	 N	 0	 0.50	 N	
SRY	 0.15	 8.0E-05	 Y	 -0.39	 1.0E-05	 Y	 0	 0.50	 N	 0	 0.50	 N	
MYC	 0.03	 0.26	 N	 -0.40	 1.0E-05	 Y	 0.53	 1.0E-05	 Y	 0.19	 2.0E-05	 Y	
NR2F1	 0.04	 0.17	 N	 -0.40	 1.0E-05	 Y	 0	 0.50	 N	 0	 0.50	 N	
RBBP7	 0.31	 1.0E-05	 Y	 -0.40	 1.0E-05	 Y	 0	 0.50	 N	 0	 0.50	 N	
CIITA	 0.25	 1.0E-05	 Y	 -0.40	 1.0E-05	 Y	 -0.40	 1.0E-05	 Y	 0.43	 1.0E-05	 Y	
GLI3	 0.21	 1.0E-05	 Y	 -0.41	 1.0E-05	 Y	 0	 0.50	 N	 0	 0.50	 N	
SPDEF	 0.54	 1.0E-05	 Y	 -0.41	 1.0E-05	 Y	 0	 0.50	 N	 0	 0.50	 N	
CREB3L1	 0.19	 2.0E-05	 Y	 -0.41	 1.0E-05	 Y	 0	 0.50	 N	 0	 0.50	 N	
BTF3	 0.42	 1.0E-05	 Y	 -0.41	 1.0E-05	 Y	 0	 0.50	 N	 0	 0.50	 N	
PIAS2	 0.16	 8.0E-05	 Y	 -0.41	 1.0E-05	 Y	 0	 0.50	 N	 0	 0.50	 N	
PHOX2A	 0.21	 1.0E-05	 Y	 -0.42	 1.0E-05	 Y	 0	 0.50	 N	 0	 0.50	 N	
RREB1	 0.18	 2.0E-05	 Y	 -0.42	 1.0E-05	 Y	 0	 0.50	 N	 0	 0.50	 N	
MEIS1	 0.29	 1.0E-05	 Y	 -0.42	 1.0E-05	 Y	 0	 0.50	 N	 0	 0.50	 N	
TP53	 0.02	 0.29	 N	 -0.42	 1.0E-05	 Y	 0.08	 0.04	 Y	 -0.22	 1.0E-05	 Y	
SIRT1	 0.52	 1.0E-05	 Y	 -0.42	 1.0E-05	 Y	 -0.27	 1.0E-05	 Y	 0.04	 0.19	 N	
POU4F1	 0.33	 1.0E-05	 Y	 -0.43	 1.0E-05	 Y	 0	 0.50	 N	 0	 0.50	 N	
SRF	 0.26	 1.0E-05	 Y	 -0.43	 1.0E-05	 Y	 0	 0.50	 N	 0.71	 1.0E-05	 Y	
PPARD	 0.26	 1.0E-05	 Y	 -0.43	 1.0E-05	 Y	 0	 0.50	 N	 0.22	 1.0E-05	 Y	
LYL1	 0.28	 1.0E-05	 Y	 -0.44	 1.0E-05	 Y	 0	 0.50	 N	 0	 0.50	 N	
SP4	 0.04	 0.20	 N	 -0.44	 1.0E-05	 Y	 0	 0.50	 N	 0	 0.50	 N	
CTNNB1	 0.22	 1.0E-05	 Y	 -0.44	 1.0E-05	 Y	 0	 0.50	 N	 0	 0.50	 N	
SOX4	 0.19	 2.0E-05	 Y	 -0.44	 1.0E-05	 Y	 0	 0.50	 N	 0	 0.50	 N	
IKBKB	 0.49	 1.0E-05	 Y	 -0.45	 1.0E-05	 Y	 0	 0.50	 N	 0	 0.50	 N	
NKX2-1	 0.16	 7.0E-05	 Y	 -0.46	 1.0E-05	 Y	 0	 0.50	 N	 0	 0.50	 N	
GATA2	 0.40	 1.0E-05	 Y	 -0.46	 1.0E-05	 Y	 0	 0.50	 N	 0	 0.50	 N	
COPS5	 0.26	 1.0E-05	 Y	 -0.46	 1.0E-05	 Y	 0	 0.50	 N	 0	 0.50	 N	
PGR	 0.44	 1.0E-05	 Y	 -0.46	 1.0E-05	 Y	 0.24	 1.0E-05	 Y	 0	 0.50	 N	
PBX2	 0.18	 3.0E-05	 Y	 -0.47	 1.0E-05	 Y	 0	 0.50	 N	 0	 0.50	 N	
LHX3	 0.17	 3.0E-05	 Y	 -0.47	 1.0E-05	 Y	 0	 0.50	 N	 0	 0.50	 N	
ELF3	 0.43	 1.0E-05	 Y	 -0.47	 1.0E-05	 Y	 0	 0.50	 N	 0	 0.50	 N	
TFCP2	 0.81	 1.0E-05	 Y	 -0.48	 1.0E-05	 Y	 0	 0.50	 N	 0	 0.50	 N	
DNMT3L	 0.78	 1.0E-05	 Y	 -0.48	 1.0E-05	 Y	 0	 0.50	 N	 0	 0.50	 N	
DLX4	 0.30	 1.0E-05	 Y	 -0.48	 1.0E-05	 Y	 0	 0.50	 N	 0	 0.50	 N	
HOXA9	 0.19	 2.0E-05	 Y	 -0.48	 1.0E-05	 Y	 0	 0.50	 N	 0	 0.50	 N	
HES6	 0.23	 1.0E-05	 Y	 -0.48	 1.0E-05	 Y	 0	 0.50	 N	 0	 0.50	 N	
LMO4	 0.20	 2.0E-05	 Y	 -0.50	 1.0E-05	 Y	 0	 0.50	 N	 0	 0.50	 N	
CBX6	 0.39	 1.0E-05	 Y	 -0.50	 1.0E-05	 Y	 0	 0.50	 N	 0	 0.50	 N	
SOX3	 0.37	 1.0E-05	 Y	 -0.50	 1.0E-05	 Y	 0	 0.50	 N	 0	 0.50	 N	
NR0B2	 0.46	 1.0E-05	 Y	 -0.51	 1.0E-05	 Y	 0	 0.50	 N	 0	 0.50	 N	
AATF	 0.39	 1.0E-05	 Y	 -0.51	 1.0E-05	 Y	 0	 0.50	 N	 0	 0.50	 N	
MEN1	 0.83	 1.0E-05	 Y	 -0.51	 1.0E-05	 Y	 0	 0.50	 N	 0	 0.50	 N	
TFAP2A	 0.42	 1.0E-05	 Y	 -0.53	 1.0E-05	 Y	 0.08	 0.02	 Y	 0.23	 1.0E-05	 Y	
NFAT5	 0.36	 1.0E-05	 Y	 -0.53	 1.0E-05	 Y	 0	 0.50	 N	 0	 0.50	 N	
TFDP3	 0.33	 1.0E-05	 Y	 -0.56	 1.0E-05	 Y	 0	 0.50	 N	 0	 0.50	 N	
NKX2-5	 0.26	 1.0E-05	 Y	 -0.57	 1.0E-05	 Y	 -0.49	 1.0E-05	 Y	 0	 0.50	 N	
HDAC2	 0.46	 1.0E-05	 Y	 -0.57	 1.0E-05	 Y	 -0.69	 1.0E-05	 Y	 -0.56	 1.0E-05	 Y	
HDAC7	 0.40	 1.0E-05	 Y	 -0.57	 1.0E-05	 Y	 -0.46	 1.0E-05	 Y	 0	 0.50	 N	
GATA1	 0.44	 1.0E-05	 Y	 -0.57	 1.0E-05	 Y	 0.27	 1.0E-05	 Y	 0.25	 1.0E-05	 Y	
PAX6	 0.41	 1.0E-05	 Y	 -0.58	 1.0E-05	 Y	 0	 0.50	 N	 0	 0.50	 N	
HOXA10	 0.49	 1.0E-05	 Y	 -0.62	 1.0E-05	 Y	 0	 0.50	 N	 0	 0.50	 N	
FOXP3	 0.34	 1.0E-05	 Y	 -0.62	 1.0E-05	 Y	 0	 0.50	 N	 0	 0.50	 N	






Master list of TFs in TCGA ovarian cancer dataset together the correlation scores 
of their activity scores with PR signatures and enrichment scores of target genes 
with PR signatures 
 
TF	 S(TF,P)	 P-value	 BH	 S(TF,R)	 P-value	 BH	 ES_P	 P-value	 BH	 ES_R	 P-value	 BH	
E2F4	 0.27	 1.0E-05	 Y	 -0.33	 1.0E-05	 Y	 0	 0.50	 N	 -0.76	 1.0E-05	 Y	
SREBF2	 -0.63	 1.0E-05	 Y	 0.63	 1.0E-05	 Y	 0	 0.50	 N	 -0.52	 1.0E-05	 Y	
RB1	 0.07	 0.05	 N	 0.16	 8.0E-05	 Y	 0	 0.50	 N	 -0.43	 1.0E-05	 Y	
BCL6	 0.15	 2.4E-04	 Y	 -0.25	 1.0E-05	 Y	 -0.49	 1.0E-05	 Y	 -0.35	 1.0E-05	 Y	
NANOG	 0.06	 0.07	 N	 -0.34	 1.0E-05	 Y	 0.03	 0.21	 N	 -0.32	 1.0E-05	 Y	
SOX9	 0.06	 0.06	 N	 -0.21	 1.0E-05	 Y	 0.39	 1.0E-05	 Y	 -0.30	 1.0E-05	 Y	
HDAC2	 0.05	 0.14	 N	 -0.20	 1.0E-05	 Y	 0	 0.50	 N	 -0.30	 1.0E-05	 Y	
SIRT1	 0.43	 1.0E-05	 Y	 -0.40	 1.0E-05	 Y	 -0.47	 1.0E-05	 Y	 -0.23	 1.0E-05	 Y	
HOXB7	 0.10	 0.01	 Y	 -0.31	 1.0E-05	 Y	 0	 0.50	 N	 0.21	 1.0E-05	 Y	
LEF1	 0.11	 3.3E-03	 Y	 -0.08	 0.03	 Y	 0	 0.50	 N	 0.21	 1.0E-05	 Y	
KLF10	 -0.41	 1.0E-05	 Y	 -0.02	 0.30	 N	 0	 0.50	 N	 0.21	 1.0E-05	 Y	
PAX5	 0.11	 3.4E-03	 Y	 -0.03	 0.22	 N	 -0.16	 8.0E-05	 Y	 0.21	 1.0E-05	 Y	
IRF1	 -0.39	 1.0E-05	 Y	 0.34	 1.0E-05	 Y	 0	 0.50	 N	 0.21	 1.0E-05	 Y	
PPARA	 -0.15	 2.7E-04	 Y	 0.05	 0.12	 N	 -0.49	 1.0E-05	 Y	 0.22	 1.0E-05	 Y	
AR	 -0.16	 9.0E-05	 Y	 0.03	 0.26	 N	 -0.13	 1.0E-03	 Y	 0.22	 1.0E-05	 Y	
FOXO3	 -0.28	 1.0E-05	 Y	 0.48	 1.0E-05	 Y	 0	 0.50	 N	 0.22	 1.0E-05	 Y	
MSC	 -0.01	 0.40	 N	 -0.28	 1.0E-05	 Y	 0	 0.50	 N	 0.26	 1.0E-05	 Y	
APEX1	 -0.03	 0.26	 N	 -0.04	 0.16	 N	 0	 0.50	 N	 0.26	 1.0E-05	 Y	
RUNX1	 -0.08	 0.03	 Y	 0.22	 1.0E-05	 Y	 0	 0.50	 N	 0.27	 1.0E-05	 Y	
PML	 -0.13	 8.5E-04	 Y	 -0.12	 1.8E-03	 Y	 0	 0.50	 N	 0.27	 1.0E-05	 Y	
CREB1	 -0.18	 1.0E-05	 Y	 0.06	 0.07	 N	 0.07	 0.05	 N	 0.28	 1.0E-05	 Y	
NFE2L2	 0.09	 0.02	 Y	 -0.03	 0.21	 N	 0	 0.50	 N	 0.29	 1.0E-05	 Y	
SP3	 -0.13	 1.0E-03	 Y	 0.34	 1.0E-05	 Y	 0.51	 1.0E-05	 Y	 0.29	 1.0E-05	 Y	
ABL1	 0.09	 0.02	 Y	 -0.02	 0.33	 N	 0	 0.50	 N	 0.30	 1.0E-05	 Y	
HMGA1	 0.10	 7.4E-03	 Y	 -0.15	 2.8E-04	 Y	 0	 0.50	 N	 0.31	 1.0E-05	 Y	
FOS	 0.11	 4.6E-03	 Y	 -0.24	 1.0E-05	 Y	 -0.36	 1.0E-05	 Y	 0.32	 1.0E-05	 Y	
MYC	 0.04	 0.16	 N	 -0.40	 1.0E-05	 Y	 0.33	 1.0E-05	 Y	 0.33	 1.0E-05	 Y	
NR1H4	 0.03	 0.26	 N	 0.16	 7.0E-05	 Y	 0	 0.50	 N	 0.33	 1.0E-05	 Y	
EGR1	 0.28	 1.0E-05	 Y	 -0.44	 1.0E-05	 Y	 0.12	 2.9E-03	 Y	 0.33	 1.0E-05	 Y	
GATA3	 -0.08	 0.03	 Y	 0.30	 1.0E-05	 Y	 -0.19	 1.0E-05	 Y	 0.33	 1.0E-05	 Y	
ATF1	 -0.02	 0.32	 N	 0.13	 1.3E-03	 Y	 0	 0.50	 N	 0.35	 1.0E-05	 Y	
PPARG	 0.04	 0.18	 N	 0.17	 3.0E-05	 Y	 -0.30	 1.0E-05	 Y	 0.35	 1.0E-05	 Y	
ERG	 -0.31	 1.0E-05	 Y	 0.35	 1.0E-05	 Y	 0.04	 0.18	 N	 0.35	 1.0E-05	 Y	
HNF4A	 -0.46	 1.0E-05	 Y	 0.41	 1.0E-05	 Y	 0	 0.50	 N	 0.36	 1.0E-05	 Y	
HIF1A	 -0.04	 0.20	 N	 -0.13	 1.3E-03	 Y	 0.21	 1.0E-05	 Y	 0.36	 1.0E-05	 Y	
CIITA	 0.20	 2.0E-05	 Y	 -0.56	 1.0E-05	 Y	 0	 0.50	 N	 0.38	 1.0E-05	 Y	
GATA1	 0.35	 1.0E-05	 Y	 -0.40	 1.0E-05	 Y	 0.24	 1.0E-05	 Y	 0.39	 1.0E-05	 Y	
MTA1	 -0.09	 0.01	 Y	 0.04	 0.20	 N	 0	 0.50	 N	 0.40	 1.0E-05	 Y	
JUN	 0.12	 2.6E-03	 Y	 0.10	 0.01	 Y	 -0.13	 9.2E-04	 Y	 0.41	 1.0E-05	 Y	
SP1	 0.10	 7.6E-03	 Y	 -0.32	 1.0E-05	 Y	 0.41	 1.0E-05	 Y	 0.41	 1.0E-05	 Y	
STAT6	 -0.01	 0.37	 N	 -0.06	 0.09	 N	 0	 0.50	 N	 0.42	 1.0E-05	 Y	
RARA	 -0.06	 0.09	 N	 -0.09	 0.02	 Y	 0	 0.50	 N	 0.42	 1.0E-05	 Y	
CTNNB1	 -0.10	 0.01	 Y	 -0.08	 0.03	 Y	 0	 0.50	 N	 0.42	 1.0E-05	 Y	
SNAI2	 -0.14	 5.8E-04	 Y	 -0.02	 0.32	 N	 -0.39	 1.0E-05	 Y	 0.42	 1.0E-05	 Y	
ETV4	 -0.15	 1.9E-04	 Y	 0.12	 1.8E-03	 Y	 0	 0.50	 N	 0.43	 1.0E-05	 Y	
CEBPB	 -0.03	 0.27	 N	 0.14	 5.3E-04	 Y	 -0.05	 0.12	 N	 0.43	 1.0E-05	 Y	
ATF2	 -0.03	 0.21	 N	 0.27	 1.0E-05	 Y	 0	 0.50	 N	 0.43	 1.0E-05	 Y	
NR3C2	 0.26	 1.0E-05	 Y	 -0.07	 0.04	 Y	 0	 0.50	 N	 0.43	 1.0E-05	 Y	
TFAP2A	 0.22	 1.0E-05	 Y	 -0.36	 1.0E-05	 Y	 -0.11	 3.2E-03	 Y	 0.43	 1.0E-05	 Y	
ETS1	 -0.15	 1.0E-04	 Y	 0.18	 3.0E-05	 Y	 0.30	 1.0E-05	 Y	 0.43	 1.0E-05	 Y	
ATM	 0.10	 0.01	 Y	 -0.08	 0.02	 Y	 0	 0.50	 N	 0.44	 1.0E-05	 Y	
SMAD3	 0.25	 1.0E-05	 Y	 -0.29	 1.0E-05	 Y	 0	 0.50	 N	 0.45	 1.0E-05	 Y	
STAT3	 0.27	 1.0E-05	 Y	 -0.28	 1.0E-05	 Y	 -0.20	 1.0E-05	 Y	 0.46	 1.0E-05	 Y	
NR1I2	 -0.08	 0.02	 Y	 0.24	 1.0E-05	 Y	 -0.46	 1.0E-05	 Y	 0.47	 1.0E-05	 Y	
CDX2	 -0.25	 1.0E-05	 Y	 0.23	 1.0E-05	 Y	 0.15	 2.0E-04	 Y	 0.50	 1.0E-05	 Y	
EP300	 0.02	 0.33	 N	 -0.17	 5.0E-05	 Y	 0.34	 1.0E-05	 Y	 0.50	 1.0E-05	 Y	
NFKB1	 -0.16	 1.0E-04	 Y	 0.19	 2.0E-05	 Y	 -0.16	 9.0E-05	 Y	 0.50	 1.0E-05	 Y	
RELA	 0.17	 3.0E-05	 Y	 -0.52	 1.0E-05	 Y	 -0.20	 1.0E-05	 Y	 0.51	 1.0E-05	 Y	
MYB	 0.08	 0.04	 Y	 -0.13	 6.7E-04	 Y	 -0.40	 1.0E-05	 Y	 0.53	 1.0E-05	 Y	
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PTTG1	 0.41	 1.0E-05	 Y	 -0.47	 1.0E-05	 Y	 0	 0.50	 N	 0.53	 1.0E-05	 Y	
SMAD4	 -0.08	 0.03	 Y	 0.22	 1.0E-05	 Y	 0	 0.50	 N	 0.54	 1.0E-05	 Y	
POU2F1	 -0.03	 0.26	 N	 0.06	 0.07	 N	 0.21	 1.0E-05	 Y	 0.55	 1.0E-05	 Y	
CEBPA	 0.28	 1.0E-05	 Y	 -0.48	 1.0E-05	 Y	 0	 0.50	 N	 0.55	 1.0E-05	 Y	
STAT1	 0.11	 5.2E-03	 Y	 -0.18	 1.0E-05	 Y	 -0.17	 4.0E-05	 Y	 0.57	 1.0E-05	 Y	
MITF	 -0.13	 1.1E-03	 Y	 0.15	 8.0E-05	 Y	 0	 0.50	 N	 0.58	 1.0E-05	 Y	
KLF5	 0.10	 8.3E-03	 Y	 0.01	 0.37	 N	 0	 0.50	 N	 0.62	 1.0E-05	 Y	
REL	 -0.10	 7.2E-03	 Y	 0.59	 1.0E-05	 Y	 0	 0.50	 N	 0.63	 1.0E-05	 Y	
SRF	 0.04	 0.15	 N	 -0.17	 6.0E-05	 Y	 0.50	 1.0E-05	 Y	 0.63	 1.0E-05	 Y	
SPI1	 0.02	 0.32	 N	 0.32	 1.0E-05	 Y	 -0.27	 1.0E-05	 Y	 0.66	 1.0E-05	 Y	
ATF4	 0.14	 5.9E-04	 Y	 -0.04	 0.18	 N	 0.50	 1.0E-05	 Y	 0.66	 1.0E-05	 Y	
RXRA	 0.25	 1.0E-05	 Y	 -0.15	 2.8E-04	 Y	 0	 0.50	 N	 0.67	 1.0E-05	 Y	
RUNX2	 -0.17	 4.0E-05	 Y	 0.22	 1.0E-05	 Y	 0	 0.50	 N	 0.67	 1.0E-05	 Y	
ETS2	 -0.15	 1.7E-04	 Y	 0.14	 3.0E-04	 Y	 0	 0.50	 N	 0.73	 1.0E-05	 Y	
EPAS1	 0.05	 0.10	 N	 -0.09	 0.01	 Y	 0	 0.50	 N	 0.95	 1.0E-05	 Y	
KLF4	 -0.10	 9.8E-03	 Y	 0.25	 1.0E-05	 Y	 -0.34	 1.0E-05	 Y	 0.19	 2.0E-05	 Y	
MYCN	 0.03	 0.24	 N	 -0.04	 0.17	 N	 0.43	 1.0E-05	 Y	 0.20	 2.0E-05	 Y	
NR3C1	 0.25	 1.0E-05	 Y	 -0.32	 1.0E-05	 Y	 -0.02	 0.36	 N	 -0.16	 7.0E-05	 Y	
JUND	 -0.11	 3.5E-03	 Y	 0.10	 0.01	 Y	 0	 0.50	 N	 0.14	 2.9E-04	 Y	
TP53	 0.15	 1.3E-04	 Y	 -0.30	 1.0E-05	 Y	 0.02	 0.31	 N	 -0.12	 1.3E-03	 Y	
KLF2	 0.11	 3.3E-03	 Y	 -0.28	 1.0E-05	 Y	 0	 0.50	 N	 0.12	 1.7E-03	 Y	
EZH2	 0.27	 1.0E-05	 Y	 -0.07	 0.04	 Y	 -0.28	 1.0E-05	 Y	 -0.11	 4.4E-03	 Y	
NFYA	 0.02	 0.28	 N	 0.04	 0.19	 N	 0	 0.50	 N	 0.11	 5.0E-03	 Y	
E2F1	 -0.63	 1.0E-05	 Y	 0.32	 1.0E-05	 Y	 0.61	 1.0E-05	 Y	 0.09	 0.01	 N	
ESR1	 -0.25	 1.0E-05	 Y	 0.09	 0.02	 Y	 0.29	 1.0E-05	 Y	 0.09	 0.02	 N	
HOXA10	 0.05	 0.14	 N	 -0.25	 1.0E-05	 Y	 0	 0.50	 N	 -0.08	 0.02	 N	
CREM	 -0.03	 0.20	 N	 -0.23	 1.0E-05	 Y	 -0.58	 1.0E-05	 Y	 -0.07	 0.05	 N	
SOX2	 0.29	 1.0E-05	 Y	 -0.18	 2.0E-05	 Y	 0.37	 1.0E-05	 Y	 0.06	 0.06	 N	
HDAC4	 0.04	 0.19	 N	 0.20	 2.0E-05	 Y	 -0.28	 1.0E-05	 Y	 0.06	 0.08	 N	
RUNX3	 -0.24	 1.0E-05	 Y	 0.38	 1.0E-05	 Y	 -0.02	 0.36	 N	 0.04	 0.19	 N	
HDAC1	 -0.22	 1.0E-05	 Y	 0.36	 1.0E-05	 Y	 -0.67	 1.0E-05	 Y	 4.1E-
03	
0.46	 N	
TRERF1	 -0.12	 2.0E-03	 Y	 -0.05	 0.10	 N	 -0.85	 1.0E-05	 Y	 0	 0.50	 N	
NFKBIA	 -2.1E-03	 0.48	 N	 -0.21	 1.0E-05	 Y	 -0.70	 1.0E-05	 Y	 0	 0.50	 N	
PITX1	 0.02	 0.32	 N	 0.24	 1.0E-05	 Y	 -0.51	 1.0E-05	 Y	 0	 0.50	 N	
GATA2	 0.30	 1.0E-05	 Y	 -0.54	 1.0E-05	 Y	 -0.47	 1.0E-05	 Y	 0	 0.50	 N	
RBMX	 -0.21	 1.0E-05	 Y	 0.34	 1.0E-05	 Y	 -0.41	 1.0E-05	 Y	 0	 0.50	 N	
CREB5	 0.34	 1.0E-05	 Y	 -0.46	 1.0E-05	 Y	 -0.35	 1.0E-05	 Y	 0	 0.50	 N	
HDAC9	 -0.25	 1.0E-05	 Y	 0.33	 1.0E-05	 Y	 -0.34	 1.0E-05	 Y	 0	 0.50	 N	
REST	 -0.11	 3.4E-03	 Y	 0.23	 1.0E-05	 Y	 -0.29	 1.0E-05	 Y	 0	 0.50	 N	
HEY1	 -0.16	 1.0E-04	 Y	 0.15	 2.0E-04	 Y	 -0.26	 1.0E-05	 Y	 0	 0.50	 N	
SREBF1	 0.08	 0.02	 Y	 -3.4E-
03	
0.47	 N	 -0.23	 1.0E-05	 Y	 0	 0.50	 N	
DNMT1	 -0.20	 1.0E-05	 Y	 0.22	 1.0E-05	 Y	 -0.23	 1.0E-05	 Y	 0	 0.50	 N	
HNF1A	 -0.32	 1.0E-05	 Y	 0.16	 7.0E-05	 Y	 0.28	 1.0E-05	 Y	 0	 0.50	 N	
TCF4	 0.13	 9.5E-04	 Y	 -0.27	 1.0E-05	 Y	 0.28	 1.0E-05	 Y	 0	 0.50	 N	
NR5A1	 0.10	 9.3E-03	 Y	 -0.12	 1.6E-03	 Y	 0.50	 1.0E-05	 Y	 0	 0.50	 N	
TFDP1	 -0.10	 0.01	 Y	 0.16	 8.0E-05	 Y	 0.95	 1.0E-05	 Y	 0	 0.50	 N	
PROX1	 -0.04	 0.16	 N	 0.24	 1.0E-05	 Y	 0.20	 2.0E-05	 Y	 0	 0.50	 N	
ATF3	 0.19	 2.0E-05	 Y	 -0.37	 1.0E-05	 Y	 -0.11	 3.9E-03	 Y	 0	 0.50	 N	
ING4	 -0.02	 0.29	 N	 -0.08	 0.02	 Y	 -0.11	 4.7E-03	 Y	 0	 0.50	 N	
POU5F1	 -0.42	 1.0E-05	 Y	 0.06	 0.09	 N	 -0.08	 0.03	 Y	 0	 0.50	 N	
DDIT3	 0.15	 9.0E-05	 Y	 0.08	 0.03	 Y	 -0.04	 0.16	 N	 0	 0.50	 N	
PGR	 0.14	 6.0E-04	 Y	 -0.23	 1.0E-05	 Y	 0.04	 0.16	 N	 0	 0.50	 N	
POU4F1	 0.44	 1.0E-05	 Y	 -0.71	 1.0E-05	 Y	 0	 0.50	 N	 0	 0.50	 N	
HOXA11	 0.23	 1.0E-05	 Y	 -0.69	 1.0E-05	 Y	 0	 0.50	 N	 0	 0.50	 N	
CBX6	 0.37	 1.0E-05	 Y	 -0.67	 1.0E-05	 Y	 0	 0.50	 N	 0	 0.50	 N	
HSF1	 0.22	 1.0E-05	 Y	 -0.66	 1.0E-05	 Y	 0	 0.50	 N	 0	 0.50	 N	
CEBPE	 0.22	 1.0E-05	 Y	 -0.64	 1.0E-05	 Y	 0	 0.50	 N	 0	 0.50	 N	
RBBP7	 0.14	 5.3E-04	 Y	 -0.63	 1.0E-05	 Y	 0	 0.50	 N	 0	 0.50	 N	
NR1H2	 0.13	 6.7E-04	 Y	 -0.60	 1.0E-05	 Y	 0	 0.50	 N	 0	 0.50	 N	
TCF3	 0.12	 2.3E-03	 Y	 -0.59	 1.0E-05	 Y	 0	 0.50	 N	 0	 0.50	 N	
PPARD	 0.25	 1.0E-05	 Y	 -0.59	 1.0E-05	 Y	 0	 0.50	 N	 0	 0.50	 N	
KLF11	 0.06	 0.06	 N	 -0.58	 1.0E-05	 Y	 0	 0.50	 N	 0	 0.50	 N	
DLX4	 0.42	 1.0E-05	 Y	 -0.56	 1.0E-05	 Y	 0	 0.50	 N	 0	 0.50	 N	
SOX4	 0.30	 1.0E-05	 Y	 -0.54	 1.0E-05	 Y	 0	 0.50	 N	 0	 0.50	 N	
SRY	 0.36	 1.0E-05	 Y	 -0.54	 1.0E-05	 Y	 0	 0.50	 N	 0	 0.50	 N	
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MEN1	 0.71	 1.0E-05	 Y	 -0.54	 1.0E-05	 Y	 0	 0.50	 N	 0	 0.50	 N	
NKX2-2	 0.19	 2.0E-05	 Y	 -0.54	 1.0E-05	 Y	 0	 0.50	 N	 0	 0.50	 N	
HOXC6	 0.13	 1.4E-03	 Y	 -0.53	 1.0E-05	 Y	 0	 0.50	 N	 0	 0.50	 N	
PHOX2A	 0.21	 1.0E-05	 Y	 -0.53	 1.0E-05	 Y	 0	 0.50	 N	 0	 0.50	 N	
TFDP3	 0.29	 1.0E-05	 Y	 -0.52	 1.0E-05	 Y	 0	 0.50	 N	 0	 0.50	 N	
TNFAIP3	 0.10	 9.7E-03	 Y	 -0.51	 1.0E-05	 Y	 0	 0.50	 N	 0	 0.50	 N	
MXD1	 0.29	 1.0E-05	 Y	 -0.50	 1.0E-05	 Y	 0	 0.50	 N	 0	 0.50	 N	
DNMT3A	 0.26	 1.0E-05	 Y	 -0.50	 1.0E-05	 Y	 0	 0.50	 N	 0	 0.50	 N	
TAL1	 0.15	 2.5E-04	 Y	 -0.50	 1.0E-05	 Y	 0	 0.50	 N	 0	 0.50	 N	
CREB3L1	 0.41	 1.0E-05	 Y	 -0.48	 1.0E-05	 Y	 0	 0.50	 N	 0	 0.50	 N	
FOXP3	 0.18	 3.0E-05	 Y	 -0.46	 1.0E-05	 Y	 0	 0.50	 N	 0	 0.50	 N	
EWSR1	 0.16	 8.0E-05	 Y	 -0.46	 1.0E-05	 Y	 0	 0.50	 N	 0	 0.50	 N	
RORA	 0.33	 1.0E-05	 Y	 -0.46	 1.0E-05	 Y	 0	 0.50	 N	 0	 0.50	 N	
ERF	 0.24	 1.0E-05	 Y	 -0.44	 1.0E-05	 Y	 0	 0.50	 N	 0	 0.50	 N	
LYL1	 0.35	 1.0E-05	 Y	 -0.44	 1.0E-05	 Y	 0	 0.50	 N	 0	 0.50	 N	
LHX3	 0.29	 1.0E-05	 Y	 -0.44	 1.0E-05	 Y	 0	 0.50	 N	 0	 0.50	 N	
NCOA6	 0.39	 1.0E-05	 Y	 -0.44	 1.0E-05	 Y	 0	 0.50	 N	 0	 0.50	 N	
PAX6	 0.42	 1.0E-05	 Y	 -0.43	 1.0E-05	 Y	 0	 0.50	 N	 0	 0.50	 N	
FOXA1	 0.26	 1.0E-05	 Y	 -0.43	 1.0E-05	 Y	 0	 0.50	 N	 0	 0.50	 N	
AATF	 0.25	 1.0E-05	 Y	 -0.42	 1.0E-05	 Y	 0	 0.50	 N	 0	 0.50	 N	
DEAF1	 0.19	 2.0E-05	 Y	 -0.42	 1.0E-05	 Y	 0	 0.50	 N	 0	 0.50	 N	
NFKB2	 0.19	 2.0E-05	 Y	 -0.42	 1.0E-05	 Y	 0	 0.50	 N	 0	 0.50	 N	
ING1	 0.25	 1.0E-05	 Y	 -0.41	 1.0E-05	 Y	 0	 0.50	 N	 0	 0.50	 N	
NR0B2	 0.46	 1.0E-05	 Y	 -0.41	 1.0E-05	 Y	 0	 0.50	 N	 0	 0.50	 N	
POU2F2	 0.35	 1.0E-05	 Y	 -0.40	 1.0E-05	 Y	 0	 0.50	 N	 0	 0.50	 N	
BCL11A	 0.06	 0.07	 N	 -0.40	 1.0E-05	 Y	 0	 0.50	 N	 0	 0.50	 N	
TFAP4	 0.23	 1.0E-05	 Y	 -0.40	 1.0E-05	 Y	 0	 0.50	 N	 0	 0.50	 N	
LDB1	 -2.4E-03	 0.48	 N	 -0.40	 1.0E-05	 Y	 0	 0.50	 N	 0	 0.50	 N	
COPS5	 0.48	 1.0E-05	 Y	 -0.39	 1.0E-05	 Y	 0	 0.50	 N	 0	 0.50	 N	
BARD1	 0.12	 2.6E-03	 Y	 -0.38	 1.0E-05	 Y	 0	 0.50	 N	 0	 0.50	 N	
HOXA7	 0.12	 2.9E-03	 Y	 -0.38	 1.0E-05	 Y	 0	 0.50	 N	 0	 0.50	 N	
NFKBIB	 0.15	 9.0E-05	 Y	 -0.38	 1.0E-05	 Y	 0	 0.50	 N	 0	 0.50	 N	
NFAT5	 0.14	 5.2E-04	 Y	 -0.37	 1.0E-05	 Y	 0	 0.50	 N	 0	 0.50	 N	
MYF5	 0.15	 8.0E-05	 Y	 -0.36	 1.0E-05	 Y	 0	 0.50	 N	 0	 0.50	 N	
FOXP1	 0.18	 2.0E-05	 Y	 -0.36	 1.0E-05	 Y	 0	 0.50	 N	 0	 0.50	 N	
SATB1	 -0.02	 0.35	 N	 -0.36	 1.0E-05	 Y	 0	 0.50	 N	 0	 0.50	 N	
TCF12	 0.04	 0.17	 N	 -0.35	 1.0E-05	 Y	 0	 0.50	 N	 0	 0.50	 N	
IRF5	 0.12	 2.2E-03	 Y	 -0.35	 1.0E-05	 Y	 0	 0.50	 N	 0	 0.50	 N	
MEF2A	 -0.05	 0.13	 N	 -0.34	 1.0E-05	 Y	 0	 0.50	 N	 0	 0.50	 N	
HLTF	 0.11	 3.5E-03	 Y	 -0.34	 1.0E-05	 Y	 0	 0.50	 N	 0	 0.50	 N	
MSX2	 0.26	 1.0E-05	 Y	 -0.34	 1.0E-05	 Y	 0	 0.50	 N	 0	 0.50	 N	
KDM2A	 0.27	 1.0E-05	 Y	 -0.33	 1.0E-05	 Y	 0	 0.50	 N	 0	 0.50	 N	
LMO4	 0.26	 1.0E-05	 Y	 -0.33	 1.0E-05	 Y	 0	 0.50	 N	 0	 0.50	 N	
SPDEF	 0.57	 1.0E-05	 Y	 -0.33	 1.0E-05	 Y	 0	 0.50	 N	 0	 0.50	 N	
OTX1	 0.07	 0.04	 N	 -0.33	 1.0E-05	 Y	 0	 0.50	 N	 0	 0.50	 N	
MDM4	 0.08	 0.03	 Y	 -0.32	 1.0E-05	 Y	 0	 0.50	 N	 0	 0.50	 N	
NKX2-5	 0.26	 1.0E-05	 Y	 -0.32	 1.0E-05	 Y	 0	 0.50	 N	 0	 0.50	 N	
PBX2	 0.17	 3.0E-05	 Y	 -0.32	 1.0E-05	 Y	 0	 0.50	 N	 0	 0.50	 N	
HSF2	 0.16	 8.0E-05	 Y	 -0.31	 1.0E-05	 Y	 0	 0.50	 N	 0	 0.50	 N	
IKBKB	 0.34	 1.0E-05	 Y	 -0.31	 1.0E-05	 Y	 0	 0.50	 N	 0	 0.50	 N	
GATA6	 0.05	 0.13	 N	 -0.30	 1.0E-05	 Y	 0	 0.50	 N	 0	 0.50	 N	
HOXA9	 0.18	 3.0E-05	 Y	 -0.30	 1.0E-05	 Y	 0	 0.50	 N	 0	 0.50	 N	
TFCP2	 0.73	 1.0E-05	 Y	 -0.30	 1.0E-05	 Y	 0	 0.50	 N	 0	 0.50	 N	
PER2	 0.24	 1.0E-05	 Y	 -0.30	 1.0E-05	 Y	 0	 0.50	 N	 0	 0.50	 N	
DNMT3L	 0.58	 1.0E-05	 Y	 -0.30	 1.0E-05	 Y	 0	 0.50	 N	 0	 0.50	 N	
HDAC7	 0.25	 1.0E-05	 Y	 -0.30	 1.0E-05	 Y	 0	 0.50	 N	 0	 0.50	 N	
NR1I3	 0.14	 2.9E-04	 Y	 -0.30	 1.0E-05	 Y	 0	 0.50	 N	 0	 0.50	 N	
TBPL1	 0.05	 0.14	 N	 -0.30	 1.0E-05	 Y	 0	 0.50	 N	 0	 0.50	 N	
ELF3	 0.14	 4.5E-04	 Y	 -0.29	 1.0E-05	 Y	 0	 0.50	 N	 0	 0.50	 N	
TCFL5	 0.15	 2.1E-04	 Y	 -0.29	 1.0E-05	 Y	 0	 0.50	 N	 0	 0.50	 N	
BHLHE41	 0.25	 1.0E-05	 Y	 -0.29	 1.0E-05	 Y	 0	 0.50	 N	 0	 0.50	 N	
MYF6	 0.22	 1.0E-05	 Y	 -0.28	 1.0E-05	 Y	 0	 0.50	 N	 0	 0.50	 N	
FOXD3	 0.08	 0.03	 Y	 -0.28	 1.0E-05	 Y	 0	 0.50	 N	 0	 0.50	 N	
CREBBP	 0.21	 1.0E-05	 Y	 -0.28	 1.0E-05	 Y	 0	 0.50	 N	 0	 0.50	 N	
SOX3	 0.22	 1.0E-05	 Y	 -0.28	 1.0E-05	 Y	 0	 0.50	 N	 0	 0.50	 N	
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HIRA	 0.12	 2.4E-03	 Y	 -0.28	 1.0E-05	 Y	 0	 0.50	 N	 0	 0.50	 N	
CEBPG	 0.17	 5.0E-05	 Y	 -0.28	 1.0E-05	 Y	 0	 0.50	 N	 0	 0.50	 N	
ELK1	 0.07	 0.06	 N	 -0.27	 1.0E-05	 Y	 0	 0.50	 N	 0	 0.50	 N	
FLI1	 0.30	 1.0E-05	 Y	 -0.27	 1.0E-05	 Y	 0	 0.50	 N	 0	 0.50	 N	
KAT6A	 0.16	 8.0E-05	 Y	 -0.27	 1.0E-05	 Y	 0	 0.50	 N	 0	 0.50	 N	
SSB	 0.18	 2.0E-05	 Y	 -0.26	 1.0E-05	 Y	 0	 0.50	 N	 0	 0.50	 N	
KLF3	 0.16	 8.0E-05	 Y	 -0.26	 1.0E-05	 Y	 0	 0.50	 N	 0	 0.50	 N	
FOXA2	 0.08	 0.03	 Y	 -0.26	 1.0E-05	 Y	 0	 0.50	 N	 0	 0.50	 N	
ATF6	 0.22	 1.0E-05	 Y	 -0.26	 1.0E-05	 Y	 0	 0.50	 N	 0	 0.50	 N	
GFI1B	 0.15	 9.0E-05	 Y	 -0.26	 1.0E-05	 Y	 0	 0.50	 N	 0	 0.50	 N	
FOSL2	 0.12	 2.5E-03	 Y	 -0.26	 1.0E-05	 Y	 0	 0.50	 N	 0	 0.50	 N	
NEUROD
1	
0.06	 0.06	 N	 -0.26	 1.0E-05	 Y	 0	 0.50	 N	 0	 0.50	 N	
PTMA	 0.29	 1.0E-05	 Y	 -0.25	 1.0E-05	 Y	 0	 0.50	 N	 0	 0.50	 N	
NR2E3	 0.24	 1.0E-05	 Y	 -0.25	 1.0E-05	 Y	 0	 0.50	 N	 0	 0.50	 N	
HEXIM1	 0.16	 8.0E-05	 Y	 -0.25	 1.0E-05	 Y	 0	 0.50	 N	 0	 0.50	 N	
NCOR2	 0.05	 0.14	 N	 -0.25	 1.0E-05	 Y	 0	 0.50	 N	 0	 0.50	 N	
SPEN	 0.01	 0.40	 N	 -0.25	 1.0E-05	 Y	 0	 0.50	 N	 0	 0.50	 N	
KLF13	 0.26	 1.0E-05	 Y	 -0.25	 1.0E-05	 Y	 0	 0.50	 N	 0	 0.50	 N	
MXI1	 0.13	 1.5E-03	 Y	 -0.25	 1.0E-05	 Y	 0	 0.50	 N	 0	 0.50	 N	
NFE2L1	 0.21	 1.0E-05	 Y	 -0.25	 1.0E-05	 Y	 0	 0.50	 N	 0	 0.50	 N	
MAFF	 0.36	 1.0E-05	 Y	 -0.25	 1.0E-05	 Y	 0	 0.50	 N	 0	 0.50	 N	
HNF4G	 0.13	 9.8E-04	 Y	 -0.24	 1.0E-05	 Y	 0	 0.50	 N	 0	 0.50	 N	
HES1	 0.08	 0.02	 Y	 -0.24	 1.0E-05	 Y	 0	 0.50	 N	 0	 0.50	 N	
MYBL2	 0.17	 3.0E-05	 Y	 -0.24	 1.0E-05	 Y	 0	 0.50	 N	 0	 0.50	 N	
GZF1	 0.27	 1.0E-05	 Y	 -0.24	 1.0E-05	 Y	 0	 0.50	 N	 0	 0.50	 N	
NFRKB	 -0.02	 0.31	 N	 -0.24	 1.0E-05	 Y	 0	 0.50	 N	 0	 0.50	 N	
IRF2	 0.09	 0.01	 Y	 -0.23	 1.0E-05	 Y	 0	 0.50	 N	 0	 0.50	 N	
CREB3	 0.09	 0.02	 Y	 -0.23	 1.0E-05	 Y	 0	 0.50	 N	 0	 0.50	 N	
KLF12	 -0.19	 1.0E-05	 Y	 -0.22	 1.0E-05	 Y	 0	 0.50	 N	 0	 0.50	 N	
DEK	 0.08	 0.04	 Y	 -0.22	 1.0E-05	 Y	 0	 0.50	 N	 0	 0.50	 N	
HAND2	 0.08	 0.04	 Y	 -0.22	 1.0E-05	 Y	 0	 0.50	 N	 0	 0.50	 N	
E4F1	 0.09	 0.02	 Y	 -0.22	 1.0E-05	 Y	 0	 0.50	 N	 0	 0.50	 N	
L3MBTL1	 0.06	 0.06	 N	 -0.22	 1.0E-05	 Y	 0	 0.50	 N	 0	 0.50	 N	
HBP1	 0.27	 1.0E-05	 Y	 -0.22	 1.0E-05	 Y	 0	 0.50	 N	 0	 0.50	 N	
ESR2	 0.13	 8.5E-04	 Y	 -0.22	 1.0E-05	 Y	 0	 0.50	 N	 0	 0.50	 N	
HOXB1	 0.17	 6.0E-05	 Y	 -0.21	 1.0E-05	 Y	 0	 0.50	 N	 0	 0.50	 N	
ING2	 0.24	 1.0E-05	 Y	 -0.21	 1.0E-05	 Y	 0	 0.50	 N	 0	 0.50	 N	
SP4	 0.24	 1.0E-05	 Y	 -0.21	 1.0E-05	 Y	 0	 0.50	 N	 0	 0.50	 N	
MLXIPL	 0.24	 1.0E-05	 Y	 -0.20	 1.0E-05	 Y	 0	 0.50	 N	 0	 0.50	 N	
ID1	 0.34	 1.0E-05	 Y	 -0.20	 1.0E-05	 Y	 0	 0.50	 N	 0	 0.50	 N	
FOXC1	 0.15	 2.0E-04	 Y	 -0.20	 1.0E-05	 Y	 0	 0.50	 N	 0	 0.50	 N	
HINFP	 -0.02	 0.30	 N	 -0.20	 1.0E-05	 Y	 0	 0.50	 N	 0	 0.50	 N	
ATOH1	 0.11	 4.3E-03	 Y	 -0.20	 1.0E-05	 Y	 0	 0.50	 N	 0	 0.50	 N	
SRSF1	 -0.08	 0.03	 Y	 -0.20	 1.0E-05	 Y	 0	 0.50	 N	 0	 0.50	 N	
SMURF2	 -0.12	 2.6E-03	 Y	 -0.20	 1.0E-05	 Y	 0	 0.50	 N	 0	 0.50	 N	
FOXQ1	 0.07	 0.04	 N	 -0.20	 1.0E-05	 Y	 0	 0.50	 N	 0	 0.50	 N	
RREB1	 0.24	 1.0E-05	 Y	 -0.19	 1.0E-05	 Y	 0	 0.50	 N	 0	 0.50	 N	
HSF4	 -0.08	 0.03	 Y	 -0.19	 1.0E-05	 Y	 0	 0.50	 N	 0	 0.50	 N	
MAFB	 0.06	 0.07	 N	 -0.19	 1.0E-05	 Y	 0	 0.50	 N	 0	 0.50	 N	
SMARCA4	 0.06	 0.09	 N	 -0.19	 1.0E-05	 Y	 0	 0.50	 N	 0	 0.50	 N	
IKZF1	 0.17	 3.0E-05	 Y	 -0.19	 1.0E-05	 Y	 0	 0.50	 N	 0	 0.50	 N	
RBL2	 0.05	 0.11	 N	 -0.19	 1.0E-05	 Y	 0	 0.50	 N	 0	 0.50	 N	
NPAS2	 0.01	 0.39	 N	 -0.19	 1.0E-05	 Y	 0	 0.50	 N	 0	 0.50	 N	
HR	 0.02	 0.32	 N	 -0.19	 1.0E-05	 Y	 0	 0.50	 N	 0	 0.50	 N	
ATRX	 0.06	 0.08	 N	 -0.19	 1.0E-05	 Y	 0	 0.50	 N	 0	 0.50	 N	
CHD4	 -0.09	 0.02	 Y	 -0.19	 1.0E-05	 Y	 0	 0.50	 N	 0	 0.50	 N	
CUX1	 -0.09	 0.01	 Y	 -0.19	 1.0E-05	 Y	 0	 0.50	 N	 0	 0.50	 N	
NF1	 0.25	 1.0E-05	 Y	 -0.19	 1.0E-05	 Y	 0	 0.50	 N	 0	 0.50	 N	
ERCC2	 0.19	 2.0E-05	 Y	 -0.18	 1.0E-05	 Y	 0	 0.50	 N	 0	 0.50	 N	
CITED2	 -0.13	 1.1E-03	 Y	 -0.18	 1.0E-05	 Y	 0	 0.50	 N	 0	 0.50	 N	
BTF3	 0.28	 1.0E-05	 Y	 -0.18	 1.0E-05	 Y	 0	 0.50	 N	 0	 0.50	 N	
CDX1	 -0.27	 1.0E-05	 Y	 0.21	 1.0E-05	 Y	 0	 0.50	 N	 0	 0.50	 N	
RARB	 -0.30	 1.0E-05	 Y	 0.21	 1.0E-05	 Y	 0	 0.50	 N	 0	 0.50	 N	
CLOCK	 -0.23	 1.0E-05	 Y	 0.21	 1.0E-05	 Y	 0	 0.50	 N	 0	 0.50	 N	
TAF1	 -0.05	 0.10	 N	 0.21	 1.0E-05	 Y	 0	 0.50	 N	 0	 0.50	 N	
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FOXO4	 -0.04	 0.19	 N	 0.21	 1.0E-05	 Y	 0	 0.50	 N	 0	 0.50	 N	
BCL3	 -0.24	 1.0E-05	 Y	 0.21	 1.0E-05	 Y	 0	 0.50	 N	 0	 0.50	 N	
CEBPZ	 -0.30	 1.0E-05	 Y	 0.21	 1.0E-05	 Y	 0	 0.50	 N	 0	 0.50	 N	
RB1CC1	 -0.14	 6.1E-04	 Y	 0.22	 1.0E-05	 Y	 0	 0.50	 N	 0	 0.50	 N	
FOXF1	 -0.12	 2.3E-03	 Y	 0.22	 1.0E-05	 Y	 0	 0.50	 N	 0	 0.50	 N	
TBX21	 -0.17	 4.0E-05	 Y	 0.22	 1.0E-05	 Y	 0	 0.50	 N	 0	 0.50	 N	
ILF2	 -0.08	 0.03	 Y	 0.22	 1.0E-05	 Y	 0	 0.50	 N	 0	 0.50	 N	
AES	 -0.02	 0.31	 N	 0.22	 1.0E-05	 Y	 0	 0.50	 N	 0	 0.50	 N	
ID2	 -0.20	 1.0E-05	 Y	 0.22	 1.0E-05	 Y	 0	 0.50	 N	 0	 0.50	 N	
KCNIP3	 -0.42	 1.0E-05	 Y	 0.22	 1.0E-05	 Y	 0	 0.50	 N	 0	 0.50	 N	
POU2AF1	 -0.27	 1.0E-05	 Y	 0.22	 1.0E-05	 Y	 0	 0.50	 N	 0	 0.50	 N	
EN1	 -0.17	 3.0E-05	 Y	 0.23	 1.0E-05	 Y	 0	 0.50	 N	 0	 0.50	 N	
PHOX2B	 -0.05	 0.11	 N	 0.23	 1.0E-05	 Y	 0	 0.50	 N	 0	 0.50	 N	
POU4F2	 -0.32	 1.0E-05	 Y	 0.23	 1.0E-05	 Y	 0	 0.50	 N	 0	 0.50	 N	
ILF3	 -0.18	 1.0E-05	 Y	 0.23	 1.0E-05	 Y	 0	 0.50	 N	 0	 0.50	 N	
SPIC	 -0.11	 5.2E-03	 Y	 0.24	 1.0E-05	 Y	 0	 0.50	 N	 0	 0.50	 N	
ELK3	 -0.06	 0.08	 N	 0.24	 1.0E-05	 Y	 0	 0.50	 N	 0	 0.50	 N	
NFIL3	 -0.19	 1.0E-05	 Y	 0.25	 1.0E-05	 Y	 0	 0.50	 N	 0	 0.50	 N	
NCOA4	 -0.21	 1.0E-05	 Y	 0.25	 1.0E-05	 Y	 0	 0.50	 N	 0	 0.50	 N	
IFI16	 -0.23	 1.0E-05	 Y	 0.25	 1.0E-05	 Y	 0	 0.50	 N	 0	 0.50	 N	
KLF6	 -0.10	 9.1E-03	 Y	 0.26	 1.0E-05	 Y	 0	 0.50	 N	 0	 0.50	 N	
CRX	 -0.22	 1.0E-05	 Y	 0.26	 1.0E-05	 Y	 0	 0.50	 N	 0	 0.50	 N	
E2F7	 -0.19	 1.0E-05	 Y	 0.26	 1.0E-05	 Y	 0	 0.50	 N	 0	 0.50	 N	
SFPQ	 -0.12	 1.4E-03	 Y	 0.26	 1.0E-05	 Y	 0	 0.50	 N	 0	 0.50	 N	
SATB2	 -0.04	 0.14	 N	 0.26	 1.0E-05	 Y	 0	 0.50	 N	 0	 0.50	 N	
TP73	 -0.61	 1.0E-05	 Y	 0.26	 1.0E-05	 Y	 0	 0.50	 N	 0	 0.50	 N	
FOXG1	 -0.08	 0.03	 Y	 0.27	 1.0E-05	 Y	 0	 0.50	 N	 0	 0.50	 N	
EAPP	 -0.09	 0.01	 Y	 0.27	 1.0E-05	 Y	 0	 0.50	 N	 0	 0.50	 N	
APC	 -0.20	 1.0E-05	 Y	 0.27	 1.0E-05	 Y	 0	 0.50	 N	 0	 0.50	 N	
MCM6	 -0.39	 1.0E-05	 Y	 0.27	 1.0E-05	 Y	 0	 0.50	 N	 0	 0.50	 N	
TEF	 -0.28	 1.0E-05	 Y	 0.28	 1.0E-05	 Y	 0	 0.50	 N	 0	 0.50	 N	
HAX1	 -0.31	 1.0E-05	 Y	 0.28	 1.0E-05	 Y	 0	 0.50	 N	 0	 0.50	 N	
CRTC1	 -0.17	 6.0E-05	 Y	 0.28	 1.0E-05	 Y	 0	 0.50	 N	 0	 0.50	 N	
HIPK2	 0.01	 0.37	 N	 0.28	 1.0E-05	 Y	 0	 0.50	 N	 0	 0.50	 N	
IRF9	 -0.21	 1.0E-05	 Y	 0.29	 1.0E-05	 Y	 0	 0.50	 N	 0	 0.50	 N	
SIX1	 -0.30	 1.0E-05	 Y	 0.29	 1.0E-05	 Y	 0	 0.50	 N	 0	 0.50	 N	
SKIL	 -0.24	 1.0E-05	 Y	 0.30	 1.0E-05	 Y	 0	 0.50	 N	 0	 0.50	 N	
MAX	 -0.28	 1.0E-05	 Y	 0.30	 1.0E-05	 Y	 0	 0.50	 N	 0	 0.50	 N	
HDAC5	 -0.03	 0.25	 N	 0.30	 1.0E-05	 Y	 0	 0.50	 N	 0	 0.50	 N	
NCOA3	 -0.22	 1.0E-05	 Y	 0.30	 1.0E-05	 Y	 0	 0.50	 N	 0	 0.50	 N	
PITX2	 7.6E-03	 0.43	 N	 0.31	 1.0E-05	 Y	 0	 0.50	 N	 0	 0.50	 N	
MTA2	 -0.24	 1.0E-05	 Y	 0.31	 1.0E-05	 Y	 0	 0.50	 N	 0	 0.50	 N	
KLF8	 -0.16	 9.0E-05	 Y	 0.31	 1.0E-05	 Y	 0	 0.50	 N	 0	 0.50	 N	
SPIB	 -0.09	 0.02	 Y	 0.32	 1.0E-05	 Y	 0	 0.50	 N	 0	 0.50	 N	
SMARCB1	 -0.10	 0.01	 Y	 0.32	 1.0E-05	 Y	 0	 0.50	 N	 0	 0.50	 N	
GFI1	 -0.34	 1.0E-05	 Y	 0.32	 1.0E-05	 Y	 0	 0.50	 N	 0	 0.50	 N	
PER1	 -0.11	 4.8E-03	 Y	 0.33	 1.0E-05	 Y	 0	 0.50	 N	 0	 0.50	 N	
MED1	 -0.03	 0.22	 N	 0.33	 1.0E-05	 Y	 0	 0.50	 N	 0	 0.50	 N	
HDAC10	 -0.21	 1.0E-05	 Y	 0.33	 1.0E-05	 Y	 0	 0.50	 N	 0	 0.50	 N	
MEF2D	 -0.25	 1.0E-05	 Y	 0.34	 1.0E-05	 Y	 0	 0.50	 N	 0	 0.50	 N	
STAT2	 -0.16	 8.0E-05	 Y	 0.34	 1.0E-05	 Y	 0	 0.50	 N	 0	 0.50	 N	
NCOR1	 -0.14	 2.8E-04	 Y	 0.34	 1.0E-05	 Y	 0	 0.50	 N	 0	 0.50	 N	
FOXL2	 -0.11	 3.6E-03	 Y	 0.35	 1.0E-05	 Y	 0	 0.50	 N	 0	 0.50	 N	
SOX11	 -0.30	 1.0E-05	 Y	 0.35	 1.0E-05	 Y	 0	 0.50	 N	 0	 0.50	 N	
PAX4	 -0.17	 5.0E-05	 Y	 0.36	 1.0E-05	 Y	 0	 0.50	 N	 0	 0.50	 N	
ATF5	 -0.28	 1.0E-05	 Y	 0.36	 1.0E-05	 Y	 0	 0.50	 N	 0	 0.50	 N	
ARNT	 0.02	 0.35	 N	 0.37	 1.0E-05	 Y	 0	 0.50	 N	 0	 0.50	 N	
NFYB	 -0.17	 3.0E-05	 Y	 0.37	 1.0E-05	 Y	 0	 0.50	 N	 0	 0.50	 N	
NFIX	 -0.30	 1.0E-05	 Y	 0.37	 1.0E-05	 Y	 0	 0.50	 N	 0	 0.50	 N	
FOXM1	 -0.42	 1.0E-05	 Y	 0.37	 1.0E-05	 Y	 0	 0.50	 N	 0	 0.50	 N	
FOSL1	 -0.18	 2.0E-05	 Y	 0.38	 1.0E-05	 Y	 0	 0.50	 N	 0	 0.50	 N	
ARNTL2	 -0.14	 6.0E-04	 Y	 0.38	 1.0E-05	 Y	 0	 0.50	 N	 0	 0.50	 N	
KDM4C	 -0.23	 1.0E-05	 Y	 0.38	 1.0E-05	 Y	 0	 0.50	 N	 0	 0.50	 N	
NFIA	 0.05	 0.14	 N	 0.38	 1.0E-05	 Y	 0	 0.50	 N	 0	 0.50	 N	
SKI	 -0.32	 1.0E-05	 Y	 0.39	 1.0E-05	 Y	 0	 0.50	 N	 0	 0.50	 N	
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HEY2	 -0.33	 1.0E-05	 Y	 0.39	 1.0E-05	 Y	 0	 0.50	 N	 0	 0.50	 N	
SND1	 -0.26	 1.0E-05	 Y	 0.39	 1.0E-05	 Y	 0	 0.50	 N	 0	 0.50	 N	
KHDRBS1	 -0.09	 0.02	 Y	 0.39	 1.0E-05	 Y	 0	 0.50	 N	 0	 0.50	 N	
ELF4	 -0.18	 2.0E-05	 Y	 0.39	 1.0E-05	 Y	 0	 0.50	 N	 0	 0.50	 N	
RFX1	 -0.05	 0.10	 N	 0.39	 1.0E-05	 Y	 0	 0.50	 N	 0	 0.50	 N	
POLR1A	 -0.29	 1.0E-05	 Y	 0.40	 1.0E-05	 Y	 0	 0.50	 N	 0	 0.50	 N	
PPARGC1
A	
-0.31	 1.0E-05	 Y	 0.40	 1.0E-05	 Y	 0	 0.50	 N	 0	 0.50	 N	
AIP	 -0.26	 1.0E-05	 Y	 0.40	 1.0E-05	 Y	 0	 0.50	 N	 0	 0.50	 N	
TCF19	 -0.59	 1.0E-05	 Y	 0.41	 1.0E-05	 Y	 0	 0.50	 N	 0	 0.50	 N	
NFYC	 0.01	 0.38	 N	 0.42	 1.0E-05	 Y	 0	 0.50	 N	 0	 0.50	 N	
ARID3A	 -0.12	 1.6E-03	 Y	 0.42	 1.0E-05	 Y	 0	 0.50	 N	 0	 0.50	 N	
DLX3	 -0.27	 1.0E-05	 Y	 0.43	 1.0E-05	 Y	 0	 0.50	 N	 0	 0.50	 N	
MTA3	 -0.27	 1.0E-05	 Y	 0.44	 1.0E-05	 Y	 0	 0.50	 N	 0	 0.50	 N	
HCFC1	 -0.08	 0.03	 Y	 0.44	 1.0E-05	 Y	 0	 0.50	 N	 0	 0.50	 N	
PIAS1	 -0.20	 1.0E-05	 Y	 0.44	 1.0E-05	 Y	 0	 0.50	 N	 0	 0.50	 N	
AHR	 -0.10	 6.9E-03	 Y	 0.45	 1.0E-05	 Y	 0	 0.50	 N	 0	 0.50	 N	
FOXL1	 -0.17	 6.0E-05	 Y	 0.45	 1.0E-05	 Y	 0	 0.50	 N	 0	 0.50	 N	
BTAF1	 -0.16	 8.0E-05	 Y	 0.45	 1.0E-05	 Y	 0	 0.50	 N	 0	 0.50	 N	
SIRT2	 -0.10	 7.0E-03	 Y	 0.45	 1.0E-05	 Y	 0	 0.50	 N	 0	 0.50	 N	
SERTAD1	 -0.26	 1.0E-05	 Y	 0.47	 1.0E-05	 Y	 0	 0.50	 N	 0	 0.50	 N	
LIMD1	 -0.27	 1.0E-05	 Y	 0.48	 1.0E-05	 Y	 0	 0.50	 N	 0	 0.50	 N	
MECP2	 -0.15	 2.3E-04	 Y	 0.48	 1.0E-05	 Y	 0	 0.50	 N	 0	 0.50	 N	
MAF	 -0.31	 1.0E-05	 Y	 0.49	 1.0E-05	 Y	 0	 0.50	 N	 0	 0.50	 N	
STAT5A	 -0.27	 1.0E-05	 Y	 0.50	 1.0E-05	 Y	 0	 0.50	 N	 0	 0.50	 N	
E2F6	 -0.63	 1.0E-05	 Y	 0.50	 1.0E-05	 Y	 0	 0.50	 N	 0	 0.50	 N	
ESRRG	 -0.23	 1.0E-05	 Y	 0.51	 1.0E-05	 Y	 0	 0.50	 N	 0	 0.50	 N	
BTG2	 -0.03	 0.22	 N	 0.51	 1.0E-05	 Y	 0	 0.50	 N	 0	 0.50	 N	
LRRFIP1	 -0.21	 1.0E-05	 Y	 0.52	 1.0E-05	 Y	 0	 0.50	 N	 0	 0.50	 N	
MBD2	 -0.35	 1.0E-05	 Y	 0.57	 1.0E-05	 Y	 0	 0.50	 N	 0	 0.50	 N	
HOXB13	 -0.31	 1.0E-05	 Y	 0.57	 1.0E-05	 Y	 0	 0.50	 N	 0	 0.50	 N	
MKL1	 -0.22	 1.0E-05	 Y	 0.57	 1.0E-05	 Y	 0	 0.50	 N	 0	 0.50	 N	
TBP	 -0.50	 1.0E-05	 Y	 0.58	 1.0E-05	 Y	 0	 0.50	 N	 0	 0.50	 N	
DDB2	 -0.08	 0.03	 Y	 0.61	 1.0E-05	 Y	 0	 0.50	 N	 0	 0.50	 N	
ESRRA	 -0.57	 1.0E-05	 Y	 0.63	 1.0E-05	 Y	 0	 0.50	 N	 0	 0.50	 N	
CTCFL	 -0.30	 1.0E-05	 Y	 0.64	 1.0E-05	 Y	 0	 0.50	 N	 0	 0.50	 N	
MCM2	 -0.35	 1.0E-05	 Y	 0.65	 1.0E-05	 Y	 0	 0.50	 N	 0	 0.50	 N	
ENO1	 -0.30	 1.0E-05	 Y	 0.75	 1.0E-05	 Y	 0	 0.50	 N	 0	 0.50	 N	
KLF16	 0.20	 2.0E-05	 Y	 -0.18	 2.0E-05	 Y	 0	 0.50	 N	 0	 0.50	 N	
PRDM1	 -0.18	 2.0E-05	 Y	 0.18	 2.0E-05	 Y	 0	 0.50	 N	 0	 0.50	 N	
TP53BP1	 -0.22	 1.0E-05	 Y	 0.18	 2.0E-05	 Y	 0	 0.50	 N	 0	 0.50	 N	
SF1	 -0.05	 0.10	 N	 0.18	 2.0E-05	 Y	 0	 0.50	 N	 0	 0.50	 N	
ID4	 -0.35	 1.0E-05	 Y	 0.19	 2.0E-05	 Y	 0	 0.50	 N	 0	 0.50	 N	
FOXF2	 -0.09	 0.02	 Y	 0.19	 2.0E-05	 Y	 0	 0.50	 N	 0	 0.50	 N	
NCOA1	 0.01	 0.37	 N	 0.19	 2.0E-05	 Y	 0	 0.50	 N	 0	 0.50	 N	
ELK4	 -0.05	 0.13	 N	 0.19	 2.0E-05	 Y	 0	 0.50	 N	 0	 0.50	 N	
PITX3	 -0.41	 1.0E-05	 Y	 0.20	 2.0E-05	 Y	 0	 0.50	 N	 0	 0.50	 N	
THRB	 -0.03	 0.21	 N	 0.20	 2.0E-05	 Y	 0	 0.50	 N	 0	 0.50	 N	
NR0B1	 -0.09	 0.02	 Y	 0.20	 2.0E-05	 Y	 0	 0.50	 N	 0	 0.50	 N	
JUNB	 -0.26	 1.0E-05	 Y	 0.20	 2.0E-05	 Y	 0	 0.50	 N	 0	 0.50	 N	
TOB1	 -0.22	 1.0E-05	 Y	 0.20	 2.0E-05	 Y	 0	 0.50	 N	 0	 0.50	 N	
GTF3A	 -0.13	 9.9E-04	 Y	 0.20	 2.0E-05	 Y	 0	 0.50	 N	 0	 0.50	 N	
ASCL1	 -0.05	 0.12	 N	 0.20	 2.0E-05	 Y	 0	 0.50	 N	 0	 0.50	 N	
HTATIP2	 0.40	 1.0E-05	 Y	 -0.17	 3.0E-05	 Y	 0	 0.50	 N	 0	 0.50	 N	
MED23	 0.04	 0.18	 N	 0.17	 3.0E-05	 Y	 0	 0.50	 N	 0	 0.50	 N	
STAT5B	 -0.08	 0.02	 Y	 0.18	 3.0E-05	 Y	 0	 0.50	 N	 0	 0.50	 N	
GLI1	 0.08	 0.03	 Y	 0.18	 3.0E-05	 Y	 0	 0.50	 N	 0	 0.50	 N	
HIC1	 0.24	 1.0E-05	 Y	 -0.17	 5.0E-05	 Y	 0	 0.50	 N	 0	 0.50	 N	
RFX3	 0.13	 1.1E-03	 Y	 -0.17	 5.0E-05	 Y	 0	 0.50	 N	 0	 0.50	 N	
SOX10	 -0.17	 5.0E-05	 Y	 0.16	 6.0E-05	 Y	 0	 0.50	 N	 0	 0.50	 N	
HDAC3	 0.03	 0.25	 N	 -0.16	 7.0E-05	 Y	 0	 0.50	 N	 0	 0.50	 N	
SLC2A4R
G	
-0.28	 1.0E-05	 Y	 0.16	 7.0E-05	 Y	 0	 0.50	 N	 0	 0.50	 N	
NR1H3	 -9.0E-03	 0.42	 N	 0.16	 7.0E-05	 Y	 0	 0.50	 N	 0	 0.50	 N	
TAF4	 -0.11	 4.7E-03	 Y	 0.16	 7.0E-05	 Y	 0	 0.50	 N	 0	 0.50	 N	
ETV6	 -0.08	 0.03	 Y	 -0.16	 8.0E-05	 Y	 0	 0.50	 N	 0	 0.50	 N	
GBX2	 -0.22	 1.0E-05	 Y	 0.15	 8.0E-05	 Y	 0	 0.50	 N	 0	 0.50	 N	
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SMARCA1	 0.02	 0.29	 N	 0.15	 8.0E-05	 Y	 0	 0.50	 N	 0	 0.50	 N	
PAX3	 -0.11	 3.6E-03	 Y	 0.16	 8.0E-05	 Y	 0	 0.50	 N	 0	 0.50	 N	
MSX1	 0.04	 0.16	 N	 0.16	 8.0E-05	 Y	 0	 0.50	 N	 0	 0.50	 N	
FUS	 -0.03	 0.26	 N	 0.16	 8.0E-05	 Y	 0	 0.50	 N	 0	 0.50	 N	
EGR3	 -0.18	 1.0E-05	 Y	 0.16	 8.0E-05	 Y	 0	 0.50	 N	 0	 0.50	 N	
PKNOX1	 5.4E-03	 0.45	 N	 -0.16	 9.0E-05	 Y	 0	 0.50	 N	 0	 0.50	 N	
PA2G4	 0.11	 3.6E-03	 Y	 -0.16	 1.0E-04	 Y	 0	 0.50	 N	 0	 0.50	 N	
KAT2B	 -0.10	 8.7E-03	 Y	 -0.16	 1.0E-04	 Y	 0	 0.50	 N	 0	 0.50	 N	
MLLT3	 0.26	 1.0E-05	 Y	 -0.15	 1.0E-04	 Y	 0	 0.50	 N	 0	 0.50	 N	
SALL4	 0.07	 0.04	 Y	 -0.15	 1.0E-04	 Y	 0	 0.50	 N	 0	 0.50	 N	
NR4A2	 -0.06	 0.09	 N	 -0.15	 1.0E-04	 Y	 0	 0.50	 N	 0	 0.50	 N	
MAML1	 -0.12	 2.2E-03	 Y	 -0.15	 1.1E-04	 Y	 0	 0.50	 N	 0	 0.50	 N	
MYOG	 -0.14	 3.7E-04	 Y	 -0.15	 1.3E-04	 Y	 0	 0.50	 N	 0	 0.50	 N	
FOXN1	 -0.02	 0.31	 N	 0.15	 1.3E-04	 Y	 0	 0.50	 N	 0	 0.50	 N	
TP63	 -0.16	 1.0E-04	 Y	 0.15	 1.3E-04	 Y	 0	 0.50	 N	 0	 0.50	 N	
NRIP1	 -0.25	 1.0E-05	 Y	 0.15	 1.4E-04	 Y	 0	 0.50	 N	 0	 0.50	 N	
ISL1	 0.08	 0.03	 Y	 -0.15	 1.6E-04	 Y	 0	 0.50	 N	 0	 0.50	 N	
NAB2	 -0.03	 0.22	 N	 -0.15	 1.7E-04	 Y	 0	 0.50	 N	 0	 0.50	 N	
NEUROG
3	
-0.12	 1.5E-03	 Y	 -0.15	 1.7E-04	 Y	 0	 0.50	 N	 0	 0.50	 N	
NKX3-1	 0.20	 2.0E-05	 Y	 -0.15	 1.9E-04	 Y	 0	 0.50	 N	 0	 0.50	 N	
SP7	 -0.01	 0.37	 N	 -0.15	 2.3E-04	 Y	 0	 0.50	 N	 0	 0.50	 N	
NFIC	 -0.18	 1.0E-05	 Y	 0.15	 2.3E-04	 Y	 0	 0.50	 N	 0	 0.50	 N	
HES6	 0.02	 0.34	 N	 -0.15	 2.8E-04	 Y	 0	 0.50	 N	 0	 0.50	 N	
ONECUT2	 0.07	 0.04	 N	 -0.14	 2.9E-04	 Y	 0	 0.50	 N	 0	 0.50	 N	
NRL	 0.15	 8.0E-05	 Y	 -0.14	 3.3E-04	 Y	 0	 0.50	 N	 0	 0.50	 N	
JDP2	 0.11	 3.7E-03	 Y	 -0.14	 3.9E-04	 Y	 0	 0.50	 N	 0	 0.50	 N	
POU3F2	 -0.07	 0.05	 N	 0.14	 4.2E-04	 Y	 0	 0.50	 N	 0	 0.50	 N	
MEIS1	 0.20	 2.0E-05	 Y	 -0.14	 5.2E-04	 Y	 0	 0.50	 N	 0	 0.50	 N	
PAX2	 0.20	 2.0E-05	 Y	 -0.14	 5.4E-04	 Y	 0	 0.50	 N	 0	 0.50	 N	
CRABP2	 -0.09	 0.01	 Y	 -0.13	 7.2E-04	 Y	 0	 0.50	 N	 0	 0.50	 N	
NR4A1	 -0.03	 0.26	 N	 -0.13	 1.0E-03	 Y	 0	 0.50	 N	 0	 0.50	 N	
RBL1	 -0.05	 0.11	 N	 -0.13	 1.1E-03	 Y	 0	 0.50	 N	 0	 0.50	 N	
SOX17	 -0.17	 4.0E-05	 Y	 -0.13	 1.1E-03	 Y	 0	 0.50	 N	 0	 0.50	 N	
HOXC10	 0.03	 0.26	 N	 0.13	 1.2E-03	 Y	 0	 0.50	 N	 0	 0.50	 N	
BACH1	 1.8E-03	 0.48	 N	 -0.13	 1.2E-03	 Y	 0	 0.50	 N	 0	 0.50	 N	
PURA	 -0.22	 1.0E-05	 Y	 0.13	 1.5E-03	 Y	 0	 0.50	 N	 0	 0.50	 N	
RARG	 -0.06	 0.07	 N	 -0.12	 1.8E-03	 Y	 0	 0.50	 N	 0	 0.50	 N	
SIM2	 0.06	 0.07	 N	 0.12	 2.0E-03	 Y	 0	 0.50	 N	 0	 0.50	 N	
PBX1	 0.15	 9.0E-05	 Y	 -0.12	 2.0E-03	 Y	 0	 0.50	 N	 0	 0.50	 N	
CBX7	 -0.04	 0.19	 N	 0.12	 2.6E-03	 Y	 0	 0.50	 N	 0	 0.50	 N	
MCM4	 -0.10	 6.9E-03	 Y	 -0.12	 2.6E-03	 Y	 0	 0.50	 N	 0	 0.50	 N	
POU1F1	 -0.07	 0.05	 N	 0.12	 2.6E-03	 Y	 0	 0.50	 N	 0	 0.50	 N	
DLX5	 -1.7E-03	 0.48	 N	 -0.12	 2.7E-03	 Y	 0	 0.50	 N	 0	 0.50	 N	
EGR2	 -0.08	 0.03	 Y	 -0.12	 2.8E-03	 Y	 0	 0.50	 N	 0	 0.50	 N	
HOXC9	 0.02	 0.33	 N	 0.12	 2.9E-03	 Y	 0	 0.50	 N	 0	 0.50	 N	
BCL11B	 -0.13	 7.6E-04	 Y	 0.12	 3.0E-03	 Y	 0	 0.50	 N	 0	 0.50	 N	
NPAS1	 -0.01	 0.40	 N	 -0.11	 3.4E-03	 Y	 0	 0.50	 N	 0	 0.50	 N	
SHOX	 0.10	 9.0E-03	 Y	 -0.11	 3.4E-03	 Y	 0	 0.50	 N	 0	 0.50	 N	
PLAG1	 -0.04	 0.14	 N	 0.11	 3.4E-03	 Y	 0	 0.50	 N	 0	 0.50	 N	
FOXO1	 0.13	 7.3E-04	 Y	 -0.11	 3.6E-03	 Y	 0	 0.50	 N	 0	 0.50	 N	
RNF14	 -0.28	 1.0E-05	 Y	 0.11	 3.8E-03	 Y	 0	 0.50	 N	 0	 0.50	 N	
NR4A3	 0.21	 1.0E-05	 Y	 0.11	 4.2E-03	 Y	 0	 0.50	 N	 0	 0.50	 N	
NFATC2	 0.12	 1.6E-03	 Y	 -0.11	 4.3E-03	 Y	 0	 0.50	 N	 0	 0.50	 N	
ARNTL	 0.04	 0.15	 N	 0.11	 4.6E-03	 Y	 0	 0.50	 N	 0	 0.50	 N	
EHMT2	 0.12	 2.1E-03	 Y	 -0.11	 4.7E-03	 Y	 0	 0.50	 N	 0	 0.50	 N	
IRF7	 0.07	 0.06	 N	 0.11	 4.7E-03	 Y	 0	 0.50	 N	 0	 0.50	 N	
HMGB2	 -0.11	 5.6E-03	 Y	 -0.10	 6.7E-03	 Y	 0	 0.50	 N	 0	 0.50	 N	
FHL2	 0.16	 8.0E-05	 Y	 -0.10	 7.0E-03	 Y	 0	 0.50	 N	 0	 0.50	 N	
PAWR	 -0.11	 4.4E-03	 Y	 0.10	 7.6E-03	 Y	 0	 0.50	 N	 0	 0.50	 N	
NFATC1	 0.14	 2.9E-04	 Y	 -0.10	 8.6E-03	 Y	 0	 0.50	 N	 0	 0.50	 N	
PIAS4	 -0.05	 0.12	 N	 -0.10	 8.6E-03	 Y	 0	 0.50	 N	 0	 0.50	 N	
SNAI1	 0.06	 0.09	 N	 -0.10	 8.9E-03	 Y	 0	 0.50	 N	 0	 0.50	 N	
IRF4	 0.03	 0.21	 N	 -0.10	 1.0E-02	 Y	 0	 0.50	 N	 0	 0.50	 N	
NFIB	 -0.03	 0.21	 N	 0.10	 0.01	 Y	 0	 0.50	 N	 0	 0.50	 N	
MLLT10	 0.02	 0.31	 N	 0.10	 0.01	 Y	 0	 0.50	 N	 0	 0.50	 N	
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MYOCD	 0.03	 0.23	 N	 -0.10	 0.01	 Y	 0	 0.50	 N	 0	 0.50	 N	
NR2F2	 -0.27	 1.0E-05	 Y	 0.10	 0.01	 Y	 0	 0.50	 N	 0	 0.50	 N	
HLF	 -0.08	 0.03	 Y	 -0.09	 0.01	 Y	 0	 0.50	 N	 0	 0.50	 N	
EIF2AK2	 0.02	 0.31	 N	 0.09	 0.01	 Y	 0	 0.50	 N	 0	 0.50	 N	
SIN3A	 -3.1E-03	 0.47	 N	 0.09	 0.01	 Y	 0	 0.50	 N	 0	 0.50	 N	
ELF1	 0.15	 1.3E-04	 Y	 0.09	 0.01	 Y	 0	 0.50	 N	 0	 0.50	 N	
PIAS2	 0.29	 1.0E-05	 Y	 -0.09	 0.01	 Y	 0	 0.50	 N	 0	 0.50	 N	
HOXD9	 -0.09	 0.01	 Y	 -0.09	 0.02	 Y	 0	 0.50	 N	 0	 0.50	 N	
HMGA2	 9.2E-03	 0.41	 N	 -0.09	 0.02	 Y	 0	 0.50	 N	 0	 0.50	 N	
NRF1	 -0.25	 1.0E-05	 Y	 0.09	 0.02	 Y	 0	 0.50	 N	 0	 0.50	 N	
FOXH1	 0.27	 1.0E-05	 Y	 -0.09	 0.02	 Y	 0	 0.50	 N	 0	 0.50	 N	
TBX3	 -0.05	 0.11	 N	 0.09	 0.02	 Y	 0	 0.50	 N	 0	 0.50	 N	
IRF8	 0.13	 1.3E-03	 Y	 0.08	 0.02	 Y	 0	 0.50	 N	 0	 0.50	 N	
NR1D1	 7.5E-03	 0.43	 N	 -0.08	 0.02	 Y	 0	 0.50	 N	 0	 0.50	 N	
TEAD4	 -0.06	 0.07	 N	 -0.08	 0.02	 Y	 0	 0.50	 N	 0	 0.50	 N	
PRDM14	 0.17	 5.0E-05	 Y	 0.08	 0.02	 Y	 0	 0.50	 N	 0	 0.50	 N	
FOXE1	 0.13	 1.1E-03	 Y	 -0.08	 0.02	 Y	 0	 0.50	 N	 0	 0.50	 N	
HOXA1	 -0.06	 0.07	 N	 0.08	 0.02	 Y	 0	 0.50	 N	 0	 0.50	 N	
TLX1	 0.11	 4.8E-03	 Y	 0.08	 0.03	 Y	 0	 0.50	 N	 0	 0.50	 N	
GLI2	 1.3E-03	 0.49	 N	 -0.08	 0.03	 Y	 0	 0.50	 N	 0	 0.50	 N	
ELF2	 -0.10	 7.0E-03	 Y	 0.08	 0.03	 Y	 0	 0.50	 N	 0	 0.50	 N	
PLAGL2	 0.09	 0.02	 Y	 -0.08	 0.03	 Y	 0	 0.50	 N	 0	 0.50	 N	
NFATC3	 0.04	 0.16	 N	 -0.08	 0.03	 Y	 0	 0.50	 N	 0	 0.50	 N	
SOX6	 -0.09	 0.01	 Y	 -0.08	 0.03	 Y	 0	 0.50	 N	 0	 0.50	 N	
LHX4	 0.10	 7.4E-03	 Y	 -0.08	 0.04	 Y	 0	 0.50	 N	 0	 0.50	 N	
OTX2	 -0.07	 0.04	 N	 -0.07	 0.04	 Y	 0	 0.50	 N	 0	 0.50	 N	
SP2	 -0.24	 1.0E-05	 Y	 0.08	 0.04	 Y	 0	 0.50	 N	 0	 0.50	 N	
ONECUT1	 0.04	 0.15	 N	 -0.07	 0.04	 Y	 0	 0.50	 N	 0	 0.50	 N	
PCGF2	 0.10	 9.7E-03	 Y	 0.07	 0.04	 Y	 0	 0.50	 N	 0	 0.50	 N	
RAD51	 0.03	 0.21	 N	 0.07	 0.04	 Y	 0	 0.50	 N	 0	 0.50	 N	
TBX2	 -0.02	 0.32	 N	 0.07	 0.04	 Y	 0	 0.50	 N	 0	 0.50	 N	
EHF	 0.08	 0.03	 Y	 -0.07	 0.04	 Y	 0	 0.50	 N	 0	 0.50	 N	
PLAGL1	 -0.31	 1.0E-05	 Y	 0.07	 0.04	 Y	 0	 0.50	 N	 0	 0.50	 N	
TFAP2C	 -0.23	 1.0E-05	 Y	 -0.07	 0.04	 Y	 0	 0.50	 N	 0	 0.50	 N	
MEF2C	 0.13	 9.8E-04	 Y	 0.07	 0.05	 N	 0	 0.50	 N	 0	 0.50	 N	
ECD	 -0.08	 0.04	 Y	 0.07	 0.05	 N	 0	 0.50	 N	 0	 0.50	 N	
THRA	 0.02	 0.30	 N	 -0.07	 0.05	 N	 0	 0.50	 N	 0	 0.50	 N	
TCF7L2	 -3.9E-03	 0.46	 N	 0.07	 0.05	 N	 0	 0.50	 N	 0	 0.50	 N	
HOPX	 -0.06	 0.07	 N	 0.07	 0.05	 N	 0	 0.50	 N	 0	 0.50	 N	
MTF1	 0.03	 0.25	 N	 -0.06	 0.06	 N	 0	 0.50	 N	 0	 0.50	 N	
PHB2	 -0.15	 1.0E-04	 Y	 -0.06	 0.06	 N	 0	 0.50	 N	 0	 0.50	 N	
PIAS3	 -0.20	 1.0E-05	 Y	 -0.06	 0.06	 N	 0	 0.50	 N	 0	 0.50	 N	
MYOD1	 -0.22	 1.0E-05	 Y	 0.06	 0.07	 N	 0	 0.50	 N	 0	 0.50	 N	
SMAD7	 -0.18	 1.0E-05	 Y	 -0.06	 0.07	 N	 0	 0.50	 N	 0	 0.50	 N	
GLI3	 0.06	 0.07	 N	 -0.06	 0.07	 N	 0	 0.50	 N	 0	 0.50	 N	
RFX5	 0.25	 1.0E-05	 Y	 -0.06	 0.07	 N	 0	 0.50	 N	 0	 0.50	 N	
NR2F1	 -0.06	 0.06	 N	 -0.06	 0.07	 N	 0	 0.50	 N	 0	 0.50	 N	
ELL	 -0.07	 0.05	 N	 -0.06	 0.07	 N	 0	 0.50	 N	 0	 0.50	 N	
GCM2	 0.02	 0.32	 N	 0.06	 0.08	 N	 0	 0.50	 N	 0	 0.50	 N	
DACH1	 -0.10	 9.7E-03	 Y	 0.06	 0.08	 N	 0	 0.50	 N	 0	 0.50	 N	
HHEX	 0.16	 8.0E-05	 Y	 0.06	 0.08	 N	 0	 0.50	 N	 0	 0.50	 N	
MZF1	 -0.27	 1.0E-05	 Y	 0.06	 0.09	 N	 0	 0.50	 N	 0	 0.50	 N	
E2F8	 8.2E-03	 0.42	 N	 0.05	 0.10	 N	 0	 0.50	 N	 0	 0.50	 N	
TFAP2B	 0.03	 0.20	 N	 0.05	 0.10	 N	 0	 0.50	 N	 0	 0.50	 N	
KAT5	 0.01	 0.37	 N	 -0.05	 0.10	 N	 0	 0.50	 N	 0	 0.50	 N	
ETV3	 0.02	 0.35	 N	 -0.05	 0.13	 N	 0	 0.50	 N	 0	 0.50	 N	
IRF3	 -0.12	 1.7E-03	 Y	 -0.05	 0.13	 N	 0	 0.50	 N	 0	 0.50	 N	
NUPR1	 0.19	 2.0E-05	 Y	 -0.04	 0.14	 N	 0	 0.50	 N	 0	 0.50	 N	
ETV2	 -0.08	 0.02	 Y	 -0.04	 0.15	 N	 0	 0.50	 N	 0	 0.50	 N	
MAFA	 6.3E-03	 0.44	 N	 0.04	 0.15	 N	 0	 0.50	 N	 0	 0.50	 N	
NKX2-1	 0.07	 0.05	 N	 -0.04	 0.15	 N	 0	 0.50	 N	 0	 0.50	 N	
CTBP1	 -0.08	 0.03	 Y	 -0.04	 0.15	 N	 0	 0.50	 N	 0	 0.50	 N	
SRCAP	 0.13	 1.1E-03	 Y	 -0.04	 0.17	 N	 0	 0.50	 N	 0	 0.50	 N	
TBX5	 0.02	 0.28	 N	 -0.04	 0.18	 N	 0	 0.50	 N	 0	 0.50	 N	
BRD7	 0.18	 2.0E-05	 Y	 -0.04	 0.18	 N	 0	 0.50	 N	 0	 0.50	 N	
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NELFCD	 -0.12	 2.0E-03	 Y	 0.04	 0.18	 N	 0	 0.50	 N	 0	 0.50	 N	
PAX8	 -0.03	 0.26	 N	 -0.04	 0.19	 N	 0	 0.50	 N	 0	 0.50	 N	
NR5A2	 -0.01	 0.37	 N	 0.04	 0.19	 N	 0	 0.50	 N	 0	 0.50	 N	
SUPT3H	 -0.14	 4.9E-04	 Y	 -0.04	 0.19	 N	 0	 0.50	 N	 0	 0.50	 N	
LMO2	 -0.13	 8.4E-04	 Y	 -0.04	 0.20	 N	 0	 0.50	 N	 0	 0.50	 N	
RFWD2	 -0.09	 0.02	 Y	 0.04	 0.20	 N	 0	 0.50	 N	 0	 0.50	 N	
NELFB	 0.05	 0.13	 N	 0.03	 0.21	 N	 0	 0.50	 N	 0	 0.50	 N	
NPM1	 0.05	 0.12	 N	 0.03	 0.21	 N	 0	 0.50	 N	 0	 0.50	 N	
DBP	 -0.03	 0.25	 N	 -0.03	 0.21	 N	 0	 0.50	 N	 0	 0.50	 N	
SALL3	 -0.07	 0.05	 N	 0.03	 0.21	 N	 0	 0.50	 N	 0	 0.50	 N	
NOTCH3	 -0.04	 0.19	 N	 0.03	 0.21	 N	 0	 0.50	 N	 0	 0.50	 N	
PDX1	 1.5E-05	 0.50	 N	 0.03	 0.22	 N	 0	 0.50	 N	 0	 0.50	 N	
CBX8	 0.12	 2.7E-03	 Y	 0.03	 0.22	 N	 0	 0.50	 N	 0	 0.50	 N	
MAZ	 0.10	 9.3E-03	 Y	 0.03	 0.22	 N	 0	 0.50	 N	 0	 0.50	 N	
LHX2	 -0.20	 1.0E-05	 Y	 -0.03	 0.23	 N	 0	 0.50	 N	 0	 0.50	 N	
NR2F6	 -0.06	 0.07	 N	 0.03	 0.23	 N	 0	 0.50	 N	 0	 0.50	 N	
KLF15	 -0.02	 0.31	 N	 -0.03	 0.25	 N	 0	 0.50	 N	 0	 0.50	 N	
EVX1	 0.19	 2.0E-05	 Y	 -0.03	 0.25	 N	 0	 0.50	 N	 0	 0.50	 N	
NR2C2	 -0.05	 0.13	 N	 -0.03	 0.27	 N	 0	 0.50	 N	 0	 0.50	 N	
ARID1B	 -0.09	 0.01	 Y	 0.03	 0.27	 N	 0	 0.50	 N	 0	 0.50	 N	
ETV5	 -0.02	 0.30	 N	 -0.02	 0.28	 N	 0	 0.50	 N	 0	 0.50	 N	
RELB	 -0.04	 0.18	 N	 0.02	 0.28	 N	 0	 0.50	 N	 0	 0.50	 N	
GATA4	 -0.05	 0.13	 N	 -0.02	 0.28	 N	 0	 0.50	 N	 0	 0.50	 N	
CTCF	 0.07	 0.06	 N	 -0.02	 0.28	 N	 0	 0.50	 N	 0	 0.50	 N	
NHLH2	 0.17	 6.0E-05	 Y	 -0.02	 0.29	 N	 0	 0.50	 N	 0	 0.50	 N	
KLF9	 -4.5E-04	 0.50	 N	 -0.02	 0.29	 N	 0	 0.50	 N	 0	 0.50	 N	
PARP1	 -0.05	 0.12	 N	 -0.02	 0.29	 N	 0	 0.50	 N	 0	 0.50	 N	
LMX1B	 0.19	 2.0E-05	 Y	 -0.02	 0.29	 N	 0	 0.50	 N	 0	 0.50	 N	
GCM1	 0.14	 4.9E-04	 Y	 0.02	 0.29	 N	 0	 0.50	 N	 0	 0.50	 N	
FOXP2	 -0.19	 1.0E-05	 Y	 -0.02	 0.30	 N	 0	 0.50	 N	 0	 0.50	 N	
HDAC11	 0.04	 0.17	 N	 0.02	 0.30	 N	 0	 0.50	 N	 0	 0.50	 N	
SETBP1	 -0.14	 4.5E-04	 Y	 0.02	 0.31	 N	 0	 0.50	 N	 0	 0.50	 N	
E2F3	 -0.05	 0.11	 N	 -0.02	 0.32	 N	 0	 0.50	 N	 0	 0.50	 N	
TRIB3	 7.5E-03	 0.43	 N	 0.02	 0.32	 N	 0	 0.50	 N	 0	 0.50	 N	
DR1	 0.10	 0.01	 Y	 0.02	 0.32	 N	 0	 0.50	 N	 0	 0.50	 N	
RBPJ	 -0.15	 1.0E-04	 Y	 0.02	 0.32	 N	 0	 0.50	 N	 0	 0.50	 N	
TEAD1	 0.06	 0.08	 N	 -0.02	 0.33	 N	 0	 0.50	 N	 0	 0.50	 N	
HDGF	 -3.9E-03	 0.46	 N	 0.02	 0.35	 N	 0	 0.50	 N	 0	 0.50	 N	
CEBPD	 -0.11	 3.2E-03	 Y	 0.02	 0.35	 N	 0	 0.50	 N	 0	 0.50	 N	
HOXA5	 0.07	 0.05	 N	 -0.02	 0.36	 N	 0	 0.50	 N	 0	 0.50	 N	
TGIF1	 0.03	 0.23	 N	 -0.01	 0.36	 N	 0	 0.50	 N	 0	 0.50	 N	
CDCA7L	 -0.18	 1.0E-05	 Y	 0.01	 0.37	 N	 0	 0.50	 N	 0	 0.50	 N	
FOSB	 -0.08	 0.03	 Y	 -0.01	 0.37	 N	 0	 0.50	 N	 0	 0.50	 N	
MBD1	 -0.10	 8.3E-03	 Y	 0.01	 0.39	 N	 0	 0.50	 N	 0	 0.50	 N	
HOXC13	 -0.13	 1.2E-03	 Y	 8.7E-03	 0.42	 N	 0	 0.50	 N	 0	 0.50	 N	
NCOA2	 -0.20	 1.0E-05	 Y	 -8.6E-
03	
0.42	 N	 0	 0.50	 N	 0	 0.50	 N	
APBB1	 -0.21	 1.0E-05	 Y	 -8.3E-
03	
0.42	 N	 0	 0.50	 N	 0	 0.50	 N	
ARID1A	 -0.08	 0.03	 Y	 -7.1E-
03	
0.43	 N	 0	 0.50	 N	 0	 0.50	 N	
SUGP1	 -0.14	 6.0E-04	 Y	 5.3E-03	 0.45	 N	 0	 0.50	 N	 0	 0.50	 N	
GTF2I	 -0.21	 1.0E-05	 Y	 -4.8E-
03	
0.45	 N	 0	 0.50	 N	 0	 0.50	 N	
GABPA	 -0.02	 0.32	 N	 -4.8E-
03	
0.45	 N	 0	 0.50	 N	 0	 0.50	 N	
RUVBL1	 0.28	 1.0E-05	 Y	 -4.5E-
03	
0.46	 N	 0	 0.50	 N	 0	 0.50	 N	
LMO3	 0.13	 6.3E-04	 Y	 2.6E-03	 0.48	 N	 0	 0.50	 N	 0	 0.50	 N	
STAT4	 0.02	 0.29	 N	 2.4E-03	 0.48	 N	 0	 0.50	 N	 0	 0.50	 N	
ANKRD1	 0.07	 0.04	 N	 5.8E-05	 0.50	 N	 0	 0.50	 N	 0	 0.50	 N	






Master list of miRNAs in TCGA colorectal cancer dataset together the correlation 
scores of their expression values with PR signatures and enrichment scores of 
target genes with PR signatures 
 
miRNA	 S(M,P)	 P-value	 BH	 S(M,R)	 P-value	 BH	 ES_P	 P-value	 BH	 ES_R	 P-value	 BH	
mir-1914	 0.25	 1.0E-05	 Y	 -0.08	 0.03	 Y	 0.29	 1.0E-05	 Y	 -0.29	 1.0E-05	 Y	
mir-1307	 0.25	 1.0E-05	 Y	 -0.14	 3.7E-04	 Y	 0.31	 1.0E-05	 Y	 -0.28	 1.0E-05	 Y	
mir-449a	 0.12	 3.0E-03	 Y	 -0.08	 0.04	 Y	 0.41	 1.0E-05	 Y	 -0.27	 1.0E-05	 Y	
mir-766	 0.20	 1.0E-05	 Y	 0.10	 9.1E-03	 Y	 0.30	 1.0E-05	 Y	 -0.23	 1.0E-05	 Y	
mir-1303	 -0.13	 1.4E-03	 Y	 0.06	 0.09	 N	 0.29	 1.0E-05	 Y	 -0.22	 1.0E-05	 Y	
mir-191	 0.12	 2.1E-03	 Y	 -0.19	 1.0E-05	 Y	 0.24	 1.0E-05	 Y	 -0.20	 1.0E-05	 Y	
mir-671	 0.21	 1.0E-05	 Y	 0.02	 0.35	 N	 0.21	 1.0E-05	 Y	 -0.19	 1.0E-05	 Y	
mir-605	 4.2E-03	 0.46	 N	 -0.08	 0.04	 Y	 0.20	 1.0E-05	 Y	 -0.18	 1.0E-05	 Y	
mir-29a	 -0.10	 0.01	 Y	 -0.04	 0.17	 N	 0.04	 0.18	 N	 0.18	 1.0E-05	 Y	
mir-150	 -0.14	 3.9E-04	 Y	 0.17	 4.0E-05	 Y	 -0.13	 1.2E-03	 Y	 0.19	 1.0E-05	 Y	
mir-346	 0.09	 0.02	 Y	 -0.09	 0.01	 Y	 0.02	 0.35	 N	 0.20	 1.0E-05	 Y	
mir-133b	 -0.21	 1.0E-05	 Y	 0.25	 1.0E-05	 Y	 -0.09	 0.02	 Y	 0.21	 1.0E-05	 Y	
mir-133a-1	 -0.24	 1.0E-05	 Y	 0.19	 1.0E-05	 Y	 -5.3E-
03	
0.45	 N	 0.21	 1.0E-05	 Y	
mir-133a-2	 -0.19	 1.0E-05	 Y	 0.27	 1.0E-05	 Y	 -5.3E-
03	
0.45	 N	 0.21	 1.0E-05	 Y	
mir-203	 -0.13	 1.3E-03	 Y	 -0.13	 7.2E-04	 Y	 0.18	 4.0E-05	 Y	 0.22	 1.0E-05	 Y	
mir-181c	 -0.30	 1.0E-05	 Y	 -0.05	 0.12	 N	 -0.17	 2.0E-05	 Y	 0.22	 1.0E-05	 Y	
mir-204	 -0.11	 3.8E-03	 Y	 -0.04	 0.19	 N	 0.02	 0.30	 N	 0.24	 1.0E-05	 Y	
mir-302d	 0.08	 0.04	 Y	 0.09	 0.02	 Y	 -0.07	 0.04	 N	 0.25	 1.0E-05	 Y	
mir-20b	 -0.14	 3.5E-04	 Y	 0.20	 1.0E-05	 Y	 0.03	 0.21	 N	 0.25	 1.0E-05	 Y	
mir-874	 -0.19	 1.0E-05	 Y	 0.02	 0.32	 N	 0.43	 1.0E-05	 Y	 0.26	 1.0E-05	 Y	
mir-146a	 0.07	 0.06	 N	 0.06	 0.09	 N	 0.06	 0.07	 N	 0.28	 1.0E-05	 Y	
mir-200c	 -0.01	 0.39	 N	 -0.11	 6.0E-03	 Y	 0.08	 0.03	 Y	 0.29	 1.0E-05	 Y	
mir-130a	 -0.13	 1.3E-03	 Y	 0.13	 9.1E-04	 Y	 -0.16	 5.0E-05	 Y	 0.30	 1.0E-05	 Y	
mir-200a	 0.02	 0.33	 N	 -0.11	 3.8E-03	 Y	 -0.09	 0.02	 Y	 0.32	 1.0E-05	 Y	
mir-146b	 -0.04	 0.16	 N	 0.34	 1.0E-05	 Y	 -0.02	 0.36	 N	 0.33	 1.0E-05	 Y	
mir-451	 0.03	 0.27	 N	 -0.04	 0.18	 N	 -0.10	 8.8E-03	 Y	 0.33	 1.0E-05	 Y	
mir-19a	 0.12	 2.5E-03	 Y	 -0.09	 0.02	 Y	 -0.03	 0.27	 N	 0.33	 1.0E-05	 Y	
mir-302a	 0.15	 3.0E-04	 Y	 -0.09	 0.02	 Y	 -0.27	 1.0E-05	 Y	 0.34	 1.0E-05	 Y	
mir-224	 -0.14	 5.4E-04	 Y	 -0.24	 1.0E-05	 Y	 -0.03	 0.24	 N	 0.37	 1.0E-05	 Y	
mir-200b	 -0.10	 9.1E-03	 Y	 -0.12	 2.2E-03	 Y	 0.09	 0.02	 Y	 0.38	 1.0E-05	 Y	
mir-429	 0.04	 0.20	 N	 -0.12	 1.5E-03	 Y	 -0.06	 0.09	 N	 0.39	 1.0E-05	 Y	
mir-143	 -0.23	 1.0E-05	 Y	 0.34	 1.0E-05	 Y	 0.11	 6.7E-03	 Y	 0.40	 1.0E-05	 Y	
mir-338	 -0.13	 6.1E-04	 Y	 0.12	 2.0E-03	 Y	 -0.40	 1.0E-05	 Y	 0.56	 1.0E-05	 Y	
mir-501	 0.07	 0.05	 N	 -0.14	 3.5E-04	 Y	 0.56	 1.0E-05	 Y	 -0.18	 2.0E-05	 Y	
mir-30c-2	 -0.06	 0.10	 N	 -0.09	 0.02	 Y	 0.29	 1.0E-05	 Y	 -0.17	 3.0E-05	 Y	
mir-137	 -7.2E-03	 0.43	 N	 0.25	 1.0E-05	 Y	 0.17	 6.0E-05	 Y	 0.18	 3.0E-05	 Y	
mir-223	 0.16	 1.9E-04	 Y	 0.29	 1.0E-05	 Y	 0.15	 1.9E-04	 Y	 0.18	 4.0E-05	 Y	
mir-140	 -0.12	 2.6E-03	 Y	 0.18	 3.0E-05	 Y	 0.08	 0.04	 Y	 0.17	 6.0E-05	 Y	
mir-205	 0.04	 0.17	 N	 0.05	 0.11	 N	 0.06	 0.09	 N	 0.16	 1.5E-04	 Y	
mir-432	 -0.08	 0.03	 Y	 0.06	 0.07	 N	 0.33	 1.0E-05	 Y	 0.15	 1.9E-04	 Y	
mir-138-1	 -0.06	 0.07	 N	 0.09	 0.02	 Y	 -0.13	 1.1E-03	 Y	 0.16	 1.9E-04	 Y	
mir-138-2	 -0.05	 0.11	 N	 0.05	 0.13	 N	 -0.13	 1.1E-03	 Y	 0.16	 1.9E-04	 Y	
mir-532	 -0.13	 7.5E-04	 Y	 -0.22	 1.0E-05	 Y	 0.31	 1.0E-05	 Y	 -0.15	 2.2E-04	 Y	
mir-503	 0.05	 0.15	 N	 0.07	 0.06	 N	 0.25	 1.0E-05	 Y	 -0.15	 2.6E-04	 Y	
mir-190	 -0.07	 0.05	 N	 0.08	 0.04	 Y	 0.34	 1.0E-05	 Y	 0.15	 2.7E-04	 Y	
mir-425	 0.07	 0.04	 Y	 -0.13	 1.2E-03	 Y	 0.24	 1.0E-05	 Y	 -0.14	 3.9E-04	 Y	
mir-18b	 0.03	 0.27	 N	 0.06	 0.09	 N	 0.21	 1.0E-05	 Y	 0.14	 4.2E-04	 Y	
mir-335	 0.02	 0.34	 N	 -0.27	 1.0E-05	 Y	 -0.14	 3.5E-04	 Y	 0.14	 5.1E-04	 Y	
mir-28	 -0.20	 1.0E-05	 Y	 0.05	 0.11	 N	 0.24	 1.0E-05	 Y	 0.14	 5.4E-04	 Y	
mir-342	 -0.05	 0.11	 N	 0.16	 1.0E-04	 Y	 0.26	 1.0E-05	 Y	 -0.14	 6.1E-04	 Y	
mir-212	 0.07	 0.05	 N	 0.34	 1.0E-05	 Y	 0.30	 1.0E-05	 Y	 -0.14	 6.1E-04	 Y	
mir-193a	 -0.17	 4.0E-05	 Y	 0.11	 5.8E-03	 Y	 0.10	 9.3E-03	 Y	 -0.13	 7.7E-04	 Y	
mir-941-1	 0.09	 0.02	 Y	 -5.7E-03	 0.45	 N	 0.19	 1.0E-05	 Y	 0.13	 8.2E-04	 Y	
mir-145	 -0.17	 5.0E-05	 Y	 0.24	 1.0E-05	 Y	 0.06	 0.08	 N	 0.13	 1.2E-03	 Y	
mir-217	 -0.29	 1.0E-05	 Y	 -0.04	 0.17	 N	 -9.4E-
03	
0.41	 N	 0.13	 1.4E-03	 Y	
mir-141	 0.09	 0.01	 Y	 -0.07	 0.04	 Y	 0.03	 0.23	 N	 0.13	 1.5E-03	 Y	
mir-365-2	 -0.08	 0.04	 Y	 0.04	 0.17	 N	 0.18	 2.0E-05	 Y	 0.13	 1.7E-03	 Y	
mir-365-1	 -0.12	 2.8E-03	 Y	 -4.9E-03	 0.45	 N	 0.18	 2.0E-05	 Y	 0.13	 1.7E-03	 Y	
mir-34c	 -0.03	 0.24	 N	 0.36	 1.0E-05	 Y	 0.36	 1.0E-05	 Y	 -0.12	 2.4E-03	 Y	
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mir-1180	 0.21	 1.0E-05	 Y	 5.4E-03	 0.45	 N	 0.21	 1.0E-05	 Y	 -0.12	 3.0E-03	 Y	
mir-124-3	 -0.02	 0.31	 N	 0.18	 3.0E-05	 Y	 0.02	 0.33	 N	 0.12	 3.1E-03	 Y	
mir-124-2	 -0.09	 0.02	 Y	 -0.06	 0.08	 N	 0.02	 0.34	 N	 0.12	 3.3E-03	 Y	
mir-124-1	 -0.06	 0.09	 N	 -5.1E-03	 0.45	 N	 0.02	 0.34	 N	 0.12	 3.3E-03	 Y	
mir-99b	 -0.14	 3.9E-04	 Y	 0.11	 5.3E-03	 Y	 0.17	 4.0E-05	 Y	 0.11	 3.8E-03	 Y	
mir-130b	 0.17	 4.0E-05	 Y	 -0.13	 9.4E-04	 Y	 0.09	 0.02	 Y	 0.11	 4.1E-03	 Y	
mir-376a-2	 -0.05	 0.14	 N	 -0.02	 0.32	 N	 0.32	 1.0E-05	 Y	 -0.11	 4.5E-03	 Y	
mir-376a-1	 -0.09	 0.02	 Y	 0.02	 0.33	 N	 0.32	 1.0E-05	 Y	 -0.11	 4.5E-03	 Y	
mir-19b-2	 0.05	 0.13	 N	 -0.09	 0.02	 Y	 0.06	 0.09	 N	 0.11	 5.2E-03	 Y	
mir-142	 -0.08	 0.02	 Y	 0.24	 1.0E-05	 Y	 0.02	 0.31	 N	 0.11	 5.5E-03	 Y	
mir-181b-1	 -0.08	 0.03	 Y	 0.09	 0.01	 Y	 0.22	 1.0E-05	 Y	 -0.11	 5.6E-03	 Y	
mir-181b-2	 -4.2E-03	 0.46	 N	 0.05	 0.13	 N	 0.22	 1.0E-05	 Y	 -0.11	 5.6E-03	 Y	
mir-625	 0.17	 4.0E-05	 Y	 0.04	 0.15	 N	 -0.06	 0.08	 N	 0.11	 6.1E-03	 Y	
mir-125b-2	 -0.22	 1.0E-05	 Y	 0.26	 1.0E-05	 Y	 0.32	 1.0E-05	 Y	 -0.11	 6.4E-03	 Y	
mir-362	 -0.08	 0.04	 Y	 -0.21	 1.0E-05	 Y	 0.45	 1.0E-05	 Y	 -0.10	 6.6E-03	 Y	
mir-935	 -0.01	 0.39	 N	 0.09	 0.02	 Y	 0.27	 1.0E-05	 Y	 -0.10	 6.7E-03	 Y	
mir-107	 -0.07	 0.05	 N	 0.07	 0.06	 N	 0.19	 1.0E-05	 Y	 0.11	 6.7E-03	 Y	
mir-148a	 -0.19	 1.0E-05	 Y	 -0.17	 2.0E-05	 Y	 0.15	 3.1E-04	 Y	 0.10	 7.2E-03	 Y	
let-7c	 -0.29	 1.0E-05	 Y	 0.26	 1.0E-05	 Y	 0.21	 1.0E-05	 Y	 -0.10	 7.3E-03	 Y	
mir-33a	 0.08	 0.02	 Y	 -0.06	 0.08	 N	 3.2E-03	 0.47	 N	 0.10	 9.3E-03	 Y	
mir-328	 -0.08	 0.04	 Y	 0.14	 5.9E-04	 Y	 0.37	 1.0E-05	 Y	 -0.10	 9.5E-03	 Y	
mir-454	 0.11	 4.3E-03	 Y	 -0.05	 0.11	 N	 0.24	 1.0E-05	 Y	 -0.10	 9.7E-03	 Y	
mir-211	 -0.01	 0.38	 N	 -0.06	 0.08	 N	 0.26	 1.0E-05	 Y	 0.10	 0.01	 Y	
mir-1260	 -0.03	 0.27	 N	 0.09	 0.02	 Y	 0.22	 1.0E-05	 Y	 -0.09	 0.01	 Y	
mir-106a	 0.15	 2.4E-04	 Y	 -0.09	 0.02	 Y	 0.19	 1.0E-05	 Y	 0.10	 0.01	 Y	
mir-29c	 -0.22	 1.0E-05	 Y	 0.26	 1.0E-05	 Y	 0.09	 0.02	 Y	 0.09	 0.01	 Y	
mir-29b-1	 -0.08	 0.03	 Y	 0.04	 0.16	 N	 0.13	 1.2E-03	 Y	 0.09	 0.01	 Y	
mir-193b	 -0.03	 0.25	 N	 0.09	 0.02	 Y	 0.31	 1.0E-05	 Y	 -0.09	 0.01	 Y	
let-7d	 0.11	 3.9E-03	 Y	 -0.11	 5.1E-03	 Y	 0.20	 1.0E-05	 Y	 -0.09	 0.02	 Y	
mir-195	 -0.20	 1.0E-05	 Y	 0.03	 0.23	 N	 0.26	 1.0E-05	 Y	 0.09	 0.02	 Y	
mir-148b	 0.03	 0.28	 N	 -0.13	 6.2E-04	 Y	 -0.04	 0.16	 N	 0.09	 0.02	 Y	
let-7g	 -0.04	 0.18	 N	 -0.08	 0.03	 Y	 0.27	 1.0E-05	 Y	 0.09	 0.02	 Y	
mir-378	 0.12	 2.8E-03	 Y	 -0.21	 1.0E-05	 Y	 0.19	 1.0E-05	 Y	 -0.08	 0.03	 Y	
mir-769	 0.09	 0.02	 Y	 -0.22	 1.0E-05	 Y	 0.25	 1.0E-05	 Y	 -0.08	 0.03	 Y	
mir-149	 -0.07	 0.05	 N	 0.11	 5.2E-03	 Y	 0.25	 1.0E-05	 Y	 -0.08	 0.03	 Y	
mir-30d	 -0.26	 1.0E-05	 Y	 -0.04	 0.17	 N	 0.16	 1.3E-04	 Y	 0.08	 0.03	 Y	
mir-215	 -0.09	 0.02	 Y	 -8.3E-03	 0.42	 N	 0.22	 1.0E-05	 Y	 -0.08	 0.03	 Y	
mir-1296	 0.10	 8.8E-03	 Y	 -0.07	 0.05	 N	 0.22	 1.0E-05	 Y	 -0.08	 0.03	 Y	
mir-548b	 -0.08	 0.03	 Y	 0.03	 0.22	 N	 -0.15	 2.6E-04	 Y	 -0.08	 0.03	 Y	
mir-34b	 -0.09	 0.01	 Y	 0.13	 1.1E-03	 Y	 0.33	 1.0E-05	 Y	 -0.08	 0.04	 Y	
mir-194-1	 -0.20	 1.0E-05	 Y	 -0.16	 1.5E-04	 Y	 -0.03	 0.22	 N	 0.08	 0.04	 Y	
mir-194-2	 -0.19	 1.0E-05	 Y	 -0.15	 1.9E-04	 Y	 -0.03	 0.22	 N	 0.08	 0.04	 Y	
mir-30e	 -0.23	 1.0E-05	 Y	 0.11	 4.9E-03	 Y	 0.20	 1.0E-05	 Y	 -0.07	 0.04	 Y	
mir-652	 -0.06	 0.10	 N	 -0.01	 0.38	 N	 0.20	 1.0E-05	 Y	 -0.07	 0.04	 N	
mir-15a	 -0.03	 0.27	 N	 0.12	 2.8E-03	 Y	 0.11	 7.0E-03	 Y	 0.07	 0.05	 N	
mir-181d	 -0.28	 1.0E-05	 Y	 -0.09	 0.01	 Y	 0.24	 1.0E-05	 Y	 0.07	 0.06	 N	
mir-375	 -0.09	 0.02	 Y	 -0.11	 3.6E-03	 Y	 0.09	 0.02	 Y	 0.07	 0.06	 N	
mir-196b	 -0.11	 6.0E-03	 Y	 -0.17	 5.0E-05	 Y	 0.28	 1.0E-05	 Y	 -0.07	 0.06	 N	
mir-497	 -0.18	 2.0E-05	 Y	 0.10	 8.5E-03	 Y	 0.36	 1.0E-05	 Y	 0.07	 0.06	 N	
mir-940	 0.20	 1.0E-05	 Y	 0.07	 0.05	 N	 0.29	 1.0E-05	 Y	 -0.07	 0.06	 N	
mir-598	 8.6E-04	 0.49	 N	 -0.02	 0.33	 N	 0.50	 1.0E-05	 Y	 -0.07	 0.06	 N	
mir-132	 -0.09	 0.02	 Y	 0.35	 1.0E-05	 Y	 0.03	 0.24	 N	 0.06	 0.07	 N	
let-7b	 -0.21	 1.0E-05	 Y	 0.17	 4.0E-05	 Y	 0.23	 1.0E-05	 Y	 -0.06	 0.08	 N	
mir-30b	 -0.01	 0.37	 N	 -0.07	 0.04	 Y	 0.18	 1.0E-05	 Y	 -0.06	 0.08	 N	
mir-185	 0.07	 0.05	 N	 0.02	 0.29	 N	 0.22	 1.0E-05	 Y	 0.06	 0.08	 N	
mir-218-2	 -0.28	 1.0E-05	 Y	 0.30	 1.0E-05	 Y	 0.14	 5.1E-04	 Y	 -0.06	 0.08	 N	
mir-192	 -0.02	 0.35	 N	 -0.27	 1.0E-05	 Y	 0.21	 1.0E-05	 Y	 -0.06	 0.08	 N	
mir-361	 -0.13	 1.2E-03	 Y	 -0.02	 0.33	 N	 0.27	 1.0E-05	 Y	 -0.06	 0.09	 N	
mir-128-1	 0.08	 0.03	 Y	 -0.08	 0.03	 Y	 0.04	 0.18	 N	 0.06	 0.09	 N	
mir-23a	 -0.08	 0.03	 Y	 0.02	 0.30	 N	 0.17	 9.0E-05	 Y	 0.06	 0.09	 N	
mir-455	 0.04	 0.20	 N	 0.06	 0.07	 N	 0.18	 2.0E-05	 Y	 0.06	 0.09	 N	
mir-301a	 0.13	 9.4E-04	 Y	 -0.05	 0.15	 N	 0.22	 1.0E-05	 Y	 0.06	 0.09	 N	
mir-331	 0.10	 9.5E-03	 Y	 0.11	 4.3E-03	 Y	 0.23	 1.0E-05	 Y	 -0.06	 0.09	 N	
mir-151	 -0.07	 0.05	 N	 -0.04	 0.19	 N	 0.26	 1.0E-05	 Y	 -0.06	 0.09	 N	
mir-374a	 -0.13	 1.1E-03	 Y	 -0.03	 0.21	 N	 0.17	 9.0E-05	 Y	 -0.05	 0.11	 N	
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mir-103-1	 -0.10	 0.01	 Y	 0.05	 0.11	 N	 0.13	 1.4E-03	 Y	 0.05	 0.11	 N	
mir-103-2	 0.15	 2.4E-04	 Y	 -2.2E-03	 0.48	 N	 0.13	 1.4E-03	 Y	 0.05	 0.11	 N	
mir-296	 0.03	 0.22	 N	 -0.16	 1.3E-04	 Y	 0.10	 7.7E-03	 Y	 0.05	 0.12	 N	
mir-26b	 -0.04	 0.17	 N	 0.04	 0.16	 N	 0.01	 0.37	 N	 0.05	 0.13	 N	
mir-96	 -0.08	 0.03	 Y	 0.06	 0.07	 N	 0.19	 1.0E-05	 Y	 0.05	 0.13	 N	
mir-100	 -0.30	 1.0E-05	 Y	 0.36	 1.0E-05	 Y	 0.14	 3.8E-04	 Y	 -0.05	 0.13	 N	
mir-320a	 0.05	 0.11	 N	 0.03	 0.23	 N	 0.19	 1.0E-05	 Y	 -0.05	 0.13	 N	
mir-590	 0.13	 1.2E-03	 Y	 -0.12	 2.4E-03	 Y	 0.25	 1.0E-05	 Y	 -0.05	 0.15	 N	
mir-186	 0.03	 0.23	 N	 -0.09	 0.02	 Y	 0.18	 4.0E-05	 Y	 -0.04	 0.15	 N	
mir-92a-1	 -0.05	 0.11	 N	 -0.15	 2.6E-04	 Y	 0.38	 1.0E-05	 Y	 -0.04	 0.15	 N	
mir-92a-2	 -6.8E-03	 0.44	 N	 -0.15	 2.6E-04	 Y	 0.20	 1.0E-05	 Y	 -0.04	 0.16	 N	
mir-98	 -0.07	 0.06	 N	 -0.02	 0.33	 N	 0.14	 3.6E-04	 Y	 -0.04	 0.16	 N	
mir-31	 0.03	 0.28	 N	 0.32	 1.0E-05	 Y	 0.10	 8.5E-03	 Y	 0.04	 0.16	 N	
mir-32	 0.12	 2.5E-03	 Y	 -5.5E-03	 0.45	 N	 0.19	 1.0E-05	 Y	 -0.04	 0.17	 N	
mir-182	 -0.12	 2.0E-03	 Y	 0.04	 0.17	 N	 0.09	 0.01	 Y	 0.04	 0.17	 N	
mir-615	 0.07	 0.05	 N	 0.24	 1.0E-05	 Y	 0.24	 1.0E-05	 Y	 -0.04	 0.18	 N	
mir-126	 -0.06	 0.10	 N	 0.12	 3.1E-03	 Y	 0.21	 1.0E-05	 Y	 -0.04	 0.18	 N	
mir-760	 0.21	 1.0E-05	 Y	 -0.04	 0.17	 N	 0.25	 1.0E-05	 Y	 -0.04	 0.18	 N	
mir-10a	 -0.07	 0.07	 N	 0.02	 0.31	 N	 0.18	 4.0E-05	 Y	 -0.04	 0.19	 N	
mir-1229	 0.11	 3.8E-03	 Y	 -6.1E-03	 0.44	 N	 0.28	 1.0E-05	 Y	 -0.04	 0.19	 N	
mir-15b	 0.18	 1.0E-05	 Y	 0.02	 0.34	 N	 0.20	 1.0E-05	 Y	 -0.04	 0.20	 N	
mir-484	 0.16	 1.0E-04	 Y	 0.04	 0.19	 N	 0.21	 1.0E-05	 Y	 -0.04	 0.20	 N	
mir-122	 0.02	 0.30	 N	 -0.12	 1.7E-03	 Y	 0.13	 8.7E-04	 Y	 0.04	 0.20	 N	
mir-504	 -0.19	 1.0E-05	 Y	 0.01	 0.39	 N	 0.16	 1.4E-04	 Y	 -0.04	 0.21	 N	
mir-330	 7.6E-05	 0.50	 N	 0.22	 1.0E-05	 Y	 0.26	 1.0E-05	 Y	 -0.03	 0.21	 N	
mir-199a-2	 -0.12	 1.6E-03	 Y	 0.19	 1.0E-05	 Y	 0.15	 2.0E-04	 Y	 0.03	 0.21	 N	
mir-199a-1	 -0.13	 6.7E-04	 Y	 0.19	 1.0E-05	 Y	 0.15	 2.0E-04	 Y	 0.03	 0.21	 N	
mir-340	 -3.1E-03	 0.47	 N	 0.10	 0.01	 Y	 0.18	 4.0E-05	 Y	 -0.03	 0.22	 N	
mir-324	 0.10	 8.8E-03	 Y	 0.07	 0.06	 N	 0.19	 1.0E-05	 Y	 -0.03	 0.22	 N	
mir-1-2	 -0.33	 1.0E-05	 Y	 0.14	 6.6E-04	 Y	 0.15	 3.4E-04	 Y	 0.03	 0.22	 N	
mir-1-1	 -0.05	 0.12	 N	 0.07	 0.05	 N	 0.15	 3.4E-04	 Y	 0.03	 0.22	 N	
mir-92b	 0.24	 1.0E-05	 Y	 0.20	 1.0E-05	 Y	 0.19	 1.0E-05	 Y	 -0.03	 0.23	 N	
mir-1226	 0.14	 4.2E-04	 Y	 -0.16	 7.0E-05	 Y	 0.20	 1.0E-05	 Y	 -0.03	 0.23	 N	
mir-373	 -0.06	 0.07	 N	 -0.06	 0.08	 N	 0.18	 3.0E-05	 Y	 -0.03	 0.23	 N	
mir-34a	 8.0E-04	 0.49	 N	 0.04	 0.19	 N	 0.24	 1.0E-05	 Y	 -0.03	 0.23	 N	
let-7a-2	 -0.25	 1.0E-05	 Y	 0.09	 0.02	 Y	 0.20	 1.0E-05	 Y	 -0.03	 0.25	 N	
let-7a-1	 -0.25	 1.0E-05	 Y	 0.08	 0.03	 Y	 0.20	 1.0E-05	 Y	 -0.03	 0.25	 N	
mir-210	 0.12	 3.7E-03	 Y	 0.04	 0.15	 N	 0.18	 4.0E-05	 Y	 0.03	 0.27	 N	
mir-505	 0.12	 2.1E-03	 Y	 -5.5E-03	 0.45	 N	 0.27	 1.0E-05	 Y	 -0.03	 0.27	 N	
mir-214	 -0.08	 0.03	 Y	 0.20	 1.0E-05	 Y	 0.11	 4.9E-03	 Y	 -0.03	 0.28	 N	
mir-221	 3.9E-05	 0.50	 N	 0.17	 6.0E-05	 Y	 0.15	 3.4E-04	 Y	 0.02	 0.28	 N	
mir-374b	 0.02	 0.35	 N	 -0.13	 6.5E-04	 Y	 0.08	 0.02	 Y	 0.02	 0.28	 N	
mir-23b	 -0.23	 1.0E-05	 Y	 0.12	 3.2E-03	 Y	 0.19	 1.0E-05	 Y	 0.02	 0.28	 N	
mir-345	 0.12	 3.5E-03	 Y	 -0.06	 0.10	 N	 0.21	 1.0E-05	 Y	 -0.02	 0.28	 N	
mir-339	 0.06	 0.10	 N	 -0.04	 0.21	 N	 0.18	 3.0E-05	 Y	 -0.02	 0.28	 N	
mir-17	 0.11	 4.4E-03	 Y	 -0.11	 4.2E-03	 Y	 0.14	 3.9E-04	 Y	 0.02	 0.28	 N	
mir-423	 0.09	 0.02	 Y	 -0.14	 3.9E-04	 Y	 0.19	 1.0E-05	 Y	 -0.02	 0.31	 N	
mir-26a-1	 0.10	 7.9E-03	 Y	 -0.14	 3.9E-04	 Y	 0.19	 1.0E-05	 Y	 0.02	 0.31	 N	
mir-27b	 -0.11	 4.3E-03	 Y	 0.05	 0.13	 N	 0.13	 9.6E-04	 Y	 -0.02	 0.31	 N	
mir-1301	 0.12	 2.4E-03	 Y	 0.02	 0.29	 N	 0.24	 1.0E-05	 Y	 0.02	 0.32	 N	
mir-708	 -0.12	 2.1E-03	 Y	 0.27	 1.0E-05	 Y	 0.21	 1.0E-05	 Y	 0.02	 0.32	 N	
mir-93	 0.08	 0.02	 Y	 -0.12	 3.2E-03	 Y	 0.18	 4.0E-05	 Y	 0.02	 0.32	 N	
mir-125b-1	 -0.20	 1.0E-05	 Y	 0.30	 1.0E-05	 Y	 0.14	 4.4E-04	 Y	 -0.02	 0.32	 N	
mir-421	 0.19	 1.0E-05	 Y	 -0.17	 5.0E-05	 Y	 0.19	 1.0E-05	 Y	 0.02	 0.33	 N	
mir-27a	 -3.7E-03	 0.46	 N	 0.06	 0.09	 N	 0.13	 1.4E-03	 Y	 0.02	 0.33	 N	
mir-744	 0.15	 1.9E-04	 Y	 -0.11	 3.7E-03	 Y	 0.17	 6.0E-05	 Y	 -0.02	 0.33	 N	
mir-155	 0.05	 0.12	 N	 0.30	 1.0E-05	 Y	 0.18	 3.0E-05	 Y	 0.02	 0.34	 N	
mir-101-1	 -0.28	 1.0E-05	 Y	 0.19	 1.0E-05	 Y	 0.17	 4.0E-05	 Y	 -0.02	 0.34	 N	
mir-101-2	 -0.10	 7.2E-03	 Y	 -0.05	 0.15	 N	 0.17	 4.0E-05	 Y	 -0.02	 0.34	 N	
mir-21	 -0.18	 1.0E-05	 Y	 0.22	 1.0E-05	 Y	 0.15	 2.0E-04	 Y	 0.02	 0.34	 N	
let-7i	 -0.04	 0.18	 N	 0.28	 1.0E-05	 Y	 0.28	 1.0E-05	 Y	 0.02	 0.35	 N	
mir-320b-2	 0.10	 8.5E-03	 Y	 0.05	 0.14	 N	 0.14	 4.2E-04	 Y	 -0.02	 0.35	 N	
mir-125a	 -0.14	 3.7E-04	 Y	 0.15	 1.9E-04	 Y	 0.18	 4.0E-05	 Y	 -0.02	 0.36	 N	
mir-18a	 0.25	 1.0E-05	 Y	 -0.06	 0.07	 N	 0.20	 1.0E-05	 Y	 0.02	 0.36	 N	
mir-25	 0.08	 0.03	 Y	 -0.09	 0.02	 Y	 0.22	 1.0E-05	 Y	 0.01	 0.37	 N	
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let-7e	 -0.15	 2.1E-04	 Y	 0.09	 0.02	 Y	 0.22	 1.0E-05	 Y	 0.01	 0.37	 N	
mir-424	 0.13	 1.5E-03	 Y	 0.07	 0.05	 N	 0.24	 1.0E-05	 Y	 0.01	 0.38	 N	
mir-30a	 -0.28	 1.0E-05	 Y	 0.19	 1.0E-05	 Y	 0.20	 1.0E-05	 Y	 0.01	 0.38	 N	
mir-20a	 0.03	 0.21	 N	 -0.09	 0.02	 Y	 0.13	 8.1E-04	 Y	 -0.01	 0.40	 N	
mir-181a-1	 -0.12	 1.7E-03	 Y	 0.13	 9.0E-04	 Y	 0.06	 0.09	 N	 -9.4E-03	 0.41	 N	
mir-10b	 -0.09	 0.02	 Y	 0.14	 5.7E-04	 Y	 0.22	 1.0E-05	 Y	 9.2E-03	 0.42	 N	
mir-196a-1	 0.05	 0.11	 N	 -0.22	 1.0E-05	 Y	 0.17	 4.0E-05	 Y	 -8.9E-03	 0.42	 N	
mir-196a-2	 0.06	 0.09	 N	 -0.12	 1.7E-03	 Y	 0.17	 4.0E-05	 Y	 -8.9E-03	 0.42	 N	
mir-183	 0.01	 0.37	 N	 -0.07	 0.06	 N	 0.22	 1.0E-05	 Y	 9.0E-03	 0.42	 N	
mir-877	 0.22	 1.0E-05	 Y	 -0.03	 0.22	 N	 0.20	 1.0E-05	 Y	 -7.9E-03	 0.43	 N	
mir-7-3	 0.20	 1.0E-05	 Y	 0.05	 0.14	 N	 0.13	 1.3E-03	 Y	 -5.0E-03	 0.45	 N	
mir-7-2	 0.30	 1.0E-05	 Y	 -4.3E-03	 0.46	 N	 0.13	 1.3E-03	 Y	 -5.0E-03	 0.45	 N	
mir-22	 -0.20	 1.0E-05	 Y	 0.26	 1.0E-05	 Y	 0.18	 4.0E-05	 Y	 5.1E-03	 0.45	 N	
mir-197	 0.15	 3.2E-04	 Y	 -0.05	 0.11	 N	 0.22	 1.0E-05	 Y	 -4.6E-03	 0.46	 N	
mir-9-2	 -0.28	 1.0E-05	 Y	 0.16	 1.9E-04	 Y	 0.16	 1.0E-04	 Y	 4.6E-03	 0.46	 N	
mir-9-1	 -0.28	 1.0E-05	 Y	 0.15	 2.0E-04	 Y	 0.16	 1.0E-04	 Y	 4.6E-03	 0.46	 N	
mir-106b	 0.22	 1.0E-05	 Y	 -0.04	 0.17	 N	 0.13	 9.0E-04	 Y	 4.1E-03	 0.46	 N	
mir-326	 0.05	 0.12	 N	 0.17	 6.0E-05	 Y	 0.13	 9.3E-04	 Y	 3.0E-03	 0.47	 N	
mir-222	 0.09	 0.02	 Y	 0.18	 1.0E-05	 Y	 0.22	 1.0E-05	 Y	 -2.5E-03	 0.47	 N	
mir-99a	 -0.28	 1.0E-05	 Y	 0.22	 1.0E-05	 Y	 0.15	 3.6E-04	 Y	 2.3E-03	 0.48	 N	
mir-592	 -0.12	 2.4E-03	 Y	 -0.26	 1.0E-05	 Y	 0	 0.50	 N	 0	 0.50	 N	
mir-506	 0.12	 2.0E-03	 Y	 -0.26	 1.0E-05	 Y	 0	 0.50	 N	 0	 0.50	 N	
mir-578	 -5.9E-03	 0.44	 N	 -0.25	 1.0E-05	 Y	 0	 0.50	 N	 0	 0.50	 N	
mir-509-1	 -9.1E-03	 0.41	 N	 -0.24	 1.0E-05	 Y	 0	 0.50	 N	 0	 0.50	 N	
mir-549	 -0.08	 0.04	 Y	 -0.22	 1.0E-05	 Y	 0	 0.50	 N	 0	 0.50	 N	
mir-527	 0.11	 4.2E-03	 Y	 -0.22	 1.0E-05	 Y	 0	 0.50	 N	 0	 0.50	 N	
mir-1246	 0.16	 1.9E-04	 Y	 -0.21	 1.0E-05	 Y	 0	 0.50	 N	 0	 0.50	 N	
mir-611	 0.23	 1.0E-05	 Y	 -0.21	 1.0E-05	 Y	 0	 0.50	 N	 0	 0.50	 N	
mir-1291	 0.15	 1.9E-04	 Y	 -0.21	 1.0E-05	 Y	 0	 0.50	 N	 0	 0.50	 N	
mir-548f-1	 0.13	 7.3E-04	 Y	 -0.20	 1.0E-05	 Y	 0	 0.50	 N	 0	 0.50	 N	
mir-452	 -0.14	 3.6E-04	 Y	 -0.20	 1.0E-05	 Y	 0	 0.50	 N	 0	 0.50	 N	
mir-2110	 0.11	 4.0E-03	 Y	 -0.20	 1.0E-05	 Y	 0	 0.50	 N	 0	 0.50	 N	
mir-552	 -0.17	 5.0E-05	 Y	 -0.19	 1.0E-05	 Y	 0	 0.50	 N	 0	 0.50	 N	
mir-208b	 0.02	 0.30	 N	 -0.19	 1.0E-05	 Y	 0	 0.50	 N	 0	 0.50	 N	
mir-509-2	 -0.08	 0.02	 Y	 -0.19	 1.0E-05	 Y	 0	 0.50	 N	 0	 0.50	 N	
mir-33b	 0.06	 0.07	 N	 0.19	 1.0E-05	 Y	 0	 0.50	 N	 0	 0.50	 N	
mir-525	 0.03	 0.28	 N	 0.20	 1.0E-05	 Y	 0	 0.50	 N	 0	 0.50	 N	
mir-873	 -0.10	 8.0E-03	 Y	 0.20	 1.0E-05	 Y	 0	 0.50	 N	 0	 0.50	 N	
mir-187	 -0.19	 1.0E-05	 Y	 0.21	 1.0E-05	 Y	 0	 0.50	 N	 0	 0.50	 N	
mir-551a	 0.14	 6.1E-04	 Y	 0.21	 1.0E-05	 Y	 0	 0.50	 N	 0	 0.50	 N	
mir-1293	 0.20	 1.0E-05	 Y	 0.21	 1.0E-05	 Y	 0	 0.50	 N	 0	 0.50	 N	
mir-654	 0.02	 0.33	 N	 0.21	 1.0E-05	 Y	 0	 0.50	 N	 0	 0.50	 N	
mir-379	 -0.10	 0.01	 Y	 0.22	 1.0E-05	 Y	 0	 0.50	 N	 0	 0.50	 N	
mir-1245	 0.04	 0.20	 N	 0.22	 1.0E-05	 Y	 0	 0.50	 N	 0	 0.50	 N	
mir-363	 -0.14	 3.6E-04	 Y	 0.24	 1.0E-05	 Y	 0	 0.50	 N	 0	 0.50	 N	
mir-511-1	 0.11	 4.3E-03	 Y	 0.27	 1.0E-05	 Y	 0	 0.50	 N	 0	 0.50	 N	
mir-490	 -0.22	 1.0E-05	 Y	 0.28	 1.0E-05	 Y	 0	 0.50	 N	 0	 0.50	 N	
mir-656	 -0.03	 0.26	 N	 0.28	 1.0E-05	 Y	 0	 0.50	 N	 0	 0.50	 N	
mir-628	 -0.15	 2.6E-04	 Y	 0.30	 1.0E-05	 Y	 0	 0.50	 N	 0	 0.50	 N	
mir-511-2	 0.07	 0.05	 N	 0.31	 1.0E-05	 Y	 0	 0.50	 N	 0	 0.50	 N	
mir-513c	 0.03	 0.27	 N	 -0.18	 2.0E-05	 Y	 0	 0.50	 N	 0	 0.50	 N	
mir-188	 0.11	 6.8E-03	 Y	 -0.18	 2.0E-05	 Y	 0	 0.50	 N	 0	 0.50	 N	
mir-942	 0.28	 1.0E-05	 Y	 -0.17	 2.0E-05	 Y	 0	 0.50	 N	 0	 0.50	 N	
mir-520b	 0.02	 0.32	 N	 0.18	 3.0E-05	 Y	 0	 0.50	 N	 0	 0.50	 N	
mir-199b	 -0.11	 4.4E-03	 Y	 0.18	 3.0E-05	 Y	 0	 0.50	 N	 0	 0.50	 N	
mir-410	 -0.09	 0.02	 Y	 0.17	 4.0E-05	 Y	 0	 0.50	 N	 0	 0.50	 N	
mir-377	 4.4E-05	 0.50	 N	 0.17	 4.0E-05	 Y	 0	 0.50	 N	 0	 0.50	 N	
mir-184	 -0.08	 0.03	 Y	 -0.17	 5.0E-05	 Y	 0	 0.50	 N	 0	 0.50	 N	
mir-892a	 0.06	 0.07	 N	 -0.16	 5.0E-05	 Y	 0	 0.50	 N	 0	 0.50	 N	
mir-937	 0.05	 0.14	 N	 0.17	 9.0E-05	 Y	 0	 0.50	 N	 0	 0.50	 N	
mir-152	 -0.17	 5.0E-05	 Y	 0.17	 1.0E-04	 Y	 0	 0.50	 N	 0	 0.50	 N	
mir-622	 0.26	 1.0E-05	 Y	 -0.16	 1.3E-04	 Y	 0	 0.50	 N	 0	 0.50	 N	
mir-1289-1	 -0.06	 0.08	 N	 -0.16	 1.5E-04	 Y	 0	 0.50	 N	 0	 0.50	 N	
mir-1305	 0.07	 0.04	 N	 0.16	 1.7E-04	 Y	 0	 0.50	 N	 0	 0.50	 N	
mir-512-1	 -2.5E-03	 0.48	 N	 0.16	 1.7E-04	 Y	 0	 0.50	 N	 0	 0.50	 N	
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mir-1251	 -7.1E-03	 0.43	 N	 0.16	 1.8E-04	 Y	 0	 0.50	 N	 0	 0.50	 N	
mir-573	 0.32	 1.0E-05	 Y	 -0.15	 1.9E-04	 Y	 0	 0.50	 N	 0	 0.50	 N	
mir-485	 -0.02	 0.33	 N	 0.15	 1.9E-04	 Y	 0	 0.50	 N	 0	 0.50	 N	
mir-758	 -0.11	 4.4E-03	 Y	 0.16	 1.9E-04	 Y	 0	 0.50	 N	 0	 0.50	 N	
mir-154	 -0.09	 0.02	 Y	 0.16	 1.9E-04	 Y	 0	 0.50	 N	 0	 0.50	 N	
mir-1281	 0.11	 4.9E-03	 Y	 -0.15	 2.5E-04	 Y	 0	 0.50	 N	 0	 0.50	 N	
mir-1292	 0.28	 1.0E-05	 Y	 -0.15	 2.6E-04	 Y	 0	 0.50	 N	 0	 0.50	 N	
mir-617	 0.13	 1.2E-03	 Y	 -0.15	 2.6E-04	 Y	 0	 0.50	 N	 0	 0.50	 N	
mir-644	 0.13	 1.2E-03	 Y	 -0.15	 2.6E-04	 Y	 0	 0.50	 N	 0	 0.50	 N	
mir-612	 0.04	 0.19	 N	 -0.14	 3.2E-04	 Y	 0	 0.50	 N	 0	 0.50	 N	
mir-627	 0.02	 0.35	 N	 -0.14	 3.6E-04	 Y	 0	 0.50	 N	 0	 0.50	 N	
mir-518a-1	 0.14	 6.2E-04	 Y	 -0.14	 3.6E-04	 Y	 0	 0.50	 N	 0	 0.50	 N	
mir-662	 -8.1E-03	 0.42	 N	 0.14	 3.6E-04	 Y	 0	 0.50	 N	 0	 0.50	 N	
mir-519a-1	 -1.5E-03	 0.48	 N	 0.15	 3.6E-04	 Y	 0	 0.50	 N	 0	 0.50	 N	
mir-411	 -0.10	 9.0E-03	 Y	 0.15	 3.6E-04	 Y	 0	 0.50	 N	 0	 0.50	 N	
mir-1539	 0.17	 1.0E-04	 Y	 -0.14	 3.9E-04	 Y	 0	 0.50	 N	 0	 0.50	 N	
mir-1179	 0.05	 0.13	 N	 -0.14	 3.9E-04	 Y	 0	 0.50	 N	 0	 0.50	 N	
mir-219-2	 -0.03	 0.23	 N	 0.14	 4.2E-04	 Y	 0	 0.50	 N	 0	 0.50	 N	
mir-139	 -0.16	 5.0E-05	 Y	 0.14	 4.9E-04	 Y	 0	 0.50	 N	 0	 0.50	 N	
mir-1234	 0.19	 1.0E-05	 Y	 -0.14	 5.0E-04	 Y	 0	 0.50	 N	 0	 0.50	 N	
mir-1287	 -0.08	 0.03	 Y	 0.14	 5.1E-04	 Y	 0	 0.50	 N	 0	 0.50	 N	
mir-127	 -0.11	 5.0E-03	 Y	 0.14	 5.1E-04	 Y	 0	 0.50	 N	 0	 0.50	 N	
mir-495	 0.03	 0.24	 N	 0.14	 5.5E-04	 Y	 0	 0.50	 N	 0	 0.50	 N	
mir-499	 -0.05	 0.10	 N	 -0.14	 5.6E-04	 Y	 0	 0.50	 N	 0	 0.50	 N	
mir-509-3	 -0.14	 3.0E-04	 Y	 -0.14	 5.8E-04	 Y	 0	 0.50	 N	 0	 0.50	 N	
mir-206	 -0.04	 0.15	 N	 -0.13	 6.1E-04	 Y	 0	 0.50	 N	 0	 0.50	 N	
mir-526b	 0.13	 1.5E-03	 Y	 0.14	 6.3E-04	 Y	 0	 0.50	 N	 0	 0.50	 N	
mir-655	 0.04	 0.20	 N	 0.14	 6.6E-04	 Y	 0	 0.50	 N	 0	 0.50	 N	
mir-660	 -0.10	 7.7E-03	 Y	 -0.13	 7.1E-04	 Y	 0	 0.50	 N	 0	 0.50	 N	
mir-1537	 0.14	 5.7E-04	 Y	 0.14	 7.3E-04	 Y	 0	 0.50	 N	 0	 0.50	 N	
mir-409	 -0.05	 0.14	 N	 0.13	 8.2E-04	 Y	 0	 0.50	 N	 0	 0.50	 N	
mir-889	 -0.06	 0.08	 N	 0.13	 8.3E-04	 Y	 0	 0.50	 N	 0	 0.50	 N	
mir-1285-1	 9.6E-03	 0.41	 N	 -0.13	 8.7E-04	 Y	 0	 0.50	 N	 0	 0.50	 N	
mir-574	 0.02	 0.30	 N	 0.13	 8.7E-04	 Y	 0	 0.50	 N	 0	 0.50	 N	
mir-320d-2	 -0.02	 0.32	 N	 0.13	 9.4E-04	 Y	 0	 0.50	 N	 0	 0.50	 N	
mir-572	 -0.12	 3.3E-03	 Y	 -0.13	 1.1E-03	 Y	 0	 0.50	 N	 0	 0.50	 N	
mir-508	 -0.20	 1.0E-05	 Y	 -0.13	 1.1E-03	 Y	 0	 0.50	 N	 0	 0.50	 N	
mir-198	 0.02	 0.28	 N	 0.13	 1.1E-03	 Y	 0	 0.50	 N	 0	 0.50	 N	
mir-577	 0.15	 2.3E-04	 Y	 -0.13	 1.2E-03	 Y	 0	 0.50	 N	 0	 0.50	 N	
mir-216b	 -0.06	 0.09	 N	 0.12	 1.8E-03	 Y	 0	 0.50	 N	 0	 0.50	 N	
mir-581	 0.17	 9.0E-05	 Y	 -0.12	 1.8E-03	 Y	 0	 0.50	 N	 0	 0.50	 N	
mir-1258	 -0.25	 1.0E-05	 Y	 0.12	 1.9E-03	 Y	 0	 0.50	 N	 0	 0.50	 N	
mir-582	 0.19	 1.0E-05	 Y	 0.12	 1.9E-03	 Y	 0	 0.50	 N	 0	 0.50	 N	
mir-1231	 0.07	 0.05	 N	 -0.12	 2.0E-03	 Y	 0	 0.50	 N	 0	 0.50	 N	
mir-559	 0.01	 0.36	 N	 -0.12	 2.2E-03	 Y	 0	 0.50	 N	 0	 0.50	 N	
mir-496	 -0.02	 0.31	 N	 0.12	 2.2E-03	 Y	 0	 0.50	 N	 0	 0.50	 N	
mir-487b	 -0.04	 0.20	 N	 0.12	 2.3E-03	 Y	 0	 0.50	 N	 0	 0.50	 N	
mir-522	 0.06	 0.08	 N	 0.12	 2.3E-03	 Y	 0	 0.50	 N	 0	 0.50	 N	
mir-1271	 -0.10	 0.01	 Y	 0.12	 2.3E-03	 Y	 0	 0.50	 N	 0	 0.50	 N	
mir-512-2	 -0.02	 0.34	 N	 0.12	 2.4E-03	 Y	 0	 0.50	 N	 0	 0.50	 N	
mir-523	 0.11	 5.1E-03	 Y	 -0.12	 2.6E-03	 Y	 0	 0.50	 N	 0	 0.50	 N	
mir-639	 0.07	 0.05	 N	 -0.12	 2.8E-03	 Y	 0	 0.50	 N	 0	 0.50	 N	
mir-936	 -0.08	 0.03	 Y	 -0.12	 2.9E-03	 Y	 0	 0.50	 N	 0	 0.50	 N	
mir-337	 -0.05	 0.11	 N	 0.12	 2.9E-03	 Y	 0	 0.50	 N	 0	 0.50	 N	
mir-518c	 -0.09	 0.02	 Y	 0.12	 2.9E-03	 Y	 0	 0.50	 N	 0	 0.50	 N	
mir-675	 0.09	 0.02	 Y	 0.12	 2.9E-03	 Y	 0	 0.50	 N	 0	 0.50	 N	
mir-1247	 -0.07	 0.05	 N	 -0.12	 3.0E-03	 Y	 0	 0.50	 N	 0	 0.50	 N	
mir-516a-1	 0.11	 6.4E-03	 Y	 0.12	 3.0E-03	 Y	 0	 0.50	 N	 0	 0.50	 N	
mir-520d	 0.07	 0.04	 N	 -0.12	 3.1E-03	 Y	 0	 0.50	 N	 0	 0.50	 N	
mir-299	 0.04	 0.19	 N	 0.12	 3.1E-03	 Y	 0	 0.50	 N	 0	 0.50	 N	
mir-1207	 0.03	 0.22	 N	 -0.12	 3.2E-03	 Y	 0	 0.50	 N	 0	 0.50	 N	
mir-1915	 0.03	 0.22	 N	 -0.12	 3.2E-03	 Y	 0	 0.50	 N	 0	 0.50	 N	
mir-635	 0.03	 0.22	 N	 -0.12	 3.2E-03	 Y	 0	 0.50	 N	 0	 0.50	 N	
mir-888	 0.03	 0.22	 N	 -0.12	 3.2E-03	 Y	 0	 0.50	 N	 0	 0.50	 N	
mir-545	 0.01	 0.38	 N	 -0.12	 3.2E-03	 Y	 0	 0.50	 N	 0	 0.50	 N	
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mir-136	 -0.08	 0.04	 Y	 0.11	 3.8E-03	 Y	 0	 0.50	 N	 0	 0.50	 N	
mir-542	 -0.11	 5.5E-03	 Y	 0.11	 3.9E-03	 Y	 0	 0.50	 N	 0	 0.50	 N	
mir-488	 -0.08	 0.04	 Y	 0.11	 4.1E-03	 Y	 0	 0.50	 N	 0	 0.50	 N	
mir-135b	 -0.12	 2.1E-03	 Y	 -0.11	 4.3E-03	 Y	 0	 0.50	 N	 0	 0.50	 N	
mir-892b	 0.09	 0.02	 Y	 -0.11	 4.4E-03	 Y	 0	 0.50	 N	 0	 0.50	 N	
mir-875	 -0.01	 0.39	 N	 -0.11	 4.5E-03	 Y	 0	 0.50	 N	 0	 0.50	 N	
mir-519a-2	 0.06	 0.07	 N	 0.11	 4.7E-03	 Y	 0	 0.50	 N	 0	 0.50	 N	
mir-887	 -0.09	 0.02	 Y	 0.11	 4.8E-03	 Y	 0	 0.50	 N	 0	 0.50	 N	
mir-623	 0.04	 0.18	 N	 0.11	 5.4E-03	 Y	 0	 0.50	 N	 0	 0.50	 N	
mir-576	 0.10	 0.01	 Y	 -0.11	 6.2E-03	 Y	 0	 0.50	 N	 0	 0.50	 N	
mir-494	 0.03	 0.25	 N	 0.10	 7.7E-03	 Y	 0	 0.50	 N	 0	 0.50	 N	
mir-516a-2	 -0.11	 3.7E-03	 Y	 0.10	 7.8E-03	 Y	 0	 0.50	 N	 0	 0.50	 N	
mir-1283-2	 0.03	 0.27	 N	 0.10	 8.5E-03	 Y	 0	 0.50	 N	 0	 0.50	 N	
mir-95	 0.01	 0.39	 N	 -0.10	 9.1E-03	 Y	 0	 0.50	 N	 0	 0.50	 N	
mir-520c	 -0.11	 3.5E-03	 Y	 0.10	 0.01	 Y	 0	 0.50	 N	 0	 0.50	 N	
mir-591	 0.13	 1.0E-03	 Y	 -0.10	 0.01	 Y	 0	 0.50	 N	 0	 0.50	 N	
mir-933	 -0.10	 0.01	 Y	 0.10	 0.01	 Y	 0	 0.50	 N	 0	 0.50	 N	
mir-502	 2.0E-03	 0.48	 N	 -0.10	 0.01	 Y	 0	 0.50	 N	 0	 0.50	 N	
mir-526a-1	 -0.07	 0.06	 N	 0.10	 0.01	 Y	 0	 0.50	 N	 0	 0.50	 N	
mir-147	 -0.05	 0.13	 N	 -0.10	 0.01	 Y	 0	 0.50	 N	 0	 0.50	 N	
mir-134	 0.04	 0.18	 N	 0.10	 0.01	 Y	 0	 0.50	 N	 0	 0.50	 N	
mir-491	 0.04	 0.21	 N	 -0.10	 0.01	 Y	 0	 0.50	 N	 0	 0.50	 N	
let-7f-2	 -0.22	 1.0E-05	 Y	 0.10	 0.01	 Y	 0	 0.50	 N	 0	 0.50	 N	
mir-516b-2	 -0.11	 4.0E-03	 Y	 0.09	 0.01	 Y	 0	 0.50	 N	 0	 0.50	 N	
mir-521-2	 -0.07	 0.05	 N	 0.09	 0.01	 Y	 0	 0.50	 N	 0	 0.50	 N	
mir-517a	 -0.02	 0.33	 N	 0.09	 0.02	 Y	 0	 0.50	 N	 0	 0.50	 N	
mir-517b	 -0.02	 0.33	 N	 0.09	 0.02	 Y	 0	 0.50	 N	 0	 0.50	 N	
mir-19b-1	 0.15	 2.2E-04	 Y	 -0.09	 0.02	 Y	 0	 0.50	 N	 0	 0.50	 N	
mir-614	 0.11	 3.9E-03	 Y	 0.09	 0.02	 Y	 0	 0.50	 N	 0	 0.50	 N	
mir-302c	 0.08	 0.04	 Y	 0.09	 0.02	 Y	 0	 0.50	 N	 0	 0.50	 N	
mir-367	 0.08	 0.04	 Y	 0.09	 0.02	 Y	 0	 0.50	 N	 0	 0.50	 N	
mir-520f	 0.09	 0.02	 Y	 0.09	 0.02	 Y	 0	 0.50	 N	 0	 0.50	 N	
mir-586	 0.10	 0.01	 Y	 -0.09	 0.02	 Y	 0	 0.50	 N	 0	 0.50	 N	
mir-1249	 -0.01	 0.40	 N	 0.09	 0.02	 Y	 0	 0.50	 N	 0	 0.50	 N	
mir-514-3	 -0.11	 4.0E-03	 Y	 -0.09	 0.02	 Y	 0	 0.50	 N	 0	 0.50	 N	
mir-584	 0.07	 0.05	 N	 -0.09	 0.02	 Y	 0	 0.50	 N	 0	 0.50	 N	
mir-613	 0.15	 2.4E-04	 Y	 0.09	 0.02	 Y	 0	 0.50	 N	 0	 0.50	 N	
mir-607	 -0.01	 0.37	 N	 0.09	 0.02	 Y	 0	 0.50	 N	 0	 0.50	 N	
mir-548f-4	 -0.03	 0.28	 N	 -0.09	 0.02	 Y	 0	 0.50	 N	 0	 0.50	 N	
mir-513a-2	 -0.11	 6.3E-03	 Y	 -0.09	 0.02	 Y	 0	 0.50	 N	 0	 0.50	 N	
mir-1468	 -0.04	 0.20	 N	 -0.09	 0.02	 Y	 0	 0.50	 N	 0	 0.50	 N	
mir-632	 0.09	 0.01	 Y	 -0.09	 0.02	 Y	 0	 0.50	 N	 0	 0.50	 N	
mir-381	 -0.02	 0.35	 N	 0.08	 0.02	 Y	 0	 0.50	 N	 0	 0.50	 N	
mir-1269	 -0.13	 6.7E-04	 Y	 -0.08	 0.03	 Y	 0	 0.50	 N	 0	 0.50	 N	
mir-493	 -0.07	 0.06	 N	 0.08	 0.03	 Y	 0	 0.50	 N	 0	 0.50	 N	
let-7a-3	 -0.25	 1.0E-05	 Y	 0.08	 0.03	 Y	 0	 0.50	 N	 0	 0.50	 N	
mir-219-1	 0.05	 0.11	 N	 -0.08	 0.03	 Y	 0	 0.50	 N	 0	 0.50	 N	
mir-1238	 0.13	 1.2E-03	 Y	 0.08	 0.03	 Y	 0	 0.50	 N	 0	 0.50	 N	
mir-1280	 0.11	 6.6E-03	 Y	 0.08	 0.03	 Y	 0	 0.50	 N	 0	 0.50	 N	
mir-767	 -0.19	 1.0E-05	 Y	 0.08	 0.03	 Y	 0	 0.50	 N	 0	 0.50	 N	
mir-658	 -0.02	 0.35	 N	 0.08	 0.03	 Y	 0	 0.50	 N	 0	 0.50	 N	
mir-521-1	 0	 0.50	 N	 0.08	 0.03	 Y	 0	 0.50	 N	 0	 0.50	 N	
mir-329-2	 0.18	 3.0E-05	 Y	 -0.08	 0.03	 Y	 0	 0.50	 N	 0	 0.50	 N	
mir-26a-2	 -0.14	 4.7E-04	 Y	 0.08	 0.03	 Y	 0	 0.50	 N	 0	 0.50	 N	
mir-938	 0.05	 0.13	 N	 0.08	 0.04	 Y	 0	 0.50	 N	 0	 0.50	 N	
mir-603	 -0.08	 0.04	 Y	 -0.08	 0.04	 Y	 0	 0.50	 N	 0	 0.50	 N	
mir-580	 0.10	 9.8E-03	 Y	 -0.08	 0.04	 Y	 0	 0.50	 N	 0	 0.50	 N	
mir-636	 0.11	 5.2E-03	 Y	 0.08	 0.04	 Y	 0	 0.50	 N	 0	 0.50	 N	
mir-621	 0.15	 2.4E-04	 Y	 -0.08	 0.04	 Y	 0	 0.50	 N	 0	 0.50	 N	
mir-492	 0.20	 1.0E-05	 Y	 -0.08	 0.04	 Y	 0	 0.50	 N	 0	 0.50	 N	
mir-556	 0.02	 0.36	 N	 -0.08	 0.04	 Y	 0	 0.50	 N	 0	 0.50	 N	
mir-431	 -0.10	 9.0E-03	 Y	 0.08	 0.04	 Y	 0	 0.50	 N	 0	 0.50	 N	
mir-190b	 -0.08	 0.04	 Y	 0.07	 0.04	 Y	 0	 0.50	 N	 0	 0.50	 N	
mir-1911	 -0.01	 0.41	 N	 -0.07	 0.04	 N	 0	 0.50	 N	 0	 0.50	 N	
mir-891a	 -0.03	 0.27	 N	 0.07	 0.04	 N	 0	 0.50	 N	 0	 0.50	 N	
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mir-1825	 0.06	 0.08	 N	 -0.07	 0.04	 N	 0	 0.50	 N	 0	 0.50	 N	
mir-1185-2	 -0.15	 2.5E-04	 Y	 0.07	 0.04	 N	 0	 0.50	 N	 0	 0.50	 N	
mir-1282	 -0.02	 0.30	 N	 -0.07	 0.04	 N	 0	 0.50	 N	 0	 0.50	 N	
mir-1178	 0.01	 0.38	 N	 -0.07	 0.04	 N	 0	 0.50	 N	 0	 0.50	 N	
mir-382	 -0.02	 0.33	 N	 0.07	 0.04	 N	 0	 0.50	 N	 0	 0.50	 N	
mir-610	 6.5E-03	 0.44	 N	 0.07	 0.05	 N	 0	 0.50	 N	 0	 0.50	 N	
mir-518f	 0.12	 2.2E-03	 Y	 -0.07	 0.05	 N	 0	 0.50	 N	 0	 0.50	 N	
mir-548d-1	 0.11	 4.5E-03	 Y	 0.07	 0.05	 N	 0	 0.50	 N	 0	 0.50	 N	
mir-543	 -0.04	 0.20	 N	 0.07	 0.05	 N	 0	 0.50	 N	 0	 0.50	 N	
mir-657	 0	 0.50	 N	 -0.07	 0.05	 N	 0	 0.50	 N	 0	 0.50	 N	
mir-1909	 0.07	 0.06	 N	 -0.07	 0.05	 N	 0	 0.50	 N	 0	 0.50	 N	
mir-520g	 -0.09	 0.02	 Y	 0.07	 0.05	 N	 0	 0.50	 N	 0	 0.50	 N	
mir-370	 -0.05	 0.11	 N	 0.07	 0.06	 N	 0	 0.50	 N	 0	 0.50	 N	
mir-489	 -0.19	 1.0E-05	 Y	 0.07	 0.06	 N	 0	 0.50	 N	 0	 0.50	 N	
mir-135a-2	 -1.3E-03	 0.49	 N	 -0.07	 0.06	 N	 0	 0.50	 N	 0	 0.50	 N	
mir-570	 -4.7E-03	 0.45	 N	 -0.07	 0.06	 N	 0	 0.50	 N	 0	 0.50	 N	
mir-202	 -9.8E-03	 0.41	 N	 0.07	 0.06	 N	 0	 0.50	 N	 0	 0.50	 N	
mir-450a-1	 0.05	 0.12	 N	 0.07	 0.06	 N	 0	 0.50	 N	 0	 0.50	 N	
mir-519e	 -0.11	 5.9E-03	 Y	 -0.07	 0.07	 N	 0	 0.50	 N	 0	 0.50	 N	
mir-450b	 -0.03	 0.25	 N	 0.06	 0.07	 N	 0	 0.50	 N	 0	 0.50	 N	
mir-1913	 0.07	 0.05	 N	 0.06	 0.07	 N	 0	 0.50	 N	 0	 0.50	 N	
mir-1908	 0.07	 0.05	 N	 0.06	 0.07	 N	 0	 0.50	 N	 0	 0.50	 N	
mir-1248	 0.10	 0.01	 Y	 0.06	 0.07	 N	 0	 0.50	 N	 0	 0.50	 N	
mir-604	 0.09	 0.02	 Y	 0.06	 0.07	 N	 0	 0.50	 N	 0	 0.50	 N	
mir-561	 5.5E-03	 0.45	 N	 0.06	 0.08	 N	 0	 0.50	 N	 0	 0.50	 N	
mir-144	 -0.05	 0.12	 N	 -0.06	 0.08	 N	 0	 0.50	 N	 0	 0.50	 N	
mir-376b	 0.08	 0.04	 Y	 0.06	 0.08	 N	 0	 0.50	 N	 0	 0.50	 N	
mir-1277	 -0.10	 6.7E-03	 Y	 0.06	 0.08	 N	 0	 0.50	 N	 0	 0.50	 N	
mir-1267	 -0.07	 0.05	 N	 0.06	 0.08	 N	 0	 0.50	 N	 0	 0.50	 N	
mir-412	 -0.03	 0.24	 N	 -0.06	 0.09	 N	 0	 0.50	 N	 0	 0.50	 N	
mir-548n	 0.02	 0.29	 N	 -0.06	 0.09	 N	 0	 0.50	 N	 0	 0.50	 N	
mir-7-1	 0.28	 1.0E-05	 Y	 -0.06	 0.09	 N	 0	 0.50	 N	 0	 0.50	 N	
mir-320d-1	 -0.02	 0.29	 N	 0.06	 0.09	 N	 0	 0.50	 N	 0	 0.50	 N	
mir-9-3	 -5.2E-03	 0.45	 N	 0.06	 0.09	 N	 0	 0.50	 N	 0	 0.50	 N	
mir-668	 0.08	 0.04	 Y	 -0.06	 0.09	 N	 0	 0.50	 N	 0	 0.50	 N	
mir-422a	 -0.08	 0.03	 Y	 0.06	 0.09	 N	 0	 0.50	 N	 0	 0.50	 N	
mir-922	 -0.08	 0.03	 Y	 0.06	 0.09	 N	 0	 0.50	 N	 0	 0.50	 N	
mir-618	 0.20	 1.0E-05	 Y	 0.06	 0.10	 N	 0	 0.50	 N	 0	 0.50	 N	
mir-1976	 -0.02	 0.34	 N	 0.05	 0.10	 N	 0	 0.50	 N	 0	 0.50	 N	
mir-147b	 0.10	 8.7E-03	 Y	 -0.05	 0.11	 N	 0	 0.50	 N	 0	 0.50	 N	
mir-631	 0.12	 2.0E-03	 Y	 -0.05	 0.12	 N	 0	 0.50	 N	 0	 0.50	 N	
mir-1181	 -0.03	 0.27	 N	 -0.05	 0.12	 N	 0	 0.50	 N	 0	 0.50	 N	
mir-579	 0.17	 4.0E-05	 Y	 0.05	 0.12	 N	 0	 0.50	 N	 0	 0.50	 N	
mir-513b	 0.12	 2.1E-03	 Y	 -0.05	 0.12	 N	 0	 0.50	 N	 0	 0.50	 N	
mir-641	 0.11	 6.4E-03	 Y	 0.05	 0.12	 N	 0	 0.50	 N	 0	 0.50	 N	
mir-449b	 0.08	 0.03	 Y	 -0.05	 0.12	 N	 0	 0.50	 N	 0	 0.50	 N	
mir-1290	 0.06	 0.09	 N	 -0.05	 0.12	 N	 0	 0.50	 N	 0	 0.50	 N	
mir-1224	 0.02	 0.32	 N	 -0.05	 0.12	 N	 0	 0.50	 N	 0	 0.50	 N	
mir-302b	 0.16	 1.0E-04	 Y	 0.05	 0.12	 N	 0	 0.50	 N	 0	 0.50	 N	
mir-651	 -0.06	 0.07	 N	 -0.05	 0.12	 N	 0	 0.50	 N	 0	 0.50	 N	
mir-616	 0.12	 3.0E-03	 Y	 -0.05	 0.13	 N	 0	 0.50	 N	 0	 0.50	 N	
mir-1284	 0.18	 4.0E-05	 Y	 -0.05	 0.13	 N	 0	 0.50	 N	 0	 0.50	 N	
mir-486	 -0.06	 0.10	 N	 0.05	 0.13	 N	 0	 0.50	 N	 0	 0.50	 N	
mir-153-2	 -0.17	 2.0E-05	 Y	 -0.05	 0.14	 N	 0	 0.50	 N	 0	 0.50	 N	
mir-520e	 0.12	 2.4E-03	 Y	 0.05	 0.14	 N	 0	 0.50	 N	 0	 0.50	 N	
mir-1228	 0.14	 5.1E-04	 Y	 0.05	 0.14	 N	 0	 0.50	 N	 0	 0.50	 N	
mir-664	 -0.25	 1.0E-05	 Y	 0.05	 0.14	 N	 0	 0.50	 N	 0	 0.50	 N	
mir-1252	 0.04	 0.19	 N	 0.05	 0.14	 N	 0	 0.50	 N	 0	 0.50	 N	
mir-1286	 0.15	 1.9E-04	 Y	 -0.05	 0.15	 N	 0	 0.50	 N	 0	 0.50	 N	
mir-606	 -0.11	 3.7E-03	 Y	 0.04	 0.15	 N	 0	 0.50	 N	 0	 0.50	 N	
mir-514-2	 -0.09	 0.02	 Y	 0.04	 0.15	 N	 0	 0.50	 N	 0	 0.50	 N	
mir-599	 0.06	 0.08	 N	 -0.04	 0.15	 N	 0	 0.50	 N	 0	 0.50	 N	
mir-1827	 -0.04	 0.16	 N	 -0.04	 0.15	 N	 0	 0.50	 N	 0	 0.50	 N	
mir-24-1	 -0.17	 4.0E-05	 Y	 0.04	 0.16	 N	 0	 0.50	 N	 0	 0.50	 N	
mir-128-2	 0.06	 0.08	 N	 -0.04	 0.16	 N	 0	 0.50	 N	 0	 0.50	 N	
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mir-630	 0.05	 0.13	 N	 0.04	 0.16	 N	 0	 0.50	 N	 0	 0.50	 N	
mir-29b-2	 -0.10	 9.8E-03	 Y	 0.04	 0.16	 N	 0	 0.50	 N	 0	 0.50	 N	
mir-323	 0.08	 0.03	 Y	 0.04	 0.17	 N	 0	 0.50	 N	 0	 0.50	 N	
mir-600	 0.10	 8.5E-03	 Y	 0.04	 0.17	 N	 0	 0.50	 N	 0	 0.50	 N	
mir-135a-1	 -0.16	 7.0E-05	 Y	 0.04	 0.17	 N	 0	 0.50	 N	 0	 0.50	 N	
mir-519d	 -0.03	 0.22	 N	 0.04	 0.17	 N	 0	 0.50	 N	 0	 0.50	 N	
mir-510	 0.09	 0.02	 Y	 -0.04	 0.18	 N	 0	 0.50	 N	 0	 0.50	 N	
mir-329-1	 0.05	 0.11	 N	 0.04	 0.18	 N	 0	 0.50	 N	 0	 0.50	 N	
mir-934	 -0.16	 1.5E-04	 Y	 0.04	 0.18	 N	 0	 0.50	 N	 0	 0.50	 N	
mir-487a	 0.02	 0.28	 N	 0.04	 0.18	 N	 0	 0.50	 N	 0	 0.50	 N	
mir-891b	 0.08	 0.03	 Y	 -0.04	 0.18	 N	 0	 0.50	 N	 0	 0.50	 N	
mir-885	 -8.6E-03	 0.42	 N	 -0.04	 0.19	 N	 0	 0.50	 N	 0	 0.50	 N	
mir-1912	 0.07	 0.06	 N	 -0.04	 0.19	 N	 0	 0.50	 N	 0	 0.50	 N	
mir-663	 0.16	 1.1E-04	 Y	 -0.04	 0.20	 N	 0	 0.50	 N	 0	 0.50	 N	
mir-181a-2	 -0.13	 6.3E-04	 Y	 -0.04	 0.20	 N	 0	 0.50	 N	 0	 0.50	 N	
mir-876	 -0.07	 0.04	 N	 0.04	 0.20	 N	 0	 0.50	 N	 0	 0.50	 N	
mir-1255a	 0.17	 4.0E-05	 Y	 0.04	 0.20	 N	 0	 0.50	 N	 0	 0.50	 N	
mir-1266	 0.27	 1.0E-05	 Y	 -0.04	 0.20	 N	 0	 0.50	 N	 0	 0.50	 N	
mir-208a	 7.3E-03	 0.43	 N	 -0.04	 0.21	 N	 0	 0.50	 N	 0	 0.50	 N	
mir-1302-3	 0.02	 0.36	 N	 0.04	 0.21	 N	 0	 0.50	 N	 0	 0.50	 N	
mir-376c	 0.04	 0.16	 N	 0.03	 0.21	 N	 0	 0.50	 N	 0	 0.50	 N	
mir-519c	 0.13	 1.6E-03	 Y	 0.03	 0.21	 N	 0	 0.50	 N	 0	 0.50	 N	
mir-551b	 -0.08	 0.03	 Y	 0.03	 0.21	 N	 0	 0.50	 N	 0	 0.50	 N	
mir-564	 0.02	 0.36	 N	 -0.03	 0.21	 N	 0	 0.50	 N	 0	 0.50	 N	
mir-518a-2	 -4.4E-03	 0.46	 N	 -0.03	 0.22	 N	 0	 0.50	 N	 0	 0.50	 N	
mir-301b	 0.18	 3.0E-05	 Y	 -0.03	 0.22	 N	 0	 0.50	 N	 0	 0.50	 N	
mir-1182	 0.15	 2.0E-04	 Y	 -0.03	 0.22	 N	 0	 0.50	 N	 0	 0.50	 N	
mir-588	 0.14	 5.1E-04	 Y	 -0.03	 0.23	 N	 0	 0.50	 N	 0	 0.50	 N	
mir-548e	 0.08	 0.03	 Y	 0.03	 0.23	 N	 0	 0.50	 N	 0	 0.50	 N	
mir-483	 0.13	 9.6E-04	 Y	 -0.03	 0.24	 N	 0	 0.50	 N	 0	 0.50	 N	
mir-602	 -0.02	 0.32	 N	 -0.03	 0.24	 N	 0	 0.50	 N	 0	 0.50	 N	
mir-585	 -0.02	 0.31	 N	 0.03	 0.24	 N	 0	 0.50	 N	 0	 0.50	 N	
mir-939	 0.12	 2.5E-03	 Y	 -0.03	 0.24	 N	 0	 0.50	 N	 0	 0.50	 N	
mir-105-1	 -0.04	 0.17	 N	 0.03	 0.24	 N	 0	 0.50	 N	 0	 0.50	 N	
mir-1225	 0.05	 0.13	 N	 0.03	 0.24	 N	 0	 0.50	 N	 0	 0.50	 N	
mir-589	 0.04	 0.17	 N	 0.03	 0.25	 N	 0	 0.50	 N	 0	 0.50	 N	
mir-369	 -0.04	 0.15	 N	 0.03	 0.25	 N	 0	 0.50	 N	 0	 0.50	 N	
mir-518e	 -0.06	 0.08	 N	 0.03	 0.25	 N	 0	 0.50	 N	 0	 0.50	 N	
mir-597	 9.4E-04	 0.49	 N	 -0.03	 0.25	 N	 0	 0.50	 N	 0	 0.50	 N	
mir-539	 -0.08	 0.04	 Y	 -0.03	 0.26	 N	 0	 0.50	 N	 0	 0.50	 N	
mir-643	 0.08	 0.03	 Y	 -0.03	 0.26	 N	 0	 0.50	 N	 0	 0.50	 N	
mir-520h	 -0.02	 0.32	 N	 0.03	 0.26	 N	 0	 0.50	 N	 0	 0.50	 N	
mir-650	 -0.04	 0.19	 N	 -0.03	 0.26	 N	 0	 0.50	 N	 0	 0.50	 N	
mir-1274b	 0.12	 2.2E-03	 Y	 0.03	 0.26	 N	 0	 0.50	 N	 0	 0.50	 N	
mir-1256	 1.4E-03	 0.49	 N	 0.03	 0.27	 N	 0	 0.50	 N	 0	 0.50	 N	
mir-1274a	 0.13	 1.3E-03	 Y	 -0.03	 0.27	 N	 0	 0.50	 N	 0	 0.50	 N	
mir-448	 1.6E-03	 0.49	 N	 -0.03	 0.27	 N	 0	 0.50	 N	 0	 0.50	 N	
mir-515-1	 -0.10	 9.1E-03	 Y	 0.03	 0.27	 N	 0	 0.50	 N	 0	 0.50	 N	
mir-1306	 0.15	 2.7E-04	 Y	 0.03	 0.28	 N	 0	 0.50	 N	 0	 0.50	 N	
mir-659	 0.03	 0.26	 N	 -0.03	 0.28	 N	 0	 0.50	 N	 0	 0.50	 N	
mir-1185-1	 0.13	 1.6E-03	 Y	 -0.03	 0.28	 N	 0	 0.50	 N	 0	 0.50	 N	
mir-24-2	 -0.02	 0.34	 N	 0.02	 0.28	 N	 0	 0.50	 N	 0	 0.50	 N	
mir-665	 -0.13	 8.1E-04	 Y	 0.02	 0.28	 N	 0	 0.50	 N	 0	 0.50	 N	
mir-802	 0.06	 0.09	 N	 -0.02	 0.29	 N	 0	 0.50	 N	 0	 0.50	 N	
mir-1298	 0.03	 0.22	 N	 0.02	 0.29	 N	 0	 0.50	 N	 0	 0.50	 N	
mir-1257	 0.24	 1.0E-05	 Y	 -0.02	 0.30	 N	 0	 0.50	 N	 0	 0.50	 N	
mir-1265	 -0.13	 1.5E-03	 Y	 0.02	 0.30	 N	 0	 0.50	 N	 0	 0.50	 N	
mir-371	 7.6E-03	 0.43	 N	 -0.02	 0.30	 N	 0	 0.50	 N	 0	 0.50	 N	
mir-1236	 0.02	 0.33	 N	 0.02	 0.30	 N	 0	 0.50	 N	 0	 0.50	 N	
mir-653	 -0.27	 1.0E-05	 Y	 -0.02	 0.30	 N	 0	 0.50	 N	 0	 0.50	 N	
mir-548j	 -0.06	 0.07	 N	 0.02	 0.30	 N	 0	 0.50	 N	 0	 0.50	 N	
mir-637	 -0.05	 0.12	 N	 -0.02	 0.31	 N	 0	 0.50	 N	 0	 0.50	 N	
mir-1288	 0.05	 0.11	 N	 -0.02	 0.31	 N	 0	 0.50	 N	 0	 0.50	 N	
mir-1243	 0.05	 0.11	 N	 0.02	 0.32	 N	 0	 0.50	 N	 0	 0.50	 N	
let-7f-1	 0.06	 0.10	 N	 0.02	 0.32	 N	 0	 0.50	 N	 0	 0.50	 N	
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mir-1283-1	 -0.02	 0.31	 N	 0.02	 0.32	 N	 0	 0.50	 N	 0	 0.50	 N	
mir-16-2	 0.29	 1.0E-05	 Y	 -0.02	 0.33	 N	 0	 0.50	 N	 0	 0.50	 N	
mir-433	 -0.02	 0.36	 N	 -0.02	 0.33	 N	 0	 0.50	 N	 0	 0.50	 N	
mir-1538	 -0.01	 0.37	 N	 0.02	 0.33	 N	 0	 0.50	 N	 0	 0.50	 N	
mir-216a	 -0.34	 1.0E-05	 Y	 -0.02	 0.34	 N	 0	 0.50	 N	 0	 0.50	 N	
mir-1322	 -0.03	 0.22	 N	 -0.02	 0.34	 N	 0	 0.50	 N	 0	 0.50	 N	
mir-548a-3	 0.01	 0.38	 N	 -0.02	 0.35	 N	 0	 0.50	 N	 0	 0.50	 N	
mir-544	 -0.11	 3.8E-03	 Y	 -0.01	 0.36	 N	 0	 0.50	 N	 0	 0.50	 N	
mir-555	 0.08	 0.04	 Y	 -0.01	 0.37	 N	 0	 0.50	 N	 0	 0.50	 N	
mir-647	 0.15	 3.4E-04	 Y	 0.01	 0.37	 N	 0	 0.50	 N	 0	 0.50	 N	
mir-498	 0.14	 4.2E-04	 Y	 0.01	 0.37	 N	 0	 0.50	 N	 0	 0.50	 N	
mir-596	 0.05	 0.11	 N	 -0.01	 0.37	 N	 0	 0.50	 N	 0	 0.50	 N	
mir-1323	 0.06	 0.09	 N	 0.01	 0.37	 N	 0	 0.50	 N	 0	 0.50	 N	
mir-513a-1	 -0.03	 0.27	 N	 -0.01	 0.38	 N	 0	 0.50	 N	 0	 0.50	 N	
mir-629	 0.05	 0.12	 N	 0.01	 0.38	 N	 0	 0.50	 N	 0	 0.50	 N	
mir-524	 0.25	 1.0E-05	 Y	 -0.01	 0.38	 N	 0	 0.50	 N	 0	 0.50	 N	
mir-1278	 -0.01	 0.37	 N	 0.01	 0.39	 N	 0	 0.50	 N	 0	 0.50	 N	
mir-1262	 -0.09	 0.02	 Y	 -0.01	 0.40	 N	 0	 0.50	 N	 0	 0.50	 N	
mir-519b	 -0.05	 0.13	 N	 0.01	 0.41	 N	 0	 0.50	 N	 0	 0.50	 N	
mir-516b-1	 0.10	 0.01	 Y	 7.1E-03	 0.44	 N	 0	 0.50	 N	 0	 0.50	 N	
mir-624	 0.01	 0.39	 N	 7.1E-03	 0.44	 N	 0	 0.50	 N	 0	 0.50	 N	
mir-30c-1	 0.14	 4.2E-04	 Y	 -6.8E-03	 0.44	 N	 0	 0.50	 N	 0	 0.50	 N	
mir-1910	 0.16	 1.0E-04	 Y	 6.6E-03	 0.44	 N	 0	 0.50	 N	 0	 0.50	 N	
mir-595	 0.09	 0.02	 Y	 -5.7E-03	 0.45	 N	 0	 0.50	 N	 0	 0.50	 N	
mir-507	 0.01	 0.38	 N	 6.0E-03	 0.45	 N	 0	 0.50	 N	 0	 0.50	 N	
mir-548k	 0.02	 0.34	 N	 -4.8E-03	 0.45	 N	 0	 0.50	 N	 0	 0.50	 N	
mir-770	 0.10	 0.01	 Y	 -4.3E-03	 0.46	 N	 0	 0.50	 N	 0	 0.50	 N	
mir-16-1	 0.08	 0.03	 Y	 4.3E-03	 0.46	 N	 0	 0.50	 N	 0	 0.50	 N	
mir-548d-2	 0.18	 3.0E-05	 Y	 -3.5E-03	 0.47	 N	 0	 0.50	 N	 0	 0.50	 N	
mir-515-2	 -0.11	 4.4E-03	 Y	 -3.4E-03	 0.47	 N	 0	 0.50	 N	 0	 0.50	 N	
mir-105-2	 -0.09	 0.02	 Y	 3.1E-03	 0.47	 N	 0	 0.50	 N	 0	 0.50	 N	
mir-450a-2	 0.11	 6.8E-03	 Y	 -2.8E-03	 0.47	 N	 0	 0.50	 N	 0	 0.50	 N	
mir-153-1	 -0.15	 1.9E-04	 Y	 -1.9E-03	 0.48	 N	 0	 0.50	 N	 0	 0.50	 N	











Master list of miRNAs in TCGA breast cancer dataset together the correlation 
scores of their expression values with PR signatures and enrichment scores of 
target genes with PR signatures 
 
miRNA	 S(M,P)	 P-value	 BH	 S(M,R)	 P-value	 BH	 ES_P	 P-value	 BH	 ES_R	 P-value	 BH	
mir-501	 0.27	 1.0E-05	 Y	 0.20	 1.0E-05	 Y	 0.54	 1.0E-05	 Y	 -0.37	 1.0E-05	 Y	
mir-1914	 0.23	 1.0E-05	 Y	 -0.07	 0.03	 Y	 0.38	 1.0E-05	 Y	 -0.27	 1.0E-05	 Y	
mir-92a-1	 0.11	 7.0E-04	 Y	 -0.18	 1.0E-05	 Y	 0.32	 1.0E-05	 Y	 -0.25	 1.0E-05	 Y	
mir-432	 -0.46	 1.0E-05	 Y	 0.46	 1.0E-05	 Y	 0.39	 1.0E-05	 Y	 -0.25	 1.0E-05	 Y	
mir-497	 -0.32	 1.0E-05	 Y	 0.13	 2.2E-04	 Y	 0.04	 0.15	 N	 -0.23	 1.0E-05	 Y	
mir-362	 0.20	 1.0E-05	 Y	 0.05	 0.07	 N	 0.44	 1.0E-05	 Y	 -0.22	 1.0E-05	 Y	
mir-671	 0.13	 1.5E-04	 Y	 -0.09	 4.5E-03	 Y	 0.11	 1.4E-03	 Y	 -0.21	 1.0E-05	 Y	
mir-500a	 0.16	 1.0E-05	 Y	 0.24	 1.0E-05	 Y	 0.31	 1.0E-05	 Y	 -0.17	 1.0E-05	 Y	
mir-193a	 -0.13	 1.9E-04	 Y	 0.08	 0.01	 Y	 0.13	 1.4E-04	 Y	 -0.17	 1.0E-05	 Y	
mir-548b	 0.33	 1.0E-05	 Y	 -0.03	 0.21	 N	 -0.09	 6.2E-03	 Y	 -0.17	 1.0E-05	 Y	
mir-328	 0.06	 0.05	 N	 5.9E-03	 0.44	 N	 0.20	 1.0E-05	 Y	 -0.17	 1.0E-05	 Y	
mir-503	 -0.09	 7.4E-03	 Y	 0.24	 1.0E-05	 Y	 0.25	 1.0E-05	 Y	 -0.17	 1.0E-05	 Y	
mir-19a	 0.32	 1.0E-05	 Y	 -0.05	 0.08	 N	 -0.22	 1.0E-05	 Y	 0.15	 1.0E-05	 Y	
mir-372	 -0.19	 1.0E-05	 Y	 0.19	 1.0E-05	 Y	 -0.37	 1.0E-05	 Y	 0.16	 1.0E-05	 Y	
mir-335	 -0.02	 0.28	 N	 0.15	 2.0E-05	 Y	 -0.14	 9.0E-05	 Y	 0.16	 1.0E-05	 Y	
mir-1307	 0.47	 1.0E-05	 Y	 -0.16	 3.0E-05	 Y	 0.26	 1.0E-05	 Y	 0.17	 1.0E-05	 Y	
mir-124-2	 0.01	 0.36	 N	 -0.07	 0.03	 Y	 -0.06	 0.06	 N	 0.18	 1.0E-05	 Y	
mir-124-1	 0.03	 0.21	 N	 -0.03	 0.24	 N	 -0.06	 0.06	 N	 0.18	 1.0E-05	 Y	
mir-124-3	 0.04	 0.12	 N	 -0.08	 0.02	 Y	 -0.06	 0.06	 N	 0.18	 1.0E-05	 Y	
mir-20b	 0.07	 0.03	 Y	 -0.03	 0.20	 N	 -0.16	 3.0E-05	 Y	 0.19	 1.0E-05	 Y	
mir-133b	 -0.11	 1.3E-03	 Y	 0.24	 1.0E-05	 Y	 -0.12	 4.1E-04	 Y	 0.19	 1.0E-05	 Y	
mir-205	 -0.25	 1.0E-05	 Y	 0.01	 0.34	 N	 -0.06	 0.05	 N	 0.21	 1.0E-05	 Y	
mir-203	 0.02	 0.25	 N	 -0.03	 0.22	 N	 0.04	 0.11	 N	 0.21	 1.0E-05	 Y	
mir-29b-1	 -0.15	 3.0E-05	 Y	 -0.06	 0.05	 N	 0.06	 0.05	 N	 0.21	 1.0E-05	 Y	
mir-302a	 0.01	 0.36	 N	 -0.08	 0.01	 Y	 -0.34	 1.0E-05	 Y	 0.22	 1.0E-05	 Y	
mir-199a-1	 -0.46	 1.0E-05	 Y	 0.46	 1.0E-05	 Y	 -0.18	 1.0E-05	 Y	 0.22	 1.0E-05	 Y	
mir-199a-2	 -0.44	 1.0E-05	 Y	 0.46	 1.0E-05	 Y	 -0.18	 1.0E-05	 Y	 0.22	 1.0E-05	 Y	
mir-224	 0.13	 1.3E-04	 Y	 0.35	 1.0E-05	 Y	 -0.02	 0.27	 N	 0.24	 1.0E-05	 Y	
mir-141	 0.09	 5.9E-03	 Y	 -0.32	 1.0E-05	 Y	 0.04	 0.11	 N	 0.24	 1.0E-05	 Y	
mir-200b	 -0.02	 0.28	 N	 -0.18	 1.0E-05	 Y	 -0.03	 0.20	 N	 0.26	 1.0E-05	 Y	
mir-150	 -0.04	 0.13	 N	 0.51	 1.0E-05	 Y	 -0.19	 1.0E-05	 Y	 0.26	 1.0E-05	 Y	
mir-204	 -0.30	 1.0E-05	 Y	 0.37	 1.0E-05	 Y	 -0.08	 9.9E-03	 Y	 0.27	 1.0E-05	 Y	
mir-200c	 0.11	 6.4E-04	 Y	 -0.30	 1.0E-05	 Y	 -0.14	 6.0E-05	 Y	 0.28	 1.0E-05	 Y	
mir-133a-2	 -0.07	 0.03	 Y	 0.19	 1.0E-05	 Y	 -0.11	 1.4E-03	 Y	 0.29	 1.0E-05	 Y	
mir-133a-1	 -0.27	 1.0E-05	 Y	 0.26	 1.0E-05	 Y	 -0.11	 1.4E-03	 Y	 0.29	 1.0E-05	 Y	
mir-146a	 0.05	 0.09	 N	 0.40	 1.0E-05	 Y	 0.04	 0.13	 N	 0.30	 1.0E-05	 Y	
mir-200a	 -3.8E-03	 0.46	 N	 -0.06	 0.05	 N	 -0.05	 0.10	 N	 0.31	 1.0E-05	 Y	
mir-137	 0.06	 0.04	 Y	 0.14	 9.0E-05	 Y	 0.19	 1.0E-05	 Y	 0.34	 1.0E-05	 Y	
mir-146b	 -0.01	 0.37	 N	 0.45	 1.0E-05	 Y	 -0.24	 1.0E-05	 Y	 0.35	 1.0E-05	 Y	
mir-130a	 -0.13	 2.3E-04	 Y	 0.21	 1.0E-05	 Y	 -0.34	 1.0E-05	 Y	 0.36	 1.0E-05	 Y	
mir-429	 0.09	 4.4E-03	 Y	 -0.10	 2.0E-03	 Y	 -0.13	 3.0E-04	 Y	 0.39	 1.0E-05	 Y	
mir-338	 -0.09	 4.6E-03	 Y	 -1.1E-04	 0.50	 N	 -0.39	 1.0E-05	 Y	 0.39	 1.0E-05	 Y	
mir-935	 -6.9E-03	 0.42	 N	 -0.01	 0.38	 N	 0.18	 1.0E-05	 Y	 -0.16	 2.0E-05	 Y	
mir-365-1	 -0.15	 3.0E-05	 Y	 -0.08	 0.01	 Y	 0.16	 1.0E-05	 Y	 -0.16	 3.0E-05	 Y	
mir-365-2	 -0.15	 3.0E-05	 Y	 -0.07	 0.03	 Y	 0.16	 1.0E-05	 Y	 -0.16	 3.0E-05	 Y	
mir-191	 -0.06	 0.06	 N	 -0.22	 1.0E-05	 Y	 0.26	 1.0E-05	 Y	 -0.15	 3.0E-05	 Y	
mir-30c-2	 -0.30	 1.0E-05	 Y	 -0.02	 0.26	 N	 0.28	 1.0E-05	 Y	 -0.14	 5.0E-05	 Y	
mir-346	 -0.08	 9.4E-03	 Y	 0.12	 4.0E-04	 Y	 -0.03	 0.21	 N	 0.14	 7.0E-05	 Y	
mir-148b	 -0.17	 1.0E-05	 Y	 -0.09	 7.0E-03	 Y	 -0.02	 0.33	 N	 0.14	 9.0E-05	 Y	
mir-425	 0.02	 0.26	 N	 -6.2E-03	 0.43	 N	 0.17	 1.0E-05	 Y	 -0.14	 1.5E-04	 Y	
mir-3200	 0.42	 1.0E-05	 Y	 -0.10	 3.9E-03	 Y	 0.22	 1.0E-05	 Y	 -0.13	 1.6E-04	 Y	
mir-1260b	 0.13	 1.4E-04	 Y	 -0.20	 1.0E-05	 Y	 0.18	 1.0E-05	 Y	 -0.13	 1.9E-04	 Y	
mir-217	 -0.21	 1.0E-05	 Y	 0.14	 7.0E-05	 Y	 -0.20	 1.0E-05	 Y	 -0.13	 2.3E-04	 Y	
let-7i	 -0.14	 1.0E-04	 Y	 0.35	 1.0E-05	 Y	 0.15	 3.0E-05	 Y	 0.13	 2.4E-04	 Y	
mir-766	 0.08	 0.02	 Y	 0.24	 1.0E-05	 Y	 0.24	 1.0E-05	 Y	 -0.13	 2.5E-04	 Y	
mir-145	 -0.35	 1.0E-05	 Y	 0.36	 1.0E-05	 Y	 0.08	 0.02	 Y	 0.12	 2.9E-04	 Y	
let-7c	 -0.49	 1.0E-05	 Y	 0.46	 1.0E-05	 Y	 0.15	 1.0E-05	 Y	 -0.13	 3.0E-04	 Y	
mir-19b-2	 0.14	 5.0E-05	 Y	 -0.13	 2.8E-04	 Y	 -0.04	 0.14	 N	 0.12	 3.1E-04	 Y	
mir-339	 -0.03	 0.23	 N	 -0.04	 0.17	 N	 0.11	 1.1E-03	 Y	 -0.12	 3.9E-04	 Y	
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mir-34b	 -0.27	 1.0E-05	 Y	 0.20	 1.0E-05	 Y	 0.03	 0.21	 N	 0.12	 4.0E-04	 Y	
mir-99b	 0.11	 1.6E-03	 Y	 -0.04	 0.14	 N	 0.16	 1.0E-05	 Y	 -0.12	 4.1E-04	 Y	
mir-1229	 0.33	 1.0E-05	 Y	 -0.11	 8.9E-04	 Y	 0.18	 1.0E-05	 Y	 -0.12	 5.9E-04	 Y	
mir-194-2	 -0.08	 0.02	 Y	 8.7E-03	 0.41	 N	 -0.30	 1.0E-05	 Y	 0.11	 6.8E-04	 Y	
mir-194-1	 -0.08	 0.01	 Y	 -4.7E-03	 0.45	 N	 -0.30	 1.0E-05	 Y	 0.11	 6.8E-04	 Y	
mir-33a	 0.30	 1.0E-05	 Y	 -0.05	 0.07	 N	 -5.6E-
03	
0.44	 N	 0.11	 7.1E-04	 Y	
mir-196b	 -0.25	 1.0E-05	 Y	 0.35	 1.0E-05	 Y	 0.14	 6.0E-05	 Y	 -0.11	 8.4E-04	 Y	
mir-99a	 -0.49	 1.0E-05	 Y	 0.44	 1.0E-05	 Y	 0.14	 6.0E-05	 Y	 -0.11	 9.6E-04	 Y	
mir-361	 -0.16	 3.0E-05	 Y	 0.18	 1.0E-05	 Y	 0.22	 1.0E-05	 Y	 -0.11	 1.1E-03	 Y	
mir-128-1	 0.14	 9.0E-05	 Y	 0.06	 0.05	 N	 0.04	 0.16	 N	 0.11	 1.2E-03	 Y	
mir-940	 0.29	 1.0E-05	 Y	 -0.07	 0.02	 Y	 0.19	 1.0E-05	 Y	 0.11	 1.3E-03	 Y	
mir-193b	 4.0E-03	 0.46	 N	 -0.07	 0.03	 Y	 0.26	 1.0E-05	 Y	 -0.11	 1.4E-03	 Y	
mir-301a	 0.51	 1.0E-05	 Y	 -0.14	 6.0E-05	 Y	 0.13	 2.4E-04	 Y	 0.11	 1.6E-03	 Y	
mir-92b	 -0.02	 0.28	 N	 -2.4E-03	 0.47	 N	 0.16	 1.0E-05	 Y	 -0.11	 1.8E-03	 Y	
mir-223	 -0.13	 2.1E-04	 Y	 0.46	 1.0E-05	 Y	 -0.13	 2.5E-04	 Y	 0.10	 1.9E-03	 Y	
mir-449a	 -0.31	 1.0E-05	 Y	 5.3E-03	 0.44	 N	 0.25	 1.0E-05	 Y	 -0.10	 1.9E-03	 Y	
mir-760	 0.17	 1.0E-05	 Y	 -0.28	 1.0E-05	 Y	 0.15	 3.0E-05	 Y	 -0.10	 2.0E-03	 Y	
mir-211	 -0.22	 1.0E-05	 Y	 0.18	 1.0E-05	 Y	 -0.06	 0.05	 N	 0.10	 2.4E-03	 Y	
mir-25	 0.21	 1.0E-05	 Y	 0.02	 0.29	 N	 0.13	 1.0E-04	 Y	 -0.09	 4.9E-03	 Y	
mir-423	 0.07	 0.03	 Y	 -0.14	 1.5E-04	 Y	 0.13	 1.7E-04	 Y	 -0.09	 5.0E-03	 Y	
mir-484	 0.10	 3.0E-03	 Y	 -0.13	 1.9E-04	 Y	 0.15	 4.0E-05	 Y	 -0.09	 5.1E-03	 Y	
mir-98	 0.11	 1.0E-03	 Y	 -0.02	 0.30	 N	 0.13	 1.7E-04	 Y	 0.09	 5.1E-03	 Y	
mir-197	 0.24	 1.0E-05	 Y	 0.11	 1.6E-03	 Y	 0.10	 1.8E-03	 Y	 -0.09	 5.8E-03	 Y	
mir-215	 7.2E-03	 0.42	 N	 0.23	 1.0E-05	 Y	 0.21	 1.0E-05	 Y	 -0.09	 5.9E-03	 Y	
mir-1226	 0.30	 1.0E-05	 Y	 -0.07	 0.02	 Y	 0.11	 1.3E-03	 Y	 -0.09	 6.1E-03	 Y	
mir-769	 0.12	 4.2E-04	 Y	 -0.08	 0.01	 Y	 0.15	 1.0E-05	 Y	 -0.09	 6.4E-03	 Y	
let-7b	 -0.40	 1.0E-05	 Y	 0.05	 0.11	 N	 0.16	 1.0E-05	 Y	 -0.09	 7.3E-03	 Y	
mir-625	 -0.18	 1.0E-05	 Y	 0.06	 0.05	 N	 -0.12	 4.1E-04	 Y	 -0.09	 8.2E-03	 Y	
mir-505	 0.27	 1.0E-05	 Y	 0.15	 1.0E-05	 Y	 0.23	 1.0E-05	 Y	 -0.09	 8.8E-03	 Y	
mir-132	 -0.15	 3.0E-05	 Y	 0.15	 3.0E-05	 Y	 0.02	 0.29	 N	 0.09	 9.1E-03	 Y	
mir-615	 0.16	 1.0E-05	 Y	 -0.14	 7.0E-05	 Y	 0.19	 1.0E-05	 Y	 -0.09	 9.2E-03	 Y	
mir-532	 0.15	 1.0E-05	 Y	 0.22	 1.0E-05	 Y	 0.18	 1.0E-05	 Y	 -0.09	 9.2E-03	 Y	
mir-96	 0.02	 0.28	 N	 -0.23	 1.0E-05	 Y	 0.13	 1.1E-04	 Y	 -0.08	 0.01	 Y	
mir-222	 -0.10	 3.6E-03	 Y	 0.31	 1.0E-05	 Y	 0.17	 1.0E-05	 Y	 -0.08	 0.01	 Y	
mir-130b	 0.36	 1.0E-05	 Y	 0.02	 0.26	 N	 -2.8E-
03	
0.47	 N	 0.08	 0.01	 Y	
mir-320c-1	 -0.06	 0.06	 N	 -0.07	 0.04	 Y	 0.25	 1.0E-05	 Y	 0.08	 0.01	 Y	
mir-320c-2	 -0.09	 9.2E-03	 Y	 -0.03	 0.19	 N	 0.25	 1.0E-05	 Y	 0.08	 0.01	 Y	
mir-181b-2	 0.07	 0.03	 Y	 0.08	 0.01	 Y	 0.14	 7.0E-05	 Y	 -0.08	 0.01	 Y	
mir-181b-1	 -0.01	 0.37	 N	 0.06	 0.05	 N	 0.14	 7.0E-05	 Y	 -0.08	 0.01	 Y	
mir-331	 0.06	 0.05	 N	 -0.06	 0.05	 N	 0.10	 2.8E-03	 Y	 -0.08	 0.01	 Y	
mir-296	 -0.24	 1.0E-05	 Y	 0.14	 5.0E-05	 Y	 0.07	 0.03	 N	 -0.08	 0.01	 Y	
mir-324	 0.19	 1.0E-05	 Y	 -0.07	 0.02	 Y	 0.13	 1.4E-04	 Y	 -0.08	 0.01	 Y	
mir-877	 0.41	 1.0E-05	 Y	 -0.04	 0.12	 N	 0.17	 1.0E-05	 Y	 -0.08	 0.02	 Y	
mir-142	 0.08	 0.02	 Y	 0.41	 1.0E-05	 Y	 -0.05	 0.06	 N	 0.08	 0.02	 Y	
mir-373	 0.08	 0.02	 Y	 0.09	 4.1E-03	 Y	 0.11	 6.2E-04	 Y	 -0.07	 0.02	 Y	
mir-92a-2	 0.16	 1.0E-05	 Y	 -0.07	 0.03	 Y	 0.14	 1.0E-04	 Y	 -0.07	 0.02	 Y	
mir-186	 0.16	 1.0E-05	 Y	 0.04	 0.13	 N	 0.13	 2.2E-04	 Y	 -0.07	 0.02	 Y	
mir-32	 0.06	 0.06	 N	 0.08	 0.01	 Y	 0.14	 9.0E-05	 Y	 -0.07	 0.02	 Y	
mir-138-2	 0.06	 0.04	 Y	 0.25	 1.0E-05	 Y	 -0.07	 0.03	 N	 0.07	 0.02	 Y	
mir-138-1	 -0.07	 0.02	 Y	 0.25	 1.0E-05	 Y	 -0.07	 0.03	 N	 0.07	 0.02	 Y	
mir-31	 -0.22	 1.0E-05	 Y	 0.36	 1.0E-05	 Y	 0.12	 2.9E-04	 Y	 0.07	 0.02	 Y	
mir-1296	 0.05	 0.07	 N	 0.03	 0.20	 N	 0.15	 2.0E-05	 Y	 -0.07	 0.03	 Y	
mir-192	 0.12	 6.1E-04	 Y	 -0.06	 0.04	 Y	 0.16	 1.0E-05	 Y	 -0.07	 0.03	 Y	
mir-26b	 -0.28	 1.0E-05	 Y	 0.07	 0.03	 Y	 0.03	 0.24	 N	 0.07	 0.03	 Y	
mir-345	 0.18	 1.0E-05	 Y	 -0.01	 0.35	 N	 0.17	 1.0E-05	 Y	 -0.07	 0.03	 Y	
mir-18a	 0.49	 1.0E-05	 Y	 7.0E-03	 0.43	 N	 0.09	 4.7E-03	 Y	 -0.07	 0.03	 Y	
mir-210	 0.37	 1.0E-05	 Y	 -0.20	 1.0E-05	 Y	 0.08	 0.01	 Y	 -0.07	 0.03	 Y	
mir-106a	 0.19	 1.0E-05	 Y	 0.01	 0.34	 N	 0.16	 1.0E-05	 Y	 0.07	 0.03	 Y	
let-7e	 -0.14	 1.3E-04	 Y	 -0.09	 4.4E-03	 Y	 0.11	 1.5E-03	 Y	 -0.07	 0.03	 N	
mir-181d	 -0.21	 1.0E-05	 Y	 -0.09	 4.7E-03	 Y	 0.16	 1.0E-05	 Y	 -0.06	 0.04	 N	
mir-151	 0.08	 0.01	 Y	 -0.04	 0.13	 N	 0.15	 5.0E-05	 Y	 -0.06	 0.04	 N	
mir-1301	 0.38	 1.0E-05	 Y	 -0.10	 2.6E-03	 Y	 0.17	 1.0E-05	 Y	 -0.06	 0.05	 N	
mir-20a	 0.29	 1.0E-05	 Y	 -0.12	 6.2E-04	 Y	 0.11	 8.0E-04	 Y	 -0.06	 0.05	 N	
mir-183	 0.11	 8.2E-04	 Y	 -0.14	 5.0E-05	 Y	 0.13	 1.7E-04	 Y	 -0.06	 0.05	 N	
mir-149	 -0.07	 0.03	 Y	 -0.17	 1.0E-05	 Y	 0.15	 1.0E-05	 Y	 -0.06	 0.05	 N	
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mir-454	 0.38	 1.0E-05	 Y	 -0.24	 1.0E-05	 Y	 0.15	 3.0E-05	 Y	 -0.06	 0.05	 N	
mir-195	 -0.39	 1.0E-05	 Y	 0.16	 1.0E-05	 Y	 0.18	 1.0E-05	 Y	 0.06	 0.05	 N	
mir-10a	 -0.34	 1.0E-05	 Y	 0.06	 0.06	 N	 0.09	 6.9E-03	 Y	 -0.06	 0.05	 N	
mir-376a-2	 -0.24	 1.0E-05	 Y	 0.24	 1.0E-05	 Y	 0.11	 1.2E-03	 Y	 0.06	 0.06	 N	
mir-376a-1	 -0.31	 1.0E-05	 Y	 0.30	 1.0E-05	 Y	 0.11	 1.2E-03	 Y	 0.06	 0.06	 N	
mir-106b	 0.30	 1.0E-05	 Y	 0.05	 0.09	 N	 0.12	 5.3E-04	 Y	 -0.06	 0.06	 N	
mir-744	 0.07	 0.02	 Y	 -0.12	 5.7E-04	 Y	 0.10	 3.1E-03	 Y	 -0.06	 0.06	 N	
mir-22	 -0.33	 1.0E-05	 Y	 0.39	 1.0E-05	 Y	 0.13	 1.0E-04	 Y	 -0.05	 0.07	 N	
mir-125a	 -0.20	 1.0E-05	 Y	 -0.08	 0.01	 Y	 0.15	 3.0E-05	 Y	 -0.05	 0.07	 N	
mir-126	 -0.19	 1.0E-05	 Y	 0.25	 1.0E-05	 Y	 0.13	 1.7E-04	 Y	 -0.05	 0.07	 N	
mir-190	 -0.26	 1.0E-05	 Y	 0.08	 0.02	 Y	 0.14	 5.0E-05	 Y	 0.05	 0.07	 N	
mir-18b	 0.27	 1.0E-05	 Y	 0.05	 0.08	 N	 0.06	 0.05	 N	 -0.05	 0.07	 N	
mir-342	 -0.28	 1.0E-05	 Y	 -0.08	 0.01	 Y	 0.12	 2.6E-04	 Y	 -0.05	 0.10	 N	
let-7d	 0.13	 1.7E-04	 Y	 0.09	 6.0E-03	 Y	 0.16	 1.0E-05	 Y	 -0.05	 0.10	 N	
mir-941-1	 0.15	 4.0E-05	 Y	 -0.14	 1.3E-04	 Y	 0.27	 1.0E-05	 Y	 0.05	 0.10	 N	
mir-93	 0.41	 1.0E-05	 Y	 -0.17	 1.0E-05	 Y	 0.11	 1.6E-03	 Y	 -0.05	 0.11	 N	
mir-504	 0.03	 0.22	 N	 0.13	 1.4E-04	 Y	 -0.11	 1.4E-03	 Y	 0.04	 0.11	 N	
mir-125b-1	 -0.49	 1.0E-05	 Y	 0.41	 1.0E-05	 Y	 0.11	 1.0E-03	 Y	 -0.04	 0.11	 N	
mir-185	 0.10	 3.8E-03	 Y	 0.06	 0.06	 N	 0.09	 5.4E-03	 Y	 -0.04	 0.11	 N	
mir-30e	 -0.17	 1.0E-05	 Y	 0.23	 1.0E-05	 Y	 0.12	 2.9E-04	 Y	 -0.04	 0.12	 N	
mir-26a-1	 -0.24	 1.0E-05	 Y	 0.15	 1.0E-05	 Y	 0.13	 1.9E-04	 Y	 -0.04	 0.13	 N	
mir-326	 3.7E-03	 0.46	 N	 0.23	 1.0E-05	 Y	 0.08	 0.02	 N	 -0.04	 0.13	 N	
let-7a-1	 -0.36	 1.0E-05	 Y	 -0.04	 0.16	 N	 0.12	 4.0E-04	 Y	 -0.04	 0.13	 N	
let-7a-2	 -0.36	 1.0E-05	 Y	 -0.03	 0.18	 N	 0.12	 4.0E-04	 Y	 -0.04	 0.13	 N	
mir-196a-2	 0.12	 5.7E-04	 Y	 -0.20	 1.0E-05	 Y	 0.15	 4.0E-05	 Y	 -0.04	 0.13	 N	
mir-196a-1	 0.05	 0.09	 N	 -0.15	 3.0E-05	 Y	 0.15	 4.0E-05	 Y	 -0.04	 0.13	 N	
mir-23a	 -0.10	 3.2E-03	 Y	 0.22	 1.0E-05	 Y	 0.15	 1.0E-05	 Y	 0.04	 0.14	 N	
mir-28	 -0.16	 2.0E-05	 Y	 0.24	 1.0E-05	 Y	 0.17	 1.0E-05	 Y	 0.04	 0.14	 N	
mir-103-2	 0.24	 1.0E-05	 Y	 0.04	 0.13	 N	 0.10	 3.2E-03	 Y	 0.04	 0.15	 N	
mir-455	 0.09	 4.3E-03	 Y	 0.22	 1.0E-05	 Y	 0.15	 1.0E-05	 Y	 -0.04	 0.16	 N	
mir-605	 -0.13	 1.6E-04	 Y	 0.16	 1.0E-05	 Y	 0.18	 1.0E-05	 Y	 -0.04	 0.17	 N	
mir-330	 0.12	 5.4E-04	 Y	 0.03	 0.24	 N	 0.14	 5.0E-05	 Y	 0.03	 0.17	 N	
mir-7-3	 0.28	 1.0E-05	 Y	 -0.12	 6.0E-04	 Y	 0.09	 5.0E-03	 Y	 -0.03	 0.17	 N	
mir-7-2	 0.14	 5.0E-05	 Y	 -0.12	 6.1E-04	 Y	 0.09	 5.0E-03	 Y	 -0.03	 0.17	 N	
mir-598	 -0.17	 1.0E-05	 Y	 0.22	 1.0E-05	 Y	 0.33	 1.0E-05	 Y	 -0.03	 0.18	 N	
let-7g	 -0.15	 3.0E-05	 Y	 0.05	 0.08	 N	 0.04	 0.16	 N	 0.03	 0.19	 N	
mir-15a	 0.02	 0.31	 N	 -0.02	 0.26	 N	 0.06	 0.06	 N	 -0.03	 0.20	 N	
mir-34a	 -0.20	 1.0E-05	 Y	 0.11	 9.3E-04	 Y	 0.21	 1.0E-05	 Y	 -0.03	 0.20	 N	
mir-302d	 -0.05	 0.06	 N	 -0.07	 0.02	 Y	 -0.28	 1.0E-05	 Y	 0.03	 0.20	 N	
mir-218-2	 -0.38	 1.0E-05	 Y	 0.36	 1.0E-05	 Y	 -0.06	 0.04	 N	 -0.03	 0.22	 N	
mir-374b	 -0.06	 0.06	 N	 0.16	 1.0E-05	 Y	 -0.10	 3.0E-03	 Y	 0.03	 0.23	 N	
mir-10b	 -0.43	 1.0E-05	 Y	 0.26	 1.0E-05	 Y	 0.11	 1.6E-03	 Y	 0.03	 0.24	 N	
mir-100	 -0.45	 1.0E-05	 Y	 0.42	 1.0E-05	 Y	 0.13	 1.3E-04	 Y	 -0.03	 0.24	 N	
mir-122	 0.11	 1.2E-03	 Y	 -0.02	 0.31	 N	 0.10	 3.6E-03	 Y	 -0.02	 0.28	 N	
mir-30b	 -0.13	 1.8E-04	 Y	 -0.08	 0.02	 Y	 0.11	 6.2E-04	 Y	 0.02	 0.29	 N	
mir-874	 -0.24	 1.0E-05	 Y	 0.06	 0.04	 Y	 0.49	 1.0E-05	 Y	 -0.02	 0.29	 N	
mir-1-2	 -0.25	 1.0E-05	 Y	 0.24	 1.0E-05	 Y	 0.10	 3.3E-03	 Y	 0.02	 0.30	 N	
mir-1-1	 -0.03	 0.23	 N	 0.09	 7.5E-03	 Y	 0.10	 3.3E-03	 Y	 0.02	 0.30	 N	
mir-424	 -0.17	 1.0E-05	 Y	 0.28	 1.0E-05	 Y	 0.22	 1.0E-05	 Y	 -0.02	 0.30	 N	
mir-101-1	 -0.34	 1.0E-05	 Y	 0.12	 5.6E-04	 Y	 0.12	 3.4E-04	 Y	 0.02	 0.30	 N	
mir-101-2	 -0.19	 1.0E-05	 Y	 0.10	 3.0E-03	 Y	 0.12	 3.4E-04	 Y	 0.02	 0.30	 N	
mir-708	 -0.27	 1.0E-05	 Y	 0.25	 1.0E-05	 Y	 0.23	 1.0E-05	 Y	 -0.02	 0.31	 N	
mir-652	 -0.02	 0.26	 N	 0.11	 1.4E-03	 Y	 0.21	 1.0E-05	 Y	 0.02	 0.33	 N	
mir-421	 0.23	 1.0E-05	 Y	 0.12	 5.3E-04	 Y	 0.13	 1.9E-04	 Y	 -0.02	 0.33	 N	
mir-9-1	 0.35	 1.0E-05	 Y	 0.02	 0.30	 N	 0.11	 8.0E-04	 Y	 -0.01	 0.35	 N	
mir-9-2	 0.36	 1.0E-05	 Y	 0.02	 0.31	 N	 0.11	 8.0E-04	 Y	 -0.01	 0.35	 N	
mir-1303	 0.08	 0.01	 Y	 -0.10	 2.3E-03	 Y	 0.13	 2.2E-04	 Y	 0.01	 0.35	 N	
mir-3176	 0.36	 1.0E-05	 Y	 -0.05	 0.09	 N	 0.36	 1.0E-05	 Y	 -0.01	 0.35	 N	
mir-1227	 0.12	 5.4E-04	 Y	 0.07	 0.02	 Y	 0.39	 1.0E-05	 Y	 -0.01	 0.36	 N	
mir-17	 0.37	 1.0E-05	 Y	 -0.09	 5.6E-03	 Y	 0.08	 0.01	 Y	 0.01	 0.38	 N	
mir-23b	 -0.16	 1.0E-05	 Y	 0.17	 1.0E-05	 Y	 0.13	 1.0E-04	 Y	 -0.01	 0.39	 N	
mir-21	 -0.14	 1.5E-04	 Y	 0.20	 1.0E-05	 Y	 0.13	 1.9E-04	 Y	 -9.9E-03	 0.39	 N	
mir-590	 0.27	 1.0E-05	 Y	 0.05	 0.06	 N	 0.18	 1.0E-05	 Y	 -9.3E-03	 0.40	 N	
mir-214	 -0.45	 1.0E-05	 Y	 0.42	 1.0E-05	 Y	 -0.05	 0.09	 N	 8.6E-03	 0.41	 N	
mir-148a	 -0.24	 1.0E-05	 Y	 0.11	 9.6E-04	 Y	 0.07	 0.02	 N	 -8.0E-03	 0.41	 N	
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mir-155	 0.03	 0.18	 N	 0.39	 1.0E-05	 Y	 0.13	 2.4E-04	 Y	 2.8E-03	 0.47	 N	
mir-182	 -0.14	 1.3E-04	 Y	 -0.14	 7.0E-05	 Y	 -2.4E-
03	
0.47	 N	 2.6E-03	 0.47	 N	
mir-374a	 -0.13	 1.9E-04	 Y	 0.24	 1.0E-05	 Y	 0.05	 0.10	 N	 -6.1E-04	 0.49	 N	
mir-1252	 0.23	 1.0E-05	 Y	 -0.29	 1.0E-05	 Y	 0	 0.50	 N	 0	 0.50	 N	
mir-1254	 0.42	 1.0E-05	 Y	 -0.24	 1.0E-05	 Y	 0	 0.50	 N	 0	 0.50	 N	
mir-33b	 0.12	 4.0E-04	 Y	 -0.22	 1.0E-05	 Y	 0	 0.50	 N	 0	 0.50	 N	
mir-190b	 -0.35	 1.0E-05	 Y	 -0.22	 1.0E-05	 Y	 0	 0.50	 N	 0	 0.50	 N	
mir-3127	 0.35	 1.0E-05	 Y	 -0.21	 1.0E-05	 Y	 0	 0.50	 N	 0	 0.50	 N	
mir-499	 0.05	 0.08	 N	 -0.19	 1.0E-05	 Y	 0	 0.50	 N	 0	 0.50	 N	
mir-219-2	 0.03	 0.21	 N	 -0.19	 1.0E-05	 Y	 0	 0.50	 N	 0	 0.50	 N	
mir-3180-4	 0.13	 1.7E-04	 Y	 -0.18	 1.0E-05	 Y	 0	 0.50	 N	 0	 0.50	 N	
mir-3619	 0.36	 1.0E-05	 Y	 -0.18	 1.0E-05	 Y	 0	 0.50	 N	 0	 0.50	 N	
mir-641	 0.18	 1.0E-05	 Y	 -0.17	 1.0E-05	 Y	 0	 0.50	 N	 0	 0.50	 N	
mir-1224	 0.07	 0.02	 Y	 -0.17	 1.0E-05	 Y	 0	 0.50	 N	 0	 0.50	 N	
mir-592	 -4.2E-03	 0.45	 N	 -0.17	 1.0E-05	 Y	 0	 0.50	 N	 0	 0.50	 N	
mir-1251	 -2.0E-03	 0.48	 N	 -0.16	 1.0E-05	 Y	 0	 0.50	 N	 0	 0.50	 N	
mir-670	 0.11	 6.4E-04	 Y	 -0.16	 1.0E-05	 Y	 0	 0.50	 N	 0	 0.50	 N	
mir-3132	 0.21	 1.0E-05	 Y	 -0.16	 1.0E-05	 Y	 0	 0.50	 N	 0	 0.50	 N	
mir-520b	 0.06	 0.05	 N	 0.15	 1.0E-05	 Y	 0	 0.50	 N	 0	 0.50	 N	
mir-24-1	 -0.13	 2.5E-04	 Y	 0.15	 1.0E-05	 Y	 0	 0.50	 N	 0	 0.50	 N	
mir-548s	 0.14	 7.0E-05	 Y	 0.16	 1.0E-05	 Y	 0	 0.50	 N	 0	 0.50	 N	
mir-1323	 9.8E-03	 0.40	 N	 0.16	 1.0E-05	 Y	 0	 0.50	 N	 0	 0.50	 N	
mir-3150b	 0.20	 1.0E-05	 Y	 0.16	 1.0E-05	 Y	 0	 0.50	 N	 0	 0.50	 N	
mir-202	 -0.32	 1.0E-05	 Y	 0.16	 1.0E-05	 Y	 0	 0.50	 N	 0	 0.50	 N	
mir-516a-1	 0.11	 1.3E-03	 Y	 0.16	 1.0E-05	 Y	 0	 0.50	 N	 0	 0.50	 N	
mir-520a	 -0.06	 0.05	 N	 0.16	 1.0E-05	 Y	 0	 0.50	 N	 0	 0.50	 N	
mir-551a	 0.03	 0.20	 N	 0.16	 1.0E-05	 Y	 0	 0.50	 N	 0	 0.50	 N	
mir-585	 -0.22	 1.0E-05	 Y	 0.16	 1.0E-05	 Y	 0	 0.50	 N	 0	 0.50	 N	
mir-1537	 0.11	 1.3E-03	 Y	 0.16	 1.0E-05	 Y	 0	 0.50	 N	 0	 0.50	 N	
mir-892a	 0.06	 0.05	 N	 0.17	 1.0E-05	 Y	 0	 0.50	 N	 0	 0.50	 N	
mir-545	 0.18	 1.0E-05	 Y	 0.17	 1.0E-05	 Y	 0	 0.50	 N	 0	 0.50	 N	
mir-1468	 0.02	 0.29	 N	 0.17	 1.0E-05	 Y	 0	 0.50	 N	 0	 0.50	 N	
mir-3926-2	 -0.31	 1.0E-05	 Y	 0.17	 1.0E-05	 Y	 0	 0.50	 N	 0	 0.50	 N	
mir-3910-2	 -0.10	 2.5E-03	 Y	 0.17	 1.0E-05	 Y	 0	 0.50	 N	 0	 0.50	 N	
mir-582	 -0.11	 1.2E-03	 Y	 0.18	 1.0E-05	 Y	 0	 0.50	 N	 0	 0.50	 N	
mir-519a-1	 0.19	 1.0E-05	 Y	 0.18	 1.0E-05	 Y	 0	 0.50	 N	 0	 0.50	 N	
mir-23c	 -0.10	 2.1E-03	 Y	 0.18	 1.0E-05	 Y	 0	 0.50	 N	 0	 0.50	 N	
mir-574	 -0.25	 1.0E-05	 Y	 0.19	 1.0E-05	 Y	 0	 0.50	 N	 0	 0.50	 N	
mir-599	 -0.06	 0.05	 N	 0.19	 1.0E-05	 Y	 0	 0.50	 N	 0	 0.50	 N	
mir-3647	 0.19	 1.0E-05	 Y	 0.19	 1.0E-05	 Y	 0	 0.50	 N	 0	 0.50	 N	
mir-378c	 0.17	 1.0E-05	 Y	 0.19	 1.0E-05	 Y	 0	 0.50	 N	 0	 0.50	 N	
mir-934	 0.17	 1.0E-05	 Y	 0.20	 1.0E-05	 Y	 0	 0.50	 N	 0	 0.50	 N	
mir-502	 0.14	 9.0E-05	 Y	 0.20	 1.0E-05	 Y	 0	 0.50	 N	 0	 0.50	 N	
mir-206	 0.02	 0.29	 N	 0.20	 1.0E-05	 Y	 0	 0.50	 N	 0	 0.50	 N	
mir-1262	 -0.21	 1.0E-05	 Y	 0.20	 1.0E-05	 Y	 0	 0.50	 N	 0	 0.50	 N	
mir-3690	 -0.10	 3.1E-03	 Y	 0.20	 1.0E-05	 Y	 0	 0.50	 N	 0	 0.50	 N	
mir-3199-1	 -0.03	 0.17	 N	 0.21	 1.0E-05	 Y	 0	 0.50	 N	 0	 0.50	 N	
let-7f-1	 -0.05	 0.08	 N	 0.21	 1.0E-05	 Y	 0	 0.50	 N	 0	 0.50	 N	
mir-518c	 -0.03	 0.20	 N	 0.21	 1.0E-05	 Y	 0	 0.50	 N	 0	 0.50	 N	
mir-518b	 -0.03	 0.21	 N	 0.22	 1.0E-05	 Y	 0	 0.50	 N	 0	 0.50	 N	
mir-1185-1	 -0.24	 1.0E-05	 Y	 0.22	 1.0E-05	 Y	 0	 0.50	 N	 0	 0.50	 N	
mir-548j	 -0.10	 3.6E-03	 Y	 0.22	 1.0E-05	 Y	 0	 0.50	 N	 0	 0.50	 N	
mir-660	 0.02	 0.26	 N	 0.23	 1.0E-05	 Y	 0	 0.50	 N	 0	 0.50	 N	
mir-500b	 0.15	 1.0E-05	 Y	 0.23	 1.0E-05	 Y	 0	 0.50	 N	 0	 0.50	 N	
mir-628	 -0.12	 3.9E-04	 Y	 0.23	 1.0E-05	 Y	 0	 0.50	 N	 0	 0.50	 N	
mir-3605	 -0.01	 0.36	 N	 0.23	 1.0E-05	 Y	 0	 0.50	 N	 0	 0.50	 N	
mir-2116	 0.09	 5.5E-03	 Y	 0.23	 1.0E-05	 Y	 0	 0.50	 N	 0	 0.50	 N	
mir-656	 -0.38	 1.0E-05	 Y	 0.24	 1.0E-05	 Y	 0	 0.50	 N	 0	 0.50	 N	
mir-2355	 5.2E-03	 0.45	 N	 0.24	 1.0E-05	 Y	 0	 0.50	 N	 0	 0.50	 N	
mir-24-2	 -0.04	 0.11	 N	 0.24	 1.0E-05	 Y	 0	 0.50	 N	 0	 0.50	 N	
mir-135b	 0.15	 3.0E-05	 Y	 0.24	 1.0E-05	 Y	 0	 0.50	 N	 0	 0.50	 N	
mir-891a	 0.07	 0.02	 Y	 0.24	 1.0E-05	 Y	 0	 0.50	 N	 0	 0.50	 N	
mir-488	 -0.21	 1.0E-05	 Y	 0.24	 1.0E-05	 Y	 0	 0.50	 N	 0	 0.50	 N	
mir-526b	 -0.03	 0.20	 N	 0.25	 1.0E-05	 Y	 0	 0.50	 N	 0	 0.50	 N	
mir-329-1	 -0.34	 1.0E-05	 Y	 0.26	 1.0E-05	 Y	 0	 0.50	 N	 0	 0.50	 N	
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mir-376b	 -0.28	 1.0E-05	 Y	 0.26	 1.0E-05	 Y	 0	 0.50	 N	 0	 0.50	 N	
mir-1271	 -0.13	 1.9E-04	 Y	 0.26	 1.0E-05	 Y	 0	 0.50	 N	 0	 0.50	 N	
mir-450a-2	 -0.26	 1.0E-05	 Y	 0.27	 1.0E-05	 Y	 0	 0.50	 N	 0	 0.50	 N	
mir-3193	 -0.10	 2.5E-03	 Y	 0.27	 1.0E-05	 Y	 0	 0.50	 N	 0	 0.50	 N	
mir-944	 -0.20	 1.0E-05	 Y	 0.27	 1.0E-05	 Y	 0	 0.50	 N	 0	 0.50	 N	
mir-1185-2	 -0.07	 0.03	 Y	 0.27	 1.0E-05	 Y	 0	 0.50	 N	 0	 0.50	 N	
mir-383	 -0.14	 1.0E-04	 Y	 0.28	 1.0E-05	 Y	 0	 0.50	 N	 0	 0.50	 N	
mir-3922	 0.02	 0.32	 N	 0.28	 1.0E-05	 Y	 0	 0.50	 N	 0	 0.50	 N	
mir-1976	 -0.09	 5.0E-03	 Y	 0.28	 1.0E-05	 Y	 0	 0.50	 N	 0	 0.50	 N	
mir-1247	 -0.27	 1.0E-05	 Y	 0.29	 1.0E-05	 Y	 0	 0.50	 N	 0	 0.50	 N	
mir-450b	 -0.26	 1.0E-05	 Y	 0.29	 1.0E-05	 Y	 0	 0.50	 N	 0	 0.50	 N	
mir-483	 -0.38	 1.0E-05	 Y	 0.29	 1.0E-05	 Y	 0	 0.50	 N	 0	 0.50	 N	
mir-1228	 -0.13	 2.3E-04	 Y	 0.29	 1.0E-05	 Y	 0	 0.50	 N	 0	 0.50	 N	
mir-494	 -0.32	 1.0E-05	 Y	 0.30	 1.0E-05	 Y	 0	 0.50	 N	 0	 0.50	 N	
mir-517b	 -9.5E-03	 0.40	 N	 0.30	 1.0E-05	 Y	 0	 0.50	 N	 0	 0.50	 N	
mir-517a	 -9.5E-03	 0.40	 N	 0.30	 1.0E-05	 Y	 0	 0.50	 N	 0	 0.50	 N	
mir-412	 -0.21	 1.0E-05	 Y	 0.30	 1.0E-05	 Y	 0	 0.50	 N	 0	 0.50	 N	
mir-1249	 -0.21	 1.0E-05	 Y	 0.30	 1.0E-05	 Y	 0	 0.50	 N	 0	 0.50	 N	
mir-380	 -0.26	 1.0E-05	 Y	 0.30	 1.0E-05	 Y	 0	 0.50	 N	 0	 0.50	 N	
mir-3926-1	 -0.40	 1.0E-05	 Y	 0.30	 1.0E-05	 Y	 0	 0.50	 N	 0	 0.50	 N	
mir-329-2	 -0.33	 1.0E-05	 Y	 0.31	 1.0E-05	 Y	 0	 0.50	 N	 0	 0.50	 N	
mir-152	 -0.37	 1.0E-05	 Y	 0.31	 1.0E-05	 Y	 0	 0.50	 N	 0	 0.50	 N	
mir-218-1	 -0.40	 1.0E-05	 Y	 0.31	 1.0E-05	 Y	 0	 0.50	 N	 0	 0.50	 N	
mir-655	 -0.41	 1.0E-05	 Y	 0.32	 1.0E-05	 Y	 0	 0.50	 N	 0	 0.50	 N	
mir-675	 -0.30	 1.0E-05	 Y	 0.32	 1.0E-05	 Y	 0	 0.50	 N	 0	 0.50	 N	
mir-450a-1	 -0.29	 1.0E-05	 Y	 0.32	 1.0E-05	 Y	 0	 0.50	 N	 0	 0.50	 N	
mir-433	 -0.34	 1.0E-05	 Y	 0.32	 1.0E-05	 Y	 0	 0.50	 N	 0	 0.50	 N	
mir-493	 -0.43	 1.0E-05	 Y	 0.33	 1.0E-05	 Y	 0	 0.50	 N	 0	 0.50	 N	
mir-3129	 -0.16	 1.0E-05	 Y	 0.33	 1.0E-05	 Y	 0	 0.50	 N	 0	 0.50	 N	
mir-376c	 -0.30	 1.0E-05	 Y	 0.33	 1.0E-05	 Y	 0	 0.50	 N	 0	 0.50	 N	
mir-542	 -0.32	 1.0E-05	 Y	 0.34	 1.0E-05	 Y	 0	 0.50	 N	 0	 0.50	 N	
mir-551b	 -0.20	 1.0E-05	 Y	 0.35	 1.0E-05	 Y	 0	 0.50	 N	 0	 0.50	 N	
mir-323b	 -0.25	 1.0E-05	 Y	 0.35	 1.0E-05	 Y	 0	 0.50	 N	 0	 0.50	 N	
mir-543	 -0.33	 1.0E-05	 Y	 0.37	 1.0E-05	 Y	 0	 0.50	 N	 0	 0.50	 N	
mir-377	 -0.42	 1.0E-05	 Y	 0.37	 1.0E-05	 Y	 0	 0.50	 N	 0	 0.50	 N	
mir-139	 -0.33	 1.0E-05	 Y	 0.38	 1.0E-05	 Y	 0	 0.50	 N	 0	 0.50	 N	
mir-541	 -0.30	 1.0E-05	 Y	 0.38	 1.0E-05	 Y	 0	 0.50	 N	 0	 0.50	 N	
mir-665	 -0.39	 1.0E-05	 Y	 0.38	 1.0E-05	 Y	 0	 0.50	 N	 0	 0.50	 N	
mir-495	 -0.41	 1.0E-05	 Y	 0.39	 1.0E-05	 Y	 0	 0.50	 N	 0	 0.50	 N	
mir-487b	 -0.39	 1.0E-05	 Y	 0.39	 1.0E-05	 Y	 0	 0.50	 N	 0	 0.50	 N	
mir-1245	 -0.29	 1.0E-05	 Y	 0.41	 1.0E-05	 Y	 0	 0.50	 N	 0	 0.50	 N	
mir-1258	 -0.25	 1.0E-05	 Y	 0.41	 1.0E-05	 Y	 0	 0.50	 N	 0	 0.50	 N	
mir-323	 -0.26	 1.0E-05	 Y	 0.42	 1.0E-05	 Y	 0	 0.50	 N	 0	 0.50	 N	
mir-511-2	 -0.06	 0.05	 N	 0.43	 1.0E-05	 Y	 0	 0.50	 N	 0	 0.50	 N	
mir-337	 -0.45	 1.0E-05	 Y	 0.43	 1.0E-05	 Y	 0	 0.50	 N	 0	 0.50	 N	
mir-411	 -0.41	 1.0E-05	 Y	 0.43	 1.0E-05	 Y	 0	 0.50	 N	 0	 0.50	 N	
mir-584	 0.03	 0.22	 N	 0.43	 1.0E-05	 Y	 0	 0.50	 N	 0	 0.50	 N	
mir-369	 -0.39	 1.0E-05	 Y	 0.43	 1.0E-05	 Y	 0	 0.50	 N	 0	 0.50	 N	
mir-889	 -0.37	 1.0E-05	 Y	 0.44	 1.0E-05	 Y	 0	 0.50	 N	 0	 0.50	 N	
mir-485	 -0.37	 1.0E-05	 Y	 0.44	 1.0E-05	 Y	 0	 0.50	 N	 0	 0.50	 N	
mir-431	 -0.39	 1.0E-05	 Y	 0.44	 1.0E-05	 Y	 0	 0.50	 N	 0	 0.50	 N	
mir-136	 -0.36	 1.0E-05	 Y	 0.44	 1.0E-05	 Y	 0	 0.50	 N	 0	 0.50	 N	
mir-539	 -0.37	 1.0E-05	 Y	 0.44	 1.0E-05	 Y	 0	 0.50	 N	 0	 0.50	 N	
mir-299	 -0.35	 1.0E-05	 Y	 0.45	 1.0E-05	 Y	 0	 0.50	 N	 0	 0.50	 N	
mir-382	 -0.46	 1.0E-05	 Y	 0.45	 1.0E-05	 Y	 0	 0.50	 N	 0	 0.50	 N	
mir-409	 -0.45	 1.0E-05	 Y	 0.46	 1.0E-05	 Y	 0	 0.50	 N	 0	 0.50	 N	
mir-487a	 -0.32	 1.0E-05	 Y	 0.46	 1.0E-05	 Y	 0	 0.50	 N	 0	 0.50	 N	
mir-452	 0.07	 0.02	 Y	 0.46	 1.0E-05	 Y	 0	 0.50	 N	 0	 0.50	 N	
mir-154	 -0.41	 1.0E-05	 Y	 0.46	 1.0E-05	 Y	 0	 0.50	 N	 0	 0.50	 N	
mir-511-1	 -0.04	 0.15	 N	 0.46	 1.0E-05	 Y	 0	 0.50	 N	 0	 0.50	 N	
mir-199b	 -0.41	 1.0E-05	 Y	 0.46	 1.0E-05	 Y	 0	 0.50	 N	 0	 0.50	 N	
mir-379	 -0.45	 1.0E-05	 Y	 0.48	 1.0E-05	 Y	 0	 0.50	 N	 0	 0.50	 N	
mir-370	 -0.46	 1.0E-05	 Y	 0.49	 1.0E-05	 Y	 0	 0.50	 N	 0	 0.50	 N	
mir-381	 -0.38	 1.0E-05	 Y	 0.49	 1.0E-05	 Y	 0	 0.50	 N	 0	 0.50	 N	
mir-127	 -0.46	 1.0E-05	 Y	 0.49	 1.0E-05	 Y	 0	 0.50	 N	 0	 0.50	 N	
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mir-134	 -0.44	 1.0E-05	 Y	 0.51	 1.0E-05	 Y	 0	 0.50	 N	 0	 0.50	 N	
mir-496	 -0.38	 1.0E-05	 Y	 0.51	 1.0E-05	 Y	 0	 0.50	 N	 0	 0.50	 N	
mir-506	 0.06	 0.06	 N	 -0.16	 2.0E-05	 Y	 0	 0.50	 N	 0	 0.50	 N	
mir-939	 0.24	 1.0E-05	 Y	 -0.16	 2.0E-05	 Y	 0	 0.50	 N	 0	 0.50	 N	
mir-1250	 0.15	 1.0E-05	 Y	 -0.15	 3.0E-05	 Y	 0	 0.50	 N	 0	 0.50	 N	
mir-718	 0.23	 1.0E-05	 Y	 -0.15	 3.0E-05	 Y	 0	 0.50	 N	 0	 0.50	 N	
mir-663b	 -0.10	 3.3E-03	 Y	 0.15	 3.0E-05	 Y	 0	 0.50	 N	 0	 0.50	 N	
mir-1287	 0.01	 0.39	 N	 0.15	 3.0E-05	 Y	 0	 0.50	 N	 0	 0.50	 N	
mir-3165	 0.09	 4.7E-03	 Y	 -0.14	 5.0E-05	 Y	 0	 0.50	 N	 0	 0.50	 N	
mir-3135	 -0.01	 0.39	 N	 0.14	 6.0E-05	 Y	 0	 0.50	 N	 0	 0.50	 N	
mir-653	 -0.29	 1.0E-05	 Y	 0.14	 7.0E-05	 Y	 0	 0.50	 N	 0	 0.50	 N	
mir-1193	 -0.06	 0.06	 N	 0.14	 7.0E-05	 Y	 0	 0.50	 N	 0	 0.50	 N	
mir-516b-1	 0.05	 0.08	 N	 0.14	 7.0E-05	 Y	 0	 0.50	 N	 0	 0.50	 N	
mir-922	 -0.06	 0.04	 Y	 0.14	 7.0E-05	 Y	 0	 0.50	 N	 0	 0.50	 N	
mir-3140	 0.15	 1.0E-05	 Y	 0.14	 8.0E-05	 Y	 0	 0.50	 N	 0	 0.50	 N	
mir-3120	 -0.05	 0.10	 N	 0.14	 8.0E-05	 Y	 0	 0.50	 N	 0	 0.50	 N	
mir-577	 0.32	 1.0E-05	 Y	 0.14	 8.0E-05	 Y	 0	 0.50	 N	 0	 0.50	 N	
mir-187	 0.05	 0.07	 N	 0.14	 9.0E-05	 Y	 0	 0.50	 N	 0	 0.50	 N	
mir-581	 -0.02	 0.31	 N	 0.13	 1.0E-04	 Y	 0	 0.50	 N	 0	 0.50	 N	
mir-448	 0.02	 0.33	 N	 0.14	 1.0E-04	 Y	 0	 0.50	 N	 0	 0.50	 N	
mir-3921	 -0.09	 5.6E-03	 Y	 0.13	 1.1E-04	 Y	 0	 0.50	 N	 0	 0.50	 N	
mir-1266	 0.08	 0.01	 Y	 -0.14	 1.3E-04	 Y	 0	 0.50	 N	 0	 0.50	 N	
mir-3150	 0.11	 1.6E-03	 Y	 -0.14	 1.5E-04	 Y	 0	 0.50	 N	 0	 0.50	 N	
mir-3156-1	 -0.03	 0.20	 N	 -0.13	 1.7E-04	 Y	 0	 0.50	 N	 0	 0.50	 N	
mir-3653	 -0.08	 0.02	 Y	 0.13	 1.7E-04	 Y	 0	 0.50	 N	 0	 0.50	 N	
mir-518e	 0.07	 0.03	 Y	 0.13	 1.7E-04	 Y	 0	 0.50	 N	 0	 0.50	 N	
mir-873	 0.05	 0.10	 N	 0.13	 1.7E-04	 Y	 0	 0.50	 N	 0	 0.50	 N	
mir-3622b	 0.05	 0.08	 N	 -0.13	 1.9E-04	 Y	 0	 0.50	 N	 0	 0.50	 N	
mir-509-2	 0.04	 0.15	 N	 0.13	 1.9E-04	 Y	 0	 0.50	 N	 0	 0.50	 N	
mir-936	 -0.11	 1.1E-03	 Y	 0.13	 1.9E-04	 Y	 0	 0.50	 N	 0	 0.50	 N	
mir-548a-1	 -0.04	 0.16	 N	 0.13	 2.2E-04	 Y	 0	 0.50	 N	 0	 0.50	 N	
mir-3180-5	 -0.04	 0.16	 N	 0.13	 2.2E-04	 Y	 0	 0.50	 N	 0	 0.50	 N	
mir-523	 -0.16	 2.0E-05	 Y	 0.13	 2.2E-04	 Y	 0	 0.50	 N	 0	 0.50	 N	
mir-597	 0.25	 1.0E-05	 Y	 -0.13	 2.3E-04	 Y	 0	 0.50	 N	 0	 0.50	 N	
mir-548q	 -0.12	 4.6E-04	 Y	 0.13	 2.4E-04	 Y	 0	 0.50	 N	 0	 0.50	 N	
mir-3156-2	 -0.09	 5.2E-03	 Y	 -0.13	 2.5E-04	 Y	 0	 0.50	 N	 0	 0.50	 N	
mir-770	 -0.04	 0.15	 N	 0.12	 2.6E-04	 Y	 0	 0.50	 N	 0	 0.50	 N	
mir-466	 -0.06	 0.06	 N	 0.12	 2.7E-04	 Y	 0	 0.50	 N	 0	 0.50	 N	
mir-216a	 -0.08	 0.01	 Y	 0.12	 2.7E-04	 Y	 0	 0.50	 N	 0	 0.50	 N	
mir-3147	 -0.09	 7.0E-03	 Y	 0.12	 2.9E-04	 Y	 0	 0.50	 N	 0	 0.50	 N	
mir-517c	 -0.10	 2.2E-03	 Y	 0.12	 2.9E-04	 Y	 0	 0.50	 N	 0	 0.50	 N	
mir-9-3	 0.16	 1.0E-05	 Y	 -0.13	 3.0E-04	 Y	 0	 0.50	 N	 0	 0.50	 N	
mir-1267	 0.13	 1.7E-04	 Y	 -0.12	 3.4E-04	 Y	 0	 0.50	 N	 0	 0.50	 N	
mir-618	 0.02	 0.28	 N	 -0.12	 3.4E-04	 Y	 0	 0.50	 N	 0	 0.50	 N	
mir-3128	 -0.12	 5.2E-04	 Y	 0.12	 3.4E-04	 Y	 0	 0.50	 N	 0	 0.50	 N	
mir-3199-2	 -0.09	 7.4E-03	 Y	 0.12	 3.4E-04	 Y	 0	 0.50	 N	 0	 0.50	 N	
mir-561	 6.3E-03	 0.43	 N	 0.12	 3.5E-04	 Y	 0	 0.50	 N	 0	 0.50	 N	
mir-3160-2	 -0.10	 2.5E-03	 Y	 0.12	 3.6E-04	 Y	 0	 0.50	 N	 0	 0.50	 N	
mir-3178	 -0.06	 0.05	 N	 -0.12	 4.1E-04	 Y	 0	 0.50	 N	 0	 0.50	 N	
mir-1265	 -0.04	 0.14	 N	 0.12	 4.4E-04	 Y	 0	 0.50	 N	 0	 0.50	 N	
mir-3656	 -0.03	 0.22	 N	 -0.12	 4.9E-04	 Y	 0	 0.50	 N	 0	 0.50	 N	
mir-135a-2	 -0.23	 1.0E-05	 Y	 -0.12	 5.0E-04	 Y	 0	 0.50	 N	 0	 0.50	 N	
mir-548o	 8.0E-03	 0.42	 N	 0.12	 5.0E-04	 Y	 0	 0.50	 N	 0	 0.50	 N	
mir-135a-1	 -0.26	 1.0E-05	 Y	 -0.12	 5.3E-04	 Y	 0	 0.50	 N	 0	 0.50	 N	
mir-3942	 0.27	 1.0E-05	 Y	 -0.12	 5.5E-04	 Y	 0	 0.50	 N	 0	 0.50	 N	
mir-559	 0.10	 2.9E-03	 Y	 0.12	 5.6E-04	 Y	 0	 0.50	 N	 0	 0.50	 N	
mir-1292	 0.27	 1.0E-05	 Y	 -0.12	 5.7E-04	 Y	 0	 0.50	 N	 0	 0.50	 N	
mir-663	 0.15	 1.0E-05	 Y	 -0.12	 6.3E-04	 Y	 0	 0.50	 N	 0	 0.50	 N	
mir-4254	 -0.04	 0.15	 N	 -0.12	 6.5E-04	 Y	 0	 0.50	 N	 0	 0.50	 N	
mir-3610	 0.23	 1.0E-05	 Y	 -0.12	 6.6E-04	 Y	 0	 0.50	 N	 0	 0.50	 N	
mir-548a-3	 0.15	 3.0E-05	 Y	 0.11	 6.9E-04	 Y	 0	 0.50	 N	 0	 0.50	 N	
mir-3622a	 0.07	 0.02	 Y	 0.11	 7.1E-04	 Y	 0	 0.50	 N	 0	 0.50	 N	
mir-548t	 -0.05	 0.09	 N	 -0.12	 7.2E-04	 Y	 0	 0.50	 N	 0	 0.50	 N	
mir-1246	 0.22	 1.0E-05	 Y	 -0.12	 7.7E-04	 Y	 0	 0.50	 N	 0	 0.50	 N	
mir-573	 0.16	 1.0E-05	 Y	 -0.11	 8.6E-04	 Y	 0	 0.50	 N	 0	 0.50	 N	
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mir-520e	 0.08	 0.02	 Y	 0.11	 8.7E-04	 Y	 0	 0.50	 N	 0	 0.50	 N	
mir-556	 0.07	 0.02	 Y	 -0.11	 9.7E-04	 Y	 0	 0.50	 N	 0	 0.50	 N	
mir-325	 0.11	 9.8E-04	 Y	 -0.11	 9.9E-04	 Y	 0	 0.50	 N	 0	 0.50	 N	
mir-3614	 0.25	 1.0E-05	 Y	 0.11	 9.9E-04	 Y	 0	 0.50	 N	 0	 0.50	 N	
mir-3941	 -0.05	 0.08	 N	 0.11	 1.1E-03	 Y	 0	 0.50	 N	 0	 0.50	 N	
mir-1277	 0.20	 1.0E-05	 Y	 -0.11	 1.1E-03	 Y	 0	 0.50	 N	 0	 0.50	 N	
mir-3661	 -0.06	 0.04	 N	 0.11	 1.3E-03	 Y	 0	 0.50	 N	 0	 0.50	 N	
mir-1913	 0.15	 3.0E-05	 Y	 0.11	 1.4E-03	 Y	 0	 0.50	 N	 0	 0.50	 N	
mir-1908	 0.12	 3.0E-04	 Y	 -0.11	 1.4E-03	 Y	 0	 0.50	 N	 0	 0.50	 N	
mir-219-1	 0.09	 4.7E-03	 Y	 -0.11	 1.4E-03	 Y	 0	 0.50	 N	 0	 0.50	 N	
mir-3682	 0.26	 1.0E-05	 Y	 0.11	 1.4E-03	 Y	 0	 0.50	 N	 0	 0.50	 N	
mir-3126	 -0.05	 0.07	 N	 0.11	 1.5E-03	 Y	 0	 0.50	 N	 0	 0.50	 N	
mir-3157	 0.16	 1.0E-05	 Y	 0.11	 1.5E-03	 Y	 0	 0.50	 N	 0	 0.50	 N	
mir-514-2	 -0.12	 4.4E-04	 Y	 0.11	 1.6E-03	 Y	 0	 0.50	 N	 0	 0.50	 N	
mir-548n	 -0.09	 7.5E-03	 Y	 0.10	 1.8E-03	 Y	 0	 0.50	 N	 0	 0.50	 N	
mir-512-2	 0.09	 5.4E-03	 Y	 0.10	 1.9E-03	 Y	 0	 0.50	 N	 0	 0.50	 N	
mir-519a-2	 0.14	 8.0E-05	 Y	 0.10	 1.9E-03	 Y	 0	 0.50	 N	 0	 0.50	 N	
mir-1264	 -0.02	 0.28	 N	 -0.11	 1.9E-03	 Y	 0	 0.50	 N	 0	 0.50	 N	
mir-374c	 -0.01	 0.37	 N	 0.10	 2.0E-03	 Y	 0	 0.50	 N	 0	 0.50	 N	
mir-371	 -0.06	 0.06	 N	 0.10	 2.0E-03	 Y	 0	 0.50	 N	 0	 0.50	 N	
mir-548f-4	 0.15	 1.0E-05	 Y	 -0.10	 2.1E-03	 Y	 0	 0.50	 N	 0	 0.50	 N	
mir-3144	 0.06	 0.06	 N	 -0.10	 2.1E-03	 Y	 0	 0.50	 N	 0	 0.50	 N	
mir-3685	 0.10	 4.0E-03	 Y	 -0.10	 2.1E-03	 Y	 0	 0.50	 N	 0	 0.50	 N	
mir-1263	 0.10	 4.0E-03	 Y	 -0.10	 2.1E-03	 Y	 0	 0.50	 N	 0	 0.50	 N	
mir-1243	 -0.08	 9.7E-03	 Y	 0.10	 2.1E-03	 Y	 0	 0.50	 N	 0	 0.50	 N	
mir-513c	 -0.02	 0.25	 N	 0.10	 2.2E-03	 Y	 0	 0.50	 N	 0	 0.50	 N	
mir-30c-1	 -0.07	 0.02	 Y	 0.10	 2.3E-03	 Y	 0	 0.50	 N	 0	 0.50	 N	
mir-491	 -0.24	 1.0E-05	 Y	 0.10	 2.4E-03	 Y	 0	 0.50	 N	 0	 0.50	 N	
mir-3130-2	 0.05	 0.07	 N	 0.10	 2.6E-03	 Y	 0	 0.50	 N	 0	 0.50	 N	
mir-1276	 0.26	 1.0E-05	 Y	 -0.10	 2.6E-03	 Y	 0	 0.50	 N	 0	 0.50	 N	
mir-1184-1	 0.11	 1.7E-03	 Y	 -0.10	 2.6E-03	 Y	 0	 0.50	 N	 0	 0.50	 N	
mir-1294	 -0.11	 8.8E-04	 Y	 0.10	 2.7E-03	 Y	 0	 0.50	 N	 0	 0.50	 N	
mir-876	 0.08	 0.02	 Y	 0.10	 2.7E-03	 Y	 0	 0.50	 N	 0	 0.50	 N	
mir-2113	 0.17	 1.0E-05	 Y	 -0.10	 2.8E-03	 Y	 0	 0.50	 N	 0	 0.50	 N	
mir-629	 0.08	 0.01	 Y	 -0.10	 2.9E-03	 Y	 0	 0.50	 N	 0	 0.50	 N	
mir-3188	 0.07	 0.02	 Y	 -0.10	 3.0E-03	 Y	 0	 0.50	 N	 0	 0.50	 N	
mir-3934	 0.19	 1.0E-05	 Y	 0.10	 3.1E-03	 Y	 0	 0.50	 N	 0	 0.50	 N	
mir-2278	 0.03	 0.19	 N	 -0.10	 3.3E-03	 Y	 0	 0.50	 N	 0	 0.50	 N	
mir-3688	 0.09	 4.1E-03	 Y	 0.10	 3.3E-03	 Y	 0	 0.50	 N	 0	 0.50	 N	
mir-933	 0.16	 1.0E-05	 Y	 -0.10	 3.3E-03	 Y	 0	 0.50	 N	 0	 0.50	 N	
mir-3191	 7.7E-03	 0.42	 N	 0.10	 3.3E-03	 Y	 0	 0.50	 N	 0	 0.50	 N	
mir-3121	 -0.05	 0.08	 N	 -0.10	 3.4E-03	 Y	 0	 0.50	 N	 0	 0.50	 N	
mir-3663	 0.13	 1.4E-04	 Y	 -0.10	 3.6E-03	 Y	 0	 0.50	 N	 0	 0.50	 N	
mir-3179-1	 -0.04	 0.15	 N	 0.10	 3.7E-03	 Y	 0	 0.50	 N	 0	 0.50	 N	
mir-1274b	 0.19	 1.0E-05	 Y	 0.10	 3.7E-03	 Y	 0	 0.50	 N	 0	 0.50	 N	
mir-1280	 1.3E-03	 0.49	 N	 -0.10	 3.8E-03	 Y	 0	 0.50	 N	 0	 0.50	 N	
mir-3141	 5.9E-03	 0.44	 N	 -0.10	 4.0E-03	 Y	 0	 0.50	 N	 0	 0.50	 N	
mir-548d-2	 0.32	 1.0E-05	 Y	 -0.10	 4.0E-03	 Y	 0	 0.50	 N	 0	 0.50	 N	
mir-188	 0.30	 1.0E-05	 Y	 0.10	 4.0E-03	 Y	 0	 0.50	 N	 0	 0.50	 N	
mir-550b-2	 0.07	 0.03	 Y	 0.09	 4.3E-03	 Y	 0	 0.50	 N	 0	 0.50	 N	
mir-492	 -0.03	 0.22	 N	 -0.09	 4.4E-03	 Y	 0	 0.50	 N	 0	 0.50	 N	
mir-648	 -0.12	 4.9E-04	 Y	 0.09	 4.4E-03	 Y	 0	 0.50	 N	 0	 0.50	 N	
mir-563	 -0.12	 4.9E-04	 Y	 0.09	 4.4E-03	 Y	 0	 0.50	 N	 0	 0.50	 N	
mir-4265	 -0.12	 4.9E-04	 Y	 0.09	 4.4E-03	 Y	 0	 0.50	 N	 0	 0.50	 N	
mir-4279	 0.01	 0.34	 N	 -0.09	 4.6E-03	 Y	 0	 0.50	 N	 0	 0.50	 N	
mir-3117	 -0.02	 0.26	 N	 0.09	 4.7E-03	 Y	 0	 0.50	 N	 0	 0.50	 N	
mir-3679	 0.15	 2.0E-05	 Y	 0.09	 5.0E-03	 Y	 0	 0.50	 N	 0	 0.50	 N	
mir-3167	 -0.03	 0.18	 N	 -0.09	 5.6E-03	 Y	 0	 0.50	 N	 0	 0.50	 N	
mir-3153	 0.05	 0.09	 N	 -0.09	 5.8E-03	 Y	 0	 0.50	 N	 0	 0.50	 N	
mir-3202-1	 0.14	 8.0E-05	 Y	 0.09	 5.8E-03	 Y	 0	 0.50	 N	 0	 0.50	 N	
mir-147b	 0.10	 3.1E-03	 Y	 0.09	 5.9E-03	 Y	 0	 0.50	 N	 0	 0.50	 N	
mir-520h	 -0.07	 0.04	 Y	 0.09	 6.0E-03	 Y	 0	 0.50	 N	 0	 0.50	 N	
mir-549	 0.02	 0.26	 N	 0.09	 6.3E-03	 Y	 0	 0.50	 N	 0	 0.50	 N	
mir-1302-3	 0.04	 0.15	 N	 0.09	 6.4E-03	 Y	 0	 0.50	 N	 0	 0.50	 N	
mir-642b	 0.05	 0.09	 N	 -0.09	 6.4E-03	 Y	 0	 0.50	 N	 0	 0.50	 N	
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mir-617	 0.04	 0.13	 N	 -0.09	 6.7E-03	 Y	 0	 0.50	 N	 0	 0.50	 N	
mir-508	 -0.06	 0.04	 N	 -0.09	 6.7E-03	 Y	 0	 0.50	 N	 0	 0.50	 N	
mir-512-1	 0.19	 1.0E-05	 Y	 0.09	 7.4E-03	 Y	 0	 0.50	 N	 0	 0.50	 N	
mir-3687	 0.25	 1.0E-05	 Y	 0.09	 7.4E-03	 Y	 0	 0.50	 N	 0	 0.50	 N	
mir-1269	 0.33	 1.0E-05	 Y	 -0.09	 7.7E-03	 Y	 0	 0.50	 N	 0	 0.50	 N	
mir-1298	 0.04	 0.16	 N	 0.09	 7.9E-03	 Y	 0	 0.50	 N	 0	 0.50	 N	
mir-892b	 0.06	 0.05	 N	 0.09	 7.9E-03	 Y	 0	 0.50	 N	 0	 0.50	 N	
mir-570	 0.10	 1.7E-03	 Y	 -0.09	 8.3E-03	 Y	 0	 0.50	 N	 0	 0.50	 N	
mir-942	 0.41	 1.0E-05	 Y	 0.09	 8.4E-03	 Y	 0	 0.50	 N	 0	 0.50	 N	
mir-3606	 -0.06	 0.05	 N	 0.09	 9.0E-03	 Y	 0	 0.50	 N	 0	 0.50	 N	
mir-647	 0.07	 0.03	 Y	 0.09	 9.0E-03	 Y	 0	 0.50	 N	 0	 0.50	 N	
mir-659	 -0.10	 2.9E-03	 Y	 0.09	 9.1E-03	 Y	 0	 0.50	 N	 0	 0.50	 N	
mir-3913-2	 -0.04	 0.16	 N	 0.09	 9.2E-03	 Y	 0	 0.50	 N	 0	 0.50	 N	
mir-3116-2	 0.11	 7.2E-04	 Y	 -0.09	 9.2E-03	 Y	 0	 0.50	 N	 0	 0.50	 N	
mir-1225	 0.19	 1.0E-05	 Y	 -0.08	 9.3E-03	 Y	 0	 0.50	 N	 0	 0.50	 N	
mir-516b-2	 0.01	 0.37	 N	 0.09	 9.4E-03	 Y	 0	 0.50	 N	 0	 0.50	 N	
mir-3675	 -0.07	 0.03	 Y	 0.08	 1.0E-02	 Y	 0	 0.50	 N	 0	 0.50	 N	
mir-3678	 -0.07	 0.02	 Y	 -0.08	 0.01	 Y	 0	 0.50	 N	 0	 0.50	 N	
mir-1469	 0.02	 0.28	 N	 0.08	 0.01	 Y	 0	 0.50	 N	 0	 0.50	 N	
mir-363	 -0.13	 2.5E-04	 Y	 0.08	 0.01	 Y	 0	 0.50	 N	 0	 0.50	 N	
mir-4322	 -0.10	 3.0E-03	 Y	 0.08	 0.01	 Y	 0	 0.50	 N	 0	 0.50	 N	
mir-128-2	 0.10	 2.5E-03	 Y	 0.08	 0.01	 Y	 0	 0.50	 N	 0	 0.50	 N	
mir-3148	 0.04	 0.12	 N	 0.08	 0.01	 Y	 0	 0.50	 N	 0	 0.50	 N	
mir-645	 0.01	 0.36	 N	 -0.08	 0.01	 Y	 0	 0.50	 N	 0	 0.50	 N	
mir-3667	 0.04	 0.15	 N	 0.08	 0.01	 Y	 0	 0.50	 N	 0	 0.50	 N	
mir-1304	 0.26	 1.0E-05	 Y	 -0.08	 0.01	 Y	 0	 0.50	 N	 0	 0.50	 N	
mir-518a-1	 0.08	 0.01	 Y	 0.08	 0.01	 Y	 0	 0.50	 N	 0	 0.50	 N	
mir-519d	 -5.1E-03	 0.44	 N	 0.08	 0.01	 Y	 0	 0.50	 N	 0	 0.50	 N	
mir-2114	 -0.17	 1.0E-05	 Y	 -0.08	 0.01	 Y	 0	 0.50	 N	 0	 0.50	 N	
mir-198	 -0.05	 0.08	 N	 0.08	 0.01	 Y	 0	 0.50	 N	 0	 0.50	 N	
mir-1273c	 -0.07	 0.03	 Y	 0.08	 0.01	 Y	 0	 0.50	 N	 0	 0.50	 N	
mir-1204	 -0.07	 0.03	 Y	 0.08	 0.01	 Y	 0	 0.50	 N	 0	 0.50	 N	
mir-3936	 0.03	 0.23	 N	 -0.08	 0.01	 Y	 0	 0.50	 N	 0	 0.50	 N	
mir-1179	 -0.03	 0.22	 N	 0.08	 0.01	 Y	 0	 0.50	 N	 0	 0.50	 N	
mir-1231	 0.04	 0.12	 N	 -0.08	 0.01	 Y	 0	 0.50	 N	 0	 0.50	 N	
mir-3658	 0.04	 0.15	 N	 0.08	 0.01	 Y	 0	 0.50	 N	 0	 0.50	 N	
mir-3689b	 0.09	 5.5E-03	 Y	 -0.08	 0.01	 Y	 0	 0.50	 N	 0	 0.50	 N	
mir-1293	 0.11	 1.1E-03	 Y	 0.08	 0.01	 Y	 0	 0.50	 N	 0	 0.50	 N	
mir-4310	 -0.07	 0.02	 Y	 -0.08	 0.01	 Y	 0	 0.50	 N	 0	 0.50	 N	
mir-887	 -5.9E-04	 0.49	 N	 -0.08	 0.01	 Y	 0	 0.50	 N	 0	 0.50	 N	
mir-320d-1	 -0.04	 0.16	 N	 0.08	 0.01	 Y	 0	 0.50	 N	 0	 0.50	 N	
mir-3692	 0.10	 1.9E-03	 Y	 0.08	 0.01	 Y	 0	 0.50	 N	 0	 0.50	 N	
mir-1291	 0.02	 0.27	 N	 -0.08	 0.01	 Y	 0	 0.50	 N	 0	 0.50	 N	
mir-2117	 0.02	 0.33	 N	 0.08	 0.02	 Y	 0	 0.50	 N	 0	 0.50	 N	
mir-676	 -0.09	 8.8E-03	 Y	 0.08	 0.02	 Y	 0	 0.50	 N	 0	 0.50	 N	
mir-3192	 0.19	 1.0E-05	 Y	 -0.08	 0.02	 Y	 0	 0.50	 N	 0	 0.50	 N	
mir-580	 0.12	 3.2E-04	 Y	 0.08	 0.02	 Y	 0	 0.50	 N	 0	 0.50	 N	
mir-3650	 0.04	 0.16	 N	 -0.08	 0.02	 Y	 0	 0.50	 N	 0	 0.50	 N	
mir-29b-2	 -0.18	 1.0E-05	 Y	 -0.08	 0.02	 Y	 0	 0.50	 N	 0	 0.50	 N	
mir-516a-2	 0.12	 3.2E-04	 Y	 0.08	 0.02	 Y	 0	 0.50	 N	 0	 0.50	 N	
mir-3618	 0.12	 2.6E-04	 Y	 0.08	 0.02	 Y	 0	 0.50	 N	 0	 0.50	 N	
mir-885	 0.03	 0.21	 N	 0.08	 0.02	 Y	 0	 0.50	 N	 0	 0.50	 N	
mir-1915	 0.22	 1.0E-05	 Y	 -0.08	 0.02	 Y	 0	 0.50	 N	 0	 0.50	 N	
mir-3677	 0.43	 1.0E-05	 Y	 -0.08	 0.02	 Y	 0	 0.50	 N	 0	 0.50	 N	
mir-643	 0.15	 3.0E-05	 Y	 -0.07	 0.02	 Y	 0	 0.50	 N	 0	 0.50	 N	
mir-3607	 -0.17	 1.0E-05	 Y	 0.07	 0.02	 Y	 0	 0.50	 N	 0	 0.50	 N	
mir-3612	 -0.16	 1.0E-05	 Y	 0.07	 0.02	 Y	 0	 0.50	 N	 0	 0.50	 N	
mir-3197	 0.08	 0.01	 Y	 -0.07	 0.02	 Y	 0	 0.50	 N	 0	 0.50	 N	
mir-3174	 0.11	 1.1E-03	 Y	 -0.07	 0.02	 Y	 0	 0.50	 N	 0	 0.50	 N	
mir-550a-2	 0.10	 3.7E-03	 Y	 -0.07	 0.02	 Y	 0	 0.50	 N	 0	 0.50	 N	
mir-3652	 0.25	 1.0E-05	 Y	 -0.07	 0.02	 Y	 0	 0.50	 N	 0	 0.50	 N	
mir-3179-3	 0.05	 0.09	 N	 -0.07	 0.02	 Y	 0	 0.50	 N	 0	 0.50	 N	
mir-3664	 0.22	 1.0E-05	 Y	 -0.07	 0.02	 Y	 0	 0.50	 N	 0	 0.50	 N	
mir-153-2	 -0.18	 1.0E-05	 Y	 0.07	 0.02	 Y	 0	 0.50	 N	 0	 0.50	 N	
mir-668	 -0.07	 0.03	 Y	 0.07	 0.02	 Y	 0	 0.50	 N	 0	 0.50	 N	
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mir-3154	 -0.09	 4.9E-03	 Y	 0.07	 0.02	 Y	 0	 0.50	 N	 0	 0.50	 N	
mir-1197	 -0.16	 1.0E-05	 Y	 0.07	 0.02	 Y	 0	 0.50	 N	 0	 0.50	 N	
mir-767	 0.22	 1.0E-05	 Y	 0.07	 0.02	 Y	 0	 0.50	 N	 0	 0.50	 N	
mir-378b	 0.12	 2.6E-04	 Y	 0.07	 0.02	 Y	 0	 0.50	 N	 0	 0.50	 N	
mir-544	 -0.09	 8.9E-03	 Y	 0.07	 0.02	 Y	 0	 0.50	 N	 0	 0.50	 N	
mir-548y	 -0.03	 0.21	 N	 0.07	 0.02	 Y	 0	 0.50	 N	 0	 0.50	 N	
mir-3616	 0.10	 3.0E-03	 Y	 -0.07	 0.03	 Y	 0	 0.50	 N	 0	 0.50	 N	
mir-3918	 -0.02	 0.28	 N	 0.07	 0.03	 Y	 0	 0.50	 N	 0	 0.50	 N	
mir-3655	 0.06	 0.05	 N	 -0.07	 0.03	 Y	 0	 0.50	 N	 0	 0.50	 N	
mir-3648	 0.22	 1.0E-05	 Y	 0.07	 0.03	 Y	 0	 0.50	 N	 0	 0.50	 N	
mir-301b	 0.47	 1.0E-05	 Y	 -0.07	 0.03	 Y	 0	 0.50	 N	 0	 0.50	 N	
mir-2276	 0.16	 1.0E-05	 Y	 -0.07	 0.03	 Y	 0	 0.50	 N	 0	 0.50	 N	
mir-16-2	 0.27	 1.0E-05	 Y	 -0.07	 0.03	 Y	 0	 0.50	 N	 0	 0.50	 N	
mir-548d-1	 0.21	 1.0E-05	 Y	 -0.07	 0.03	 Y	 0	 0.50	 N	 0	 0.50	 N	
mir-3166	 -0.10	 2.6E-03	 Y	 -0.07	 0.03	 Y	 0	 0.50	 N	 0	 0.50	 N	
mir-1234	 0.02	 0.32	 N	 0.07	 0.03	 Y	 0	 0.50	 N	 0	 0.50	 N	
mir-3122	 -0.07	 0.04	 Y	 0.07	 0.03	 Y	 0	 0.50	 N	 0	 0.50	 N	
mir-498	 -0.03	 0.21	 N	 -0.07	 0.03	 Y	 0	 0.50	 N	 0	 0.50	 N	
mir-3151	 0.21	 1.0E-05	 Y	 -0.07	 0.03	 Y	 0	 0.50	 N	 0	 0.50	 N	
mir-3171	 -0.06	 0.04	 Y	 0.07	 0.03	 Y	 0	 0.50	 N	 0	 0.50	 N	
mir-1278	 0.06	 0.04	 N	 -0.07	 0.04	 Y	 0	 0.50	 N	 0	 0.50	 N	
mir-3198	 0.22	 1.0E-05	 Y	 -0.07	 0.04	 Y	 0	 0.50	 N	 0	 0.50	 N	
mir-7-1	 -7.2E-03	 0.42	 N	 -0.06	 0.04	 Y	 0	 0.50	 N	 0	 0.50	 N	
mir-1283-1	 0.13	 1.4E-04	 Y	 0.06	 0.04	 Y	 0	 0.50	 N	 0	 0.50	 N	
mir-521-1	 0.05	 0.06	 N	 0.06	 0.04	 Y	 0	 0.50	 N	 0	 0.50	 N	
mir-105-2	 0.33	 1.0E-05	 Y	 0.06	 0.04	 Y	 0	 0.50	 N	 0	 0.50	 N	
mir-1284	 -0.06	 0.04	 N	 0.06	 0.04	 Y	 0	 0.50	 N	 0	 0.50	 N	
mir-548e	 -5.6E-03	 0.44	 N	 0.06	 0.04	 Y	 0	 0.50	 N	 0	 0.50	 N	
mir-3681	 -0.02	 0.27	 N	 0.06	 0.04	 Y	 0	 0.50	 N	 0	 0.50	 N	
mir-2110	 0.02	 0.27	 N	 0.06	 0.04	 Y	 0	 0.50	 N	 0	 0.50	 N	
mir-3195	 0.07	 0.02	 Y	 0.06	 0.04	 Y	 0	 0.50	 N	 0	 0.50	 N	
mir-1270-1	 0.06	 0.05	 N	 -0.06	 0.04	 Y	 0	 0.50	 N	 0	 0.50	 N	
mir-572	 0.10	 2.2E-03	 Y	 -0.06	 0.04	 Y	 0	 0.50	 N	 0	 0.50	 N	
mir-3914-1	 -0.08	 0.01	 Y	 0.06	 0.04	 Y	 0	 0.50	 N	 0	 0.50	 N	
mir-507	 0.02	 0.27	 N	 0.06	 0.04	 N	 0	 0.50	 N	 0	 0.50	 N	
mir-658	 0.09	 5.0E-03	 Y	 -0.06	 0.04	 N	 0	 0.50	 N	 0	 0.50	 N	
mir-664	 -0.33	 1.0E-05	 Y	 -0.06	 0.04	 N	 0	 0.50	 N	 0	 0.50	 N	
mir-3139	 0.03	 0.20	 N	 0.06	 0.04	 N	 0	 0.50	 N	 0	 0.50	 N	
mir-208a	 0.05	 0.09	 N	 0.06	 0.05	 N	 0	 0.50	 N	 0	 0.50	 N	
mir-564	 -0.06	 0.06	 N	 0.06	 0.05	 N	 0	 0.50	 N	 0	 0.50	 N	
mir-3654	 -7.4E-03	 0.42	 N	 0.06	 0.05	 N	 0	 0.50	 N	 0	 0.50	 N	
mir-544b	 0.04	 0.13	 N	 -0.06	 0.05	 N	 0	 0.50	 N	 0	 0.50	 N	
mir-3115	 0.21	 1.0E-05	 Y	 -0.06	 0.05	 N	 0	 0.50	 N	 0	 0.50	 N	
mir-1538	 0.07	 0.03	 Y	 0.06	 0.05	 N	 0	 0.50	 N	 0	 0.50	 N	
mir-567	 0.05	 0.10	 N	 -0.06	 0.05	 N	 0	 0.50	 N	 0	 0.50	 N	
mir-208b	 0.08	 0.01	 Y	 -0.06	 0.05	 N	 0	 0.50	 N	 0	 0.50	 N	
mir-1281	 -0.05	 0.09	 N	 0.06	 0.05	 N	 0	 0.50	 N	 0	 0.50	 N	
mir-527	 0.12	 4.0E-04	 Y	 0.06	 0.06	 N	 0	 0.50	 N	 0	 0.50	 N	
mir-548f-1	 0.25	 1.0E-05	 Y	 -0.06	 0.06	 N	 0	 0.50	 N	 0	 0.50	 N	
mir-642a	 -8.1E-03	 0.41	 N	 -0.06	 0.06	 N	 0	 0.50	 N	 0	 0.50	 N	
mir-3684	 0.16	 1.0E-05	 Y	 0.06	 0.06	 N	 0	 0.50	 N	 0	 0.50	 N	
mir-510	 -0.06	 0.06	 N	 0.06	 0.06	 N	 0	 0.50	 N	 0	 0.50	 N	
mir-4320	 -0.06	 0.06	 N	 0.06	 0.06	 N	 0	 0.50	 N	 0	 0.50	 N	
mir-607	 -0.04	 0.12	 N	 0.06	 0.06	 N	 0	 0.50	 N	 0	 0.50	 N	
mir-3149	 0.11	 7.0E-04	 Y	 -0.06	 0.06	 N	 0	 0.50	 N	 0	 0.50	 N	
mir-3186	 0.10	 1.7E-03	 Y	 -0.06	 0.06	 N	 0	 0.50	 N	 0	 0.50	 N	
mir-3925	 0.18	 1.0E-05	 Y	 0.06	 0.06	 N	 0	 0.50	 N	 0	 0.50	 N	
mir-3935	 0.08	 0.02	 Y	 0.05	 0.06	 N	 0	 0.50	 N	 0	 0.50	 N	
mir-875	 0.02	 0.28	 N	 0.05	 0.07	 N	 0	 0.50	 N	 0	 0.50	 N	
mir-1286	 0.17	 1.0E-05	 Y	 -0.05	 0.07	 N	 0	 0.50	 N	 0	 0.50	 N	
mir-3662	 0.23	 1.0E-05	 Y	 -0.05	 0.07	 N	 0	 0.50	 N	 0	 0.50	 N	
mir-1283-2	 0.12	 5.4E-04	 Y	 0.05	 0.07	 N	 0	 0.50	 N	 0	 0.50	 N	
mir-1297	 0.05	 0.10	 N	 -0.05	 0.07	 N	 0	 0.50	 N	 0	 0.50	 N	
mir-3613	 0.11	 9.8E-04	 Y	 0.05	 0.07	 N	 0	 0.50	 N	 0	 0.50	 N	
mir-520f	 0.07	 0.03	 Y	 0.05	 0.07	 N	 0	 0.50	 N	 0	 0.50	 N	
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mir-2115	 -0.12	 5.5E-04	 Y	 0.05	 0.07	 N	 0	 0.50	 N	 0	 0.50	 N	
mir-651	 0.10	 2.3E-03	 Y	 0.05	 0.07	 N	 0	 0.50	 N	 0	 0.50	 N	
mir-520g	 -0.02	 0.25	 N	 0.05	 0.08	 N	 0	 0.50	 N	 0	 0.50	 N	
mir-519c	 0.05	 0.07	 N	 0.05	 0.08	 N	 0	 0.50	 N	 0	 0.50	 N	
mir-3152	 -0.07	 0.03	 Y	 0.05	 0.08	 N	 0	 0.50	 N	 0	 0.50	 N	
mir-515-2	 -0.10	 4.0E-03	 Y	 0.05	 0.08	 N	 0	 0.50	 N	 0	 0.50	 N	
mir-548k	 0.16	 1.0E-05	 Y	 -0.05	 0.08	 N	 0	 0.50	 N	 0	 0.50	 N	
mir-526a-1	 0.09	 7.1E-03	 Y	 -0.05	 0.09	 N	 0	 0.50	 N	 0	 0.50	 N	
mir-4257	 0.09	 7.1E-03	 Y	 -0.05	 0.09	 N	 0	 0.50	 N	 0	 0.50	 N	
mir-3657	 0.09	 6.7E-03	 Y	 0.05	 0.09	 N	 0	 0.50	 N	 0	 0.50	 N	
mir-4315-1	 0.10	 3.6E-03	 Y	 -0.05	 0.09	 N	 0	 0.50	 N	 0	 0.50	 N	
mir-3175	 0.05	 0.10	 N	 0.05	 0.09	 N	 0	 0.50	 N	 0	 0.50	 N	
mir-2861	 -4.9E-03	 0.44	 N	 0.05	 0.09	 N	 0	 0.50	 N	 0	 0.50	 N	
mir-3202-2	 -0.09	 8.7E-03	 Y	 0.05	 0.09	 N	 0	 0.50	 N	 0	 0.50	 N	
mir-4328	 -0.05	 0.10	 N	 -0.05	 0.09	 N	 0	 0.50	 N	 0	 0.50	 N	
mir-1244-2	 0.03	 0.21	 N	 -0.05	 0.10	 N	 0	 0.50	 N	 0	 0.50	 N	
mir-105-1	 0.27	 1.0E-05	 Y	 0.05	 0.10	 N	 0	 0.50	 N	 0	 0.50	 N	
mir-3189	 0.14	 8.0E-05	 Y	 -0.05	 0.10	 N	 0	 0.50	 N	 0	 0.50	 N	
mir-623	 6.3E-03	 0.43	 N	 0.05	 0.10	 N	 0	 0.50	 N	 0	 0.50	 N	
mir-3155	 0.15	 1.0E-05	 Y	 -0.05	 0.10	 N	 0	 0.50	 N	 0	 0.50	 N	
mir-3194	 0.07	 0.03	 Y	 0.05	 0.10	 N	 0	 0.50	 N	 0	 0.50	 N	
mir-603	 0.10	 2.4E-03	 Y	 -0.05	 0.10	 N	 0	 0.50	 N	 0	 0.50	 N	
mir-3944	 0.13	 1.7E-04	 Y	 0.05	 0.10	 N	 0	 0.50	 N	 0	 0.50	 N	
mir-1305	 0.10	 3.8E-03	 Y	 0.05	 0.10	 N	 0	 0.50	 N	 0	 0.50	 N	
mir-4326	 0.34	 1.0E-05	 Y	 -0.05	 0.11	 N	 0	 0.50	 N	 0	 0.50	 N	
mir-1910	 0.23	 1.0E-05	 Y	 -0.05	 0.11	 N	 0	 0.50	 N	 0	 0.50	 N	
mir-525	 -0.05	 0.07	 N	 0.04	 0.11	 N	 0	 0.50	 N	 0	 0.50	 N	
mir-518f	 0.04	 0.14	 N	 0.04	 0.11	 N	 0	 0.50	 N	 0	 0.50	 N	
mir-3913-1	 -0.21	 1.0E-05	 Y	 -0.04	 0.11	 N	 0	 0.50	 N	 0	 0.50	 N	
mir-938	 -4.2E-03	 0.45	 N	 0.04	 0.11	 N	 0	 0.50	 N	 0	 0.50	 N	
mir-16-1	 0.08	 0.02	 Y	 0.04	 0.12	 N	 0	 0.50	 N	 0	 0.50	 N	
mir-490	 -0.03	 0.18	 N	 -0.04	 0.12	 N	 0	 0.50	 N	 0	 0.50	 N	
mir-1290	 0.17	 1.0E-05	 Y	 -0.04	 0.12	 N	 0	 0.50	 N	 0	 0.50	 N	
mir-3943	 -0.09	 6.1E-03	 Y	 -0.04	 0.12	 N	 0	 0.50	 N	 0	 0.50	 N	
mir-3929	 0.11	 1.5E-03	 Y	 -0.04	 0.12	 N	 0	 0.50	 N	 0	 0.50	 N	
mir-3180-2	 0.01	 0.39	 N	 0.04	 0.12	 N	 0	 0.50	 N	 0	 0.50	 N	
mir-3143	 0.24	 1.0E-05	 Y	 -0.04	 0.12	 N	 0	 0.50	 N	 0	 0.50	 N	
mir-3916	 -0.07	 0.03	 Y	 0.04	 0.13	 N	 0	 0.50	 N	 0	 0.50	 N	
mir-489	 -0.25	 1.0E-05	 Y	 0.04	 0.13	 N	 0	 0.50	 N	 0	 0.50	 N	
mir-3185	 -0.02	 0.26	 N	 0.04	 0.13	 N	 0	 0.50	 N	 0	 0.50	 N	
mir-1322	 0.11	 1.6E-03	 Y	 -0.04	 0.13	 N	 0	 0.50	 N	 0	 0.50	 N	
mir-4306	 9.9E-03	 0.40	 N	 0.04	 0.13	 N	 0	 0.50	 N	 0	 0.50	 N	
mir-3184	 -0.12	 4.4E-04	 Y	 -0.04	 0.13	 N	 0	 0.50	 N	 0	 0.50	 N	
mir-513a-2	 0.04	 0.12	 N	 -0.04	 0.13	 N	 0	 0.50	 N	 0	 0.50	 N	
mir-520d	 0.09	 4.9E-03	 Y	 -0.04	 0.13	 N	 0	 0.50	 N	 0	 0.50	 N	
mir-3065	 -0.08	 0.02	 Y	 -0.04	 0.14	 N	 0	 0.50	 N	 0	 0.50	 N	
mir-518a-2	 0.08	 9.6E-03	 Y	 0.04	 0.14	 N	 0	 0.50	 N	 0	 0.50	 N	
mir-937	 0.39	 1.0E-05	 Y	 -0.04	 0.14	 N	 0	 0.50	 N	 0	 0.50	 N	
mir-1248	 0.12	 4.8E-04	 Y	 -0.04	 0.15	 N	 0	 0.50	 N	 0	 0.50	 N	
mir-602	 0.04	 0.15	 N	 0.04	 0.15	 N	 0	 0.50	 N	 0	 0.50	 N	
mir-1178	 0.03	 0.17	 N	 0.04	 0.15	 N	 0	 0.50	 N	 0	 0.50	 N	
mir-1238	 0.02	 0.30	 N	 -0.04	 0.16	 N	 0	 0.50	 N	 0	 0.50	 N	
mir-1306	 0.24	 1.0E-05	 Y	 0.04	 0.16	 N	 0	 0.50	 N	 0	 0.50	 N	
mir-578	 -0.11	 9.6E-04	 Y	 -0.04	 0.16	 N	 0	 0.50	 N	 0	 0.50	 N	
mir-3945	 0.10	 1.9E-03	 Y	 0.04	 0.16	 N	 0	 0.50	 N	 0	 0.50	 N	
mir-548x	 -0.07	 0.03	 Y	 0.04	 0.16	 N	 0	 0.50	 N	 0	 0.50	 N	
mir-3159	 0.08	 9.9E-03	 Y	 0.04	 0.16	 N	 0	 0.50	 N	 0	 0.50	 N	
let-7a-3	 -0.36	 1.0E-05	 Y	 -0.04	 0.16	 N	 0	 0.50	 N	 0	 0.50	 N	
mir-621	 0.13	 1.4E-04	 Y	 -0.04	 0.16	 N	 0	 0.50	 N	 0	 0.50	 N	
mir-3937	 0.08	 0.01	 Y	 -0.04	 0.16	 N	 0	 0.50	 N	 0	 0.50	 N	
mir-3183	 0.11	 9.1E-04	 Y	 0.03	 0.17	 N	 0	 0.50	 N	 0	 0.50	 N	
mir-891b	 0.08	 0.02	 Y	 0.03	 0.17	 N	 0	 0.50	 N	 0	 0.50	 N	
mir-3074	 0.17	 1.0E-05	 Y	 -0.03	 0.17	 N	 0	 0.50	 N	 0	 0.50	 N	
mir-1285-1	 0.10	 1.9E-03	 Y	 0.03	 0.17	 N	 0	 0.50	 N	 0	 0.50	 N	
mir-3611	 0.05	 0.09	 N	 -0.03	 0.18	 N	 0	 0.50	 N	 0	 0.50	 N	
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mir-513a-1	 0.02	 0.26	 N	 -0.03	 0.18	 N	 0	 0.50	 N	 0	 0.50	 N	
mir-4289	 0.03	 0.23	 N	 0.03	 0.18	 N	 0	 0.50	 N	 0	 0.50	 N	
mir-95	 -0.05	 0.07	 N	 -0.03	 0.18	 N	 0	 0.50	 N	 0	 0.50	 N	
mir-614	 0.03	 0.24	 N	 0.03	 0.18	 N	 0	 0.50	 N	 0	 0.50	 N	
mir-1255a	 -0.03	 0.21	 N	 -0.03	 0.18	 N	 0	 0.50	 N	 0	 0.50	 N	
mir-3146	 0.13	 1.8E-04	 Y	 -0.03	 0.18	 N	 0	 0.50	 N	 0	 0.50	 N	
mir-1256	 0.05	 0.08	 N	 -0.03	 0.18	 N	 0	 0.50	 N	 0	 0.50	 N	
mir-449b	 -0.19	 1.0E-05	 Y	 -0.03	 0.18	 N	 0	 0.50	 N	 0	 0.50	 N	
mir-3915	 0.01	 0.37	 N	 0.03	 0.18	 N	 0	 0.50	 N	 0	 0.50	 N	
mir-802	 0.15	 4.0E-05	 Y	 -0.03	 0.18	 N	 0	 0.50	 N	 0	 0.50	 N	
mir-612	 0.06	 0.04	 Y	 -0.03	 0.18	 N	 0	 0.50	 N	 0	 0.50	 N	
mir-1911	 6.9E-03	 0.43	 N	 -0.03	 0.19	 N	 0	 0.50	 N	 0	 0.50	 N	
mir-320e	 0.01	 0.36	 N	 -0.03	 0.19	 N	 0	 0.50	 N	 0	 0.50	 N	
mir-3177	 0.09	 6.3E-03	 Y	 0.03	 0.19	 N	 0	 0.50	 N	 0	 0.50	 N	
mir-3919	 -0.12	 6.0E-04	 Y	 0.03	 0.19	 N	 0	 0.50	 N	 0	 0.50	 N	
let-7f-2	 -0.25	 1.0E-05	 Y	 0.03	 0.19	 N	 0	 0.50	 N	 0	 0.50	 N	
mir-3660	 0.10	 3.6E-03	 Y	 -0.03	 0.20	 N	 0	 0.50	 N	 0	 0.50	 N	
mir-662	 0.14	 5.0E-05	 Y	 0.03	 0.20	 N	 0	 0.50	 N	 0	 0.50	 N	
mir-3158-2	 0.12	 3.1E-04	 Y	 -0.03	 0.20	 N	 0	 0.50	 N	 0	 0.50	 N	
mir-3909	 0.26	 1.0E-05	 Y	 0.03	 0.20	 N	 0	 0.50	 N	 0	 0.50	 N	
mir-3646	 -0.09	 8.0E-03	 Y	 0.03	 0.20	 N	 0	 0.50	 N	 0	 0.50	 N	
mir-1825	 -0.01	 0.37	 N	 -0.03	 0.20	 N	 0	 0.50	 N	 0	 0.50	 N	
mir-509-3	 0.15	 4.0E-05	 Y	 0.03	 0.21	 N	 0	 0.50	 N	 0	 0.50	 N	
mir-888	 -0.06	 0.05	 N	 -0.03	 0.21	 N	 0	 0.50	 N	 0	 0.50	 N	
mir-554	 0.01	 0.36	 N	 -0.03	 0.21	 N	 0	 0.50	 N	 0	 0.50	 N	
mir-3680	 0.19	 1.0E-05	 Y	 0.03	 0.21	 N	 0	 0.50	 N	 0	 0.50	 N	
mir-3938	 0.13	 1.7E-04	 Y	 -0.03	 0.21	 N	 0	 0.50	 N	 0	 0.50	 N	
mir-524	 4.2E-03	 0.46	 N	 -0.03	 0.21	 N	 0	 0.50	 N	 0	 0.50	 N	
mir-548l	 0.09	 6.8E-03	 Y	 0.03	 0.21	 N	 0	 0.50	 N	 0	 0.50	 N	
mir-522	 0.17	 1.0E-05	 Y	 0.03	 0.21	 N	 0	 0.50	 N	 0	 0.50	 N	
mir-3164	 0.16	 1.0E-05	 Y	 0.03	 0.22	 N	 0	 0.50	 N	 0	 0.50	 N	
mir-610	 0.10	 2.6E-03	 Y	 -0.03	 0.22	 N	 0	 0.50	 N	 0	 0.50	 N	
mir-513b	 0.06	 0.05	 N	 -0.03	 0.23	 N	 0	 0.50	 N	 0	 0.50	 N	
mir-3136	 0.20	 1.0E-05	 Y	 0.03	 0.23	 N	 0	 0.50	 N	 0	 0.50	 N	
mir-509-1	 0.06	 0.04	 Y	 0.03	 0.23	 N	 0	 0.50	 N	 0	 0.50	 N	
mir-3124	 0.16	 1.0E-05	 Y	 -0.03	 0.24	 N	 0	 0.50	 N	 0	 0.50	 N	
mir-3137	 0.18	 1.0E-05	 Y	 0.03	 0.24	 N	 0	 0.50	 N	 0	 0.50	 N	
mir-514-3	 -0.08	 0.01	 Y	 0.03	 0.24	 N	 0	 0.50	 N	 0	 0.50	 N	
mir-622	 0.05	 0.08	 N	 0.02	 0.25	 N	 0	 0.50	 N	 0	 0.50	 N	
mir-631	 0.02	 0.33	 N	 0.02	 0.25	 N	 0	 0.50	 N	 0	 0.50	 N	
mir-1236	 0.24	 1.0E-05	 Y	 0.02	 0.25	 N	 0	 0.50	 N	 0	 0.50	 N	
mir-3920	 -0.07	 0.03	 Y	 0.02	 0.25	 N	 0	 0.50	 N	 0	 0.50	 N	
mir-3617	 0.06	 0.05	 N	 -0.02	 0.25	 N	 0	 0.50	 N	 0	 0.50	 N	
mir-3158-1	 0.05	 0.10	 N	 0.02	 0.25	 N	 0	 0.50	 N	 0	 0.50	 N	
mir-3173	 0.09	 6.4E-03	 Y	 0.02	 0.26	 N	 0	 0.50	 N	 0	 0.50	 N	
mir-1912	 -0.14	 6.0E-05	 Y	 0.02	 0.27	 N	 0	 0.50	 N	 0	 0.50	 N	
mir-3912	 -0.02	 0.34	 N	 -0.02	 0.27	 N	 0	 0.50	 N	 0	 0.50	 N	
mir-3125	 0.10	 2.9E-03	 Y	 -0.02	 0.27	 N	 0	 0.50	 N	 0	 0.50	 N	
mir-639	 0.08	 0.02	 Y	 -0.02	 0.27	 N	 0	 0.50	 N	 0	 0.50	 N	
mir-3145	 0.21	 1.0E-05	 Y	 0.02	 0.27	 N	 0	 0.50	 N	 0	 0.50	 N	
mir-3651	 0.14	 9.0E-05	 Y	 -0.02	 0.27	 N	 0	 0.50	 N	 0	 0.50	 N	
mir-609	 -0.12	 3.4E-04	 Y	 0.02	 0.27	 N	 0	 0.50	 N	 0	 0.50	 N	
mir-596	 -0.08	 0.01	 Y	 -0.02	 0.28	 N	 0	 0.50	 N	 0	 0.50	 N	
mir-449c	 -0.19	 1.0E-05	 Y	 0.02	 0.28	 N	 0	 0.50	 N	 0	 0.50	 N	
mir-3907	 0.04	 0.14	 N	 -0.02	 0.28	 N	 0	 0.50	 N	 0	 0.50	 N	
mir-550a-1	 0.21	 1.0E-05	 Y	 -0.02	 0.29	 N	 0	 0.50	 N	 0	 0.50	 N	
mir-3156-3	 -0.09	 5.4E-03	 Y	 -0.02	 0.29	 N	 0	 0.50	 N	 0	 0.50	 N	
mir-514b	 8.5E-03	 0.41	 N	 -0.02	 0.29	 N	 0	 0.50	 N	 0	 0.50	 N	
mir-216b	 0.04	 0.16	 N	 -0.02	 0.29	 N	 0	 0.50	 N	 0	 0.50	 N	
mir-765	 0.07	 0.02	 Y	 -0.02	 0.29	 N	 0	 0.50	 N	 0	 0.50	 N	
mir-3923	 0.04	 0.16	 N	 0.02	 0.29	 N	 0	 0.50	 N	 0	 0.50	 N	
mir-3131	 0.08	 0.01	 Y	 0.02	 0.30	 N	 0	 0.50	 N	 0	 0.50	 N	
mir-630	 -0.09	 5.8E-03	 Y	 0.02	 0.30	 N	 0	 0.50	 N	 0	 0.50	 N	
mir-3939	 0.13	 1.7E-04	 Y	 -0.02	 0.31	 N	 0	 0.50	 N	 0	 0.50	 N	
mir-588	 0.29	 1.0E-05	 Y	 0.02	 0.31	 N	 0	 0.50	 N	 0	 0.50	 N	
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mir-720	 0.02	 0.25	 N	 -0.02	 0.31	 N	 0	 0.50	 N	 0	 0.50	 N	
mir-550b-1	 9.2E-03	 0.40	 N	 -0.02	 0.31	 N	 0	 0.50	 N	 0	 0.50	 N	
mir-595	 0.07	 0.02	 Y	 -0.02	 0.32	 N	 0	 0.50	 N	 0	 0.50	 N	
mir-3927	 0.05	 0.08	 N	 0.02	 0.32	 N	 0	 0.50	 N	 0	 0.50	 N	
mir-3659	 -0.04	 0.15	 N	 -0.02	 0.32	 N	 0	 0.50	 N	 0	 0.50	 N	
mir-514-1	 -0.10	 2.2E-03	 Y	 0.02	 0.33	 N	 0	 0.50	 N	 0	 0.50	 N	
mir-3168	 -1.3E-03	 0.48	 N	 0.02	 0.33	 N	 0	 0.50	 N	 0	 0.50	 N	
mir-2277	 0.29	 1.0E-05	 Y	 0.01	 0.34	 N	 0	 0.50	 N	 0	 0.50	 N	
mir-3162	 -0.03	 0.24	 N	 -0.01	 0.35	 N	 0	 0.50	 N	 0	 0.50	 N	
mir-1289-1	 -0.02	 0.30	 N	 0.01	 0.36	 N	 0	 0.50	 N	 0	 0.50	 N	
mir-583	 -0.01	 0.34	 N	 0.01	 0.36	 N	 0	 0.50	 N	 0	 0.50	 N	
mir-1257	 0.05	 0.09	 N	 -0.01	 0.36	 N	 0	 0.50	 N	 0	 0.50	 N	
mir-4286	 -0.04	 0.15	 N	 -0.01	 0.36	 N	 0	 0.50	 N	 0	 0.50	 N	
mir-4284	 0.08	 0.01	 Y	 0.01	 0.37	 N	 0	 0.50	 N	 0	 0.50	 N	
mir-3187	 0.21	 1.0E-05	 Y	 -0.01	 0.37	 N	 0	 0.50	 N	 0	 0.50	 N	
mir-422a	 0.06	 0.05	 N	 0.01	 0.37	 N	 0	 0.50	 N	 0	 0.50	 N	
mir-19b-1	 0.17	 1.0E-05	 Y	 0.01	 0.37	 N	 0	 0.50	 N	 0	 0.50	 N	
mir-552	 0.10	 1.8E-03	 Y	 -0.01	 0.38	 N	 0	 0.50	 N	 0	 0.50	 N	
mir-3161	 0.01	 0.38	 N	 0.01	 0.38	 N	 0	 0.50	 N	 0	 0.50	 N	
mir-650	 0.12	 5.9E-04	 Y	 -0.01	 0.38	 N	 0	 0.50	 N	 0	 0.50	 N	
mir-515-1	 -0.02	 0.26	 N	 0.01	 0.38	 N	 0	 0.50	 N	 0	 0.50	 N	
mir-153-1	 -0.10	 2.0E-03	 Y	 -0.01	 0.39	 N	 0	 0.50	 N	 0	 0.50	 N	
mir-1181	 0.02	 0.33	 N	 -9.8E-03	 0.39	 N	 0	 0.50	 N	 0	 0.50	 N	
mir-579	 0.34	 1.0E-05	 Y	 -9.5E-03	 0.40	 N	 0	 0.50	 N	 0	 0.50	 N	
mir-520c	 -8.6E-03	 0.40	 N	 9.7E-03	 0.40	 N	 0	 0.50	 N	 0	 0.50	 N	
mir-519b	 0.10	 2.3E-03	 Y	 9.1E-03	 0.40	 N	 0	 0.50	 N	 0	 0.50	 N	
mir-616	 0.27	 1.0E-05	 Y	 -8.6E-03	 0.40	 N	 0	 0.50	 N	 0	 0.50	 N	
mir-3138	 0.06	 0.04	 Y	 -8.1E-03	 0.41	 N	 0	 0.50	 N	 0	 0.50	 N	
mir-593	 0.01	 0.34	 N	 -7.9E-03	 0.41	 N	 0	 0.50	 N	 0	 0.50	 N	
mir-3190	 -0.06	 0.05	 N	 -7.7E-03	 0.41	 N	 0	 0.50	 N	 0	 0.50	 N	
mir-632	 -0.08	 0.02	 Y	 -7.6E-03	 0.41	 N	 0	 0.50	 N	 0	 0.50	 N	
mir-1909	 0.22	 1.0E-05	 Y	 -7.5E-03	 0.42	 N	 0	 0.50	 N	 0	 0.50	 N	
mir-1275	 -0.09	 6.5E-03	 Y	 -7.4E-03	 0.42	 N	 0	 0.50	 N	 0	 0.50	 N	
mir-3163	 -0.06	 0.05	 N	 -7.0E-03	 0.42	 N	 0	 0.50	 N	 0	 0.50	 N	
mir-1270-2	 1.9E-03	 0.48	 N	 -6.8E-03	 0.42	 N	 0	 0.50	 N	 0	 0.50	 N	
mir-1539	 0.17	 1.0E-05	 Y	 7.2E-03	 0.42	 N	 0	 0.50	 N	 0	 0.50	 N	
mir-3940	 0.25	 1.0E-05	 Y	 -6.5E-03	 0.43	 N	 0	 0.50	 N	 0	 0.50	 N	
mir-606	 -0.08	 0.02	 Y	 -6.3E-03	 0.43	 N	 0	 0.50	 N	 0	 0.50	 N	
mir-3621	 -0.08	 0.02	 Y	 -6.3E-03	 0.43	 N	 0	 0.50	 N	 0	 0.50	 N	
mir-586	 -0.05	 0.07	 N	 6.3E-03	 0.43	 N	 0	 0.50	 N	 0	 0.50	 N	
mir-600	 -0.06	 0.04	 Y	 -5.6E-03	 0.44	 N	 0	 0.50	 N	 0	 0.50	 N	
mir-3928	 0.22	 1.0E-05	 Y	 -5.2E-03	 0.44	 N	 0	 0.50	 N	 0	 0.50	 N	
mir-1237	 0.26	 1.0E-05	 Y	 5.6E-03	 0.44	 N	 0	 0.50	 N	 0	 0.50	 N	
mir-320d-2	 -0.05	 0.09	 N	 5.4E-03	 0.44	 N	 0	 0.50	 N	 0	 0.50	 N	
mir-657	 -0.09	 8.9E-03	 Y	 4.9E-03	 0.45	 N	 0	 0.50	 N	 0	 0.50	 N	
mir-3181	 -0.07	 0.03	 Y	 -4.2E-03	 0.45	 N	 0	 0.50	 N	 0	 0.50	 N	
mir-548v	 -0.01	 0.39	 N	 -4.2E-03	 0.45	 N	 0	 0.50	 N	 0	 0.50	 N	
mir-3911	 0.19	 1.0E-05	 Y	 4.3E-03	 0.46	 N	 0	 0.50	 N	 0	 0.50	 N	
mir-611	 0.11	 1.5E-03	 Y	 -3.8E-03	 0.46	 N	 0	 0.50	 N	 0	 0.50	 N	
mir-3170	 0.06	 0.06	 N	 -3.7E-03	 0.46	 N	 0	 0.50	 N	 0	 0.50	 N	
mir-1288	 0.01	 0.39	 N	 -3.7E-03	 0.46	 N	 0	 0.50	 N	 0	 0.50	 N	
mir-519e	 0.03	 0.20	 N	 -3.5E-03	 0.46	 N	 0	 0.50	 N	 0	 0.50	 N	
mir-576	 0.28	 1.0E-05	 Y	 -3.5E-03	 0.46	 N	 0	 0.50	 N	 0	 0.50	 N	
mir-555	 0.13	 1.9E-04	 Y	 -3.4E-03	 0.46	 N	 0	 0.50	 N	 0	 0.50	 N	
mir-636	 0.32	 1.0E-05	 Y	 3.5E-03	 0.46	 N	 0	 0.50	 N	 0	 0.50	 N	
mir-3179-2	 0.06	 0.05	 N	 3.5E-03	 0.47	 N	 0	 0.50	 N	 0	 0.50	 N	
mir-3620	 0.23	 1.0E-05	 Y	 -2.2E-03	 0.47	 N	 0	 0.50	 N	 0	 0.50	 N	
mir-3609	 0.04	 0.13	 N	 2.6E-03	 0.48	 N	 0	 0.50	 N	 0	 0.50	 N	
mir-943	 0.22	 1.0E-05	 Y	 2.5E-03	 0.48	 N	 0	 0.50	 N	 0	 0.50	 N	
mir-521-2	 0.16	 1.0E-05	 Y	 -1.8E-03	 0.48	 N	 0	 0.50	 N	 0	 0.50	 N	
mir-3691	 0.15	 1.0E-05	 Y	 -1.6E-03	 0.48	 N	 0	 0.50	 N	 0	 0.50	 N	
mir-627	 -0.04	 0.17	 N	 1.7E-03	 0.48	 N	 0	 0.50	 N	 0	 0.50	 N	
mir-604	 -0.04	 0.11	 N	 -7.0E-04	 0.49	 N	 0	 0.50	 N	 0	 0.50	 N	
mir-3160-1	 -0.12	 4.1E-04	 Y	 1.2E-04	 0.50	 N	 0	 0.50	 N	 0	 0.50	 N	
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miRNA	 S(M,P)	 P-value	 BH	 S(M,R)	 P-value	 BH	 ES_P	 P-value	 BH	 ES_R	 P-value	 BH	
mir-376a-2	 0.02	 0.29	 N	 -0.02	 0.28	 N	 0.45	 1.0E-05	 Y	 -0.42	 1.0E-05	 Y	
mir-376a-1	 0.08	 0.02	 Y	 -0.01	 0.37	 N	 0.45	 1.0E-05	 Y	 -0.42	 1.0E-05	 Y	
mir-501	 0.09	 0.01	 Y	 2.2E-03	 0.48	 N	 0.45	 1.0E-05	 Y	 -0.26	 1.0E-05	 Y	
mir-598	 -0.10	 7.7E-03	 Y	 0.01	 0.39	 N	 0.45	 1.0E-05	 Y	 -0.21	 1.0E-05	 Y	
mir-1303	 0.07	 0.05	 N	 -0.02	 0.28	 N	 0.08	 0.02	 Y	 0.16	 1.0E-05	 Y	
mir-18b	 0.18	 1.0E-05	 Y	 -0.06	 0.09	 N	 0.06	 0.06	 N	 0.16	 1.0E-05	 Y	
mir-194-2	 -0.02	 0.32	 N	 -0.05	 0.11	 N	 0.14	 2.0E-04	 Y	 0.16	 1.0E-05	 Y	
mir-194-1	 -0.02	 0.31	 N	 -0.05	 0.12	 N	 0.14	 2.0E-04	 Y	 0.16	 1.0E-05	 Y	
mir-1307	 0.09	 0.02	 Y	 -1.3E-03	 0.49	 N	 0.34	 1.0E-05	 Y	 0.17	 1.0E-05	 Y	
mir-132	 -0.04	 0.16	 N	 0.21	 1.0E-05	 Y	 0.01	 0.40	 N	 0.18	 1.0E-05	 Y	
mir-140	 -0.05	 0.11	 N	 0.18	 1.0E-05	 Y	 6.9E-03	 0.44	 N	 0.18	 1.0E-05	 Y	
mir-19b-2	 0.03	 0.23	 N	 -0.06	 0.07	 N	 0.08	 0.03	 N	 0.18	 1.0E-05	 Y	
mir-130b	 0.21	 1.0E-05	 Y	 -0.02	 0.31	 N	 0.09	 0.01	 Y	 0.19	 1.0E-05	 Y	
mir-138-1	 -0.02	 0.32	 N	 0.08	 0.02	 Y	 0.07	 0.04	 N	 0.19	 1.0E-05	 Y	
mir-138-2	 0.08	 0.02	 Y	 -0.03	 0.20	 N	 0.07	 0.04	 N	 0.19	 1.0E-05	 Y	
mir-124-2	 -0.05	 0.13	 N	 0.08	 0.02	 Y	 -1.4E-
03	
0.49	 N	 0.19	 1.0E-05	 Y	
mir-124-1	 -0.07	 0.05	 N	 0.05	 0.11	 N	 -1.4E-
03	
0.49	 N	 0.19	 1.0E-05	 Y	
mir-124-3	 -7.2E-03	 0.43	 N	 0.02	 0.29	 N	 -4.1E-
03	
0.46	 N	 0.19	 1.0E-05	 Y	
mir-181c	 -0.03	 0.23	 N	 -0.09	 0.01	 Y	 0.16	 1.0E-05	 Y	 0.20	 1.0E-05	 Y	
mir-941-1	 0.05	 0.11	 N	 0.06	 0.09	 N	 0.18	 1.0E-05	 Y	 0.21	 1.0E-05	 Y	
mir-143	 -5.8E-03	 0.44	 N	 0.17	 1.0E-05	 Y	 0.13	 8.7E-04	 Y	 0.21	 1.0E-05	 Y	
mir-29a	 -0.19	 2.0E-05	 Y	 0.06	 0.08	 N	 0.09	 0.02	 Y	 0.21	 1.0E-05	 Y	
mir-224	 -0.02	 0.32	 N	 0.22	 1.0E-05	 Y	 0.19	 1.0E-05	 Y	 0.22	 1.0E-05	 Y	
mir-374b	 0.06	 0.06	 N	 -0.02	 0.34	 N	 0.04	 0.15	 N	 0.22	 1.0E-05	 Y	
mir-211	 -0.02	 0.30	 N	 -0.07	 0.05	 N	 0.10	 9.9E-03	 Y	 0.23	 1.0E-05	 Y	
mir-33a	 0.15	 7.0E-05	 Y	 0.08	 0.03	 Y	 0.04	 0.14	 N	 0.23	 1.0E-05	 Y	
mir-137	 -0.02	 0.28	 N	 0.07	 0.03	 Y	 0.11	 4.8E-03	 Y	 0.23	 1.0E-05	 Y	
mir-146a	 -0.04	 0.16	 N	 0.24	 1.0E-05	 Y	 0.02	 0.33	 N	 0.26	 1.0E-05	 Y	
mir-200b	 -0.02	 0.28	 N	 -0.08	 0.03	 Y	 0.05	 0.13	 N	 0.27	 1.0E-05	 Y	
mir-133a-2	 -0.03	 0.25	 N	 0.16	 1.0E-05	 Y	 -0.10	 8.2E-03	 Y	 0.28	 1.0E-05	 Y	
mir-133a-1	 -0.06	 0.08	 N	 0.30	 1.0E-05	 Y	 -0.10	 8.2E-03	 Y	 0.28	 1.0E-05	 Y	
mir-141	 0.05	 0.13	 N	 -0.16	 3.0E-05	 Y	 0.08	 0.03	 N	 0.29	 1.0E-05	 Y	
mir-146b	 -0.06	 0.06	 N	 0.01	 0.41	 N	 -0.03	 0.22	 N	 0.29	 1.0E-05	 Y	
mir-199a-2	 -0.11	 3.6E-03	 Y	 0.34	 1.0E-05	 Y	 -0.19	 2.0E-05	 Y	 0.29	 1.0E-05	 Y	
mir-199a-1	 -0.12	 1.7E-03	 Y	 0.35	 1.0E-05	 Y	 -0.19	 2.0E-05	 Y	 0.29	 1.0E-05	 Y	
mir-205	 -5.4E-03	 0.45	 N	 0.04	 0.18	 N	 -0.09	 0.01	 Y	 0.30	 1.0E-05	 Y	
mir-203	 -0.07	 0.04	 Y	 0.08	 0.02	 Y	 0.12	 1.9E-03	 Y	 0.31	 1.0E-05	 Y	
mir-200a	 0.09	 0.02	 Y	 -0.15	 2.0E-04	 Y	 0.06	 0.06	 N	 0.32	 1.0E-05	 Y	
mir-200c	 -0.08	 0.03	 Y	 -0.13	 5.2E-04	 Y	 0.08	 0.03	 N	 0.32	 1.0E-05	 Y	
mir-19a	 0.14	 1.7E-04	 Y	 -0.12	 1.0E-03	 Y	 -0.12	 1.2E-03	 Y	 0.32	 1.0E-05	 Y	
mir-150	 -0.02	 0.35	 N	 0.40	 1.0E-05	 Y	 2.2E-03	 0.48	 N	 0.37	 1.0E-05	 Y	
mir-429	 0.06	 0.06	 N	 -0.10	 9.3E-03	 Y	 -0.09	 0.02	 Y	 0.37	 1.0E-05	 Y	
mir-130a	 0.14	 2.5E-04	 Y	 -0.15	 2.6E-04	 Y	 -0.07	 0.04	 N	 0.39	 1.0E-05	 Y	
mir-372	 0.03	 0.26	 N	 -0.10	 5.3E-03	 Y	 -0.18	 2.0E-05	 Y	 0.53	 1.0E-05	 Y	
mir-766	 0.14	 5.0E-04	 Y	 0.20	 1.0E-05	 Y	 0.18	 1.0E-05	 Y	 -0.19	 2.0E-05	 Y	
mir-625	 0.11	 5.3E-03	 Y	 -0.11	 4.3E-03	 Y	 -0.16	 3.0E-05	 Y	 0.15	 6.0E-05	 Y	
mir-1227	 0.04	 0.18	 N	 -0.06	 0.08	 N	 0.31	 1.0E-05	 Y	 -0.15	 1.1E-04	 Y	
mir-335	 0.09	 0.01	 Y	 -0.12	 1.0E-03	 Y	 -0.15	 1.1E-04	 Y	 0.15	 1.1E-04	 Y	
mir-671	 0.11	 2.8E-03	 Y	 -0.01	 0.38	 N	 0.16	 1.0E-05	 Y	 -0.15	 1.3E-04	 Y	
mir-103-2	 0.19	 1.0E-05	 Y	 -0.06	 0.06	 N	 0.14	 4.3E-04	 Y	 0.14	 1.7E-04	 Y	
mir-103-1	 0.01	 0.36	 N	 -0.03	 0.26	 N	 0.14	 4.3E-04	 Y	 0.14	 1.7E-04	 Y	
mir-214	 -0.10	 5.6E-03	 Y	 0.44	 1.0E-05	 Y	 0.10	 6.0E-03	 Y	 0.14	 1.7E-04	 Y	
let-7g	 -0.06	 0.06	 N	 0.03	 0.27	 N	 0.23	 1.0E-05	 Y	 0.14	 3.4E-04	 Y	
mir-374a	 -0.02	 0.33	 N	 0.07	 0.05	 N	 0.11	 4.6E-03	 Y	 0.14	 3.6E-04	 Y	
mir-217	 0.03	 0.26	 N	 0.22	 1.0E-05	 Y	 0.10	 7.3E-03	 Y	 0.13	 6.6E-04	 Y	
mir-98	 0.02	 0.33	 N	 2.6E-04	 0.50	 N	 0.11	 4.0E-03	 Y	 0.13	 7.5E-04	 Y	
mir-29b-1	 -0.11	 2.2E-03	 Y	 6.9E-03	 0.44	 N	 0.12	 2.7E-03	 Y	 0.13	 7.9E-04	 Y	
mir-92a-1	 -0.02	 0.34	 N	 -0.07	 0.05	 N	 0.22	 1.0E-05	 Y	 -0.13	 8.1E-04	 Y	
mir-30d	 -0.11	 2.7E-03	 Y	 -0.04	 0.15	 N	 0.06	 0.06	 N	 0.13	 8.5E-04	 Y	
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mir-345	 0.22	 1.0E-05	 Y	 -0.12	 1.4E-03	 Y	 0.24	 1.0E-05	 Y	 0.13	 8.9E-04	 Y	
mir-301a	 0.16	 1.0E-05	 Y	 -0.16	 8.0E-05	 Y	 0.22	 1.0E-05	 Y	 0.13	 1.1E-03	 Y	
mir-212	 0.06	 0.07	 N	 0.25	 1.0E-05	 Y	 0.20	 1.0E-05	 Y	 -0.12	 1.2E-03	 Y	
mir-375	 -0.03	 0.25	 N	 -0.16	 3.0E-05	 Y	 0.12	 1.3E-03	 Y	 0.13	 1.2E-03	 Y	
mir-142	 0.03	 0.23	 N	 0.29	 1.0E-05	 Y	 0.07	 0.05	 N	 0.12	 1.4E-03	 Y	
mir-346	 -0.05	 0.13	 N	 0.13	 1.2E-03	 Y	 -0.11	 4.0E-03	 Y	 0.12	 1.5E-03	 Y	
mir-29c	 -0.10	 8.9E-03	 Y	 0.04	 0.19	 N	 0.22	 1.0E-05	 Y	 0.12	 1.5E-03	 Y	
mir-532	 0.04	 0.19	 N	 -0.03	 0.21	 N	 0.26	 1.0E-05	 Y	 -0.12	 1.5E-03	 Y	
mir-190	 0.05	 0.14	 N	 7.7E-03	 0.43	 N	 0.04	 0.14	 N	 0.12	 1.6E-03	 Y	
mir-223	 -0.09	 0.02	 Y	 0.30	 1.0E-05	 Y	 0.01	 0.40	 N	 0.12	 1.8E-03	 Y	
mir-195	 -0.11	 2.5E-03	 Y	 0.12	 2.7E-03	 Y	 0.08	 0.03	 N	 0.12	 1.9E-03	 Y	
mir-96	 0.01	 0.36	 N	 -0.15	 1.6E-04	 Y	 0.15	 7.0E-05	 Y	 0.12	 2.2E-03	 Y	
mir-708	 -0.03	 0.21	 N	 0.05	 0.12	 N	 0.28	 1.0E-05	 Y	 -0.11	 2.4E-03	 Y	
mir-155	 0.01	 0.40	 N	 0.17	 1.0E-05	 Y	 0.15	 2.0E-05	 Y	 0.12	 2.5E-03	 Y	
mir-1914	 0.19	 1.0E-05	 Y	 -0.03	 0.20	 N	 0.23	 1.0E-05	 Y	 -0.11	 2.8E-03	 Y	
mir-145	 -0.12	 1.0E-03	 Y	 0.26	 1.0E-05	 Y	 0.10	 9.5E-03	 Y	 0.11	 2.8E-03	 Y	
mir-30a	 -0.04	 0.19	 N	 -0.05	 0.09	 N	 0.18	 1.0E-05	 Y	 0.11	 2.8E-03	 Y	
mir-590	 0.12	 2.2E-03	 Y	 -0.04	 0.18	 N	 0.15	 4.0E-05	 Y	 0.11	 3.1E-03	 Y	
mir-365-2	 -0.06	 0.06	 N	 0.06	 0.06	 N	 -0.03	 0.20	 N	 0.11	 4.6E-03	 Y	
mir-365-1	 -0.07	 0.05	 N	 0.05	 0.10	 N	 -0.03	 0.20	 N	 0.11	 4.6E-03	 Y	
mir-362	 0.08	 0.03	 Y	 -0.10	 6.9E-03	 Y	 0.54	 1.0E-05	 Y	 0.11	 5.4E-03	 Y	
mir-302a	 -0.04	 0.18	 N	 0.01	 0.41	 N	 0.09	 0.01	 Y	 0.10	 5.5E-03	 Y	
mir-320c-2	 -0.06	 0.06	 N	 -0.08	 0.02	 Y	 0.19	 1.0E-05	 Y	 0.10	 5.8E-03	 Y	
mir-320c-1	 -0.12	 1.5E-03	 Y	 0.01	 0.37	 N	 0.19	 1.0E-05	 Y	 0.10	 5.8E-03	 Y	
mir-21	 -0.04	 0.17	 N	 0.28	 1.0E-05	 Y	 0.17	 1.0E-05	 Y	 0.10	 6.2E-03	 Y	
mir-10b	 0.08	 0.02	 Y	 -0.13	 8.9E-04	 Y	 0.13	 7.7E-04	 Y	 0.10	 6.8E-03	 Y	
mir-373	 0.10	 6.0E-03	 Y	 -0.08	 0.03	 Y	 0.17	 1.0E-05	 Y	 0.10	 7.1E-03	 Y	
mir-34b	 -0.05	 0.10	 N	 -0.12	 1.1E-03	 Y	 0.12	 1.4E-03	 Y	 0.10	 7.2E-03	 Y	
mir-548b	 0.09	 0.02	 Y	 -0.04	 0.14	 N	 -0.03	 0.23	 N	 0.10	 8.3E-03	 Y	
mir-148b	 -5.5E-03	 0.45	 N	 -0.10	 5.1E-03	 Y	 0.04	 0.15	 N	 0.10	 8.8E-03	 Y	
mir-133b	 -0.02	 0.30	 N	 0.12	 1.7E-03	 Y	 -0.17	 3.0E-05	 Y	 0.09	 0.01	 Y	
mir-148a	 -0.09	 0.02	 Y	 -0.01	 0.37	 N	 0.22	 1.0E-05	 Y	 0.09	 0.01	 Y	
mir-128-1	 0.09	 0.01	 Y	 -0.06	 0.06	 N	 0.10	 7.7E-03	 Y	 0.09	 0.01	 Y	
mir-424	 0.02	 0.34	 N	 0.01	 0.38	 N	 0.27	 1.0E-05	 Y	 0.09	 0.01	 Y	
mir-1-2	 3.4E-03	 0.47	 N	 0.10	 5.9E-03	 Y	 0.15	 1.4E-04	 Y	 0.09	 0.01	 Y	
mir-1-1	 0.02	 0.33	 N	 0.02	 0.35	 N	 0.15	 1.4E-04	 Y	 0.09	 0.01	 Y	
mir-497	 -0.02	 0.33	 N	 0.04	 0.16	 N	 0.18	 1.0E-05	 Y	 -0.09	 0.01	 Y	
mir-27b	 -0.02	 0.35	 N	 0.07	 0.04	 Y	 0.18	 1.0E-05	 Y	 0.09	 0.02	 Y	
mir-330	 0.06	 0.07	 N	 0.05	 0.14	 N	 0.06	 0.07	 N	 0.09	 0.02	 Y	
mir-183	 0.07	 0.03	 Y	 -0.17	 3.0E-05	 Y	 0.18	 1.0E-05	 Y	 0.08	 0.02	 Y	
mir-1180	 0.09	 0.01	 Y	 -0.12	 1.1E-03	 Y	 0.13	 7.1E-04	 Y	 -0.08	 0.03	 Y	
mir-23a	 -0.06	 0.06	 N	 0.08	 0.03	 Y	 0.24	 1.0E-05	 Y	 0.08	 0.03	 Y	
mir-339	 0.11	 3.2E-03	 Y	 -0.04	 0.15	 N	 0.24	 1.0E-05	 Y	 -0.08	 0.03	 Y	
mir-500	 0.05	 0.14	 N	 0.03	 0.20	 N	 0.35	 1.0E-05	 Y	 0.08	 0.03	 Y	
mir-1296	 0.12	 1.6E-03	 Y	 -6.3E-03	 0.44	 N	 0.32	 1.0E-05	 Y	 -0.08	 0.03	 Y	
mir-328	 -0.05	 0.12	 N	 -0.14	 5.0E-04	 Y	 0.18	 1.0E-05	 Y	 -0.07	 0.04	 Y	
mir-1260	 -0.03	 0.25	 N	 -5.9E-03	 0.44	 N	 0.26	 1.0E-05	 Y	 -0.07	 0.04	 N	
mir-26b	 -0.01	 0.38	 N	 -0.08	 0.02	 Y	 0.05	 0.10	 N	 0.07	 0.04	 N	
mir-17	 0.07	 0.05	 N	 -0.08	 0.02	 Y	 0.10	 7.9E-03	 Y	 0.07	 0.05	 N	
mir-101-2	 -0.09	 0.01	 Y	 -0.06	 0.08	 N	 0.22	 1.0E-05	 Y	 0.07	 0.05	 N	
mir-101-1	 -0.12	 1.5E-03	 Y	 -7.5E-03	 0.43	 N	 0.22	 1.0E-05	 Y	 0.07	 0.05	 N	
mir-340	 0.02	 0.31	 N	 0.08	 0.03	 Y	 0.16	 1.0E-05	 Y	 0.07	 0.05	 N	
mir-26a-1	 0.14	 4.4E-04	 Y	 -0.11	 3.1E-03	 Y	 0.14	 4.4E-04	 Y	 0.06	 0.06	 N	
mir-122	 0.04	 0.19	 N	 -0.09	 0.01	 Y	 0.16	 1.0E-05	 Y	 0.06	 0.06	 N	
mir-30b	 -0.02	 0.35	 N	 -0.07	 0.04	 Y	 0.18	 1.0E-05	 Y	 0.06	 0.06	 N	
mir-449a	 -0.09	 0.01	 Y	 -0.17	 3.0E-05	 Y	 0.22	 1.0E-05	 Y	 -0.06	 0.07	 N	
mir-326	 0.01	 0.36	 N	 0.12	 2.5E-03	 Y	 0.15	 1.5E-04	 Y	 -0.06	 0.07	 N	
mir-106b	 0.13	 7.4E-04	 Y	 -0.06	 0.08	 N	 0.14	 3.6E-04	 Y	 0.06	 0.08	 N	
mir-760	 0.13	 7.0E-04	 Y	 -0.09	 0.02	 Y	 0.20	 1.0E-05	 Y	 -0.06	 0.08	 N	
mir-454	 0.19	 1.0E-05	 Y	 -0.10	 7.3E-03	 Y	 0.25	 1.0E-05	 Y	 0.06	 0.09	 N	
mir-197	 0.08	 0.02	 Y	 0.02	 0.28	 N	 0.18	 1.0E-05	 Y	 -0.06	 0.09	 N	
mir-191	 0.05	 0.13	 N	 -0.18	 2.0E-05	 Y	 0.24	 1.0E-05	 Y	 -0.06	 0.09	 N	
mir-93	 0.10	 6.6E-03	 Y	 -0.09	 0.01	 Y	 0.13	 6.0E-04	 Y	 0.06	 0.09	 N	
mir-193a	 -0.11	 4.5E-03	 Y	 0.17	 1.0E-05	 Y	 0.10	 7.5E-03	 Y	 -0.05	 0.09	 N	
mir-503	 0.09	 0.01	 Y	 0.02	 0.29	 N	 0.25	 1.0E-05	 Y	 -0.05	 0.10	 N	
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mir-99b	 0.09	 0.02	 Y	 -0.02	 0.35	 N	 0.22	 1.0E-05	 Y	 -0.05	 0.10	 N	
mir-125a	 -0.11	 3.3E-03	 Y	 0.07	 0.04	 Y	 0.10	 8.3E-03	 Y	 0.05	 0.10	 N	
mir-215	 -0.05	 0.12	 N	 0.01	 0.40	 N	 0.24	 1.0E-05	 Y	 0.05	 0.13	 N	
mir-935	 0.03	 0.27	 N	 -0.07	 0.05	 N	 0.22	 1.0E-05	 Y	 -0.05	 0.13	 N	
mir-221	 -0.11	 3.0E-03	 Y	 0.16	 1.0E-05	 Y	 0.20	 1.0E-05	 Y	 0.05	 0.14	 N	
mir-182	 0.07	 0.06	 N	 -0.17	 3.0E-05	 Y	 0.18	 1.0E-05	 Y	 0.04	 0.14	 N	
let-7b	 -0.15	 1.8E-04	 Y	 0.22	 1.0E-05	 Y	 0.18	 1.0E-05	 Y	 -0.04	 0.14	 N	
mir-9-1	 0.10	 6.5E-03	 Y	 -0.19	 2.0E-05	 Y	 0.13	 5.4E-04	 Y	 0.04	 0.14	 N	
mir-9-2	 0.10	 6.3E-03	 Y	 -0.18	 2.0E-05	 Y	 0.13	 5.4E-04	 Y	 0.04	 0.14	 N	
mir-30c-2	 -0.04	 0.19	 N	 -0.07	 0.05	 N	 0.13	 7.6E-04	 Y	 0.04	 0.15	 N	
mir-874	 0.05	 0.13	 N	 -0.02	 0.33	 N	 0.39	 1.0E-05	 Y	 -0.04	 0.15	 N	
mir-151	 0.04	 0.18	 N	 0.06	 0.08	 N	 0.20	 1.0E-05	 Y	 0.04	 0.15	 N	
mir-193b	 -0.07	 0.05	 N	 0.08	 0.03	 Y	 0.25	 1.0E-05	 Y	 -0.04	 0.15	 N	
mir-185	 0.09	 0.02	 Y	 0.11	 4.4E-03	 Y	 0.23	 1.0E-05	 Y	 0.04	 0.15	 N	
mir-361	 3.3E-03	 0.47	 N	 -6.4E-03	 0.44	 N	 0.20	 1.0E-05	 Y	 -0.04	 0.15	 N	
mir-181a-1	 -0.04	 0.15	 N	 0.17	 1.0E-05	 Y	 0.09	 0.02	 Y	 0.04	 0.16	 N	
mir-615	 0.03	 0.21	 N	 -7.0E-03	 0.43	 N	 0.20	 1.0E-05	 Y	 -0.04	 0.16	 N	
mir-324	 0.11	 3.0E-03	 Y	 -0.05	 0.10	 N	 0.18	 1.0E-05	 Y	 -0.04	 0.16	 N	
mir-421	 0.15	 1.0E-04	 Y	 0.03	 0.25	 N	 0.13	 8.9E-04	 Y	 -0.04	 0.17	 N	
mir-92b	 0.04	 0.19	 N	 -0.12	 1.3E-03	 Y	 0.20	 1.0E-05	 Y	 -0.04	 0.17	 N	
mir-27a	 -4.1E-03	 0.46	 N	 0.07	 0.04	 N	 0.14	 5.0E-04	 Y	 0.04	 0.18	 N	
mir-192	 0.05	 0.10	 N	 -0.10	 7.1E-03	 Y	 0.21	 1.0E-05	 Y	 0.04	 0.18	 N	
mir-222	 -0.13	 8.1E-04	 Y	 0.18	 1.0E-05	 Y	 0.22	 1.0E-05	 Y	 0.04	 0.18	 N	
let-7d	 3.9E-03	 0.46	 N	 0.05	 0.10	 N	 0.18	 1.0E-05	 Y	 -0.04	 0.18	 N	
mir-605	 -0.05	 0.13	 N	 0.31	 1.0E-05	 Y	 0.15	 1.1E-04	 Y	 -0.03	 0.21	 N	
mir-1226	 0.06	 0.06	 N	 -0.08	 0.03	 Y	 0.18	 1.0E-05	 Y	 0.03	 0.21	 N	
mir-425	 0.09	 0.02	 Y	 -0.10	 7.3E-03	 Y	 0.28	 1.0E-05	 Y	 -0.03	 0.22	 N	
mir-331	 0.14	 4.3E-04	 Y	 -0.04	 0.14	 N	 0.13	 7.9E-04	 Y	 -0.03	 0.23	 N	
mir-7-3	 0.08	 0.02	 Y	 -0.05	 0.12	 N	 0.09	 0.01	 Y	 0.03	 0.23	 N	
mir-7-2	 -0.02	 0.30	 N	 -0.03	 0.27	 N	 0.09	 0.01	 Y	 0.03	 0.23	 N	
mir-210	 0.13	 5.4E-04	 Y	 -0.07	 0.05	 N	 0.22	 1.0E-05	 Y	 0.03	 0.23	 N	
mir-10a	 -0.06	 0.07	 N	 0.04	 0.15	 N	 0.14	 3.4E-04	 Y	 0.03	 0.24	 N	
mir-504	 -0.06	 0.08	 N	 0.02	 0.30	 N	 0.03	 0.23	 N	 0.03	 0.25	 N	
mir-22	 -0.02	 0.27	 N	 0.34	 1.0E-05	 Y	 0.19	 1.0E-05	 Y	 0.03	 0.25	 N	
mir-32	 0.31	 1.0E-05	 Y	 -0.16	 3.0E-05	 Y	 0.17	 1.0E-05	 Y	 -0.03	 0.26	 N	
mir-92a-2	 0.05	 0.11	 N	 -0.11	 3.9E-03	 Y	 0.14	 2.5E-04	 Y	 -0.03	 0.26	 N	
mir-30e	 0.01	 0.40	 N	 -0.14	 4.0E-04	 Y	 0.19	 1.0E-05	 Y	 -0.03	 0.26	 N	
mir-940	 0.20	 1.0E-05	 Y	 -0.05	 0.13	 N	 0.03	 0.22	 N	 0.03	 0.26	 N	
let-7a-1	 -0.09	 0.01	 Y	 0.15	 1.7E-04	 Y	 0.15	 1.2E-04	 Y	 -0.03	 0.26	 N	
let-7a-2	 -0.10	 6.4E-03	 Y	 0.14	 2.9E-04	 Y	 0.15	 1.2E-04	 Y	 -0.03	 0.26	 N	
mir-18a	 0.22	 1.0E-05	 Y	 -0.10	 5.0E-03	 Y	 0.17	 1.0E-05	 Y	 0.02	 0.28	 N	
mir-196a-2	 0.06	 0.06	 N	 0.04	 0.15	 N	 0.21	 1.0E-05	 Y	 -0.02	 0.29	 N	
mir-196a-1	 0.09	 0.01	 Y	 0.03	 0.26	 N	 0.21	 1.0E-05	 Y	 -0.02	 0.29	 N	
let-7c	 -0.05	 0.12	 N	 -0.03	 0.22	 N	 0.15	 7.0E-05	 Y	 -0.02	 0.29	 N	
mir-23b	 -0.03	 0.25	 N	 0.08	 0.02	 Y	 0.13	 7.3E-04	 Y	 0.02	 0.29	 N	
mir-320a	 -3.3E-03	 0.47	 N	 -0.04	 0.16	 N	 0.18	 1.0E-05	 Y	 -0.02	 0.30	 N	
mir-1229	 -0.03	 0.25	 N	 0.02	 0.34	 N	 0.30	 1.0E-05	 Y	 -0.02	 0.30	 N	
mir-34a	 -0.07	 0.04	 Y	 0.18	 1.0E-05	 Y	 0.23	 1.0E-05	 Y	 0.02	 0.32	 N	
mir-186	 0.04	 0.19	 N	 -0.06	 0.08	 N	 0.16	 1.0E-05	 Y	 -0.02	 0.33	 N	
let-7e	 -5.1E-03	 0.45	 N	 0.14	 3.2E-04	 Y	 0.20	 1.0E-05	 Y	 -0.02	 0.34	 N	
mir-455	 -0.05	 0.10	 N	 0.21	 1.0E-05	 Y	 0.14	 4.4E-04	 Y	 0.02	 0.35	 N	
mir-126	 0.11	 3.5E-03	 Y	 0.03	 0.24	 N	 0.22	 1.0E-05	 Y	 0.02	 0.35	 N	
mir-181d	 -0.03	 0.24	 N	 -0.02	 0.27	 N	 0.29	 1.0E-05	 Y	 0.02	 0.36	 N	
mir-15b	 0.16	 1.0E-05	 Y	 -0.02	 0.35	 N	 0.20	 1.0E-05	 Y	 -0.01	 0.36	 N	
mir-25	 0.12	 2.0E-03	 Y	 -0.15	 8.0E-05	 Y	 0.16	 1.0E-05	 Y	 0.02	 0.36	 N	
mir-342	 -0.02	 0.29	 N	 0.16	 1.0E-05	 Y	 0.18	 1.0E-05	 Y	 -0.01	 0.37	 N	
mir-877	 0.10	 7.8E-03	 Y	 0.03	 0.26	 N	 0.21	 1.0E-05	 Y	 -0.01	 0.38	 N	
mir-744	 -0.04	 0.15	 N	 0.06	 0.07	 N	 0.12	 1.7E-03	 Y	 -0.01	 0.38	 N	
mir-423	 -0.04	 0.15	 N	 0.05	 0.12	 N	 0.14	 4.4E-04	 Y	 0.01	 0.38	 N	
mir-99a	 -0.02	 0.31	 N	 -0.08	 0.03	 Y	 0.17	 1.0E-05	 Y	 0.01	 0.39	 N	
mir-28	 0.04	 0.19	 N	 0.03	 0.21	 N	 0.21	 1.0E-05	 Y	 0.01	 0.39	 N	
mir-378	 -2.0E-03	 0.48	 N	 0.01	 0.39	 N	 0.15	 1.0E-04	 Y	 -0.01	 0.40	 N	
mir-125b-1	 -0.10	 7.0E-03	 Y	 -0.02	 0.27	 N	 0.13	 1.2E-03	 Y	 0.01	 0.40	 N	
mir-320b-2	 8.8E-03	 0.42	 N	 -0.05	 0.12	 N	 0.15	 2.0E-05	 Y	 -8.7E-03	 0.41	 N	
mir-320b-1	 0.03	 0.26	 N	 -9.0E-03	 0.41	 N	 0.15	 2.0E-05	 Y	 -8.7E-03	 0.41	 N	
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let-7i	 -0.06	 0.08	 N	 0.11	 4.3E-03	 Y	 0.41	 1.0E-05	 Y	 -7.2E-03	 0.43	 N	
mir-196b	 0.09	 0.01	 Y	 0.13	 8.5E-04	 Y	 0.11	 5.2E-03	 Y	 -6.1E-03	 0.44	 N	
mir-1301	 0.15	 7.0E-05	 Y	 -0.13	 7.2E-04	 Y	 0.24	 1.0E-05	 Y	 5.9E-03	 0.45	 N	
mir-769	 0.18	 1.0E-05	 Y	 -0.10	 8.6E-03	 Y	 0.16	 1.0E-05	 Y	 5.8E-03	 0.45	 N	
mir-181b-2	 0.04	 0.14	 N	 0.11	 4.8E-03	 Y	 0.15	 5.0E-05	 Y	 -4.1E-03	 0.46	 N	
mir-181b-1	 0.03	 0.23	 N	 0.04	 0.18	 N	 0.15	 5.0E-05	 Y	 -4.1E-03	 0.46	 N	
mir-505	 0.06	 0.07	 N	 -0.06	 0.07	 N	 0.17	 1.0E-05	 Y	 -2.8E-03	 0.47	 N	
mir-100	 -0.07	 0.04	 N	 0.06	 0.06	 N	 0.19	 1.0E-05	 Y	 2.5E-03	 0.48	 N	
mir-296	 0.07	 0.05	 N	 -0.19	 2.0E-05	 Y	 0.12	 1.9E-03	 Y	 2.4E-03	 0.48	 N	
mir-125b-2	 1.1E-03	 0.49	 N	 -0.04	 0.18	 N	 0.17	 1.0E-05	 Y	 -1.7E-03	 0.48	 N	
mir-149	 -0.08	 0.02	 Y	 -0.03	 0.27	 N	 0.18	 1.0E-05	 Y	 1.6E-03	 0.49	 N	
mir-484	 0.05	 0.11	 N	 -0.05	 0.09	 N	 0.17	 1.0E-05	 Y	 1.2E-03	 0.49	 N	
mir-652	 0.01	 0.38	 N	 -0.02	 0.35	 N	 0.18	 1.0E-05	 Y	 4.4E-04	 0.50	 N	
mir-509-1	 -0.09	 0.01	 Y	 -0.29	 1.0E-05	 Y	 0	 0.50	 N	 0	 0.50	 N	
mir-514-1	 -0.03	 0.21	 N	 -0.29	 1.0E-05	 Y	 0	 0.50	 N	 0	 0.50	 N	
mir-508	 -0.11	 2.5E-03	 Y	 -0.28	 1.0E-05	 Y	 0	 0.50	 N	 0	 0.50	 N	
mir-509-3	 -0.09	 0.01	 Y	 -0.28	 1.0E-05	 Y	 0	 0.50	 N	 0	 0.50	 N	
mir-509-2	 -0.10	 5.3E-03	 Y	 -0.28	 1.0E-05	 Y	 0	 0.50	 N	 0	 0.50	 N	
mir-513c	 -0.12	 1.2E-03	 Y	 -0.27	 1.0E-05	 Y	 0	 0.50	 N	 0	 0.50	 N	
mir-513a-2	 -0.09	 0.01	 Y	 -0.26	 1.0E-05	 Y	 0	 0.50	 N	 0	 0.50	 N	
mir-506	 -0.10	 6.0E-03	 Y	 -0.25	 1.0E-05	 Y	 0	 0.50	 N	 0	 0.50	 N	
mir-514-2	 -0.07	 0.04	 Y	 -0.24	 1.0E-05	 Y	 0	 0.50	 N	 0	 0.50	 N	
mir-507	 -0.08	 0.03	 Y	 -0.23	 1.0E-05	 Y	 0	 0.50	 N	 0	 0.50	 N	
mir-514-3	 -0.09	 0.02	 Y	 -0.23	 1.0E-05	 Y	 0	 0.50	 N	 0	 0.50	 N	
mir-513a-1	 -0.12	 1.6E-03	 Y	 -0.23	 1.0E-05	 Y	 0	 0.50	 N	 0	 0.50	 N	
mir-135a-1	 0.06	 0.08	 N	 -0.23	 1.0E-05	 Y	 0	 0.50	 N	 0	 0.50	 N	
mir-513b	 -0.10	 4.9E-03	 Y	 -0.22	 1.0E-05	 Y	 0	 0.50	 N	 0	 0.50	 N	
mir-510	 -0.10	 5.1E-03	 Y	 -0.20	 1.0E-05	 Y	 0	 0.50	 N	 0	 0.50	 N	
mir-486	 -0.03	 0.27	 N	 0.16	 1.0E-05	 Y	 0	 0.50	 N	 0	 0.50	 N	
mir-543	 -0.06	 0.07	 N	 0.17	 1.0E-05	 Y	 0	 0.50	 N	 0	 0.50	 N	
mir-1197	 2.1E-03	 0.48	 N	 0.17	 1.0E-05	 Y	 0	 0.50	 N	 0	 0.50	 N	
mir-412	 -7.1E-03	 0.43	 N	 0.17	 1.0E-05	 Y	 0	 0.50	 N	 0	 0.50	 N	
mir-511-2	 0.01	 0.40	 N	 0.17	 1.0E-05	 Y	 0	 0.50	 N	 0	 0.50	 N	
mir-139	 -0.04	 0.16	 N	 0.18	 1.0E-05	 Y	 0	 0.50	 N	 0	 0.50	 N	
mir-574	 -0.12	 1.2E-03	 Y	 0.18	 1.0E-05	 Y	 0	 0.50	 N	 0	 0.50	 N	
mir-431	 -0.09	 9.9E-03	 Y	 0.18	 1.0E-05	 Y	 0	 0.50	 N	 0	 0.50	 N	
mir-511-1	 -2.4E-03	 0.47	 N	 0.19	 1.0E-05	 Y	 0	 0.50	 N	 0	 0.50	 N	
mir-323	 -0.07	 0.05	 N	 0.19	 1.0E-05	 Y	 0	 0.50	 N	 0	 0.50	 N	
mir-494	 -0.05	 0.12	 N	 0.19	 1.0E-05	 Y	 0	 0.50	 N	 0	 0.50	 N	
mir-329-1	 -0.07	 0.04	 Y	 0.19	 1.0E-05	 Y	 0	 0.50	 N	 0	 0.50	 N	
mir-618	 -0.03	 0.23	 N	 0.20	 1.0E-05	 Y	 0	 0.50	 N	 0	 0.50	 N	
mir-136	 -0.05	 0.11	 N	 0.20	 1.0E-05	 Y	 0	 0.50	 N	 0	 0.50	 N	
mir-410	 -0.08	 0.03	 Y	 0.20	 1.0E-05	 Y	 0	 0.50	 N	 0	 0.50	 N	
mir-379	 -0.02	 0.30	 N	 0.21	 1.0E-05	 Y	 0	 0.50	 N	 0	 0.50	 N	
mir-541	 0.02	 0.35	 N	 0.22	 1.0E-05	 Y	 0	 0.50	 N	 0	 0.50	 N	
mir-329-2	 -0.05	 0.13	 N	 0.22	 1.0E-05	 Y	 0	 0.50	 N	 0	 0.50	 N	
mir-1976	 -0.08	 0.03	 Y	 0.22	 1.0E-05	 Y	 0	 0.50	 N	 0	 0.50	 N	
mir-369	 -0.06	 0.06	 N	 0.22	 1.0E-05	 Y	 0	 0.50	 N	 0	 0.50	 N	
mir-539	 -0.03	 0.21	 N	 0.22	 1.0E-05	 Y	 0	 0.50	 N	 0	 0.50	 N	
mir-433	 -0.13	 5.5E-04	 Y	 0.23	 1.0E-05	 Y	 0	 0.50	 N	 0	 0.50	 N	
mir-487b	 -0.09	 0.01	 Y	 0.23	 1.0E-05	 Y	 0	 0.50	 N	 0	 0.50	 N	
mir-411	 -7.3E-03	 0.43	 N	 0.23	 1.0E-05	 Y	 0	 0.50	 N	 0	 0.50	 N	
mir-381	 -0.06	 0.06	 N	 0.24	 1.0E-05	 Y	 0	 0.50	 N	 0	 0.50	 N	
mir-154	 -0.06	 0.07	 N	 0.25	 1.0E-05	 Y	 0	 0.50	 N	 0	 0.50	 N	
mir-1249	 -0.05	 0.09	 N	 0.26	 1.0E-05	 Y	 0	 0.50	 N	 0	 0.50	 N	
mir-496	 -0.05	 0.12	 N	 0.26	 1.0E-05	 Y	 0	 0.50	 N	 0	 0.50	 N	
mir-654	 -0.10	 8.6E-03	 Y	 0.26	 1.0E-05	 Y	 0	 0.50	 N	 0	 0.50	 N	
mir-1295	 -0.10	 4.7E-03	 Y	 0.26	 1.0E-05	 Y	 0	 0.50	 N	 0	 0.50	 N	
mir-337	 -0.07	 0.04	 N	 0.27	 1.0E-05	 Y	 0	 0.50	 N	 0	 0.50	 N	
mir-127	 -0.11	 3.1E-03	 Y	 0.27	 1.0E-05	 Y	 0	 0.50	 N	 0	 0.50	 N	
mir-377	 -0.12	 1.7E-03	 Y	 0.27	 1.0E-05	 Y	 0	 0.50	 N	 0	 0.50	 N	
mir-758	 -0.05	 0.12	 N	 0.27	 1.0E-05	 Y	 0	 0.50	 N	 0	 0.50	 N	
mir-370	 -0.09	 0.01	 Y	 0.27	 1.0E-05	 Y	 0	 0.50	 N	 0	 0.50	 N	
mir-1294	 -0.11	 2.4E-03	 Y	 0.27	 1.0E-05	 Y	 0	 0.50	 N	 0	 0.50	 N	
mir-134	 -0.08	 0.02	 Y	 0.29	 1.0E-05	 Y	 0	 0.50	 N	 0	 0.50	 N	
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mir-487a	 -0.07	 0.05	 N	 0.30	 1.0E-05	 Y	 0	 0.50	 N	 0	 0.50	 N	
mir-382	 -0.08	 0.03	 Y	 0.30	 1.0E-05	 Y	 0	 0.50	 N	 0	 0.50	 N	
mir-299	 -0.06	 0.08	 N	 0.30	 1.0E-05	 Y	 0	 0.50	 N	 0	 0.50	 N	
mir-1228	 -0.02	 0.31	 N	 0.31	 1.0E-05	 Y	 0	 0.50	 N	 0	 0.50	 N	
mir-485	 -0.12	 1.0E-03	 Y	 0.32	 1.0E-05	 Y	 0	 0.50	 N	 0	 0.50	 N	
mir-199b	 -0.07	 0.05	 N	 0.33	 1.0E-05	 Y	 0	 0.50	 N	 0	 0.50	 N	
mir-409	 -0.06	 0.06	 N	 0.34	 1.0E-05	 Y	 0	 0.50	 N	 0	 0.50	 N	
mir-1245	 -0.03	 0.22	 N	 0.36	 1.0E-05	 Y	 0	 0.50	 N	 0	 0.50	 N	
mir-1247	 -0.10	 6.1E-03	 Y	 0.36	 1.0E-05	 Y	 0	 0.50	 N	 0	 0.50	 N	
mir-577	 0.17	 1.0E-05	 Y	 -0.20	 2.0E-05	 Y	 0	 0.50	 N	 0	 0.50	 N	
mir-202	 -0.10	 6.7E-03	 Y	 -0.19	 2.0E-05	 Y	 0	 0.50	 N	 0	 0.50	 N	
mir-488	 0.03	 0.27	 N	 -0.19	 2.0E-05	 Y	 0	 0.50	 N	 0	 0.50	 N	
mir-1251	 0.05	 0.11	 N	 -0.17	 2.0E-05	 Y	 0	 0.50	 N	 0	 0.50	 N	
mir-449b	 -0.05	 0.11	 N	 -0.17	 3.0E-05	 Y	 0	 0.50	 N	 0	 0.50	 N	
mir-1248	 -0.21	 1.0E-05	 Y	 0.15	 6.0E-05	 Y	 0	 0.50	 N	 0	 0.50	 N	
let-7a-3	 -0.09	 0.01	 Y	 0.14	 1.7E-04	 Y	 0	 0.50	 N	 0	 0.50	 N	
mir-490	 0.01	 0.37	 N	 -0.15	 2.5E-04	 Y	 0	 0.50	 N	 0	 0.50	 N	
mir-129-1	 0.06	 0.09	 N	 -0.15	 2.5E-04	 Y	 0	 0.50	 N	 0	 0.50	 N	
mir-1266	 0.06	 0.08	 N	 -0.14	 3.4E-04	 Y	 0	 0.50	 N	 0	 0.50	 N	
mir-1911	 0.04	 0.17	 N	 -0.13	 5.1E-04	 Y	 0	 0.50	 N	 0	 0.50	 N	
mir-1298	 0.08	 0.03	 Y	 -0.13	 5.1E-04	 Y	 0	 0.50	 N	 0	 0.50	 N	
mir-129-2	 0.05	 0.13	 N	 -0.13	 5.5E-04	 Y	 0	 0.50	 N	 0	 0.50	 N	
mir-1269	 0.02	 0.32	 N	 -0.13	 5.5E-04	 Y	 0	 0.50	 N	 0	 0.50	 N	
mir-1915	 0.08	 0.03	 Y	 -0.13	 6.6E-04	 Y	 0	 0.50	 N	 0	 0.50	 N	
mir-889	 0.03	 0.24	 N	 0.13	 7.7E-04	 Y	 0	 0.50	 N	 0	 0.50	 N	
mir-187	 0.02	 0.29	 N	 -0.13	 7.8E-04	 Y	 0	 0.50	 N	 0	 0.50	 N	
mir-483	 2.7E-03	 0.48	 N	 0.13	 8.3E-04	 Y	 0	 0.50	 N	 0	 0.50	 N	
let-7f-1	 -0.02	 0.31	 N	 0.13	 1.0E-03	 Y	 0	 0.50	 N	 0	 0.50	 N	
mir-448	 0.06	 0.07	 N	 -0.12	 1.2E-03	 Y	 0	 0.50	 N	 0	 0.50	 N	
mir-933	 0.16	 1.0E-05	 Y	 -0.12	 1.2E-03	 Y	 0	 0.50	 N	 0	 0.50	 N	
mir-641	 0.13	 7.9E-04	 Y	 -0.12	 1.4E-03	 Y	 0	 0.50	 N	 0	 0.50	 N	
mir-219-1	 0.05	 0.10	 N	 -0.12	 1.4E-03	 Y	 0	 0.50	 N	 0	 0.50	 N	
mir-665	 -0.05	 0.13	 N	 0.12	 1.8E-03	 Y	 0	 0.50	 N	 0	 0.50	 N	
mir-639	 0.04	 0.17	 N	 -0.12	 2.1E-03	 Y	 0	 0.50	 N	 0	 0.50	 N	
mir-24-1	 0.11	 4.0E-03	 Y	 0.12	 2.5E-03	 Y	 0	 0.50	 N	 0	 0.50	 N	
mir-588	 0.16	 1.0E-05	 Y	 0.12	 2.5E-03	 Y	 0	 0.50	 N	 0	 0.50	 N	
mir-33b	 0.10	 9.0E-03	 Y	 0.12	 2.5E-03	 Y	 0	 0.50	 N	 0	 0.50	 N	
mir-765	 -0.01	 0.40	 N	 0.12	 2.6E-03	 Y	 0	 0.50	 N	 0	 0.50	 N	
mir-545	 0.06	 0.08	 N	 0.11	 2.8E-03	 Y	 0	 0.50	 N	 0	 0.50	 N	
mir-720	 0.09	 0.02	 Y	 -0.11	 3.3E-03	 Y	 0	 0.50	 N	 0	 0.50	 N	
mir-320d-2	 -0.08	 0.03	 Y	 -0.11	 3.9E-03	 Y	 0	 0.50	 N	 0	 0.50	 N	
mir-609	 0.04	 0.20	 N	 -0.11	 4.0E-03	 Y	 0	 0.50	 N	 0	 0.50	 N	
mir-873	 0.03	 0.24	 N	 0.11	 4.2E-03	 Y	 0	 0.50	 N	 0	 0.50	 N	
mir-190b	 -8.5E-03	 0.42	 N	 -0.10	 4.9E-03	 Y	 0	 0.50	 N	 0	 0.50	 N	
mir-453	 0.09	 0.01	 Y	 0.11	 5.0E-03	 Y	 0	 0.50	 N	 0	 0.50	 N	
mir-578	 0.07	 0.05	 N	 -0.10	 5.1E-03	 Y	 0	 0.50	 N	 0	 0.50	 N	
mir-616	 0.11	 3.6E-03	 Y	 -0.10	 5.6E-03	 Y	 0	 0.50	 N	 0	 0.50	 N	
mir-647	 0.11	 5.4E-03	 Y	 -0.10	 6.3E-03	 Y	 0	 0.50	 N	 0	 0.50	 N	
mir-1262	 0.06	 0.07	 N	 -0.10	 6.4E-03	 Y	 0	 0.50	 N	 0	 0.50	 N	
mir-599	 -0.08	 0.03	 Y	 0.10	 7.1E-03	 Y	 0	 0.50	 N	 0	 0.50	 N	
mir-612	 0.06	 0.07	 N	 0.10	 7.5E-03	 Y	 0	 0.50	 N	 0	 0.50	 N	
mir-589	 0.06	 0.06	 N	 0.10	 8.6E-03	 Y	 0	 0.50	 N	 0	 0.50	 N	
mir-371	 0.01	 0.40	 N	 -0.10	 8.7E-03	 Y	 0	 0.50	 N	 0	 0.50	 N	
mir-655	 0.03	 0.21	 N	 0.10	 8.9E-03	 Y	 0	 0.50	 N	 0	 0.50	 N	
mir-105-2	 0.08	 0.02	 Y	 -0.10	 9.0E-03	 Y	 0	 0.50	 N	 0	 0.50	 N	
mir-29b-2	 -0.10	 7.2E-03	 Y	 -0.09	 0.01	 Y	 0	 0.50	 N	 0	 0.50	 N	
mir-651	 0.07	 0.04	 Y	 -0.09	 0.01	 Y	 0	 0.50	 N	 0	 0.50	 N	
mir-668	 -0.07	 0.04	 Y	 0.09	 0.01	 Y	 0	 0.50	 N	 0	 0.50	 N	
mir-518b	 -0.03	 0.20	 N	 0.09	 0.01	 Y	 0	 0.50	 N	 0	 0.50	 N	
let-7f-2	 -0.04	 0.17	 N	 0.09	 0.01	 Y	 0	 0.50	 N	 0	 0.50	 N	
mir-885	 -0.07	 0.04	 Y	 -0.09	 0.01	 Y	 0	 0.50	 N	 0	 0.50	 N	
mir-629	 0.05	 0.09	 N	 0.09	 0.01	 Y	 0	 0.50	 N	 0	 0.50	 N	
mir-1912	 0.02	 0.34	 N	 -0.09	 0.01	 Y	 0	 0.50	 N	 0	 0.50	 N	
mir-1246	 0.13	 9.2E-04	 Y	 0.09	 0.01	 Y	 0	 0.50	 N	 0	 0.50	 N	
mir-642	 -0.01	 0.37	 N	 0.09	 0.01	 Y	 0	 0.50	 N	 0	 0.50	 N	
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mir-1292	 8.4E-03	 0.42	 N	 -0.09	 0.01	 Y	 0	 0.50	 N	 0	 0.50	 N	
mir-1276	 0.11	 3.2E-03	 Y	 -0.09	 0.01	 Y	 0	 0.50	 N	 0	 0.50	 N	
mir-548d-2	 -1.0E-03	 0.49	 N	 -0.09	 0.01	 Y	 0	 0.50	 N	 0	 0.50	 N	
mir-2110	 -0.06	 0.08	 N	 0.09	 0.02	 Y	 0	 0.50	 N	 0	 0.50	 N	
mir-675	 4.0E-03	 0.46	 N	 0.09	 0.02	 Y	 0	 0.50	 N	 0	 0.50	 N	
mir-499	 0.06	 0.08	 N	 -0.09	 0.02	 Y	 0	 0.50	 N	 0	 0.50	 N	
mir-636	 0.11	 3.3E-03	 Y	 -0.09	 0.02	 Y	 0	 0.50	 N	 0	 0.50	 N	
mir-517b	 -0.02	 0.35	 N	 0.08	 0.02	 Y	 0	 0.50	 N	 0	 0.50	 N	
mir-650	 -0.02	 0.32	 N	 0.08	 0.02	 Y	 0	 0.50	 N	 0	 0.50	 N	
mir-934	 -0.14	 3.5E-04	 Y	 0.08	 0.02	 Y	 0	 0.50	 N	 0	 0.50	 N	
mir-1825	 0.03	 0.27	 N	 0.08	 0.02	 Y	 0	 0.50	 N	 0	 0.50	 N	
mir-638	 0.03	 0.22	 N	 0.08	 0.02	 Y	 0	 0.50	 N	 0	 0.50	 N	
mir-517a	 -0.02	 0.31	 N	 0.08	 0.02	 Y	 0	 0.50	 N	 0	 0.50	 N	
mir-549	 -0.03	 0.22	 N	 0.08	 0.02	 Y	 0	 0.50	 N	 0	 0.50	 N	
mir-188	 0.07	 0.04	 Y	 -0.08	 0.03	 Y	 0	 0.50	 N	 0	 0.50	 N	
mir-1286	 -0.02	 0.33	 N	 -0.08	 0.03	 Y	 0	 0.50	 N	 0	 0.50	 N	
mir-600	 0.02	 0.28	 N	 -0.08	 0.03	 Y	 0	 0.50	 N	 0	 0.50	 N	
mir-1287	 0.10	 0.01	 Y	 -0.08	 0.03	 Y	 0	 0.50	 N	 0	 0.50	 N	
mir-657	 -5.3E-03	 0.45	 N	 0.08	 0.03	 Y	 0	 0.50	 N	 0	 0.50	 N	
mir-614	 -0.07	 0.05	 N	 0.08	 0.03	 Y	 0	 0.50	 N	 0	 0.50	 N	
mir-30c-1	 0.04	 0.18	 N	 -0.08	 0.03	 Y	 0	 0.50	 N	 0	 0.50	 N	
mir-216a	 3.1E-03	 0.47	 N	 0.07	 0.03	 Y	 0	 0.50	 N	 0	 0.50	 N	
mir-147	 -0.03	 0.27	 N	 0.07	 0.04	 Y	 0	 0.50	 N	 0	 0.50	 N	
mir-548k	 -0.04	 0.19	 N	 -0.07	 0.04	 Y	 0	 0.50	 N	 0	 0.50	 N	
mir-1178	 4.5E-03	 0.46	 N	 -0.07	 0.04	 Y	 0	 0.50	 N	 0	 0.50	 N	
mir-19b-1	 0.05	 0.12	 N	 -0.07	 0.04	 Y	 0	 0.50	 N	 0	 0.50	 N	
mir-7-1	 0.26	 1.0E-05	 Y	 -0.07	 0.04	 Y	 0	 0.50	 N	 0	 0.50	 N	
mir-520d	 0.02	 0.35	 N	 0.07	 0.04	 Y	 0	 0.50	 N	 0	 0.50	 N	
mir-571	 -0.06	 0.08	 N	 0.07	 0.04	 Y	 0	 0.50	 N	 0	 0.50	 N	
mir-552	 0.05	 0.13	 N	 0.07	 0.04	 N	 0	 0.50	 N	 0	 0.50	 N	
mir-2113	 0.05	 0.10	 N	 -0.07	 0.04	 N	 0	 0.50	 N	 0	 0.50	 N	
mir-301b	 0.17	 1.0E-05	 Y	 -0.07	 0.04	 N	 0	 0.50	 N	 0	 0.50	 N	
mir-1255a	 0.04	 0.18	 N	 0.07	 0.05	 N	 0	 0.50	 N	 0	 0.50	 N	
mir-1183	 -0.06	 0.09	 N	 0.07	 0.05	 N	 0	 0.50	 N	 0	 0.50	 N	
mir-587	 -0.06	 0.09	 N	 0.07	 0.05	 N	 0	 0.50	 N	 0	 0.50	 N	
mir-1234	 -9.5E-03	 0.41	 N	 0.07	 0.05	 N	 0	 0.50	 N	 0	 0.50	 N	
mir-559	 0.04	 0.17	 N	 -0.07	 0.05	 N	 0	 0.50	 N	 0	 0.50	 N	
mir-1185-2	 0.03	 0.21	 N	 0.07	 0.05	 N	 0	 0.50	 N	 0	 0.50	 N	
mir-572	 0.04	 0.20	 N	 -0.07	 0.05	 N	 0	 0.50	 N	 0	 0.50	 N	
mir-1185-1	 0.05	 0.11	 N	 0.07	 0.06	 N	 0	 0.50	 N	 0	 0.50	 N	
mir-645	 0.05	 0.13	 N	 -0.07	 0.06	 N	 0	 0.50	 N	 0	 0.50	 N	
mir-921	 0.05	 0.13	 N	 -0.07	 0.06	 N	 0	 0.50	 N	 0	 0.50	 N	
mir-888	 0.05	 0.09	 N	 0.06	 0.06	 N	 0	 0.50	 N	 0	 0.50	 N	
mir-519d	 4.8E-03	 0.46	 N	 0.06	 0.06	 N	 0	 0.50	 N	 0	 0.50	 N	
mir-298	 -0.01	 0.39	 N	 -0.06	 0.06	 N	 0	 0.50	 N	 0	 0.50	 N	
mir-1253	 0.08	 0.03	 Y	 -0.06	 0.06	 N	 0	 0.50	 N	 0	 0.50	 N	
mir-1910	 0.07	 0.05	 N	 -0.06	 0.06	 N	 0	 0.50	 N	 0	 0.50	 N	
mir-519b	 6.1E-03	 0.44	 N	 0.06	 0.06	 N	 0	 0.50	 N	 0	 0.50	 N	
mir-1538	 -0.01	 0.38	 N	 0.06	 0.06	 N	 0	 0.50	 N	 0	 0.50	 N	
mir-579	 0.10	 8.5E-03	 Y	 -0.06	 0.07	 N	 0	 0.50	 N	 0	 0.50	 N	
mir-1826	 0.01	 0.40	 N	 0.06	 0.07	 N	 0	 0.50	 N	 0	 0.50	 N	
mir-554	 -0.06	 0.07	 N	 0.06	 0.07	 N	 0	 0.50	 N	 0	 0.50	 N	
mir-1271	 -0.01	 0.39	 N	 0.06	 0.07	 N	 0	 0.50	 N	 0	 0.50	 N	
mir-1323	 -0.04	 0.14	 N	 0.06	 0.07	 N	 0	 0.50	 N	 0	 0.50	 N	
mir-661	 -0.09	 0.02	 Y	 -0.06	 0.07	 N	 0	 0.50	 N	 0	 0.50	 N	
mir-1908	 0.15	 1.0E-04	 Y	 0.06	 0.07	 N	 0	 0.50	 N	 0	 0.50	 N	
mir-648	 -0.03	 0.20	 N	 0.06	 0.07	 N	 0	 0.50	 N	 0	 0.50	 N	
mir-626	 1.7E-04	 0.50	 N	 -0.06	 0.07	 N	 0	 0.50	 N	 0	 0.50	 N	
mir-1257	 0.04	 0.17	 N	 -0.06	 0.07	 N	 0	 0.50	 N	 0	 0.50	 N	
mir-450a-1	 0.02	 0.29	 N	 -0.06	 0.07	 N	 0	 0.50	 N	 0	 0.50	 N	
mir-582	 0.07	 0.05	 N	 -0.06	 0.07	 N	 0	 0.50	 N	 0	 0.50	 N	
mir-607	 0.07	 0.04	 Y	 0.06	 0.07	 N	 0	 0.50	 N	 0	 0.50	 N	
mir-1283-1	 0.02	 0.33	 N	 -0.06	 0.08	 N	 0	 0.50	 N	 0	 0.50	 N	
mir-649	 -9.6E-03	 0.40	 N	 -0.06	 0.08	 N	 0	 0.50	 N	 0	 0.50	 N	
mir-922	 0.11	 3.5E-03	 Y	 0.06	 0.08	 N	 0	 0.50	 N	 0	 0.50	 N	
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mir-561	 0.06	 0.09	 N	 -0.06	 0.08	 N	 0	 0.50	 N	 0	 0.50	 N	
mir-1979	 0.04	 0.17	 N	 -0.06	 0.08	 N	 0	 0.50	 N	 0	 0.50	 N	
mir-942	 0.16	 1.0E-05	 Y	 -0.06	 0.08	 N	 0	 0.50	 N	 0	 0.50	 N	
mir-548j	 -0.03	 0.23	 N	 0.06	 0.08	 N	 0	 0.50	 N	 0	 0.50	 N	
mir-320d-1	 -0.06	 0.08	 N	 -0.06	 0.09	 N	 0	 0.50	 N	 0	 0.50	 N	
mir-632	 0.07	 0.05	 N	 0.06	 0.09	 N	 0	 0.50	 N	 0	 0.50	 N	
mir-592	 -1.7E-03	 0.48	 N	 -0.06	 0.09	 N	 0	 0.50	 N	 0	 0.50	 N	
mir-24-2	 -0.01	 0.36	 N	 0.06	 0.09	 N	 0	 0.50	 N	 0	 0.50	 N	
mir-380	 0.11	 3.7E-03	 Y	 0.06	 0.09	 N	 0	 0.50	 N	 0	 0.50	 N	
mir-770	 0.02	 0.33	 N	 0.06	 0.09	 N	 0	 0.50	 N	 0	 0.50	 N	
mir-573	 0.04	 0.18	 N	 -0.05	 0.09	 N	 0	 0.50	 N	 0	 0.50	 N	
mir-498	 7.6E-03	 0.43	 N	 0.05	 0.09	 N	 0	 0.50	 N	 0	 0.50	 N	
mir-1263	 0.07	 0.04	 Y	 -0.05	 0.09	 N	 0	 0.50	 N	 0	 0.50	 N	
mir-548e	 0.02	 0.33	 N	 -0.05	 0.09	 N	 0	 0.50	 N	 0	 0.50	 N	
mir-1304	 0.04	 0.16	 N	 0.05	 0.09	 N	 0	 0.50	 N	 0	 0.50	 N	
mir-886	 0.02	 0.32	 N	 0.05	 0.10	 N	 0	 0.50	 N	 0	 0.50	 N	
mir-1290	 0.13	 6.5E-04	 Y	 -0.05	 0.10	 N	 0	 0.50	 N	 0	 0.50	 N	
mir-516b-2	 -0.03	 0.25	 N	 0.05	 0.10	 N	 0	 0.50	 N	 0	 0.50	 N	
mir-1293	 0.05	 0.10	 N	 0.05	 0.10	 N	 0	 0.50	 N	 0	 0.50	 N	
mir-526b	 0.04	 0.19	 N	 0.05	 0.10	 N	 0	 0.50	 N	 0	 0.50	 N	
mir-575	 -6.8E-03	 0.43	 N	 0.05	 0.10	 N	 0	 0.50	 N	 0	 0.50	 N	
mir-520g	 -0.02	 0.30	 N	 0.05	 0.10	 N	 0	 0.50	 N	 0	 0.50	 N	
mir-662	 -0.02	 0.31	 N	 0.05	 0.10	 N	 0	 0.50	 N	 0	 0.50	 N	
mir-551a	 0.20	 1.0E-05	 Y	 -0.05	 0.11	 N	 0	 0.50	 N	 0	 0.50	 N	
mir-450b	 -0.02	 0.29	 N	 -0.05	 0.11	 N	 0	 0.50	 N	 0	 0.50	 N	
mir-518d	 0.04	 0.14	 N	 -0.05	 0.11	 N	 0	 0.50	 N	 0	 0.50	 N	
mir-544	 0.08	 0.02	 Y	 -0.05	 0.11	 N	 0	 0.50	 N	 0	 0.50	 N	
mir-1909	 4.9E-03	 0.45	 N	 0.05	 0.11	 N	 0	 0.50	 N	 0	 0.50	 N	
mir-526a-1	 0.04	 0.16	 N	 -0.05	 0.11	 N	 0	 0.50	 N	 0	 0.50	 N	
mir-875	 0.07	 0.04	 Y	 0.05	 0.12	 N	 0	 0.50	 N	 0	 0.50	 N	
mir-1270	 -0.02	 0.28	 N	 0.05	 0.12	 N	 0	 0.50	 N	 0	 0.50	 N	
mir-1265	 0.11	 4.7E-03	 Y	 0.05	 0.12	 N	 0	 0.50	 N	 0	 0.50	 N	
mir-1289-1	 0.12	 1.6E-03	 Y	 -0.05	 0.12	 N	 0	 0.50	 N	 0	 0.50	 N	
mir-596	 -0.06	 0.06	 N	 -0.05	 0.12	 N	 0	 0.50	 N	 0	 0.50	 N	
mir-383	 -0.12	 1.3E-03	 Y	 -0.05	 0.13	 N	 0	 0.50	 N	 0	 0.50	 N	
mir-548i-2	 0.04	 0.15	 N	 -0.05	 0.13	 N	 0	 0.50	 N	 0	 0.50	 N	
mir-938	 0.11	 4.0E-03	 Y	 -0.05	 0.13	 N	 0	 0.50	 N	 0	 0.50	 N	
mir-1225	 0.05	 0.13	 N	 -0.05	 0.13	 N	 0	 0.50	 N	 0	 0.50	 N	
mir-198	 0.07	 0.05	 N	 0.05	 0.13	 N	 0	 0.50	 N	 0	 0.50	 N	
mir-105-1	 0.04	 0.14	 N	 -0.05	 0.13	 N	 0	 0.50	 N	 0	 0.50	 N	
mir-550-2	 0.05	 0.09	 N	 -0.04	 0.14	 N	 0	 0.50	 N	 0	 0.50	 N	
mir-944	 0.06	 0.07	 N	 0.05	 0.14	 N	 0	 0.50	 N	 0	 0.50	 N	
mir-450a-2	 0.04	 0.15	 N	 0.04	 0.14	 N	 0	 0.50	 N	 0	 0.50	 N	
mir-181a-2	 0.09	 0.02	 Y	 -0.04	 0.14	 N	 0	 0.50	 N	 0	 0.50	 N	
mir-128-2	 0.08	 0.03	 Y	 -0.04	 0.14	 N	 0	 0.50	 N	 0	 0.50	 N	
mir-520c	 0.02	 0.33	 N	 -0.04	 0.15	 N	 0	 0.50	 N	 0	 0.50	 N	
mir-603	 0.09	 0.01	 Y	 -0.04	 0.15	 N	 0	 0.50	 N	 0	 0.50	 N	
mir-1238	 8.4E-03	 0.42	 N	 0.04	 0.15	 N	 0	 0.50	 N	 0	 0.50	 N	
mir-16-1	 0.16	 1.0E-05	 Y	 -0.04	 0.15	 N	 0	 0.50	 N	 0	 0.50	 N	
mir-376c	 0.05	 0.12	 N	 0.04	 0.16	 N	 0	 0.50	 N	 0	 0.50	 N	
mir-1272	 -0.04	 0.14	 N	 -0.04	 0.16	 N	 0	 0.50	 N	 0	 0.50	 N	
mir-564	 5.6E-03	 0.45	 N	 -0.04	 0.16	 N	 0	 0.50	 N	 0	 0.50	 N	
mir-519c	 -0.03	 0.25	 N	 -0.04	 0.16	 N	 0	 0.50	 N	 0	 0.50	 N	
mir-1244	 0.07	 0.04	 Y	 -0.04	 0.16	 N	 0	 0.50	 N	 0	 0.50	 N	
mir-640	 0.09	 0.02	 Y	 -0.04	 0.16	 N	 0	 0.50	 N	 0	 0.50	 N	
mir-637	 0.04	 0.17	 N	 -0.04	 0.16	 N	 0	 0.50	 N	 0	 0.50	 N	
mir-1264	 0.01	 0.39	 N	 -0.04	 0.17	 N	 0	 0.50	 N	 0	 0.50	 N	
mir-548a-3	 0.02	 0.34	 N	 -0.04	 0.17	 N	 0	 0.50	 N	 0	 0.50	 N	
mir-520e	 1.3E-03	 0.49	 N	 -0.04	 0.17	 N	 0	 0.50	 N	 0	 0.50	 N	
mir-1539	 3.0E-03	 0.47	 N	 -0.04	 0.17	 N	 0	 0.50	 N	 0	 0.50	 N	
mir-602	 0.08	 0.02	 Y	 -0.04	 0.17	 N	 0	 0.50	 N	 0	 0.50	 N	
mir-1204	 0.07	 0.05	 N	 -0.04	 0.18	 N	 0	 0.50	 N	 0	 0.50	 N	
mir-1268	 -0.01	 0.40	 N	 0.04	 0.18	 N	 0	 0.50	 N	 0	 0.50	 N	
mir-422a	 -0.02	 0.30	 N	 -0.04	 0.18	 N	 0	 0.50	 N	 0	 0.50	 N	
mir-1224	 9.2E-03	 0.42	 N	 0.04	 0.18	 N	 0	 0.50	 N	 0	 0.50	 N	
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mir-208a	 0.06	 0.09	 N	 -0.04	 0.18	 N	 0	 0.50	 N	 0	 0.50	 N	
mir-216b	 0.02	 0.32	 N	 0.04	 0.19	 N	 0	 0.50	 N	 0	 0.50	 N	
mir-1236	 0.02	 0.29	 N	 -0.04	 0.19	 N	 0	 0.50	 N	 0	 0.50	 N	
mir-147b	 0.05	 0.09	 N	 0.04	 0.20	 N	 0	 0.50	 N	 0	 0.50	 N	
mir-516b-1	 0.02	 0.34	 N	 0.04	 0.20	 N	 0	 0.50	 N	 0	 0.50	 N	
mir-595	 0.02	 0.32	 N	 -0.03	 0.20	 N	 0	 0.50	 N	 0	 0.50	 N	
mir-622	 0.03	 0.21	 N	 -0.03	 0.20	 N	 0	 0.50	 N	 0	 0.50	 N	
mir-1470	 0.06	 0.06	 N	 0.04	 0.20	 N	 0	 0.50	 N	 0	 0.50	 N	
mir-520h	 -0.02	 0.34	 N	 0.03	 0.20	 N	 0	 0.50	 N	 0	 0.50	 N	
mir-9-3	 -0.01	 0.37	 N	 -0.03	 0.21	 N	 0	 0.50	 N	 0	 0.50	 N	
mir-220b	 0.02	 0.36	 N	 -0.03	 0.21	 N	 0	 0.50	 N	 0	 0.50	 N	
mir-519a-1	 -7.5E-04	 0.49	 N	 -0.03	 0.21	 N	 0	 0.50	 N	 0	 0.50	 N	
mir-1284	 0.11	 2.8E-03	 Y	 -0.03	 0.21	 N	 0	 0.50	 N	 0	 0.50	 N	
mir-939	 5.8E-03	 0.45	 N	 0.03	 0.21	 N	 0	 0.50	 N	 0	 0.50	 N	
mir-1205	 -0.03	 0.26	 N	 0.03	 0.21	 N	 0	 0.50	 N	 0	 0.50	 N	
mir-1250	 0.09	 0.01	 Y	 -0.03	 0.22	 N	 0	 0.50	 N	 0	 0.50	 N	
mir-489	 0.05	 0.12	 N	 0.03	 0.22	 N	 0	 0.50	 N	 0	 0.50	 N	
mir-555	 -0.02	 0.35	 N	 0.03	 0.22	 N	 0	 0.50	 N	 0	 0.50	 N	
mir-1181	 0.07	 0.05	 N	 0.03	 0.23	 N	 0	 0.50	 N	 0	 0.50	 N	
mir-517c	 -4.2E-03	 0.46	 N	 0.03	 0.23	 N	 0	 0.50	 N	 0	 0.50	 N	
mir-220a	 0.06	 0.09	 N	 -0.03	 0.23	 N	 0	 0.50	 N	 0	 0.50	 N	
mir-524	 0.02	 0.33	 N	 -0.03	 0.23	 N	 0	 0.50	 N	 0	 0.50	 N	
mir-1237	 -0.02	 0.28	 N	 0.03	 0.23	 N	 0	 0.50	 N	 0	 0.50	 N	
mir-1978	 -0.03	 0.22	 N	 -0.03	 0.24	 N	 0	 0.50	 N	 0	 0.50	 N	
mir-604	 -0.03	 0.25	 N	 -0.03	 0.24	 N	 0	 0.50	 N	 0	 0.50	 N	
mir-1254	 0.07	 0.05	 N	 -0.03	 0.24	 N	 0	 0.50	 N	 0	 0.50	 N	
mir-1208	 -0.03	 0.21	 N	 -0.03	 0.24	 N	 0	 0.50	 N	 0	 0.50	 N	
mir-518c	 0.01	 0.39	 N	 0.03	 0.25	 N	 0	 0.50	 N	 0	 0.50	 N	
mir-1231	 0.02	 0.31	 N	 0.03	 0.26	 N	 0	 0.50	 N	 0	 0.50	 N	
mir-492	 -0.06	 0.06	 N	 0.03	 0.26	 N	 0	 0.50	 N	 0	 0.50	 N	
mir-597	 1.5E-03	 0.49	 N	 0.03	 0.26	 N	 0	 0.50	 N	 0	 0.50	 N	
mir-1977	 0.09	 0.02	 Y	 -0.03	 0.26	 N	 0	 0.50	 N	 0	 0.50	 N	
mir-548l	 0.03	 0.21	 N	 0.03	 0.26	 N	 0	 0.50	 N	 0	 0.50	 N	
mir-1289-2	 -0.02	 0.33	 N	 0.03	 0.26	 N	 0	 0.50	 N	 0	 0.50	 N	
mir-659	 -0.04	 0.14	 N	 -0.03	 0.27	 N	 0	 0.50	 N	 0	 0.50	 N	
mir-518a-2	 0.04	 0.16	 N	 0.03	 0.27	 N	 0	 0.50	 N	 0	 0.50	 N	
mir-1282	 -0.01	 0.38	 N	 -0.03	 0.27	 N	 0	 0.50	 N	 0	 0.50	 N	
mir-1322	 -3.4E-03	 0.46	 N	 0.03	 0.27	 N	 0	 0.50	 N	 0	 0.50	 N	
mir-556	 0.07	 0.04	 Y	 0.03	 0.27	 N	 0	 0.50	 N	 0	 0.50	 N	
mir-1258	 0.10	 6.3E-03	 Y	 0.03	 0.27	 N	 0	 0.50	 N	 0	 0.50	 N	
mir-1306	 0.14	 2.5E-04	 Y	 0.03	 0.27	 N	 0	 0.50	 N	 0	 0.50	 N	
mir-890	 7.9E-03	 0.43	 N	 0.03	 0.27	 N	 0	 0.50	 N	 0	 0.50	 N	
mir-1302-3	 0.05	 0.11	 N	 -0.02	 0.28	 N	 0	 0.50	 N	 0	 0.50	 N	
mir-1243	 0.04	 0.18	 N	 -0.02	 0.28	 N	 0	 0.50	 N	 0	 0.50	 N	
mir-611	 6.4E-03	 0.44	 N	 0.02	 0.28	 N	 0	 0.50	 N	 0	 0.50	 N	
mir-521-1	 0.07	 0.04	 Y	 0.02	 0.28	 N	 0	 0.50	 N	 0	 0.50	 N	
mir-943	 0.03	 0.27	 N	 0.02	 0.29	 N	 0	 0.50	 N	 0	 0.50	 N	
mir-548f-1	 -0.04	 0.14	 N	 0.02	 0.29	 N	 0	 0.50	 N	 0	 0.50	 N	
mir-658	 0.02	 0.33	 N	 -0.02	 0.29	 N	 0	 0.50	 N	 0	 0.50	 N	
mir-1913	 0.02	 0.32	 N	 -0.02	 0.30	 N	 0	 0.50	 N	 0	 0.50	 N	
mir-153-1	 -4.1E-03	 0.46	 N	 -0.02	 0.30	 N	 0	 0.50	 N	 0	 0.50	 N	
mir-1278	 -0.04	 0.19	 N	 0.02	 0.30	 N	 0	 0.50	 N	 0	 0.50	 N	
mir-1267	 -0.06	 0.06	 N	 -0.02	 0.30	 N	 0	 0.50	 N	 0	 0.50	 N	
mir-591	 4.1E-03	 0.46	 N	 -0.02	 0.30	 N	 0	 0.50	 N	 0	 0.50	 N	
mir-522	 0.02	 0.32	 N	 0.02	 0.30	 N	 0	 0.50	 N	 0	 0.50	 N	
mir-26a-2	 -0.09	 0.01	 Y	 0.02	 0.30	 N	 0	 0.50	 N	 0	 0.50	 N	
mir-767	 0.03	 0.21	 N	 -0.02	 0.30	 N	 0	 0.50	 N	 0	 0.50	 N	
mir-663b	 -0.01	 0.37	 N	 0.02	 0.30	 N	 0	 0.50	 N	 0	 0.50	 N	
mir-1974	 0.07	 0.05	 N	 -0.02	 0.31	 N	 0	 0.50	 N	 0	 0.50	 N	
mir-2052	 0.08	 0.03	 Y	 -0.02	 0.31	 N	 0	 0.50	 N	 0	 0.50	 N	
mir-376b	 0.06	 0.09	 N	 0.02	 0.31	 N	 0	 0.50	 N	 0	 0.50	 N	
mir-581	 0.03	 0.24	 N	 0.02	 0.31	 N	 0	 0.50	 N	 0	 0.50	 N	
mir-644	 0.02	 0.31	 N	 -0.02	 0.32	 N	 0	 0.50	 N	 0	 0.50	 N	
mir-624	 -0.04	 0.16	 N	 -0.02	 0.33	 N	 0	 0.50	 N	 0	 0.50	 N	
mir-219-2	 0.03	 0.27	 N	 0.02	 0.33	 N	 0	 0.50	 N	 0	 0.50	 N	
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mir-515-1	 0.04	 0.15	 N	 -0.02	 0.33	 N	 0	 0.50	 N	 0	 0.50	 N	
mir-570	 0.08	 0.03	 Y	 0.02	 0.33	 N	 0	 0.50	 N	 0	 0.50	 N	
mir-1288	 0.06	 0.08	 N	 -0.02	 0.33	 N	 0	 0.50	 N	 0	 0.50	 N	
mir-1256	 0.05	 0.13	 N	 0.02	 0.34	 N	 0	 0.50	 N	 0	 0.50	 N	
mir-586	 -0.07	 0.05	 N	 0.02	 0.34	 N	 0	 0.50	 N	 0	 0.50	 N	
mir-892b	 -0.01	 0.40	 N	 -0.02	 0.34	 N	 0	 0.50	 N	 0	 0.50	 N	
mir-1283-2	 0.03	 0.25	 N	 -0.02	 0.35	 N	 0	 0.50	 N	 0	 0.50	 N	
mir-518e	 0.01	 0.38	 N	 0.02	 0.35	 N	 0	 0.50	 N	 0	 0.50	 N	
mir-512-1	 -0.01	 0.40	 N	 0.02	 0.35	 N	 0	 0.50	 N	 0	 0.50	 N	
mir-516a-2	 -2.1E-03	 0.48	 N	 -0.02	 0.35	 N	 0	 0.50	 N	 0	 0.50	 N	
mir-16-2	 0.17	 1.0E-05	 Y	 0.02	 0.35	 N	 0	 0.50	 N	 0	 0.50	 N	
mir-1972	 -0.04	 0.18	 N	 -0.02	 0.35	 N	 0	 0.50	 N	 0	 0.50	 N	
mir-548o	 2.0E-03	 0.48	 N	 0.02	 0.36	 N	 0	 0.50	 N	 0	 0.50	 N	
mir-520a	 0.08	 0.03	 Y	 0.02	 0.36	 N	 0	 0.50	 N	 0	 0.50	 N	
mir-542	 0.04	 0.20	 N	 0.02	 0.36	 N	 0	 0.50	 N	 0	 0.50	 N	
mir-1299	 -0.07	 0.04	 N	 -0.01	 0.36	 N	 0	 0.50	 N	 0	 0.50	 N	
mir-628	 0.03	 0.26	 N	 0.02	 0.36	 N	 0	 0.50	 N	 0	 0.50	 N	
mir-663	 0.23	 1.0E-05	 Y	 -0.01	 0.36	 N	 0	 0.50	 N	 0	 0.50	 N	
mir-1184	 9.5E-03	 0.41	 N	 0.01	 0.36	 N	 0	 0.50	 N	 0	 0.50	 N	
mir-491	 0.06	 0.08	 N	 -0.01	 0.36	 N	 0	 0.50	 N	 0	 0.50	 N	
mir-653	 -4.5E-03	 0.45	 N	 0.01	 0.36	 N	 0	 0.50	 N	 0	 0.50	 N	
mir-1280	 0.02	 0.31	 N	 0.01	 0.37	 N	 0	 0.50	 N	 0	 0.50	 N	
mir-551b	 0.08	 0.02	 Y	 -0.01	 0.37	 N	 0	 0.50	 N	 0	 0.50	 N	
mir-518a-1	 0.06	 0.06	 N	 -0.01	 0.37	 N	 0	 0.50	 N	 0	 0.50	 N	
mir-520b	 -0.04	 0.17	 N	 -0.01	 0.38	 N	 0	 0.50	 N	 0	 0.50	 N	
mir-512-2	 0.02	 0.33	 N	 0.01	 0.39	 N	 0	 0.50	 N	 0	 0.50	 N	
mir-153-2	 -0.03	 0.21	 N	 0.01	 0.39	 N	 0	 0.50	 N	 0	 0.50	 N	
mir-891b	 0.05	 0.09	 N	 -0.01	 0.39	 N	 0	 0.50	 N	 0	 0.50	 N	
mir-920	 -0.03	 0.24	 N	 -0.01	 0.39	 N	 0	 0.50	 N	 0	 0.50	 N	
mir-623	 -0.03	 0.26	 N	 0.01	 0.39	 N	 0	 0.50	 N	 0	 0.50	 N	
mir-519e	 4.7E-03	 0.46	 N	 -0.01	 0.39	 N	 0	 0.50	 N	 0	 0.50	 N	
mir-1274b	 0.10	 5.8E-03	 Y	 0.01	 0.39	 N	 0	 0.50	 N	 0	 0.50	 N	
mir-527	 4.1E-04	 0.50	 N	 -0.01	 0.40	 N	 0	 0.50	 N	 0	 0.50	 N	
mir-876	 0.02	 0.33	 N	 0.01	 0.40	 N	 0	 0.50	 N	 0	 0.50	 N	
mir-1259	 -0.03	 0.23	 N	 0.01	 0.40	 N	 0	 0.50	 N	 0	 0.50	 N	
mir-580	 0.04	 0.18	 N	 0.01	 0.40	 N	 0	 0.50	 N	 0	 0.50	 N	
mir-1203	 0.03	 0.23	 N	 -9.9E-03	 0.40	 N	 0	 0.50	 N	 0	 0.50	 N	
mir-593	 8.3E-03	 0.42	 N	 0.01	 0.41	 N	 0	 0.50	 N	 0	 0.50	 N	
mir-516a-1	 -0.02	 0.33	 N	 -9.5E-03	 0.41	 N	 0	 0.50	 N	 0	 0.50	 N	
mir-1285-1	 -0.01	 0.38	 N	 -9.3E-03	 0.41	 N	 0	 0.50	 N	 0	 0.50	 N	
mir-1469	 -0.08	 0.02	 Y	 9.9E-03	 0.41	 N	 0	 0.50	 N	 0	 0.50	 N	
mir-563	 -0.02	 0.31	 N	 -8.6E-03	 0.41	 N	 0	 0.50	 N	 0	 0.50	 N	
mir-1277	 0.10	 7.6E-03	 Y	 9.0E-03	 0.42	 N	 0	 0.50	 N	 0	 0.50	 N	
mir-518f	 5.7E-03	 0.45	 N	 8.3E-03	 0.42	 N	 0	 0.50	 N	 0	 0.50	 N	
mir-520f	 -0.02	 0.30	 N	 -7.7E-03	 0.42	 N	 0	 0.50	 N	 0	 0.50	 N	
mir-937	 0.05	 0.10	 N	 8.2E-03	 0.42	 N	 0	 0.50	 N	 0	 0.50	 N	
mir-936	 -0.06	 0.07	 N	 -7.6E-03	 0.42	 N	 0	 0.50	 N	 0	 0.50	 N	
mir-521-2	 -0.03	 0.26	 N	 8.0E-03	 0.43	 N	 0	 0.50	 N	 0	 0.50	 N	
mir-656	 0.02	 0.36	 N	 7.7E-03	 0.43	 N	 0	 0.50	 N	 0	 0.50	 N	
mir-1297	 0.04	 0.19	 N	 -6.9E-03	 0.43	 N	 0	 0.50	 N	 0	 0.50	 N	
mir-610	 0.03	 0.23	 N	 7.5E-03	 0.43	 N	 0	 0.50	 N	 0	 0.50	 N	
mir-892a	 0.06	 0.08	 N	 -6.7E-03	 0.43	 N	 0	 0.50	 N	 0	 0.50	 N	
mir-1182	 -0.02	 0.33	 N	 -6.6E-03	 0.43	 N	 0	 0.50	 N	 0	 0.50	 N	
mir-630	 0.02	 0.34	 N	 -5.9E-03	 0.44	 N	 0	 0.50	 N	 0	 0.50	 N	
mir-635	 -0.06	 0.08	 N	 -5.6E-03	 0.44	 N	 0	 0.50	 N	 0	 0.50	 N	
mir-576	 0.04	 0.14	 N	 -5.3E-03	 0.45	 N	 0	 0.50	 N	 0	 0.50	 N	
mir-523	 -0.02	 0.32	 N	 -5.2E-03	 0.45	 N	 0	 0.50	 N	 0	 0.50	 N	
mir-525	 0.01	 0.39	 N	 5.3E-03	 0.45	 N	 0	 0.50	 N	 0	 0.50	 N	
mir-135b	 -0.10	 6.2E-03	 Y	 -4.6E-03	 0.45	 N	 0	 0.50	 N	 0	 0.50	 N	
mir-1281	 1.0E-03	 0.49	 N	 5.0E-03	 0.45	 N	 0	 0.50	 N	 0	 0.50	 N	
mir-1291	 0.04	 0.16	 N	 -4.2E-03	 0.46	 N	 0	 0.50	 N	 0	 0.50	 N	
mir-558	 -0.02	 0.34	 N	 -3.9E-03	 0.46	 N	 0	 0.50	 N	 0	 0.50	 N	
mir-553	 -0.02	 0.34	 N	 -3.9E-03	 0.46	 N	 0	 0.50	 N	 0	 0.50	 N	
mir-515-2	 0.03	 0.27	 N	 3.7E-03	 0.47	 N	 0	 0.50	 N	 0	 0.50	 N	
mir-1275	 -0.15	 1.8E-04	 Y	 -3.2E-03	 0.47	 N	 0	 0.50	 N	 0	 0.50	 N	
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mir-526a-2	 0.05	 0.10	 N	 3.3E-03	 0.47	 N	 0	 0.50	 N	 0	 0.50	 N	
mir-302c	 -9.0E-03	 0.41	 N	 3.2E-03	 0.47	 N	 0	 0.50	 N	 0	 0.50	 N	
mir-627	 -0.02	 0.30	 N	 -2.8E-03	 0.47	 N	 0	 0.50	 N	 0	 0.50	 N	
mir-643	 2.4E-03	 0.48	 N	 3.1E-03	 0.47	 N	 0	 0.50	 N	 0	 0.50	 N	
mir-660	 0.02	 0.31	 N	 -2.3E-03	 0.48	 N	 0	 0.50	 N	 0	 0.50	 N	
mir-631	 0.02	 0.29	 N	 2.3E-03	 0.48	 N	 0	 0.50	 N	 0	 0.50	 N	
mir-1305	 -0.02	 0.33	 N	 2.2E-03	 0.48	 N	 0	 0.50	 N	 0	 0.50	 N	
mir-1201	 3.1E-03	 0.47	 N	 -1.6E-03	 0.48	 N	 0	 0.50	 N	 0	 0.50	 N	
mir-606	 -0.02	 0.30	 N	 1.9E-03	 0.48	 N	 0	 0.50	 N	 0	 0.50	 N	
mir-548d-1	 8.7E-03	 0.42	 N	 1.8E-03	 0.48	 N	 0	 0.50	 N	 0	 0.50	 N	
mir-1179	 0.02	 0.29	 N	 1.1E-03	 0.49	 N	 0	 0.50	 N	 0	 0.50	 N	
mir-519a-2	 0.03	 0.25	 N	 8.4E-04	 0.49	 N	 0	 0.50	 N	 0	 0.50	 N	
mir-502	 0.02	 0.29	 N	 -4.7E-04	 0.49	 N	 0	 0.50	 N	 0	 0.50	 N	
mir-621	 1.0E-03	 0.49	 N	 6.6E-04	 0.50	 N	 0	 0.50	 N	 0	 0.50	 N	







Assignment of samples into P, R and K groups in CRCSC cohort 
 
Sample	 P	group	 R	group	 K	group	
GSM327282	 P+	 R-	 K-	
GSM327283	 P+	 R-	 K-	
GSM327284	 P-	 R-	 K-	
GSM327285	 P-	 R-	 K-	
GSM327286	 P-	 R+	 K-	
GSM327287	 P+	 R-	 K+	
GSM327288	 P+	 R+	 K-	
GSM327289	 P+	 R+	 K-	
GSM327290	 P+	 R-	 K-	
GSM327291	 P-	 R+	 K-	
GSM327292	 P+	 R-	 K-	
GSM327293	 P+	 R+	 K-	
GSM327294	 P+	 R-	 K-	
GSM327295	 P+	 R-	 K-	
GSM327296	 P+	 R-	 K-	
GSM327297	 P-	 R+	 K+	
GSM327298	 P-	 R+	 K-	
GSM327299	 P-	 R-	 K-	
GSM327300	 P-	 R+	 K-	
GSM327301	 P+	 R-	 K+	
GSM327302	 P-	 R+	 K-	
GSM327303	 P+	 R+	 K-	
GSM327304	 P+	 R-	 K+	
GSM327305	 P+	 R-	 K-	
GSM327306	 P+	 R-	 K-	
GSM327307	 P+	 R-	 K-	
GSM327308	 P+	 R-	 K-	
GSM327309	 P+	 R-	 K-	
GSM327310	 P+	 R-	 K+	
GSM327311	 P+	 R-	 K-	
GSM327312	 P-	 R-	 K-	
GSM327313	 P+	 R+	 K+	
GSM327314	 P+	 R-	 K-	
GSM327315	 P-	 R+	 K-	
GSM327316	 P+	 R-	 K-	
GSM327317	 P+	 R+	 K+	
GSM327318	 P+	 R-	 K-	
GSM327319	 P+	 R-	 K-	
GSM327320	 P+	 R+	 K-	
GSM327321	 P+	 R+	 K-	
GSM327322	 P+	 R+	 K-	
GSM327323	 P+	 R-	 K-	
GSM327324	 P+	 R-	 K-	
GSM327325	 P+	 R+	 K-	
GSM327326	 P+	 R-	 K-	
GSM327327	 P+	 R+	 K-	
GSM327328	 P+	 R+	 K-	
GSM327329	 P-	 R-	 K-	
GSM327330	 P+	 R+	 K-	
GSM327331	 P+	 R+	 K+	
GSM327332	 P+	 R+	 K-	
GSM327333	 P-	 R+	 K-	
GSM327334	 P+	 R-	 K-	
GSM327335	 P-	 R-	 K-	
GSM327336	 P-	 R-	 K-	
GSM327337	 P+	 R-	 K-	
GSM327338	 P+	 R-	 K-	
GSM327339	 P-	 R+	 K-	
GSM327340	 P-	 R-	 K-	
GSM327341	 P-	 R-	 K-	
GSM327342	 P-	 R-	 K-	
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GSM327343	 P-	 R-	 K+	
GSM327344	 P-	 R+	 K+	
GSM327345	 P-	 R+	 K-	
GSM327346	 P-	 R-	 K-	
GSM327347	 P-	 R+	 K-	
GSM327348	 P-	 R+	 K+	
GSM327349	 P-	 R-	 K-	
GSM327350	 P-	 R-	 K-	
GSM327351	 P-	 R+	 K-	
GSM327352	 P-	 R-	 K-	
GSM327353	 P+	 R-	 K-	
GSM327354	 P-	 R-	 K-	
GSM327355	 P-	 R-	 K-	
GSM335510	 P+	 R-	 K-	
GSM335511	 P-	 R-	 K-	
GSM335512	 P+	 R+	 K-	
GSM335513	 P-	 R+	 K-	
GSM335514	 P+	 R+	 K-	
GSM335515	 P+	 R+	 K-	
GSM335516	 P+	 R+	 K-	
GSM335517	 P+	 R-	 K-	
GSM335518	 P+	 R+	 K-	
GSM335519	 P+	 R+	 K-	
GSM335520	 P-	 R+	 K-	
GSM335521	 P+	 R+	 K-	
GSM335522	 P+	 R+	 K-	
GSM335523	 P-	 R+	 K-	
GSM335524	 P+	 R+	 K-	
GSM335525	 P-	 R+	 K-	
GSM335526	 P-	 R+	 K-	
GSM335527	 P-	 R+	 K-	
GSM335528	 P-	 R+	 K-	
GSM335529	 P+	 R+	 K-	
GSM335530	 P+	 R+	 K-	
GSM335531	 P+	 R+	 K-	
GSM335532	 P+	 R+	 K-	
GSM335533	 P+	 R+	 K-	
GSM335534	 P-	 R+	 K-	
GSM335535	 P-	 R+	 K-	
GSM335536	 P+	 R+	 K-	
GSM335537	 P+	 R-	 K-	
GSM335538	 P-	 R+	 K-	
GSM335539	 P+	 R+	 K-	
GSM335540	 P-	 R-	 K-	
GSM335541	 P-	 R+	 K-	
GSM335542	 P+	 R+	 K-	
GSM335543	 P-	 R+	 K-	
GSM335544	 P+	 R+	 K+	
GSM335545	 P-	 R+	 K-	
GSM335546	 P-	 R+	 K-	
GSM335547	 P+	 R-	 K-	
GSM335548	 P+	 R-	 K-	
GSM335549	 P+	 R-	 K-	
GSM335550	 P+	 R-	 K-	
GSM335551	 P+	 R+	 K+	
GSM335552	 P-	 R+	 K+	
GSM335553	 P-	 R-	 K+	
GSM335554	 P+	 R-	 K-	
GSM335555	 P+	 R-	 K-	
GSM335556	 P+	 R-	 K-	
GSM335557	 P+	 R-	 K-	
GSM335558	 P+	 R-	 K-	
GSM335559	 P-	 R-	 K-	
GSM335560	 P+	 R-	 K-	
GSM335561	 P-	 R-	 K-	
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GSM335562	 P+	 R-	 K-	
GSM335563	 P-	 R-	 K-	
GSM335564	 P-	 R+	 K-	
GSM335565	 P+	 R+	 K+	
GSM335566	 P+	 R-	 K-	
GSM335567	 P-	 R-	 K-	
GSM335568	 P+	 R+	 K-	
GSM335569	 P-	 R-	 K-	
GSM335570	 P+	 R-	 K-	
GSM335571	 P+	 R-	 K-	
GSM335572	 P-	 R-	 K-	
GSM335573	 P+	 R-	 K+	
GSM335574	 P+	 R+	 K-	
GSM335575	 P-	 R-	 K+	
GSM335576	 P+	 R+	 K+	
GSM335577	 P+	 R-	 K-	
GSM335578	 P+	 R-	 K-	
GSM335579	 P+	 R-	 K-	
GSM335580	 P-	 R+	 K+	
GSM335581	 P-	 R-	 K-	
GSM335582	 P+	 R-	 K-	
GSM335583	 P+	 R-	 K-	
GSM335584	 P+	 R-	 K-	
GSM335585	 P+	 R-	 K-	
GSM335586	 P-	 R-	 K-	
GSM335587	 P+	 R-	 K+	
GSM335588	 P+	 R+	 K-	
GSM335589	 P-	 R-	 K-	
GSM335590	 P-	 R+	 K-	
GSM335591	 P+	 R-	 K-	
GSM335592	 P+	 R-	 K-	
GSM335593	 P-	 R-	 K-	
GSM335594	 P-	 R-	 K-	
GSM335595	 P-	 R-	 K-	
GSM335596	 P-	 R-	 K-	
GSM335597	 P-	 R-	 K+	
GSM335598	 P-	 R-	 K+	
GSM335599	 P+	 R-	 K-	
GSM335600	 P-	 R-	 K-	
GSM335601	 P+	 R-	 K-	
GSM335602	 P-	 R-	 K+	
GSM335603	 P-	 R-	 K-	
GSM335604	 P-	 R+	 K+	
GSM335605	 P-	 R-	 K-	
GSM335606	 P-	 R-	 K+	
GSM335607	 P-	 R-	 K-	
GSM335608	 P-	 R+	 K-	
GSM335609	 P+	 R-	 K-	
GSM335610	 P-	 R-	 K-	
GSM335611	 P-	 R-	 K-	
GSM335612	 P-	 R+	 K-	
GSM335613	 P-	 R+	 K-	
GSM335614	 P+	 R+	 K-	
GSM335615	 P+	 R-	 K-	
GSM335616	 P-	 R-	 K-	
GSM335617	 P-	 R+	 K-	
GSM335618	 P+	 R-	 K-	
GSM335619	 P+	 R+	 K+	
GSM335620	 P-	 R+	 K+	
GSM335621	 P+	 R-	 K-	
GSM335622	 P+	 R+	 K+	
GSM335623	 P+	 R+	 K-	
GSM335624	 P-	 R-	 K-	
GSM335625	 P-	 R-	 K+	
GSM335626	 P-	 R-	 K-	
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GSM335627	 P-	 R-	 K-	
GSM335628	 P+	 R-	 K-	
GSM335629	 P+	 R+	 K+	
GSM335630	 P+	 R-	 K-	
GSM335631	 P+	 R-	 K-	
GSM335632	 P+	 R-	 K-	
GSM335633	 P-	 R+	 K+	
GSM335634	 P-	 R-	 K-	
GSM335635	 P+	 R-	 K-	
GSM335636	 P+	 R-	 K-	
GSM335637	 P-	 R+	 K+	
GSM335638	 P-	 R-	 K+	
GSM335639	 P+	 R-	 K-	
GSM335640	 P+	 R+	 K-	
GSM335641	 P+	 R-	 K+	
GSM335642	 P-	 R-	 K-	
GSM335643	 P+	 R-	 K-	
GSM335644	 P+	 R-	 K-	
GSM335645	 P+	 R+	 K-	
GSM335646	 P+	 R-	 K+	
GSM335647	 P-	 R-	 K+	
GSM335648	 P-	 R-	 K-	
GSM335649	 P+	 R+	 K-	
GSM335650	 P+	 R-	 K-	
GSM335651	 P+	 R-	 K-	
GSM335652	 P+	 R+	 K-	
GSM335653	 P+	 R+	 K+	
GSM335654	 P-	 R+	 K-	
GSM335655	 P+	 R+	 K-	
GSM335656	 P+	 R-	 K-	
GSM335657	 P+	 R-	 K-	
GSM335658	 P-	 R+	 K-	
GSM335659	 P-	 R+	 K+	
GSM335660	 P-	 R+	 K-	
GSM335661	 P-	 R-	 K-	
GSM335662	 P+	 R+	 K-	
GSM335663	 P-	 R-	 K-	
GSM335664	 P+	 R+	 K+	
GSM358342	 P-	 R+	 K-	
GSM358343	 P+	 R+	 K-	
GSM358344	 P-	 R+	 K-	
GSM358345	 P-	 R+	 K+	
GSM358354	 P+	 R-	 K-	
GSM358355	 P-	 R-	 K-	
GSM358357	 P+	 R-	 K-	
GSM358359	 P-	 R+	 K+	
GSM358362	 P-	 R-	 K-	
GSM358363	 P-	 R-	 K-	
GSM358364	 P-	 R+	 K-	
GSM358369	 P-	 R-	 K-	
GSM358370	 P+	 R-	 K-	
GSM358371	 P+	 R-	 K-	
GSM358372	 P+	 R-	 K-	
GSM358373	 P+	 R-	 K-	
GSM358374	 P+	 R+	 K-	
GSM358375	 P+	 R-	 K-	
GSM358376	 P+	 R-	 K-	
GSM358377	 P+	 R-	 K-	
GSM358378	 P+	 R-	 K-	
GSM358379	 P+	 R-	 K-	
GSM358380	 P+	 R-	 K-	
GSM358381	 P+	 R-	 K-	
GSM358382	 P+	 R+	 K-	
GSM358383	 P-	 R+	 K-	
GSM358384	 P-	 R+	 K-	
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GSM358386	 P-	 R+	 K-	
GSM358387	 P+	 R-	 K+	
GSM358389	 P-	 R+	 K-	
GSM358390	 P-	 R+	 K-	
GSM358394	 P-	 R+	 K-	
GSM358395	 P-	 R+	 K-	
GSM358399	 P+	 R-	 K-	
GSM358402	 P+	 R-	 K-	
GSM358403	 P-	 R+	 K-	
GSM358406	 P-	 R+	 K-	
GSM358407	 P-	 R-	 K-	
GSM358409	 P-	 R+	 K+	
GSM358413	 P-	 R+	 K+	
GSM358416	 P-	 R+	 K-	
GSM358421	 P-	 R-	 K-	
GSM358422	 P+	 R-	 K+	
GSM358426	 P-	 R-	 K+	
GSM358428	 P-	 R-	 K-	
GSM358439	 P+	 R-	 K-	
GSM358440	 P+	 R+	 K-	
GSM358442	 P+	 R-	 K-	
GSM358443	 P-	 R-	 K-	
GSM358444	 P+	 R+	 K-	
GSM358445	 P+	 R-	 K-	
GSM358446	 P-	 R+	 K-	
GSM358447	 P+	 R+	 K-	
GSM358448	 P+	 R-	 K-	
GSM358449	 P+	 R-	 K-	
GSM358450	 P-	 R+	 K-	
GSM358451	 P+	 R-	 K-	
GSM358452	 P-	 R-	 K-	
GSM358453	 P+	 R-	 K-	
GSM358454	 P+	 R-	 K-	
GSM358455	 P-	 R-	 K-	
GSM358456	 P+	 R-	 K-	
GSM358457	 P+	 R-	 K-	
GSM358458	 P+	 R+	 K-	
GSM358459	 P+	 R-	 K-	
GSM358460	 P-	 R-	 K-	
GSM358461	 P+	 R-	 K-	
GSM358462	 P-	 R+	 K-	
GSM358463	 P+	 R-	 K-	
GSM358464	 P-	 R-	 K-	
GSM358465	 P+	 R+	 K-	
GSM358466	 P-	 R-	 K-	
GSM358467	 P-	 R+	 K-	
GSM358468	 P-	 R+	 K-	
GSM358469	 P+	 R-	 K-	
GSM358470	 P-	 R+	 K-	
GSM358471	 P+	 R+	 K-	
GSM358472	 P-	 R+	 K-	
GSM358473	 P-	 R-	 K-	
GSM358474	 P+	 R-	 K-	
GSM358475	 P-	 R+	 K-	
GSM358476	 P+	 R+	 K-	
GSM358477	 P+	 R+	 K-	
GSM358478	 P-	 R+	 K-	
GSM358480	 P-	 R-	 K-	
GSM358486	 P-	 R+	 K-	
GSM358490	 P+	 R+	 K-	
GSM358492	 P-	 R+	 K-	
GSM358502	 P-	 R+	 K-	
GSM358504	 P-	 R+	 K-	
GSM358512	 P-	 R-	 K+	
GSM358513	 P-	 R+	 K+	
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GSM358514	 P+	 R+	 K+	
GSM358526	 P+	 R+	 K-	
GSM358527	 P+	 R+	 K-	
GSM358530	 P-	 R-	 K+	
GSM358532	 P-	 R+	 K-	
GSM358533	 P-	 R+	 K-	
GSM358535	 P+	 R+	 K-	
GSM358540	 P-	 R-	 K-	
GSM358541	 P-	 R+	 K-	
GSM358542	 P-	 R-	 K-	
GSM358543	 P-	 R-	 K-	
GSM358544	 P-	 R-	 K-	
GSM358545	 P+	 R-	 K-	
GSM358546	 P+	 R+	 K-	
GSM358547	 P+	 R-	 K-	
GSM358548	 P+	 R-	 K-	
GSM358549	 P+	 R-	 K-	
GSM358550	 P+	 R-	 K-	
GSM358551	 P+	 R+	 K+	
GSM358552	 P+	 R-	 K-	
GSM358553	 P+	 R+	 K-	
GSM358554	 P+	 R+	 K-	
GSM358555	 P+	 R+	 K-	
GSM358556	 P+	 R-	 K-	
GSM358557	 P-	 R-	 K-	
GSM358558	 P-	 R-	 K+	
GSM358559	 P+	 R-	 K-	
GSM358560	 P+	 R-	 K-	
GSM358561	 P+	 R+	 K-	
GSM358562	 P+	 R-	 K-	
GSM358563	 P+	 R+	 K-	
GSM358564	 P-	 R-	 K-	
GSM358565	 P-	 R-	 K-	
GSM358566	 P+	 R-	 K-	
GSM358567	 P-	 R+	 K-	
GSM358568	 P-	 R+	 K-	
GSM358569	 P-	 R-	 K-	
GSM358570	 P+	 R+	 K+	
GSM358573	 P+	 R+	 K-	
GSM358575	 P-	 R+	 K+	
GSM358582	 P+	 R+	 K-	
GSM358591	 P-	 R+	 K-	
GSM358599	 P-	 R+	 K-	
GSM358600	 P-	 R-	 K-	
GSM358608	 P+	 R-	 K-	
GSM358611	 P-	 R+	 K-	
GSM358612	 P+	 R-	 K-	
GSM358613	 P+	 R-	 K-	
GSM358614	 P-	 R-	 K-	
GSM358615	 P-	 R-	 K-	
GSM358616	 P+	 R+	 K-	
GSM358617	 P-	 R+	 K-	
GSM358618	 P+	 R+	 K-	
GSM358619	 P+	 R-	 K-	
GSM358620	 P-	 R-	 K-	
GSM358621	 P-	 R+	 K-	
GSM358622	 P-	 R-	 K-	
GSM358623	 P+	 R-	 K-	
GSM358624	 P-	 R-	 K-	
GSM358625	 P-	 R+	 K-	
GSM358626	 P+	 R-	 K-	
GSM358627	 P+	 R-	 K-	
GSM358628	 P+	 R+	 K+	
GSM358629	 P+	 R-	 K-	
GSM358630	 P+	 R+	 K-	
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GSM437093	 P+	 R+	 K-	
GSM437094	 P-	 R-	 K-	
GSM437095	 P-	 R-	 K-	
GSM437096	 P+	 R-	 K-	
GSM437097	 P+	 R-	 K-	
GSM437098	 P+	 R+	 K-	
GSM437099	 P+	 R-	 K-	
GSM437100	 P-	 R+	 K-	
GSM437101	 P+	 R-	 K-	
GSM437102	 P-	 R+	 K-	
GSM437103	 P+	 R+	 K-	
GSM437104	 P-	 R-	 K-	
GSM437105	 P-	 R-	 K-	
GSM437106	 P+	 R-	 K-	
GSM437107	 P+	 R-	 K-	
GSM437108	 P+	 R-	 K-	
GSM437109	 P-	 R+	 K-	
GSM437110	 P-	 R-	 K-	
GSM437111	 P-	 R+	 K+	
GSM437112	 P+	 R-	 K-	
GSM437113	 P-	 R-	 K-	
GSM437114	 P+	 R-	 K-	
GSM437115	 P-	 R-	 K-	
GSM437116	 P-	 R+	 K-	
GSM437117	 P+	 R+	 K-	
GSM437118	 P+	 R-	 K+	
GSM437119	 P-	 R+	 K-	
GSM437120	 P+	 R+	 K-	
GSM437121	 P+	 R-	 K-	
GSM437122	 P+	 R-	 K-	
GSM437123	 P-	 R+	 K-	
GSM437124	 P+	 R-	 K-	
GSM437125	 P+	 R+	 K-	
GSM437126	 P+	 R-	 K-	
GSM437127	 P-	 R+	 K+	
GSM437128	 P+	 R-	 K-	
GSM437129	 P+	 R-	 K-	
GSM437130	 P+	 R+	 K-	
GSM437131	 P-	 R-	 K-	
GSM437132	 P+	 R-	 K-	
GSM437133	 P+	 R+	 K-	
GSM437134	 P-	 R+	 K+	
GSM437135	 P-	 R+	 K-	
GSM437136	 P-	 R-	 K-	
GSM437137	 P+	 R-	 K-	
GSM437138	 P+	 R-	 K-	
GSM437139	 P+	 R-	 K-	
GSM437140	 P+	 R-	 K-	
GSM437141	 P+	 R-	 K-	
GSM437142	 P+	 R-	 K-	
GSM437143	 P+	 R-	 K-	
GSM437144	 P+	 R+	 K-	
GSM437145	 P+	 R+	 K-	
GSM437146	 P+	 R-	 K-	
GSM437147	 P+	 R-	 K-	
GSM437148	 P+	 R-	 K-	
GSM437149	 P-	 R+	 K-	
GSM437150	 P-	 R-	 K-	
GSM437151	 P-	 R-	 K-	
GSM437152	 P-	 R+	 K-	
GSM437153	 P-	 R-	 K-	
GSM437154	 P-	 R-	 K-	
GSM437155	 P-	 R+	 K-	
GSM437156	 P-	 R-	 K-	
GSM437157	 P+	 R+	 K-	
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GSM437158	 P+	 R-	 K-	
GSM437159	 P+	 R+	 K+	
GSM437160	 P+	 R-	 K-	
GSM437161	 P+	 R+	 K-	
GSM437162	 P-	 R-	 K-	
GSM437163	 P-	 R+	 K+	
GSM437164	 P-	 R-	 K-	
GSM437165	 P+	 R-	 K-	
GSM437166	 P+	 R+	 K-	
GSM437167	 P+	 R-	 K-	
GSM437168	 P+	 R-	 K-	
GSM437169	 P-	 R-	 K-	
GSM437170	 P-	 R+	 K-	
GSM437171	 P+	 R+	 K-	
GSM437172	 P+	 R-	 K-	
GSM437173	 P+	 R+	 K-	
GSM437174	 P+	 R+	 K-	
GSM437175	 P+	 R+	 K-	
GSM437176	 P-	 R-	 K-	
GSM437177	 P+	 R-	 K-	
GSM437178	 P+	 R+	 K-	
GSM437179	 P-	 R-	 K-	
GSM437180	 P-	 R+	 K-	
GSM437181	 P+	 R+	 K-	
GSM437182	 P+	 R+	 K-	
GSM437183	 P+	 R-	 K-	
GSM437184	 P+	 R+	 K-	
GSM437185	 P-	 R-	 K-	
GSM437186	 P+	 R-	 K-	
GSM437187	 P-	 R+	 K-	
GSM437188	 P+	 R-	 K-	
GSM437189	 P-	 R+	 K-	
GSM437190	 P+	 R+	 K-	
GSM437191	 P-	 R+	 K-	
GSM437192	 P+	 R+	 K-	
GSM437193	 P+	 R-	 K-	
GSM437194	 P-	 R-	 K-	
GSM437195	 P-	 R+	 K-	
GSM437196	 P+	 R-	 K-	
GSM437197	 P-	 R+	 K-	
GSM437198	 P+	 R+	 K-	
GSM437199	 P-	 R+	 K-	
GSM437200	 P+	 R+	 K-	
GSM437201	 P-	 R+	 K-	
GSM437202	 P+	 R+	 K-	
GSM437203	 P+	 R-	 K-	
GSM437204	 P-	 R+	 K-	
GSM437205	 P-	 R-	 K+	
GSM437206	 P+	 R-	 K-	
GSM437207	 P+	 R-	 K-	
GSM437208	 P-	 R-	 K-	
GSM437209	 P-	 R+	 K-	
GSM437210	 P+	 R+	 K+	
GSM437211	 P+	 R+	 K-	
GSM437212	 P+	 R-	 K-	
GSM437213	 P+	 R-	 K-	
GSM437214	 P-	 R-	 K-	
GSM437215	 P-	 R+	 K+	
GSM437216	 P+	 R-	 K-	
GSM437217	 P+	 R-	 K-	
GSM437218	 P+	 R-	 K-	
GSM437219	 P-	 R-	 K-	
GSM437220	 P-	 R-	 K-	
GSM437221	 P+	 R-	 K-	
GSM437222	 P-	 R+	 K-	
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GSM437223	 P+	 R+	 K-	
GSM437224	 P+	 R+	 K-	
GSM437225	 P+	 R+	 K+	
GSM437226	 P-	 R+	 K-	
GSM437227	 P-	 R-	 K-	
GSM437228	 P-	 R-	 K-	
GSM437229	 P-	 R+	 K+	
GSM437230	 P-	 R-	 K-	
GSM437231	 P-	 R+	 K-	
GSM437232	 P-	 R-	 K-	
GSM437233	 P-	 R+	 K-	
GSM437234	 P+	 R+	 K-	
GSM437235	 P+	 R+	 K-	
GSM437236	 P+	 R-	 K-	
GSM437237	 P+	 R-	 K-	
GSM437238	 P+	 R-	 K-	
GSM437239	 P+	 R+	 K+	
GSM437240	 P+	 R-	 K-	
GSM437241	 P-	 R-	 K-	
GSM437242	 P+	 R-	 K+	
GSM437243	 P+	 R+	 K-	
GSM437244	 P+	 R-	 K-	
GSM437245	 P+	 R+	 K+	
GSM437246	 P+	 R-	 K-	
GSM437247	 P+	 R-	 K-	
GSM437248	 P+	 R-	 K-	
GSM437249	 P+	 R-	 K-	
GSM437250	 P-	 R+	 K-	
GSM437251	 P-	 R+	 K-	
GSM437252	 P-	 R-	 K-	
GSM437253	 P+	 R-	 K-	
GSM437254	 P+	 R+	 K-	
GSM437255	 P-	 R-	 K-	
GSM437256	 P+	 R-	 K+	
GSM437257	 P+	 R+	 K-	
GSM437258	 P-	 R-	 K-	
GSM437259	 P-	 R-	 K-	
GSM437260	 P-	 R-	 K-	
GSM437261	 P-	 R-	 K-	
GSM437262	 P-	 R-	 K-	
GSM437263	 P-	 R+	 K-	
GSM437264	 P+	 R-	 K-	
GSM437265	 P+	 R+	 K-	
GSM437266	 P-	 R-	 K-	
GSM437267	 P+	 R-	 K-	
GSM437268	 P+	 R-	 K-	
GSM437269	 P+	 R-	 K-	
GSM523242	 P-	 R+	 K-	
GSM523243	 P-	 R-	 K-	
GSM523244	 P+	 R-	 K-	
GSM523245	 P-	 R-	 K-	
GSM523246	 P-	 R-	 K-	
GSM523247	 P+	 R-	 K-	
GSM523248	 P+	 R-	 K-	
GSM523249	 P+	 R-	 K-	
GSM523250	 P+	 R-	 K-	
GSM523251	 P+	 R-	 K-	
GSM523252	 P+	 R-	 K-	
GSM523253	 P+	 R-	 K+	
GSM523254	 P+	 R-	 K-	
GSM523255	 P-	 R-	 K-	
GSM523256	 P+	 R-	 K-	
GSM523257	 P+	 R-	 K-	
GSM523258	 P+	 R-	 K-	
GSM523259	 P+	 R-	 K-	
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GSM523260	 P-	 R-	 K-	
GSM523261	 P+	 R-	 K-	
GSM523262	 P+	 R-	 K-	
GSM523263	 P+	 R-	 K-	
GSM523264	 P-	 R-	 K-	
GSM523265	 P-	 R-	 K-	
GSM523266	 P+	 R-	 K-	
GSM523267	 P-	 R-	 K-	
GSM523268	 P-	 R-	 K-	
GSM523269	 P-	 R-	 K-	
GSM523270	 P-	 R-	 K-	
GSM523271	 P-	 R-	 K-	
GSM523272	 P-	 R-	 K-	
GSM523273	 P-	 R+	 K-	
GSM523274	 P-	 R+	 K-	
GSM523275	 P+	 R-	 K-	
GSM523276	 P-	 R-	 K-	
GSM523277	 P+	 R-	 K-	
GSM523278	 P+	 R-	 K-	
GSM523279	 P+	 R-	 K-	
GSM523280	 P-	 R-	 K-	
GSM523281	 P+	 R-	 K-	
GSM523282	 P+	 R+	 K-	
GSM523283	 P-	 R+	 K+	
GSM523284	 P-	 R+	 K+	
GSM523285	 P+	 R+	 K+	
GSM523286	 P-	 R-	 K-	
GSM523287	 P+	 R+	 K-	
GSM523288	 P+	 R-	 K-	
GSM523289	 P-	 R+	 K-	
GSM523290	 P-	 R+	 K-	
GSM523291	 P-	 R+	 K-	
GSM523292	 P+	 R+	 K-	
GSM523293	 P-	 R+	 K-	
GSM523294	 P+	 R+	 K-	
GSM523295	 P+	 R-	 K-	
GSM523296	 P-	 R+	 K-	
GSM523297	 P-	 R-	 K-	
GSM523298	 P+	 R-	 K-	
GSM523299	 P-	 R+	 K-	
GSM523300	 P+	 R+	 K-	
GSM523301	 P+	 R+	 K-	
GSM523302	 P+	 R-	 K-	
GSM523303	 P-	 R+	 K-	
GSM523304	 P-	 R+	 K-	
GSM523305	 P+	 R+	 K-	
GSM523306	 P+	 R+	 K-	
GSM523307	 P+	 R+	 K-	
GSM523308	 P+	 R-	 K-	
GSM523309	 P-	 R-	 K+	
GSM523310	 P-	 R+	 K-	
GSM523311	 P-	 R+	 K-	
GSM523312	 P-	 R+	 K-	
GSM523313	 P+	 R-	 K+	
GSM523314	 P-	 R+	 K-	
GSM523315	 P+	 R+	 K+	
GSM523316	 P-	 R+	 K-	
GSM523317	 P+	 R+	 K-	
GSM523318	 P+	 R+	 K+	
GSM523319	 P-	 R+	 K-	
GSM523320	 P-	 R+	 K-	
GSM523321	 P+	 R+	 K-	
GSM523322	 P+	 R-	 K-	
GSM523323	 P+	 R+	 K-	
GSM523324	 P-	 R+	 K-	
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GSM523325	 P+	 R+	 K+	
GSM523326	 P+	 R-	 K+	
GSM523327	 P-	 R+	 K-	
GSM523328	 P+	 R-	 K-	
GSM523329	 P+	 R-	 K+	
GSM523330	 P-	 R+	 K-	
GSM523331	 P+	 R+	 K-	
GSM523332	 P-	 R+	 K+	
GSM523333	 P+	 R-	 K+	
GSM523334	 P-	 R-	 K-	
GSM523335	 P+	 R-	 K+	
GSM523336	 P+	 R+	 K-	
GSM523337	 P+	 R-	 K+	
GSM523338	 P-	 R+	 K-	
GSM523339	 P+	 R+	 K-	
GSM523340	 P+	 R-	 K-	
GSM523341	 P+	 R-	 K+	
GSM523342	 P-	 R-	 K-	
GSM523343	 P+	 R+	 K-	
GSM523344	 P+	 R+	 K+	
GSM523345	 P+	 R+	 K-	
GSM523346	 P+	 R+	 K-	
GSM523347	 P-	 R-	 K-	
GSM523348	 P+	 R-	 K+	
GSM523349	 P-	 R+	 K-	
GSM523350	 P-	 R+	 K+	
GSM523351	 P+	 R+	 K-	
GSM523352	 P+	 R+	 K-	
GSM523353	 P-	 R-	 K-	
GSM523354	 P+	 R+	 K-	
GSM523355	 P-	 R+	 K-	
GSM523356	 P-	 R-	 K-	
GSM523357	 P+	 R+	 K+	
GSM523358	 P-	 R-	 K-	
GSM523359	 P+	 R+	 K+	
GSM523360	 P-	 R+	 K-	
GSM523361	 P-	 R-	 K-	
GSM523362	 P+	 R-	 K+	
GSM523363	 P+	 R+	 K-	
GSM523364	 P-	 R+	 K-	
GSM523365	 P-	 R+	 K-	
GSM523366	 P-	 R+	 K-	
GSM523367	 P+	 R+	 K-	
GSM523368	 P+	 R+	 K-	
GSM523369	 P-	 R+	 K-	
GSM523370	 P-	 R+	 K-	
GSM523371	 P+	 R-	 K-	
GSM523372	 P+	 R-	 K-	
GSM523373	 P-	 R+	 K-	
GSM523374	 P+	 R+	 K+	
GSM523375	 P+	 R-	 K-	
GSM523376	 P-	 R-	 K-	
GSM523377	 P-	 R+	 K-	
GSM523378	 P+	 R+	 K-	
GSM523379	 P+	 R+	 K-	
GSM523380	 P+	 R-	 K+	
GSM523381	 P+	 R+	 K+	
GSM523382	 P+	 R+	 K-	
GSM523383	 P-	 R+	 K-	
GSM523384	 P+	 R+	 K-	
GSM523385	 P-	 R+	 K-	
GSM523386	 P+	 R-	 K-	
GSM102429	 P+	 R+	 K-	
GSM102431	 P+	 R-	 K-	
GSM102436	 P-	 R+	 K-	
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GSM102460	 P-	 R-	 K-	
GSM102472	 P-	 R-	 K-	
GSM102485	 P-	 R+	 K-	
GSM102493	 P-	 R-	 K-	
GSM102497	 P-	 R+	 K-	
GSM102501	 P-	 R-	 K-	
GSM102513	 P+	 R-	 K-	
GSM102516	 P-	 R+	 K+	
GSM102518	 P-	 R-	 K+	
GSM102519	 P-	 R-	 K-	
GSM102521	 P-	 R+	 K+	
GSM102524	 P-	 R+	 K-	
GSM102533	 P-	 R-	 K-	
GSM102540	 P+	 R-	 K-	
GSM102549	 P-	 R-	 K-	
GSM102550	 P+	 R+	 K-	
GSM102551	 P+	 R+	 K-	
GSM102559	 P-	 R-	 K-	
GSM102561	 P+	 R+	 K-	
GSM102568	 P-	 R+	 K-	
GSM102572	 P-	 R-	 K-	
GSM102574	 P-	 R-	 K-	
GSM102577	 P+	 R-	 K-	
GSM102579	 P+	 R-	 K-	
GSM102581	 P+	 R+	 K-	
GSM117635	 P+	 R-	 K+	
GSM117642	 P+	 R+	 K-	
GSM117649	 P-	 R+	 K-	
GSM117656	 P+	 R-	 K-	
GSM117662	 P+	 R-	 K-	
GSM117664	 P-	 R-	 K+	
GSM117672	 P-	 R-	 K-	
GSM117673	 P-	 R-	 K+	
GSM117676	 P-	 R-	 K-	
GSM117678	 P+	 R+	 K+	
GSM117681	 P+	 R+	 K+	
GSM117709	 P+	 R+	 K-	
GSM117720	 P+	 R-	 K-	
GSM117728	 P-	 R-	 K-	
GSM117738	 P-	 R+	 K-	
GSM117742	 P-	 R-	 K-	
GSM117746	 P+	 R+	 K+	
GSM117747	 P-	 R-	 K-	
GSM117752	 P-	 R-	 K-	
GSM117760	 P-	 R+	 K-	
GSM117775	 P-	 R-	 K-	
GSM137922	 P-	 R-	 K-	
GSM137926	 P-	 R+	 K-	
GSM137929	 P-	 R+	 K+	
GSM137942	 P-	 R-	 K+	
GSM137947	 P+	 R+	 K-	
GSM137949	 P-	 R-	 K+	
GSM137967	 P+	 R-	 K-	
GSM137972	 P-	 R-	 K+	
GSM137993	 P-	 R-	 K+	
GSM137997	 P-	 R-	 K-	
GSM137998	 P-	 R-	 K+	
GSM138005	 P-	 R+	 K-	
GSM138007	 P+	 R-	 K-	
GSM138015	 P-	 R+	 K-	
GSM138018	 P-	 R+	 K-	
GSM138022	 P+	 R-	 K-	
GSM138032	 P-	 R-	 K+	
GSM138036	 P-	 R-	 K+	
GSM138037	 P-	 R-	 K+	
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GSM138042	 P-	 R+	 K+	
GSM138044	 P+	 R+	 K-	
GSM138048	 P+	 R-	 K-	
GSM138050	 P+	 R-	 K-	
GSM138052	 P+	 R-	 K-	
GSM152573	 P+	 R-	 K-	
GSM152579	 P+	 R-	 K+	
GSM152582	 P-	 R+	 K-	
GSM152591	 P+	 R-	 K-	
GSM152602	 P+	 R-	 K-	
GSM152610	 P-	 R+	 K-	
GSM152613	 P-	 R+	 K-	
GSM152614	 P+	 R-	 K-	
GSM152632	 P-	 R+	 K-	
GSM152638	 P+	 R+	 K-	
GSM152658	 P+	 R-	 K-	
GSM152664	 P+	 R-	 K-	
GSM152666	 P-	 R-	 K+	
GSM152684	 P-	 R+	 K-	
GSM152692	 P-	 R-	 K-	
GSM152695	 P+	 R-	 K-	
GSM152714	 P-	 R-	 K-	
GSM152720	 P+	 R-	 K-	
GSM152725	 P-	 R-	 K-	
GSM152730	 P-	 R+	 K-	
GSM152762	 P-	 R-	 K-	
GSM152780	 P+	 R-	 K-	
GSM152790	 P-	 R+	 K-	
GSM152799	 P-	 R-	 K-	
GSM179778	 P-	 R+	 K-	
GSM179793	 P+	 R+	 K-	
GSM179795	 P+	 R-	 K-	
GSM179803	 P-	 R+	 K-	
GSM179804	 P+	 R-	 K-	
GSM179805	 P+	 R+	 K-	
GSM179816	 P+	 R+	 K-	
GSM179820	 P-	 R-	 K-	
GSM179831	 P-	 R+	 K-	
GSM179838	 P+	 R-	 K-	
GSM179839	 P+	 R-	 K-	
GSM179844	 P+	 R+	 K-	
GSM179859	 P+	 R-	 K-	
GSM179860	 P+	 R-	 K-	
GSM179867	 P-	 R-	 K-	
GSM179868	 P-	 R-	 K-	
GSM179880	 P+	 R+	 K-	
GSM179882	 P+	 R-	 K-	
GSM179887	 P+	 R-	 K-	
GSM179888	 P-	 R-	 K-	
GSM179889	 P+	 R-	 K-	
GSM179897	 P+	 R-	 K-	
GSM179899	 P+	 R-	 K-	
GSM179908	 P+	 R+	 K-	
GSM179913	 P-	 R+	 K-	
GSM179922	 P-	 R+	 K-	
GSM179924	 P-	 R+	 K-	
GSM179925	 P-	 R-	 K-	
GSM179928	 P+	 R+	 K+	
GSM179930	 P-	 R+	 K-	
GSM179937	 P+	 R-	 K+	
GSM179948	 P+	 R-	 K+	
GSM203625	 P+	 R+	 K-	
GSM203627	 P-	 R-	 K-	
GSM203640	 P+	 R-	 K-	
GSM203642	 P+	 R+	 K-	
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GSM203645	 P+	 R-	 K-	
GSM203653	 P+	 R+	 K-	
GSM203657	 P+	 R-	 K+	
GSM203667	 P+	 R-	 K+	
GSM203673	 P+	 R-	 K-	
GSM203674	 P+	 R-	 K-	
GSM203684	 P-	 R+	 K-	
GSM203687	 P+	 R-	 K-	
GSM203688	 P+	 R+	 K+	
GSM203691	 P+	 R-	 K-	
GSM203700	 P+	 R-	 K-	
GSM203702	 P+	 R+	 K-	
GSM203705	 P+	 R+	 K+	
GSM203723	 P-	 R-	 K+	
GSM203724	 P-	 R+	 K-	
GSM203728	 P+	 R+	 K-	
GSM203731	 P+	 R-	 K-	
GSM203733	 P+	 R-	 K-	
GSM203743	 P+	 R+	 K-	
GSM203755	 P+	 R+	 K-	
GSM203763	 P+	 R+	 K-	
GSM203782	 P+	 R+	 K-	
GSM203800	 P-	 R-	 K-	
GSM231868	 P-	 R-	 K+	
GSM231875	 P-	 R+	 K-	
GSM231879	 P+	 R-	 K-	
GSM231904	 P+	 R-	 K-	
GSM231905	 P+	 R+	 K-	
GSM231908	 P-	 R+	 K-	
GSM231915	 P+	 R-	 K-	
GSM231921	 P-	 R+	 K+	
GSM231928	 P+	 R-	 K-	
GSM231936	 P-	 R-	 K-	
GSM231939	 P-	 R-	 K-	
GSM231953	 P-	 R-	 K-	
GSM231955	 P-	 R+	 K-	
GSM231956	 P+	 R+	 K-	
GSM231958	 P+	 R+	 K-	
GSM231959	 P+	 R-	 K-	
GSM231961	 P+	 R-	 K-	
GSM231964	 P-	 R-	 K-	
GSM231971	 P-	 R-	 K-	
GSM231988	 P+	 R+	 K-	
GSM277680	 P+	 R+	 K-	
GSM277689	 P+	 R-	 K-	
GSM277690	 P+	 R-	 K-	
GSM277728	 P+	 R+	 K-	
GSM277731	 P+	 R+	 K+	
GSM301656	 P+	 R+	 K-	
GSM325805	 P+	 R-	 K-	
GSM325806	 P+	 R-	 K-	
GSM325829	 P-	 R+	 K-	
GSM325840	 P-	 R+	 K-	
GSM325841	 P+	 R+	 K-	
GSM353883	 P-	 R+	 K-	
GSM353890	 P+	 R-	 K-	
GSM353895	 P-	 R+	 K-	
GSM353900	 P-	 R-	 K-	
GSM353901	 P+	 R-	 K-	
GSM353939	 P+	 R+	 K-	
GSM38055	 P+	 R+	 K-	
GSM38061	 P+	 R+	 K-	
GSM38074	 P+	 R+	 K-	
GSM38075	 P+	 R+	 K-	
GSM38077	 P+	 R+	 K-	
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GSM38078	 P-	 R+	 K-	
GSM38089	 P+	 R+	 K-	
GSM38098	 P+	 R+	 K-	
GSM38105	 P+	 R+	 K-	
GSM38107	 P-	 R+	 K-	
GSM46823	 P+	 R-	 K-	
GSM46832	 P+	 R-	 K+	
GSM46841	 P+	 R+	 K-	
GSM46845	 P+	 R+	 K-	
GSM46857	 P+	 R+	 K-	
GSM46861	 P+	 R+	 K-	
GSM46864	 P+	 R-	 K-	
GSM46865	 P+	 R+	 K-	
GSM46877	 P+	 R+	 K-	
GSM46878	 P+	 R+	 K-	
GSM46887	 P+	 R+	 K-	
GSM46895	 P-	 R+	 K-	
GSM46899	 P+	 R-	 K-	
GSM46915	 P+	 R+	 K-	
GSM46921	 P+	 R+	 K-	
GSM46924	 P+	 R-	 K-	
GSM46930	 P-	 R+	 K-	
GSM46931	 P+	 R-	 K-	
GSM46940	 P+	 R-	 K-	
GSM46956	 P+	 R+	 K-	
GSM46967	 P-	 R+	 K-	
GSM53045	 P-	 R-	 K-	
GSM53047	 P+	 R-	 K-	
GSM53051	 P-	 R-	 K-	
GSM53055	 P-	 R-	 K-	
GSM53070	 P-	 R-	 K-	
GSM53073	 P-	 R+	 K+	
GSM53083	 P+	 R-	 K+	
GSM53106	 P+	 R-	 K+	
GSM53111	 P-	 R-	 K-	
GSM53113	 P-	 R-	 K-	
GSM53126	 P-	 R+	 K-	
GSM53135	 P-	 R-	 K+	
GSM53142	 P-	 R+	 K+	
GSM53146	 P-	 R+	 K-	
GSM53148	 P-	 R-	 K+	
GSM53153	 P-	 R-	 K-	
GSM53156	 P-	 R-	 K-	
GSM53169	 P+	 R-	 K-	
GSM53178	 P-	 R+	 K-	
GSM76490	 P-	 R-	 K-	
GSM76501	 P+	 R-	 K-	
GSM76512	 P-	 R+	 K+	
GSM76519	 P+	 R-	 K-	
GSM76520	 P+	 R+	 K-	
GSM76522	 P-	 R-	 K-	
GSM76524	 P-	 R+	 K+	
GSM76526	 P+	 R-	 K-	
GSM76529	 P-	 R-	 K-	
GSM76530	 P+	 R-	 K-	
GSM76531	 P-	 R+	 K+	
GSM76548	 P+	 R+	 K-	
GSM76555	 P-	 R-	 K-	
GSM76573	 P-	 R-	 K-	
GSM76576	 P-	 R-	 K-	
GSM76583	 P+	 R-	 K+	
GSM76598	 P-	 R-	 K-	
GSM76605	 P-	 R-	 K+	
GSM76607	 P-	 R-	 K-	
GSM76608	 P+	 R-	 K-	
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GSM76610	 P+	 R-	 K-	
GSM76611	 P-	 R+	 K+	
GSM76615	 P-	 R+	 K-	
GSM76617	 P+	 R+	 K-	
GSM76618	 P+	 R-	 K+	
GSM76629	 P-	 R-	 K-	
GSM76639	 P-	 R+	 K-	
GSM88945	 P-	 R-	 K-	
GSM88963	 P+	 R+	 K-	
GSM88965	 P-	 R-	 K-	
GSM88968	 P+	 R+	 K-	
GSM88994	 P+	 R-	 K+	
GSM88999	 P+	 R-	 K-	
GSM89002	 P-	 R+	 K-	
GSM89004	 P+	 R-	 K-	
GSM89007	 P+	 R-	 K-	
GSM89026	 P+	 R-	 K-	
GSM89037	 P+	 R-	 K+	
GSM89040	 P-	 R+	 K-	
GSM89044	 P-	 R+	 K-	
GSM89047	 P+	 R-	 K-	
GSM89049	 P-	 R-	 K+	
GSM89052	 P+	 R-	 K-	
GSM89053	 P+	 R-	 K-	
GSM89061	 P+	 R-	 K-	
GSM89062	 P+	 R+	 K-	
GSM89069	 P+	 R-	 K-	
GSM89090	 P+	 R+	 K-	
GSM89098	 P+	 R-	 K-	
GSM89103	 P-	 R+	 K+	
GSM588828	 P+	 R-	 K-	
GSM588829	 P+	 R-	 K-	
GSM588830	 P+	 R-	 K-	
GSM588831	 P+	 R-	 K+	
GSM588832	 P+	 R-	 K-	
GSM588833	 P+	 R-	 K-	
GSM588834	 P-	 R+	 K-	
GSM588835	 P+	 R-	 K-	
GSM588836	 P+	 R+	 K+	
GSM588837	 P+	 R-	 K-	
GSM588838	 P+	 R+	 K-	
GSM588839	 P+	 R+	 K-	
GSM588840	 P+	 R-	 K+	
GSM588841	 P+	 R-	 K+	
GSM588842	 P+	 R-	 K+	
GSM588843	 P+	 R-	 K+	
GSM588844	 P+	 R-	 K-	
GSM588845	 P+	 R-	 K-	
GSM588846	 P-	 R-	 K-	
GSM588847	 P-	 R+	 K+	
GSM588848	 P+	 R-	 K-	
GSM588849	 P+	 R-	 K+	
GSM588850	 P+	 R-	 K-	
GSM588851	 P+	 R+	 K-	
GSM588852	 P+	 R+	 K-	
GSM588853	 P+	 R-	 K-	
GSM588854	 P+	 R+	 K+	
GSM588855	 P+	 R+	 K-	
GSM588856	 P-	 R+	 K+	
GSM588857	 P-	 R-	 K+	
GSM588858	 P-	 R-	 K+	
GSM588859	 P+	 R-	 K+	
GSM588860	 P-	 R-	 K+	
GSM588861	 P+	 R-	 K+	
GSM588862	 P+	 R+	 K-	
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GSM588863	 P-	 R+	 K-	
GSM588864	 P+	 R-	 K-	
GSM588865	 P-	 R+	 K-	
GSM588866	 P-	 R+	 K-	
GSM588867	 P-	 R-	 K-	
GSM588868	 P-	 R+	 K-	
GSM588869	 P-	 R+	 K-	
GSM588870	 P-	 R+	 K-	
GSM588871	 P+	 R+	 K-	
GSM588872	 P+	 R-	 K-	
GSM588873	 P+	 R-	 K-	
GSM588874	 P+	 R+	 K-	
GSM588875	 P+	 R+	 K-	
GSM588876	 P-	 R+	 K-	
GSM588877	 P-	 R+	 K-	
GSM588878	 P-	 R+	 K-	
GSM588879	 P-	 R+	 K-	
GSM588880	 P-	 R+	 K-	
GSM588881	 P-	 R+	 K-	
GSM588882	 P-	 R-	 K-	
GSM588883	 P-	 R+	 K-	
GSM588884	 P-	 R+	 K-	
GSM588885	 P-	 R+	 K-	
GSM588886	 P-	 R-	 K-	
GSM820048	 P+	 R+	 K-	
GSM820049	 P+	 R-	 K-	
GSM820050	 P+	 R+	 K-	
GSM820051	 P+	 R+	 K-	
GSM820052	 P+	 R-	 K-	
GSM820053	 P+	 R+	 K-	
GSM820054	 P+	 R+	 K-	
GSM820055	 P+	 R+	 K-	
GSM820056	 P+	 R+	 K-	
GSM820057	 P-	 R+	 K-	
GSM820058	 P-	 R-	 K-	
GSM820059	 P+	 R+	 K-	
GSM820060	 P+	 R+	 K-	
GSM820061	 P-	 R+	 K-	
GSM820062	 P+	 R-	 K-	
GSM820063	 P+	 R-	 K-	
GSM820064	 P+	 R-	 K-	
GSM820065	 P+	 R+	 K-	
GSM820066	 P-	 R-	 K-	
GSM820067	 P+	 R+	 K-	
GSM820068	 P+	 R-	 K-	
GSM820069	 P-	 R-	 K-	
GSM820070	 P+	 R-	 K-	
GSM820071	 P+	 R+	 K+	
GSM820072	 P-	 R+	 K-	
GSM820073	 P-	 R-	 K-	
GSM820074	 P+	 R+	 K-	
GSM820075	 P+	 R-	 K-	
GSM820076	 P-	 R+	 K-	
GSM820077	 P-	 R+	 K-	
GSM820078	 P+	 R-	 K-	
GSM820079	 P-	 R-	 K-	
GSM820080	 P+	 R-	 K-	
GSM820081	 P+	 R+	 K+	
GSM820082	 P+	 R-	 K+	
GSM820083	 P-	 R+	 K-	
GSM820084	 P-	 R-	 K-	
GSM820085	 P-	 R+	 K-	
GSM820086	 P-	 R-	 K-	
GSM820087	 P-	 R-	 K-	
GSM820088	 P-	 R+	 K-	
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GSM820089	 P-	 R-	 K-	
GSM820090	 P-	 R+	 K-	
GSM820091	 P-	 R+	 K+	
GSM820092	 P-	 R+	 K-	
GSM820093	 P-	 R-	 K-	
GSM820094	 P-	 R+	 K-	
GSM820095	 P-	 R-	 K-	
GSM820096	 P-	 R+	 K+	
GSM820097	 P-	 R+	 K-	
GSM820098	 P+	 R-	 K-	
GSM820099	 P-	 R-	 K-	
GSM820100	 P-	 R-	 K-	
GSM820101	 P+	 R-	 K-	
GSM820102	 P-	 R+	 K+	
GSM820103	 P-	 R-	 K-	
GSM820104	 P-	 R+	 K-	
GSM820105	 P+	 R-	 K-	
GSM820106	 P-	 R-	 K-	
GSM820107	 P-	 R+	 K-	
GSM820108	 P-	 R-	 K-	
GSM820109	 P-	 R+	 K-	
GSM820110	 P-	 R-	 K-	
GSM820111	 P-	 R-	 K-	
GSM820112	 P-	 R+	 K-	
GSM820113	 P-	 R-	 K-	
GSM820114	 P-	 R+	 K-	
GSM820115	 P+	 R-	 K-	
GSM820116	 P-	 R-	 K-	
GSM820117	 P-	 R+	 K-	
GSM820118	 P+	 R-	 K-	
GSM820119	 P-	 R+	 K-	
GSM820120	 P-	 R-	 K-	
GSM820121	 P+	 R+	 K-	
GSM820122	 P+	 R+	 K-	
GSM820123	 P-	 R+	 K-	
GSM820124	 P+	 R+	 K-	
GSM820125	 P+	 R-	 K-	
GSM820126	 P+	 R-	 K-	
GSM820127	 P+	 R+	 K+	
GSM820128	 P+	 R-	 K+	
GSM820129	 P-	 R+	 K-	
GSM820130	 P-	 R+	 K-	
GSM820131	 P+	 R+	 K-	
GSM820132	 P+	 R-	 K-	
GSM820133	 P+	 R-	 K-	
GSM820134	 P+	 R-	 K-	
GSM820135	 P+	 R+	 K-	
GSM820136	 P-	 R+	 K-	
GSM820137	 P+	 R-	 K-	
GSM929494	 P+	 R-	 K-	
GSM929495	 P-	 R-	 K-	
GSM929496	 P+	 R-	 K-	
GSM929497	 P-	 R-	 K-	
GSM929498	 P+	 R-	 K-	
GSM929499	 P-	 R+	 K+	
GSM929500	 P+	 R-	 K+	
GSM929501	 P-	 R+	 K-	
GSM929502	 P+	 R-	 K+	
GSM929503	 P-	 R+	 K-	
GSM929504	 P-	 R+	 K-	
GSM929505	 P-	 R+	 K-	
GSM929506	 P+	 R-	 K-	
GSM929507	 P-	 R+	 K-	
GSM929508	 P-	 R+	 K-	
GSM929509	 P-	 R+	 K-	
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GSM929510	 P+	 R-	 K-	
GSM929511	 P+	 R+	 K+	
GSM929512	 P-	 R-	 K-	
GSM929513	 P-	 R+	 K-	
GSM929514	 P+	 R-	 K-	
GSM929515	 P+	 R-	 K-	
GSM929516	 P-	 R-	 K-	
GSM929517	 P-	 R-	 K-	
GSM929518	 P-	 R-	 K-	
GSM929519	 P+	 R-	 K-	
GSM929520	 P+	 R-	 K-	
GSM929521	 P+	 R+	 K+	
GSM929522	 P-	 R-	 K-	
GSM929523	 P+	 R+	 K-	
GSM929524	 P+	 R-	 K-	
GSM929525	 P-	 R-	 K-	
GSM929526	 P+	 R-	 K-	
GSM929527	 P-	 R-	 K+	
GSM929528	 P+	 R-	 K-	
GSM929529	 P-	 R-	 K-	
GSM929530	 P-	 R+	 K-	
GSM929531	 P-	 R+	 K-	
GSM929532	 P+	 R-	 K-	
GSM929533	 P+	 R-	 K-	
GSM929534	 P+	 R-	 K-	
GSM929535	 P+	 R-	 K-	
GSM929536	 P+	 R-	 K-	
GSM929537	 P+	 R-	 K-	
GSM929538	 P+	 R-	 K-	
GSM929539	 P-	 R+	 K-	
GSM929540	 P+	 R-	 K-	
GSM929541	 P-	 R-	 K-	
GSM929542	 P+	 R-	 K-	
GSM929543	 P+	 R-	 K-	
GSM929544	 P+	 R+	 K-	
GSM929545	 P+	 R-	 K-	
GSM929546	 P+	 R-	 K-	
GSM929547	 P+	 R-	 K-	
GSM929548	 P-	 R+	 K-	
GSM929549	 P-	 R+	 K-	
GSM929550	 P+	 R-	 K-	
GSM929551	 P+	 R-	 K-	
GSM929552	 P+	 R+	 K-	
GSM929553	 P-	 R+	 K-	
GSM929554	 P+	 R+	 K+	
GSM929555	 P+	 R+	 K-	
GSM929556	 P+	 R-	 K-	
GSM929557	 P+	 R-	 K+	
GSM929558	 P+	 R-	 K-	
GSM929559	 P-	 R+	 K-	
GSM929560	 P+	 R-	 K-	
GSM929561	 P+	 R-	 K-	
GSM929562	 P-	 R+	 K-	
GSM929563	 P+	 R-	 K+	
GSM929564	 P-	 R-	 K-	
GSM929565	 P-	 R-	 K-	
GSM929566	 P+	 R-	 K-	
GSM929567	 P-	 R-	 K-	
GSM929568	 P-	 R-	 K-	
GSM929569	 P-	 R-	 K-	
GSM929570	 P+	 R-	 K-	
GSM929571	 P-	 R-	 K+	
GSM929572	 P-	 R+	 K-	
GSM929573	 P-	 R+	 K-	
GSM929574	 P-	 R-	 K-	
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GSM929575	 P-	 R+	 K-	
GSM929576	 P-	 R-	 K+	
GSM929577	 P-	 R-	 K-	
GSM929578	 P-	 R+	 K-	
GSM929579	 P+	 R-	 K-	
GSM929580	 P+	 R-	 K-	
GSM929581	 P+	 R-	 K-	
GSM929582	 P-	 R+	 K-	
GSM929583	 P+	 R-	 K-	
GSM929584	 P+	 R-	 K-	
GSM929585	 P-	 R-	 K-	
GSM929586	 P+	 R-	 K-	
GSM929587	 P+	 R-	 K-	
GSM929588	 P+	 R-	 K-	
GSM929589	 P+	 R-	 K-	
GSM929590	 P-	 R+	 K+	
GSM929591	 P-	 R+	 K-	
GSM929592	 P-	 R+	 K+	
GSM929593	 P-	 R+	 K-	
GSM929594	 P-	 R+	 K-	
GSM929595	 P+	 R-	 K-	
GSM929596	 P+	 R-	 K-	
GSM929597	 P-	 R-	 K-	
GSM929598	 P+	 R+	 K-	
GSM929599	 P+	 R+	 K-	
GSM929600	 P-	 R+	 K-	
GSM929601	 P-	 R+	 K-	
GSM929602	 P+	 R-	 K-	
GSM929603	 P-	 R+	 K+	
GSM929604	 P+	 R+	 K-	
GSM929605	 P+	 R-	 K-	
GSM929606	 P-	 R+	 K+	
GSM929607	 P+	 R+	 K+	
GSM929608	 P+	 R-	 K-	
GSM929609	 P+	 R+	 K+	
GSM929610	 P-	 R-	 K-	
GSM929611	 P+	 R+	 K-	
GSM929612	 P+	 R-	 K-	
GSM929613	 P+	 R-	 K-	
GSM929614	 P+	 R+	 K-	
GSM929615	 P+	 R-	 K-	
GSM929616	 P+	 R+	 K+	
GSM929617	 P-	 R+	 K-	
GSM929618	 P+	 R-	 K+	
GSM929619	 P+	 R+	 K-	
GSM929620	 P-	 R+	 K-	
GSM929621	 P+	 R+	 K+	
GSM929622	 P-	 R+	 K-	
GSM929623	 P-	 R+	 K-	
GSM971957	 P+	 R+	 K+	
GSM971958	 P+	 R+	 K-	
GSM971959	 P+	 R-	 K+	
GSM971960	 P+	 R-	 K-	
GSM971961	 P-	 R+	 K-	
GSM971962	 P-	 R+	 K-	
GSM971963	 P+	 R+	 K-	
GSM971964	 P+	 R-	 K-	
GSM971965	 P-	 R+	 K-	
GSM971966	 P+	 R-	 K-	
GSM971967	 P+	 R-	 K-	
GSM971968	 P+	 R+	 K-	
GSM971969	 P+	 R-	 K-	
GSM971970	 P+	 R-	 K+	
GSM971971	 P+	 R-	 K-	
GSM971972	 P+	 R-	 K+	
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GSM971973	 P+	 R-	 K-	
GSM971974	 P-	 R+	 K-	
GSM971975	 P+	 R-	 K-	
GSM971976	 P+	 R-	 K-	
GSM971977	 P-	 R+	 K-	
GSM971978	 P+	 R-	 K-	
GSM971979	 P+	 R+	 K+	
GSM971980	 P-	 R+	 K-	
GSM971981	 P+	 R-	 K-	
GSM971982	 P+	 R+	 K-	
GSM971983	 P+	 R+	 K-	
GSM971984	 P+	 R-	 K-	
GSM971985	 P-	 R-	 K-	
GSM971986	 P-	 R+	 K-	
GSM971987	 P-	 R+	 K-	
GSM971988	 P-	 R-	 K+	
GSM971989	 P-	 R-	 K-	
GSM971990	 P+	 R-	 K-	
GSM971991	 P-	 R-	 K-	
GSM971992	 P+	 R-	 K-	
GSM971993	 P+	 R-	 K-	
GSM971994	 P+	 R-	 K+	
GSM971995	 P-	 R-	 K-	
GSM971996	 P-	 R+	 K+	
GSM971997	 P+	 R-	 K-	
GSM971998	 P-	 R+	 K-	
GSM971999	 P+	 R+	 K-	
GSM972000	 P-	 R-	 K-	
GSM972001	 P+	 R-	 K-	
GSM972002	 P+	 R-	 K+	
GSM972003	 P-	 R-	 K-	
GSM972004	 P-	 R-	 K-	
GSM972005	 P-	 R-	 K-	
GSM972006	 P-	 R+	 K-	
GSM972007	 P-	 R+	 K+	
GSM972008	 P+	 R+	 K+	
GSM972009	 P-	 R+	 K-	
GSM972010	 P+	 R+	 K-	
GSM972011	 P-	 R+	 K-	
GSM972012	 P-	 R-	 K-	
GSM972013	 P+	 R-	 K-	
GSM972014	 P+	 R-	 K-	
GSM972015	 P+	 R-	 K+	
GSM972016	 P+	 R+	 K-	
GSM972017	 P-	 R-	 K-	
GSM972018	 P-	 R+	 K-	
GSM972019	 P-	 R+	 K-	
GSM972020	 P+	 R+	 K-	
GSM972021	 P+	 R-	 K-	
GSM972022	 P-	 R-	 K-	
GSM972023	 P+	 R+	 K-	
GSM972024	 P+	 R-	 K-	
GSM972025	 P-	 R-	 K-	
GSM972026	 P+	 R+	 K-	
GSM972027	 P-	 R-	 K-	
GSM972028	 P-	 R+	 K-	
GSM972029	 P-	 R+	 K-	
GSM972030	 P-	 R+	 K-	
GSM972031	 P-	 R-	 K-	
GSM972032	 P+	 R-	 K-	
GSM972033	 P-	 R-	 K-	
GSM972034	 P-	 R-	 K-	
GSM972035	 P+	 R-	 K-	
GSM972036	 P-	 R-	 K+	
GSM972037	 P+	 R-	 K-	
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GSM972038	 P+	 R-	 K-	
GSM972039	 P-	 R+	 K-	
GSM972040	 P+	 R-	 K-	
GSM972041	 P-	 R-	 K-	
GSM972042	 P+	 R-	 K-	
GSM972043	 P+	 R-	 K-	
GSM972044	 P+	 R-	 K-	
GSM972045	 P+	 R-	 K-	
GSM972046	 P-	 R+	 K-	
GSM972047	 P+	 R-	 K-	
GSM972048	 P+	 R-	 K-	
GSM972049	 P+	 R-	 K+	
GSM972050	 P-	 R-	 K-	
GSM972051	 P-	 R+	 K-	
GSM972052	 P+	 R-	 K-	
GSM972053	 P+	 R-	 K-	
GSM972054	 P-	 R+	 K-	
GSM972055	 P-	 R+	 K+	
GSM972056	 P+	 R-	 K+	
GSM972057	 P-	 R-	 K-	
GSM972058	 P+	 R+	 K+	
GSM972059	 P-	 R+	 K+	
GSM972060	 P+	 R-	 K-	
GSM972061	 P-	 R-	 K-	
GSM972062	 P+	 R-	 K-	
GSM972063	 P+	 R+	 K-	
GSM972064	 P-	 R+	 K-	
GSM972065	 P+	 R+	 K-	
GSM972066	 P+	 R-	 K-	
GSM972067	 P+	 R+	 K-	
GSM972068	 P-	 R+	 K-	
GSM972069	 P+	 R-	 K-	
GSM972070	 P-	 R+	 K-	
GSM972071	 P+	 R-	 K-	
GSM972072	 P+	 R+	 K-	
GSM972073	 P+	 R+	 K+	
GSM972074	 P-	 R-	 K-	
GSM972075	 P+	 R-	 K-	
GSM972076	 P+	 R+	 K-	
GSM972077	 P-	 R+	 K+	
GSM972078	 P+	 R+	 K+	
GSM972079	 P-	 R+	 K+	
GSM972080	 P+	 R+	 K+	
GSM972081	 P+	 R-	 K-	
GSM972082	 P-	 R+	 K-	
GSM972083	 P-	 R+	 K-	
GSM972084	 P-	 R+	 K-	
GSM972085	 P+	 R+	 K-	
GSM972086	 P+	 R-	 K-	
GSM972087	 P+	 R-	 K-	
GSM972088	 P-	 R+	 K-	
GSM972089	 P-	 R+	 K-	
GSM972090	 P+	 R-	 K-	
GSM972091	 P+	 R-	 K-	
GSM972092	 P+	 R+	 K-	
GSM972093	 P-	 R+	 K-	
GSM972094	 P+	 R+	 K-	
GSM972095	 P+	 R+	 K-	
GSM972096	 P-	 R-	 K-	
GSM972097	 P-	 R+	 K-	
GSM972098	 P-	 R-	 K-	
GSM972099	 P+	 R-	 K-	
GSM972100	 P-	 R-	 K-	
GSM972101	 P-	 R-	 K-	
GSM972102	 P-	 R+	 K-	
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GSM972103	 P+	 R+	 K+	
GSM972104	 P-	 R+	 K-	
GSM972105	 P-	 R-	 K-	
GSM972106	 P+	 R-	 K-	
GSM972107	 P-	 R+	 K-	
GSM972108	 P+	 R-	 K-	
GSM972109	 P+	 R-	 K-	
GSM972110	 P-	 R-	 K-	
GSM972111	 P-	 R-	 K-	
GSM972112	 P-	 R+	 K-	
GSM972113	 P-	 R+	 K-	
GSM972114	 P+	 R-	 K-	
GSM972115	 P-	 R-	 K-	
GSM972116	 P-	 R+	 K-	
GSM972117	 P-	 R+	 K-	
GSM972118	 P+	 R-	 K-	
GSM972119	 P+	 R-	 K-	
GSM972120	 P+	 R+	 K+	
GSM972121	 P-	 R-	 K-	
GSM972122	 P+	 R-	 K-	
GSM972123	 P+	 R-	 K-	
GSM972124	 P-	 R+	 K-	
GSM972125	 P-	 R+	 K-	
GSM972126	 P+	 R-	 K-	
GSM972127	 P-	 R+	 K-	
GSM972128	 P+	 R+	 K+	
GSM972129	 P+	 R-	 K-	
GSM972130	 P-	 R-	 K-	
GSM972131	 P-	 R+	 K-	
GSM972132	 P+	 R+	 K-	
GSM972133	 P-	 R+	 K-	
GSM972134	 P+	 R+	 K-	
GSM972135	 P+	 R-	 K-	
GSM972136	 P+	 R-	 K-	
GSM972137	 P+	 R-	 K-	
GSM972138	 P+	 R-	 K-	
GSM972139	 P-	 R-	 K-	
GSM972140	 P-	 R+	 K-	
GSM972141	 P+	 R+	 K-	
GSM972142	 P+	 R-	 K-	
GSM972143	 P+	 R-	 K-	
GSM972144	 P-	 R-	 K-	
GSM972145	 P-	 R-	 K-	
GSM972146	 P+	 R+	 K-	
GSM972147	 P+	 R-	 K-	
GSM972148	 P+	 R-	 K-	
GSM972149	 P-	 R-	 K-	
GSM972150	 P-	 R-	 K-	
GSM972151	 P+	 R-	 K-	
GSM972152	 P+	 R-	 K-	
GSM972153	 P+	 R-	 K-	
GSM972154	 P+	 R-	 K-	
GSM972155	 P+	 R-	 K-	
GSM972156	 P+	 R-	 K-	
GSM972157	 P+	 R-	 K-	
GSM972158	 P-	 R+	 K-	
GSM972159	 P+	 R-	 K+	
GSM972160	 P+	 R-	 K-	
GSM972161	 P+	 R-	 K-	
GSM972162	 P+	 R+	 K+	
GSM972163	 P-	 R-	 K-	
GSM972164	 P+	 R+	 K-	
GSM972165	 P+	 R+	 K-	
GSM972166	 P-	 R-	 K-	
GSM972167	 P+	 R-	 K-	
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GSM972168	 P+	 R+	 K+	
GSM972169	 P+	 R-	 K-	
GSM972170	 P+	 R-	 K-	
GSM972171	 P+	 R+	 K-	
GSM972172	 P-	 R-	 K-	
GSM972173	 P-	 R-	 K-	
GSM972174	 P-	 R-	 K-	
GSM972175	 P-	 R-	 K-	
GSM972176	 P-	 R+	 K-	
GSM972177	 P-	 R-	 K-	
GSM972178	 P-	 R-	 K-	
GSM972179	 P-	 R+	 K-	
GSM972180	 P+	 R-	 K-	
GSM972181	 P-	 R+	 K-	
GSM972182	 P-	 R-	 K-	
GSM972183	 P-	 R-	 K-	
GSM972184	 P-	 R+	 K-	
GSM972185	 P-	 R-	 K-	
GSM972186	 P-	 R+	 K-	
GSM972187	 P+	 R+	 K-	
GSM972188	 P-	 R-	 K-	
GSM972189	 P+	 R-	 K+	
GSM972190	 P-	 R-	 K-	
GSM972191	 P+	 R-	 K-	
GSM972192	 P-	 R+	 K+	
GSM972193	 P-	 R-	 K-	
GSM972194	 P+	 R-	 K-	
GSM972195	 P+	 R-	 K-	
GSM972196	 P+	 R-	 K-	
GSM972197	 P+	 R-	 K-	
GSM972198	 P+	 R-	 K-	
GSM972199	 P+	 R-	 K-	
GSM972200	 P+	 R-	 K-	
GSM972201	 P-	 R+	 K-	
GSM972202	 P+	 R-	 K-	
GSM972203	 P+	 R-	 K-	
GSM972204	 P+	 R+	 K-	
GSM972205	 P+	 R-	 K-	
GSM972206	 P-	 R+	 K-	
GSM972207	 P+	 R-	 K-	
GSM972208	 P-	 R+	 K-	
GSM972209	 P+	 R-	 K-	
GSM972210	 P-	 R-	 K-	
GSM972211	 P-	 R-	 K-	
GSM972212	 P+	 R-	 K-	
GSM972213	 P+	 R-	 K-	
GSM972214	 P+	 R-	 K-	
GSM972215	 P+	 R+	 K-	
GSM972216	 P+	 R-	 K-	
GSM972217	 P+	 R-	 K-	
GSM972218	 P+	 R-	 K-	
GSM972219	 P+	 R-	 K-	
GSM972220	 P+	 R+	 K-	
GSM972221	 P+	 R-	 K-	
GSM972222	 P+	 R-	 K-	
GSM972223	 P+	 R+	 K-	
GSM972224	 P-	 R+	 K+	
GSM972225	 P+	 R-	 K-	
GSM972226	 P-	 R+	 K-	
GSM972227	 P+	 R-	 K-	
GSM972228	 P-	 R-	 K-	
GSM972229	 P+	 R+	 K-	
GSM972230	 P+	 R-	 K+	
GSM972231	 P-	 R+	 K-	
GSM972232	 P-	 R+	 K-	
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GSM972233	 P+	 R-	 K+	
GSM972234	 P-	 R+	 K-	
GSM972235	 P+	 R+	 K-	
GSM972236	 P+	 R-	 K-	
GSM972237	 P+	 R-	 K+	
GSM972238	 P+	 R+	 K-	
GSM972239	 P+	 R-	 K-	
GSM972240	 P-	 R+	 K-	
GSM972241	 P+	 R-	 K-	
GSM972242	 P+	 R+	 K-	
GSM972243	 P-	 R-	 K-	
GSM972244	 P-	 R-	 K-	
GSM972245	 P-	 R-	 K+	
GSM972246	 P+	 R-	 K-	
GSM972247	 P-	 R-	 K-	
GSM972248	 P-	 R-	 K-	
GSM972249	 P+	 R-	 K-	
GSM972250	 P+	 R-	 K-	
GSM972251	 P-	 R+	 K-	
GSM972252	 P+	 R+	 K-	
GSM972253	 P-	 R-	 K-	
GSM972254	 P-	 R+	 K-	
GSM972255	 P+	 R+	 K-	
GSM972256	 P-	 R-	 K-	
GSM972257	 P-	 R-	 K-	
GSM972258	 P-	 R-	 K-	
GSM972259	 P-	 R-	 K-	
GSM972260	 P-	 R+	 K+	
GSM972261	 P+	 R+	 K-	
GSM972262	 P-	 R+	 K-	
GSM972263	 P+	 R+	 K-	
GSM972264	 P+	 R-	 K-	
GSM972265	 P+	 R-	 K+	
GSM972266	 P+	 R-	 K-	
GSM972267	 P-	 R-	 K-	
GSM972268	 P-	 R-	 K-	
GSM972269	 P-	 R-	 K-	
GSM972270	 P+	 R-	 K+	
GSM972271	 P-	 R-	 K-	
GSM972272	 P-	 R-	 K-	
GSM972273	 P-	 R-	 K-	
GSM972274	 P+	 R+	 K-	
GSM972275	 P+	 R+	 K-	
GSM972276	 P+	 R-	 K-	
GSM972277	 P+	 R-	 K-	
GSM972278	 P+	 R-	 K-	
GSM972279	 P+	 R+	 K+	
GSM972280	 P+	 R+	 K+	
GSM972281	 P+	 R+	 K-	
GSM972282	 P+	 R-	 K-	
GSM972283	 P+	 R+	 K+	
GSM972284	 P-	 R-	 K-	
GSM972285	 P-	 R+	 K+	
GSM972286	 P+	 R+	 K+	
GSM972287	 P+	 R+	 K+	
GSM972288	 P-	 R-	 K-	
GSM972289	 P+	 R-	 K-	
GSM972290	 P+	 R+	 K-	
GSM972291	 P+	 R-	 K-	
GSM972292	 P+	 R+	 K+	
GSM972293	 P-	 R+	 K+	
GSM972294	 P+	 R+	 K-	
GSM972295	 P-	 R-	 K-	
GSM972296	 P+	 R-	 K-	
GSM972297	 P-	 R+	 K-	
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GSM972298	 P+	 R-	 K-	
GSM972299	 P-	 R-	 K-	
GSM972300	 P-	 R-	 K-	
GSM972301	 P-	 R+	 K-	
GSM972302	 P+	 R-	 K-	
GSM972303	 P+	 R-	 K-	
GSM972304	 P-	 R-	 K-	
GSM972305	 P-	 R+	 K-	
GSM972306	 P-	 R-	 K-	
GSM972307	 P-	 R-	 K-	
GSM972308	 P+	 R-	 K-	
GSM972309	 P+	 R-	 K-	
GSM972310	 P+	 R+	 K-	
GSM972311	 P-	 R-	 K-	
GSM972312	 P+	 R-	 K-	
GSM972313	 P+	 R-	 K-	
GSM972314	 P+	 R-	 K-	
GSM972315	 P-	 R-	 K-	
GSM972316	 P+	 R-	 K+	
GSM972317	 P+	 R-	 K-	
GSM972318	 P+	 R-	 K-	
GSM972319	 P+	 R-	 K-	
GSM972320	 P-	 R-	 K-	
GSM972321	 P+	 R+	 K-	
GSM972322	 P-	 R+	 K-	
GSM972323	 P+	 R-	 K-	
GSM972324	 P-	 R-	 K-	
GSM972325	 P+	 R+	 K+	
GSM972326	 P-	 R-	 K-	
GSM972327	 P-	 R+	 K-	
GSM972328	 P+	 R-	 K-	
GSM972329	 P-	 R+	 K-	
GSM972330	 P-	 R+	 K+	
GSM972331	 P+	 R-	 K-	
GSM972332	 P+	 R+	 K+	
GSM972333	 P+	 R-	 K-	
GSM972334	 P+	 R+	 K+	
GSM972335	 P+	 R-	 K-	
GSM972336	 P+	 R-	 K-	
GSM972337	 P-	 R+	 K-	
GSM972338	 P-	 R-	 K-	
GSM972339	 P+	 R-	 K-	
GSM972340	 P-	 R-	 K-	
GSM972341	 P+	 R-	 K-	
GSM972342	 P-	 R+	 K-	
GSM972343	 P+	 R-	 K-	
GSM972344	 P+	 R-	 K-	
GSM972345	 P-	 R+	 K-	
GSM972346	 P+	 R-	 K-	
GSM972347	 P+	 R-	 K-	
GSM972348	 P+	 R-	 K-	
GSM972349	 P-	 R+	 K-	
GSM972350	 P+	 R-	 K-	
GSM972351	 P-	 R-	 K-	
GSM972352	 P-	 R+	 K-	
GSM972353	 P+	 R+	 K-	
GSM972354	 P+	 R-	 K-	
GSM972355	 P-	 R+	 K+	
GSM972356	 P+	 R-	 K-	
GSM972357	 P-	 R+	 K-	
GSM972358	 P+	 R-	 K-	
GSM972359	 P-	 R+	 K-	
GSM972360	 P+	 R+	 K-	
GSM972361	 P+	 R+	 K-	
GSM972362	 P+	 R-	 K-	
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GSM972363	 P+	 R-	 K+	
GSM972364	 P+	 R-	 K-	
GSM972365	 P-	 R+	 K-	
GSM972366	 P-	 R+	 K-	
GSM972367	 P-	 R+	 K-	
GSM972368	 P+	 R-	 K-	
GSM972369	 P-	 R+	 K+	
GSM972370	 P-	 R-	 K-	
GSM972371	 P+	 R-	 K-	
GSM972372	 P+	 R+	 K-	
GSM972373	 P-	 R-	 K-	
GSM972374	 P-	 R-	 K-	
GSM972375	 P-	 R+	 K-	
GSM972376	 P+	 R+	 K-	
GSM972377	 P-	 R+	 K+	
GSM972378	 P-	 R+	 K+	
GSM972379	 P-	 R-	 K-	
GSM972380	 P+	 R+	 K+	
GSM972381	 P-	 R-	 K-	
GSM972382	 P+	 R-	 K-	
GSM972383	 P-	 R-	 K-	
GSM972384	 P+	 R-	 K-	
GSM972385	 P-	 R+	 K-	
GSM972386	 P+	 R-	 K-	
GSM972387	 P+	 R-	 K+	
GSM972388	 P+	 R-	 K+	
GSM972389	 P+	 R-	 K-	
GSM972390	 P-	 R-	 K-	
GSM972391	 P-	 R+	 K+	
GSM972392	 P+	 R-	 K-	
GSM972393	 P+	 R+	 K-	
GSM972394	 P-	 R+	 K-	
GSM972395	 P+	 R-	 K-	
GSM972396	 P-	 R-	 K-	
GSM972397	 P+	 R-	 K-	
GSM972398	 P+	 R-	 K-	
GSM972399	 P+	 R-	 K-	
GSM972400	 P-	 R+	 K-	
GSM972401	 P-	 R+	 K-	
GSM972402	 P-	 R+	 K-	
GSM972403	 P+	 R-	 K+	
GSM972404	 P+	 R+	 K-	
GSM972405	 P-	 R+	 K+	
GSM972406	 P+	 R+	 K-	
GSM972407	 P+	 R+	 K+	
GSM972408	 P-	 R+	 K-	
GSM972409	 P-	 R+	 K-	
GSM972410	 P-	 R+	 K+	
GSM972411	 P+	 R-	 K-	
GSM972412	 P-	 R-	 K-	
GSM972413	 P-	 R+	 K-	
GSM972414	 P+	 R-	 K-	
GSM972415	 P+	 R-	 K-	
GSM972416	 P-	 R-	 K+	
GSM972417	 P+	 R-	 K-	
GSM972418	 P-	 R-	 K-	
GSM972419	 P+	 R+	 K+	
GSM972420	 P-	 R+	 K+	
GSM972421	 P-	 R+	 K-	
GSM972422	 P-	 R+	 K-	
GSM972423	 P-	 R+	 K-	
GSM972424	 P-	 R-	 K+	
GSM972425	 P-	 R+	 K-	
GSM972426	 P-	 R+	 K-	
GSM972427	 P-	 R+	 K+	
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GSM972428	 P-	 R+	 K-	
GSM972429	 P-	 R-	 K-	
GSM972430	 P+	 R+	 K-	
GSM972431	 P+	 R+	 K+	
GSM972432	 P-	 R+	 K-	
GSM972433	 P-	 R+	 K-	
GSM972434	 P+	 R-	 K-	
GSM972435	 P-	 R-	 K-	
GSM972436	 P-	 R-	 K-	
GSM972437	 P-	 R+	 K+	
GSM972438	 P-	 R+	 K-	
GSM972439	 P-	 R-	 K-	
GSM972440	 P+	 R+	 K-	
GSM972441	 P-	 R+	 K-	
GSM972442	 P+	 R-	 K-	
GSM972443	 P+	 R-	 K+	
GSM972444	 P+	 R+	 K-	
GSM972445	 P+	 R-	 K-	
GSM972446	 P+	 R+	 K+	
GSM972447	 P+	 R+	 K-	
GSM972448	 P-	 R-	 K-	
GSM972449	 P+	 R+	 K-	
GSM972450	 P+	 R-	 K-	
GSM972451	 P+	 R-	 K-	
GSM972452	 P+	 R+	 K+	
GSM972453	 P-	 R-	 K-	
GSM972454	 P+	 R-	 K-	
GSM972455	 P-	 R+	 K+	
GSM972456	 P+	 R-	 K-	
GSM972457	 P-	 R-	 K-	
GSM972458	 P+	 R+	 K-	
GSM972459	 P-	 R-	 K-	
GSM972460	 P-	 R-	 K-	
GSM972461	 P+	 R-	 K-	
GSM972462	 P+	 R-	 K-	
GSM972463	 P-	 R-	 K-	
GSM972464	 P-	 R+	 K-	
GSM972465	 P+	 R-	 K+	
GSM972466	 P+	 R-	 K+	
GSM972467	 P-	 R+	 K-	
GSM972468	 P+	 R-	 K-	
GSM972469	 P-	 R-	 K-	
GSM972470	 P+	 R+	 K-	
GSM972471	 P+	 R+	 K-	
GSM972472	 P+	 R-	 K-	
GSM972473	 P+	 R+	 K+	
GSM972474	 P+	 R+	 K-	
GSM972475	 P-	 R-	 K-	
GSM972476	 P-	 R+	 K-	
GSM972477	 P+	 R-	 K-	
GSM972478	 P-	 R-	 K-	
GSM972479	 P-	 R+	 K-	
GSM972480	 P-	 R-	 K-	
GSM972481	 P+	 R+	 K-	
GSM972482	 P-	 R+	 K-	
GSM972483	 P+	 R-	 K-	
GSM972484	 P+	 R+	 K+	
GSM972485	 P-	 R-	 K+	
GSM972486	 P-	 R+	 K+	
GSM972487	 P-	 R-	 K-	
GSM972488	 P+	 R+	 K-	
GSM972489	 P-	 R+	 K-	
GSM972490	 P+	 R-	 K+	
GSM972491	 P+	 R-	 K-	
GSM972492	 P+	 R-	 K-	
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GSM972493	 P+	 R+	 K-	
GSM972494	 P-	 R+	 K-	
GSM972495	 P-	 R-	 K-	
GSM972496	 P-	 R-	 K-	
GSM972497	 P+	 R-	 K-	
GSM972498	 P+	 R-	 K-	
GSM972499	 P+	 R-	 K-	
GSM972500	 P-	 R+	 K+	
GSM972501	 P-	 R+	 K-	
GSM972502	 P-	 R-	 K-	
GSM972503	 P-	 R+	 K-	
GSM972504	 P-	 R+	 K+	
GSM972505	 P-	 R+	 K+	
GSM972506	 P-	 R+	 K-	
GSM972507	 P+	 R-	 K-	
GSM972508	 P+	 R-	 K-	
GSM972509	 P+	 R-	 K-	
GSM972510	 P-	 R-	 K-	
GSM972511	 P+	 R-	 K-	
GSM972512	 P+	 R-	 K-	
GSM972513	 P+	 R-	 K-	
GSM972514	 P+	 R-	 K-	
GSM972515	 P+	 R-	 K-	
GSM972516	 P+	 R-	 K-	
GSM972517	 P+	 R+	 K-	
GSM972518	 P-	 R+	 K-	
GSM972519	 P-	 R+	 K+	
GSM972520	 P+	 R-	 K-	
GSM972521	 P+	 R+	 K-	
GSM972522	 P-	 R+	 K-	
TCGA-F4-6461	 P-	 R+	 K-	
TCGA-A6-6653	 P+	 R+	 K+	
TCGA-A6-A56B	 P+	 R-	 K-	
TCGA-D5-6532	 P+	 R-	 K-	
TCGA-AD-6963	 P+	 R-	 K-	
TCGA-A6-6138	 P-	 R+	 K-	
TCGA-AA-3655	 P+	 R+	 K-	
TCGA-DM-A1D7	 P+	 R-	 K-	
TCGA-AY-6386	 P+	 R+	 K+	
TCGA-DM-A280	 P+	 R-	 K+	
TCGA-AD-6965	 P+	 R-	 K-	
TCGA-A6-4105	 P+	 R+	 K-	
TCGA-AD-A5EK	 P+	 R-	 K-	
TCGA-D5-5538	 P-	 R+	 K-	
TCGA-CM-4743	 P+	 R-	 K-	
TCGA-CM-6166	 P+	 R-	 K-	
TCGA-D5-6922	 P-	 R+	 K-	
TCGA-CM-5862	 P+	 R-	 K-	
TCGA-DM-A1D9	 P+	 R-	 K-	
TCGA-AZ-6605	 P-	 R+	 K-	
TCGA-CM-6161	 P+	 R+	 K-	
TCGA-DM-A0XF	 P+	 R-	 K-	
TCGA-D5-6924	 P-	 R+	 K-	
TCGA-G4-6626	 P+	 R-	 K-	
TCGA-CM-5860	 P+	 R+	 K-	
TCGA-DM-A28G	 P-	 R-	 K-	
TCGA-AA-A01Z	 P+	 R-	 K-	
TCGA-AZ-5407	 P+	 R-	 K-	
TCGA-AA-3495	 P-	 R-	 K-	
TCGA-AD-6548	 P+	 R+	 K+	
TCGA-D5-6529	 P-	 R+	 K-	
TCGA-CM-4747	 P-	 R-	 K-	
TCGA-AA-3697	 P+	 R-	 K+	
TCGA-G4-6303	 P-	 R+	 K-	
TCGA-DM-A0X9	 P+	 R-	 K-	
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TCGA-F4-6857	 P-	 R+	 K-	
TCGA-DM-A282	 P-	 R-	 K-	
TCGA-CM-6680	 P-	 R+	 K-	
TCGA-CK-4947	 P+	 R+	 K-	
TCGA-CA-5796	 P-	 R-	 K-	
TCGA-D5-6540	 P+	 R+	 K-	
TCGA-NH-A50V	 P-	 R+	 K-	
TCGA-AA-3506	 P-	 R+	 K-	
TCGA-A6-2684	 P-	 R+	 K-	
TCGA-CM-6165	 P-	 R+	 K-	
TCGA-F4-6808	 P+	 R-	 K-	
TCGA-CM-6172	 P+	 R-	 K-	
TCGA-D5-6536	 P-	 R+	 K-	
TCGA-AA-3713	 P+	 R+	 K-	
TCGA-A6-A566	 P-	 R+	 K-	
TCGA-CM-6164	 P-	 R-	 K-	
TCGA-D5-6530	 P-	 R-	 K-	
TCGA-AA-3496	 P-	 R+	 K-	
TCGA-CK-4948	 P+	 R+	 K-	
TCGA-AY-5543	 P+	 R-	 K+	
TCGA-A6-6781	 P-	 R+	 K-	
TCGA-AD-A5EJ	 P+	 R-	 K-	
TCGA-DM-A28H	 P+	 R-	 K-	
TCGA-DM-A285	 P+	 R-	 K-	
TCGA-CA-5797	 P+	 R+	 K-	
TCGA-A6-5661	 P+	 R-	 K+	
TCGA-AA-3663	 P+	 R-	 K-	
TCGA-AZ-4313	 P+	 R-	 K-	
TCGA-DM-A0XD	 P+	 R-	 K-	
TCGA-G4-6586	 P+	 R-	 K+	
TCGA-AZ-4616	 P+	 R-	 K-	
TCGA-CM-5349	 P-	 R+	 K-	
TCGA-F4-6569	 P-	 R+	 K-	
TCGA-QG-A5YW	 P-	 R-	 K-	
TCGA-AZ-4323	 P-	 R+	 K-	
TCGA-AU-3779	 P-	 R+	 K-	
TCGA-CM-6168	 P-	 R+	 K-	
TCGA-G4-6321	 P-	 R+	 K+	
TCGA-DM-A28M	 P+	 R-	 K-	
TCGA-A6-5664	 P-	 R+	 K-	
TCGA-G4-6628	 P+	 R+	 K-	
TCGA-A6-5667	 P+	 R-	 K-	
TCGA-AZ-6599	 P-	 R-	 K-	
TCGA-QG-A5YV	 P+	 R-	 K-	
TCGA-A6-5656	 P-	 R-	 K-	
TCGA-AA-3511	 P-	 R+	 K-	
TCGA-AZ-6607	 P-	 R+	 K-	
TCGA-A6-6648	 P+	 R-	 K-	
TCGA-CM-5344	 P-	 R+	 K-	
TCGA-AZ-6606	 P+	 R-	 K+	
TCGA-AA-3660	 P+	 R-	 K-	
TCGA-CM-6163	 P-	 R+	 K-	
TCGA-AD-6901	 P-	 R+	 K-	
TCGA-AZ-6600	 P-	 R+	 K+	
TCGA-A6-5660	 P-	 R-	 K-	
TCGA-D5-5539	 P-	 R+	 K-	
TCGA-F4-6703	 P-	 R+	 K-	
TCGA-AZ-4684	 P-	 R+	 K-	
TCGA-D5-6927	 P+	 R+	 K-	
TCGA-QG-A5Z2	 P-	 R-	 K+	
TCGA-CM-5861	 P+	 R-	 K-	
TCGA-AD-5900	 P+	 R+	 K+	
TCGA-CK-5914	 P+	 R-	 K-	
TCGA-D5-6533	 P+	 R-	 K-	
TCGA-DM-A1D0	 P+	 R-	 K-	
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TCGA-A6-A567	 P-	 R-	 K-	
TCGA-F4-6805	 P-	 R+	 K-	
TCGA-QG-A5YX	 P+	 R-	 K+	
TCGA-G4-6322	 P+	 R-	 K-	
TCGA-F4-6809	 P-	 R+	 K-	
TCGA-AZ-6608	 P+	 R-	 K-	
TCGA-CA-5255	 P-	 R-	 K-	
TCGA-CK-6746	 P+	 R-	 K-	
TCGA-CM-6170	 P-	 R+	 K-	
TCGA-AD-6890	 P+	 R-	 K+	
TCGA-CA-5254	 P-	 R-	 K-	
TCGA-AZ-5403	 P+	 R-	 K-	
TCGA-AY-6197	 P+	 R-	 K-	
TCGA-G4-6314	 P-	 R+	 K-	
TCGA-AD-6888	 P+	 R-	 K+	
TCGA-F4-6806	 P-	 R+	 K-	
TCGA-G4-6625	 P-	 R+	 K-	
TCGA-A6-6137	 P-	 R+	 K-	
TCGA-D5-5537	 P-	 R-	 K-	
TCGA-A6-6782	 P-	 R+	 K-	
TCGA-AY-6196	 P-	 R+	 K-	
TCGA-D5-5540	 P+	 R-	 K-	
TCGA-CM-6679	 P-	 R+	 K-	
TCGA-CM-6167	 P-	 R+	 K-	
TCGA-G4-6320	 P+	 R-	 K-	
TCGA-AZ-4315	 P+	 R-	 K-	
TCGA-CM-5864	 P+	 R-	 K-	
TCGA-CK-6751	 P+	 R+	 K-	
TCGA-A6-6140	 P+	 R-	 K-	
TCGA-D5-6930	 P+	 R+	 K+	
TCGA-AA-3492	 P+	 R-	 K+	
TCGA-DM-A1DB	 P+	 R-	 K-	
TCGA-CM-6171	 P+	 R+	 K-	
TCGA-A6-6654	 P-	 R+	 K-	
TCGA-CM-6675	 P+	 R-	 K-	
TCGA-G4-6323	 P-	 R-	 K-	
TCGA-CK-5913	 P+	 R+	 K-	
TCGA-D5-6541	 P-	 R+	 K-	
TCGA-AY-A54L	 P+	 R-	 K+	
TCGA-CK-4951	 P+	 R+	 K-	
TCGA-A6-A565	 P-	 R+	 K-	
TCGA-CK-5916	 P+	 R+	 K-	
TCGA-D5-6537	 P+	 R-	 K-	
TCGA-F4-6854	 P+	 R+	 K-	
TCGA-CM-5348	 P-	 R+	 K-	
TCGA-G4-6307	 P+	 R-	 K-	
TCGA-CM-5863	 P-	 R+	 K-	
TCGA-F4-6570	 P-	 R+	 K+	
TCGA-AA-3489	 P-	 R+	 K-	
TCGA-D5-6535	 P-	 R+	 K-	
TCGA-CM-6162	 P-	 R+	 K-	
TCGA-AZ-6598	 P+	 R-	 K-	
TCGA-CM-6676	 P-	 R-	 K-	
TCGA-D5-6538	 P+	 R-	 K-	
TCGA-A6-A5ZU	 P-	 R+	 K-	
TCGA-CM-4751	 P-	 R+	 K-	
TCGA-CK-6747	 P+	 R-	 K+	
TCGA-G4-6294	 P-	 R-	 K-	
TCGA-CM-6677	 P+	 R-	 K-	
TCGA-G4-6299	 P+	 R+	 K-	
TCGA-D5-6926	 P-	 R+	 K-	
TCGA-AD-6889	 P+	 R-	 K-	
TCGA-F4-6855	 P-	 R+	 K-	
TCGA-DM-A1D6	 P+	 R-	 K-	
TCGA-DM-A1HB	 P+	 R-	 K+	
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TCGA-A6-2675	 P-	 R+	 K-	
TCGA-CK-5915	 P+	 R-	 K-	
TCGA-AM-5820	 P+	 R-	 K-	
TCGA-AA-3662	 P-	 R+	 K-	
TCGA-G4-6588	 P+	 R+	 K-	
TCGA-A6-6652	 P-	 R-	 K-	
TCGA-D5-6539	 P-	 R+	 K-	
TCGA-D5-6920	 P-	 R+	 K-	
TCGA-A6-6141	 P-	 R+	 K-	
TCGA-F4-6807	 P-	 R+	 K-	
TCGA-G4-6627	 P-	 R+	 K-	
TCGA-CA-6715	 P+	 R-	 K-	
TCGA-CK-5912	 P+	 R-	 K-	
TCGA-F4-6856	 P+	 R-	 K+	
TCGA-AA-A02K	 P+	 R-	 K-	
TCGA-CM-6678	 P-	 R-	 K-	
TCGA-A6-5659	 P+	 R-	 K-	
TCGA-AD-6899	 P-	 R+	 K-	
TCGA-AA-A01P	 P+	 R+	 K-	
TCGA-CA-6719	 P-	 R+	 K-	
TCGA-AA-3509	 P-	 R-	 K-	
TCGA-AD-6964	 P-	 R+	 K-	
TCGA-CM-6169	 P-	 R+	 K-	
TCGA-A6-5665	 P+	 R-	 K+	
TCGA-CA-6717	 P-	 R+	 K-	
TCGA-A6-6651	 P-	 R+	 K-	
TCGA-G4-6297	 P-	 R+	 K-	
TCGA-DM-A1DA	 P+	 R-	 K+	
TCGA-CA-6718	 P+	 R+	 K-	
TCGA-A6-6780	 P+	 R-	 K-	
TCGA-QG-A5Z1	 P-	 R-	 K-	
TCGA-AZ-4614	 P+	 R-	 K-	
TCGA-CK-4952	 P+	 R-	 K-	
TCGA-G4-6315	 P+	 R-	 K+	
TCGA-CK-4950	 P-	 R+	 K-	
TCGA-AZ-4615	 P+	 R+	 K-	
TCGA-G4-6306	 P-	 R-	 K+	
TCGA-AM-5821	 P+	 R+	 K-	
TCGA-A6-6649	 P-	 R+	 K-	
TCGA-AD-6895	 P+	 R+	 K-	
TCGA-D5-6531	 P+	 R+	 K-	
TCGA-G4-6298	 P-	 R-	 K-	
TCGA-DM-A1D4	 P+	 R-	 K-	
TCGA-D5-5541	 P+	 R-	 K-	
TCGA-D5-6928	 P-	 R+	 K-	
TCGA-AZ-6603	 P-	 R+	 K-	
TCGA-AA-3502	 P-	 R-	 K-	
TCGA-A6-6142	 P-	 R+	 K-	
TCGA-G4-6295	 P+	 R-	 K-	
TCGA-A6-6650	 P+	 R-	 K-	
TCGA-DM-A288	 P+	 R-	 K-	
TCGA-F4-6704	 P-	 R+	 K-	
TCGA-AA-A01X	 P-	 R-	 K-	
TCGA-G4-6309	 P+	 R-	 K-	
TCGA-CK-6748	 P-	 R+	 K-	
TCGA-F4-6463	 P-	 R+	 K-	
TCGA-G4-6302	 P-	 R+	 K-	
TCGA-CA-6716	 P-	 R-	 K-	
TCGA-G4-6293	 P-	 R+	 K+	
TCGA-G4-6311	 P+	 R+	 K-	
TCGA-DM-A1D8	 P+	 R-	 K-	
TCGA-F4-6459	 P-	 R+	 K-	
TCGA-D5-6932	 P-	 R+	 K-	
TCGA-CA-5256	 P+	 R-	 K-	
TCGA-AA-3712	 P+	 R+	 K-	
PRK sample group assignment in CRCSC cohort 226 
TCGA-AU-6004	 P-	 R+	 K+	
TCGA-D5-6898	 P-	 R+	 K-	
TCGA-NH-A50T	 P+	 R-	 K-	
TCGA-A6-2685	 P-	 R+	 K-	
TCGA-D5-6931	 P+	 R+	 K-	
TCGA-CM-6674	 P+	 R+	 K-	
TCGA-F4-6460	 P-	 R+	 K-	
TCGA-A6-2682	 P-	 R+	 K-	
TCGA-G4-6304	 P+	 R-	 K-	
TCGA-CM-5868	 P+	 R-	 K-	
TCGA-D5-6929	 P-	 R+	 K-	
TCGA-AZ-6601	 P+	 R+	 K-	
TCGA-G4-6317	 P+	 R-	 K-	
TCGA-D5-6534	 P-	 R+	 K-	
TCGA-A6-5666	 P+	 R-	 K-	
TCGA-DM-A1HA	 P+	 R-	 K-	
TCGA-A6-5662	 P-	 R-	 K-	
TCGA-G4-6310	 P-	 R-	 K-	
TCGA-CI-6621	 P+	 R+	 K-	
TCGA-CI-6623	 P+	 R-	 K+	
TCGA-DC-5869	 P+	 R-	 K-	
TCGA-DC-6160	 P+	 R-	 K-	
TCGA-EI-6512	 P+	 R-	 K+	
TCGA-G5-6572	 P-	 R+	 K-	
TCGA-AG-3742	 P+	 R-	 K-	
TCGA-AH-6549	 P+	 R+	 K-	
TCGA-AF-2690	 P-	 R+	 K-	
TCGA-AF-5654	 P+	 R-	 K-	
TCGA-EF-5830	 P-	 R-	 K-	
TCGA-F5-6814	 P+	 R-	 K-	
TCGA-F5-6465	 P-	 R+	 K-	
TCGA-EI-6506	 P-	 R+	 K-	
TCGA-G5-6235	 P-	 R-	 K-	
TCGA-AG-3591	 P-	 R-	 K-	
TCGA-DC-6154	 P-	 R-	 K-	
TCGA-F5-6861	 P+	 R-	 K-	
TCGA-EI-6513	 P+	 R-	 K-	
TCGA-DY-A1DE	 P+	 R-	 K-	
TCGA-EI-6511	 P+	 R+	 K-	
TCGA-DC-6155	 P-	 R-	 K-	
TCGA-AH-6903	 P-	 R-	 K-	
TCGA-F5-6702	 P-	 R+	 K-	
TCGA-EI-7004	 P-	 R+	 K-	
TCGA-CI-6619	 P-	 R+	 K-	
TCGA-AG-4022	 P-	 R+	 K-	
TCGA-AH-6544	 P+	 R-	 K-	
TCGA-AF-2693	 P+	 R+	 K-	
TCGA-AG-4021	 P+	 R+	 K-	
TCGA-EI-6510	 P+	 R-	 K-	
TCGA-EF-5831	 P+	 R-	 K-	
TCGA-EI-7002	 P-	 R+	 K-	
TCGA-DT-5265	 P-	 R+	 K-	
TCGA-CI-6622	 P-	 R-	 K-	
TCGA-DY-A0XA	 P+	 R-	 K-	
TCGA-AF-6672	 P-	 R-	 K-	
TCGA-DC-5337	 P+	 R-	 K-	
TCGA-CL-4957	 P+	 R-	 K-	
TCGA-F5-6811	 P-	 R+	 K-	
TCGA-EI-6514	 P-	 R+	 K+	
TCGA-DC-6682	 P+	 R-	 K-	
TCGA-EI-6885	 P-	 R+	 K-	
TCGA-F5-6813	 P+	 R+	 K-	
TCGA-BM-6198	 P-	 R+	 K-	
TCGA-AF-6136	 P+	 R-	 K+	
TCGA-DY-A1H8	 P+	 R-	 K-	
PRK sample group assignment in CRCSC cohort 227 
TCGA-CL-5917	 P+	 R-	 K-	
TCGA-CI-6624	 P-	 R+	 K+	
TCGA-AG-3725	 P-	 R-	 K-	
TCGA-CI-6620	 P+	 R+	 K-	
TCGA-EI-6508	 P+	 R-	 K-	
TCGA-DC-6158	 P-	 R+	 K-	
TCGA-F5-6464	 P-	 R+	 K-	
TCGA-AH-6897	 P+	 R-	 K-	
TCGA-EI-6882	 P+	 R+	 K-	
TCGA-EI-6884	 P-	 R+	 K-	
TCGA-AG-3592	 P+	 R-	 K-	
TCGA-CL-5918	 P+	 R-	 K-	
TCGA-EI-6883	 P-	 R-	 K-	
TCGA-AF-4110	 P-	 R+	 K-	
TCGA-F5-6864	 P-	 R+	 K-	
TCGA-F5-6812	 P-	 R+	 K-	
TCGA-DY-A1DD	 P-	 R-	 K-	
TCGA-AH-6644	 P-	 R+	 K-	
TCGA-DC-4749	 P+	 R-	 K+	
TCGA-DC-6683	 P-	 R-	 K+	
TCGA-DY-A1DC	 P+	 R-	 K-	
TCGA-EI-6507	 P-	 R+	 K-	
TCGA-AF-3911	 P+	 R-	 K-	
TCGA-DC-6157	 P+	 R-	 K-	
TCGA-EI-6509	 P-	 R-	 K-	
TCGA-AH-6547	 P-	 R+	 K-	
TCGA-AF-2687	 P-	 R+	 K-	
TCGA-G5-6233	 P+	 R-	 K-	
TCGA-F5-6810	 P+	 R+	 K-	
TCGA-EI-6917	 P+	 R+	 K-	
TCGA-AH-6643	 P+	 R+	 K-	
TCGA-DC-6156	 P-	 R+	 K-	
TCGA-AG-3732	 P-	 R+	 K+	
TCGA-AF-6655	 P+	 R+	 K-	
TCGA-F5-6571	 P-	 R+	 K-	
TCGA-DY-A1DF	 P-	 R-	 K-	
TCGA-F5-6863	 P-	 R-	 K-	
TCGA-AA-A01I	 P+	 R-	 K-	
TCGA-AA-3684	 P-	 R+	 K-	
TCGA-AA-A004	 P-	 R+	 K-	
TCGA-AA-3680	 P-	 R-	 K-	
TCGA-A6-2670	 P-	 R+	 K-	
TCGA-AA-3870	 P-	 R+	 K-	
TCGA-AA-3560	 P-	 R-	 K-	
TCGA-AA-3811	 P+	 R+	 K-	
TCGA-AA-A00O	 P-	 R+	 K-	
TCGA-AA-3862	 P+	 R-	 K-	
TCGA-AA-3519	 P+	 R-	 K-	
TCGA-AA-3977	 P+	 R+	 K-	
TCGA-AA-3517	 P-	 R+	 K-	
TCGA-AA-A024	 P-	 R-	 K-	
TCGA-AA-3525	 P+	 R-	 K-	
TCGA-AA-A01D	 P-	 R+	 K+	
TCGA-AA-A01Q	 P+	 R-	 K-	
TCGA-AA-3833	 P-	 R+	 K+	
TCGA-AA-3548	 P-	 R-	 K-	
TCGA-AA-3666	 P+	 R-	 K-	
TCGA-AA-3976	 P+	 R-	 K-	
TCGA-AA-3819	 P-	 R-	 K-	
TCGA-AA-3556	 P+	 R-	 K+	
TCGA-CM-4746	 P+	 R-	 K-	
TCGA-AA-3543	 P-	 R+	 K-	
TCGA-AA-3939	 P+	 R-	 K-	
TCGA-A6-3808	 P-	 R+	 K-	
TCGA-A6-2681	 P-	 R+	 K-	
PRK sample group assignment in CRCSC cohort 228 
TCGA-AA-A02E	 P-	 R-	 K-	
TCGA-AA-3860	 P+	 R+	 K-	
TCGA-AA-3858	 P+	 R-	 K-	
TCGA-AA-3555	 P+	 R+	 K-	
TCGA-A6-2677	 P+	 R-	 K-	
TCGA-AA-A00R	 P+	 R+	 K-	
TCGA-AA-3856	 P-	 R-	 K-	
TCGA-AA-3531	 P+	 R-	 K-	
TCGA-AA-3973	 P-	 R-	 K-	
TCGA-CM-4750	 P+	 R-	 K+	
TCGA-A6-2680	 P-	 R+	 K+	
TCGA-AA-3875	 P+	 R-	 K-	
TCGA-AA-3850	 P-	 R+	 K+	
TCGA-AA-A00U	 P+	 R-	 K-	
TCGA-AA-3844	 P+	 R-	 K-	
TCGA-AA-3867	 P-	 R+	 K-	
TCGA-AA-3672	 P-	 R+	 K-	
TCGA-AA-3877	 P+	 R+	 K-	
TCGA-AA-3664	 P+	 R-	 K-	
TCGA-AA-3544	 P-	 R+	 K-	
TCGA-AA-A022	 P-	 R+	 K-	
TCGA-AA-A03J	 P-	 R+	 K-	
TCGA-AA-A01R	 P+	 R-	 K-	
TCGA-AA-3941	 P+	 R-	 K+	
TCGA-AA-A00F	 P-	 R+	 K-	
TCGA-AA-A03F	 P-	 R-	 K+	
TCGA-AA-3679	 P+	 R-	 K+	
TCGA-AA-3667	 P-	 R+	 K+	
TCGA-AA-3861	 P-	 R-	 K-	
TCGA-AA-3982	 P-	 R+	 K+	
TCGA-AA-A01V	 P-	 R-	 K-	
TCGA-A6-2672	 P+	 R+	 K-	
TCGA-AA-3869	 P+	 R+	 K-	
TCGA-AA-A00J	 P+	 R+	 K-	
TCGA-AA-3549	 P-	 R+	 K+	
TCGA-CM-4752	 P-	 R-	 K-	
TCGA-AA-3538	 P+	 R+	 K-	
TCGA-AA-3979	 P+	 R-	 K-	
TCGA-AA-3521	 P-	 R+	 K-	
TCGA-AA-3950	 P+	 R+	 K-	
TCGA-AA-3984	 P+	 R+	 K-	
TCGA-A6-3810	 P-	 R+	 K-	
TCGA-AA-A00N	 P-	 R+	 K-	
TCGA-AA-A00A	 P+	 R+	 K-	
TCGA-AA-3692	 P-	 R-	 K-	
TCGA-AA-3947	 P+	 R-	 K-	
TCGA-A6-2683	 P-	 R-	 K-	
TCGA-AA-A010	 P+	 R-	 K-	
TCGA-AA-3956	 P-	 R+	 K-	
TCGA-AA-3851	 P-	 R+	 K-	
TCGA-AZ-4681	 P+	 R-	 K-	
TCGA-AA-3678	 P-	 R-	 K-	
TCGA-AA-3527	 P-	 R+	 K+	
TCGA-AA-3975	 P-	 R+	 K-	
TCGA-AA-3494	 P-	 R-	 K-	
TCGA-AA-3715	 P-	 R+	 K-	
TCGA-AA-3534	 P+	 R+	 K-	
TCGA-AA-3846	 P+	 R-	 K-	
TCGA-AA-3518	 P+	 R-	 K-	
TCGA-A6-3809	 P+	 R+	 K-	
TCGA-AA-3542	 P+	 R-	 K+	
TCGA-AA-3529	 P-	 R-	 K-	
TCGA-AY-4071	 P-	 R+	 K+	
TCGA-AA-3831	 P+	 R-	 K-	
TCGA-AA-A029	 P+	 R-	 K+	
PRK sample group assignment in CRCSC cohort 229 
TCGA-A6-2674	 P-	 R+	 K-	
TCGA-AY-4070	 P-	 R+	 K-	
TCGA-A6-2671	 P+	 R+	 K-	
TCGA-AA-A01G	 P+	 R-	 K-	
TCGA-AA-A017	 P-	 R-	 K-	
TCGA-AA-A01F	 P+	 R-	 K-	
TCGA-AA-A00L	 P+	 R-	 K-	
TCGA-AA-3814	 P-	 R+	 K-	
TCGA-AA-3866	 P+	 R+	 K-	
TCGA-AA-3532	 P+	 R+	 K-	
TCGA-AA-A01C	 P+	 R-	 K-	
TCGA-AA-3842	 P+	 R-	 K-	
TCGA-AA-A00D	 P+	 R+	 K-	
TCGA-AA-3854	 P+	 R-	 K-	
TCGA-AA-3695	 P+	 R-	 K-	
TCGA-AA-3520	 P+	 R+	 K-	
TCGA-AA-A00K	 P+	 R-	 K-	
TCGA-AA-3972	 P+	 R-	 K-	
TCGA-AA-3864	 P+	 R-	 K-	
TCGA-AA-3968	 P+	 R+	 K-	
TCGA-AA-3516	 P+	 R+	 K-	
TCGA-A6-2678	 P+	 R-	 K-	
TCGA-CM-4748	 P-	 R+	 K-	
TCGA-AA-3952	 P-	 R-	 K-	
TCGA-AA-3855	 P-	 R+	 K-	
TCGA-AA-3971	 P-	 R+	 K-	
TCGA-AA-A01K	 P-	 R+	 K-	
TCGA-AA-3986	 P-	 R+	 K-	
TCGA-AA-A02J	 P+	 R-	 K-	
TCGA-AA-A02H	 P-	 R-	 K-	
TCGA-AA-3710	 P+	 R+	 K-	
TCGA-AA-A01S	 P+	 R-	 K-	
TCGA-AA-3524	 P+	 R-	 K-	
TCGA-AZ-4308	 P-	 R+	 K-	
TCGA-AA-A00E	 P+	 R+	 K-	
TCGA-AA-3949	 P+	 R+	 K-	
TCGA-A6-4107	 P-	 R+	 K+	
TCGA-CM-5341	 P+	 R-	 K-	
TCGA-AA-3514	 P-	 R+	 K+	
TCGA-AA-3552	 P-	 R+	 K-	
TCGA-AA-3812	 P-	 R+	 K-	
TCGA-AA-3554	 P-	 R+	 K-	
TCGA-AA-3553	 P+	 R+	 K-	
TCGA-AA-A02O	 P-	 R-	 K-	
TCGA-AA-3845	 P+	 R+	 K-	
TCGA-AA-A00W	 P+	 R-	 K-	
TCGA-AA-3696	 P-	 R-	 K-	
TCGA-AA-A00Z	 P+	 R-	 K-	
TCGA-AA-3561	 P+	 R-	 K-	
TCGA-A6-3807	 P-	 R+	 K-	
TCGA-AA-3966	 P-	 R+	 K-	
TCGA-AA-3818	 P+	 R-	 K-	
TCGA-AA-3688	 P+	 R-	 K-	
TCGA-A6-2676	 P+	 R+	 K-	
TCGA-AA-3821	 P+	 R-	 K-	
TCGA-AA-3837	 P-	 R+	 K-	
TCGA-AA-3562	 P-	 R-	 K-	
TCGA-AA-3980	 P+	 R-	 K-	
TCGA-AA-3930	 P+	 R-	 K-	
TCGA-AA-3994	 P-	 R+	 K-	
TCGA-AA-3530	 P-	 R-	 K-	
TCGA-AA-3970	 P-	 R-	 K-	
TCGA-AA-3872	 P-	 R+	 K+	
TCGA-AA-3693	 P+	 R-	 K-	
TCGA-AA-3852	 P-	 R+	 K-	
PRK sample group assignment in CRCSC cohort 230 
TCGA-AA-A01T	 P+	 R-	 K-	
TCGA-AA-A00Q	 P-	 R-	 K-	
TCGA-AA-A02R	 P+	 R+	 K-	
TCGA-AA-3955	 P+	 R-	 K+	
TCGA-A6-2679	 P-	 R+	 K-	
TCGA-AA-A02W	 P+	 R-	 K-	
TCGA-AA-3673	 P+	 R+	 K-	
TCGA-AA-3989	 P-	 R+	 K-	
TCGA-AA-A02F	 P+	 R-	 K-	
TCGA-AA-3522	 P-	 R-	 K-	
TCGA-AA-3841	 P-	 R+	 K+	
TCGA-AA-3488	 P+	 R-	 K-	
TCGA-AA-3815	 P+	 R+	 K-	
TCGA-AA-3681	 P+	 R+	 K+	
TCGA-AA-3848	 P-	 R-	 K-	
TCGA-AF-2691	 P-	 R+	 K-	
TCGA-AG-3611	 P-	 R-	 K-	
TCGA-AG-3593	 P+	 R-	 K-	
TCGA-AG-A015	 P+	 R-	 K-	
TCGA-AG-3881	 P-	 R+	 K-	
TCGA-AG-3605	 P+	 R-	 K-	
TCGA-AG-A00H	 P-	 R+	 K-	
TCGA-AF-3400	 P-	 R+	 K-	
TCGA-AG-3892	 P+	 R-	 K-	
TCGA-AG-A02G	 P-	 R-	 K-	
TCGA-AG-3598	 P+	 R-	 K-	
TCGA-AG-A01Y	 P+	 R-	 K-	
TCGA-AG-3882	 P-	 R+	 K+	
TCGA-AG-3726	 P-	 R+	 K+	
TCGA-AG-A023	 P-	 R+	 K+	
TCGA-AG-A01N	 P+	 R-	 K-	
TCGA-AG-A025	 P+	 R-	 K-	
TCGA-AG-A01L	 P-	 R-	 K+	
TCGA-AG-3575	 P+	 R+	 K-	
TCGA-AG-A020	 P+	 R-	 K+	
TCGA-AG-A011	 P-	 R-	 K-	
TCGA-AG-3999	 P-	 R-	 K-	
TCGA-AG-3901	 P-	 R+	 K-	
TCGA-AG-A01J	 P-	 R-	 K-	
TCGA-AG-A014	 P+	 R-	 K-	
TCGA-AG-3580	 P+	 R-	 K-	
TCGA-AG-3896	 P+	 R+	 K-	
TCGA-AG-A032	 P-	 R-	 K-	
TCGA-AG-4007	 P-	 R+	 K+	
TCGA-AG-3578	 P-	 R-	 K-	
TCGA-AG-3583	 P+	 R-	 K-	
TCGA-AG-3885	 P-	 R+	 K+	
TCGA-AG-3599	 P+	 R-	 K+	
TCGA-AG-4001	 P-	 R+	 K-	
TCGA-AG-4005	 P+	 R+	 K-	
TCGA-AG-A02N	 P-	 R-	 K+	
TCGA-AF-3913	 P+	 R-	 K-	
TCGA-AG-3727	 P-	 R+	 K+	
TCGA-AF-2692	 P+	 R+	 K-	
TCGA-AG-A02X	 P+	 R-	 K+	
TCGA-AG-4015	 P+	 R-	 K+	
TCGA-AG-3601	 P-	 R-	 K-	
TCGA-AG-3582	 P+	 R+	 K-	
TCGA-AG-4008	 P-	 R+	 K-	
TCGA-AG-3728	 P-	 R+	 K+	
TCGA-AG-3586	 P+	 R-	 K-	
TCGA-AG-3600	 P+	 R-	 K+	
TCGA-AG-A01W	 P+	 R-	 K-	
TCGA-AG-3609	 P-	 R+	 K+	
TCGA-AG-3883	 P-	 R+	 K+	
PRK sample group assignment in CRCSC cohort 231 
TCGA-AG-A002	 P+	 R-	 K-	
TCGA-AG-A008	 P+	 R-	 K-	
TCGA-AG-3574	 P-	 R-	 K-	
TCGA-AG-A00Y	 P+	 R-	 K+	
TCGA-AG-3587	 P+	 R-	 K-	
TCGA-AG-3894	 P+	 R-	 K-	
TCGA-AG-3612	 P+	 R+	 K-	
TCGA-AG-3909	 P-	 R+	 K-	
TCGA-AG-3890	 P-	 R+	 K-	
TCGA-AG-3602	 P+	 R-	 K+	
TCGA-AG-3878	 P-	 R+	 K-	
TCGA-AG-A036	 P+	 R-	 K-	
TCGA-AG-3584	 P-	 R+	 K-	
TCGA-AG-3608	 P-	 R-	 K+	
TCGA-AG-3893	 P-	 R+	 K-	
TCGA-AG-3898	 P+	 R+	 K-	
TCGA-AG-A026	 P-	 R-	 K-	
TCGA-AG-A016	 P+	 R-	 K-	
TCGA-AG-3887	 P+	 R-	 K-	
TCGA-AG-3581	 P-	 R+	 K-	
TCGA-AG-A00C	 P-	 R-	 K-	




















































































































































List of genes in cell proliferation gene signature 
 
TP73 TP53 CCND1 CDK2 DGKZ FBXO31 RFWD3 RPS27L TP63 PTPN6 BID E2F1
 PLK5 INO80 FGF10 EGFR PIM1 AKT1 ADAM17 WNT9A HUS1 NBN HRAS TGFB1
 RB1 CDKN2B RPL24 DLG1 USP17L2 PTEN PRMT2 PTEN FHL1 BRD7 BACH1 CDC45
 E2F6 DHFR TYMS RB1 CDK1 POLA1 PCNA CCNE1 RRM2 CCNA1 CDC6 HINFP
 CDT1 NPAT ORC1 GFI1 FBXO5 E2F4 E2F6 RB1 E2F1 ITGB1 PSMD11 PSMD12
 PSMD9 CDC7 PSMD14 PPP6C PSMA7 PSMD3 ORC5 ORC4 CDC45 PSMD10 CCNE2 DHFR
 TYMS ITGB1 RB1 CDK1 EIF4E POLA1 UBB UBC BCL2 CDK4 PCNA CCNB1
 GSPT1 RPA2 PSMC3 RCC1 PSMB1 RPS6KB1 CDK2 MCM3 PSMA1 PSMA2 PSMA3 PSMA4
 RPA1 PSMB8 PSMB9 PSMA5 PSMB4 PSMB6 PSMB5 WEE1 CDC25A RRM2 MCM4 MCM5
 MCM7 RPA3 PSMC2 ACVR1B PSMB10 CDKN2A CDKN2C PSMC4 ID4 PSMD8 CDC34 PRIM1
 PRIM2 PSMB3 PSMB2 MCM2 CDK7 PSMD7 CCNH MNAT1 BCAT1 PSMD4 POLE2 PSMA6
 PSMC1 PSMC5 PSMC6 RPS27A UBA52 SKP1 CCNA1 CDK3 CDK6 E2F1 PPP3CA RPA4
 PSMD2 EIF4EBP1 CAMK2B CAMK2D POLA2 TFDP1 PSMD6 CDKN3 IQGAP3 PSMF1 CDCA5
 MARK4 RBBP8 CDC6 HINFP CDT1 PIM2 ORC3 DBF4 MCM8 ORC6 PSME3 CKS1B
 PSME1 SKP2 ORC1 ORC2 MCM6 PSMD5 RHOU MCM10 PSMB7 PSMD1 PKMYT1 FBXO5
 PSME2 PSMD13 GPR132 PHF8 LATS2 CAMK2A IQGAP3 CDKN2D CDC25A NFATC1 INHBA SPDYA
 CAMK2A NFATC1 ITGB1 ACVR1 CUL1 CUL2 CUL3 CUL4A TFDP3 USP37 CUL5 NBN
 TICRR WRNIP1 CDT1 TNKS CCDC111 POLA1 PRIM1 PRIM2 HELB CCDC111 ORC5L MCM7
 GMNC POLA1 RFC3 RFC5 POLE POLA2 LIG1 ORC5 SSBP1 ORC4 TNFAIP1 ORC2
 DNAJC2 BRCA1 MCM7 POLN POLD2 ORC2 NFIX RFC3 NFIX RFC4 SSBP1 NFIA
 GINS4 BRCA1 POLE ORC3 BRCA1 MCM8 MCM5 MCM4 POLN POLE SSBP1 POLD1
 BRCA1 GINS3 FHIT POLQ RRM1 POLN MCM3 POLA2 LIG1 ORC4 NFIA POLE
 MCM2 FEN1 MCM2 BLM MCM7 POLD4 PRIM1 POLE REV3L NFIX POLQ POLD3
 MCM7 BLM RRM1 PRIM1 DNA2 NFIX POLD2 NFIA RFC5 NFIC TK2 CDC7
 NFIB CHEK1 ORC5 ORC4 MCM3AP RAD1 KIN HUS1 POLQ CDC45 RNASEH2A
 RAD17 RECQL4 KAT7 EGF TK1 TYMS IGF1 CDK1 NFIC KRT7 CHTF8 HSMCR30
 TOP1 TOP2A PCNA RPA2 LIG1 TYMP PTMS ACHE RRM1 MCM3 RPA1 POLD1
 CTGF RBMS1 CDC25A CDC25C RRM2 DUT MCM5 MCM7 PHB RPA3 RFC2 BRCA1
 IGHMBP2 FEN1 RECQL POLD2 NASP CENPF PRIM1 PRIM2 MCM2 FHIT LIG3 LIG4
 NUP98 BLM NAP1L1 POLE2 SET SSBP1 POLE SSRP1 RBBP4 NFIA CHAF1A CHAF1B
 ORC1 ORC2 ATR NAE1 TNFAIP1 POLA2 WRN NCOA6 GINS1 NFIX SPHAR MED1
 RBBP7 BRCA1 TBRG1 C8orf45 MCM10 LIN9 PAPD7 E4F1 RAD9B NOL8 MCM10 RRM2B
 TICRR POLN STRA8 PAPD5 HELB CHTF18 ATRIP ING5 KCTD13 UPF1 RMI2 SIRT1
 CCDC111 RBM14 PEO1 WRNIP1 SIN3A DNAJC2 RAD9A CDC6 GINS4 GINS3 POLD4 CINP
 REPIN1 CDT1 TMX1 RMI1 CLSPN POLD4 NT5M POLE3 MCM9 DTL ORC3 POLK
 DBF4 REV1 LRWD1 POLL POLG2 MCM8 POLI ING4 GINS2 POLH SUPT16H ORC6
 MCM7 MCM2 MCM7 MCM2 MCM7 HMGA1 MCM7 MCM2 PURA RAD51 MCM6 RAD51
 PEO1 CCDC88A PCNA CDK2 PPP2R1A ACVRL1 PPP2CA ID3 CCDC88A ESCO2
 ESCO1 DSCC1 SMC3 POLD1 KIAA2022 TNKS2 CDK9 DKC1 RFC1 TERF2 RAD50
 PINX1 TNKS1BP1 POT1 TERF2IP PML TERF1 POT1 POLD1 FEN1 DNA2 KIAA2022
 C9JGY3 GMNN D6R920 IDAS GMNN HCRT HUS1 GMNN RAD17 TGFB1 TP53 TGFB3
 S100A11 NF2 TERF1 ATR TTF1 PDS5A ENPP7 WAPAL MAPK15 CDC6 GTPBP4 TSPYL2
 GDF2 TIPIN TERF1 TERF2 MCM7 CDC45 MCM2 MCM7 CDC45 MCM5 MCM2 CDC45
 MCM4 MCM5 CDC45 MCM5 MCM2 ORC5 ORC4 CDC45 CCNE1 MCM3 MCM4 MCM5
 MCM7 CDC34 PRIM1 PRIM2 MCM2 POLE2 PURA POLE RPA4 ORC1 ORC2 POLA2
 MCM6 LRWD1 CDC45 PCNA RPA2 LIG1 MCM3 RPA1 POLD1 MCM4 MCM5 MCM7
 RPA3 RFC4 RFC2 RFC1 FEN1 RFC5 RFC3 POLD2 PRIM1 PRIM2 MCM2 DNA2
 POLA2 MCM6 GINS1 POLD3 GINS4 POLD4 MCM8 GINS2 SLBP CACYBP SHC1 MET
 ATF1 FGF10 HRAS INS EPO PLA2G1B CSF2 MAS1 IL6 JUN INSR CDK1
 IGF1R GLI1 IL3 GLI2 TGFB3 AREG PDGFRA ATF1 KITLG CALR SHC1 DNA2
 UCN CTC1 CDC42 CACYBP OBFC1 CACYBP PDGFC BLM TIPIN INO80 TK2 RRM2B
 POLG RRM2B DNAJA3 TEFM STRA13 BLM FANCM APITD1 CDK2AP1 REV3L POLB TOP2A
 RPA2 RPA1 RFC1 POLG TFAM TOP2B RPAIN PNKP MCMBP BAZ1A POLG2 MRE11A
 SMC1A STAG2 FBXW7 SMC3 POLA1 PCNA RPA2 LIG1 RPA1 POLD1 RPA3 RFC4
 RFC2 RFC1 FEN1 RFC5 RFC3 POLD2 PRIM1 PRIM2 DNA2 POLE2 POLE POLA2
 POLD3 POLD4 P10266 P63128 P63132 P63133 P63135 P63136 TERT ERVK6 Q9QC07 Q9UQG0
 ERVK6 ACD TINF2 TERF1 TERF2 TNKS TERF1 TERF2 ERCC4 DCLRE1B TERF2 ACD
 DCLRE1B ZSCAN4 TINF2 OBFC1 TERF2IP TNKS2 DKC1 RFC1 TERF2 RAD50 PINX1 TNKS1BP1
 POT1 TERF2IP MYC PIF1 PML TERF1 POT1 ERCC1 TERF2 TINF2 ERCC4 LIG1
 RFC4 RFC2 RFC1 RFC5 RFC3 POLE2 POLE TEP1 TERF1 TERF2 TERT WRAP53
 POT1 TERF2 TINF2 TERF2IP TERF2 DCLRE1B POLA1 PCNA RPA2 LIG1 RPA1 POLD1
 RPA3 RFC4 RFC2 RFC1 FEN1 RFC5 RFC3 POLD2 PRIM1 PRIM2 DNA2 POLE2
 POLE POLA2 POLD3 POLD4 DCLRE1C POT1 PRKDC DKC1 NBN PARP1 POLA1 PCNA
 XRCC6 XRCC5 RPA2 LIG1 RPA1 POLD1 RPA3 RFC4 RFC2 RFC1 FEN1 RFC5
 RFC3 POLD2 PRIM1 PRIM2 DNA2 POLE2 PRKDC POLE POLA2 WRN POLD3 PTGES3




NCAPD3 PAPD7 PHF13 TTN CDCA5 NUSAP1 CHMP1A SMC4 SEP15 H1FNT TSSK6 HELLS
 CENPV HELLS HMGA2 BAHD1 NCAPD2 NCAPH NCAPD2 ABCA4 NCAPD2 PRM1 PRM2 CDK1
 HMGA2 HILS1 NCAPH2 H1FNT NCAPG2 AIFM2 PRM3 HAT1 PRM1 PRM2 NAA10 KAT6A
 ASH1L MYST3 TSPY8 TSPY4 H2AFV NAP1L6 TSPY8 TSPY2 SET TSPY2 HIST1H2BC
 SET H3F3A H2AFY NAP1L2 MCM2 H2AFV NAP1L4 H2AFV NAP1L4 H2AFJ TSPY10 MCM2
 NAP1L4 H2AFY H2AFV TSPY10 TSPY3 H1F0 TSPY8 NAP1L1 NAP1L3 NAP1L5 HIST1H4A
 NAP1L1 NAP1L4b TSPY8 CENPA SHPRH OIP5 HIST1H2BK H2AFY HIST1H2AB HIST1H2BJ
 H1F0 H2AFZ HIST1H2AL H2BFM H2AFB1 H2AFB3 TSPY3 TSPY4 TSPY8 TSPY10 HIST1H1E
 H2AFX HIST1H1B HIST1H1D HIST1H1C HIST1H2AD HIST1H1T
 HIST1H2BO HMGB2 HIST1H2BB SOX9 CENPA MCM2 NAP1L1 H2BFS HIST1H2BD
 HILS1 HIST1H4K HIST1H3G H3F3B SET TSPY1 HIST1H1A RBBP4 ITGB3BP
 SHPRH RBBP7 HIST3H3 HIST2H2AC HIST2H2BE HIST2H2BF H2AFY2 HIST2H3PS2
 SET HIST2H2BC HIST2H2BD HIST2H2AA3 CENPP H3F3C MIS18BP1 HIST2H3A
 MLF1IP H2AFV CENPQ HIST3H2A H2BFWT TSPYL5 HIST2H2AB H1FOO HIST3H2BB
 TSPYL6 HJURP CASC5 KAT6B H1FX CENPI KAT6A HIST1H2AC HIST1H2BH
 HIST1H2BA CENPN HIST1H2AH NAP1L5 HIST1H2AA NAP1L3 HIST1H4G NAP1L4
 HIST1H2BN HIST1H2AJ HIST1H2BM HIST1H2BL CENPK H2AFJ CENPO TSPYL1
 TSPYL2 CENPH TSPY26P ASF1B MIS18A H2AFY2 TSPYL4 NAP1L2 RUVBL1 ASF1A NAP1L1 HMGA1
 CDKN2A HMGA2 STRA8 CCNB1 SMARCA5 HIST1H1E HIST1H1D HIST1H1C
 CTCF RSF1 CHAF1A CHAF1B DFFB TOP2A ACIN1 SYCP3 RBBP4 CHAF1A CHAF1B C2orf65
 OIP5 SMARCA5 NPM1 CENPA HIST1H4K RBBP4 ITGB3BP RBBP7 CENPP MIS18BP1
 MLF1IP CENPQ CASC5 CENPI CENPN RSF1 CENPK CENPO CENPH MIS18A RUVBL1 ESPL1
 RB1 WAPAL CDCA5 HORMAD1 ZW10 CCNB1 CENPE RRS1 PSRC1 KIF18A PINX1
 CCDC99 SEH1L CDCA5 CDC23 NEK2 CDC42 RACGAP1 ECT2 CENPF SPICE1 FMN2
 STRA13 TOP2A MLH1 TOP2B FANCM APITD1 ERCC4 LATS1 TOP2A TOP2B MSH4 MSH5
 ESPL1 STRA8 NDC80 BUB3 SGOL1 CASC5 AURKB AURKC HORMAD1 CENPE DLGAP5
 CDC6 RB1 NIPBL BUB3 BUB1 BUB3 KIF2B AURKB KIF2C CENPH ABCA4 RIOK3
 NDC80 BIRC5 RGS14 RAD21 BRD4 CIAO1 TOP3B PTTG1 SLC25A5 ERCC2 RCC1 PPP2R1A
 BRCA1 CTCF NEK2 UBE2I ESPL1 SGOL2 SGOL1 PMF1 PHF13 SKA3 NUP43 NUP37
 CASC5 SKA2 STAG1 USP9X SKA1 ARL8A SEH1L NSL1 SRPK1 CDK5RAP2 SETDB2
 MMS19 CENPO METTL11A NUF2 NDEL1 CENPH DSN1 RAD21L1 FAM96A NAA60 SPC25
 NEK6 INCENP ARL8B STAG3 FAM96B MAU2 BUB1 AKAP8 SMC2 NCAPD3 PAPD7 PHF13
 TTN CDCA5 NUSAP1 CHMP1A SMC4 RB1 ZNF828 BRCA2 BUB3 NEK2 KIFC1 CIT
 NDC80 SMC4 MAD2L1 BUB3 ZW10 ZWINT NUSAP1 NEK2 ESPL1 SMC1A DDX11 KIF25
 INO80 SMC1A NIPBL POGZ GSG2 PDS5B SEH1L ZNF828 CTCF AXIN2 CCNB1 RAD51C
 REC8 MRE11A SMC1A PAPD7 STAG2 FBXW7 DDX11 MCMBP NBN CDK1 CCNA2 CCNG1
 HMGA2 FOXO4 TOP2A TOP2B HSPA2 FHL1 USP47 CDC45 RAD17 POLA1 CDC6 TIPIN
 CDT1 RAD9A STRA8 NAE1 TICRR CLSPN CCNB2 CENPF PKIA PRKCQ CDKN2A CCNB3
 BRD4 BACH1 TAF1 PLK4 CHEK1 CEP290 PPM1D BIRC5 CCP110 ENSA SSNA1 OFD1
 DCTN3 CDK14 CEP152 CCNB2 PCNT FGFR1OP LATS1 TUBB4 CDK1 TUBB HSP90AA1
 ABCB1 PRKACA CCNA2 TUBG1 GADD45A CDK2 PPP2R1A WEE1 CDC25A CDC25C PRKAR2B
 CDKN1A CETN2 CDKN2B PAFAH1B1 CSNK1E DNM2 CDK7 CCNH MNAT1 NEK2 PLK1
 TERF1 ARPP19 YWHAE DYNLL1 TUBA4A TUBB2C CCNA1 KHDRBS1 DCTN2 MELK NUMA1 PCM1
 CEP78 CNTRL CEP57 CEP76 CEP192 TUBGCP3 DDX11 MARK4 TUBGCP6 TUBGCP5
 CDK5RAP2 TUBGCP2 CEP250 FBXL15 CENPJ HAUS2 CEP72 ANAPC5 ANAPC4 ANAPC10
 NINL DCTN1 DYNC1H1 ACTR1A SKP2 DYNC1I2 PKMYT1 AZI1 CEP63 TUBG2 NES
 CSNK1D YWHAG MAPRE1 TUBA1A CLASP1 CCNY CEP70 NEDD1 TSGA14 NDE1 TUBGCP4
 USH1C JMJD5 CEP164 CHEK1 SDCCAG8 SFI1 CKAP5 TPD52L1 ODF2 CEP135 TAF2
 ALMS1 AKAP9 PLCB1 WNT9B POU5F1 BLM TXNIP WNT3A FZD7 HOXB4 BMI1 NOTCH1
 WNT3A TGFB2 CDKN2A VANGL2 ANXA11 SPAST FGFR2 DCT VEGF MEN1 EREG FIGF
 PDGFB TGFA TGFB1 IGF2 IL1A IL1B PPBP CAT PDGFA FGF1 FGF4 FGF2
 TGFB3 FGF6 FGF3 FGF5 OSM VEGFA TAL1 PTN MDK FGF7 FGFR2 APC
 FGF9 BTC HTR2B PGF VEGFB VEGFC FGF8 PROK1 TGFB2 YBX1 CSPP1 MACC1
 NKX3-1 PDGFD MEN1 PDGFC GKN1 RGS14 CDC42 KIF23 CSPP1 PKP4 CDC6 AURKC
 DAXX APC MYH10 APC DAXX APC MYH10 NUSAP1 TOP1 ERCC2 PIK3CB DPPA3
 AATF STX2 TIAL1 WWTR1 RACGAP1 FMN2 CCP110 PRPF40A CETN2 CALM3 PDXP
 BBS4 ASPM LEF1 IGF1R CENPV PARD3 RACGAP1 POU3F2 DIXDC1 GNB2L1 KIF18B
 CABLES1 CABLES2 AURKB DSTN ARHGEF11 BIRC5 SEPT4 DAPK3 PRC1 DIAPH2 ROCK2
 DCTN3 KIF20A RALA RALB SON STX2 MYH9 ARL3 PLK1 DSTN RAB11A KIF23
 ROCK1 SEPT6 BECN1 ESPL1 RAB35 SEPT7 TTC19 RAB11FIP4 CNTROB PIK3C3 NEK7
 AHCTF1 AURKB NOX5 SEPT5 CECR2 ROPN1B RACGAP1 KIF13A NEK6 INCENP ANLN
 BIN3 KLHL9 KLHL13 SEPT3 KLHL21 VPS4A AURKC NUDC VPS24 ZFYVE26 RASA1 ASPM
 SFRP2 SAC3D1 MCM5 CDC37L1 CDC7 CDK10 CDCA7L CENPH PAFAH1B1 CDC27 CDCA7
 CDK4 CDK19 CDCA7 CDC20 CCNA1 PAFAH1B1 CCNB1 NCAPH NCAPD2 KIF2A CDC7
 UBE2C NDC80 AURKA CETN3 ZW10 OIP5 RGS14 BUB1 BUB3 ENSA RAD21 SSSCA1
 EVI5 CCNT1 BUB1B CCNT2 CLASP2 VPS4B TACC1 KATNA1 CDC123 CCNK RNF8 JTB
 CDK14 HAUS5 CCNB2 ZWINT SMC2 LATS1 PTTG1 CCNE2 GNAI2 RB1 CDK1 TUBB
 GNAI3 HSMCR30 CDK4 CCNB1 RCC1 LIG1 CCNA2 CCNO CCND1 CCNE1 CDK2
 CCND2 CCND3 WEE1 CDC25A CDC25B CDC25C CKS2 PPP1CC CCNF CETN2 NCAPD3 CSNK1A1




HMGA2 IST1 TERF1 ARPP19 BCAR1 CKS1B PPP1CA PPP1CB RAN GNAI1 DYNLT1 UBE2I
 TUBA1B CCNA1 TXNL4A CDK3 CDK6 CDK5 CENPE CETN1 CDC20 CDC16 MAD2L1 CKAP5
 NEDD9 SMC1A NCAPH SEPT2 NCAPD2 SYCP1 MAPRE2 MAPRE1 CCNG2 UBE2S PDS5A ERCC6L
 PLK5 MAP9 CEP55 KLHL22 CDCA8 SGOL2 SGOL1 CDC2L6 CDC42 CDC16 KIAA1009
 CCNB1 PAPD7 E4F1 PPP2R2D HAUS3 CDCA2 SPECC1L MIS18BP1 PMF1 LLGL2 PSRC1
 BORA SYCE2 DCLRE1A SEPT14 TUBA1A MAEA CHMP1B POGZ CLASP1 HAUS6 WAPAL CDC16
 CNTRL CENPV USP37 CUZD1 ZC3HC1 NCAPG2 PHF13 SKA3 SIRT2 SEPT12 CDK20 ASPM
 SYCP3 SYCE1 SPICE1 STAG2 KIF2B SPC24 CCNY PAPD5 NUP43 NUP37 CASC5 NEDD1
 CDC26 TTDN1 NEK9 PARD3B CCNE2 PDCD6IP SKA2 STAG1 CCNB3 SEPT1 ARHGEF2
 USP9X SKA1 ARL8A HAUS1 ANAPC16 CCDC99 SEH1L CHFR CDCA5 MASTL SENP5
 BOD1 NSL1 LMLN CEP63 ZNF830 NEK1 KIF20B SPAG5 SETDB2 CDCA3 KIF2C CDC6
 TSG101 HAUS7 NCAPG TUBA1C LZTS2 PELO ANAPC13 HAUS8 MCMBP FSD1 CENPO
 KATNB1 TIPIN KIFC1 CINP SYCP2 NUSAP1 PARD6G PARD6B NUF2 LRRCC1 MIS12 USP44
 ANAPC1 CENPH DSN1 FAM83D HAUS4 ZWILCH ACTR8 SPC25 CENPJ CHMP1A PARD6A SETD8
 LATS2 HELLS PDS5B SMC4 SEPT11 ARL8B C12orf11 HAUS2 NDE1 ANAPC11 MIS18A
 SEPT10 RCC2 SPAST SEPT9 MAD2L2 CDC23 ANAPC7 ANAPC5 ANAPC4 ANAPC2 FBXO5 INO80
 TPX2 FZR1 ANAPC10 CDC14A TIMELESS CEP164 MAPRE3 SMC3 RUVBL1 CD2AP
 USP16 MAD1L1 DYNC1LI1 MAU2 NUMB NUMBL CIT JTB RHOC BRCA2 RHOB









List of genes in tissue remodelling gene signature 
 
ZC3HAV1 TICAM1 CD86 ZFPM1 IL29 LEF1 APOA1 EREG GATA6 IL18 HIF1A
 F2R SPHK1 S1PR3 SPHK1 NOD1 TLR3 CD36 NOD2 CD36 TNFRSF1A TLR4
 TLR3 RIPK2 TLR2 JAK2 SASH3 IFNG PF4 CD14 CD36 TNFRSF1A IL12B
 FCER1G FADD RIPK1 IL18 TWIST1 NOD1 MAVS TICAM1 CCL19 MYD88 CARD9 IL23A
 TLR9 NOD1 IL1RL1 IL33 RARA IL1RL1 NLRP12 TRPM4 NLRP12 IRF1 TLR4 IFNG
 IRF1 RELA REL LTB TNFRSF8 TLR4 TIRAP ITK AVPR2 ITK TLR4 SASH3
 IL4 HSPD1 TNFSF4 CD40LG FCER1G XCL1 CD83 TIGIT IL20RB IL21 NOD2 TLR9
 IL17F IFNA2 TGFB2 SMAD3 SMAD4 HIF1A CMA1 GPAM CD24 TLR3 IL12B CEBPG
 EBI3 CD276 ZFPM1 IL27 TNFRSF13C IL21 TLR9 TLR8 TLR7 FCER1A CD80
 SYK TNF APOA1 APOA2 IL10 TNFSF4 IFNG CSF2 IL17A IL17RA MYD88 IL9
 CD83 NDFIP1 FOXP3 LEF1 IFNAR1 IFNAR1 IRF9 IRF3 MYD88 GSTP1 NCKAP1L TLR4
 IFNG PRNP TNFSF4 IL12A IL12B NCKAP1L BCL10 FCER1G NLRP3 BTK IL33 IL4
 RARA TNFSF4 CD74 TIRAP TLR4 BCL10 APOA2 ELANE TLR8 TLR7 PRG3 NLRP3
 TLR3 TLR9 TLR8 TLR7 TIA1 RNF128 FOXP3 ASB1 TBK1 TRIL WNT11 TGFB1
 IL15 IL2 IL18 IL23R MYD88 IL21 NOD2 EREG AGPAT2 SOD1 AGT TNF
 ADRA2A LEP HTR2B SLC11A1 NFAM1 PELI1 C1orf190 AGPAT1 CARD11 TGFB1 TGFB3 TGFB2
 IRAK3 F2RL1 AZU1 IFNA2 IFNB1 F2R IFNAR1 WNT5A TLR4 RIPK2 SASH3 LTA
 TNF IL1B CD3E IFNAR1 BCL3 ZP3 TNFSF4 KLRK1 CD40LG WNT5A CCR2 SLC11A1
 IRF8 FZD5 IL27RA IL29 KLRK1 IL12RB2 SMAD3 HSPB1 SMAD3 JAK2 HSPB1 SMAD3
 IL18 NOD2 P2RX7 WNT5A TRIM16 IFNG WNT5A NLRP12 PYDC1 NLRP3 PANX1 CCL19
 NLRP1 NOD2 NLRP2 PYCARD CARD8 SAA1 IL29 FOXP3 LEF1 IRF4 STAT5B STAT5A
 CARD11 IL1A IL1B CD4 CD3E CD28 CD80 CD86 STAT5A STAT5B PRKCQ IRF4
 CD28 GLMN CARD11 IL1B IL12B IL18 IL23R IL23A IL18 PTGS2 MAP3K7 SASH3
 TNFSF4 XCL1 TRAF2 MALT1 TRAF6 HMOX1 HMOX1 BCL6 PCSK5 CD28 CEBPE PCSK5
 IL17F IL6R BPI ARRB1 ADAM17 TLR9 NDRG2 KLRF2 LYN MS4A2 AGT LYN
 MS4A2 LCP2 NOX5 S100A13 C3AR1 C3 IL1A ARNT ADORA2B PTGS2 FLT4
 IL6ST GATA4 C3AR1 HIF1A HPSE NOX1 TSPO CHRNA7 HSF1 NOD2 TLR4 CIDEA
 POMC GSTP1 RARA ACP5 BPI LBP TNFAIP3 AXL TSPO ARRB2 HSF1 MC1R
 TWIST1 ADIPOQ SELS CHRNA7 TWIST2 SELS FOXP3 NOD2 IRAK3 TIRAP TRAF3 RNF216
 F2RL1 IFNG ADAM8 AFAP1L2 MAP3K7 RIPK2 SASH3 TNFSF4 CCR2 CD83 TRAF2 MALT1
 TRAF6 SLC11A1 INPP5D NLRP12 INPP5D GHSR GHRL SEMA7A TLR4 SEMA7A CD74 CD36
 WNT5A SLC11A1 IL4 XCL1 TLR4 DDX58 HSPD1 IRF7 IFIH1 TBK1 MAST2 NFAT5
 CD4 DBH G6PD FABP4 TNFSF4 PTAFR TXK REL ITK NFATC2 CD226 ZCCHC11
 NFATC2IP S1PR3 FOXP3 IRAK4 CD4 BCL3 IRF4 IL4 IL12B IL18 TNF
 IFNG IL1B HMOX1 WNT5A TICAM1 MYD88 WNT5A F2R WNT5A CAMK4 BCL3 IL10
 GHSR GHRL IL1RL1 NOD2 SCGB1A1 TLR4 IL33 PRNP RARA SCGB1A1 TNFSF4 XCL1
 IL1RL1 IL20RB GIMAP5 FOXP3 NOD2 ELANE SIGIRR CARD9 CHRNA7 NCKAP1L TNFRSF1A
 TLR4 TNF GBA BPI TNFRSF1A TNFAIP3 IL10 ARRB2 ARRB1 NCKAP1L SELS
 CHRNA7 SELS FOXP3 TLR9 KLF2 CCR7 CCL19 XCL1 FURIN GATA6 RPS6KA5 RPS6KA4
 SLC11A1 NDRG2 IL6 CCL2 CCR2 NDRG2 CIDEA IL6 SRGN TNFSF4 TNFRSF4 NLRP12
 CX3CL1 O3FAR1 BTN2A2 FOXP3 SASH3 IL33 CD3E RARA ZP3 TNFSF4 GATA3 IL20RB
 XCL1 FOXP3 ATP6AP2 THBS1 CX3CL1 FOXP3 ICOSLG CD86 IRF4 IFNA2 SNAI2 IL10
 GATA3 INHA INHBA CD276 FOXP3 IRF3 WNT5A F2RL1 ZNF287 MAP2K3 IGF2BP3 GATA3
 IL12B MAP2K3 ZNF287 IGF2BP1 IGF2BP2 IL12B JAK3 IL23R FOXP3 IL23A NOD2 THBS1
 ACP5 ARRB2 JAK3 TIGIT CMKLR1 NOD2 IL1B TWIST1 ADIPOQ LAG3 SFTPD CD276
 FOXP3 VSIG4 NOD2 PRNP TNFAIP3 XCL1 IL20RB HDAC7 KAT5 NOD2 VSIG4 PLA2G1B
 CEBPB IL17F CARD9 INHBB P2RX7 PANX1 PNP GPAM TLR4 RAC1 SMAD3 SMAD3
 CREB1 SMAD3 JAK3 S100A13 P2RX7 TNFSF15 CRTAM INS TNF IL1A SAA1 CD14
 FGR MIF IL10 HTR2B IRF3 CLEC6A CLEC9A SCAMP5 GLMN PANX1 CADM1 IL26
 CLEC5A CLEC4E TLR4 TLR3 RIPK2 TLR2 TNF LBP ADORA2B P2RY2 ADAM17
 IL18 HIF1A TLR9 TLR7 ELANE BCL3 IL18 BCL10 IL17F CHRNA7 GSTP1 ACP5
 TNFAIP3 ARRB2 CHRNA7 GHSR GHRL TRIB2 NOD1 XCL1 MAVS TLR4 TLR3 TLR5
 IL1B SERPINE1 CALCA LBP TIRAP FADD RIPK1 IL18 ADIPOQ MAVS AFAP1L2
 TLR7 BCL10 IL19 GIMAP5 IL21 AZU1 PTGS2 CCR7 AIM2 ABCA1 F2RL1 NLRC4
 NOD1 P2RX7 CD36 TLR3 CD36 NOD2 CD36 WNT5A TLR4 MAPK13 TLR3 RIPK2
 FIGF TLR2 IL33 TNF IL1A IL1B IL6 IL6R HSPD1 CD36 LBP TNFSF4
 ADORA2B FCER1G WNT5A UCN AKIRIN2 NOD1 TICAM1 MYD88 CARD9 NOD2 TLR9
 TLR7 NOD1 CALCA IL1RL1 IL33 C5 IL4R IL1RL1 CHIA IL18 PAWR TLR2
 TLR9 FCER1A SYK SLC11A1 TLR3 CD36 NOD2 CD36 TLR4 TLR3 TLR2 HSPD1
 CD36 TNFSF4 CD40 IL12B CD40LG CCR7 TIRAP IRF8 IL23R CCL19 NOD2 IL23A
 PLCB1 TLR9 MAVS IL17F TIRAP IL17F CARD9 CCR7 TLR3 TLR4 POLR3A TLR3
 TLR2 POLR3D RNF135 POLR3C IFIH1 POLR3F TLR9 POLR3B TBK1 EREG IFNG IL1B
 TIRAP TLR1 TLR6 TLR4 TICAM1 TLR9 TLR8 TLR7 TBK1 HSPB1 SPN TLR4
 HSPB1 THBS1 SPN LBP AZU1 TNFRSF8 CCR2 TLR1 IL13 ELF1 SFTPD UBASH3A
 TRAF3 ELF1 ACE2 ZBTB32 HSPD1 WNT11 TRIM56 PTGS2 XCL1 UBE2L6 ATG12 DDX58
 ISG15 UBB UBC TNFAIP3 UBA7 UBE2D3 RPS27A UBA52 TRAF3 PIN1 IKBKE TRIM25
IRF3 PCBP2 MAVS NLRX1 TAX1BP1 NLRC5 RNF135 RNF125 OTUD5 ITCH IFIH1 ATG5




MINK1 TSC1 ONECUT1 DDR1 ITGAL ITGA4 L1CAM FERMT3 OLR1 FERMT3 OLR1
 ITGB2 ICAM1 ITGB1 APOA4 CALCA ITGA5 CCL5 ITGA4 EZR SELP SELE ITGAL
 MSN CD40LG L1CAM SYK OLR1 ROCK1 TSTA3 CERCAM FERMT3 CLEC4M CD209 ADA
 DPP4 FERMT3 CX3CL1 SPN MYO1F ADAMDEC1 DSCAM KNG1 SPN RASA1 ERBB3
 ACVRL1 ARHGDIA ARHGDIB CDH13 CD164 PDE3B ANGPT1 TGFBI MIA3 CBLL1 DSCAML1
 RND1 SIPA1 ARHGDIG SRCIN1 ADAM22 ITGA6 VTN ICAM1 ADAM17 ADAM9 JUP
 THBS4 CYP1B1 PODXL CXCL13 CCL5 PIEZO1 ZAP70 JAK2 PODXL TGFB1 WNT1 CDH1
 NF2 B4GALNT2 TNR GTPBP4 EPB41L5 LEF1 ROCK2 EPHA3 EFNA5 ROCK1 MACF1
 UNCX BMPR1B ACAN BMPR1B COL2A1 MYCN MGP FGF4 FGF6 COL11A1 MYF5 BMP1
 SOX9 PKD1 ALX1 OTOR BARX2 TRPM7 PPAP2B L1CAM CXADR PTPRU CCL21 ASTN1
 NCAM2 CDK5R1 CNTN4 NLGN2 TNR NLGN3 NINJ2 CTNND2 TNF IL1B VCL IHH
 CDC42 PLEKHA7 BVES KIFC3 CAMSAP3 CTNNA3 MYH9 NRCAM CTNNB1 SHC1 CTNNB1
 JUP NRCAM NRCAM CTNNB1 ICAM1 ASTN1 THY1 PDPN NPHP1 SRPX2 CTNND1 NPHP4
 ANXA9 VNN1 NTN1 EGFR THY1 CD2 PKHD1 BCL2 COL6A2 ICAM2 JUP PVR
 DSP CD44 CD58 CD24 COL8A2 CTNNA2 CD34 SHC1 ICAM3 CTNNB1 MYH9 PSEN1
 ITGA8 CDH11 CDH12 JAM2 DSG1 COL14A1 FOXF1 DLG1 ITGAD SCRIB FAT1 ICAM4
 COL19A1 PVRL1 CDSN RAPGEF1 CTNNA3 COL13A1 CBLL1 PDPN RAPGEF1 NLGN2 DLG5 PKD1L1
 GPR98 PTPRU NRCAM CYFIP2 PKP2 ROPN1B SIGLEC1 CDH19 VEZT CDH20 CD93 IGSF5
 CRNN CTNNA3 CDH9 CDH7 ICAM5 FNDC3A ZAN CDH10 ILK MERTK LAMA5 FZD7
 FN1 LAMB1 LAMC1 EFNA1 EPHA1 AXL BRCA1 EPHB3 TYRO3 MERTK ILK VAMP3
 BVES SRCIN1 ANTXR1 PEAK1 FZD4 C22orf28 SDC4 SDC4 KDR SMAD3 PTPRJ SFRP1
 TSC1 EPB41L5 ITGA4 CADM1 L1CAM CADM1 ICAM1 ITGA5 ITGA4 SELP SELE CDH2
 VCAM1 ITGAL L1CAM LGALS7 CDH4 NRXN1 CXADR CD164 REG3A PVRL1 AMIGO2 AMIGO1
 AMIGO3 AMICA1 CADM3 NLGN1 CADM1 CD209 TMEM8B ITGBL1 CTNNB1 ITGB8 ITGBL1 C17orf57
 SNED1 CTNNB1 BCL2L11 ITGB6 ITGB1 RHOA ITGB1 ITGA6 EPDR1 RAPH1 EDA NPNT
 EPDR1 CTNNB1 ITGB1 CTNNB1 ITGB2 MUC4 BCL2L11 NPNT CTNNB1 MUC4 ITGB6 PXN
 ITGBL1 ITGB2 ITGB7 PXN ITGB7 ITGB7 PXN ITGB6 ITGB1BP1 BCL2L11 SGCE
 PPFIA2 TECTA ITGA10 ECM2 ITGBL1 AGT COL3A1 VTN ITGB3 ITGB2 ITGB1 ITGAV
 ITGA2B NID1 CD44 ITGB4 ITGA2 ITGB5 VCL ITGB6 COL5A3 ITGA3 ITGB7 ITGB8
 HOXD3 CTNNB1 PXN THBS3 BCAM ITGA8 ITGA1 RHOA RAC1 PKD1 CDK5 CNTN2
 PPFIA1 ITGAD ILK ADAM9 ADAM15 ITGA7 NID2 FREM1 COL13A1 RAPH1 ADAMTS13
 SNED1 TSC1 EDA DEFB118 MUC4 SORBS1 JAM3 SIGLEC1 PARVG FBLN5 ITGA11 EPDR1
 COL17A1 TNN HPSE C22orf28 ANGPTL3 FXC1 LYVE1 CUZD1 EPB41L5 TNFRSF12A
 COL11A2 COL11A2 SSPO LAMB4 CDHR4 CNTNAP3 TMEM8B TSPEAR COL27A1 HSPB11 STAB2
 COL11A2 HSPB11 SIGLEC16 NLGN4Y COL6A6 CDH8 CELSR1 ITGB2 TSPEAR CDH2 ITGB2
 COL6A5 PCDH15 SPP1 MADCAM1 ITGA10 ITGBL1 SCARB1 ITGA3 PCDHB12 PCDH8
 CD34 ITGB8 CDH18 NLGN4Y COMP B4GALT1 NINJ2 PCDHB14 ITGBL1 THBS3 PCDHB11
 VCL C17orf57 CD34 NR2C2AP ITGAV SCARB1 ITGAL ITGA3 CTNNA1 NCAM1 CD44
 HAPLN2 DDR1 CDH12 DDR1 NCAM2 ITGA2B EMB PCDH15 SCARB1 DDR1 CTNNA2 TGFBI
 COL11A2 CDHR5 PCDH15 CDH2 COL11A2 ITGB6 C9JA99 CELSR1 LMLN PTK2B PCDH15 TSPEAR
 ITGB1 ITGA6 COL12A1 COL11A1 RHOA ITGB1 CDH13 SPP1 NLGN3 SPP1 D6RA20 PCDH1
 SPON2 PCDH1 HAPLN1 TGFBI SPON2 SCARB2 CDH18 SPON2 CDH6 COL12A1 DDR1 VCAN
 PCDH18 SPON2 CDH18 CDH10 CNTNAP3 CTNNA1 ITGB2 PTK2B CTNNA1 ITGB2 PTK2B
 CDH17 PTK2B PCDH15 SCARB2 PCDH15 ITGA2 ACAN COL11A2 CDH24 COL11A2 CDH17 CDHR1
 DDR1 COL11A2 DDR1 ACAN ITGA4 CD44 DDR1 CDH5 DDR1 PCDHB13 PCDH15
 ITGB1 PCDH15 CDH23 ITGB1 CD36 THBS4 ITGA4 ITGA2 COL11A2 DCBLD2 COL11A2 CD36
 DDR1 ITGB1 CPXM2 DDR1 CDH23 DDR1 CD36 PCDH11X DDR1 ITGB2 CD36
 ITGAV CD36 NRP1 ACAN CNTNAP3B PCDH19 ITGA2 COL11A2 DCHS2 CD36 PCDH10
 COL11A1 DCBLD1 FAT2 CNTNAP4 ITGA9 COL11A2 ITGB6 NRP1 CDH23 VCAN NRP2
 COMP CNTNAP4 DCHS2 PCDHB13 COL20A1 NRP1 CD36 CD44 NCAM1 ITGB1
 CD36 FAT3 ITGB1 CDON CDHR1 CTNNA3 CNTNAP3B CNTNAP3 PCDH7 CTNNA1
 ITGA10 CDH4 CDH1 COL18A1 COL21A1 MFGE8 ITGBL1 ITGA11 CADM1 ITGB2 CNTNAP4
 CDH16 ITGA11 COL15A1 NRP2 CDH19 MADCAM1 CDH13 CDH11 NRP2 NINJ2 PCDH1
 ITGA10 LAMC2 PCDHB6 CD4 PCDHB12 TYRO3 SCARB1 THBS3 MADCAM1 SCARB1
 VCL DCHS2 NELL2 MADCAM1 CDH7 CDH13 CDH5 NELL1 ITGB7 MFGE8 VCL
 CDH13 FAT3 ITGA8 CDH1 CADM1 NRP1 CTNNA1 ITGB7 ITGB7 NELL2 TSPEAR DSC2
 CTNNA1 SCARB1 LMLN ITGB6 ROBO2 NINJ2 LMLN COL18A1 COL24A1 ARVCF CHL1 ISLR
 BAI1 PTPRT ASTN1 NCAN NRP1 PCDH17 CASK PDZD2 INPPL1 SIGLEC5 NCAM2 RS1
 FLRT2 ADAM12 EFS TGFB1I1 MTSS1 CHST10 PSTPIP1 SIGLEC6 EDIL3 PCDH7 SUSD5 PCDHGA12
 NRP2 DSCAM PLXNC1 MPZL2 NPHS1 SORBS3 LPXN CTNND1 SDC3 ADAM23 CDH16 LRRN2
 CLDN11 ITGA10 WISP2 CNTN5 NFASC CLSTN1 PCDH8 CD44 WISP1 CLDN1 ITGBL1 F8
 ADA CD4 FN1 AMBP BGLAP VTN VWF APP ITGB3 ITGB2 ICAM1 ITGB1
 ITGAV GP1BA LAMB1 THBS1 ITGA2B ITGA5 RPSA FREM3 SPP1 PTPRF HAPLN1 LAMC1
 ITGAM COL11A1 COL6A1 COL6A3 F5 GP1BB CCL4 CCL2 NCAM1 VCAN ITGA4 COL11A2
 SELL CD99 NID1 GP9 B4GALT1 SELP ACAN ITGB4 PECAM1 SELE FER ATP2A2
 CD36 ITGA2 ENG ITGB5 VCL ITGB6 CDH2 CD58 VCAM1 CD33 CD22 ITGAL
 ITGAX COL9A1 COL5A1 MAG KITLG EPHA1 IBSP CD72 CD9 TNXB CDH3 NME2
 ITGA6 KAL1 OMG PRPH2 IL32 TNC APC FPR2 COL5A3 ITGA3 ITGB7 ITGB8
DPP4 COL8A1 PTPRM CTGF EPHA2 EPHA3 CD6 L1CAM CCR1 DSG3 CDH5 CTNNA1




MCAM CXCL12 CD151 CD97 PXN CX3CR1 CXCR3 THBS3 COMP ENTPD1 BCAM RAB13
 CCL11 CCR3 CCR8 APLP1 BMX PRKX EFNB2 EPHB4 EPHA4 SLURP1 MFAP4 MLLT4
 LAMB2 CDH4 CDH6 CDH8 CDH11 CDH15 ITGA1 LGALS4 BCAR1 NRXN1 NRXN2 IL2
 RHOA RND3 ARF6 RHOB RAC1 CXADR SIRPA CNTNAP1 CLDN10 OLR1 RELN
 ADAM17 SRPX TNFAIP6 MUC5AC DGCR2 HSPG2 EFNB1 MYBPC1 COL4A3 CNTN2 COL7A1 APBA1
 DSC2 DST ROM1 CD164 TYRO3 COL16A1 DPT PCDH1 DDR1 LGALS3BP MFGE8
 DSC1 SPOCK1 CD47 SIGLEC14 TROAP TRO CNTN1 CDH17 AIMP1 ARHGAP5
 MMRN1 MYBPH PTK7 PTPRS ITGB3BP MSLN ADAM15 LSAMP MADCAM1 SEMA5A CDH18
 TPBG ITGA7 ALCAM LAMB3 LAMC2 ITGA9 PKP1 BYSL COL4A6 SCARB2 NID2 DSG2
 DGCR6 SCARF1 LY6D SELPLG EMR1 FLOT2 F8B PTK2B MYBPC2 HES1 NEDD9 FAT1
 HABP2 DSC3 SSPN MYBPC3 GPNMB OPCML COL19A1 HEPACAM POSTN PGM5 PVRL1
 PTPRK CDSN TRIP6 CD226 ZYX IGFBP7 MOG DDR2 AOC3 COL24A1 THBS3 COL28A1
 opn CDON SVEP1 FBLN7 SDK2 IGSF11 FREM1 CD34 NRP1 COL11A2 FREM2 HAPLN2
 CERCAM HES5 TLN1 THEMIS2 PCDH9 DKFZp686I11137 RGMB EMB KIRREL2 MPZL3 OLFM4
 AMTN NPNT FAT4 PCDHJ DCHS2 CDHR3 MAEA NEGR1 SDK1 COL11A2 AMIGO2 DSG4
 CUZD1 HAPLN4 FERMT3 CD44 VCAN PPFIBP1 AMIGO1 AMIGO3 NR2C2AP AMICA1 AEBP1
 EGFL6 CNTN4 CDH26 IZUMO1 COL27A1 NLGN4X CADM3 CTNNA1 NLGN1 AGGF1 CPXM2 PCDH20
 DCBLD1 CHST4 BVES COL22A1 NLGN4Y CADM4 PCDH19 CD99L2 SPACA4 FAT3 SCARB1 TSPEAR
 FBLIM1 STAB2 MUC16 CNTNAP5 PVRL2 PTPRU TNR SYMPK NELL1 HAS1 SEMA4D
 NEO1 NINJ1 LPP FERMT2 PERP VMP1 SCARF2 BCAN ITGAL JUB RADIL CDHR1
 DCHS1 hucep-12 MEGF10 MSLNL LMLN CDH19 SIGLEC10 CNTNAP3B PVRL4
 COL21A1 DCBLD2 SIGLEC12 BTBD9 PCDH15 MAGI1 SIGLEC11 ERBB2IP HAPLN3 CPXM1
 PCDHB17 PCDHB18 CSF3R MUC4 AMELX NELL2 PKP4 CGREF1 FEZ1 COL12A1
 CIB1 ADAM2 OMD FERMT1 CLSTN3 LRFN3 SPON2 BOC JAM3 EMILIN2 CADM1 CDHR2
 CNTNAP3 PCDH11X PCDH11Y CNTNAP4 HAPLN2 PCDHAC1 CDH23
 PNN TTYH1 CLSTN2 CDHR5 LY9 PARVG PARVB PCDH9 MUC5B SPON1 PCDH18 TMEM8A
 CELSR2 NRXN3 CD209 AMBN TNFRSF12A PCDH12 SLAMF7 CASS4 PCDHB16 PARVA
 STAB1 AATF CELSR1 CELSR3 FAT2 SIGLEC8 PODXL2 NLGN3 NINJ2 FLRT3 FLRT1 NTM
 SIRPG COL20A1 CNTN3 PCDH10 NRXN2 CTNNAL1 FBLN5 CFDP1 CD300A CNTNAP2
 EMR2 CD84 CDH1 CDH22 LEF1 TINAG AJAP1 ITGA11 NRXN1 CLEC4A PCDHB8 PCDHB10
 PCDHGC3 PCDHGB4 PCDHA7 PCDHA6 PCDHA4 PCDHA12 CNTN6 CTNND2 CLCA2
 GNE HPSE SIGLEC7 SSX2IP SIGLEC9 PKP3 TLN1 NRXN3 TLN2 LOXL2 HSPB11 PCDHB9
 PCDHB7 PCDHB6 PCDHB5 PCDHB4 PCDHB3 PCDHB2 PCDHB15 PCDHB14 PCDHB13
 PCDHB12 PCDHB11 PCDHB1 PCDHGC5 PCDHGC4 PCDHGB7 PCDHGB6
 PCDHGB5 PCDHGB3 PCDHGB2 PCDHGB1 PCDHGA9 PCDHGA8
 PCDHGA7 PCDHGA6 PCDHGA5 PCDHGA4 PCDHGA3 PCDHGA2
 PCDHGA11 PCDHGA10 PCDHGA1 PCDHA9 PCDHA8 PCDHA5 PCDHA3 PCDHA2 PCDHA13
 PCDHA11 PCDHA10 PCDHA1 PCDHAC2 LYVE1 F11R NPTN EMILIN1 LAMC3
 ROBO1 MADCAM1 IL1RN ADIPOQ VTN CDHR4 CDH26 CDH8 CELSR1 CDH2 PCDH15
 PCDHB12 PCDH8 CDH18 PCDHB14 PCDHB11 CDH5 CLSTN1 CDH12 PCDH15
 CDH2 PIK3CB CDHR5 PCDH15 CDH2 C9JA99 CELSR1 PCDH15 CDH2 PIK3CB CDHR3 CDH13
 PIK3CB D6RA20 FAT1 CDH18 CDH6 PCDH18 CDH18 CDH10 CDH17 CDH24 CDH17 CDHR1
 L1CAM CDH5 CDH9 PCDHB13 PCDH15 CDHR3 PCDH15 PCDH11X PCDH19 DCHS2
 PCDH10 FAT2 CDHR3 CDH23 DCHS2 L1CAM PCDHB13 FAT3 CDHR1 PCDH7 CDH4
 CDH1 CDH3 CADM1 CDHR3 L1CAM CLSTN3 CDH16 CDH19 CDH13 CDH11 PCDH1 PCDHB6
 PCDHB12 DCHS2 CDH7 CDH13 CDH5 CDH11 CDH13 FAT3 CDH1 CADM1 DSC2
 CDHR3 PTPRT PCDH17 PCDH7 PCDHGA12 MPZL2 CDH16 CLSTN1 PCDH8 ITGB1 RET
 PTPRF CEACAM1 CDH2 CDH3 PTPRM L1CAM DSG3 CDH5 PIK3CB CDH4 CDH6
 CDH8 CDH11 CDH12 CDH13 CDH15 PKD1 DSG1 DSC2 PCDH1 DSC1 TRO CDH17
 CDH18 DSG2 FAT1 DSC3 PVRL1 FREM2 CLSTN3 PCDH9 DKFZp686I11137 FAT4 PCDHJ
 DCHS2 CDHR3 AMIGO2 DSG4 CDH24 AMIGO1 CDH26 CADM3 PCDH20 PCDH19 DSCAML1
 FAT3 PVRL2 ESAM CDHR1 DCHS1 CDH19 PCDH15 PCDHB17 PCDHB18 CLSTN3
 RET CADM1 CDHR2 PCDH11X PCDH11Y PCDHAC1 CDH19 CDH23 CLSTN2
 CDHR5 CDH20 PCDH9 ROBO2 PCDH18 CELSR2 PCDH12 PVRL3 PCDHB16 CELSR1 CELSR3
 FAT2 PCDH10 CD84 CDH1 CDH22 CDH9 CDH7 PCDHB8 PCDHB10 PCDHGC3
 PCDHGB4 PCDHA7 PCDHA6 PCDHA4 PCDHA12 PCDHB9 PCDHB7 PCDHB6 PCDHB5 PCDHB4
 PCDHB3 PCDHB2 PCDHB15 PCDHB14 PCDHB13 PCDHB12 PCDHB11
 PCDHB1 PCDHGC5 PCDHGC4 PCDHGB7 PCDHGB6 PCDHGB5 PCDHGB3
 PCDHGB2 PCDHGB1 PCDHGA9 PCDHGA8 PCDHGA7 PCDHGA6
 PCDHGA5 PCDHGA4 PCDHGA3 PCDHGA2 PCDHGA11 PCDHGA10
 PCDHGA1 PCDHA9 PCDHA8 PCDHA5 PCDHA3 PCDHA2 PCDHA13 PCDHA11 PCDHA10
 PCDHA1 PCDHAC2 NPTN ROBO1 CDH10 THBS1 RASA1 HOXA7 NF2 BCL6 CDKN2A
 ACER2 PLAU ILK CSF1 CCL21 CSF1 CD36 EPHA1 CCR7 UTRN GSK3B CDH13
 CDK6 ILK SFRP1 PLEKHA2 ANGPT1 APC ANGPT1 APC RHOC VAV3 PLD2 IFNG
 ERBB2 FGF1 ITGAV PRSS2 RHOC TPM1 CCL5 VAV1 VEGFA SELP ALOX12 AZU1
 TGM2 APC IL12A IL12B CCR7 ADAM8 CX3CL1 NRG1 PTPRJ LDB1 CHRD VAV3
 ITGAL ITGA6 KIF26B L1CAM SMAD7 FSTL3 ITGAL L1CAM CD47 KIF26B CITED2 SIRPG
 LEF1 TNF SELP SELE VCAM1 LEP ROCK1 SELPLG CHST4 PODXL2 ITGA4 CYR61
DNAJB6 ITGA4 VCAM1 LEF1 PLAU EFNA1 EPHA2 EPHA8 PTK2 PTPN11 TESC CLDN2




CLDN12 CLDN17 CLDN18 CLDN20 CLDN2 CLDN10 CLDN19 CLDN22 CLDN23 CLDN16 JAM3 LAMA3
 STAT5B STAT5A LAMA4 SRF LAMA2 DLL1 PPP1R12A LAMA5 CYTH3 NUAK1 CYTIP
 ROCK2 ABL1 ICAM1 GSN FES IL8 SRF S1PR1 LAMA2 LAMA1 EPHA8 PPP2R1A
 STAT5A ABL2 SOX9 STAT5B PRKX PPP1CB PPP2CA PTPRJ ROCK1 IL18 CYTH1 LAMA4
 LAMA3 FAF1 GSN LAMA3 CYTH2 SERPINI1 CYTH4 FAF1 WNT4 EFNA5 EPHB3 WNT4
 ADAM8 EPHA7 NRARP MINK1 CELSR2 LEF1 SMOC2 VIT FBLN2 PRKCE COL8A1 ITGA6
 NDNF NPNT NDNF EGFLAM RELL2 COL8A1 NPNT CYR61 EDIL3 JAK2 ECM2 VTN
 ITGB1 SPP1 NID1 COL8A1 ARL2 PRKCE FOXF1 VWC2 HSD17B12 ECM2 CCDC80
 ABI3BP RELL2 NDNF EMILIN1 LGALS1 JUB THY1 TESK2 LAMA5 THY1 BCL2 ACTN1
 ACTN2 ACTN3 PTK2B PTPRK TRIP6 JUB DLC1 TESK2 SORBS1 TAOK2 TNFSF11 CCL5
 SNAI2 SERPINE1 PDE3B ACER2 GAS6 GAS6 PPARD SMAD6 SORBS3 VWF CORO1A
 PRKX EPHB1 PPARD JUB CDH17 CDH2 CDH13 NRXN1 ATP2C1 DSG1 CDH17 NLGN1
 JUB DCHS1 CDH23 CDHR5 PCDHB16 PCDHB10 PCDHGC3 PCDHGB4
 PCDHB9 PCDHB7 PCDHB6 PCDHB5 PCDHB4 PCDHB3 PCDHB2 PCDHB14 PCDHB13 PCDHB11
 ARHGAP6 THBS1 ACVRL1 MMP14 PTEN ATP5B FOXA1 WNT3A FOXA2 MAP2K1 ZNF703
 SERPINE1 ITGB1 ITGA5 L1CAM ADAM9 PKD1 ANGPT2 FZD7 PLG COL1A1 WNT1
 LGALS1 NOTCH1 TBCD FZD4 FXYD5 NCKAP1L CCL21 NCKAP1L ADAM9 SFRP2 FOXC2 STXBP3
 PLEK GATA1 PDGFRA WNT3A STXBP1 FERMT3 VCL CLDN19 FBF1 TRPV4 GJA4 GJA5
 GJC1 LIM2 DSG1 TJP1 HDAC7 PARD6B TRPV4 TLN1 TLN2 ITGA5 ITGA6 TNS1
 TLN1 SIRPB1 FYB TYROBP CTNND1 SKAP2 CLDN9 CLDN14 KRT14 ITGB1 ACTN1 CDH1
 SRC KRT5 JUP PVR ITGB4 CDH2 FLNA CDH3 ITGA6 PTPN6 CDH5 CTNNA1
 SFTPD PRKCI LIMS1 CD151 PXN VASP MLLT4 CDH4 CDH6 CDH8 CDH11 CDH12
 CDH13 CDH15 CLDN15 CLDN12 CLDN17 CLDN18 CLDN20 ACTB GRB2 ACTG1 SIRPA PTPN11
 CD47 ILK CDH18 LAMB3 LAMC2 PTK2B FLNC ARHGEF6 PLEC PVRL1 RSU1
 TESK1 LAMA3 LIMS2 CDH24 SFTPA2 SFTPA1 CADM3 CADM2 MPP5 CLDN22 INADL PARD3
 FBLIM1 PVRL2 FERMT2 CLDN23 PVRL4 CRB3 CADM1 PARD6G PARD6B PARVB PARD6A PVRL3
 PARVA SIRPG CDH9 CDH7 COL17A1 F11R CDH10 MPZ NLGN2 PARD6A CCM2 CTNND1
 CLDN9 CLDN14 TGFB1 TGFB3 CDH1 JUP PVR CDH2 CDH3 CDH5 CTNNA1 NF2
 HNF4A MLLT4 CDH4 CDH6 CDH8 CDH11 CDH12 CDH13 CDH15 CLDN15 CLDN12 CLDN17
 CLDN18 CLDN20 ACTB TGFB2 ACTG1 CXADR SMAD3 CDH18 PVRL1 CDH24 NLGN4X CADM3
 CADM2 MPP5 CLDN22 INADL PARD3 PVRL2 CLDN23 PVRL4 CRB3 CADM1 PARD6G PARD6B
 PARD6A PVRL3 CDH9 CDH7 HEG1 F11R CDH10 ROCK2 EPHA3 EFNA5 ROCK1 MACF1
 GJB1 GJB2 CTNNA1 GJC1 GJD3 CTNNA1 JUB THY1 TESK2 LAMA5 THY1 BCL2
 ACTN1 ACTN2 ACTN3 PTK2B PTPRK TRIP6 JUB DLC1 TESK2 SORBS1 TAOK2 PLEKHA7
 KIFC3 CAMSAP3 SDC4 SDC4 KDR SMAD3 PTPRJ SFRP1 TSC1 EPB41L5 KRT14
 LAMC1 KRT5 ITGA6 CD151 DST LAMB3 LAMC2 LAMA3 ARHGAP6 THBS1 ACVRL1
 MMP14 PTEN CTNND1 CDH1 JUP PVR DSP CDH2 CDH3 CDH5 CTNNA1 MLLT4
 CDH4 CDH6 CDH8 CDH11 CDH12 CDH13 CDH15 ACTB ACTG1 CDH18 PVRL1 CDC42
 CDH24 CADM3 CADM2 PVRL2 PVRL4 CADM1 PVRL3 CDH9 CDH7 CDH10 NUMBL STRN
 CLDN9 CLDN14 WNT11 ITGB1 CDH1 APC ARL2 PRKCI CLDN15 CLDN12 CLDN17 CLDN18
 CLDN20 DLG1 MPP7 FRMPD2 MTDH MPP5 CLDN22 INADL CLDN23 TBCD CRB3 PARD6G
 PARD6B ECT2 PARD6A F11R SMAD7 VCL TBCD ZNF703 GNPAT CD9 CNTNAP1
 AKT2 AKT2 CBLL1 MAPK1 ILK RRAS2 SMAD3 PLD1 AKT2 CBLL1 PTK2B APC
 PIK3R1 PTK2B AKT2 PIK3R1 ERBB4 APC CSF1 ITGB1 RRAS2 RHOC ITGB1 C3AR1
 SMAD3 FLT1 JAK2 PDPN MYO1F CCL24 PODXL CYR61 ADAM10 PLD2 SNAI2 CREB3
 SPAG9 FGFR1OP ONECUT2 WNT11 EGFR F10 PDGFB INS COL1A1 CXCL10
 FGF1 EDN1 ITGB1 INSR ITGAV LAMB1 IGF1R RHOC F7 ADRA2A VIL1 CSF1
 PDGFRB FGR FURIN BMP2 TDGF1 F3 PDGFRA FER FLT1 S1PR1 EPHA1 DRD1
 APC F2R MAPK1 CORO1A AKT2 IRS1 CCR2 CCL11 AIF1 F2RL1 CDH13 BCAR1
 RRAS2 GNB2L1 ADAM8 CX3CL1 ADAM17 SMAD3 ROR2 MAP2K1 FOXF1 TRIM32 PLD1 ILK
 PTK2B ERBB4 TRIP6 C3AR1 CXCL12 DKFZp686D0662 CBLL1 PDPN SYNE2 PTP4A1 HBEGF
 WNT5B CXCL16 ZNF703 SPHK1 ONECUT1 SUN2 AIF1 CCL26 IRS2 ANGPTL3
 VEGFA MESP2 MESP1 TGFBR1 PPAP2A PPAP2B TGFB1 HMGCR ITGB1 TGFBR1 CXADR FOXC1
 CXCL12 CCR2 BMPER CCL5 PECAM1 SAA1 CCL2 CCL5 XCL1 ADAM8 CX3CL1 CXCL16
 CKLF CCL2 GIPC1 PLEKHG5 GIPC1 TNFSF12 CALCA SCG2 S100P DPP4 S100A2
 NOS3 PRSS3 PRKX CDH13 PTEN FAP CYP1B1 TRY6 GPR124 HIF1A ACVR1 NRP2
 ACVR1 ACVR1 ISL1 ACVR1 LAMA5 TBX1 ZEB2 NRP2 FOXD2 FGF19 RET EDN3
 KITLG EDNRB GDNF HTR2B GBX2 SOX8 ISL1 EFNB1 ACVR1 FOXD4 SEMA3F SHH
 HIF1A FOXD1 FOXD4L6 FOXD4L5 FOXD4L4 NRTN SMO SEMA3C OVOL2 FOXD4L1 LEF1 FOXD3
 PAX3 FOXD4L2 AXL TYRO3 MPP1 NOD2 MPP1 JAM3 NOD2 MYH10 SDCBP OPHN1
 MYH10 CD2AP FUT7 RELN ARX LHX6 NRP1 HSPB1 NR4A1 EGR3 PRKD1 PRKD2
 PDGFRB C3AR1 THBS1 CCL2 CCL5 CX3CL1 C3AR1 CMKLR1 RARRES2 MACF1 SLIT2 TNF
 SELP SELE VCAM1 LEP ROCK1 SELPLG CHST4 PODXL2 DRD2 DRD1 CNTN2 DRD2
 ARX LHX6 NR2E1 TSPO AZU1 TSPO TGFB2 NDN NR2E1 MMP9 FGF7 ADAM9
 HBEGF CXCL12 TNR FOXB1 B4GALT1 CD34 ITGA6 AIMP1 PIK3R2 PODXL ANGPT2 SLC16A3
 CCL25 DOK2 SLC16A8 F2 NRAS HRAS KRAS IL1B COL1A1 FN1 MMP1 PROC
 APOB ATP1B1 ITGB3 ITGB2 ICAM1 ITGB1 LCK FYN CD2 ITGAV THBD PROS1
 YES1 LYN COL1A2 SLC3A2 ELANE ITGA5 DBH CD48 ITGAM SRC ITGA4 SELL
ATP1B2 B4GALT1 SELP SPN PECAM1 PLCG1 CD58 ITGAL ITGAX MAG ITGA6 ITGA3




ATP1B3 F2RL1 JAM2 PPIA GRB2 CXADR SIRPA OLR1 SLC7A9 SLC7A5 TEK CAV1
 PTPN11 SOS1 CD47 MERTK AIMP1 PPIL2 ROCK1 SELPLG GAS6 GRB14 GRB7 ANGPT1
 AMICA1 CD177 NKX2-3 SLC7A6 INPP5D ESAM JAM3 CD244 GP6 TREM1 SLC7A10 SIRPG
 SLC7A8 CD84 SLC7A7 SLC7A11 ANGPT4 F11R NANOS1 FAT2 GREM1 SLIT2 S100A7 S100A14
 ILK SLIT2 SERPINE1 IGFBP3 IGFBP5 LRP1 ILK ADIPOQ TRIB1 ANGPT2 TGFB1
 APOE THBS1 FGF2 AGTR2 VASH1 DLL4 GDF2 ANGPT4 VEGFA SELP SELE ZP3
 BDKRB1 ADAM8 MADCAM1 MIA3 SLIT2 PDGFRB HGF HOXB9 ENG HMGB2 AGTR1
 ARRB2 EPHB1 ITGA1 BCAR1 RHOG ARHGEF16 DOCK4 ELMO2 LEF1 ARX SLIT1
 SLIT3 SLIT2 THBS4 SIX1 SIX4 LBP SLIT2 ROBO1 RTN4 RTN4 PDGFB PDGFA
 PDGFRB C5 SELE ADAM8 JAM3 JUB LAMA3 AKT1 GAB1 LAMA4 GNA13 LAMA2
 LAMA5 UNC5C NTN1 TGFB1 LMNA SERPINE2 EDN3 LAMA2 LAMA1 AKT2 PRKX
 SST RHOA TMSB4X RAC1 JAG1 CDK5 NEXN MAP3K1 ENPP2 GNA13 LAMA4 LAMA3
 AMOT WDR44 LAMA3 MINK1 ROBO4 JUB PARD6B SRCIN1 RTN4 TBCCD1 ABI3 JAG2
 CCL21 FIGF CCL5 VEGFA VEGFB VEGFC XCL1 TNFSF11 PDGFB CALCA IL6 IL6R
 CCL2 FLT1 TNFRSF11A CCR2 RPS6KB1 NRP1 VTN IGF1 BCL2 CCL5 F3
 RPS6KB1 IL6ST P2RY2 RAPGEF4 HIST1H2BA EFNA1 NF1 EPHA2 ACVRL1 KRIT1 SLIT2
 BMP10 APOH THBS1 NR2F2 PTPRM ACVRL1 GDF2 SELP ROBO4 ABHD6 ABHD6 ACAN
 TIE1 THY1 SRF ABR SLC9A3R1 SMAD7 ALOX15B BMP10 WNT11 PDGFB THY1
 SERPINE1 ABHD2 TPM1 RAP2A RRAS BCL2 BCR SRF DRD2 VCL NF1
 EPHA1 DRD1 DRD5 IGFBP5 NF2 TIE1 ACVRL1 NKX2-1 CX3CR1 PTEN RAP2B ARAP3
 PTPRJ ABR NOG DAG1 PTPRK SHH ADIPOQ MIA3 RNF20 DRD2 PODN SFRP1
 SCAI ARAP3 ROBO4 SFRP2 CNN2 TBX5 CITED2 ABHD6 GTPBP4 CHRD TIE1 EGFL7
 NISCH RAP2C CLIC4 STK24 PLCB1 AZU1 ATP5B CCR7 CCL19 MESP1 PLXNA2 ADAM10
 CXCL13 S100A7 WNT5A CCR2 XCL1 ADAM17 MESP1 HDAC5 C5 ZAP70 WNT7A CX3CL1
 MCC SEMA3A DAB2IP NUP85 NUP85 SAA1 CCL2 CCL5 AZU1 EDN2 EDNRB SFTPD
 CX3CR1 NUP85 CKLF PPARD KRT2 PPARD KPG_004 FERMT1 AMOT FOXH1 CER1 AMOT
 NODAL WNT8A WNT5B MIXL1 SERPINE1 S100A7 CCR2 CXCL12 PLA2G7 S100A14 CCR3
 CCL11 PIP5K1A ZFAND5 SGPL1 ARID5B PIP5K1A TNS1 SCHIP1 CUZD1 EPB41L5 TNFRSF12A
 OGDH SLIT1 OGDH LRRK2 GAS6 TOP2B MET NR2F2 APBB2 PTK2 PEX5 PAFAH1B1
 NR4A2 FEZF1 DRGX CHL1 NR4A2 FZD3 FYN PTK2 FYN PTK2 FYN PTK2
 MYH10 PSEN1 DCX GAS6 TOP2B APBB2 ROBO3 PEX5 PEX7 DCX TLX3 GFRA3
 KATNA1 CDKL5 NTN1 CCK NR2F1 FGFR1 GJA1 NR2F2 ITGA3 AXL CCKAR MYH10
 NR4A2 NKX2-1 LHX1 PSEN1 MNX1 ASCL1 CCR4 YWHAE RELN CDK5 CNTN2 ALKBH1
 PRKG1 CDK5R1 TWIST1 NTRK3 VAX1 BARHL1 KIAA0319 NR4A2 MARK2 NAV1 MDGA1
 DNER NDNF DYX1C1 ESR2 NRCAM ATOH1 PEX13 ROBO3 ARX PHOX2B NDN TUBB2B
 BARHL1 NDEL1 NEUROG2 CELSR2 NEUROD4 DISC1 BARHL2 CELSR1 CELSR3 MARK1
 SATB2 FEZF1 CXCL12 CXCL13 TBX5 FMNL1 PDGFB EPHA8 VEGFC ANKS1A PDGFB TGFB1
 THBS1 PRKCA PLCG1 AKT1 VEGFC ANGPT1 ANGPT4 PRKDC KIT KITLG PRKDC ICAM1
 ADAM8 CYR61 GATA3 TBX21 IL8 CSF3R IFNG IL1B SAA1 PLA2G1B ITGB2 EDN1
 IL8 CCL2 EDN3 CXCL3 EDN2 C5AR1 CXCR2 FCER1G SYK XCL1 NCKAP1L CXADR
 CX3CL1 AMICA1 CKLF CCR2 WASF2 CXCL12 LEF1 SLIT2 AGER TGFB1 THBS1 AGER
 IL33 ADA HMOX1 ADORA1 HOXA7 CAMK1D POU3F2 CDK5R1 DIXDC1 NDEL1 LHX6 FSCN1
 RPS6KB1 NCK1 CDH2 FSCN1 CDH2 FSCN1 TNS3 NCK1 TNS3 NCK1 CTHRC1 ITGA4
 NCK2 CLASP2 BCAR1 LAMB1 NCK2 ASTN1 VAV3 GSK3A BCAR1 PODXL ASTN1 ITGB1BP1
 NRP1 LAMA5 PLXNB1 NCK2 NRD1 PROP1 PRPF40A PAK4 FN1 ANG ITGB1 CDK1
 THBS1 LAMC1 FGFR1 PSG2 CEACAM1 JUP PVR NCK1 ENG FLT1 CDH2
 HOXA5 EFNA1 COL5A1 FGFR4 RPS6KB1 APC CD24 EPHA3 IL12A IL12B BDKRB1 GSK3A
 VAV2 EPHB3 BCAR1 PTEN TGFB2 BTG1 TGFBR3 ENPEP BAMBI PTK7 FOXE3 DGKZ
 CUL3 SHROOM2 TNFAIP1 SCRIB DOCK1 HES1 FAT1 PTPRK FSCN1 GAB4 CCDC88A
 PAX3 CDC42BPA LRRC16A TNS3 ARC SRGAP1 FMNL3 WWC1 PARP9 SCYL3 RASGEF1A
 USP33 NANOS1 KCTD13 MYO18A TMEM18 SH3KBP1 RHBDF1 CTHRC1 NODAL PPP1R9B PIP5K1A FUT8
 PEAK1 ABI2 PAK7 ZRANB1 LIMD1 VAV3 TAOK2 FAM40B TNN CDC42BPB NOX1
 ITGB3 AAMP NRP1 NRP2 AGT ITGB3 EDN1 THBS1 ANXA3 BMP4 VEGFA ALOX12
 GATA3 FLT4 KDR AAMP BMPR2 ANGPT1 SCARB1 PROX1 FOXC2 ANGPT4 APOA1 HSPB1
 GPX1 MYH9 SOX18 VHL ID1 PTK2B SCARB1 PEX5 EGFR PSEN1 EGFR EGFR
 NKX2-1 CX3CR1 PSEN1 PEX13 CCR3 CCL5 SCG2 CCL11 FOXB1 CXCL10 IL6 F7
 EDN3 EDN2 XCL1 F2RL1 ADAM17 XCL1 CCL2 CCR2 MMP14 DVL2 POU4F1 FOXB1
 CCL21 HMGB1 CCL5 CXCR1 CXCR2 CCR1 CCR7 CCR2 CCR5 CCR6 CXCR4 TRPM4
 CCL19 SRPX2 PTGS2 HDAC7 FOXC2 HDAC9 SRF SLIT2 ITGB1 SRF VEGFA NR4A1
 EFNB2 EPHB4 EGR3 ROBO1 HIF1A FGF10 CTSH FGF10 VIL1 CTSH PLCG1 TAC1
 TACR1 SOX9 TGFB2 BMPR2 HIF1A EPB41L5 HDAC6 NR2E1 CDK5 LRP8 NR2E1 XCL1
 NCKAP1L EDNRA C3AR1 CCL21 CD74 EDN1 IL8 LBP EDNRA CCR7 THBS4 XCL1
 NCKAP1L TIRAP C3AR1 CAMK1D CCL19 IL23A PF4 S100A9 IL10 CORO1A CX3CL1 IL16
 MT-RNR2 LYST SBDS STK10 MSN MET CCR7 JUB ITGA5 COL5A1 MSX2 ACVRL1
 MMP12 SCNN1B SCNN1G ADAM17 JUB HBEGF PLAU PDGFA ACE HDAC5 ANXA2P2 PLCD1
 SHC1 ANGPT1 POFUT1 PTK2 HIF1A MEIS1 FGFR1 RTN4 EPAS1 SCG2 C1GALT1
 PTK2B SCG2 UBP1 C1GALT1 UBP1 FGF10 ANGPT1 PTK2B PTK2B PTK2 PTK2B
 PKNOX1 MAPK14 MEIS1 THY1 FGFR1 MEIS1 EREG LAMA5 FGF10 MAP3K7 HOXA3 TBX1
FIGF HS6ST1 FZD6 NRP2 GREM1 SRPX2 FGF18 HAND1 PLAU EGF TGFA COL4A1




ITGA5 HMOX1 IL8 FGF6 BMP4 CCL2 SCG2 CEACAM1 HOXB3 ANPEP VEGFA
 NCL TYMP S1PR1 SAT1 FGFR2 PTPRB COL8A2 COL8A1 EPHB2 SHC1 S100A7 HOXA7
 FGF9 MYH9 SOX18 KDR GJA5 ACVRL1 COL15A1 VHL ID1 ELK3 PIK3CA PGF
 VEGFC MEOX2 MMP14 PRKX VAV2 EFNB2 EPHB3 EPHB4 EPHB1 PKNOX1 TBX4 PTEN
 HAND2 TGFB2 ADAM8 SRPK2 JAG1 HSPG2 TEK TNFAIP2 ENPEP MFGE8 AIMP1 ADAM15
 FZD5 AAMP KLF5 IL18 VEZF1 PTK2B CASP8 SHB TGFBI MED1 CYP1B1 DICER1
 CSPG4 EPGN CXCL17 ARHGAP22 TMPRSS6 PLXDC1 PNPLA6 ARHGAP24 PLCD3 STAB2
 ROBO4 NRCAM HOXB13 NUS1 APOLD1 MMP19 EPAS1 OVOL2 PDCD10 JAM3 NAA15 WNT5B
 POFUT1 SOX17 PROK2 NRXN3 SH2D2A TNFRSF12A ESM1 RTN4 DLL4 C1GALT1
 ERAP1 UBP1 EGFL7 SLC12A6 ATPIF1 VAV3 DICER1 HEY1 NOX1 WASF2 NRXN1 ZC3H12A
 ANGPTL6 KLF5 ECSCR SERPINE1 FOXO6 BAI2 BAI3 TIE1 LECT1 KRIT1
 BAI1 ANGPT2 BAI2 BAI3 ROCK2 LECT1 APOH PF4 CXCL10 HRG KLK3 COL4A2
 CCL2 LIF NPR1 NPPB HOXA5 NF1 PTPRM PML THBS2 THBS4 TIE1 SERPINF1
 CCR2 FASLG CX3CR1 GTF2I FOXO4 HHEX CRHR2 ROCK1 AMOT THBS2 VASH1 IL17F
 TNMD TIE1 SPINK5 STAB1 GHRL MEG3 GDF2 ANGPT4 B4GALT1 ITGB3 GPX1 SRF
 B4GALT1 CX3CL1 DKFZp686D0662 SRPX2 PTGS2 HDAC7 FOXC2 HDAC9 TNFAIP3 SRF SLIT2
 ITGB1 SRF VEGFA NR4A1 EFNB2 EPHB4 EGR3 ROBO1 MAPK7 CXCL13 TSPAN12 KRT1
 ERBB2 IL6 FGF2 HMOX1 RNH1 EFNA1 NF1 ADORA2B EPHA2 CTNNB1 ID1
 PROK1 MAPK7 SFRP1 GPR124 HTATIP2 CYR61 BMP4 ACVRL1 NRARP BMPER SEMA5A CTNNB1
 EDNRA ENG ACVR1 GNA13 FLT1 ENG SRF NRP1 FOXS1 EDN1 SRF VEGFA
 ENG FLT1 EDNRA TGFBR2 GBX2 PPP3R1 ACVR1 NFATC3 STK4 SEMA5A GNA13 IHH
 SHH NRARP SFRP2 RBM15 NOTCH4 FOXC2 LEF1 GDF2 TBX20 PLXND1 PPP3R1 CXCL12
 NR2E1 HMOX1 DDAH1 GATA2 VASH2 ERAP1 NOS3 CCR3 C3AR1 TNFRSF1A ANGPT2
 TNFSF12 DDAH1 C3 C5 IL1A IL1B SERPINE1 FGF1 FGF2 HMOX1 ANXA3
 CCL5 F3 MMP9 FLT1 PLCG1 TNFRSF1A EPHA1 GATA2 NOS3 AQP1 KDR
 WNT5A GATA4 CX3CR1 CCL11 CCR3 BTG1 RHOB CX3CL1 RUNX1 TWIST1 C3AR1 ECM1
 HIF1A DKFZp686N2176 DKFZp686D0662 ADM2 MTDH VASH2 HIPK1 AGGF1 GATA6 SFRP2
 ANGPTL4 HIPK2 SPHK1 GDF2 UTS2R ANGPT4 NR2E1 ANGPTL3 FOXC2 FLT1
 THBS1 FLT1 FLT4 NOTCH1 CDH13 JMJD6 CCBE1 GPR124 LEF1 MYLK3 CTNNBIP1
 FCER1A FCER1G PIK3CG IL6 OSM TAC1 IL6ST PIK3CG ADAM8 NPY5R OSMR CCR7
 CHRNA7 SPECC1L CALCRL ADORA2A NR1H3 ADORA2A ADORA2A NR1H3 ADORA2A
 NR1H3 CALCRL ABR ADA SERPINC1 IL2RA APOE SAA1 GBA ADRB2 ELANE
 BCR ACP5 TNFRSF1B TNFAIP3 NT5E IL10 GATA3 ZFP36 AOAH CNR2 SERPINF1
 IL2 PRKCD FOXF1 ABR NR1H3 CALCRL O3FAR1 CD276 CHRNA7 NR1H3 GHSR SELS
 NDFIP1 UACA SHARPIN GHRL P2RX1 F3 MGST3 ALOX5 ALOX5AP LTC4S MGST2 C3
 MASP1 SELS INS ANXA1 IL4 GSTP1 ADORA1 PPARG ANXA1 INS DUSP10 CD28
 F3 ANO6 PTGER3 IL1A EPHA3 TRPV1 PDE5A PDE5A CHIA FCER1G ADORA2B
 LBP LTA TNF CXCL13 VNN1 S100A8 S100A9 THBS1 VCAM1 CCL11 UNC13D CD44
 HMOX1 ELANE CCL5 IL2RA HMGB1 IL20RB PNMA1 IL25 F12 KLKB1 TNF IL1B
 CCL5 CNR1 PTGS2 PTGER3 PLA2G4A LBP AGER STAT5B IL1RL1 STAT5A EDNRA TNFRSF1A
 JAK2 TLR4 PDE2A MAPK13 TLR3 TLR2 IL33 SERPINE1 ACE PLA2G2A FABP4
 TNFRSF1A ZP3 TGM2 TNFSF4 EDNRA IL12B AGTR1 IL15 WNT5A CCR2 STAT5A
 PLA2G4A STAT5B NLRP12 IL2 CX3CL1 IL1RL1 CD47 PLA2G7 IL18 AGER IL21 IL23A
 TLR9 TLR7 C5 SELE ADAM8 JAM3 IL20RB SERPINE1 ZP3 CNR1 IL4
 FOXP3 PRDX2 TNF IL1B LYN LYN TLR4 SLC7A2 STAT5B TSC2 SAA1 SAA2
 SAAL1 TFRC PLSCR1 F8 F2 ASS1 SERPINA1 SERPINA3 INS SAA1
 CRP APCS FN1 ORM1 AHSG TFRC IL6 SERPINF2 IL6R MBL2 CEBPB
 IL1RN ORM2 SAA3P SAA4 STAT3 CEBPA TSC2 STAT5B REG3A ITIH4 ASS1 SIGIRR
 REG3G CD163 SAAL1 MRGPRX1 APOL2 IL22 B4GALT1 VNN1 APOA2 S100A8 ALOX5
 B4GALT1 VCAM1 TNFSF4 TACR1 DEFB1 ACVR1 KL IRGM C4B-1 C4A NCF1B RXRA
 BMP6 C3 IGFBP4 TNFRSF1A LAT AKT1 TP73 IL8 CCRL2 NFKBIZ TMEM23
 CD14 CD14 BMPR1B MECOM SCN9A SCN9A CD14 P2RX7 MECOM MS4A2 MAP2K3 C4B
 TNFRSF1A OLR1 TNFRSF1A PDPN C4B F8VX64 C4A CCL24 PIK3CD CCRL2
 CCL21 CCL22 CXCL11 IKBKB NCR3 KDM6B CHUK TP73 CCL25 CCL16 MEFV IRAK2
 RIPK2 LIAS CHST1 LY75 TPST1 TLR5 CRCP RPS6KA5 RPS6KA4 ATRN APOL3 IL18RAP
 VNN1 LY86 SERPINA1 SERPINA3 C3 C5 KNG1 FOS TGFB1 NGF
 TNF IFNA2 IL1A CRP ORM1 CXCL10 KLKB1 ANXA1 CYBB ITGB2 S100A8 IL5
 IL6 S100A9 CRH CD14 CXCL1 LTA4H C4A C4B PLA2G4B IL8 CCL3 SPP1
 BMP2 CCL4 CYBA CCL2 SCG2 MIF NCF1 IL9 ALOX15 SELP SELE CCL3L1
 NPPB CEBPB ITGB6 TNFRSF1A RXRA NFKB1 CXCL2 CXCL3 AZU1 TAC1 ITGAL
 BMP6 IL10 GAL IGFBP4 CXCR1 CXCR2 FPR2 TACR1 PTAFR F2R CD40 PTX3
 AOAH ADORA2A CD40LG PRDX5 BDKRB2 AXL ADORA1 CCR1 CCR7 ADORA3 EPHX2
 IL13 HRH1 CCR2 TNFRSF4 XCR1 BDKRB1 MAP2K3 PIK3CG CD97 SLC11A1 CCL11 CCR3
 CCR4 CCR5 NDST1 AIF1 F2RL1 UCN CCL23 CCL18 HDAC4 CARD18 TIRAP CXCR4
 LYZ RAC1 ADAM8 OLR1 KCNJ10 ELF3 CCL20 CCL8 CCL7 CXCL6 S100A12 TNFAIP6
 MS4A2 MECOM RELA REG3A AOX1 CXCL9 IL10RB AIMP1 NFATC3 NFX1 NMI NFE2L1
 NFATC4 AGER TLR1 LTB4R GPR68 SMAD1 IL17A CAMK4 C3AR1 AOC3 CDO1 SPHK1
 C4A DARC THEMIS2 IL23R GGT5 NFRKB C4B REG3G TRIL PXK CD163 TICAM2
PDPN EVI1 CAMK1D TICAM1 SCUBE1 AFAP1L2 CHST4 ABCF1 NFAM1 IL27 CCL4L2 NFKBID




MGLL CCL19 CLEC7A TLR10 NFKBIZ SIGLEC1 IL22 TOLLIP HRH4 CYP4F11 PROK2 MMP25
 IL1RAP NOX4 TLR8 STAB1 SPHK1 PLA2G2E IL17C IL36A TBK1 IL17B PARP4 HDAC9
 CELA1 PLA2G2D PLA2G4C HDAC5 NOD1 CCL26 PLAA CYSLTR1 TLR6 CHST2 NOX1 F11R
 IKBKG LY96 A2M SERPING1 NOD2 PSMA1 PSMB4 IL12B NOD2 SCGB1A1 RELA
 SEMA7A JAK2 SEMA7A CALCA AHSG IL4 SCGB1A1 SELE GGT1 TNFSF4 CMA1 AGTR1
 PTGS2 BCL6 XCL1 SLC7A2 PSMA6 RELA SETD6 PARK7 MGLL MYD88 ACE2 NLRP1
 NOD2 IL20 SBNO2 C3 FCER1G TNFSF11 hRANKL 3 TNFRSF11A HIF1A TGFB1
 F2R HIF1A MYLK3 CTNNBIP1 PIK3CG IL6 OSM TAC1 IL6ST PIK3CG ADAM8
 NPY5R OSMR GAS6 PROC F2RL2 TFPI KLKB1 TFPI KIAA1715 F2 DTNBP1
 AP3B1 PROC GAS6 F11 F2 EFEMP2 HPS5 AP3B1 THBD PROC F7 KIF2A
 STXBP3 AP3B1 F2RL2 LEFTY2 PDE2A PIK3R2 SH2B2 KIF3C ATP2A1 KIF3B ANGPT2 RAD51B
 SLC16A3 ABCC4 MAFG PDPK1 RAD51C LAT AKAP10 ACTN4 CALU FIGF KDM1A DOK2
 JAK2 MAFK WDR1 GUCY1B2 DGKI PDE5A PDE9A MFN2 KIF4A RASGRP1 RAPGEF3
 GNA14 SLC16A8 EFEMP2 SOD1 ABL1 CFD PLAU PLAT SERPINA1 TIMP1 NRAS
 HRAS KRAS PDGFB EGF TGFB1 IFNA1 IFNA2 IFNA10 IFNA7 IFNA21 IFNA5 IFNA14
 IFNA17 IFNB1 HBD HBE1 COL1A1 APOA1 C9 FN1 ALB PPBP PF4 TF
 MMP1 RAF1 ALDOA PDGFA APOB HRG TP53 GNAI2 IFNA6 IFNA4 IFNA16 IGF1
 ATP1B1 APP ITGB3 ITGB2 SERPINB2 SERPINE1 PRKCG SERPIND1 ITGB1
 PRKCB LCK FYN CD2 ITGAV PROS1 PSAP PFN1 YES1 LYN THBS1 COL1A2
 SLC3A2 ITGA2B PLEK ITGA5 SERPINF2 GNAI3 ANXA5 ADRA2A CD63 CD48 SPARC
 FGR SRGN MYB TGFB3 PRKAR1A CLU IRF1 HSPA5 ITGAM ACTN1 SRC
 LAMP2 ITGA4 PRKAR2A ANXA8 CD59 SELL HGF IRF2 ATP1B2 RAC2 VAV1
 VEGFA GATA1 SELP SPN PECAM1 PDE6A ATP2A2 CD36 PLCG2 PRKCA ITGA2 PRKACA
 PTPN1 ADRA2B VCL PDE6G ADRA2C PLCG1 CD58 ATP2B1 RAB5A ITGAL ITGAX C4BPB
 MAG FLNA TBXA2R CD9 PRKACG PRKACB PROZ ITGA6 CFL1 ATP2B4 DGKA GATA2
 GATA3 PRKCH CDK2 F2R ITGA3 MAPK3 PIK3R1 MAPK1 ADORA2A PTPN6 SHC1
 NOS3 NOS1 GNA11 FCER1G WEE1 GNA15 PRKAR1B PRKAR2B AKT1 L1CAM ARRB2 SLC8A1
 IFNA8 GUCY1A2 NOS2 ACTN2 BSG PDE6B GGCX THPO MPL HNF4A CSK
 PIK3CA PIK3CB WAS PTGIR SYK GATA4 CBX5 CRK PLA2G4A CAPZA2 CAPZB P2RY1
 TFPI2 PIK3CG LMAN1 ARRB1 DGKG VEGFB VEGFC ENTPD1 GNAQ RAB27A P2RX1 DGKE
 KIF11 VAV2 DGKQ CAPZA1 SLC16A1 ATP1B3 PDE1A BCAR1 JAM2 SLC8A3 GNG2 ACTB
 CDC42 RAP1B RHOA TGFB2 CALM3 TMSB4X RHOB RAP1A GNB1 PPIA GRB2 RAC1
 GNAS GNAI1 YWHAZ ACTG1 TUBA4A HIST1H3G HBB HBG1 HBG2 CXADR SIRPA
 OLR1 SLC7A9 RHOG H3F3B CDK5 PDE1B CAP1 SLC7A5 ATP2B2 GUCY1A3 GUCY1B3
 PRKCE CENPE KIF23 TEK GNA12 CAV1 PRKCQ PTK2 PRKCZ PRKCD PTPN11 KLC1
 SOS1 CD47 KCNMA1 KIF5A STX4 MERTK LCP2 MMRN1 PRKG2 PABPC4 PPIL2 PDE3B
 TRPC3 HDAC1 ITPK1 DGKZ STIM1 PRKG1 LRP8 DOCK1 SELPLG GNA13 GAS6 PDE3A
 GRB14 GRB7 ITPR2 ITPR3 ITPR1 KIF22 ANGPT1 SHH JMJD1C MAPK14 KCNMB1 NFE2
 ATP2B3 DGKD KIF4B DOCK11 HABP4 DGKK PIK3R6 LRRC16A HIST2H3A RASGRP2 APBB1IP
 KCNMB4 DGKH AMICA1 HPS6 SCUBE1 ZFPM1 KIF2B CD177 DAGLB DOCK8 KIF18A CABLES1
 ZFPM2 SCG3 PIK3R5 TTN RAPGEF4 SLC7A6 PIK3R3 AKAP1 HDAC2 INPP5D KIFAP3 HPS1
 GATA6 ATP2A3 ESAM PHF21A ORAI1 DTNBP1 DOCK6 CPB2 F2RL3 SIN3A KIF2C MGLL
 KIFC1 GATA5 JAM3 POTEKP DOCK9 CD244 LNP KLC2 RACGAP1 ZFYVE20 P2RY12
 EHD1 KIF9 GP6 PDE11A TRPC7 TREM1 KCNMB3 HPS4 F13A1 SH2B1 PLSCR4 VPS45
 SLC7A10 KIF15 EHD3 EHD2 HMG20B SIRPG SLC7A8 CD84 AK3 RCOR1 VAV3 PLDN
 BRPF3 KIF26A MAFF SLC7A7 PROCR SLC8A2 SLC7A11 HPS5 SH2B3 TRPC6 PDE10A ANGPT4
 TLN1 KIF3A DAGLA F11R KCNMB2 MRVI1 DGKB WNT7A B4GALT1 ITGB3 GPX1 SRF
 B4GALT1 CX3CL1 DKFZp686D0662 F9 F10 F7 TFPI F3 MYH10 MYH10 TRIM72
 MYOF P2RX1 MGST3 ALOX5 ALOX5AP LTC4S MGST2 MASP1 INS DUSP10 ANXA2P2 F2
 PLG PLAU PLAT HRG KRT1 SERPINB2 SERPINE1 ANXA2 GP1BA SERPINF2
 PLAUR TMPRSS6 SERPINE2 RPS6KB1 MET F2RL2 NGFR MDK CASP3 SERPINE2
 CD81 ADM CTSB CD81 CTSB CD81 MDK FGFR1OP2 F2RL2 NRP1 KLK8
 F2 TGFB1 FN1 PDGFA VWF WNT1 CYP1A1 GPX1 CTSB NGFR ABHD2 PATE4
 CLU VCAN F3 GFAP ITGB4 GAP43 MDK FGF7 ACHE RPS6KB1 TNC F2R
 PAX6 CTGF PEBP1 CCR1 ADORA3 ADM CCR2 CASP3 SLC1A3 SLC1A2 SOX2 CX3CR1
 CD81 RAC1 CDK5 POU5F1 ID3 DST HHEX GRIN2A AIMP1 GRIN2C AGER
 DKFZp686D0662 HOXB13 KLK6 F2RL3 SMO FGFR1OP2 PLLP LYVE1 CD28 F3
 ANO6 CHIA FOXF1 VTN ADRA2A HBEGF CXCL13 VNN1 S100A8 S100A9 THBS1 VCAM1
 CCL11 WNT7A FZD7 IGF1 UNC13D CCL5 F2 F12 APOH SERPINE1 THBS1
 F7 CD36 F2R PRDX2 NFE2L2 HPSE IL2RA HMGB1 IL20RB PNMA1 IL25 TNF
 IL1B CCL5 CNR1 PTGS2 PTGER3 PLA2G4A F8 F2 F9 F10 A2M KNG1
 APOH F11 KLKB1 VWF SERPING1 GP1BA GP1BB GP9 GP5 PRCP C1QBP
 AGER STAT5B IL1RL1 STAT5A EDNRA TNFRSF1A JAK2 TLR4 PDE2A MAPK13 TLR3
 TLR2 IL33 SERPINE1 ACE PLA2G2A FABP4 TNFRSF1A ZP3 TGM2 TNFSF4
 EDNRA IL12B AGTR1 IL15 WNT5A CCR2 STAT5A PLA2G4A STAT5B NLRP12 IL2 CX3CL1
 IL1RL1 CD47 PLA2G7 IL18 AGER IL21 IL23A TLR9 TLR7 FZD6 FGB ENTPD1
 PIK3CB PIK3CB PIK3CB FGA MERTK GNA13 STXBP3 F2RL2 LEFTY2 PDE2A PIK3R2 ATP2A1
 PLSCR1 ABCC4 PDPK1 LAT ACTN4 CALU FIGF WDR1 GUCY1B2 DGKI PDE5A
PDE9A RASGRP1 GNA14 SOD1 F8 F13A1 CFD PLG SERPINA1 A2M TIMP1




ALB PPBP TF RAF1 ALDOA PDGFA APOB GNAI2 IGF1 APP ITGB3 SERPINE1
 PRKCG SERPING1 IL6 PRKCB LCK FYN PROS1 PSAP PFN1 LYN THBS1
 COL1A2 ITGA2B PLEK SERPINF2 GNAI3 CD63 SPARC FGR SRGN TGFB3 CLU
 HSPA5 F5 ACTN1 SRC LAMP2 HGF GP9 RAC2 VAV1 VEGFA SELP PECAM1
 PDE6A ATP2A2 CD36 PLCG2 PRKCA VCL PDE6G ATP2B1 IL11 FLNA TBXA2R CFL1
 ATP2B4 DGKA PRKCH CD40 MAPK3 PIK3R1 MAPK1 PTPN6 NOS3 NOS1 CD40LG GNA11
 FCER1G AXL GNA15 AKT1 ARRB2 SLC8A1 GUCY1A2 NOS2 ACTN2 PDE6B GP5
 THPO MPL PIK3CA PIK3CB PTGIR SYK PLA2G4A P2RY1 PIK3CG ARRB1 DGKG VEGFB
 VEGFC GNAQ P2RX1 DGKE VAV2 DGKQ PDE1A SLC8A3 GNG2 RHOA TGFB2 CALM3
 TMSB4X RHOB GNB1 PPIA RAC1 GNAS GNAI1 YWHAZ TUBA4A CX3CL1 RHOG PDE1B
 CAP1 ATP2B2 GUCY1A3 GUCY1B3 PRKCE GNA12 PRKCQ PRKCZ PRKCD PTPN11
 TYRO3 KCNMA1 STX4 MERTK LCP2 MMRN1 PRKG2 PDE3B TRPC3 DGKZ STIM1 PRKG1
 LRP8 GNA13 GAS6 PDE3A ITPR2 ITPR3 ITPR1 MAPK14 KCNMB1 ATP2B3 DGKD HABP4
 DGKK PIK3R6 FGA BLOC1S3 ADAMTS13 RASGRP2 ENTPD1 KCNMB4 DGKH DAGLB SCG3
 PIK3R5 TTN PIK3R3 ATP2A3 ORAI1 F2RL3 MGLL POTEKP P2RY12 PDE11A TRPC7 KCNMB3
 VAV3 BRPF3 SLC8A2 TRPC6 PDE10A TLN1 DAGLA ENTPD2 KCNMB2 MRVI1 DGKB GAP43
 NINJ2 SERPINE1 FGF10 E5RH35 E5RJA8 E5RJP8 E5RJZ7 NINJ2 TIMP3 NINJ2 FGF10
 PLG SERPINE1 GSN IGFBP1 CCNB1 TIMP3 NOTCH1 TM4SF4 GATM NOTCH2 PRKCQ
 ADAM15 INA GSN PLG APOA5 IGSF10 MUSTN1 KLK6 NINJ1 NINJ2 SERPINA10
 NOTCH3 PGCP SERPINE1 ZP3 IL4 FOXP3 PRDX2 CYR61 B4GALT1 WNT7A FGF10
 FZD7 B4GALT1 MMP12 KLK8 EPHA4 XYLT1 LYN LYN TLR4 SLC7A2 STAT5B TSC2
 SAA1 SAA2 SAAL1 TFRC PLSCR1 F8 F2 ASS1 SERPINA1 SERPINA3
 INS SAA1 CRP APCS FN1 ORM1 AHSG TFRC IL6 SERPINF2 IL6R
 MBL2 CEBPB IL1RN ORM2 SAA3P SAA4 STAT3 CEBPA TSC2 STAT5B REG3A ITIH4
 ASS1 SIGIRR REG3G CD163 SAAL1 MRGPRX1 APOL2 IL22 B4GALT1 VNN1 APOA2
 S100A8 ALOX5 B4GALT1 VCAM1 TNFSF4 TACR1 DEFB1 ACVR1 KL TNR IRGM C4B-1
 C4A NCF1B RXRA BMP6 C3 IGFBP4 TNFRSF1A LAT AKT1 TP73 IL8
 CCRL2 NFKBIZ TMEM23 CD14 CD14 BMPR1B MECOM SCN9A SCN9A CD14 P2RX7 MECOM
 MS4A2 MAP2K3 C4B TNFRSF1A OLR1 TNFRSF1A PDPN C4B F8VX64 C4A
 CCL24 PIK3CD CCRL2 CCL21 CCL22 CXCL11 IKBKB NCR3 KDM6B CHUK TP73 CCL25
 CCL16 MEFV IRAK2 RIPK2 LIAS CHST1 LY75 TPST1 TLR5 CRCP RPS6KA5 RPS6KA4
 ATRN APOL3 IL18RAP VNN1 LY86 SERPINA1 SERPINA3 C3 C5 KNG1
 FOS TGFB1 NGF TNF IFNA2 IL1A CRP ORM1 CXCL10 KLKB1 ANXA1 CYBB
 ITGB2 S100A8 IL5 IL6 S100A9 CRH CD14 CXCL1 LTA4H C4A C4B PLA2G4B
 IL8 CCL3 SPP1 BMP2 CCL4 CYBA CCL2 SCG2 MIF NCF1 IL9 ALOX15
 SELP SELE CCL3L1 NPPB CEBPB ITGB6 TNFRSF1A RXRA NFKB1 CXCL2 CXCL3
 AZU1 TAC1 ITGAL BMP6 IL10 GAL IGFBP4 CXCR1 CXCR2 FPR2 TACR1 PTAFR
 F2R CD40 PTX3 AOAH ADORA2A CD40LG PRDX5 BDKRB2 AXL ADORA1 CCR1
 CCR7 ADORA3 EPHX2 IL13 HRH1 CCR2 TNFRSF4 XCR1 BDKRB1 MAP2K3 PIK3CG CD97
 SLC11A1 CCL11 CCR3 CCR4 CCR5 NDST1 AIF1 F2RL1 UCN CCL23 CCL18 HDAC4
 CARD18 TIRAP CXCR4 LYZ RAC1 ADAM8 OLR1 KCNJ10 ELF3 CCL20 CCL8 CCL7
 CXCL6 S100A12 TNFAIP6 MS4A2 MECOM RELA REG3A AOX1 CXCL9 IL10RB AIMP1 NFATC3
 NFX1 NMI NFE2L1 NFATC4 AGER TLR1 LTB4R GPR68 SMAD1 IL17A CAMK4 C3AR1
 AOC3 CDO1 SPHK1 C4A DARC THEMIS2 IL23R GGT5 NFRKB C4B REG3G TRIL
 PXK CD163 TICAM2 PDPN EVI1 CAMK1D TICAM1 SCUBE1 AFAP1L2 CHST4 ABCF1 NFAM1
 IL27 CCL4L2 NFKBID IL17D BLNK CCL17 HIST1H2BA KLRG1 ITCH NLRP3 IL17F
 CD180 S1PR3 CCL13 MGLL CCL19 CLEC7A TLR10 NFKBIZ SIGLEC1 IL22 TOLLIP HRH4
 CYP4F11 PROK2 MMP25 IL1RAP NOX4 TLR8 STAB1 SPHK1 PLA2G2E IL17C IL36A TBK1
 IL17B PARP4 HDAC9 CELA1 PLA2G2D PLA2G4C HDAC5 NOD1 CCL26 PLAA CYSLTR1 TLR6
 CHST2 NOX1 F11R IKBKG LY96 A2M SERPING1 STXBP3 PLEK GATA1 PDGFRA
 WNT3A STXBP1 FERMT3 HIF1A TGFB1 F2R HIF1A FCER1A FCER1G NTRK3 CCR7 CHRNA7
 SPECC1L CALCRL ADORA2A NR1H3 ADORA2A ADORA2A NR1H3 ADORA2A
 NR1H3 CALCRL ABR ADA SERPINC1 IL2RA APOE SAA1 GBA ADRB2 ELANE
 BCR ACP5 TNFRSF1B TNFAIP3 NT5E IL10 GATA3 ZFP36 AOAH CNR2 SERPINF1
 IL2 PRKCD FOXF1 ABR NR1H3 CALCRL O3FAR1 CD276 CHRNA7 NR1H3 GHSR SELS
 NDFIP1 UACA SHARPIN GHRL TNFAIP3 SERPINF2 F2 PLG APOH SERPINE1
 THBD THBS1 SERPINF2 USF1 CPB2 F3 MYOD1 F11 F2 F11 GP1BA
 F2R F2RL1 CAV1 VKORC1 FOXA2 C3 SELS INS ANXA1 IL4 GSTP1 ADORA1
 PPARG ANXA1 RXRA ISL1 JAK2 JUN BCL2 VCAN RXRA CTNNA1 ISL1 C5orf13
 RTN4RL1 RTN4RL2 CTNNA1 SERPINE1 PDE5A PDE5A PTGER3 IL1A EPHA3 TRPV1 FCER1G
 ADORA2B LBP LTA TNF CD44 HMOX1 STK24 PLG F12 F11 KLKB1
 ELANE LBP F12 KLKB1 MSTN SOX15 PLAU GPX1 ENO3 GJA1 MYF6 PAX7
 MTPN PLAUR ANO6 IL20RB C5 SELE ADAM8 JAM3 F2 PDGFB APOE PDGFA
 THBD PDGFRA NOS3 CNR1 MYOD1 SERPINE1 TNF IL1B KNG1 APOE APOH
 VTN PROC SERPINE1 EDN1 THBD TSPAN8 SPP1 TSPO SOD2 PCSK1 LYN
 ERBB2 SOD2 SOD1 EPO SOD2 ERBB2 ARG1 CDK1 LYN FGF2 LGALS1 GIP
 DRD2 ARF4 PCSK1 TSPO MAP1B GIPR AIF1 MAX ARG2 MAP2K1 SHH NTRK3
 LTC4S DRD2 TXN2 UCK2 AIF1 PPARA PDGFRA SMAD1 SDC2 SDC2 SERPINB2
GRHL3 POU2F3 SPARC WNT5B PPARA WNT5B SPARC WNT5B PPARD EREG TGFA INS




DSP PDGFRA ENG SDC1 NF1 FGF7 ERBB3 DRD5 LOX SDC2 MSX2 TGFBR1
 WNT5A P2RY2 ELK3 SLC11A1 TGFB2 SMAD3 PPARD FMOD PPARA MAP3K1 ITGA9 SMAD1
 KGFLP2 KGFLP1 TIMP1 MIA3 FUT10 SDC2 C6orf89 ARHGEF19 GRHL3 SCARB1 DCBLD2
 CNN2 KLF6 SPRR3 POU2F3 MACF1 VIL1 PLAU VIL1 CNTF SCARF1 NDEL1 NOD2
 PSMA1 PSMB4 IL12B NOD2 SCGB1A1 RELA SEMA7A JAK2 SEMA7A CALCA AHSG IL4
 SCGB1A1 SELE GGT1 TNFSF4 CMA1 AGTR1 PTGS2 BCL6 XCL1 SLC7A2 PSMA6 RELA
 SETD6 PARK7 MGLL MYD88 ACE2 NLRP1 NOD2 IL20 SBNO2 TSPO TNC APOE
 TNC TSPO MAP1B CHST3 C3 FCER1G PDPN TLR4 PLEK SELP PDPN JUB
 ITGA5 COL5A1 MSX2 ACVRL1 MMP12 SCNN1B SCNN1G ADAM17 JUB HBEGF FOXC2 TNFSF11





List of genes in EMT signature (GO:0001837) 
 
S100A4 BMP2 TRIM28 TGFB3 HGF BMP7 TGFB1 CTNNB1 TGFB2 
 
List of genes in mesenchyme development signature (GO:0060485) 
 
EOMES RTN4 WNT2 BMP2 TGFB2 TGFBR3 ADAM15 RTN4 WNT16 HES1 GREM1 EPHA3
 BCL2 BMP7 BMPR1A TBX20 BMP2 SOX9 ISL1 LRP6 MYC HIF1A SNAI1 HGF
 BMP7 S100A4 CTNNB1 TGFBR1 WNT5A SOX9 GSK3B HMGA2 WNT4 PPP3R1 TGFBR3 FOXF2
 TRIM28 HIF1A HNRNPAB LEF1 AMELX PPP3R1 BMP7 SMAD4 OSR1 SMAD4 WT1
 BASP1 PAX2 SIX1 OSR1 SIX4 LRP6 WNT8A HIF1A ACVR1 NRP2 ACVR1 ACVR1
 ISL1 ACVR1 LAMA5 TBX1 ZEB2 NRP2 FOXD2 FGF19 RET EDN3 KITLG EDNRB
 GDNF HTR2B GBX2 SOX8 ISL1 EFNB1 ACVR1 FOXD4 SEMA3F SHH HIF1A FOXD1
 FOXD4L6 FOXD4L5 FOXD4L4 NRTN SMO SEMA3C OVOL2 FOXD4L1 LEF1 FOXD3 PAX3 FOXD4L2
 EFNA1 NKX2-1 FOXA1 PPP2CA DAB2IP SFRP1 SFRP2 TBX5 FOXA2 OSR1 TBX5 BMP4
 ERBB3 GATA4 FOXF1 CRELD1 TBX5 FOXS1 FOXC1 SFRP1 FOXC2 WNT8A HEYL MSX2
 HEYL HEY1 BMP7 FGFR1 FGFR1 WNT11 HOXA5 FGFR2 FGF9 CTNNB1 WNT7B PTK7
 SHH EFNA1 BMP7 SHH HAND2 EDNRA ALDH1A2 CYP26A1 SNAI2 ALDH1A2
 EDN1 EDNRA SOX11 SOX9 HAND2 NRG1 FOXC1 CYP26A1 CYP26C1 RDH10 FOXC2 LRP6
 HTR2B MEF2C FRZB WNT10A TGFB1I1 COL1A1 BMP2 NOTCH1 SMAD3 BAMBI SMAD4 TWIST1
 SMAD2 BCL9L SMAD4 WWTR1 ZNF703 EPB41L5 LEF1 AXIN2 FGFR2 FOXF1 NKX2-5 FGFR1
 ISL1 FGFR1 BMP2 BMP7 FGFR2 TGFBR1 ISL1 PLAUR FOXC1 NOG TCF21 WNT4
 PAX2 OSR1 
 
List of genes in immune cell infiltration signature (Yoshihara et al. 2013) 
 
LCP2 LSP1 FYB PLEK HCK IL10RA LILRB1 NCKAP1L LAIR1 NCF2 CYBB PTPRC
 IL7R LAPTM5 CD53 EVI2B SLA ITGB2 GIMAP4 MYO1F HCLS1 MNDA IL2RG CD48
 AOAH CCL5 LTB GMFG GIMAP6 GZMK LST1 GPR65 LILRB2 WIPF1 CD37 BIN2
 FCER1G IKZF1 TYROBP FGL2 FLI1 IRF8 ARHGAP15 SH2B3 TNFRSF1B DOCK2
 CD2 ARHGEF6 CORO1A LY96 LYZ ITGAL TNFAIP3 RNASE6 TGFB1 PSTPIP1 CST7
 RGS1 FGR SELL MICAL1 TRAF3IP3 ITGA4 MAFB ARHGDIB IL4R RHOH HLA-DPA1
 NKG7 NCF4 LPXN ITK SELPLG HLA-DPB1 CD3D CD300A IL2RB ADCY7 PTGER4
 SRGN CD247 CCR7 MSN ALOX5AP PTGER2 RAC2 GBP2 VAV1 CLEC2B P2RY14 NFKBIA
 S100A9 IFI30 MFSD1 RASSF2 TPP1 RHOG CLEC4A GZMB PVRIG S100A8 CASP1 BCL2A1
 HLA-E KLRB1 GNLY RAB27A IL18RAP TPST2 EMP3 GMIP LCK IL32 PTPRCAP
 LGALS9 CCDC69 SAMHD1 TAP1 GBP1 CTSS GZMH ADAM8 GLRX PRF1 CD69 HLA-B
 HLA-DMA CD74 KLRK1 PTPRE HLA-DRA VNN2 TCIRG1 RABGAP1L CSTA ZAP70
 HLA-F HLA-G CD52 CD302 CD27 
 
List of genes in stromal tissue signature (Yoshihara et al. 2013) 
 
DCN PAPPA SFRP4 THBS2 LY86 CXCL14 FOXF1 COL10A1 ACTG2 APBB1IP SH2D1A SULF1
 MSR1 C3AR1 FAP PTGIS ITGBL1 BGN CXCL12 ECM2 FCGR2A MS4A4A WISP1 COL1A2
 MS4A6A EDNRA VCAM1 GPR124 SCUBE2 AIF1 HEPH LUM PTGER3 RUNX1T1 CDH5
 PIK3R5 RAMP3 LDB2 COX7A1 EDIL3 DDR2 FCGR2B LPPR4 COL15A1 AOC3 ITIH3 FMO1
 PRKG1 PLXDC1 VSIG4 COL6A3 SGCD COL3A1 F13A1 OLFML1 IGSF6 COMP HGF GIMAP5
 ABCA6 ITGAM MAF ITM2A CLEC7A ASPN LRRC15 ERG CD86 TRAT1 COL8A2 TCF21
 CD93 CD163 GREM1 LMOD1 TLR2 ZEB2 C1QB KCNJ8 KDR CD33 RASGRP3 TNFSF4
 CCR1 CSF1R BTK MFAP5 MXRA5 ISLR ARHGAP28 ZFPM2 TLR7 ADAM12 OLFML2B
 ENPP2 CILP SIGLEC1 SPON2 PLXNC1 ADAMTS5 SAMSN1 CH25H COL14A1 EMCN RGS4
 PCDH12 RARRES2 CD248 PDGFRB C1QA COL5A3 IGF1 SP140 TFEC TNN ATP8B4 ZNF423
 FRZB SERPING1 ENPEP CD14 DIO2 FPR1 IL18R1 HDC TXNDC3 PDE2A RSAD2
 ITIH5 FASLG MMP3 NOX4 WNT2 LRRC32 CXCL9 ODZ4 FBLN2 EGFL6 IL1B SPON1
 CD200 
 
List of genes in response to wounding signature (GO:0009611) 
 
MYLK3 CTNNBIP1 PIK3CG IL6 OSM TAC1 IL6ST PIK3CG ADAM8 NPY5R OSMR
 GAS6 PROC F2RL2 TFPI KLKB1 TFPI KIAA1715 F2 DTNBP1 AP3B1 PROC
 GAS6 F11 F2 EFEMP2 HPS5 AP3B1 THBD PROC F7 KIF2A STXBP3 AP3B1
 F2RL2 LEFTY2 PDE2A PIK3R2 SH2B2 KIF3C ATP2A1 KIF3B ANGPT2 RAD51B SLC16A3 ABCC4
 MAFG PDPK1 RAD51C LAT AKAP10 ACTN4 CALU FIGF KDM1A DOK2 JAK2 MAFK
Response to wounding signature 
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WDR1 GUCY1B2 DGKI PDE5A PDE9A MFN2 KIF4A RASGRP1 RAPGEF3 GNA14 SLC16A8
 EFEMP2 SOD1 ABL1 CFD PLAU PLAT SERPINA1 TIMP1 NRAS HRAS KRAS
 PDGFB EGF TGFB1 IFNA1 IFNA2 IFNA10 IFNA7 IFNA21 IFNA5 IFNA14 IFNA17 IFNB1
 HBD HBE1 COL1A1 APOA1 C9 FN1 ALB PPBP PF4 TF MMP1 RAF1
 ALDOA PDGFA APOB HRG TP53 GNAI2 IFNA6 IFNA4 IFNA16 IGF1 ATP1B1 APP
 ITGB3 ITGB2 SERPINB2 SERPINE1 PRKCG SERPIND1 ITGB1 PRKCB LCK
 FYN CD2 ITGAV PROS1 PSAP PFN1 YES1 LYN THBS1 COL1A2 SLC3A2 ITGA2B
 PLEK ITGA5 SERPINF2 GNAI3 ANXA5 ADRA2A CD63 CD48 SPARC FGR SRGN
 MYB TGFB3 PRKAR1A CLU IRF1 HSPA5 ITGAM ACTN1 SRC LAMP2 ITGA4
 PRKAR2A ANXA8 CD59 SELL HGF IRF2 ATP1B2 RAC2 VAV1 VEGFA GATA1
 SELP SPN PECAM1 PDE6A ATP2A2 CD36 PLCG2 PRKCA ITGA2 PRKACA PTPN1 ADRA2B
 VCL PDE6G ADRA2C PLCG1 CD58 ATP2B1 RAB5A ITGAL ITGAX C4BPB MAG FLNA
 TBXA2R CD9 PRKACG PRKACB PROZ ITGA6 CFL1 ATP2B4 DGKA GATA2 GATA3 PRKCH
 CDK2 F2R ITGA3 MAPK3 PIK3R1 MAPK1 ADORA2A PTPN6 SHC1 NOS3 NOS1
 GNA11 FCER1G WEE1 GNA15 PRKAR1B PRKAR2B AKT1 L1CAM ARRB2 SLC8A1 IFNA8 GUCY1A2
 NOS2 ACTN2 BSG PDE6B GGCX THPO MPL HNF4A CSK PIK3CA PIK3CB WAS
 PTGIR SYK GATA4 CBX5 CRK PLA2G4A CAPZA2 CAPZB P2RY1 TFPI2 PIK3CG LMAN1
 ARRB1 DGKG VEGFB VEGFC ENTPD1 GNAQ RAB27A P2RX1 DGKE KIF11 VAV2 DGKQ
 CAPZA1 SLC16A1 ATP1B3 PDE1A BCAR1 JAM2 SLC8A3 GNG2 ACTB CDC42 RAP1B RHOA
 TGFB2 CALM3 TMSB4X RHOB RAP1A GNB1 PPIA GRB2 RAC1 GNAS GNAI1 YWHAZ
 ACTG1 TUBA4A HIST1H3G HBB HBG1 HBG2 CXADR SIRPA OLR1 SLC7A9 RHOG
 H3F3B CDK5 PDE1B CAP1 SLC7A5 ATP2B2 GUCY1A3 GUCY1B3 PRKCE CENPE
 KIF23 TEK GNA12 CAV1 PRKCQ PTK2 PRKCZ PRKCD PTPN11 KLC1 SOS1 CD47
 KCNMA1 KIF5A STX4 MERTK LCP2 MMRN1 PRKG2 PABPC4 PPIL2 PDE3B TRPC3 HDAC1
 ITPK1 DGKZ STIM1 PRKG1 LRP8 DOCK1 SELPLG GNA13 GAS6 PDE3A GRB14 GRB7
 ITPR2 ITPR3 ITPR1 KIF22 ANGPT1 SHH JMJD1C MAPK14 KCNMB1 NFE2 ATP2B3 DGKD
 KIF4B DOCK11 HABP4 DGKK PIK3R6 LRRC16A HIST2H3A RASGRP2 APBB1IP KCNMB4 DGKH
 AMICA1 HPS6 SCUBE1 ZFPM1 KIF2B CD177 DAGLB DOCK8 KIF18A CABLES1 ZFPM2 SCG3
 PIK3R5 TTN RAPGEF4 SLC7A6 PIK3R3 AKAP1 HDAC2 INPP5D KIFAP3 HPS1 GATA6 ATP2A3
 ESAM PHF21A ORAI1 DTNBP1 DOCK6 CPB2 F2RL3 SIN3A KIF2C MGLL KIFC1 GATA5
 JAM3 POTEKP DOCK9 CD244 LNP KLC2 RACGAP1 ZFYVE20 P2RY12 EHD1 KIF9
 GP6 PDE11A TRPC7 TREM1 KCNMB3 HPS4 F13A1 SH2B1 PLSCR4 VPS45 SLC7A10 KIF15
 EHD3 EHD2 HMG20B SIRPG SLC7A8 CD84 AK3 RCOR1 VAV3 PLDN BRPF3 KIF26A
 MAFF SLC7A7 PROCR SLC8A2 SLC7A11 HPS5 SH2B3 TRPC6 PDE10A ANGPT4 TLN1 KIF3A
 DAGLA F11R KCNMB2 MRVI1 DGKB WNT7A B4GALT1 ITGB3 GPX1 SRF B4GALT1 CX3CL1
 DKFZp686D0662 F9 F10 F7 TFPI F3 MYH10 MYH10 TRIM72 MYOF P2RX1
 MGST3 ALOX5 ALOX5AP LTC4S MGST2 MASP1 INS DUSP10 ANXA2P2 F2 PLG PLAU
 PLAT HRG KRT1 SERPINB2 SERPINE1 ANXA2 GP1BA SERPINF2 PLAUR
 TMPRSS6 SERPINE2 RPS6KB1 MET F2RL2 NGFR MDK CASP3 SERPINE2 CD81
 ADM CTSB CD81 CTSB CD81 MDK FGFR1OP2 F2RL2 NRP1 KLK8 F2
 TGFB1 FN1 PDGFA VWF WNT1 CYP1A1 GPX1 CTSB NGFR ABHD2 PATE4 CLU
 VCAN F3 GFAP ITGB4 GAP43 MDK FGF7 ACHE RPS6KB1 TNC F2R PAX6
 CTGF PEBP1 CCR1 ADORA3 ADM CCR2 CASP3 SLC1A3 SLC1A2 SOX2 CX3CR1 CD81
 RAC1 CDK5 POU5F1 ID3 DST HHEX GRIN2A AIMP1 GRIN2C AGER DKFZp686D0662
 HOXB13 KLK6 F2RL3 SMO FGFR1OP2 PLLP LYVE1 CD28 F3 ANO6 CHIA
 FOXF1 VTN ADRA2A HBEGF CXCL13 VNN1 S100A8 S100A9 THBS1 VCAM1 CCL11 WNT7A
 FZD7 IGF1 UNC13D CCL5 F2 F12 APOH SERPINE1 THBS1 F7 CD36
 F2R PRDX2 NFE2L2 HPSE IL2RA HMGB1 IL20RB PNMA1 IL25 TNF IL1B CCL5
 CNR1 PTGS2 PTGER3 PLA2G4A F8 F2 F9 F10 A2M KNG1 APOH F11
 KLKB1 VWF SERPING1 GP1BA GP1BB GP9 GP5 PRCP C1QBP AGER STAT5B
 IL1RL1 STAT5A EDNRA TNFRSF1A JAK2 TLR4 PDE2A MAPK13 TLR3 TLR2 IL33
 SERPINE1 ACE PLA2G2A FABP4 TNFRSF1A ZP3 TGM2 TNFSF4 EDNRA IL12B
 AGTR1 IL15 WNT5A CCR2 STAT5A PLA2G4A STAT5B NLRP12 IL2 CX3CL1 IL1RL1 CD47
 PLA2G7 IL18 AGER IL21 IL23A TLR9 TLR7 FZD6 FGB ENTPD1 PIK3CB PIK3CB
 PIK3CB FGA MERTK GNA13 STXBP3 F2RL2 LEFTY2 PDE2A PIK3R2 ATP2A1 PLSCR1 ABCC4
 PDPK1 LAT ACTN4 CALU FIGF WDR1 GUCY1B2 DGKI PDE5A PDE9A RASGRP1
 GNA14 SOD1 F8 F13A1 CFD PLG SERPINA1 A2M TIMP1 KNG1 PDGFB
 EGF TGFB1 COL1A1 COL3A1 APOA1 FGA FGB FGG SAA1 FN1 ALB PPBP
 TF RAF1 ALDOA PDGFA APOB GNAI2 IGF1 APP ITGB3 SERPINE1 PRKCG
 SERPING1 IL6 PRKCB LCK FYN PROS1 PSAP PFN1 LYN THBS1 COL1A2
 ITGA2B PLEK SERPINF2 GNAI3 CD63 SPARC FGR SRGN TGFB3 CLU HSPA5
 F5 ACTN1 SRC LAMP2 HGF GP9 RAC2 VAV1 VEGFA SELP PECAM1 PDE6A
 ATP2A2 CD36 PLCG2 PRKCA VCL PDE6G ATP2B1 IL11 FLNA TBXA2R CFL1 ATP2B4
 DGKA PRKCH CD40 MAPK3 PIK3R1 MAPK1 PTPN6 NOS3 NOS1 CD40LG GNA11 FCER1G
 AXL GNA15 AKT1 ARRB2 SLC8A1 GUCY1A2 NOS2 ACTN2 PDE6B GP5 THPO
 MPL PIK3CA PIK3CB PTGIR SYK PLA2G4A P2RY1 PIK3CG ARRB1 DGKG VEGFB VEGFC
 GNAQ P2RX1 DGKE VAV2 DGKQ PDE1A SLC8A3 GNG2 RHOA TGFB2 CALM3 TMSB4X
 RHOB GNB1 PPIA RAC1 GNAS GNAI1 YWHAZ TUBA4A CX3CL1 RHOG PDE1B CAP1
 ATP2B2 GUCY1A3 GUCY1B3 PRKCE GNA12 PRKCQ PRKCZ PRKCD PTPN11 TYRO3
 KCNMA1 STX4 MERTK LCP2 MMRN1 PRKG2 PDE3B TRPC3 DGKZ STIM1 PRKG1 LRP8
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GNA13 GAS6 PDE3A ITPR2 ITPR3 ITPR1 MAPK14 KCNMB1 ATP2B3 DGKD HABP4 DGKK
 PIK3R6 FGA BLOC1S3 ADAMTS13 RASGRP2 ENTPD1 KCNMB4 DGKH DAGLB SCG3 PIK3R5
 TTN PIK3R3 ATP2A3 ORAI1 F2RL3 MGLL POTEKP P2RY12 PDE11A TRPC7 KCNMB3 VAV3
 BRPF3 SLC8A2 TRPC6 PDE10A TLN1 DAGLA ENTPD2 KCNMB2 MRVI1 DGKB GAP43 NINJ2
 SERPINE1 FGF10 E5RH35 E5RJA8 E5RJP8 E5RJZ7 NINJ2 TIMP3 NINJ2 FGF10 PLG
 SERPINE1 GSN IGFBP1 CCNB1 TIMP3 NOTCH1 TM4SF4 GATM NOTCH2 PRKCQ ADAM15
 INA GSN PLG APOA5 IGSF10 MUSTN1 KLK6 NINJ1 NINJ2 SERPINA10 NOTCH3
 PGCP SERPINE1 ZP3 IL4 FOXP3 PRDX2 CYR61 B4GALT1 WNT7A FGF10 FZD7
 B4GALT1 MMP12 KLK8 EPHA4 XYLT1 LYN LYN TLR4 SLC7A2 STAT5B TSC2 SAA1
 SAA2 SAAL1 TFRC PLSCR1 F8 F2 ASS1 SERPINA1 SERPINA3 INS
 SAA1 CRP APCS FN1 ORM1 AHSG TFRC IL6 SERPINF2 IL6R MBL2
 CEBPB IL1RN ORM2 SAA3P SAA4 STAT3 CEBPA TSC2 STAT5B REG3A ITIH4 ASS1
 SIGIRR REG3G CD163 SAAL1 MRGPRX1 APOL2 IL22 B4GALT1 VNN1 APOA2 S100A8
 ALOX5 B4GALT1 VCAM1 TNFSF4 TACR1 DEFB1 ACVR1 KL TNR IRGM C4B-1 C4A
 NCF1B RXRA BMP6 C3 IGFBP4 TNFRSF1A LAT AKT1 TP73 IL8 CCRL2
 NFKBIZ TMEM23 CD14 CD14 BMPR1B MECOM SCN9A SCN9A CD14 P2RX7 MECOM MS4A2
 MAP2K3 C4B TNFRSF1A OLR1 TNFRSF1A PDPN C4B F8VX64 C4A CCL24
 PIK3CD CCRL2 CCL21 CCL22 CXCL11 IKBKB NCR3 KDM6B CHUK TP73 CCL25 CCL16
 MEFV IRAK2 RIPK2 LIAS CHST1 LY75 TPST1 TLR5 CRCP RPS6KA5 RPS6KA4 ATRN
 APOL3 IL18RAP VNN1 LY86 SERPINA1 SERPINA3 C3 C5 KNG1 FOS
 TGFB1 NGF TNF IFNA2 IL1A CRP ORM1 CXCL10 KLKB1 ANXA1 CYBB ITGB2
 S100A8 IL5 IL6 S100A9 CRH CD14 CXCL1 LTA4H C4A C4B PLA2G4B IL8
 CCL3 SPP1 BMP2 CCL4 CYBA CCL2 SCG2 MIF NCF1 IL9 ALOX15 SELP
 SELE CCL3L1 NPPB CEBPB ITGB6 TNFRSF1A RXRA NFKB1 CXCL2 CXCL3 AZU1
 TAC1 ITGAL BMP6 IL10 GAL IGFBP4 CXCR1 CXCR2 FPR2 TACR1 PTAFR F2R
 CD40 PTX3 AOAH ADORA2A CD40LG PRDX5 BDKRB2 AXL ADORA1 CCR1 CCR7
 ADORA3 EPHX2 IL13 HRH1 CCR2 TNFRSF4 XCR1 BDKRB1 MAP2K3 PIK3CG CD97 SLC11A1
 CCL11 CCR3 CCR4 CCR5 NDST1 AIF1 F2RL1 UCN CCL23 CCL18 HDAC4 CARD18
 TIRAP CXCR4 LYZ RAC1 ADAM8 OLR1 KCNJ10 ELF3 CCL20 CCL8 CCL7 CXCL6
 S100A12 TNFAIP6 MS4A2 MECOM RELA REG3A AOX1 CXCL9 IL10RB AIMP1 NFATC3 NFX1
 NMI NFE2L1 NFATC4 AGER TLR1 LTB4R GPR68 SMAD1 IL17A CAMK4 C3AR1 AOC3
 CDO1 SPHK1 C4A DARC THEMIS2 IL23R GGT5 NFRKB C4B REG3G TRIL PXK
 CD163 TICAM2 PDPN EVI1 CAMK1D TICAM1 SCUBE1 AFAP1L2 CHST4 ABCF1 NFAM1 IL27
 CCL4L2 NFKBID IL17D BLNK CCL17 HIST1H2BA KLRG1 ITCH NLRP3 IL17F CD180
 S1PR3 CCL13 MGLL CCL19 CLEC7A TLR10 NFKBIZ SIGLEC1 IL22 TOLLIP HRH4 CYP4F11
 PROK2 MMP25 IL1RAP NOX4 TLR8 STAB1 SPHK1 PLA2G2E IL17C IL36A TBK1 IL17B
 PARP4 HDAC9 CELA1 PLA2G2D PLA2G4C HDAC5 NOD1 CCL26 PLAA CYSLTR1 TLR6 CHST2
 NOX1 F11R IKBKG LY96 A2M SERPING1 STXBP3 PLEK GATA1 PDGFRA WNT3A
 STXBP1 FERMT3 HIF1A TGFB1 F2R HIF1A FCER1A FCER1G NTRK3 CCR7 CHRNA7 SPECC1L
 CALCRL ADORA2A NR1H3 ADORA2A ADORA2A NR1H3 ADORA2A NR1H3
 CALCRL ABR ADA SERPINC1 IL2RA APOE SAA1 GBA ADRB2 ELANE BCR
 ACP5 TNFRSF1B TNFAIP3 NT5E IL10 GATA3 ZFP36 AOAH CNR2 SERPINF1
 IL2 PRKCD FOXF1 ABR NR1H3 CALCRL O3FAR1 CD276 CHRNA7 NR1H3 GHSR SELS
 NDFIP1 UACA SHARPIN GHRL TNFAIP3 SERPINF2 F2 PLG APOH SERPINE1
 THBD THBS1 SERPINF2 USF1 CPB2 F3 MYOD1 F11 F2 F11 GP1BA
 F2R F2RL1 CAV1 VKORC1 FOXA2 C3 SELS INS ANXA1 IL4 GSTP1 ADORA1
 PPARG ANXA1 RXRA ISL1 JAK2 JUN BCL2 VCAN RXRA CTNNA1 ISL1 C5orf13
 RTN4RL1 RTN4RL2 CTNNA1 SERPINE1 PDE5A PDE5A PTGER3 IL1A EPHA3 TRPV1 FCER1G
 ADORA2B LBP LTA TNF CD44 HMOX1 STK24 PLG F12 F11 KLKB1
 ELANE LBP F12 KLKB1 MSTN SOX15 PLAU GPX1 ENO3 GJA1 MYF6 PAX7
 MTPN PLAUR ANO6 IL20RB C5 SELE ADAM8 JAM3 F2 PDGFB APOE PDGFA
 THBD PDGFRA NOS3 CNR1 MYOD1 SERPINE1 TNF IL1B KNG1 APOE APOH
 VTN PROC SERPINE1 EDN1 THBD TSPAN8 SPP1 TSPO SOD2 PCSK1 LYN
 ERBB2 SOD2 SOD1 EPO SOD2 ERBB2 ARG1 CDK1 LYN FGF2 LGALS1 GIP
 DRD2 ARF4 PCSK1 TSPO MAP1B GIPR AIF1 MAX ARG2 MAP2K1 SHH NTRK3
 LTC4S DRD2 TXN2 UCK2 AIF1 PPARA PDGFRA SMAD1 SDC2 SDC2 SERPINB2
 GRHL3 POU2F3 SPARC WNT5B PPARA WNT5B SPARC WNT5B PPARD EREG TGFA INS
 IL1A IL1B PDGFA ERBB2 ITGB3 S100A8 ADRB2 DCN MMP3 ADRB1 FGF2 TPM1
 DSP PDGFRA ENG SDC1 NF1 FGF7 ERBB3 DRD5 LOX SDC2 MSX2 TGFBR1
 WNT5A P2RY2 ELK3 SLC11A1 TGFB2 SMAD3 PPARD FMOD PPARA MAP3K1 ITGA9 SMAD1
 KGFLP2 KGFLP1 TIMP1 MIA3 FUT10 SDC2 C6orf89 ARHGEF19 GRHL3 SCARB1 DCBLD2
 CNN2 KLF6 SPRR3 POU2F3 MACF1 VIL1 PLAU VIL1 CNTF SCARF1 NDEL1 NOD2
 PSMA1 PSMB4 IL12B NOD2 SCGB1A1 RELA SEMA7A JAK2 SEMA7A CALCA AHSG IL4
 SCGB1A1 SELE GGT1 TNFSF4 CMA1 AGTR1 PTGS2 BCL6 XCL1 SLC7A2 PSMA6 RELA
 SETD6 PARK7 MGLL MYD88 ACE2 NLRP1 NOD2 IL20 SBNO2 TSPO TNC APOE
 TNC TSPO MAP1B CHST3 C3 FCER1G PDPN TLR4 PLEK SELP PDPN JUB
 ITGA5 COL5A1 MSX2 ACVRL1 MMP12 SCNN1B SCNN1G ADAM17 JUB HBEGF FOXC2 TNFSF11
 hRANKL 3 TNFRSF11A OMG 
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# load TRRUST database 
TRRUST = read.table("trrust_rawdata.txt", sep="\t") 
colnames(TRRUST) = c("TF", "Target", "Type", "PMID") 
# indices for unknown interactions 
unknown_idx = which(TRRUST$Type == "Unknown") 
# get all known interactions (activation and repression) 
TRRUST_known = TRRUST[-unknown_idx,] 
TRRUST_toUse = TRRUST_known 
 
# One of the inputs for the inference model is gene expression. 
# Firstly, filter out the genes with no hit in TRRUST_toUse. 
# 'exp' is gene expression values where each row is a gene 
# and each column is a sample. 
# second column of 'TRRUST_toUse' table ('Target') is target gene. 
exp = exp[which(!is.na(match(rownames(exp), unique(TRRUST_toUse$Target)))),] 
 
# get unique TFs in TRRUST_toUse 
uniqTF =  as.vector(unique(TRRUST_toUse$TF)) 
 
# Another input for the inference model is hit matrix. 
# build the hit matrix (T matrix in main text). 
# pre-define the matrix with zeroes (no interaction). 
hit_mat = matrix(data = 0, nrow = nrow(exp), ncol = length(uniqTF)) 
rownames(hit_mat) = rownames(exp) 
colnames(hit_mat) = uniqTF 
 
# exclude duplicated interactions 
TRRUST_noDup = cbind(as.vector(TRRUST_toUse$TF),  
                     as.vector(TRRUST_toUse$Target),  
                     as.vector(TRRUST_toUse$Type)) 
TRRUST_noDup = unique(TRRUST_noDup) 
 
# assign 1 or -1 in each iteration if the interaction is activating  
# or repressing, respectively. 
for (t in 1:length(uniqTF)) { 
  cur_TF = uniqTF[t] 
  # get the index of current TF in the hit matrix 
  TF_idx = which(colnames(hit_mat) == cur_TF) 
   
  # get indices of activating interactions for TF in this iteration 
  act_idx = intersect(which(TRRUST_noDup[,1] %in% cur_TF),  
                      which(TRRUST_noDup[,3] == "Activation")) 
  # if there is at least 1 activating interaction 
  if (length(act_idx) > 0) { 
    # get the target genes from the database 
    act_TG = unique(as.vector(TRRUST_noDup[act_idx,2])) 
    # get indices of these target genes in the hit matrix 
    actTG_idx = which(rownames(hit_mat) %in% act_TG) 
    hit_mat[actTG_idx,TF_idx] = 1 # activating = 1 
  } 
   
  # get indices of repressing interactions for TF in this iteration 
  repr_idx = intersect(which(TRRUST_noDup[,1] %in% cur_TF),  
                       which(TRRUST_noDup[,3] == "Repression")) 
  # if there is at least 1 repressing interaction 
  if (length(repr_idx) > 0) { 
    repr_TG = unique(as.vector(TRRUST_noDup[repr_idx,2])) 
    reprTG_idx = which(rownames(hit_mat) %in% repr_TG) 
    hit_mat[reprTG_idx,TF_idx] = -1 # repressing = -1 
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  } 
} 
 
# use lsfit to solve the linear least squares model 
TF_lsfit = lsfit(hit_mat, exp) 
# access the least squares estimates of the coefficients in the model 
# to retrieve TF activity scores
TF_act = TF_lsfit$coefficients 
# remove the intercept (first row) 
TF_act = TF_act[-1,] 
colnames(TF_act) = colnames(exp) 
 
# exclude TFs with standard deviation of activity scores = 0 
sd0_rows = NULL 
# collect indices of rows with SD = 0 in each iteration 
for (r in 1:nrow(TF_act)){ 
  if(sd(as.numeric(TF_act[r,])) == 0) { 
    sd0_rows = c(sd0_rows, r) 
  } 
} 
# 'TF_act' below is the output of the inference model 
TF_act = TF_act[-sd0_rows,] 
 
 
Source codes for Benjamini-Hochberg correction 
 
# function definition of BH procedure with controlling FDR 
# based on http://www.biostathandbook.com/multiplecomparisons.html 
BH_FDR_p.adjust <- function(pvalues, Q) { 
  # order of p-values 
  rank <- order(pvalues) 
  # order of rank for returning later 
  rev_rank <- order(rank) 
  pvalues_ranked <- pvalues[rank] 
  # calculate BH critical value 
  crit_values <- as.numeric(as.numeric(rank/length(pvalues))*Q) 
  max_idx <- max(which(pvalues_ranked < crit_values)) 
   
  sigFlag = NULL 
  sigFlag[1:max_idx] = "Y" 
  sigFlag[max_idx+1:length(pvalues)] = "N" 
   
  return(sigFlag[rev_rank]) 
}  
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# load cell proliferation signature 
Psig = system("more /work/halim/signatures/Proliferation_sig.txt", 
              intern = TRUE) 
Psig = unlist(strsplit(Psig, "\\\t")) 
Psig = unique(Psig[-c(1,2)]) 
 
# load tissue remodelling signature 
Rsig = system("more /work/halim/signatures/Remodeling_sig.txt",  
              intern = TRUE) 
Rsig = unlist(strsplit(Rsig, "\\\t")) 
Rsig = unique(Rsig[-c(1,2)]) 
 
# read in gene expression data 
geneExp = read.delim("coad.exp_agilent_g4502a.dt_matrix.mRNA_siRNA.txt") 
 
# signature to use 
sig = Psig # when P signature is in use 
#sig = Rsig # when R signature is in use 
 
# to build matrix S 
# below are indices of genes that appear in the signature 
sig_idx = which(!is.na(match(geneExp$Gene, sig))) 
# below are indices of genes that don't appear in the signature 
nonSig_idx = which(is.na(match(geneExp$Gene, sig))) 
 
# hg score 
A = 1/length(sig_idx) # 1/m if gEL 
B = 1/(nrow(geneExp) - length(sig_idx)) # -(1/(n-m)) otherwise 
matrixS = matrix(data = 0, nrow = nrow(geneExp), ncol = 1) 
matrixS[sig_idx] = A 
matrixS[nonSig_idx] = -B 
 
# function from the Reduce documentation that cumulatively adds 
cadd <- function(x) Reduce("+", x, accumulate = TRUE) 
 
# function definition of 'callPerm'. It calls 'permute' function and 
# calculates cumulative score matrix for current iteration then  
# returns its maximum and minimum values 
callPerm <- function(permNumber, matrixS) { 
  permS = permute(matrixS) 
  permX = cadd((permS)) 
  permX_max = max(permX) 
  permX_min = min(permX) 
   
  return(c(permX_max, permX_min)) 
} 
 
# number of permutations 
permNumber = 100000 
 
# call 'callPerm' function as many times as assigned to 'permNumber' 
# with parallelization  
res = mclapply(1:permNumber,callPerm,matrixS, mc.cores =  
                 getOption("mc.cores", 28L)) 
 




results = unlist(res) 
# create indices to grab all permX_max 
odd_indices<-seq(1,2*permNumber,2) 
# create indices to grab all permX_min 
even_indices<-seq(2,2*permNumber,2) 
allPermX_max = results[odd_indices] 
allPermX_min = results[even_indices] 
 
# initialise variables 
Xmax = NULL 
Xmin = NULL 
Pmax = NULL 
Pmin = NULL 
Xbest = NULL 
# correction to a less bias p-value estimate, i.e. p = (r+1)/(n+1) 
# go through expression (expr) values for every sample. 
# start from 3 as the first 2 columns in geneExp are gene names 
for (c in 3:ncol(geneExp)) { 
  exp = as.matrix(geneExp[,c]) 
  # sort expr values 
  sortExp = exp[order(exp, decreasing = TRUE)] 
  # sort reference score matrix based on the order of expr values 
  sortS = matrixS[order(exp, decreasing = TRUE)] 
   
  # round cumulative score matrix to 6 decimal places 
  matrixX = round(cadd(sortS), digits = 6) 
  # enrichment score at the upper tail 
  Xmax = c(Xmax,max(matrixX)) 
  # enrichment score at the lower tail 
  Xmin = c(Xmin,min(matrixX)) 
   
  # use 'c-2' as we start from 'c=3' 
  Cmax = length(which(as.numeric(allPermX_max) >= as.numeric(Xmax[c-2]))) 
  Cmin = length(which(as.numeric(allPermX_min) <= as.numeric(Xmin[c-2]))) 
   
  Pmax = c(Pmax,(Cmax+1)/(permNumber+1)) # p-value for Xmax 
  Pmin = c(Pmin,(Cmin+1)/(permNumber+1)) # p-value for Xmin 
   
  # to decide the enrichment score to report based on p-value at both tails 
  if (as.numeric(Pmax[c-2]) < as.numeric(Pmin[c-2])) { 
    Xbest = c(Xbest, Xmax[c-2]) 
  } else if (as.numeric(Pmax[c-2]) == as.numeric(Pmin[c-2])) { 
    # when Pmax=Pmin, Xbest = Xmax+Xmin 
    Xbest = c(Xbest, Xmax[c-2]+Xmin[c-2]) 
  } else { 
    Xbest = c(Xbest, Xmin[c-2]) 
  } 
   
} 
# Xbest is the enrichment score to report 
Xbest_P = Xbest # when P signature is in use 
#Xbest_R = Xbest # when R signature is in use 
  
 
